



Standard Commercial Prior Authorization Guidelines



STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

1. **Formulary Agents**

Drug products that are listed in the Formulary as Prior Authorization (PA) require evaluation, per MedImpact Pharmacy and Therapeutics Committee guidelines, when the member presents a prescription to a network pharmacy. Each request will be reviewed on individual patient need. If the request does not meet the criteria established by the P & T Committee, the request will not be approved and alternative therapy will be recommended.

2. **Non-Formulary Agents**

Any product not found in the Formulary listing, or any Formulary updates published by MedImpact, shall be considered a Non-Formulary drug. Coverage for non-formulary agents may be applied for in advance. When a member gives a prescription order for a non-formulary drug to a pharmacist, the pharmacist will evaluate the patient's drug history and contact the physician to determine if there is a legitimate medical need for a non-formulary drug. Each request will be reviewed on individual patient need. The following basic criteria are used:

- a. The use of Formulary Drug Products is contraindicated in the patient.
- b. The patient has failed an appropriate trial of Formulary or related agents.
- c. The choices available in the Drug Formulary are not suited for the present patient care need, and the drug selected is required for patient safety.
- d. The use of a Formulary drug may provoke an underlying condition, which would be detrimental to patient care.

If the request does not meet the criteria established by the P & T Committee, the request will not be approved and alternative therapy will be recommended.

3. **Obtaining Coverage**

Coverage may be obtained by:

- a. Faxing a completed **Medication Request Form** to MedImpact at (858) 790-7100.
- b. Contacting MedImpact at (800) 788-2949 and providing all necessary information requested.

MedImpact will provide an authorization number, specific for the medical need, for all approved requests. Non-approved requests may be appealed. The prescriber must provide information to support the appeal on the basis of medical necessity.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ABALOPARATIDE

Generic	Brand			
ABALOPARATIDE	TYMLOS			

GUIDELINES FOR USE

Our guideline named **ABALOPARATIDE (Tymlos)** requires the following rule(s) be met for approval:

A. The request is for ONE of the following:

1. Postmenopausal osteoporosis (a type of bone condition)
2. Increase bone density in a male patient with osteoporosis (a type of bone condition)

B. **If the request is for postmenopausal osteoporosis, approval also requires:**

1. You have NOT received a total of 24 months or more of treatment with any parathyroid hormone therapy (such as Tymlos [abaloparatide], Forteo [teriparatide])
2. You meet ONE of the following (a, b, or c):
 - a. You have high risk for fractures defined as ONE of the following:
 - i. History of osteoporotic fracture(s) (broken bones) due to trauma (injury) or fragility (weakness)
 - ii. Two or more risk factors for fracture such as history of multiple recent low trauma fractures, bone mineral density T-score (a type of lab test) less than or equal to -2.5, corticosteroid use, or use of GnRH (gonadotropin-releasing hormone) analogs such as Synarel (nafarelin)
 - iii. No prior treatment for osteoporosis AND FRAX (Fracture Risk Assessment Tool) score greater than or equal to 20 percent for any major fracture OR greater than or equal to 3 percent for hip fracture
 - b. You are unable to use oral therapy due to upper gastrointestinal (stomach and intestine) problems, you cannot tolerate oral medication, you have lower gastrointestinal problems (unable to absorb oral medications), you have trouble remembering to take oral medications or cannot plan to use an oral bisphosphonate (such as Fosamax [alendronate], Actonel [risedronate], Boniva [ibandronate]) with other oral medications in your daily routine
 - c. You had a trial of, intolerance (side effect) to, or a contraindication (harmful for) to a bisphosphonate (such as Fosamax [alendronate], Actonel [risedronate], Boniva [ibandronate])

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ABALOPARATIDE

GUIDELINES FOR USE (CONTINUED)

C. If the request is to increase bone density in a male patient with osteoporosis, approval also requires:

1. You have NOT received a total of 24 months or more of treatment with any parathyroid hormone therapy (such as Tymlos [abaloparatide], Forteo [teriparatide])
2. You meet ONE of the following (a or b):
 - a. You have high risk for fractures defined as ONE of the following:
 - i. History of osteoporotic fracture (such as fragility [weakness] fracture, low trauma [injury] fracture)
 - ii. Multiple risk factors for fracture (such as history of multiple recent low trauma fractures, bone mineral density T-score (a type of lab test) less than or equal to -2.5, corticosteroid use, use of GnRH [gonadotropin-releasing hormone] analogs such as Synarel [nafarelin])
 - b. You have failed or are intolerant (side effect) to other available osteoporosis therapy (such as Forteo [teriparatide], Prolia [denosumab], Fosamax [alendronate], Actonel [risedronate])

Effective: 04/17/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ABATACEPT - IV

Generic	Brand				
ABATACEPT/ MALTOSE	ORENCIA				

NOTE: For requests for the SQ dosage form of Orencia, please see the ABATACEPT - SQ PA guideline.

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ABATACEPT - IV (Orencia intravenous)** requires the following rule(s) be met for approval:

You have ONE of the following:

Moderate to severe rheumatoid arthritis (RA: a type of joint condition)

Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)

Psoriatic arthritis (PsA: a type of skin and joint condition)

Prophylaxis (prevention) of acute graft versus host disease (aGVHD: a short-term type of immune disorder)

If you have moderate to severe rheumatoid arthritis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)

You will NOT use Orencia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq [upadacitinib]], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis

You have tried at least 3 months of or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease-modifying antirheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

You meet ONE of the following:

You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)

You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ABATACEPT - IV

INITIAL CRITERIA (CONTINUED)

If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:

You are 6 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)

You will NOT use Orencia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz IR (tofacitinib immediate-release), Rinvoq (upadacitinib)

If you have psoriatic arthritis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)

You will NOT use Orencia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Taltz (ixekizumab), Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ABATACEPT - IV

INITIAL CRITERIA (CONTINUED)

If the request is for prophylaxis of acute graft versus host disease, approval also requires:

You are 2 years of age or older

You are undergoing hematopoietic stem cell transplantation (HSCT: a type of cell transplantation) from a matched or one allele (version of a gene)-mismatched unrelated-donor

Orencia will be used in combination with a calcineurin inhibitor (such as cyclosporine or tacrolimus) and methotrexate

You will NOT use Orencia concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of acute graft versus host disease prophylaxis

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

RENEWAL CRITERIA

NOTE: For the diagnosis of acute graft versus host disease (aGVHD), please refer to the Initial Criteria section.

Our guideline named **ABATACEPT - IV (Orencia intravenous)** requires the following rule(s) be met for renewal:

You have ONE of the following:

Moderate to severe rheumatoid arthritis (RA: a type of joint condition)

Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)

Psoriatic arthritis (PsA: a type of skin and joint condition)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ABATACEPT - IV

RENEWAL CRITERIA (CONTINUED)

If you have moderate to severe rheumatoid arthritis, renewal also requires:

You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy

You will NOT use Orencia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis

You meet ONE of the following:

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)

You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

If you have moderate to severe polyarticular juvenile idiopathic arthritis, renewal also requires:

You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy

You will NOT use Orencia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz IR (tofacitinib immediate-release), Rinvoq (upadacitinib)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ABATACEPT - IV

RENEWAL CRITERIA (CONTINUED)

If you have psoriatic arthritis, renewal also requires:

You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy

You will NOT use Orencia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Taltz (ixekizumab), Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ABATACEPT - SQ

Generic	Brand			
ABATACEPT	ORENCIA, ORENCIA CLICKJECT			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ABATACEPT - SQ (Orencia subcutaneous)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
 2. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
 3. Psoriatic arthritis (PsA: a type of skin and joint condition)
- B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use Orencia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
 4. You have tried at least 3 months of or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease-modifying antirheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
 5. You meet ONE of the following:
 - a. You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ABATACEPT – SQ

INITIAL CRITERIA (CONTINUED)

C. If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Orencia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
4. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz IR (tofacitinib immediate-release), Rinvoq (upadacitinib)

D. If you have psoriatic arthritis, approval also requires:

1. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
2. You will NOT use Orencia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
3. You meet ONE of the following:
 - a. You are 2 to 5 years of age AND have tried or have a contraindication to (harmful for you to use) BOTH of the preferred medications: Enbrel (etanercept), Rinvoq (upadacitinib)
 - b. You are 6 to 17 years of age AND have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Rinvoq (upadacitinib)
 - c. You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Taltz (ixekizumab), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ABATACEPT – SQ

RENEWAL CRITERIA

Our guideline named **ABATACEPT - SQ (Orencia subcutaneous)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
3. Psoriatic arthritis (PsA: a type of skin and joint condition)

B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Orencia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
3. You meet ONE of the following:
 - a. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

C. **If you have moderate to severe polyarticular juvenile idiopathic arthritis, renewal also requires:**

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Orencia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
3. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz IR (tofacitinib immediate-release), Rinvoq (upadacitinib)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ABATACEPT - SQ

RENEWAL CRITERIA (CONTINUED)

D. If you have psoriatic arthritis, renewal also requires:

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Orencia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
3. You meet ONE of the following:
 - a. You are 2 to 5 years of age AND have tried or have a contraindication to (harmful for you to use) BOTH of the preferred medications: Enbrel (etanercept), Rinvoq (upadacitinib)
 - b. You are 6 to 17 years of age AND have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Rinvoq (upadacitinib)
 - c. You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Taltz (ixekizumab), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ABEMACICLIB

Generic	Brand			
ABEMACICLIB	VERZENIO			

GUIDELINES FOR USE

Our guideline named **ABEMACICLIB (Verzenio)** requires the following rule(s) be met for approval:

A. You have breast cancer

B. **If you have early breast cancer, approval also requires:**

1. Your cancer is hormone receptor (HR: a type of protein)-positive, human epidermal growth factor receptor 2 (HER2: a type of protein)-negative, node-positive (cancer that has spread to the lymph nodes)
2. Verzenio will be used in combination with endocrine therapy (tamoxifen or an aromatase inhibitor [such as letrozole, anastrozole, exemestane]) for adjuvant (add-on) treatment
3. You are at high risk of recurrence (disease returning)

C. **If you have advanced or metastatic breast cancer, approval also requires:**

1. Your cancer is hormone receptor (HR: a type of protein)-positive, human epidermal growth factor receptor 2 (HER2: a type of protein)-negative
2. You meet ONE of the following:
 - a. Verzenio will be used in combination with an aromatase inhibitor (such as letrozole, anastrozole, exemestane) as initial endocrine (hormone)-based therapy
 - b. Verzenio will be used in combination with fulvestrant (Faslodex); AND you have experienced disease progression following endocrine therapy (such as letrozole, anastrozole, tamoxifen)
 - c. Verzenio will be used as monotherapy (one medication treatment); AND you have experienced disease progression following endocrine therapy (such as letrozole, anastrozole, tamoxifen) as well as prior chemotherapy (drugs used to treat cancer) in the metastatic setting (cancer that has spread to other parts of the body)

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ABROCITINIB

Generic	Brand				
ABROCITINIB	CIBINQO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ABROCITINIB (Cibinqo)** requires the following rule(s) be met for approval:

- A. You have refractory, moderate to severe atopic dermatitis (AD: a type of skin condition)
- B. You are 12 years of age or older
- C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
- D. You have atopic dermatitis involving at least 10 percent of body surface area (BSA) OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas (areas between skin folds)
- E. You have TWO of the following: intractable pruritus (severe itching), cracking and oozing/bleeding of affected skin, impaired activities of daily living
- F. You have tried or have a contraindication to (harmful for you to use) THREE preferred medications: Dupixent (dupilumab), Rinvoq (upadacitinib), Adbry (tralokinumab-ldrm)
- G. You will NOT use Cibinqo concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Eucrisa (crisaborole)]) for the treatment of atopic dermatitis

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ABROCITINIB

RENEWAL CRITERIA

Our guideline named **ABROCITINIB (Cibinqo)** requires the following rule(s) be met for renewal:

- A. You have refractory, moderate to severe atopic dermatitis (AD: a type of skin condition)
- B. You have shown improvement while on Cibinqo
- C. You have tried or have a contraindication to (harmful for you to use) THREE preferred medications: Dupixent (dupilumab), Rinvoq (upadacitinib), Adbry (tralokinumab-ldrm)
- D. You will NOT use Cibinqo concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Eucrisa (crisaborole)]) for the treatment of atopic dermatitis

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ACALABRUTINIB

Generic	Brand				
ACALABRUTINIB	CALQUENCE				
ACALABRUTINIB MALEATE	CALQUENCE				

GUIDELINES FOR USE

Our guideline named **ACALABRUTINIB (Calquence)** requires the following rules be met for approval:

- A. You have ONE of the following:
 - 1. Mantle cell lymphoma (MCL: a type of blood cancer)
 - 2. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
 - 3. Small lymphocytic lymphoma (SLL: a type of blood cancer)
- B. **If you have untreated mantle cell lymphoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Calquence will be used in combination with bendamustine and rituximab
 - 3. You are NOT eligible for autologous hematopoietic stem cell transplantation (HSCT: a type of procedure to replace damaged bone marrow with your own healthy blood-forming cells)
- C. **If you have previously treated mantle cell lymphoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have received at least one prior therapy (such as R-CHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone])
- D. **If you have chronic lymphocytic leukemia or small lymphocytic lymphoma, approval also requires:**
 - 1. You are 18 years of age or older

Effective: 02/17/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ACETAMINOPHEN DAILY LIMIT OVERRIDE

Generic	Brand			
N/A	N/A			

GUIDELINES FOR USE

Our guideline named **ACETAMINOPHEN DAILY LIMIT OVERRIDE** will cause a denied claim for acetaminophen when the total daily dose acetaminophen exceeds 4000mg. The claim will also deny if the requested drug is being used at the same time with other acetaminophen containing product(s) and the combination exceeds 4000mg of acetaminophen per day limit.

Approval requires the following rule be met:

- A. You will discontinue the other acetaminophen containing drug(s) that cause the daily acetaminophen dose to exceed 4000mg.

Effective: 05/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ACNE AGE RESTRICTION OVERRIDE

Generic	Brand				
ADAPALENE	DIFFERIN				
TAZAROTENE	TAZAROTENE, TAZORAC				
TRETINOIN MICROSPHERES	RETIN-A MICRO, RETIN-A MICRO PUMP, TRETINOIN MICROSPHERES				
TRIFAROTENE	AKLIEF				

GUIDELINES FOR USE

Our guideline named **ACNE AGE RESTRICTION OVERRIDE** requires the following rule(s) be met for approval:

The request is for a non-cosmetic (not for appearance) diagnosis (such as melasma, photoaging, wrinkles)

You had a trial of TWO low cost generic medications (such as Adapalene lotion, cream or gel, Tretinoin cream or gel, Adapalene/Benzoyl Peroxide gel)

Effective: 01/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ACORAMIDIS

Generic	Brand				
ACORAMIDIS HCL	ATTRUBY				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ACORAMIDIS (Attruby)** requires the following rule(s) be met for approval:

- A. You have cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM: heart disease caused by a build-up of a type of protein)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor), transthyretin amyloidosis (ATTR) specialist, or medical geneticist (doctor who treats gene disorders)
- D. You have New York Heart Association (NYHA) Class I, II, or III heart failure (classification of heart failure symptoms)
- E. You will NOT use Attruby concurrently (at the same time) with other ATTR-CM TTR (transthyretin) stabilizers (such as tafamidis [Vyndaqel, Vyndamax])
- F. Your diagnosis is confirmed by ONE of the following:
 - 1. A bone scan (scintigraphy) strongly positive for myocardial uptake of TC-99m-PYP (a type of imaging test) (Note: Strongly positive defined as heart to contralateral lung [H/CL] ratio of at least 1.5 or Grade 2 or greater localization to the heart using the Perugini Grade 1-3 scoring system)
 - 2. A biopsy of tissue of the affected organ(s) (removal of cells or tissue from the body for examination) (can be heart or non-heart related organs) to confirm amyloid (type of protein) presence AND chemical typing to confirm presence of transthyretin (TTR) protein

RENEWAL CRITERIA

Our guideline named **ACORAMIDIS (Attruby)** requires the following rule(s) be met for renewal:

- A. You have cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM: heart disease caused by a build-up of a type of protein)
- B. You will NOT use Attruby concurrently (at the same time) with other ATTR-CM TTR (transthyretin) stabilizers (such as tafamidis [Vyndaqel, Vyndamax])

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADAGRASIB

Generic	Brand					
ADAGRASIB	KRAZATI					

GUIDELINES FOR USE

Our guideline named **ADAGRASIB (Krazati)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Locally advanced or metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to nearby tissue or lymph nodes or to other parts of the body)
 2. Locally advanced or metastatic colorectal cancer (CRC: a type of digestive tract cancer that has spread to nearby tissue or lymph nodes or to other parts of the body)
- B. **If you have locally advanced or metastatic non-small cell lung cancer, approval also requires:**
1. You are 18 years of age or older
 2. Your cancer has a KRAS G12C mutation (a type of abnormal gene) as determined by a Food and Drug Administration (FDA)-approved test
 3. You have received at least one prior systemic therapy
- C. **If you have locally advanced or metastatic colorectal cancer, approval also requires:**
1. You are 18 years of age or older
 2. Your cancer has a KRAS G12C mutation (a type of abnormal gene) as determined by a Food and Drug Administration (FDA)-approved test
 3. Krazati will be used in combination with Erbitux (cetuximab)
 4. You have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (drugs used to treat cancer)

Effective: 08/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB

Generic	Brand			
ADALIMUMAB	HUMIRA			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ADALIMUMAB (Humira)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
 2. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
 3. Psoriatic arthritis (PsA: a type of skin and joint condition)
 4. Ankylosing spondylitis (AS: a type of joint condition)
 5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
 6. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
 7. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
 8. Moderate to severe hidradenitis suppurativa (HS: a type of skin condition)
 9. Non-infectious intermediate posterior and panuveitis (a type of eye condition)
- B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use Humira concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
 4. You have tried at least 3 months of or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
 5. You are switching from a Humira biosimilar (such as Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm]) OR you have tried or have a contraindication to adalimumab-adaz or Simlandi

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB

INITIAL CRITERIA (CONTINUED)

- C. If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:**
1. You are 2 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use Humira concurrently (at the same time) with another systemic biologic (such as Enbrel [etanercept]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
 4. You are switching from a Humira biosimilar (such as Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm]) OR you have tried or have a contraindication to (harmful for you to use) adalimumab-adaz or Simlandi
- D. If you have psoriatic arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
 3. You will NOT use Humira concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
 4. You are switching from a Humira biosimilar (such as Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm]) OR you have tried or have a contraindication to (harmful for you to use) adalimumab-adaz or Simlandi
- E. If you have ankylosing spondylitis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use Humira concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
 4. You have tried or have a contraindication to (harmful for you to use) an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)
 5. You are switching from a Humira biosimilar (such as Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm]) OR you have tried or have a contraindication to adalimumab-adaz or Simlandi

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB

INITIAL CRITERIA (CONTINUED)

F. If you have moderate to severe plaque psoriasis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
3. You will NOT use Humira concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
4. You are switching from a Humira biosimilar (such as Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm]) OR you have tried or have a contraindication to (harmful for you to use) adalimumab-adaz or Simlandi
5. You meet ONE of the following:
 - a. You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis
 - b. You have a contraindication or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) and PUVA (phototherapy) for the treatment of plaque psoriasis
 - c. You are switching from a different biologic (such as Remicade [infliximab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication
6. You meet ONE of the following:
 - a. You were previously stable on another biologic and are switching to Humira
 - b. You have psoriasis covering 3 percent or more of body surface area (BSA)
 - c. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, face, or scalp

G. If you have moderate to severe Crohn's disease, approval also requires:

1. You are 6 years of age or older
2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
3. You will NOT use Humira concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
4. You are switching from a Humira biosimilar (such as Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm]) OR you have tried or have a contraindication to (harmful for you to use) adalimumab-adaz or Simlandi

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB

INITIAL CRITERIA (CONTINUED)

- H. If you have moderate to severe ulcerative colitis, approval also requires:**
1. You are 5 years of age or older
 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 3. You will NOT use Humira concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
 4. You are switching from a Humira biosimilar (such as Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm]) OR you have tried or have a contraindication to (harmful for you to use) adalimumab-adaz or Simlandi
- I. If you have moderate to severe hidradenitis suppurativa, approval also requires:**
1. You are 12 years of age or older
 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 3. You will NOT use Humira concurrently (at the same time) with another systemic biologic (such as Cosentyx [secukinumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of hidradenitis suppurativa
 4. You are switching from a Humira biosimilar (such as Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm]) OR you have tried or have a contraindication to (harmful for you to use) adalimumab-adaz or Simlandi
- J. If you have non-infectious intermediate, posterior and panuveitis, approval also requires:**
1. You are 2 years of age or older
 2. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor)
 3. You do NOT have isolated anterior uveitis (a different type of eye inflammation)
 4. You will NOT use Humira concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of uveitis
 5. You are switching from a Humira biosimilar (such as Amjevita [adalimumab-atto], Cyltezo [adalimumab-adbm]) OR you have tried or have a contraindication to (harmful for you to use) adalimumab-adaz or Simlandi

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB

RENEWAL CRITERIA

Our guideline named **ADALIMUMAB (Humira)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
3. Psoriatic arthritis (PsA: a type of skin and joint condition)
4. Ankylosing spondylitis (AS: a type of joint condition)
5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
6. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
7. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
8. Moderate to severe hidradenitis suppurativa (HS: a type of skin condition)
9. Non-infectious intermediate posterior and panuveitis (a type of eye condition)

B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Humira concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
3. If you are requesting Humira 40mg weekly dosing OR Humira 80mg every other week dosing, at least a 3-month trial of Humira 40mg every other week dosing is required

C. **If you have moderate to severe polyarticular juvenile idiopathic arthritis, renewal also requires:**

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Humira concurrently (at the same time) with another systemic biologic (such as Enbrel [etanercept]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis

D. **If you have psoriatic arthritis, renewal also requires:**

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Humira concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB

RENEWAL CRITERIA (CONTINUED)

E. If you have ankylosing spondylitis, renewal also requires:

1. You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
2. You will NOT use Humira concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis

F. If you have moderate to severe plaque psoriasis, renewal also requires:

1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50 percent or more while on therapy
2. You will NOT use Humira concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis

G. If you have moderate to severe Crohn's disease, renewal also requires:

1. You will NOT use Humira concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease

H. If you have moderate to severe ulcerative colitis, renewal also requires:

1. You will NOT use Humira concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

I. If you have moderate to severe hidradenitis suppurativa, renewal also requires:

1. You have shown improvement in your hidradenitis suppurativa symptoms
2. You will NOT use Humira concurrently (at the same time) with another systemic biologic (such as Cosentyx [secukinumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of hidradenitis suppurativa

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB

RENEWAL CRITERIA (CONTINUED)

- J. If you have non-infectious intermediate, posterior and panuveitis, renewal also requires:**
1. You will NOT use Humira concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of uveitis
 2. You have NOT experienced treatment failure, defined as ONE of the following:
 - a. You have developed new inflammatory chorioretinal or retinal vascular lesions (types of eye tumors)
 - b. You have a 2-step increase from baseline in anterior chamber cell grade or vitreous haze grade (types of classifications on severity of eye inflammation)
 - c. Your best-corrected visual acuity (BCVA) has worsened by at least 15 letters relative to your best visual acuity achieved

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB-ADAZ

Generic	Brand				
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ADALIMUMAB-ADAZ** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
 2. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
 3. Psoriatic arthritis (PsA: a type of skin and joint condition)
 4. Ankylosing spondylitis (AS: a type of joint condition)
 5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
 6. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
 7. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
 8. Moderate to severe hidradenitis suppurativa (HS: a type of skin condition)
 9. Non-infectious intermediate posterior and panuveitis (a type of eye condition)
- B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
 4. You have tried at least 3 months of or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB-ADAZ

INITIAL CRITERIA (CONTINUED)

- C. If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:**
1. You are 2 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Enbrel [etanercept]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
- D. If you have psoriatic arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
 3. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
- E. If you have ankylosing spondylitis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
 4. You have tried or have a contraindication to (harmful for you to use) an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB-ADAZ

INITIAL CRITERIA (CONTINUED)

- F. If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 3. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
 4. You meet ONE of the following:
 - a. You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis
 - b. You have a contraindication (harmful for you to use) or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) and PUVA (phototherapy) for the treatment of plaque psoriasis
 - c. You are switching from a different biologic (such as Remicade [infliximab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication
 5. You meet ONE of the following:
 - a. You were previously stable on another biologic and are switching to the requested medication
 - b. You have psoriasis covering 3 percent or more of body surface area (BSA)
 - c. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, face, or scalp
- G. If you have moderate to severe Crohn's disease, approval also requires:**
1. You are 6 years of age or older
 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 3. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB-ADAZ

INITIAL CRITERIA (CONTINUED)

- H. If you have moderate to severe ulcerative colitis, approval also requires:**
1. You are 5 years of age or older
 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 3. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
- I. If you have moderate to severe hidradenitis suppurativa, approval also requires:**
1. You are 12 years of age or older
 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 3. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Cosentyx [secukinumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of hidradenitis suppurativa
- J. If you have non-infectious intermediate, posterior and panuveitis, approval also requires:**
1. You are 2 years of age or older
 2. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor)
 3. You do NOT have isolated anterior uveitis (a different type of eye inflammation)
 4. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of uveitis

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB-ADAZ

RENEWAL CRITERIA

Our guideline named **ADALIMUMAB-ADAZ** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
3. Psoriatic arthritis (PsA: a type of skin and joint condition)
4. Ankylosing spondylitis (AS: a type of joint condition)
5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
6. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
7. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
8. Moderate to severe hidradenitis suppurativa (HS: a type of skin condition)
9. Non-infectious intermediate posterior and panuveitis (a type of eye condition)

B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
3. If you are requesting adalimumab-adaz 40mg weekly dosing OR adalimumab-adaz 80mg every other week dosing, at least a 3-month trial of adalimumab-adaz 40mg every other week dosing is required

C. **If you have moderate to severe polyarticular juvenile idiopathic arthritis, renewal also requires:**

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Enbrel [etanercept]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB-ADAZ

RENEWAL CRITERIA (CONTINUED)

D. If you have psoriatic arthritis, renewal also requires:

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

E. If you have ankylosing spondylitis, renewal also requires:

1. You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
2. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis

F. If you have moderate to severe plaque psoriasis, renewal also requires:

1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50 percent or more while on therapy
2. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis

G. If you have moderate to severe Crohn's disease, renewal also requires:

1. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease

H. If you have moderate to severe ulcerative colitis, renewal also requires:

1. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB-ADAZ

RENEWAL CRITERIA (CONTINUED)

- I. **If you have moderate to severe hidradenitis suppurativa, renewal also requires:**
 - 1. You have shown improvement in your hidradenitis suppurativa symptoms
 - 2. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Cosentyx [secukinumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of hidradenitis suppurativa
- J. **If you have non-infectious intermediate, posterior and panuveitis, renewal also requires:**
 - 1. You will NOT use the requested medication concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of uveitis
 - 2. You have NOT experienced treatment failure, defined as ONE of the following:
 - a. You have developed new inflammatory chorioretinal or retinal vascular lesions (types of eye tumors)
 - b. You have a 2-step increase from baseline in anterior chamber cell grade or vitreous haze grade (types of classifications on severity of eye inflammation)
 - c. Your best-corrected visual acuity (BCVA) has worsened by at least 15 letters relative to your best visual acuity achieved

Effective: 05/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB-RYVK

Generic	Brand				
ADALIMUMAB-RYVK	SIMLANDI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ADALIMUMAB-RYVK (Simlandi)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
 2. Moderate to severe polyarticular juvenile idiopathic arthritis (pJIA: a type of joint condition)
 3. Psoriatic arthritis (PsA: a type of skin and joint condition)
 4. Ankylosing spondylitis (AS: a type of joint condition)
 5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
 6. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
 7. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
 8. Moderate to severe hidradenitis suppurativa (HS: a type of skin condition)
 9. Non-infectious intermediate, posterior, and panuveitis (a type of eye condition)
- B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You have tried at least 3 months of or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
 4. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB-RYVK

INITIAL CRITERIA (CONTINUED)

- C. If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:**
1. You are 2 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic (such as Enbrel [etanercept]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
- D. If you have psoriatic arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
 3. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
- E. If you have ankylosing spondylitis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
 4. You have tried or have a contraindication to (harmful for you to use) an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)
- (Initial criteria continued on next page)**

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB-RYVK

INITIAL CRITERIA (CONTINUED)

- F. If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 3. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
 4. You meet ONE of the following:
 - a. You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis
 - b. You have a contraindication (harmful for you to use) or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) and PUVA (phototherapy) for the treatment of plaque psoriasis
 - c. You are switching from a different biologic (such as Remicade [infliximab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication
 5. You meet ONE of the following:
 - d. You were previously stable on another biologic and are switching to Simlandi
 - e. You have psoriasis covering 3 percent or more of body surface area (BSA)
 - f. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, face, or scalp
- G. If you have moderate to severe Crohn's disease, approval also requires:**
1. You are 6 years of age or older
 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 3. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
- (Initial criteria continued on next page)***

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB-RYVK

INITIAL CRITERIA (CONTINUED)

- H. If you have moderate to severe ulcerative colitis, approval also requires:**
1. You are 5 years of age or older
 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 3. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
- I. If you have moderate to severe hidradenitis suppurativa, approval also requires:**
1. You are 12 years of age or older
 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 3. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic (such as Cosentyx [secukinumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of hidradenitis suppurativa
- J. If you have non-infectious intermediate, posterior, and panuveitis, approval also requires:**
1. You are 2 years of age or older
 2. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor)
 3. You do NOT have isolated anterior uveitis (a different type of eye inflammation)
 4. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of uveitis

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB-RYVK

RENEWAL CRITERIA

Our guideline named **ADALIMUMAB-RYVK (Simlandi)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Moderate to severe polyarticular juvenile idiopathic arthritis (pJIA: a type of joint condition)
3. Psoriatic arthritis (PsA: a type of skin and joint condition)
4. Ankylosing spondylitis (AS: a type of joint condition)
5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
6. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
7. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
8. Moderate to severe hidradenitis suppurativa (HS: a type of skin condition)
9. Non-infectious intermediate, posterior, and panuveitis (a type of eye condition)

B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**

1. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
2. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
3. If you are requesting Simlandi 40mg weekly dosing OR Simlandi 80mg every other week dosing, at least a 3-month trial of Simlandi 40mg every other week dosing is required

C. **If you have moderate to severe polyarticular juvenile idiopathic arthritis, renewal also requires:**

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic (such as Enbrel [etanercept]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB-RYVK

RENEWAL CRITERIA (CONTINUED)

D. If you have psoriatic arthritis, renewal also requires:

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

E. If you have ankylosing spondylitis, renewal also requires:

1. You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
2. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of ankylosing spondylitis

F. If you have moderate to severe plaque psoriasis, renewal also requires:

1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50 percent or more while on therapy
2. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis

G. If you have moderate to severe Crohn's disease, renewal also requires:

1. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease

H. If you have moderate to severe ulcerative colitis, renewal also requires:

1. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic (such as Remicade [infliximab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADALIMUMAB-RYVK

RENEWAL CRITERIA (CONTINUED)

- I. **If you have moderate to severe hidradenitis suppurativa, renewal also requires:**
 - 1. You have shown improvement in your hidradenitis suppurativa symptoms
 - 2. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic (such as Cosentyx [secukinumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of hidradenitis suppurativa
- J. **If you have non-infectious intermediate, posterior, and panuveitis, renewal also requires:**
 - 1. You will NOT use Simlandi concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of uveitis
 - 2. You have NOT experienced treatment failure, defined as ONE of the following:
 - a. You have developed new inflammatory chorioretinal or retinal vascular lesions (types of eye tumors)
 - b. You have a 2-step increase from baseline in anterior chamber cell grade or vitreous haze grade (types of classifications on severity of eye inflammation)
 - c. Your best-corrected visual acuity (BCVA) has worsened by at least 15 letters relative to your best visual acuity achieved

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADAPALENE-BENZOYL-CLINDAMYCIN

Generic	Brand				
ADAPALENE/BENZOYL/ CLINDAMYCIN	CABTREO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ADAPALENE-BENZOYL-CLINDAMYCIN (Cabtreo)** requires the following rule(s) be met for approval:

The request is NOT for a cosmetic (for appearance) diagnosis (such as melasma [freckle-like spots on your skin], photoaging [skin damage from the sun], wrinkles)

You have acne vulgaris (a type of skin condition usually called pimples)

You are 12 years of age or older

Cabtreo will NOT be used at the same time with other acne therapies that are only available as brand name (such as Akliief, Winlevi)

You have tried or have a contraindication to (harmful for you to use) ONE medication in each of the following categories:

Benzoyl peroxide product

Topical retinoid (such as adapalene, tretinoin)

Topical antibiotic (such as clindamycin, erythromycin)

RENEWAL CRITERIA

Our guideline named **ADAPALENE-BENZOYL-CLINDAMYCIN (Cabtreo)** requires the following rule(s) be met for renewal:

You have acne vulgaris (a type of skin condition usually called pimples)

Cabtreo will NOT be used at the same time with other acne therapies that are only available as brand name (such as Akliief, Winlevi)

You have shown improvement in acne symptoms (the treatment is working)

Effective: 01/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADO-TRASTUZUMAB EMTANSINE

Generic					
ADO-TRASTUZUMAB EMTANSINE					

GUIDELINES FOR USE

Our guideline named **ADO-TRASTUZUMAB EMTANSINE (Kadcyla)** requires the following rule(s) be met for approval:

You have breast cancer

If you have metastatic breast cancer (cancer that has spread to other parts of the body), approval also requires:

Your cancer is human epidermal growth factor receptor 2 (HER2: a type of protein)-positive

You have previously received trastuzumab and a taxane (such as docetaxel, paclitaxel)

You have received prior therapy for metastatic disease OR have developed disease recurrence (disease has returned) during or within 6 months of completing adjuvant (add-on) therapy

If you have early breast cancer (cancer has not spread to other parts of the body), approval also requires:

Your cancer is human epidermal growth factor receptor 2 (HER2: a type of protein)-positive

You have residual (remaining) invasive disease after neoadjuvant (given before main treatment) taxane and trastuzumab-based treatment (types of cancer treatment)

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AFATINIB

Generic	Brand			
AFATINIB DIMALATE	GILOTRIF			

GUIDELINES FOR USE

Our guideline named **AFATINIB (Gilotrif)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Metastatic squamous non-small cell lung cancer (type of lung cancer that has spread to other parts of the body)
 - 2. Metastatic non-small cell lung cancer (a different type of lung cancer that has spread to other parts of the body)
- B. **If you have metastatic squamous non-small cell lung cancer, approval also requires:**
 - 1. Your disease has worsened after using platinum-based chemotherapy (such as cisplatin, carboplatin, oxaliplatin)
- C. **If you have metastatic non-small cell lung cancer, approval also requires:**
 - 1. Your tumors have non-resistant epidermal growth factor receptor (EGFR: type of protein) mutations as shown by an FDA (Food and Drug Administration)-approved test
 - 2. You will NOT be using Gilotrif concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva [erlotinib], Tagrisso [Osimertinib], Iressa [gefitinib])

Effective: 07/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ALECTINIB

Generic	Brand			
ALECTINIB HCL	ALECENSA			

GUIDELINES FOR USE

Our guideline named **ALECTINIB (Alecensa)** requires the following rules be met for approval:

- A. You have ONE of the following:
 - 1. Metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to other parts of the body)
 - 2. Non-small cell lung cancer (NSCLC: a type of lung cancer)
- B. **If you have metastatic non-small cell lung cancer, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Your tumor is anaplastic lymphoma kinase (ALK)-positive (a type of abnormal gene change), as detected by a Food and Drug Administration (FDA)-approved test
- C. **If you have non-small cell lung cancer, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Your cancer is node positive (cancer that has spread to the lymph nodes), or you have tumors that are at least 4cm
 - 3. Your tumor is anaplastic lymphoma kinase (ALK)-positive (a type of abnormal gene change), as detected by a Food and Drug Administration (FDA)-approved test
 - 4. Alecensa will be used as adjuvant (additional) treatment following tumor resection (surgical removal of a tumor)

Effective: 05/17/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ALGLUCOSIDASE ALFA

Generic	Brand				
ALGLUCOSIDASE ALFA	LUMIZYME				

GUIDELINES FOR USE

Our guideline named **ALGLUCOSIDASE ALFA (Lumizyme)** requires the following rule(s) be met for approval:

- A. You have Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) (a type of genetic disorder)

Effective: 02/24/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ALLERGEN EXTRACT-HOUSE DUST MITE

Generic	Brand			
MITE,D.FARINAE-D.PTERONYSSINUS	ODACTRA			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ALLERGEN EXTRACT-HOUSE DUST MITE (Odactra)** requires the following rule(s) be met for approval:

- A. You have allergic rhinitis (itchy, watery eyes, sneezing) caused by house dust mites
- B. You are 5 to 65 years of age
- C. Your diagnosis is confirmed by in vitro testing (testing outside of the body in a tube) for IgE (immunoglobulin E) antibodies to *Dermatophagoides farinae* or *Dermatophagoides pteronyssinus* house dust mites, OR by skin testing to licensed house dust mite allergen extracts
- D. Therapy is prescribed by or in consultation with an allergist (allergy doctor), immunologist (immune system doctor), or other physician experienced in the diagnosis and treatment of allergic diseases
- E. You have persistent symptoms of allergic rhinitis (defined as symptoms presenting for at least 4 days a week or for at least 4 weeks)
- F. You have moderate to severe symptoms of allergic rhinitis (including one or more of the following: troublesome symptoms, sleep disturbance, impairment of daily activities, impairment of school or work)
- G. You have a current claim or prescription for an auto-injectable epinephrine within the past 365 days

RENEWAL CRITERIA

Our guideline named **ALLERGEN EXTRACT-HOUSE DUST MITE (Odactra)** requires the following rule(s) is met for renewal:

- A. You have experienced an improvement in signs and symptoms of allergic rhinitis (itchy, watery eyes, sneezing) from baseline (before treatment)

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ALLERGEN EXTRACT-MIXED GRASS POLLEN

Generic	Brand			
GR POL-ORC/SW VER/RYE/KENT/TIM	ORALAIR			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ALLERGEN EXTRACT-MIXED GRASS POLLEN (Oralair)** requires the following rule(s) be met for approval:

- A. You have a diagnosis of allergic rhinitis (itchy, watery eyes, sneezing) caused by grass pollen
- B. Your diagnosis is confirmed by a positive skin prick test and/or a positive titer (the amount of antibodies in the blood) to specific IgE (Immunoglobulin E) antibodies for any of the five grass types included in Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens)
- C. Therapy is prescribed by or given in consultation with an allergist (allergy doctor), immunologist (immune system doctor), or other physician experienced in the diagnosis and treatment of allergic diseases
- D. You have persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)
- E. You have a current claim or prescription for auto-injectable epinephrine
- F. You are between 5 and 65 years of age

RENEWAL CRITERIA

Our guideline named **ALLERGEN EXTRACT-MIXED GRASS POLLEN (Oralair)** requires the following rules be met for renewal:

- A. You have experienced an improvement in signs and symptoms of allergic rhinitis (itchy, watery eyes, sneezing) from baseline

Effective: 05/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ALLERGEN EXTRACT-SHORT RAGWEED POLLEN

Generic	Brand			
WEED POLLEN- SHORT RAGWEED	RAGWITEK			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ALLERGEN EXTRACT-SHORT RAGWEED POLLEN (Ragwitek)** requires the following rule(s) be met for approval:

- A. You have allergic rhinitis (itchy, watery eyes, sneezing) caused by short ragweed pollen
- B. You are between 5 and 65 years of age
- C. Your diagnosis is confirmed by a positive skin test or in vitro testing (testing outside of your body in a tube) for pollen-specific IgE (Immunoglobulin E) antibodies for short ragweed pollen
- D. Therapy is prescribed by or given in consultation with an allergist (allergy doctor), immunologist (immune system doctor), or other physician experienced in the diagnosis and treatment of allergic diseases
- E. You have persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)
- F. You have a current claim or prescription for auto-injectable epinephrine

RENEWAL CRITERIA

Our guideline named **ALLERGEN EXTRACT-SHORT RAGWEED POLLEN (Ragwitek)** requires the following rule(s) be met for renewal:

- A. You have experienced an improvement in signs and symptoms of allergic rhinitis from baseline

Effective: 06/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ALLERGEN EXTRACT-TIMOTHY GRASS POLLEN

Generic	Brand				
GRASS POLLEN- TIMOTHY, STD	GRASTEK				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ALLERGEN EXTRACT-TIMOTHY GRASS POLLEN (Grastek)** requires the following rule(s) be met for approval:

- A. You have allergic rhinitis (itchy, watery eyes, sneezing) caused by grass pollen
- B. You are between 5 and 65 years of age
- C. Your diagnosis is confirmed a positive skin prick test and/or a positive titre (the amount of antibodies in the blood) to specific IgE (Immunoglobulin E) antibodies for Timothy grass or cross-reactive grass pollens
- D. Therapy is prescribed by or in consultation with an allergist (allergy doctor), immunologist (immune system doctor), or other physician experienced in the diagnosis and treatment of allergic diseases
- E. You have persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)
- F. You have a current claim or prescription for auto-injectable epinephrine

RENEWAL CRITERIA

Our guideline named **ALLERGEN EXTRACT-TIMOTHY GRASS POLLEN (Grastek)** requires the following rule be met for renewal:

- A. You have experienced an improvement in signs and symptoms of allergic rhinitis (itchy, watery eyes, sneezing) from baseline

Effective: 01/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ALPELISIB-PIQRAY

Generic	Brand				
ALPELISIB	PIQRAY				

GUIDELINES FOR USE

Our guideline named **ALPELISIB-PIQRAY** requires the following rule(s) be met for approval:

- A. You have advanced or metastatic breast cancer (breast cancer that has spread to other parts of the body)
- B. Piqray will be used in combination with Faslodex (fulvestrant)
- C. Your breast cancer is hormone receptor (HR: a type of protein)-positive, human epidermal growth factor receptor 2 (HER2: a type of protein)-negative
- D. Your tumor has a PIK3CA mutation (abnormal change in a type of gene) as detected by a Food and Drug Administration (FDA)-approved test
- E. You have disease progression (condition has worsened) on or after an endocrine (hormone)-based regimen (such as letrozole, anastrozole, tamoxifen)

Effective: 02/12/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ALPELISIB - VIJOICE

Generic	Brand				
ALPELISIB	VIJOICE				

GUIDELINES FOR USE

Our guideline named **ALPELISIB - VIJOICE** requires the following rule(s) be met for approval:

- A. You have PIK3CA-related overgrowth spectrum (PROS: group of disorders that cause overgrowth of parts of the body due to mutations in a type of gene)
- B. You are 2 years of age or older
- C. You have severe manifestations of PROS that require systemic therapy (treatment that targets the entire body)

Effective: 10/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AMANTADINE EXTENDED RELEASE

Generic	Brand			
AMANTADINE EXTENDED RELEASE	GOCOVRI			
AMANTADINE HCL	OSMOLEX ER			

**** Please use the criteria for the specific drug requested ****

GUIDELINES FOR USE

GOCOVRI

Our guideline named **AMANTADINE EXTENDED RELEASE (Gocovri)** requires the following rule(s) be met for approval:

- A. You have Parkinson's disease (nervous system disorder that affects movement)
 - B. **If you have dyskinesia (abnormal involuntary movements), approval also requires:**
 - 1. You are receiving levodopa-based therapy
 - 2. You have previously tried generic amantadine capsules, tablets, or solution
- C. **If you are experiencing 'off' episodes (when the medication stops working), approval also requires:**
 - 1. You are also receiving levodopa-carbidopa therapy
 - 2. You have previously tried generic amantadine capsules, tablets, or solution

OSMOLEX ER

Our guideline named **AMANTADINE EXTENDED RELEASE (Osmolex ER)** requires the following rule(s) be met for approval:

- A. You have Parkinson's disease (nervous system disorder that affects movement) OR you are being treated for drug-induced extrapyramidal symptoms (group of movement disorders)
- B. Therapy is prescribed by or given in consultation with a psychiatrist (mental disorder doctor), neurologist (nerve doctor), or geriatrician (doctor who treats elderly people)
- C. You have previously tried generic amantadine immediate-release capsules, tablets or solution
- D. **If you are being treated for drug-induced extrapyramidal symptoms, approval also requires:**
 - 1. You are 18 years of age or older

Effective: 07/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AMBRISENTAN

Generic	Brand				
AMBRISENTAN	LETAIRIS, AMBRISENTAN				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **AMBRISENTAN (Letairis)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
- C. You do NOT have idiopathic pulmonary fibrosis (scarring of the lungs due to an unknown cause)
- D. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
 2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
 3. Pulmonary vascular resistance (PVR) greater than 2 Wood units

RENEWAL CRITERIA

Our guideline named **AMBRISENTAN (Letairis)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AMIFAMPRIDINE

Generic	Brand			
AMIFAMPRIDINE	FIRDAPSE			
AMIFAMPRIDINE	RUZURGI			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **AMIFAMPRIDINE (Firdapse, Ruzurgi)** requires the following rule(s) be met for approval:

- A. You have Lambert-Eaton myasthenic syndrome (a type of muscle disorder)
- B. Therapy is prescribed by or in consultation with a neurologist (type of brain doctor) or hematologist-oncologist (a type of blood-cancer doctor)
- C. Your diagnosis is confirmed by ALL of the following:
 - 1. Electrodiagnostic studies and/or voltage-gated calcium channel (types of lab tests) antibody testing
 - 2. Three clinical symptoms of muscle weakness, autonomic dysfunction (nerve dysfunction), and decreased tendon reflexes
- D. **If you are requesting Firdapse, approval also requires:**
 - 1. You are 6 years of age or older

RENEWAL CRITERIA

Our guideline named **AMIFAMPRIDINE (Firdapse, Ruzurgi)** requires the following rule(s) be met for renewal:

- A. You have Lambert-Eaton myasthenic syndrome (a type of muscle disorder)
- B. You have experienced improvement or stabilization in muscle weakness compared to baseline

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AMIKACIN LIPOSOMAL INHALATION

Generic	Brand			
AMIKACIN LIPOSOMAL/NEB. ACCESSR	ARIKAYCE			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

Our guideline named **AMIKACIN LIPOSOMAL INHALATION (Arikayce)** requires the following rule(s) be met for approval:

- A. You have *Mycobacterium avium complex* (MAC: a type of bacteria) lung disease with limited or no alternative treatment options
- B. You are 18 years of age or older
- C. You have NOT achieved negative sputum cultures (mucus tests) after using multidrug background regimen therapy for at least 6 months in a row
- D. Arikayce will be used as part of a combination antibacterial drug regimen
- E. Arikayce is being prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or infectious disease specialist physician

RENEWAL CRITERIA

Our guideline named **AMIKACIN LIPOSOMAL INHALATION (Arikayce)** requires the following rule(s) be met for renewal:

- A. You have *Mycobacterium avium complex* (MAC: a type of bacteria) lung disease
- B. You have NOT had a positive *Mycobacterium avium complex* sputum culture (mucus test) after repeated negative cultures
- C. You have experienced an improvement in symptoms
- D. You meet ONE of the following:
 - 1. For first renewal requests, approval also requires you have at least ONE negative sputum culture (mucus test) for *Mycobacterium avium complex* by 6 months of Arikayce treatment
 - 2. For second or later renewal requests, approval also requires you have at least THREE negative sputum cultures (mucus test) for *Mycobacterium avium complex* by 12 months of Arikayce treatment

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AMLODIPINE SUSPENSION

Generic	Brand				
AMLODIPINE BENZOATE	KATERZIA				

GUIDELINES FOR USE

Our guideline named **AMLODIPINE SUSPENSION (Katerzia)** requires the following rule(s) be met for approval:

- A. You are unable to swallow oral amlodipine tablets at prescribed dose

Effective: 04/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AMPHETAMINE SULFATE

Generic	Brand			
AMPHETAMINE SULFATE	EVEKEO			

GUIDELINES FOR USE

Our guideline named **AMPHETAMINE SULFATE (Evekeo)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Narcolepsy (condition where you suddenly fall asleep)
 - 2. Attention deficit disorder with hyperactivity (difficulty paying attention)
 - 3. Use for weight loss or exogenous obesity (overweight due to overeating)
- B. **If you have narcolepsy, approval also requires:**
 - 1. You are 6 years of age or older
- C. **If you have attention deficit disorder with hyperactivity, approval also requires:**
 - 1. You are 3 years of age or older
 - 2. You had a previous trial of at least ONE of the following stimulant medications: mixed amphetamine salts (Adderall immediate release), methylphenidate (Ritalin immediate release), dextroamphetamine (Dexedrine)
- D. **If the request is for weight loss or exogenous obesity, approval also requires:**
 - 1. You are 12 years of age or older
 - 2. You had a previous trial of other weight loss medications such as Contrave, Belviq, Qsymia, Xenical, phentermine, phendimetrazine, benzphetamine, diethylpropion

Note: The approval of Evekeo for use as a short-term adjunct (add-on) in a regimen of weight reduction is for a maximum duration of 12 weeks

Effective: 05/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ANABOLIC STEROIDS

Generic	Brand			
OXYMETHOLONE	ANADROL-50			
OXANDROLONE	OXANDRIN			

****Please use the criteria for the specific drug requested****

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

ANADROL-50

Our guideline named **ANABOLIC STEROIDS (Anadrol-50)** requires the following rule(s) be met for approval:

- A. You have anemia (lack of healthy red blood cells) or cachexia (condition with extreme weight loss and muscle loss) associated with AIDS (acquired immune deficiency syndrome)
- B. You will be monitored for peliosis hepatis (blood-filled spaces in the liver), liver cell tumors and blood lipid (fats) changes
- C. You do not have ANY of the following reasons why you cannot use anabolic steroid therapy:
 - 1. Known or suspected prostate or breast cancer in male patients
 - 2. Known or suspected breast cancer in females with hypercalcemia (high calcium levels)
 - 3. Known or suspected nephrosis (the nephrotic phase of nephritis-kidney inflammation)
 - 4. Known or suspected hypercalcemia (high calcium levels)
 - 5. Severe hepatic (liver) dysfunction
- D. **If you have anemia, approval also requires:**
 - 1. The anemia is caused by one of the following conditions: acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias, or Fanconi's
- E. **If you have cachexia associated with AIDS, approval also requires:**
 - 1. You are on anti-retroviral therapy (therapy that treats a type of immune system virus)
 - 2. You have a documented viral load (amount of virus in your blood) of less than 200 copies per mL dated within the past 3 months
 - 3. Therapy is prescribed by or given in recommendation with a gastroenterologist (doctor of the stomach, intestine and related organs), nutritional support specialist (SBS), or infectious disease specialist

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ANABOLIC STEROIDS

INITIAL CRITERIA - ANADROL-50 (CONTINUED)

4. You meet ONE of the following:
 - a. You have 10% unintentional weight loss over 12 months
 - b. You have 7.5% unintentional weight loss over 6 months
 - c. You have 5% body cell mass (BCM) loss within 6 months
 - d. You have a BCM of less than 35% (men) and a body mass index (BMI) of less than 27 kg per meter squared
 - e. You have a BCM of less than 23% (women) of total body weight and a body mass index (BMI) of less than 27 kg per meter squared
 - f. You have a BMI of less than 18.5 kg per meter squared

OXANDRIN

Our guideline named **ANABOLIC STEROIDS (Oxandrin)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 1. Weight loss
 2. Protein catabolism (breakdown) caused by long-term use of corticosteroids
 3. Bone pain accompanying osteoporosis (weak and brittle bones)
 4. Cachexia (condition with extreme weight loss and muscle loss) associated with AIDS (acquired immune deficiency syndrome)
 5. Turner's Syndrome (disorder where female has one X chromosome)
 - B. You will be monitored for peliosis hepatis (blood-filled spaces in the liver), liver cell tumors and blood lipid (fats) changes
 - C. You do not have ANY of the following reasons why you cannot use anabolic steroid therapy:
 1. Known or suspected prostate or breast cancer in male patients
 2. Known or suspected breast cancer in females with hypercalcemia (high calcium levels)
 3. Known or suspected nephrosis (the nephrotic phase of nephritis-kidney inflammation)
 4. Known or suspected hypercalcemia (high calcium levels)
 5. Severe hepatic (liver) dysfunction
 - D. **If you have weight loss, approval also requires:**
 1. Your weight loss is caused by extensive surgery, chronic infections, or severe trauma
 2. Medication is being used as add-on therapy to help weight gain
- (Initial criteria continued on next page)**

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ANABOLIC STEROIDS

INITIAL CRITERIA - OXANDRIN (CONTINUED)

E. If you have cachexia associated with AIDS, approval also requires:

1. You are on anti-retroviral therapy (therapy that treats a type of immune system virus)
2. You have a documented viral load (amount of virus in your blood) of less than 200 copies per mL dated within the past 3 months
3. Therapy is prescribed by or given in consultation with a gastroenterologist (doctor of the stomach, intestine and related organs), nutritional support specialist (SBS) or infectious disease specialist
4. You meet ONE of the following:
 - a. You have 10% unintentional weight loss over 12 months
 - b. You have 7.5% unintentional weight loss over 6 months
 - c. You have 5% body cell mass (BCM) loss within 6 months
 - d. You have a BCM of less than 35% (men) and a body mass index (BMI) of less than 27 kg per meter squared
 - e. You have a BCM of less than 23% (women) of total body weight and a body mass index (BMI) of less than 27 kg per meter squared
 - f. You have a BMI of less than 18.5 kg per meter squared

RENEWAL CRITERIA

(NOTE: For the diagnosis of anemia, weight loss, protein catabolism associated with prolonged administration of corticosteroids, bone pain accompanying osteoporosis, or Turner's Syndrome, please refer to the Initial Criteria section)

OXANDRIN and ANADROL-50

Our guideline named **ANABOLIC STEROIDS (Oxandrin and Anadrol-50)** requires the following rule(s) be met for renewal:

- A. You have cachexia (condition with extreme weight loss and muscle loss) associated with AIDS (acquired immune deficiency syndrome)
- B. You are on anti-retroviral therapy (therapy that treats a type of immune system virus)
- C. Your viral load (amount of virus in your blood) is less than 200 copies per mL within the past 3 months
- D. You have a 10% increase in weight from baseline (current weight must have been measured within the last 4 weeks, document date of measurement)
- E. You have not received more than 24 weeks of therapy in a calendar year

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ANAKINRA

Generic	Brand			
ANAKINRA	KINERET			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ANAKINRA (Kineret)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
 2. Cryopyrin-associated periodic syndromes (CAPS: a type of immune disorder) including neonatal-onset multisystem inflammatory disease (NOMID: a types of immune system disorder)
 3. Deficiency of interleukin-1 receptor antagonist (DIRA: a type of immune system disorder)
- B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use Kineret concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
 4. You have tried at least 3 months of or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
 5. You meet ONE of the following:
 - a. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ANAKINRA

INITIAL CRITERIA (CONTINUED)

C. If you have cryopyrin-associated periodic syndromes, including neonatal-onset multisystem inflammatory disease, approval also requires:

1. You had genetic testing for gain-of-function mutations (abnormal change in gene) in the *NLRP3* gene (a type of gene) OR you have inflammatory markers (elevated C-reactive protein [CRP: a measure of how much inflammation is in the body], erythrocyte sedimentation rate [ESR: a measure of how much inflammation is in the body], serum amyloid A protein [SAA: a type of protein] or S100 proteins [a type of protein])
2. You have TWO of the following: urticarial-like rash (neutrophilic dermatitis: a type of skin condition), cold-triggered episodes, sensorineural hearing loss (SNHL: a type of hearing loss), musculoskeletal symptoms (symptoms related to the skin and bones), chronic aseptic meningitis (inflammation of the brain and spinal cord), skeletal (bone) abnormalities
3. You will NOT use Kineret concurrently (at the same time) with another systemic biologic (such as Arcalyst [rilonacept]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Cryopyrin-Associated Periodic Syndromes, including Neonatal-Onset Multisystem Inflammatory Disease

D. If you have deficiency of interleukin-1 receptor antagonist, approval also requires:

1. You had genetic testing for gain-of-function mutations (abnormal change in gene) in the *IL1RN* gene (a type of gene) OR you have inflammatory markers (elevated C-reactive protein [CRP: a measure of how much inflammation is in the body], erythrocyte sedimentation rate [ESR: a measure of how much inflammation is in the body])
2. You have ONE of the following: pustular psoriasis-like rashes (a type of skin condition), osteomyelitis (bone infection), absence of bacterial osteomyelitis, nail changes (onychomadesis: nail shedding)
3. You will NOT use Kineret concurrently (at the same time) with another systemic biologic (such as Arcalyst [rilonacept]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Deficiency of Interleukin-1 Receptor Antagonist

E. NOTE: Kineret will not be approved for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ANAKINRA

RENEWAL CRITERIA

NOTE: For the diagnoses of cryopyrin-associated periodic syndromes (CAPS), including neonatal-onset multisystem inflammatory disease (NOMID), and deficiency of interleukin-1 receptor antagonist (DIRA), please refer to the Initial Criteria section.

Our guideline named **ANAKINRA (Kineret)** requires the following rule(s) be met for renewal:

- A. You have moderate to severe rheumatoid arthritis (RA: a type of joint condition)
- B. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
- C. You will NOT use Kineret concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
- D. You meet ONE of the following:
 - 1. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - 2. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

APALUTAMIDE

Generic	Brand			
APALUTAMIDE	ERLEADA			

GUIDELINES FOR USE

Our guideline named **APALUTAMIDE (Erleada)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Non-metastatic castration-resistant prostate cancer (nmCRPC: prostate cancer that does not respond to hormone reduction therapy and has not spread to other parts of the body)
 - 2. Metastatic castration-sensitive prostate cancer (mCSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)
- B. You meet ONE of the following:
 - 1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
 - 2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
 - 3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)
- C. **If you have a non-metastatic castration-resistant prostate cancer, approval also requires:**
 - 1. You have high risk prostate cancer (rapidly increasing prostate specific antigen [PSA] levels)

RENEWAL CRITERIA

Our guideline named **APALUTAMIDE (Erleada)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
 - 1. Non-metastatic castration-resistant prostate cancer (nmCRPC: prostate cancer that does not respond to hormone reduction therapy but has not spread)
 - 2. Metastatic castration-sensitive prostate cancer (mCSPC: prostate cancer that has spread and responds to hormone therapy)
- B. You meet ONE of the following:
 - 1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
 - 2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
 - 3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)

Effective: 07/01/23

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

APOMORPHINE - APOKYN

Generic	Brand				
APOMORPHINE HCL	APOKYN, APOMORPHINE HCL				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **APOMORPHINE - APOKYN** requires the following rule(s) be met for approval:

- A. You have a diagnosis of advanced Parkinson's disease (PD: a type of movement disorder)
- B. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
- C. The requested medication will be used for acute, intermittent treatment of hypomobility, 'OFF' episodes (short and sudden episodes where there is decreased ability to move) associated with advanced Parkinson's disease
- D. Your doctor has optimized your medication therapy as shown by BOTH of the following:
 - 1. You had a change in levodopa/carbidopa dosing strategy or formulation
 - 2. You have tried or have a contraindication to (harmful for you to use) TWO Parkinson disease medications from two different classes: dopamine agonist (ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitors (MAO-I) (selegiline, rasagiline), catechol-O-methyl transferase (COMT) inhibitors (entacapone, tolcapone)

RENEWAL CRITERIA

Our guideline named **APOMORPHINE - APOKYN** requires the following rule(s) be met for renewal:

- A. You have a diagnosis of advanced Parkinson's disease (PD: a type of movement disorder)
- B. You have experienced improvement with motor fluctuations (changes in the ability to move) during 'OFF' episodes with the use of the requested medication (such as improvement in speech, facial expression, tremor [shaking] at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair)

Effective: 03/10/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

APOMORPHINE - SL

Generic	Brand				
APOMORPHINE	KYNMOBI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **APOMORPHINE (Kynmobi)** requires the following rule(s) be met for approval:

- A. You have Parkinson's disease (central nervous system disorder that affects movement, often including tremors)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or given in consultation with a neurologist
- D. The physician has optimized drug therapy as evidenced by **BOTH** of the following:
 - 1. Change in levodopa/carbidopa dosing strategy or formulation
 - 2. Trial of or contraindication to at least two Parkinson's agents from two different classes: dopamine agonist (i.e., ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitor (MAO-I) (i.e., selegiline, rasagiline), or catechol-o-methyl transferase (COMT) inhibitors (i.e., entacapone, tolcapone)
- E. The requested medication is being used for acute, intermittent treatment (sudden and periodic treatment) of 'OFF' episodes (when symptoms return due to your medication for Parkinson's disease wearing off)

RENEWAL CRITERIA

Our guideline named **APOMORPHINE (Kynmobi)** requires the following rule(s) be met for renewal:

- A. You have Parkinson's disease (central nervous system disorder that affects movement, often including tremors)
- B. You had improvement with motor fluctuations during 'OFF' episodes (when symptoms return due to your medications for Parkinson's disease wearing off) with the use of Kynmobi (such as improvement in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair)

Effective: 10/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

APOMORPHINE - ONAPGO

Generic	Brand				
APOMORPHINE HCL	ONAPGO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **APOMORPHINE - ONAPGO** requires the following rule(s) be met for approval:

- A. You have advanced Parkinson's disease (PD: a type of movement disorder)
- B. Onapgo will be used for the treatment of motor fluctuations (changes in the ability to move) associated with Parkinson's disease
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
- D. Your disease is responsive to treatment with levodopa
- E. Your current medication regimen (treatment plan), including levodopa, has been at a stable dose for at least 28 days
- F. Your motor symptoms are currently uncontrolled (defined as an average 'off' time of at least 3 hours per day, with a minimum of 2 hours each day)
- G. You do not have any of the following: orthostatic hypotension (a type of low blood pressure), history of prolonged QTc (a type of irregular heart rhythm) (greater than 450 msec for male or greater than 470 msec for female), active or uncontrolled psychosis (a type of mental health disorder), active or uncontrolled depression (a type of mental health disorder)

RENEWAL CRITERIA

Our guideline named **APOMORPHINE - ONAPGO** requires the following rule(s) be met for renewal:

- A. You have advanced Parkinson's disease (PD: a type of movement disorder)
- B. You have experienced improvement in motor symptoms while on Onapgo

Effective: 03/10/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

APREMILAST

Generic	Brand			
APREMILAST	OTEZLA			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **APREMILAST (Otezla)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Psoriatic arthritis (PsA: a type of skin and joint condition)
 2. Plaque psoriasis (PsO: a type of skin condition)
 3. Behcet's disease (a type of inflammation disorder) with oral ulcers or history of recurrent oral ulcers based on clinical symptoms
- B. **If you have psoriatic arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
 3. You will NOT use Otezla concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of psoriatic arthritis
- C. **If you have mild plaque psoriasis, approval also requires:**
1. You are 18 years of age or older
 2. You have tried or have a contraindication to (harmful for you to use) one conventional (standard) systemic (treatment that targets the entire body) medication (such as methotrexate, acitretin, cyclosporine) OR one conventional topical medication (such as topical corticosteroids [such as betamethasone dipropionate, clobetasol propionate])
 3. You will NOT use Otezla concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Zoryve (roflumilast)]) for the treatment of mild plaque psoriasis
 4. You meet ONE of the following:
 - a. You were previously stable on another biologic and are switching to Otezla
 - b. You have a static Physician Global Assessment (sPGA: a measure used to evaluate severity of the disease) score of 2
 - c. You have a Psoriasis Area and Severity Index (PASI: used to measure the severity and extent of psoriasis) score of 2 to 9

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

APREMILAST

INITIAL CRITERIA (CONTINUED)

- D. If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 6 to 17 years of age and weigh at least 20 kilograms (44 pounds), OR you are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 3. You will NOT use Otezla concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Zoryve (roflumilast)]) for the treatment of moderate to severe plaque psoriasis
 4. You meet ONE of the following:
 - a. You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis
 - b. You have a contraindication (harmful for you to use) or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) and PUVA (phototherapy) for the treatment of plaque psoriasis
 - c. You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor, or JAK (Janus kinase) inhibitor for the same indication
 5. You meet ONE of the following:
 - a. You were previously stable on another biologic and are switching to Otezla
 - b. You have psoriasis covering 3 percent or more of body surface area (BSA)
 - c. You have psoriatic lesions (rashes) affecting your hands, feet, face, genital area, or scalp
- E. If you have Behcet's disease with oral ulcers or history of recurrent oral ulcers based on clinical symptoms, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You have tried or have a contraindication to (harmful for you to use) ONE or more conservative treatments (such as colchicine, topical corticosteroid [such as triamcinolone], oral corticosteroid [such as prednisolone])
 4. You will NOT use Otezla concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Behcet's disease

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

APREMILAST

RENEWAL CRITERIA

Our guideline named **APREMILAST (Otezla)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Psoriatic arthritis (PsA: a type of skin and joint condition)
 - 2. Plaque psoriasis (PsO: a type of skin condition)
 - 3. Behcet's disease (a type of inflammation disorder) with oral ulcers or history of recurrent oral ulcers based on clinical symptoms
- B. **If you have psoriatic arthritis, renewal also requires:**
 - 1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 - 2. You will NOT use Otezla concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of psoriatic arthritis
- C. **If you have mild plaque psoriasis, renewal also requires:**
 - 1. You have achieved or maintained clear or minimal disease OR a decrease in Psoriasis Area and Severity Index (PASI: used to measure the severity and extent of psoriasis) of at least 50 percent or more OR a decrease in static Physician Global Assessment (sPGA: a measure used to evaluate severity of the disease) by at least a 2-point reduction from baseline
 - 2. You will NOT use Otezla concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Zoryve (roflumilast)]) for the treatment of mild plaque psoriasis
- D. **If you have moderate to severe plaque psoriasis, renewal also requires:**
 - 1. You have achieved or maintained clear or minimal disease OR a decrease in Psoriasis Area and Severity Index (PASI: used to measure the severity and extent of psoriasis) of at least 50 percent or more
 - 2. You will NOT use Otezla concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Zoryve (roflumilast)]) for the treatment of moderate to severe plaque psoriasis
- E. **If you have Behcet's disease with oral ulcers or history of recurrent oral ulcers based on clinical symptoms, renewal also requires:**
 - 1. You have achieved or maintained clinical benefit compared to baseline (such as an improvement in pain scores, number of ulcers)
 - 2. You will NOT use Otezla concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Behcet's disease

Effective: 04/01/25

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

APROCITENTAN

Generic	Brand				
APROCITENTAN	TRYVIO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **APROCITENTAN (Tryvio)** requires the following rule(s) be met for approval:

- A. You have hypertension (high blood pressure)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor), nephrologist (a type of kidney doctor), or endocrinologist (a type of hormone doctor)
- D. Your blood pressure is NOT controlled on at least three anti-hypertensive medications (drugs used to treat high blood pressure) with different mechanisms of action (such as an angiotensin receptor blocker [such as valsartan], a calcium channel blocker [such as amlodipine], a diuretic [such as hydrochlorothiazide]) at a maximally tolerated dose for at least 4 weeks
- E. You do NOT have resistant hypertension (a type of high blood pressure) due to white coat effect (a condition where blood pressure is higher in a medical setting), medical inertia (when healthcare providers do not make changes to treatment even if the medical condition is poorly controlled), poor therapeutic adherence (not keeping up with therapy), or secondary causes of hypertension (high blood pressure that is caused by another medical condition) (except sleep apnea [a type of sleep condition with difficulty breathing])
- F. You will use Tryvio concurrently (at the same time) with at least three other anti-hypertensive medications (drugs used to treat high blood pressure such as valsartan, amlodipine, hydrochlorothiazide) at maximally tolerated doses
- G. You have tried or have a contraindication to (harmful for you to use) a potent diuretic (chlorthalidone or indapamide) AND a mineralocorticoid receptor antagonist (spironolactone or eplerenone)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

APROCITENTAN

RENEWAL CRITERIA

Our guideline named **APROCITENTAN (Tryvio)** requires the following rule(s) be met for renewal:

- A. You have hypertension (high blood pressure)
- B. You continue to benefit from Tryvio
- C. You will use Tryvio concurrently (at the same time) with at least three other anti-hypertensive medications (drugs used to treat high blood pressure such as valsartan, amlodipine, hydrochlorothiazide) at maximally tolerated doses

Effective: 09/23/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ARIMOCLOMOL

Generic	Brand				
ARIMOCLOMOL CITRATE	MIPLYFFA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ARIMOCLOMOL (Miplyffa)** requires the following rule(s) be met for approval:

- A. You have Niemann-Pick disease type C (NPC: a type of genetic condition)
- B. You are 2 years of age or older
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor) or geneticist (a doctor who treats gene disorders)
- D. Miplyffa will used in combination with miglustat (Zavesca)

RENEWAL CRITERIA

Our guideline named **ARIMOCLOMOL (Miplyffa)** requires the following rule(s) be met for renewal:

- A. You have Niemann-Pick disease type C (NPC: a type of genetic condition)
- B. You have shown improvement or a slowing of disease progression

Effective: 10/14/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ARIPIRAZOLE SENSOR TABS

Generic	Brand				
ARIPIRAZOLE TABLETS WITH SENSOR	ABILIFY MYCITE				

GUIDELINES FOR USE

Our guideline named **ARIPIRAZOLE SENSOR TABS (Abilify MyCite)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - a. Schizophrenia (a type of mental health disorder)
 - b. Bipolar I disorder (a type of mood disorder)
 - c. Major depressive disorder (MDD: a type of mental health disorder)
- B. **If you have schizophrenia, approval also requires:**
 - a. You are 18 years of age or older
 - b. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
 - c. You have a medical necessity for medication ingestion tracking
- C. **If you have major depressive disorder, approval also requires:**
 - a. You are 18 years of age or older
 - b. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
 - c. Abilify MyCite will be used as an adjunctive (add-on) treatment
 - d. You have a medical necessity for medication ingestion tracking
- D. **If you have bipolar I disorder, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
 - 3. You have a medical necessity for medication ingestion tracking
 - 4. You meet ONE of the following:
 - i. The request is for acute (short-term) treatment of manic and mixed episodes as monotherapy (used alone), OR as an adjunct (add-on) to lithium or valproate
 - ii. The request is for maintenance treatment as monotherapy, OR as an adjunct to lithium or valproate

Effective: 10/24/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ASCIMINIB

Generic	Brand				
ASCIMINIB HYDROCHLORIDE	SCSEMBLIX				

GUIDELINES FOR USE

Our guideline named **ASCIMINIB (Scemblix)** requires the following rule(s) be met for approval:

- A. You have Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML: a type of blood cell cancer) in chronic phase (CP)
- B. You are 18 years of age or older
- C. You meet ONE of the following:
 - 1. Your cancer is newly diagnosed
 - 2. Your cancer has the T315I mutation (abnormal change in a type of gene) AND you had a mutational analysis (a type of lab test) prior to the start of therapy and Scemblix is appropriate based on the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on the profile for the breakpoint cluster region-Abelson murine leukemia 1 (BCR-ABL1: a type of gene) mutation
 - 3. You have been previously treated AND you had a mutational analysis prior to the start of therapy and Scemblix is appropriate based on the NCCN guideline table for treatment recommendations based on the profile for the BCR-ABL1 mutation

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ASPARAGINASE ERWINIA-RYWN

Generic	Brand				
ASPARAGINASE ERWINIA-RYWN	RYLAZE				

GUIDELINES FOR USE

Our guideline named **ASPARAGINASE ERWINIA-RYWN (Rylaze)** requires the following rule(s) be met for approval:

- A. You have acute lymphoblastic leukemia (ALL: type of blood cancer) or lymphoblastic lymphoma (LBL: type of cancer affecting the immune system)
- B. You are 1 month of age or older
- C. You have developed hypersensitivity to E.coli-derived asparaginase (you are allergic to an enzyme/protein that is from a type of bacteria)
- D. Rylaze will be used as a component of a multi-agent chemotherapeutic regimen

Effective: 01/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ASFOTASE ALFA

Generic	Brand			
ASFOTASE ALFA	STRENSIQ			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ASFOTASE ALFA (Strensiq)** requires the following rules be met for approval:

- A. You have a documented diagnosis of perinatal/infantile-onset hypophosphatasia (HPP: a type of genetic condition) or juvenile-onset hypophosphatasia (HPP).
- B. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
- C. You are NOT currently receiving treatment with a bisphosphonate [such as Boniva (ibandronate), Fosamax (alendronate), Actonel (risedronate)]
- D. **If you have perinatal/infantile-onset hypophosphatasia, approval also requires:**
 1. You were 6 months of age or younger at hypophosphatasia onset
 2. You are positive for a tissue non-specific alkaline phosphatase (a type of enzyme) (ALPL) gene mutation as confirmed by genetic testing OR you meet at least TWO of the following criteria:
 - a. Serum alkaline phosphatase (type of enzyme) level below that of normal range for your age
 - b. Serum pyridoxal-5'-phosphate (PLP) levels elevated AND you have not received vitamin B6 supplementation in the previous week
 - c. Urine phosphoethanolamine (PEA) level above that of normal range for your age
 - d. Radiographic evidence of hypophosphatasia [such as flared and frayed metaphyses (narrow part of long bone), osteopenia (bone loss), widened growth plates, areas of radiolucency (ability to see through with x-rays/ radiation) or sclerosis (hardening of an area)]
 - e. Presence of two or more of the following:
 - i. Rachitic chest deformity (chest bones are not normal)
 - ii. Craniosynostosis (premature closure of skull bones)
 - iii. Delay in skeletal growth resulting in delay of motor development
 - iv. History of vitamin B6 dependent seizures
 - v. Nephrocalcinosis (high calcium levels in kidney) or history of elevated serum calcium
 - vi. History or presence of fracture after birth not due to injury or delayed fracture healing

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ASFOTASE ALFA

INITIAL CRITERIA (CONTINUED)

E. If you have juvenile-onset hypophosphatasia, approval also requires:

1. You were 18 years of age or younger at hypophosphatasia onset
2. You are positive for a tissue non-specific alkaline phosphatase (TNSALP) (ALPL) gene mutation as confirmed by genetic testing OR meet at least TWO of the following criteria:
 - a. Serum alkaline phosphatase (type of enzyme) level below that of normal range for your age
 - b. Serum pyridoxal-5'-phosphate (PLP) levels elevated AND you have not received vitamin B6 supplementation in the previous week
 - c. Urine phosphoethanolamine (PEA) level above that of normal range for your age
 - d. Radiographic evidence of hypophosphatasia [such as flared and frayed metaphyses (narrow part of long bone), osteopenia (bone loss), osteomalacia (bone softening), widened growth plates, areas of radiolucency or sclerosis (hardening of an area)]
 - e. Presence of two or more of the following:
 - i. Rachitic deformities (rachitic chest, bowed legs, knock-knees)
 - ii. Premature loss of primary teeth prior to 5 years of age
 - iii. Delay in skeletal growth leading to motor development delay
 - iv. History or presence of fracture after birth not due to injury or delayed fracture healing

Strensiq will not be approved if you meet any of the following:

1. Your serum calcium or phosphate level is below the normal range
2. You have a treatable form of rickets (softening and weakening of bones in children, usually due to low vitamin D)

RENEWAL CRITERIA

Our guideline named **ASFOTASE ALFA (Strensiq)** requires that the following rule(s) be met for renewal:

- A. You have experienced improvement in the skeletal characteristics of hypophosphatasia (HPP: genetic disorder causing abnormal development of bones and teeth). Characteristics may include irregularity of the provisional zone of calcification (area on long bone for calcium build-up), physeal widening (area of bone that helps length growth), metaphyseal flaring (a narrow part of long bone grows), radiolucencies (ability to see with x-rays/radiation), patchy osteosclerosis (parts of abnormal hardening of bone), ratio of mid-diaphyseal cortex to bone thickness, gracile (slender) bones, bone formation and fractures.
- B. You are NOT currently receiving treatment with a bisphosphonate [such as Boniva (ibandronate), Fosamax (alendronate), Actonel (risedronate)].

Effective: 07/01/22

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ASPIRIN ER

Generic	Brand			
ASPIRIN ER	DURLAZA			

GUIDELINES FOR USE

Our guideline named **ASPIRIN ER (Durlaza)** requires the following rules be met for approval:

1. You have ONE of the following:
 - a. Diagnosis of chronic coronary artery disease [damage or disease in the heart's major blood vessels; may include a history of myocardial infarction (heart attack) or unstable angina (chest pain when your heart doesn't get enough oxygen)] OR
 - b. History of an ischemic stroke or transient ischemic attack (arteries to your brain become narrowed or blocked, causing blood flow loss).
2. You have previously tried aspirin over-the-counter (OTC)
3. Durlaza is NOT being used for acute treatment (short term treatment) of myocardial infarction (heart attack) or before percutaneous coronary intervention (non-surgical procedure used to treat narrowing of the coronary arteries of the heart)

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ASPIRIN-OMEPRAZOLE

Generic	Brand			
ASPIRIN- OMEPRAZOLE	YOSPRALA, ASPIRIN- OMEPRAZOLE			

GUIDELINES FOR USE

Our guideline named **ASPIRIN-OMEPRAZOLE (Yosprala)** requires the following rule(s) be met for approval:

- A. The request is for secondary prevention of cardiovascular (related to heart and blood vessels) or cerebrovascular (related brain and blood vessels) events
- B. You have ONE of the following:
 - 1. Ischemic stroke (arteries to your brain become narrowed or blocked, causing less blood flow)
 - 2. Transient ischemia of the brain due to fibrin platelet emboli (blood flow to your brain gets cut off for a short time due to temporary blockage)
 - 3. Previous myocardial infarction (heart attack)
 - 4. Unstable angina pectoris (chest pain when your heart doesn't get enough oxygen)
 - 5. Chronic stable angina pectoris (chest pain when your heart doesn't get enough oxygen)
 - 6. History of undergoing revascularization procedures (procedures that restore blood flow to heart such as coronary artery bypass graft, percutaneous transluminal coronary angioplasty)
- C. You have a risk of developing aspirin associated gastrointestinal (GI) ulcers due to age (55 years or older) **AND** have a documented history of gastrointestinal (GI) ulcers
- D. You have tried both aspirin over-the-counter (OTC) **AND** generic proton pump inhibitors (such as omeprazole, lansoprazole, pantoprazole, rabeprazole)

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ATOGEPAANT

Generic	Brand				
ATOGEPAANT	QULIPTA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ATOGEPAANT (Qulipta)** requires the following rule(s) be met for approval:

- A. You have migraines (a type of headache)
- B. **If you have episodic migraines (0-14 headache days per month), approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Qulipta is prescribed for the preventive treatment of migraines
 - 3. You will NOT use Qulipta concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy [fremanezumab-vfrm], Aimovig [erenumab-aooe], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet]) for migraine prevention
 - 4. You have tried or have a contraindication to (harmful for you to use) ONE of the following preventive migraine treatments: divalproex sodium/sodium valproate, topiramate, propranolol, timolol, metoprolol, atenolol, nadolol, amitriptyline, venlafaxine
- C. **If you have chronic migraines (15 or more headache days per month), approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Qulipta is prescribed for the preventive treatment of migraines
 - 3. You will NOT use Qulipta concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy [fremanezumab-vfrm], Aimovig [erenumab-aooe], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet]) for migraine prevention
 - 4. You have tried or have a contraindication to (harmful for you to use) ONE of the following preventive migraine treatments: divalproex sodium/sodium valproate, topiramate, propranolol, timolol, metoprolol, atenolol, nadolol, amitriptyline, venlafaxine, Botox [Note: For Botox, previous trial of only **National Drug Code (NDC)** 00023-1145-01 or NDC 00023-3921-02 are allowable]

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ATOGEPANT

RENEWAL CRITERIA

Our guideline named **ATOGEPANT (Qulipta)** requires the following rule(s) be met for renewal:

- A. Qulipta is prescribed for the preventive treatment of migraines
- B. You will NOT use Qulipta concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy [fremanezumab-vfrm], Aimovig [erenumab-aooe], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet]) for migraine prevention
- C. You meet ONE of the following:
 - 1. You have experienced a reduction in migraine or headache frequency of at least 2 days per month with Qulipta therapy
 - 2. You have experienced a reduction in migraine severity with Qulipta therapy
 - 3. You have experienced a reduction in migraine duration with Qulipta therapy

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ATORVASTATIN

Generic	Brand				
ATORVASTATIN CALCIUM	ATORVALIQ				

GUIDELINES FOR USE

Our guideline named **ATORVASTATIN (Atorvaliq)** requires the following rule(s) be met for approval:

- A. The request is for ONE of the following:
1. To reduce the risk of one of the following and you are 18 years of age or older:
 - i. Myocardial infarction (MI: heart attack), stroke, revascularization procedures (restoring blood flow to heart and other areas), or angina (chest pain) and you have multiple risk factors for coronary heart disease (CHD: heart arteries get blocked with fats and plaques) but without clinically evident CHD
 - ii. MI or stroke and you have type 2 diabetes mellitus (a disorder with high blood sugar) and multiple risk factors for CHD but without clinically evident CHD
 - iii. Non-fatal (not deadly) MI, fatal (deadly) or non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure (a type of heart failure), or angina and you have clinically evident CHD
 2. Primary hyperlipidemia (high level of fat in the blood due to genetic causes)
 3. Heterozygous familial hypercholesterolemia (HeFH: a type of inherited high cholesterol)
 4. Homozygous familial hypercholesterolemia (HoFH: a type of inherited high cholesterol)
 5. Primary dysbetalipoproteinemia (a condition leading to increased total cholesterol and triglyceride levels in the blood)
 6. Hypertriglyceridemia (high level of fat in the blood)
- B. You had a trial of or contraindication (harmful for) to generic atorvastatin tablets
- C. You cannot swallow atorvastatin tablets AND had a trial of rosuvastatin (Ezallor) sprinkle capsule
- D. **If you have primary hyperlipidemia, approval also requires:**
1. You are 18 years of age or older
 2. Atorvaliq will be used in addition to diet
- E. **If you have heterozygous familial hypercholesterolemia, approval also requires:**
1. You are 10 years of age or older
 2. Atorvaliq will be used in addition to diet

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ATORVASTATIN

GUIDELINES FOR USE (CONTINUED)

- F. If you have homozygous familial hypercholesterolemia, approval also requires:**
 - 1. You are 10 years of age or older
 - 2. Atorvaliq will be used in addition to other LDL-C lowering therapies (such as ezetimibe, fenofibrate) OR will be used alone if other LDL-C lowering therapies are unavailable
- G. If you have dysbetalipoproteinemia or hypertriglyceridemia, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Atorvaliq will be used in addition to diet
- H. Requests for zero dollar cost share also requires the following:**
 - 1. You are between 40 to 75 years old
 - 2. The requested quantity is within the low to moderate intensity daily dosage of 10 to 20mg
 - 3. You are not concurrently (at the same time) taking any of the below secondary prevention medications for cardiovascular disease (heart disease):
 - a. Aspirin/dipyridamole (Aggrenox)
 - b. Clopidogrel (Plavix)
 - c. Dipyridamole
 - d. Nitroglycerin (oral, sublingual, transdermal, translingual dosage forms)
 - e. Prasugrel (Effient)
 - f. Ticagrelor (Brilinta)
 - g. Ticlopidine
 - h. Vorapaxar (Zontivity)

Effective: 03/03/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ATRASENTAN

Generic	Brand				
ATRASENTAN HYDROCHLORIDE	VANRAFIA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ATRASENTAN (Vanrafia)** requires the following rule(s) be met for approval:

- A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
- B. You are 18 years of age or older
- C. You are at risk of rapid disease progression (such as a urine protein-to-creatinine ratio [UPCR: a test that measures the amount of protein in urine] of at least 1.5 g/g)
- D. Therapy is prescribed by or in consultation with a nephrologist (a type of kidney doctor)
- E. Your diagnosis is confirmed by a biopsy (removal of cells or tissue for examination)
- F. You have proteinuria (high levels of protein in the urine) of at least 1 g/day
- G. You have an estimated glomerular filtration rate (eGFR: a tool for evaluating kidney function) of at least 30 mL/min/1.73 m(2)
- H. You have tried an angiotensin converting enzyme inhibitor (ACE-I: a type of medication used to protect kidneys, such as benazepril, lisinopril) or an angiotensin receptor blocker (ARB: a type of medication used to protect kidneys, such as losartan, valsartan) for at least 3 months at a maximum tolerated dose and will continue use, OR you have a contraindication to (harmful for you to use) both of these medication classes
- I. You have tried a sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor: a type of medication used to protect kidneys, such as Farxiga [dapagliflozin], Jardiance [empagliflozin]) and will continue use, OR you have a contraindication to an SGLT2 inhibitor
- J. You will NOT use Vanrafia concurrently (at the same time) with Fabhalta (iptacopan) or Filspari (sparsentan)

RENEWAL CRITERIA

Our guideline named **ATRASENTAN (Vanrafia)** requires the following rule(s) be met for renewal:

- A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
- B. You have improved or stable kidney function compared to baseline (before starting Vanrafia) OR you have a reduction (decrease) in proteinuria (a condition with high levels of protein in the urine)
- C. You will NOT use Vanrafia concurrently (at the same time) with Fabhalta (iptacopan) or Filspari (sparsentan)

Effective: 05/12/25

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 6/11/2025

Page 87 of 1007



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AVACOPAN

Generic	Brand				
AVACOPAN	TAVNEOS				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **AVACOPAN (Tavneos)** requires the following rule(s) be met for approval:

- A. You have severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (inflammation of blood vessels) (granulomatosis with polyangiitis [GPA: condition that affects the blood vessels] or microscopic polyangiitis [MPA: condition that affects the blood vessels])
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or nephrologist (a type of kidney doctor)
- D. You are ANCA seropositive for anti-PR3 or anti-MPO (a type of lab test)
- E. Tavneos will be used as adjunctive (add-on) therapy in combination with standard therapy including glucocorticoids (such as methylprednisolone, prednisone)

RENEWAL CRITERIA

Our guideline named **AVACOPAN (Tavneos)** requires the following rule(s) be met for renewal:

- A. You have severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (inflammation of blood vessels) (granulomatosis with polyangiitis [GPA: condition that affects the blood vessels] or microscopic polyangiitis [MPA: condition that affects the blood vessels])
- B. You continue to benefit from the medication

Effective: 10/24/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AVAPRITINIB

Generic	Brand				
AVAPRITINIB	AYVAKIT				

GUIDELINES FOR USE

Our guideline named **AVAPRITINIB (Ayvakit)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Unresectable or metastatic gastrointestinal stromal tumor (GIST: a type of digestive tumor that cannot be removed through surgery or has spread to other parts of the body)
 2. Advanced systemic mastocytosis (AdvSM: a type of blood disorder), including aggressive systemic mastocytosis (ASM: a type of blood disorder), systemic mastocytosis with an associated hematological neoplasm (SM-AHN: a type of blood disorder), or mast cell leukemia (MCL: a type of blood cancer)
 3. Indolent systemic mastocytosis (ISM: a type of blood disorder)
- B. **If you have unresectable or metastatic gastrointestinal stromal tumor, approval also requires:**
1. You are 18 years of age or older
 2. You have a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations (a type of gene mutation)
- C. **If you have advanced systemic mastocytosis, approval also requires:**
1. You are 18 years of age or older
- D. **If you have indolent systemic mastocytosis, approval also requires:**
1. You are 18 years of age or older

Effective: 08/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AVATROMBOPAG

Generic	Brand			
AVATROMBOPAG	DOPTELET			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **AVATROMBOPAG (Doptelet)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Thrombocytopenia (a type of blood disorder) in chronic (long-term) liver disease
 - 2. Chronic immune thrombocytopenia (cITP: a type of blood disorder)
- B. **If you have thrombocytopenia in chronic liver disease, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You are scheduled to undergo a procedure 10 to 13 days after starting Doptelet therapy
 - 3. You have a platelet (a type of blood cell) count of less than $50 \times 10^9/L$
 - 4. You will NOT use Doptelet concurrently (at the same time) with other thrombopoietin receptor agonists (TPO-RAs, such as Nplate [romiplostim], Promacta [eltrombopag])
- C. **If you have chronic immune thrombocytopenia, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have tried or have a contraindication to (harmful for you to use) corticosteroids or immunoglobulins, OR you did not have a good enough response to a splenectomy (spleen removal)
 - 3. You will NOT use Doptelet concurrently (at the same time) with other thrombopoietin receptor agonists (TPO-RAs, such as Nplate [romiplostim], Promacta [eltrombopag], Alvaiz [eltrombopag]) or a spleen tyrosine kinase (SYK) inhibitor (such as Tavalisse [fostamatinib])
 - 4. You meet ONE of the following:
 - a. You have a platelet (a type of blood cell) count of less than $30 \times 10^9/L$
 - b. You have a platelet count of less than $50 \times 10^9/L$ AND a prior bleeding event

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AVATROMBOPAG

RENEWAL CRITERIA

NOTE: For the diagnosis of thrombocytopenia in chronic liver disease, please refer to the Initial Criteria section.

Our guideline named **AVATROMBOPAG (Doptelet)** requires the following rule(s) be met for renewal:

- A. You have chronic immune thrombocytopenia (cITP: a type of blood disorder)
- B. You have shown a clinical response to therapy, defined as having an improvement in platelet (a type of blood cell) count from baseline (before starting Doptelet) OR a decrease in bleeding events
- C. You will NOT use Doptelet concurrently (at the same time) with other thrombopoietin receptor agonists (TPO-RAs, such as Nplate [romiplostim], Promacta [eltrombopag], Alvaiz [eltrombopag]) or a spleen tyrosine kinase (SYK) inhibitor (such as Tavalisse [fostamatinib])

Effective: 10/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AVUTOMETINIB-DEFACTINIB

Generic	Brand				
AVUTOMETINIB-DEFACTINIB	AVMAPKI-FAKZYNJA				

GUIDELINES FOR USE

Our guideline named **AVUTOMETINIB-DEFACTINIB (Avmapki-Fakzynja)** requires the following rule(s) be met for approval:

- A. You have recurrent low-grade serous ovarian cancer (LGSOC: a type of reproductive system cancer that has returned)
- B. You are 18 years of age or older
- C. Your cancer has a KRAS mutation (a type of abnormal gene)
- D. You have received prior systemic therapy (such as platinum-based chemotherapy [a type of therapy to treat cancer])

Effective: 06/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AXATILIMAB-CSFR

Generic	Brand				
AXATILIMAB-CSFR	NIKTIMVO				

GUIDELINES FOR USE

Our guideline named **AXATILIMAB-CSFR (Niktimvo)** requires the following rule(s) be met for approval:

- a. You have chronic graft-versus-host disease (cGVHD: a type of long-term immune disorder)
- b. You weigh at least 40 kilograms (88 pounds)
- c. You have failed at least TWO lines of systemic therapy (treatment that targets the entire body, such as prednisone, methotrexate, mycophenolate mofetil), one of which must be a trial of or contraindication to (harmful for you to use) Jakafi (ruxolitinib)
- d. You will NOT use Niktimvo concurrently (at the same time) with Jakafi (ruxolitinib), Rezurock (belumosudil), or Imbruvica (ibrutinib)

Effective: 06/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AXITINIB

Generic	Brand			
AXITINIB	INLYTA			

GUIDELINES FOR USE

Our guideline named **AXITINIB (Inlyta)** requires the following rule(s) be met for approval:

- A. You have advanced renal cell carcinoma (RCC; type of kidney cancer)
- B. You also meet ONE of the following:
 - 1. You have tried at least ONE systemic therapy (treatment that spreads throughout the body) for the treatment of renal cell carcinoma such as Nexavar (sorafenib), Torisel (temsirolimus), Sutent (sunitinib), Votrient (pazopanib), or Avastin (bevacizumab) in combination with interferon
 - 2. Inlyta will be used in combination with avelumab (Bavencio) as a first-line treatment
 - 3. Inlyta will be used in combination with pembrolizumab (Keytruda) as a first-line treatment

Effective: 04/10/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AZACITIDINE

Generic	Brand				
AZACITIDINE	ONUREG				

GUIDELINES FOR USE

Our guideline named **AZACITIDINE (Onureg)** requires the following rule(s) be met for approval:

- A. You have acute myeloid leukemia (AML: type of blood and bone marrow cancer with too many white blood cells)
- B. You are 18 years of age or older
- C. You have achieved first complete remission (CR: signs or symptoms of cancer have disappeared) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy (medications for cancer)
- D. You are not able to complete intensive curative therapy (treatment to cure the disease)

Effective: 01/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AZTREONAM INHALED

Generic	Brand			
AZTREONAM LYSINE	CAYSTON			

GUIDELINES FOR USE

Our guideline named **AZTREONAM INHALED** requires the following rule(s) be met for approval:

- A. You have a diagnosis of cystic fibrosis (inherited life-threatening disorder that damages the lungs and digestive system)
- B. You are 7 years of age or older
- C. You have a lung infection with a Gram negative species such as *Pseudomonas aeruginosa*

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BACLOFEN

Generic	Brand				
BACLOFEN	OZOBAX, OZOBAX DS, BACLOFEN				
BACLOFEN	FLEQSUVY, BACLOFEN				
BACLOFEN	LYVISPAH				

GUIDELINES FOR USE

Our guideline named **BACLOFEN (Ozobax, Ozobax DS, Fleqsuvy, Lyvispah)** requires the following rule(s) be met for approval:

- A. You have tried or have a contraindication (harmful for you to use) to generic baclofen tablets
- B. You are unable to swallow generic baclofen tablets

Effective: 11/13/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BARICITINIB

Generic	Brand			
BARICITINIB	OLUMIANT			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **BARICITINIB (Olumiant)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
 - 2. Severe alopecia areata (a type of hair loss)
- B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 - 3. You will NOT use Olumiant concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
 - 4. You have tried at least 3 months of or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
 - 5. You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
- C. **If you have severe alopecia areata, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 - 3. You have had at least 50 percent scalp hair loss as measured by the Severity of Alopecia Tool (SALT: a type of disease evaluation tool) for more than 6 months
 - 4. You will NOT use Olumiant concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Litfulo (ritlecitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of alopecia areata
- D. **NOTE:** Olumiant will not be approved for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults.

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BARICITINIB

RENEWAL CRITERIA

Our guideline named **BARICITINIB (Olumiant)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
 - 2. Severe alopecia areata (a type of hair loss)
- B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**
 - 1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 - 2. You will NOT use Olumiant concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq [upadacitinib]], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
 - 3. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
- C. **If you have severe alopecia areata, renewal also requires:**
 - 1. You have experienced improvement while on therapy (such as scalp hair coverage)
 - 2. You will NOT use Olumiant concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Litfulo (ritlecitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of alopecia areata

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BEDAQUILINE FUMARATE

Generic	Brand			
BEDAQUILINE FUMARATE	SIRTURO			

GUIDELINES FOR USE

Our guideline named **BEDAQUILINE (Sirturo)** requires the following rule(s) be met for approval:

You have pulmonary tuberculosis (TB: a type of lung infection)

You meet ONE of the following:

You have an isolate of *Mycobacterium tuberculosis* (a type of bacterium) that is resistant to rifampin and isoniazid; you are 5 years of age or older; and you will use Sirturo in combination with at least 3 other antibiotics

You have an isolate of *Mycobacterium tuberculosis* that is resistant to rifampin and isoniazid; you are 18 years of age or older; and you will use Sirturo in combination with pretomanid and linezolid

You have an isolate of *Mycobacterium tuberculosis* that is resistant to isoniazid, rifampin, a fluoroquinolone, and an aminoglycoside antibiotic; you are 18 years of age or older; and you will use Sirturo in combination with pretomanid and linezolid

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BELIMUMAB

Generic	Brand				
BELIMUMAB	BENLYSTA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **BELIMUMAB (Benlysta)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Systemic lupus erythematosus (SLE: a type of immune condition)
 - 2. Lupus nephritis (LN: a type of immune condition that affects the kidneys)
- B. **If you have systemic lupus erythematosus, approval also requires:**
 - 1. You are 5 years of age or older
 - 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 - 3. You are currently using corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), or immunosuppressives (standard therapy for the treatment of systemic lupus erythematosus [SLE])
 - 4. You will NOT use Benlysta concurrently (at the same time) with another systemic biologic (such as Sahnelo [anifrolumab-fnia]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of SLE
- C. **If you have lupus nephritis, approval also requires:**
 - 1. You are 5 years of age or older
 - 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or nephrologist (a type of kidney doctor)
 - 3. You are receiving standard treatment (such as steroids, antimalarials, nonsteroidal anti-inflammatory drugs [NSAIDs], or immunosuppressives
 - 4. You will NOT use Benlysta concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of lupus nephritis

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BELIMUMAB

RENEWAL CRITERIA

Our guideline named **BELIMUMAB (Benlysta)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Systemic lupus erythematosus (SLE: a type of immune condition)
 - 2. Lupus nephritis (LN: a type of immune condition that affects the kidneys)
- B. **If you have systemic lupus erythematosus, renewal also requires:**
 - 1. You have shown clinical improvement while on Benlysta
 - 2. You will NOT use Benlysta concurrently (at the same time) with another systemic biologic (such as Sahnelo [anifrolumab-fnia]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of systemic lupus erythematosus
- C. **If you have lupus nephritis, renewal also requires:**
 - 1. You have shown clinical improvement in renal (kidney) response as compared to baseline (before starting Benlysta) laboratory values (estimated glomerular filtration rate [eGFR: a tool for evaluating kidney function] or proteinuria [level of protein in the urine]), and/or clinical parameters (such as fluid retention, use of rescue drugs, glucocorticoid dose)
 - 2. You will NOT use Benlysta concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of lupus nephritis

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BELUMOSUDIL

Generic	Brand				
BELUMOSUDIL MESYLATE	REZUROCK				

GUIDELINES FOR USE

Our guideline named **BELUMOSUDIL (Rezurock)** requires the following rule(s) be met for approval:

- A. You have chronic graft-versus-host-disease (cGVHD: a type of long-term immune disorder)
- B. You are 12 years of age or older
- C. You have failed at least TWO lines of systemic therapy (treatment that targets the entire body, such as prednisone, methotrexate, mycophenolate mofetil), one of which must be a trial of or contraindication to (harmful for you to use) Jakafi (ruxolitinib)
- D. You will NOT use Rezurock concurrently (at the same time) with Jakafi (ruxolitinib), Niktimvo (axatilimab-csfr), or Imbruvica (ibrutinib)

Effective: 02/24/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BELZUTIFAN

Generic	Brand				
BELZUTIFAN	WELIREG				

GUIDELINES FOR USE

Our guideline named **BELZUTIFAN (Welireg)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Von Hippel-Lindau (VHL) disease (a genetic disorder that causes tumors to grow in the body)
2. Advanced renal cell carcinoma (RCC: a type of kidney cancer)
3. Locally advanced (spread from where it started to nearby tissue or lymph nodes), unresectable (cannot be removed by surgery), or metastatic (has spread to other parts of the body) pheochromocytoma (a type of rare tumor) or paraganglioma (a type of nerve condition)

B. If you have von Hippel-Lindau disease, approval also requires:

1. You are 18 years of age or older
2. You require therapy for associated renal cell carcinoma (RCC: a type of kidney cancer), central nervous system (CNS) hemangioblastomas (tumor in the brain or spinal cord), or pancreatic neuroendocrine tumors (pNET: tumor in the pancreas)
3. You do NOT require immediate surgery

C. If you have advanced renal cell carcinoma, approval also requires:

1. You are 18 years of age or older
2. Your tumor cells have a clear cell component (cells that are bubble-like in appearance)
3. You were previously treated with a programmed death receptor-1 (PD-1) inhibitor (such as Keytruda [pembrolizumab]) OR a programmed death-ligand 1 (PD-L1) inhibitor (such as Bavencio [avelumab])
4. You were previously treated with a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI) (such as Nexavar [sorafenib])

D. If you have locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma, approval also requires:

1. You are 12 years of age or older

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BENRALIZUMAB

Generic	Brand				
BENRALIZUMAB	FASENRA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **BENRALIZUMAB (Fasenra)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Severe asthma with an eosinophilic phenotype (a type of lung condition with inflammation)
2. Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome (a type of immune system disorder with inflammation of blood vessels)

B. If you have severe asthma with an eosinophilic phenotype, approval also requires:

1. You are 6 years of age or older
2. Therapy is prescribed by or in consultation with a physician specializing in pulmonary (relating to lungs/breathing) medicine or allergy medicine
3. You have a blood eosinophil level (a type of lab test) of at least 150 cells/mcL within the past 12 months
4. Fasenra will be used in combination with a medium, high-dose, or maximally tolerated dose of an inhaled corticosteroid (such as beclomethasone, mometasone, budesonide) AND at least ONE other maintenance medication (taken on a regular basis) (such as a long-acting inhaled beta2-agonist [such as formoterol, salmeterol], a long-acting muscarinic antagonist [such as Tudorza (aclidinium), Spiriva (tiotropium), Incruse Ellipta (umeclidinium)], a leukotriene receptor antagonist [such as montelukast, zafirlukast], theophylline, or an oral corticosteroid [such as prednisone])
5. You will NOT use Fasenra concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of eosinophilic phenotype asthma

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BENRALIZUMAB

INITIAL CRITERIA (CONTINUED)

6. You meet ONE of the following:
 1. You have experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid (such as prednisone) burst lasting at least 3 days within the past 12 months
 2. You have experienced at least ONE serious asthma exacerbation requiring a hospitalization or an emergency room visit within the past 12 months
 3. You have poor symptom control despite current therapy as shown by at least THREE of the following within the past 4 weeks:
 - i. Daytime asthma symptoms more than twice per week
 - ii. Any night waking due to asthma
 - iii. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
 - iv. Any activity limitation due to asthma
- C. **If you have eosinophilic granulomatosis with polyangiitis, approval also requires:**
 1. You are 18 years of age or older
 2. You will NOT use Fasenra concurrently (at the same time) with another systemic biologic (such as Nucala [mepolizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of eosinophilic granulomatosis with polyangiitis

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BENRALIZUMAB

RENEWAL CRITERIA

Our guideline named **BENRALIZUMAB (Fasenra)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Severe asthma with an eosinophilic phenotype (a type of lung condition with inflammation)
2. Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome (a type of immune system disorder with inflammation of blood vessels)

B. **If you have severe asthma with an eosinophilic phenotype, renewal also requires:**

1. You will continue to use an inhaled corticosteroid (such as beclomethasone, mometasone, budesonide) AND at least ONE other maintenance medication (taken on a regular basis), such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as Tudorza [aclidinium], Spiriva [tiotropium], Incruse Ellipta [umeclidinium]), a leukotriene receptor antagonist (such as montelukast, zafirlukast), theophylline, or an oral corticosteroid (such as prednisone)
2. You will NOT use Fasenra concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of eosinophilic phenotype asthma
3. You have shown a clinical response as evidenced by ONE of the following:
 1. You have experienced a decrease in asthma exacerbations (worsening of symptoms) from baseline (before starting Fasenra)
 2. You have decreased your use of rescue medications (such as albuterol)
 3. Your percent predicted FEV1 (a type of lung test) has increased from pre-treatment baseline (before starting Fasenra)
 4. You have experienced a decrease in the severity or frequency of asthma-related symptoms (such as wheezing, shortness of breath, coughing)

C. **If you have eosinophilic granulomatosis with polyangiitis, renewal also requires:**

1. You have a reduction in eosinophilic granulomatosis with polyangiitis (EGPA) symptoms compared to baseline (before starting Fasenra), OR you have been able to decrease or eliminate (stop) corticosteroid (such as prednisone) use
2. You will NOT use Fasenra concurrently (at the same time) with another systemic biologic (such as Nucala [mepolizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of EGPA

Effective: 11/04/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BERDAZIMER

Generic	Brand				
BERDAZIMER SODIUM	ZELSUVMI				

GUIDELINES FOR USE

Our guideline named **BERDAZIMER (Zelsuvmi)** requires the following rule(s) be met for approval:

- A. You have molluscum contagiosum (MC: a viral skin infection)
- B. You are 1 year of age or older

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BEROTRALSTAT

Generic	Brand				
BEROTRALSTAT HYDROCHLORIDE	ORLADEYO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **BEROTRALSTAT (Orladeyo)** requires the following rule(s) be met for approval:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You are 12 years of age or older
- C. Orladeyo will be used for the prevention of hereditary angioedema attacks
- D. Your diagnosis is confirmed by ONE of the following complement tests: C1-INH protein levels, C4 protein levels, C1-INH functional levels, C1q (a type of lab test)
- E. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor), hematologist (a type of blood doctor), or pulmonologist (lung/breathing doctor)
- F. You will NOT use Orladeyo concurrently (at the same time) with an alternative preventive medication for HAE (such as Takhzyro [lanadelumab-flyo], Cinryze [C1 esterase inhibitor], Haegarda [C1 esterase inhibitor], danazol)

RENEWAL CRITERIA

Our guideline named **BEROTRALSTAT (Orladeyo)** requires the following rule(s) be met for renewal:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You have experienced an improvement in hereditary angioedema attacks (reductions in attack frequency or attack severity) compared to baseline
- C. You will NOT use Orladeyo concurrently (at the same time) with an alternative preventive medication for HAE (such as Takhzyro [lanadelumab-flyo], Cinryze [C1 esterase inhibitor], Haegarda [C1 esterase inhibitor], danazol)

Effective: 03/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BETAINE

Generic	Brand				
BETAINE	CYSTADANE, BETAINE ANHYDROUS				

GUIDELINES FOR USE

Our guideline named **BETAINE (Cystadane)** requires the following rule(s) be met for approval:

- A. You have homocystinuria (a type of genetic metabolic disorder), including cystathionine beta-synthase (CBS: a type of enzyme) deficiency, 5,10-methylenetetrahydrofolate reductase (MTHFR: a type of enzyme) deficiency, and cobalamin cofactor metabolism (cbl: vitamin B12 that is required for enzyme activity) defect

Effective: 04/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BEXAROTENE

Generic	Brand				
BEXAROTENE SOFTGEL	TARGRETIN, BEXAROTENE				
BEXAROTENE 1% TOPICAL GEL	TARGRETIN, BEXAROTENE				

GUIDELINES FOR USE

TARGRETIN (BEXAROTENE) CAPSULE

Our guideline named **BEXAROTENE (Targretin capsule)** requires the following rule(s) be met for approval:

- A. You have cutaneous T-cell lymphoma (CTCL: a type of blood cancer)
- B. You are refractory (resistant) to at least one prior systemic therapy (therapy that spreads through the blood) such as gemcitabine, methotrexate, liposomal doxorubicin, or bortezomib

TARGRETIN (BEXAROTENE) GEL

Our guideline named **BEXAROTENE (Targretin gel)** requires the following rule(s) to be met for approval:

- A. You have cutaneous T-cell lymphoma (CTCL: a type of blood cancer) (stage IA or IB)
- B. You meet ONE of the following:
 - a. You have refractory (resistant) or persistent disease after other therapies
 - b. You have not tolerated other therapies

Effective: 06/15/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BIMEKIZUMAB-BKZX

Generic	Brand				
BIMEKIZUMAB-BKZX	BIMZELX				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **BIMEKIZUMAB-BKZX (Bimzelx)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
 2. Psoriatic arthritis (PsA: a type of skin and joint condition)
 3. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
 4. Ankylosing spondylitis (AS: a type of joint condition)
 5. Moderate to severe hidradenitis suppurativa (HS: a type of skin condition)
- B. **If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 3. You are a candidate for systemic therapy (treatment that targets the entire body) or phototherapy (light therapy)
 4. You have psoriasis covering 3 percent or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, face, or scalp
 5. You will NOT use Bimzelx concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
 6. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BIMEKIZUMAB-BKZX

INITIAL CRITERIA (CONTINUED)

7. You meet ONE of the following:
 - a. You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis
 - b. You have a contraindication or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) AND PUVA (phototherapy) for the treatment of plaque psoriasis
 - c. You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication
- C. **If you have psoriatic arthritis, approval also requires:**
 1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
 3. You will NOT use Bimzelx concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
 4. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BIMEKIZUMAB-BKZX

INITIAL CRITERIA (CONTINUED)

D. If you have non-radiographic axial spondyloarthritis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Bimzelx concurrently (at the same time) with another systemic biologic (such as Taltz [ixekizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of non-radiographic axial spondyloarthritis
4. You have tried or have a contraindication to (harmful for you to use) an NSAID (nonsteroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)
5. You have tried or have a contraindication to ONE of the following preferred medications: Cimzia (certolizumab), Rinvoq (upadacitinib), Taltz (ixekizumab)
6. You have ONE of the following signs of inflammation:
 - a. C-reactive protein (CRP: a measure of how much inflammation is in the body) levels above the upper limit of normal
 - b. Sacroiliitis (a type of inflammation where lower spine and pelvis connect) on magnetic resonance imaging (MRI: a type of imaging lab)

E. If you have ankylosing spondylitis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Bimzelx concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
4. You have tried or have a contraindication to (harmful for you to use) an NSAID (nonsteroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)
5. You have tried or have a contraindication to ONE of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BIMEKIZUMAB-BKZX

INITIAL CRITERIA (CONTINUED)

F. If you have moderate to severe hidradenitis suppurativa, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
3. You will NOT use Bimzelx concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of hidradenitis suppurativa
4. You have tried or have a contraindication to (harmful for you to use) ONE topical therapy (such as clindamycin, resorcinol, chlorhexidine, zinc pyrithione, benzoyl peroxide) or an oral antibiotic (such as tetracycline, dapsone)
5. You have tried or have a contraindication to ONE of the following preferred medications: Humira (adalimumab), adalimumab-adaz, Simlandi

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

RENEWAL CRITERIA

Our guideline named **BIMEKIZUMAB-BKZX (Bimzelx)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
2. Psoriatic arthritis (PsA: a type of skin and joint condition)
3. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
4. Ankylosing spondylitis (AS: a type of joint condition)
5. Moderate to severe hidradenitis suppurativa (HS: a type of skin condition)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BIMEKIZUMAB-BKZX

RENEWAL CRITERIA (CONTINUED)

B. If you have moderate to severe plaque psoriasis, renewal also requires:

1. You have achieved or maintained clear or minimal disease OR a decrease in PASI (Psoriasis Area and Severity Index: a tool for evaluating the severity of psoriasis) of at least 50 percent or more while on therapy
2. You will NOT use Bimzelx concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
3. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)

C. If you have psoriatic arthritis, renewal also requires:

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Bimzelx concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
3. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BIMEKIZUMAB-BKZX

RENEWAL CRITERIA (CONTINUED)

D. If you have non-radiographic axial spondyloarthritis, renewal also requires:

1. You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
2. You will NOT use Bimzelx concurrently (at the same time) with another systemic biologic (such as Taltz [ixekizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of non-radiographic axial spondyloarthritis
3. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Cimzia (certolizumab), Rinvoq (upadacitinib), Taltz (ixekizumab)

E. If you have ankylosing spondylitis, renewal also requires:

1. You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
2. You will NOT use Bimzelx concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
3. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

F. If you have moderate to severe hidradenitis suppurativa, renewal also requires:

1. You have shown improvement in your hidradenitis suppurativa symptoms
2. You will NOT use Bimzelx concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of hidradenitis suppurativa
3. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Humira (adalimumab), adalimumab-adaz, Simlandi

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 04/01/25

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 6/11/2025

Page 117 of 1007



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BINIMETINIB

Generic	Brand			
BINIMETINIB	MEKTOVI			

GUIDELINES FOR USE

Our guideline named **BINIMETINIB (Mektovi)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Unresectable or metastatic melanoma (a type of skin cancer that cannot be removed by surgery or has spread to other parts of the body)
 - 2. Metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to other parts of the body)
- B. **If you have unresectable or metastatic melanoma, approval also requires:**
 - 1. You have a BRAF V600E or V600K mutation (types of gene mutations), as detected by a Food and Drug Administration (FDA)-approved test
 - 2. Mektovi will be used in combination with Braftovi (encorafenib)
- C. **If you have metastatic non-small cell lung cancer, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have a BRAF V600E mutation (a type of gene mutation), as detected by a Food and Drug Administration (FDA)-approved test
 - 3. Mektovi will be used in combination with Braftovi (encorafenib)

Effective: 11/13/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BIRCH BARK EXTRACT

Generic	Brand				
BIRCH BARK EXTRACT	FILSUVEZ				

GUIDELINES FOR USE

Our guideline named **BIRCH BARK EXTRACT (Filsuvez)** requires the following rule(s) be met for approval:

- A. You have epidermolysis bullosa (EB: a type of genetic skin disorder)
- B. You are 6 months of age or older
- C. Filsuvez will be used for the treatment of wounds associated with dystrophic or junctional epidermolysis bullosa (types of genetic skin disorders)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BOSENTAN

Generic	Brand				
BOSENTAN	TRACLEER, BOSENTAN				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **BOSENTAN (Tracleer)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. You are 3 years of age and older
- C. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
- D. You do NOT have idiopathic pulmonary fibrosis (scarring of the lungs due to an unknown cause)
- E. You will NOT use Tracleer concurrently (at the same time) with cyclosporine A or glyburide
- F. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - 1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
 - 2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
 - 3. Pulmonary vascular resistance (PVR) greater than 2 Wood units

RENEWAL CRITERIA

Our guideline named **BOSENTAN (Tracleer)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. You will NOT use Tracleer concurrently (at the same time) with cyclosporine A or glyburide

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BOSUTINIB

Generic	Brand			
BOSUTINIB	BOSULIF			

GUIDELINES FOR USE

Our guideline named **BOSUTINIB (Bosulif)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML; a type of blood cancer)
 - 2. Accelerated phase (AP) or blast phase (BP) Philadelphia chromosome-positive chronic myelogenous leukemia
- B. **If you have chronic phase Philadelphia chromosome-positive chronic myeloid leukemia, approval also requires:**
 - 1. You are 1 year of age or older
 - 2. You meet ONE of the following:
 - a. You are newly diagnosed
 - b. You had resistance or intolerance to prior therapy [such as Gleevec (imatinib), Sprycel (dasatinib), Tasigna (nilotinib)] AND you had a mutational analysis prior to initiation of therapy AND Bosulif is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1: a type of abnormal gene) profile
- C. If you have accelerated or blast phase Philadelphia chromosome-positive chronic myeloid leukemia, approval also requires:
 - 1. You are 18 years of age or older
 - 2. You had resistance or intolerance to prior therapy [such as Gleevec (imatinib), Sprycel (dasatinib), Tasigna (nilotinib)]
 - 3. You had a mutational analysis prior to initiation of therapy
 - 4. Bosulif is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1: a type of abnormal gene) profile

Effective: 01/22/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BREMELANOTIDE

Generic	Brand			
BREMELANOTIDE	VYLEESI			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

Our guideline named **BREMELANOTIDE (Vyleesi)** requires the following rule(s) be met for approval:

- A. You have a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD; also referred to as female sexual interest/arousal disorder where you do not desire sexual activity), as defined by **ALL** of the following:
 - 1. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
 - 2. HSDD is **NOT** a result of a co-existing medical or psychiatric (mental) condition, a problem within the relationship or the effects of a medication or drug substance
 - 3. HSDD symptom causes marked distress or interpersonal difficulty
- B. You are a premenopausal female
- C. You are 18 years of age or older
- D. You had a previous trial of bupropion, unless there is a medical reason why you cannot (contraindication)
- E. You are **NOT** currently using Addyi (flibanserin)

RENEWAL CRITERIA

Our guideline named **BREMELANOTIDE (Vyleesi)** requires the following rule(s) be met for approval:

- A. You have a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD; also referred to as female sexual interest/arousal disorder [FSIAD] where you do not desire sexual activity), as defined by **ALL** of the following:
 - 1. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
 - 2. HSDD is **NOT** a result of a co-existing medical or psychiatric (mental) condition, a problem within the relationship or the effects of a medication or drug substance
 - 3. HSDD symptom causes marked distress or interpersonal difficulty
- B. You are a premenopausal female
- C. You are **NOT** currently using Addyi (flibanserin)
- D. You have experienced continued improvement in symptoms of HSDD/FSIAD such as increased sexual desire, lessened distress)

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BRENTUXIMAB

Generic	Brand				
BRENTUXIMAB VEDOTIN	ADCETRIS				

GUIDELINES FOR USE

Our guideline named **BRENTUXIMAB (Adcetris)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Classical Hodgkin lymphoma (a type of blood cancer)
 2. Systemic anaplastic large cell lymphoma (a type of blood cancer)
 3. CD30-expressing peripheral T-cell lymphomas (a type of blood cancer)
 4. Primary cutaneous anaplastic large cell lymphoma (a type of blood cancer)
 5. Mycosis fungoides (a type of blood cancer affecting the skin)
 6. Large B-cell lymphoma (LBCL), which includes diffuse large B-cell lymphoma (DLBCL) not other specified, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL) (types of blood cancer)
- B. **If you have classical Hodgkin lymphoma, approval also requires ONE of the following:**
1. Your cancer is stage III or IV; you are 18 years of age or older; you have not been previously treated; AND Adcetris will be used in combination with doxorubicin, vinblastine, and dacarbazine
 2. Your cancer is considered high-risk; you are 2 years of age or older; you have not been previously treated; AND Adcetris will be used in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide
 3. You are at high risk for relapse (disease comes back) or disease progression (disease gets worse) after having autologous hematopoietic stem cell transplant (auto-HSCT) (defined as refractory [disease does not respond to treatment], relapse within 12 months, or relapse at least 12 months with extranodal [area outside of the lymph node] disease); you are 18 years of age or older; AND you have obtained complete/partial remission (little or no sign of cancer in your body), or stable disease to most recent pre-auto-HSCT salvage therapy
 4. Your cancer has relapsed; you are 18 years of age or older; AND you have failed autologous hematopoietic stem cell transplant (auto-HSCT: transplant cells are from your own body)
 5. Your cancer has relapsed; you are 18 years of age or older; you are not a candidate for auto-HSCT; AND you have failed at least two multi-agent chemotherapy regimens (such as ABVD [doxorubicin, bleomycin, vinblastine, dacarbazine], Stanford V [doxorubicin, vinblastine, mechlorethamine, etoposide, vincristine, bleomycin, prednisone], BEACOPP [bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone])

(Criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BRENTUXIMAB

GUIDELINES FOR USE (CONTINUED)

- C. If you have systemic anaplastic large cell lymphoma, approval also requires:**
1. You are 18 years of age or older
 2. You meet ONE of the following:
 - a. You have not been previously treated AND Adcetris will be used in combination with cyclophosphamide, doxorubicin, and prednisone
 - b. Your cancer has relapsed (disease that has returned) AND you have failed at least one multi-agent chemotherapy regimen (such as CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone], CHOEP [cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone])
- D. If you have CD30-expressing peripheral T-cell lymphomas, including angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified, approval also requires:**
1. You are 18 years of age or older
 2. You have not been previously treated
 3. Adcetris will be used in combination with cyclophosphamide, doxorubicin, and prednisone
- E. If you have primary cutaneous anaplastic large cell lymphoma, approval also requires:**
1. You are 18 years of age or older
 2. You have received prior systemic therapy (treatment that targets the entire body such as CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone], methotrexate)
- F. If you have mycosis fungoides, approval also requires:**
1. You are 18 years of age or older
 2. Your cancer is CD30 (a type of protein)-positive
 3. You have received prior systemic therapy (treatment that targets the entire body such as Istodax [romidepsin], methotrexate)

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BRENTUXIMAB

GUIDELINES FOR USE (CONTINUED)

- G. If you have large B-cell lymphoma, which includes diffuse large B-cell lymphoma not other specified, diffuse large B-cell lymphoma arising from indolent lymphoma, or high-grade B-cell lymphoma, approval also requires:**
1. You are 18 years of age or older
 2. Your cancer is relapsed (disease that has returned) or refractory (did not respond to treatment)
 3. Adcetris will be used in combination with Revlimid (lenalidomide) AND a rituximab product (such as Rituxan [rituximab], Truxima [rituximab-abbs])
 4. You have has tried at least two lines of systemic therapy (such as R-CHOP [rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone], GemOx [gemcitabine, oxaliplatin])
 5. You are not eligible for autologous hematopoietic stem cell transplantation (auto-HSCT: a type of procedure to replace damaged bone marrow with your own healthy blood-forming cells) or chimeric antigen receptor (CAR) T-cell therapy (such as Yescarta [axicabtagene ciloleucel], Kymriah [tisagenlecleucel])

Effective: 03/10/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BRIGATINIB

Generic	Brand			
BRIGATINIB	ALUNBRIG			

GUIDELINES FOR USE

Our guideline named **BRIGATINIB (Alunbrig)** requires the following rule(s) be met for approval:

- A. You have metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
- B. You are 18 years of age or older
- C. You are positive for anaplastic lymphoma kinase (ALK) fusion oncogene (a type of gene mutation that causes a change in your DNA) as detected by a Food and Drug Administration (FDA)-approved test

Effective: 04/10/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BRODALUMAB

Generic	Brand			
BRODALUMAB	SILIQ			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **BRODALUMAB (Siliq)** requires the following rule(s) be met for approval:

- A. You have moderate to severe plaque psoriasis (PsO: a type of skin condition)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
- D. You have psoriasis covering 3 percent or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, face, or scalp
- E. You have been counseled on and express an understanding of the risk of suicidal thoughts and behavior
- F. You will NOT use Siliq concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
- G. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)
- H. You meet ONE of the following:
 - 1. You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) OR PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis
 - 2. You have a contraindication or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) AND PUVA (phototherapy) for the treatment of plaque psoriasis
 - 3. You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BRODALUMAB

RENEWAL CRITERIA

Our guideline named **BRODALUMAB (Siliq)** requires the following rule(s) be met for renewal:

- A. You have moderate to severe plaque psoriasis (PsO: a type of skin condition)
- B. You have achieved or maintained clear or minimal disease OR a decrease in PASI (Psoriasis Area and Severity Index: a tool for evaluating the severity of psoriasis) of at least 50 percent or more
- C. You have NOT developed or reported worsening depressive symptoms or suicidal thoughts and behaviors while on treatment with Siliq
- D. You will NOT use Siliq concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
- E. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BUDESONIDE-EOHILIA

Generic	Brand				
BUDESONIDE	EOHILIA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **BUDESONIDE-EOHILIA** requires the following rule(s) be met for approval:

- A. You have eosinophilic esophagitis (a type of immune system disorder)
- B. You are 11 years of age or older
- C. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions) or allergist (a type of allergy doctor)
- D. You have at least 15 eosinophils/high powered field (a type of lab test) in the esophagus as confirmed by a biopsy (removal of cells or tissue from the body for examination)
- E. You have tried or have a contraindication to (harmful for you to use) one inhaled corticosteroid (such as Flovent [fluticasone], Pulmicort [budesonide]) OR one proton pump inhibitor (such as omeprazole, lansoprazole, pantoprazole)

RENEWAL CRITERIA

Our guideline named **BUDESONIDE-EOHILIA** requires the following rule(s) be met for renewal:

- A. You have eosinophilic esophagitis (EoE: a type of immune system disorder)
- B. You meet ONE of the following:
 - 1. You have less than 15 eosinophils/high powered field (eos/hpf: a type of lab test) in the esophagus after treatment with Eohilia
 - 2. You have experienced an improvement in dysphagia (difficulty swallowing) compared to baseline

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BUDESONIDE - ORTIKOS

Generic	Brand				
BUDESONIDE	ORTIKOS				

GUIDELINES FOR USE

Our guideline named **BUDESONIDE - ORTIKOS** requires the following rule(s) be met for approval:

- A. You have mild to moderate Crohn's Disease (a type of bowel disorder)
- B. **If you have mild to moderate active Crohn's Disease, approval also requires:**
 - 1. You are 8 years of age or older
 - 2. You have tried generic budesonide 3mg capsules OR you cannot tolerate the pill burden associated with the generic product
- C. **If you have mild to moderate Crohn's Disease, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. The requested medication is being used for the maintenance of clinical remission (signs and symptoms of disease have either improved or disappeared)
 - 3. You have tried generic budesonide 3mg capsules OR you cannot tolerate the pill burden associated with the generic product

Effective: 01/17/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BUDESONIDE - TARPEYO

Generic	Brand				
BUDESONIDE	TARPEYO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **BUDESONIDE - TARPEYO** requires the following rule(s) be met for approval:

- A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a nephrologist (a type of kidney doctor)
- D. Your diagnosis is confirmed by a renal biopsy (removal of cells or tissue from the kidney for examination)
- E. You have a progressively declining glomerular filtration rate (GFR: a tool for evaluating kidney function) and/or worsening proteinuria (increased levels of protein in the urine, such as greater than 1 gram protein in a 24-hour urine collection or at least 1 g/g urine protein to creatinine ratio [UPCR: a test that measures the amount of protein in urine])
- F. You have an estimated glomerular filtration rate (eGFR: a tool for evaluating kidney function) of at least 35 mL/min/1.73m²
- G. You have tried an angiotensin converting enzyme inhibitor (ACE-I: a type of medication used to protect kidneys, such as benazepril, lisinopril) or an angiotensin receptor blocker (ARB: a type of medication used to protect kidneys, such as losartan, valsartan) for at least 3 months at a maximum tolerated dose and will continue use, OR you have a contraindication to (harmful for you to use) both of these medication classes
- H. You have tried a sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor: a type of medication used to protect kidneys, such as Farxiga [dapagliflozin], Jardiance [empagliflozin]) and will continue use, OR you have a contraindication to an SGLT2 inhibitor

RENEWAL CRITERIA

Our guideline named **BUDESONIDE - TARPEYO** requires the following rule(s) be met for renewal:

- A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
- B. You have improved or stable kidney function compared to baseline (before starting Tarpeyo) OR you have a reduction in proteinuria (lowered levels of protein in the urine)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

BUPRENORPHINE EXTENDED-RELEASE

Generic	Brand				
BUPRENORPHINE	SUBLOCADE				

GUIDELINES FOR USE

Our guideline named **BUPRENORPHINE EXTENDED-RELEASE (Sublocade)** requires the following rule(s) be met for approval:

- A. You have moderate to severe opioid use disorder (misuse of a type of pain medication)
- B. You started treatment with a single dose of a transmucosal (medication that enters the body through a mucous layer like those in the mouth) buprenorphine product (such as Suboxone [buprenorphine/naloxone], Zubsolv [buprenorphine/naloxone]), OR you are already being treated with buprenorphine

Effective: 03/17/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

C1 ESTERASE INHIBITOR - BERINERT

Generic	Brand				
C1 ESTERASE INHIBITOR	BERINERT				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **C1 ESTERASE INHIBITOR - BERINERT** requires the following rule(s) be met for approval:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. Berinert will be used for the treatment of acute (sudden and severe) attacks of hereditary angioedema
- C. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor), hematologist (a type of blood doctor), or pulmonologist (lung/breathing doctor)
- D. Your diagnosis is confirmed by ONE of the following complement tests: C1-INH protein levels, C4 protein levels, C1-INH functional levels, C1q (a type of lab test)
- E. You will NOT use Berinert concurrently (at the same time) with other medications used for the treatment of acute HAE attacks (such as Ruconest [C1 esterase inhibitor], Firazyr [icatibant], Kalbitor [ecallantide])

RENEWAL CRITERIA

Our guideline named **C1 ESTERASE INHIBITOR - BERINERT** requires the following rule(s) be met for renewal:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You have experienced a reduction (decrease) in the severity or duration of HAE attacks
- C. You will NOT use Berinert concurrently (at the same time) with other medications used for the treatment of acute HAE attacks (such as Ruconest [C1 esterase inhibitor], Firazyr [icatibant], Kalbitor [ecallantide])

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

C1 ESTERASE INHIBITOR - CINRYZE

Generic	Brand				
C1 ESTERASE INHIBITOR	CINRYZE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **C1 ESTERASE INHIBITOR - CINRYZE** requires the following rule(s) be met for approval:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You are 6 years of age or older
- C. Cinryze will be used for the prevention of hereditary angioedema attacks
- D. Your diagnosis is confirmed by ONE of the following complement tests: C1-INH protein levels, C4 protein levels, C1-INH functional levels, C1q (a type of blood test)
- E. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor), hematologist (a type of blood doctor), or pulmonologist (lung/breathing doctor)
- F. You will NOT use Cinryze concurrently (at the same time) with an alternative preventive medication for HAE (such as Takhzyro [lanadelumab-flyo], Haegarda [C1 esterase inhibitor], danazol, Orladeyo [berotralstat])

RENEWAL CRITERIA

Our guideline named **C1 ESTERASE INHIBITOR - CINRYZE** requires the following rule(s) be met for renewal:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You have experienced an improvement in hereditary angioedema attacks (reductions in attack frequency or attack severity) compared to baseline
- C. You will NOT use Cinryze concurrently (at the same time) with an alternative preventive medication for HAE (such as Takhzyro [lanadelumab-flyo], Haegarda [C1 esterase inhibitor], danazol, Orladeyo [berotralstat])

Effective: 03/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

C1 ESTERASE INHIBITOR - HAEGARDA

Generic	Brand				
C1 ESTERASE INHIBITOR	HAEGARDA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **C1 ESTERASE INHIBITOR - HAEGARDA** requires the following rule(s) be met for approval:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You are 6 years of age or older
- C. Haegarda will be used for the prevention of hereditary angioedema attacks
- D. Your diagnosis is confirmed by ONE of the following complement tests: C1-INH protein levels, C4 protein levels, C1-INH functional levels, C1q (a type of blood test)
- E. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor), hematologist (a type of blood doctor), or pulmonologist (lung/breathing doctor)
- F. You will NOT use Haegarda concurrently (at the same time) with an alternative preventive medication for HAE (such as Takhzyro [lanadelumab-flyo], Cinryze [C1 esterase inhibitor], danazol, Orladeyo [berotralstat])

RENEWAL CRITERIA

Our guideline named **C1 ESTERASE INHIBITOR - HAEGARDA** requires the following rule(s) be met for renewal:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You have experienced an improvement in hereditary angioedema attacks (reductions in attack frequency or attack severity) compared to baseline
- C. You will NOT use Haegarda concurrently (at the same time) with an alternative preventive medication for HAE (such as Takhzyro [lanadelumab-flyo], Cinryze [C1 esterase inhibitor], danazol, Orladeyo [berotralstat])

Effective: 03/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

C1 ESTERASE INHIBITOR - RUCONEST

Generic	Brand				
C1 ESTERASE INHIBITOR, RECOMBINANT	RUCONEST				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **C1 ESTERASE INHIBITOR - RUCONEST** requires the following rule(s) be met for approval:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. Ruconest will be used for the treatment of acute (sudden and severe) attacks of hereditary angioedema
- C. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor), hematologist (a type of blood doctor), or pulmonologist (lung/breathing doctor)
- D. Your diagnosis is confirmed by ONE of the following complement tests: C1-INH protein levels, C4 protein levels, C1-INH functional levels, C1q (a type of lab test)
- E. You will NOT use Ruconest concurrently (at the same time) with other medications used for the treatment of acute HAE attacks (such as Berinert [C1 esterase inhibitor], Firazyr [icatibant], Kalbitor [ecallantide])

RENEWAL CRITERIA

Our guideline named **C1 ESTERASE INHIBITOR - RUCONEST** requires the following rule(s) be met for renewal:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You have experienced a reduction (decrease) in the severity or duration of HAE attacks
- C. You will NOT use Ruconest concurrently (at the same time) with other medications used for the treatment of acute HAE attacks (such as Berinert [C1 esterase inhibitor], Firazyr [icatibant], Kalbitor [ecallantide])

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CABOZANTINIB TABLET

Generic	Brand				
CABOZANTINIB S-MALATE	CABOMETYX				

GUIDELINES FOR USE

Our guideline named **CABOZANTINIB TABLET (Cabometyx)** requires the following rule(s) be met for approval:

You have **ONE** of the following:

Advanced renal cell carcinoma (RCC: a type of kidney cancer)

Hepatocellular carcinoma (HCC: a type of liver cancer)

Locally advanced or metastatic differentiated thyroid cancer (DTC: a type of thyroid cancer that has spread to nearby tissue/lymph nodes or to other parts of the body)

Pancreatic neuroendocrine tumor (pNET: tumor that began in the pancreas)

Extra-pancreatic neuroendocrine tumor (epNET: tumor that began outside of the pancreas)

If you have advanced renal cell carcinoma, approval also requires ONE of the following:

Cabometyx will be used as a single agent (used alone)

Cabometyx will be used in combination with Opdivo (nivolumab) as first-line treatment (You have not received prior treatment for advanced renal cell carcinoma)

If you have hepatocellular carcinoma, approval also requires:

You have been previously treated with Nexavar (sorafenib)

If you have locally advanced or metastatic differentiated thyroid cancer, approval also requires:

You are 12 years of age or older

You have disease progression (worsening) following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy (such as Lenvima [lenvatinib])

You are radioactive iodine-refractory (resistant to) or ineligible

If you have a pancreatic or extra-pancreatic neuroendocrine tumor, approval also requires:

You are 12 years of age or older

Your tumor is unresectable (unable to remove by surgery), locally advanced or metastatic (cancer that has spread to nearby tissue/lymph nodes or to other parts of the body), and well-differentiated

Your tumor has been previously treated

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CALASPARGASE PEGOL-MKNL

Generic	Brand				
CALASPARGASE PEGOL-MKNL	ASPARLAS				

GUIDELINES FOR USE

Our guideline named **CALASPARGASE PEGOL-MKNL (Asparlas)** requires the following rule(s) be met for approval:

- A. You have acute lymphoblastic leukemia (ALL: a type of blood cancer)
- B. You are 1 month to 21 years of age
- C. Asparlas will be used as a part of a chemotherapeutic (medications used to treat cancer) plan that contains multiple medications

Effective: 02/24/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CANAKINUMAB

Generic	Brand				
CANAKINUMAB/PF	ILARIS				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **CANAKINUMAB (Ilaris)** requires the following rule(s) be met for approval:
You have ONE of the following:

- Cryopyrin-Associated Periodic Syndromes (CAPS: a type of immune disorder), including
Familial Cold Auto-inflammatory Syndrome (FCAS: a type of immune disorder) or
Muckle-Wells Syndrome (MWS: a type of immune disorder)
- Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS: a type of genetic disease)
- Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) (types of genetic disorders)
- Familial Mediterranean Fever (FMF: a type of genetic disorder)
- Adult-Onset Still's Disease (AOSD: an autoinflammatory disease)
- Systemic juvenile idiopathic arthritis (SJIA: a type of joint condition)
- Gout flares (episodes of pain or swelling associated with a type of joint condition)

If you have Cryopyrin-Associated Periodic Syndromes, including Familial Cold Auto-inflammatory Syndrome or Muckle-Wells Syndrome, approval also requires:

- You are 4 years of age or older
- You had genetic testing for gain-of-function mutations (abnormal change in gene) in the *NLRP3* gene (a type of gene) OR you have inflammatory markers (elevated C-reactive protein [CRP: a measure of how much inflammation is in the body], erythrocyte sedimentation rate [ESR: a measure of how much inflammation is in the body], serum amyloid A protein [SAA: a type of protein] or S100 proteins [a type of protein])
- You have TWO of the following: urticarial-like rash (neutrophilic dermatitis: a type of skin condition), cold-triggered episodes, sensorineural hearing loss (SNHL: a type of hearing loss), musculoskeletal symptoms (symptoms related to the skin and bones), chronic aseptic meningitis (inflammation of the brain and spinal cord), and skeletal (bone) abnormalities
- You will NOT use Ilaris concurrently (at the same time) with another systemic biologic (such as Arcalyst [rilonacept]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Cryopyrin-Associated Periodic Syndromes, including Familial Cold Auto-inflammatory Syndrome or Muckle-Wells Syndrome

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CANAKINUMAB

INITIAL CRITERIA (CONTINUED)

If you have Tumor Necrosis Factor Receptor Associated Periodic Syndrome, approval also requires:

You will NOT use Ilaris concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome

If you have Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency, approval also requires:

You will NOT use Ilaris concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency

If you have Familial Mediterranean Fever, approval also requires:

You will NOT use Ilaris concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Familial Mediterranean Fever

If you have Adult-Onset Still's Disease, approval also requires:

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor), dermatologist (a type of skin doctor), or immunologist (a type of immune system doctor)

You will NOT use Ilaris concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Adult-Onset Still's Disease

You have tried or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CANAKINUMAB

INITIAL CRITERIA (CONTINUED)

If you have systemic juvenile idiopathic arthritis, approval also requires:

You are 2 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor), dermatologist (a type of skin doctor), or immunologist (a type of immune system doctor)

You will NOT use Ilaris concurrently (at the same time) with another systemic biologic (such as Actemra [tocilizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of systemic juvenile idiopathic arthritis

You have tried or have a contraindication to (harmful for you to use) the following preferred medication: Tyenne (tocilizumab-aazg)

If you have gout flares, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)

You will NOT use Ilaris concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of gout flares

You have tried or have a contraindication to (harmful for you to use) **ALL** of the following:

Colchicine

An NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, indomethacin)

A corticosteroid (such as triamcinolone, methylprednisolone, prednisone, prednisolone)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CANAKINUMAB

RENEWAL CRITERIA

NOTE: For the diagnoses of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), or Familial Mediterranean Fever (FMF), please refer to the Initial Criteria section.

Our guideline named **CANAKINUMAB (Ilaris)** requires the following rule(s) be met for renewal:
You have ONE of the following:

- Adult-Onset Still's Disease (AOSD: an autoinflammatory disease)
- Systemic juvenile idiopathic arthritis (SJIA: a type of joint condition)
- Gout flares (episodes of pain or swelling associated with a type of joint condition)

If you have Adult-Onset Still's Disease, renewal also requires:

You will NOT use Ilaris concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Adult-Onset Still's Disease

You meet ONE of the following:

- You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
- You have maintained or improved systemic inflammatory disease (such as fevers, pain, rash, arthritis)

If you have systemic juvenile idiopathic arthritis, renewal also requires:

You will NOT use Ilaris concurrently (at the same time) with another systemic biologic (such as Actemra [tocilizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of systemic juvenile idiopathic arthritis

You have tried or have a contraindication to (harmful for you to use) the following preferred medication: Tyenne (tocilizumab-aazg)

You meet ONE of the following:

- You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
- You have maintained or improved systemic inflammatory disease (such as fevers, pain, rash, arthritis)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CANAKINUMAB

RENEWAL CRITERIA (CONTINUED)

If you have gout flares, renewal also requires:

You have shown improvement of gout flares while on Ilaris

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)

You will NOT use Ilaris concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of gout flares

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CANTHARIDIN

Generic	Brand				
CANTHARIDIN	YCANTH				

GUIDELINES FOR USE

Our guideline named **CANTHARIDIN (Ycanth)** requires the following rule(s) be met for approval:

- A. You have molluscum contagiosum (a viral skin infection)
- B. You are 2 years of age or older

Effective: 12/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CAPECITABINE

Generic	Brand			
CAPECITABINE	XELODA			

GUIDELINES FOR USE

Our guideline named **CAPECITABINE (Xeloda)** requires the following rule(s) to be met for approval:

- A. You have ONE of the following diagnoses:
1. Stage III colon cancer (colon cancer that has spread to lymph nodes)
 2. Locally advanced rectal cancer (cancer that has spread from where it started to nearby tissue or lymph nodes)
 3. Unresectable (unable to remove by surgery) or metastatic colorectal cancer (a type of digestive cancer that has spread to other parts of the body)
 4. Metastatic breast cancer (breast cancer that has spread to other parts of the body)
 5. Unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer (a type of digestive system cancer that has spread to other parts of the body)
 6. HER2 (a type of protein)-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma (a type of digestive system cancer that has spread to other parts of the body)
 7. Pancreatic adenocarcinoma (a type of cancer of the pancreas)
- B. **If you have Stage III colon cancer, approval also requires:**
1. The requested medication will be used as adjuvant (add-on) treatment
- C. **If you have locally advanced rectal cancer, approval also requires:**
1. You are 18 years of age or older
 2. The requested medication will be used as perioperative (the time period before and after surgery) treatment
 3. The requested medication will be used as part of chemoradiotherapy (a type of cancer treatment)
- D. **If you have advanced or metastatic breast cancer, approval also requires ONE of the following:**
1. The requested medication will be used as a single agent (used alone), if an anthracycline (such as doxorubicin, daunorubicin)- or taxane (such as paclitaxel, docetaxel)-containing chemotherapy is not indicated
 2. The requested medication will be used in combination with docetaxel after disease progression (worsens) on prior anthracycline (such as doxorubicin, daunorubicin)-containing chemotherapy

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CAPECITABINE

GUIDELINES FOR USE (CONTINUED)

- E. If you have unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. The requested medication will be used as part of a combination chemotherapy (drugs used to treat cancer) regimen
- F. If you have HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have not received prior treatment for metastatic disease
 - 3. The requested medication will be used as part of a combination regimen (such as with cisplatin, trastuzumab)
- G. If you have pancreatic adenocarcinoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. The requested medication will be used as adjuvant (add-on) treatment
 - 3. The requested medication will be used as part of a combination chemotherapy regimen (such as with gemcitabine)

Effective: 01/23/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CAPIVASERTIB

Generic	Brand				
CAPIVASERTIB	TRUQAP				

GUIDELINES FOR USE

Our guideline named **CAPIVASERTIB (Truqap)** requires the following rule(s) be met for approval:

You have locally advanced or metastatic breast cancer (breast cancer that has spread from where it started to nearby tissue or lymph nodes or to other parts of the body)

Truqap will be used together with Faslodex (fulvestrant)

Your breast cancer is hormone receptor (HR: a type of protein)-positive, human epidermal growth factor receptor 2 (HER2: a type of protein)-negative, with one or more PIK3CA/AKT1/PTEN-mutations (abnormal changes in a type of gene) as detected by a Food and Drug Administration (FDA)-approved test

You have experienced disease progression (your condition has worsened) on an endocrine (hormone)-based regimen (such as letrozole, anastrozole, tamoxifen)

Effective: 01/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CAPLACIZUMAB-YHDP

Generic	Brand			
CAPLACIZUMAB-YHDP	CABLIVI			

GUIDELINES FOR USE

Our guideline named **CAPLACIZUMAB-YHDP (Cablivi)** requires the following rule(s) be met for approval:

- A. You have a diagnosis of acquired thrombotic thrombocytopenia purpura (aTTP- a type of blood disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or given in consultation with a hematologist (blood specialist)
- D. You have NOT experienced more than two recurrences of acquired thrombotic thrombocytopenia purpura, while on Cablivi therapy. For example there's a new drop in platelet count requiring repeat plasma exchange during 30 days post-plasma exchange therapy (process of replacing a liquid part of the blood) and up to 28 days of extended therapy
- E. You also meet ONE of the following:
 - 1. Your request is for continuation of Cablivi therapy from inpatient (hospital) setting and you previously received plasma exchange and immunosuppressive therapy (treatment that weakens your immune system) within the inpatient setting
 - 2. Your request is for continuation of Cablivi therapy from the initial 30 days treatment course (no break in therapy) AND:
 - a. You are receiving immunosuppressive therapy, and
 - b. You are experiencing signs of persistent underlying disease (such as suppressed ADAMTS13 [a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13: type of blood clot disorder] activity level remain present)

Effective: 11/21/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CAPMATINIB

Generic	Brand				
CAPMATINIB HYDROCHLORI DE	TABRECTA				

GUIDELINES FOR USE

Our guideline named **CAPMATINIB (Tabrecta)** requires the following rule(s) be met for approval:

- A. You have metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
- B. You are 18 years of age or older
- C. Your tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping (an abnormal change in a gene that makes MET protein) as detected by an FDA-approved test

Effective: 04/10/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CAPSAICIN

Generic	Brand			
CAPSAICIN 8% PATCH	QUTENZA			

GUIDELINES FOR USE

Our guideline named **CAPSAICIN (Qutenza)** requires the following rule be met for approval:

- A. You have a diagnosis of neuropathic pain associated with ONE of the following conditions:
- Postherpetic neuralgia (PHN) (painful condition that affects the nerve fibers and skin after having shingles)
 - Diabetic peripheral neuropathy (DPN) of the feet (numbness of the feet that is caused by diabetes)

Effective: 08/24/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CARBIDOPA-LEVODOPA

Generic	Brand			
CARBIDOPA/LEVODOPA	DUOPA			

GUIDELINES FOR USE

Our guideline named **CARBIDOPA-LEVODOPA (Duopa)** requires the following rule be met for approval:

- A. You have a diagnosis of advanced Parkinson's disease (nerve system disorder that affects movement)

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CARBOXYMETHYLCELLULOSE-CITRIC

Generic	Brand				
CARBOXYMETHYLCELLULOSE /CITRIC	PLENITY				

GUIDELINES FOR USE

Our guideline named **CARBOXYMETHYLCELLULOSE-CITRIC (Plenity)** requires the following rule(s) be met for approval:

- A. The request is for weight management
- B. You are 18 years of age or older
- C. You have a body mass index (BMI) of 25 to 40 kg/m(2)
- D. Plenity will be used in conjunction (together) with diet and exercise

Effective: 04/13/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CARGLUMIC ACID

Generic	Brand				
CARGLUMIC ACID	CARBAGLU CARGLUMIC ACID				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **CARGLUMIC ACID (Carbaglu)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Acute or chronic hyperammonemia (HA) due to N-acetylglutamate synthase (NAGS) deficiency (short-term or long-term high ammonia blood levels due to a genetic disorder)
 - 2. Acute hyperammonemia (HA) due to propionic acidemia (PA) or methylmalonic acidemia (MMA) (short-term high ammonia blood levels due to a genetic disorder)
- B. **If you have acute or chronic hyperammonemia due to N-acetylglutamate synthase deficiency, approval also requires:**
 - 1. Your N-acetylglutamate synthase gene mutation is confirmed by biochemical or genetic testing (types of lab test)
 - 2. Requests for brand Carbaglu requires a trial of generic carglumic acid
- C. **If you have acute hyperammonemia due to propionic acidemia, approval also requires:**
 - 1. Your diagnosis is confirmed by the presence of elevated methylcitric acid and normal methylmalonic acid (substances that indicate presence of a disease) OR genetic testing confirming mutation in the PCCA or PCCB gene (types of abnormal genes)
- D. **If you have acute hyperammonemia due to methylmalonic acidemia, approval also requires:**
 - 1. Your diagnosis is confirmed by the presence of elevated methylmalonic acid, methylcitric acid OR genetic testing confirming mutation in the MMUT, MMA, MMAB or MMADHC genes (types of abnormal genes)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CARGLUMIC ACID

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For the diagnoses of acute hyperammonemia (HA) due to N-acetylglutamate synthase (NAGS) deficiency or acute hyperammonemia (HA) due to propionic acidemia (PA) or methylmalonic acidemia (MMA), please refer to the Initial Criteria section.

Our guideline named **CARGLUMIC ACID (Carbaglu)** requires the following rule(s) be met for renewal:

- A. You have chronic hyperammonemia (HA) due to N-acetylglutamate synthase (NAGS) (long-term high ammonia blood levels due to a genetic disorder)
- B. You have clinical improvement or improved plasma (blood) ammonia levels

Effective: 07/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CASIMERSEN

Generic	Brand				
CASIMERSEN	AMONDYS-45				

GUIDELINES FOR USE

Our guideline named **CASIMERSEN (Amondys-45)** requires the following rule(s) be met for approval:

- A. You have Duchenne muscular dystrophy (DMD: a type of muscle disorder)
- B. You have a confirmed mutation in the DMD gene that is responsive to exon 45 skipping (a type of gene mutation)

Effective: 02/24/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CELECOXIB

Generic	Brand				
CELECOXIB	ELYXYB				

GUIDELINES FOR USE

Our guideline named **CELECOXIB (Elyxyb)** requires the following rule(s) be met for approval:

- A. The request is for the acute (quick onset) treatment of migraines
- B. You are 18 years of age or older
- C. You had a trial of generic celecoxib AND over-the-counter (OTC) or generic aspirin, diclofenac, ibuprofen, or naproxen
- D. You are unable to swallow pills (such as tablets or capsules)

Effective: 04/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CENERGERMIN-BKBJ

Generic	Brand			
CENERGERMIN-BKBJ	OXERVATE			

GUIDELINES FOR USE

Our guideline named **CENERGERMIN-BKBJ (Oxervate)** requires the following rule(s) be met for approval:

- A. You have neurotrophic keratitis (an eye disease due to a damaged eye nerve)
- B. Therapy is prescribed by or in consultation with an ophthalmologist (eye doctor)
- C. You have a medical history that supports a cause for trigeminal nerve damage (damage to a nerve in the head) (such as herpes zoster infection [shingles virus], multiple sclerosis [type of nerve disorder], diabetes (a disorder with high blood sugar), ocular surgical [eye surgery] damage)
- D. You have loss of corneal (a part of the eye) sensitivity, corneal epithelium changes, and/or loss of tear production
- E. You are refractory (not fully responsive) to conservative management (artificial tears, ocular lubricants, topical antibiotics, therapeutic contact lenses)

Effective: 01/17/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CEQR SIMPLICITY INSULIN DEVICE

Generic	Brand				
BOLUS INSULIN PUMP, 200 UNIT	CEQR SIMPLICITY				
DIABETIC SUPPLIES,MISCELL	CEQR SIMPLICITY INSERTER				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **CEQR SIMPLICITY INSULIN DEVICE** requires the following rule(s) be met for approval:

- A. You have diabetes mellitus (type 1 or type 2) (a disorder with high blood sugar)
- B. You are 21 years of age or older
- C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
- D. You follow a maintenance program of at least 3 injections of insulin per day
- E. You have worked with the physician to adjust the dose of insulin for the past 6 months and have not met glucose (blood sugar) goals
- F. You require bolus insulin dosing in increments of 2 units per bolus
- G. You had a trial of ONE of the following preferred devices: Omnipod, Omnipod Dash, V-Go
- H. If requesting more than 10 patches per month, then you must be using more than 180 units of insulin per 72 hours
- I. You are on a multiple daily insulin injection regimen and meet ONE of the following criteria:
 1. You have a glycosylated hemoglobin level (HbA1c: a type of lab test) greater than 7 percent
 2. You have a history of recurring hypoglycemia (low blood sugar)
 3. You have wide fluctuations (variations) in blood glucose before mealtime
 4. You experience the dawn phenomenon (abnormal early morning increase in blood sugar, usually between 2 a.m. and 8 a.m.) with fasting blood glucose levels frequently exceeding 200 mg/dL
 5. You have a history of severe glycemic excursions (sudden spikes in blood sugar levels)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CEQR SIMPLICITY INSULIN DEVICE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **CEQR SIMPLICITY INSULIN DEVICE** requires the following rule(s) be met for renewal:

- A. You have diabetes mellitus (type 1 or type 2) (a disorder with high blood sugar)
- B. You have shown a positive response to therapy
- C. You are adherent to your doctor follow-up visits
- D. If requesting more than 10 patches per month, you are using more than 180 units of insulin per 72 hours

Effective: 04/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CERITINIB

Generic	Brand			
CERITINIB	ZYKADIA			

GUIDELINES FOR USE

Our guideline named **CERITINIB (Zykadia)** requires the following rule(s) be met for approval:

- A. You have metastatic non-small cell lung cancer (type of lung cancer that has spread)
- B. You are 18 years of age or older
- C. Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme) positive as confirmed by a Food and Drug Administration-approved test

Effective: 10/25/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CERTOLIZUMAB PEGOL

Generic	Brand			
CERTOLIZUMAB PEGOL	CIMZIA			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **CERTOLIZUMAB PEGOL (Cimzia)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
 2. Polyarticular juvenile idiopathic arthritis (pJIA: a type of joint condition)
 3. Psoriatic arthritis (PsA: a type of skin and joint condition)
 4. Ankylosing spondylitis (AS: a type of joint condition)
 5. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
 6. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
 7. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
- B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use Cimzia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
 4. You have tried at least 3 months of or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
 5. You meet ONE of the following:
 - a. You are pregnant, breastfeeding, or trying to become pregnant
 - b. You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - c. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CERTOLIZUMAB PEGOL

INITIAL CRITERIA (CONTINUED)

C. If you have polyarticular juvenile idiopathic arthritis, approval also requires:

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Cimzia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
4. You meet ONE of the following:
 - a. You are pregnant, breastfeeding, or trying to become pregnant
 - b. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz IR (tofacitinib immediate-release), Rinvoq (upadacitinib)

D. If you have psoriatic arthritis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
3. You will NOT use Cimzia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
4. You meet ONE of the following:
 - a. You are pregnant, breastfeeding, or trying to become pregnant
 - b. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CERTOLIZUMAB PEGOL

INITIAL CRITERIA (CONTINUED)

E. If you have ankylosing spondylitis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Cimzia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
4. You have tried or have a contraindication to (harmful for you to use) an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)
5. You meet ONE of the following:
 - a. You are pregnant, breastfeeding, or trying to become pregnant
 - b. You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

F. If you have non-radiographic axial spondyloarthritis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Cimzia concurrently (at the same time) with another systemic biologic (such as Taltz [ixekizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of non-radiographic axial spondyloarthritis
4. You have tried or have a contraindication to (harmful for you to use) an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)
5. You meet ONE of the following:
 - a. You were previously stable on another biologic and are switching to Cimzia
 - b. You have C-reactive protein (CRP: a measure of how much inflammation is in the body) levels above the upper limit of normal
 - c. You have sacroiliitis (a type of inflammation where lower spine and pelvis connect) on magnetic resonance imaging (MRI: a type of imaging lab)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CERTOLIZUMAB PEGOL

INITIAL CRITERIA (CONTINUED)

- G. If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 3. You have psoriasis covering 3 percent or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, face, or scalp
 4. You will NOT use Cimzia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
 5. You meet ONE of the following:
 - a. You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis
 - b. You have a contraindication (harmful for you to use) or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) and PUVA (phototherapy) for the treatment of plaque psoriasis
 - c. You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication
 6. You meet ONE of the following:
 - a. You are pregnant, breastfeeding, or trying to become pregnant
 - b. You have tried or have a contraindication to TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CERTOLIZUMAB PEGOL

INITIAL CRITERIA (CONTINUED)

H. If you have moderate to severe Crohn's disease, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
3. You will NOT use Cimzia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
4. You meet ONE of the following:
 - a. You are pregnant, breastfeeding, or trying to become pregnant
 - b. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CERTOLIZUMAB PEGOL

RENEWAL CRITERIA

Our guideline named **CERTOLIZUMAB PEGOL (Cimzia)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Polyarticular juvenile idiopathic arthritis (pJIA: a type of joint condition)
3. Psoriatic arthritis (PsA: a type of skin and joint condition)
4. Ankylosing spondylitis (AS: a type of joint condition)
5. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
6. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
7. Moderate to severe Crohn's disease (CD: a type of bowel disorder)

B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Cimzia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
3. You meet ONE of the following:
 - a. You are pregnant, breastfeeding, or trying to become pregnant
 - b. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - c. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CERTOLIZUMAB PEGOL

RENEWAL CRITERIA (CONTINUED)

C. If you have polyarticular juvenile idiopathic arthritis, renewal also requires:

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Cimzia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
3. You meet ONE of the following:
 - a. You are pregnant, breastfeeding, or trying to become pregnant
 - b. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz IR (tofacitinib immediate-release), Rinvoq (upadacitinib)

D. If you have psoriatic arthritis, renewal also requires:

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Cimzia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
3. You meet ONE of the following:
 - a. You are pregnant, breastfeeding, or trying to become pregnant
 - b. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CERTOLIZUMAB PEGOL

RENEWAL CRITERIA (CONTINUED)

E. If you have ankylosing spondylitis, renewal also requires:

1. You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
2. You will NOT use Cimzia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
3. You meet ONE of the following:
 - a. You are pregnant, breastfeeding, or trying to become pregnant
 - b. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

F. If you have non-radiographic axial spondyloarthritis, renewal also requires:

1. You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
2. You will NOT use Cimzia concurrently (at the same time) with another systemic biologic (such as Taltz [ixekizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of non-radiographic axial spondyloarthritis

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CERTOLIZUMAB PEGOL

RENEWAL CRITERIA (CONTINUED)

G. If you have moderate to severe plaque psoriasis, renewal also requires:

1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50 percent or more while on therapy
2. You will NOT use Cimzia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
3. You meet ONE of the following:
 - a. You are pregnant, breastfeeding, or trying to become pregnant
 - b. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)

H. If you have moderate to severe Crohn's disease, renewal also requires:

1. You will NOT use Cimzia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
2. You meet ONE of the following:
 - a. You are pregnant, breastfeeding, or trying to become pregnant
 - b. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 05/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CETUXIMAB

Generic	Brand				
CETUXIMAB	ERBITUX				

GUIDELINES FOR USE

Our guideline named **CETUXIMAB (Erbix)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN: a type of head and neck cancer that has spread from where it started to nearby tissue or lymph nodes)
 2. Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck (SCCHN: a type of head and neck cancer that has returned or has spread to other parts of the body)
 3. Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN: a type of head and neck cancer that has returned or has spread to other parts of the body)
 4. Metastatic colorectal cancer (mCRC: a type of digestive system cancer that has spread to other parts of the body)
- B. **If you have locally or regionally advanced squamous cell carcinoma of the head and neck, approval also requires:**
1. Erbitux will be used in combination with radiation therapy
- C. **If you have recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck, approval also requires:**
1. Erbitux will be used in combination with platinum-based therapy (such as cisplatin, carboplatin, oxaliplatin) and 5-fluorouracil (5-FU)
- D. **If you have recurrent or metastatic squamous cell carcinoma of the head and neck, approval also requires:**
1. You have previously failed platinum-based therapy (such as cisplatin, carboplatin, oxaliplatin)

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CETUXIMAB

GUIDELINES FOR USE (CONTINUED)

- E. If you have metastatic colorectal cancer (mCRC), approval also requires ONE of the following:**
1. Erbitux will be used in combination with Krazati (adagrasib)
 2. Your cancer is KRAS wild-type (a type of gene with no mutation), epidermal growth factor receptor (EGFR)-expressing, as determined by a Food and Drug Administration (FDA)-approved test, AND you meet ONE of the following:
 - a. Erbitux will be used in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin)
 - b. Erbitux will be used in combination with irinotecan and you are refractory (resistant) to irinotecan-based chemotherapy
 - c. You have failed oxaliplatin-based and irinotecan-based chemotherapy OR you are intolerant to irinotecan
 3. Your cancer has a BRAF V600E mutation (abnormal change in a type of gene), as determined by a Food and Drug Administration (FDA)-approved test and you meet ONE of the following:
 - a. Erbitux will be used in combination with Braftovi (encorafenib) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin)
 - b. Erbitux will be used in combination with Braftovi (encorafenib) after prior therapy, and you are 18 years of age or older

Effective: 01/17/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CHENODIOL

Generic	Brand			
CHENODIOL	CHENODAL, CTEXLI			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **CHENODIOL (Chenodal, Ctexli)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Cerebrotendinous xanthomatosis (a type of genetic disorder)
2. Radiolucent gallstone(s) (hardened deposits of bile in your gall bladder that are barely seen on X-rays [a type of imaging test])

B. **If you have radiolucent gallstone(s), approval also requires:**

1. You have tried or have a contraindication to (harmful for you to use) ursodiol
2. You have NOT previously received chenodiol therapy for more than a total of 24 months
3. Your request is for Chenodal

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CHENODIOL

RENEWAL CRITERIA

Our guideline named **CHENODIOL (Chenodal, Ctexli)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Radiolucent gallstone(s) (hardened deposits of bile in your gall bladder that are barely seen on X-rays [a type of imaging test])
 - 2. Cerebrotendinous xanthomatosis (a type of genetic disorder)
- B. **If you have radiolucent gallstone(s), renewal also requires:**
 - 1. You have NOT previously received chenodiol therapy for more than a total of 24 months
 - 2. You have NOT experienced complete gallstone dissolution (breaking down) or zero gallstone dissolution, as seen on imaging (such as oral cholecystogram, ultrasonogram [types of imaging tests]) after 12 months of therapy
 - 3. You HAVE experienced partial gallstone dissolution, as seen on imaging (such as oral cholecystogram, ultrasonogram) after 12 months of therapy
 - 4. Your request is for Chenodal
- C. **If you have cerebrotendinous xanthomatosis, renewal also requires you have experienced improvement as defined by ONE of the following:**
 - 1. Normalization of elevated (high levels of) serum (blood) or urine bile alcohols (a type of bile acid)
 - 2. Normalization of elevated serum cholestanol (a type of fat) levels
 - 3. Improvement in neurologic and psychiatric symptoms (dementia [a type of memory disorder], pyramidal tract [a nerve pathway in the brain] and cerebellar [brain] signs)

Effective: 04/07/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CHOLIC ACID

Generic	Brand			
CHOLIC ACID	CHOLBAM			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **CHOLIC ACID (Cholbam)** requires the following rule(s) be met for approval:

- A. You show signs of liver disease, steatorrhea (excess fat in feces), or complications from your body not being able to absorb fat-soluble vitamins that occur from ONE of the following conditions:
1. Bile acid synthesis disorders (your body has a problem making bile acid)
 2. Peroxisomal disorders (Zellweger spectrum disorders) (problems with a part of a cell that contains enzymes)

RENEWAL CRITERIA

Our guideline named **CHOLIC ACID (Cholbam)** requires the following rule(s) be met for renewal:

- A. You have experienced an improvement in your liver function as defined by at least ONE of the following criteria:
1. ALT (alanine aminotransferase) or AST (aspartate transaminase) (types of liver enzymes) values have been lowered to less than 50 U/L or baseline levels reduced by 80%
 2. Total bilirubin values reduced to less than 1 mg/dL
 3. No evidence of cholestasis (condition where bile cannot flow from liver) on liver biopsy

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CLADRIBINE

Generic	Brand			
CLADRIBINE	MAVENCLAD			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **CLADRIBINE (Mavenclad)** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: disease where body attacks its own nerves and returns after having no symptoms). This includes relapsing- remitting MS [RRMS], active secondary progressive MS [SPMS], etc.
- B. You are 18 years of age or older

RENEWAL CRITERIA

Our guideline named **CLADRIBINE (Mavenclad)** requires the following rule(s) be met for renewal:

- A. You have a relapsing form of multiple sclerosis (MS: disease where body attacks its own nerves and returns after having no symptoms). This includes relapsing- remitting MS [RRMS], active secondary progressive MS [SPMS], etc.
- B. You have demonstrated a clinical benefit compared to pre-treatment baseline (before you started therapy)
- C. You do not have lymphopenia (low amount of a type of white blood cell called lymphocyte)
- D. You have not received a total of two years of treatment with Mavenclad

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CLASCOTERONE

Generic	Brand				
CLASCOTERONE	WINLEVI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **CLASCOTERONE (Winlevi)** requires the following rule(s) be met for approval:

- A. You have acne vulgaris (skin condition in which hair follicles become plugged with oil and dead skin cells)
- B. You are 12 years of age or older
- C. Therapy is prescribed by or given in consultation with a dermatologist (skin doctor)
- D. You have previously tried BOTH of the following unless there is a medical reason why you cannot (contraindication):
 - 1. ONE oral acne agent (such as oral antibiotics or oral isotretinoin)
 - 2. TWO topical acne agents (such as topical retinoids, topical antibiotics, benzoyl peroxide)

RENEWAL CRITERIA

Our guideline named **CLASCOTERONE (Winlevi)** requires the following rule(s) be met for approval:

- A. You have acne vulgaris (skin condition in which hair follicles become plugged with oil and dead skin cells)
- B. You had improvement of acne lesions

Effective: 01/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CLOBAZAM-SYMPAZAN

Generic	Brand			
CLOBAZAM	SYMPAZAN			

GUIDELINES FOR USE

Our guideline named **CLOBAZAM-SYMPAZAN** requires the following rule(s) be met for approval:

- A. You have Lennox-Gastaut Syndrome (a type of seizure disorder in young children)
- B. You are 2 years of age or older
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
- D. Sympazan will be used for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome
- E. You are unable to take tablets or suspension
- F. You had a trial of or contraindication (harmful for) to generic/branded clobazam products (Onfi)

Effective: 07/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

COBIMETINIB

Generic	Brand			
COBIMETINIB FUMARATE	COTELLIC			

GUIDELINES FOR USE

Our guideline named **COBIMETINIB (Cotellic)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Unresectable or metastatic melanoma (skin cancer that has spread or cannot be completely removed with surgery)
 - 2. Histiocytic neoplasms (a type of white blood cell disorder)
- B. **If you have unresectable or metastatic melanoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Your tumor has a BRAF V600E OR V600K mutation (a type of gene mutation)
 - 3. Cobimetinib will be used in combination with vemurafenib (Zelboraf)
- C. **If you have histiocytic neoplasms, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Cobimetinib will be used as a single agent

Effective: 11/21/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

COLLAGENASE TOPICAL

Generic	Brand				
COLLAGENASE CLOSTRIDIUM HIST.	SANTYL				

GUIDELINES FOR USE

Our guideline named **COLLAGENASE TOPICAL (Santyl)** requires the following rule(s) be met for approval:

- A. You have chronic dermal (skin) ulcer(s) or severe burn(s) that require(s) debridement (removal of damaged tissue from a wound)
- B. **If the requested quantity is more than one tube (30 grams), approval also requires:**
 - 1. The higher quantity is based on the size of your wound (width/length) and the anticipated duration of therapy, using the Santyl dosing calculator (<https://santyl.com/hcp/dosing>)

Effective: 04/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CONCIZUMAB-MTCI

Generic	Brand				
CONCIZUMAB-MTCI	ALHEMO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **CONCIZUMAB-MTCI (Alhemo)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Hemophilia A (congenital factor VIII deficiency: a type of bleeding disorder)
 - 2. Hemophilia B (congenital factor IX deficiency: a type of bleeding disorder)
- B. **If you have hemophilia A (congenital factor VIII deficiency), approval also requires:**
 - 1. You are 12 years of age or older
 - 2. Your hemophilia has FVIII inhibitors (a type of protein)
 - 3. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
 - 4. Alhemo will be used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes
 - 5. You will NOT use Alhemo concurrently (at the same time) with another non-factor prophylaxis therapy (such as Hemlibra [emicizumab-kxwh], Hympavzi [marstacimab-hncq])
- C. **If you have hemophilia B (congenital factor IX deficiency), approval also requires:**
 - 1. You are 12 years of age or older
 - 2. Your hemophilia has FIX inhibitors (a type of protein)
 - 3. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
 - 4. Alhemo will be used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes
 - 5. You will NOT use Alhemo concurrently (at the same time) with another non-factor prophylaxis therapy (such as Hemlibra [emicizumab-kxwh], Hympavzi [marstacimab-hncq])

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CONCIZUMAB-MTCI

RENEWAL CRITERIA

Our guideline named **CONCIZUMAB-MTCI (Alhemo)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Hemophilia A (congenital factor VIII deficiency: a type of bleeding disorder)
 - 2. Hemophilia B (congenital factor IX deficiency: a type of bleeding disorder)
- B. **If you have hemophilia A (congenital factor VIII deficiency), renewal also requires:**
 - 1. Your hemophilia has FVIII inhibitors (a type of protein)
 - 2. You will NOT use Alhemo concurrently (at the same time) with another non-factor prophylaxis therapy (such as Hemlibra [emicizumab-kxwh], Hympavzi [marstacimab-hncq])
 - 3. You have shown a clinical benefit compared to baseline (before starting Alhemo)
- C. **If you have hemophilia B (congenital factor IX deficiency), renewal also requires:**
 - 1. Your hemophilia has FIX inhibitors (a type of protein)
 - 2. You will NOT use Alhemo concurrently (at the same time) with another non-factor prophylaxis therapy (such as Hemlibra [emicizumab-kxwh], Hympavzi [marstacimab-hncq])
 - 3. You have shown a clinical benefit compared to baseline (before starting Alhemo)

Effective: 02/10/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CONTINUOUS GLUCOSE MONITORS STEP OVERRIDE

Generic	Brand				
CONTINUOUS BLOOD-GLUCOSE METER/RECEIVER, FLASH GLUCOSE SCANNING READER	DEXCOM G6, G7 RECEIVER, FREESTYLE LIBRE 2, 3, 10, 14 READER				
BLOOD-GLUCOSE TRANSMITTER	DEXCOM G6 TRANSMITTER				
BLOOD-GLUCOSE SENSOR	DEXCOM G6, G7 SENSOR, FREESTYLE LIBRE 2, 3 PLUS SENSOR				
FLASH GLUCOSE SENSOR, BLOOD GLUCOSE SENSOR	FREESTYLE LIBRE 2, 3, 10, 14 SENSOR				

GUIDELINES FOR USE

Our guideline named **CONTINUOUS GLUCOSE MONITORS STEP OVERRIDE** requires the following rule(s) be met for approval:

A. You meet ONE of the following:

1. You are being treated with insulin (such as Humalog [insulin lispro], Lantus [insulin glargine])
2. You have a clinical need that cannot be managed with self-monitoring of blood glucose (such as frequent hypoglycemia [low blood sugar], hypoglycemic unawareness, unable to achieve control of diabetes [a disorder with high blood sugar])
3. You are currently stable on the requested agent

Effective: 10/21/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CONTINUOUS GLUCOSE MONITORS - STAND-ALONE

Generic	Brand				
CONTINUOUS BLOOD-GLUCOSE METER/RECEIVER	DEXCOM G4, DEXCOM G5				
BLOOD-GLUCOSE TRANSMITTER	DEXCOM G4, DEXCOM G5, EVERSENSE SMART TRANSMITTER, EVERSENSE E3 SMART TRANSMITTER, EVERSENSE 365 TRANSMITTER, GUARDIAN CONNECT TRANSMITTER, GUARDIAN LINK 3 TRANSMITTER, GUARDIAN 4 TRANSMITTER				
BLOOD-GLUCOSE SENSOR	DEXCOM G5-G4 SENSOR, DEXCOM G4 SENSOR, GUARDIAN SENSOR 3, GUARDIAN 4 GLUCOSE SENSOR, EVERSENSE SENSOR- HOLDER, EVERSENSE E3 SENSOR-HLDR, EVERSENSE 365 SENSOR				

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CONTINUOUS GLUCOSE MONITORS - STAND-ALONE

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **CONTINUOUS GLUCOSE MONITORS - STAND-ALONE** requires the following rule(s) be met for approval:

- A. You have type 1, type 2, or gestational (during pregnancy) diabetes (a disorder with high blood sugar)
- B. You have tried or have a contraindication to (harmful for you to use) Dexcom G6, Dexcom G7, or Freestyle Libre, OR all three products are not compatible with your current insulin pump
- C. You meet ONE of the following:
 - 1. You are being treated with insulin (such as Humalog [insulin lispro], Lantus [insulin glargine])
 - 2. You have a clinical need that cannot be managed with self-monitoring of blood glucose (such as frequent hypoglycemia [low blood sugar], hypoglycemic unawareness, unable to achieve control of diabetes)
- D. **If you are requesting Dexcom G4 or Dexcom G5 system (meter, sensor, transmitter), approval also requires:**
 - 1. You are 2 years of age or older
- E. **If you are requesting Guardian Connect (sensor, transmitter), approval also requires:**
 - 1. You are 14 to 75 years of age
- F. **If you are requesting Guardian 3 (sensor, link transmitter) or Guardian 4 (sensor, transmitter), approval also requires:**
 - 1. You are 7 years of age or older
- G. **If you are requesting Eversense (sensor, smart transmitter), Eversense E3 (sensor, smart transmitter) or Eversense 365 (sensor, transmitter), approval also requires:**
 - 1. You are 18 years of age or older

RENEWAL CRITERIA

Our guideline named **CONTINUOUS GLUCOSE MONITORS - STAND-ALONE** requires the following rule(s) be met for renewal:

- A. You continue to require continuous glucose monitoring

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CORTICOTROPIN

Generic	Brand				
CORTICOTROPIN	ACTHAR , ACTHAR SELFJECT, CORTROPHIN				

GUIDELINES FOR USE

Our guideline named **CORTICOTROPIN (Acthar, Cortrophin)** requires the following rule(s) be met for approval:

- A. You have infantile spasms (a type of seizure disorder in infancy and childhood)
- B. You are less than 2 years of age
- C. Your request is for Acthar or Cortrophin vial

Acthar or Cortrophin vial will not be approved for any other indication other than infantile spasms. Acthar or Cortrophin have not demonstrated proven benefits or advantage over synthetic steroids in the treatment of other indications.

Acthar pre-filled SelfJect or Cortrophin pre-filled syringe will not be approved for infantile spasms (not Food and Drug Administration [FDA]-indicated) or any other indication. Acthar or Cortrophin have not demonstrated proven benefits or advantage over synthetic steroids in the treatment of other indications.

Effective: 04/07/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CRINECERFONT

Generic	Brand				
CRINECERFONT	CRENESSITY				

GUIDELINES FOR USE

Our guideline named **CRINECERFONT (Crenessity)** requires the following rule(s) be met for approval:

- A. You have classic congenital adrenal hyperplasia (CAH: a type of rare genetic condition)
- B. You are 4 years of age or older
- C. Crenessity will be used as adjunctive (additional) treatment with glucocorticoid replacement therapy
- D. If the request is for Crenessity solution, approval also requires that you are unable to swallow Crenessity capsules

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CRIZOTINIB

Generic	Brand			
CRIZOTINIB	XALKORI			

GUIDELINES FOR USE

Our guideline named **CRIZOTINIB (Xalkori)** requires the following rule(s) be met for approval:

You have ONE of the following:

Metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to other parts of the body)

Relapsed (disease that has returned) or refractory (disease does not respond to treatment), systemic anaplastic large cell lymphoma (ALCL: a type of blood cell cancer)

Unresectable (unable to remove by surgery), recurrent, or refractory (disease does not respond to treatment) inflammatory myofibroblastic tumor (IMT: a rare type of tumor)

If you have metastatic non-small cell lung cancer, approval also requires:

You are 18 years of age or older

Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme)-positive or ROS1 (a type of gene)-positive as detected by a Food and Drug Administration (FDA)-approved test

If you have relapsed or refractory systemic anaplastic large cell lymphoma, approval also requires:

You are 1 year of age or older

Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme)-positive

If you have unresectable, recurrent, or refractory inflammatory myofibroblastic tumor, approval also requires:

You are 1 year of age or older

Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme)-positive

If the request is for Xalkori oral pellets, approval also requires:

You are unable to swallow capsules

Effective: 01/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CYCLOSPORINE - VERKAZIA

Generic	Brand				
CYCLOSPORINE	VERKAZIA				

GUIDELINES FOR USE

Our guideline named **CYCLOSPORINE - VERKAZIA** requires the following rule(s) be met for approval:

- B. You have vernal keratoconjunctivitis (allergic eye disease)
- C. You have tried or have a contraindication to (harmful for you to use) TWO ophthalmic dual-acting mast cell stabilizer/antihistamines (such as ketotifen) or mast cell stabilizers (such as cromolyn)

Effective: 01/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CYCLOSPORINE - VEVYE

Generic	Brand				
CYCLOSPORINE	VEVYE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **CYCLOSPORINE - VEVYE** requires the following rule(s) be met for approval:

- A. You have dry eye disease (DED: a type of eye condition)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with an ophthalmologist or optometrist (types of eye doctors)
- D. You have ONE positive diagnostic test (such as tear breakup time, tear film osmolarity, ocular surface staining, Schirmer test)
- E. You have tried or have a contraindication to (harmful for you to use) ONE ocular lubricant (such as carboxymethylcellulose [such as Refresh, Celluvise, TheraTears], polyvinyl alcohol [such as LiquiTears, Refresh Classic], or a wetting agent [such as Systane, Lacri-Lube])
- F. You have tried or have a contraindication to TWO of the following preferred medications: Miebo (perfluorohexyloctane), Restasis (cyclosporine), Xiidra (lifitegrast), Tyrvaya (varenicline)

RENEWAL CRITERIA

Our guideline named **CYCLOSPORINE - VEVYE** requires the following rule(s) be met for renewal:

- A. You have dry eye disease (DED: a type of eye condition)
- B. You have demonstrated improvement of your dry eye disease (the treatment is working)

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CYSTEAMINE BITARTRATE

Generic	Brand			
CYSTEAMINE BITARTRATE	PROCYSBI			

GUIDELINES FOR USE

Our guideline named **CYSTEAMINE BITARTRATE (Procysbi)** requires the following rule(s) be met for approval:

- A. You have nephropathic cystinosis (rare genetic, metabolic disease which results in an abnormal accumulation of a protein known as cysteine)
- B. You are 1 year of age or older
- C. You have previously tried an immediate-release formulation of cysteamine bitartrate such as Cystagon

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CYSTEAMINE HYDROCHLORIDE

Generic	Brand			
CYSTEAMINE HCL	CYSTARAN			

GUIDELINES FOR USE

Our guideline named **CYSTEAMINE HYDROCHLORIDE (Cystaran/Cystadrops)** requires the following rule(s) be met for approval:

- A. You have cystinosis (a type of genetic disorder where a substance called cysteine builds up in body organs)
- B. You require treatment for corneal cystine crystal accumulation or deposits (build up of cysteine in the eye)

Effective: 10/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DABIGATRAN

Generic	Brand				
DABIGATRAN ETEXILATE MESELATE	PRADAXA				

GUIDELINES FOR USE

Our guideline named **DABIGATRAN (Pradaxa)** requires the following rule(s) be met for approval:

- A. The request is for ONE of the following:
 - 1. Treatment of a venous thromboembolic event (VTE: a type of blood clot disease in your veins)
 - 2. Reduce the risk of venous thromboembolic event recurrence (happening again)
- B. You meet ONE of the following:
 - 1. You are 3 months to 7 years of age
 - 2. You are 8 to 11 years of age AND are unable to swallow dabigatran (Pradaxa) capsules
- C. You have tried or have a contraindication (harmful for) to rivaroxaban (Xarelto) suspension
- D. **If the request is for the treatment of a venous thromboembolic event, approval also requires:**
 - 1. You have been treated with parenteral anticoagulation agent (type of medication) for at least 5 days
- E. **If the request is to reduce the risk of venous thromboembolic event recurrence, approval also requires:**
 - 1. You have been previously treated

Effective: 07/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DABRAFENIB

Generic	Brand			
DABRAFENIB MESYLATE	TAFINLAR			

GUIDELINES FOR USE

Our guideline named **DABRAFENIB (Tafinlar)** requires the following rule(s) be met for approval:

- A. You have **ONE** of the following diagnoses:
1. Unresectable or metastatic melanoma (skin cancer that cannot be completely removed by surgery or has spread to other parts of the body)
 2. Melanoma (a type of skin cancer)
 3. Metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
 4. Locally advanced or metastatic anaplastic thyroid cancer (ATC: a type of thyroid cancer that has spread from where it started to nearby tissue or lymph nodes, or it has spread to other parts of the body)
 5. Unresectable or metastatic solid tumor (tumor that cannot be completely removed by surgery or has spread to other parts of the body)
 6. Low-grade glioma (LGG: a type of brain cancer)
- B. **If you have unresectable or metastatic melanoma, approval also requires ONE of the following:**
1. You have a BRAF V600E mutation (type of gene mutation) as detected by an FDA (Food and Drug Administration)-approved test AND the requested medication will be used as a single agent (by itself)
 2. You have a BRAF V600E or V600K mutation (types of gene mutations) as detected by an FDA (Food and Drug Administration)-approved test AND the requested medication will be used in combination with Mekinist (trametinib)
- C. **If you have melanoma, approval also requires:**
1. You have a BRAF V600E or V600K mutation (types of gene mutations) as detected by an FDA (Food and Drug Administration)-approved test
 2. The requested medication has not previously been used for more than one year
 3. The requested medication will be used in combination with Mekinist (trametinib) for adjuvant (additional) treatment
 4. There is involvement of lymph node(s) following complete resection (removal by surgery)
- D. **If you have metastatic non-small cell lung cancer, approval also requires:**
1. You have a BRAF V600E mutation (type of gene mutation) as detected by an FDA (Food and Drug Administration)-approved test
 2. The requested medication will be used in combination with Mekinist (trametinib)

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DABRAFENIB

GUIDELINES FOR USE (CONTINUED)

- E. If you have locally advanced or metastatic anaplastic thyroid cancer, approval also requires:**
 - 1. You have a BRAF V600E mutation (type of gene mutation)
 - 2. The requested medication will be used in combination with Mekinist (trametinib)
 - 3. You have no satisfactory locoregional (restricted to a localized region of the body) treatment options available
- F. If you have an unresectable or metastatic solid tumor, approval also requires:**
 - 1. You are 1 year of age or older
 - 2. You have a BRAF V600E mutation (type of gene mutation)
 - 3. The requested medication will be used in combination with Mekinist (trametinib)
 - 4. Your disease has progressed following prior treatment and have no satisfactory alternative treatment options
- G. If you have low-grade glioma, approval also requires:**
 - 1. You are 1 to 17 years of age
 - 2. You have a BRAF V600E mutation (type of gene mutation)
 - 3. The requested medication will be used in combination with Mekinist (trametinib)
 - 4. You require systemic therapy (treatment that targets the entire body)
- H. If the request is for the tablet for oral suspension, approval also requires:**
 - 1. You cannot swallow Tafinlar (dabrafenib) capsules

Effective: 10/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DACOMITINIB

Generic	Brand			
DACOMITINIB	VIZIMPRO			

GUIDELINES FOR USE

Our guideline named **DACOMITINIB (Vizimpro)** requires the following rule(s) be met for approval:

- A. You have metastatic non-small cell lung cancer (type of cancer that has spread) to other parts of the body)
- B. You have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations (types of gene mutations) as detected by an FDA (Food and Drug Administration)-approved test
- C. Vizimpro will be used as first-line treatment
- D. You will NOT be using Vizimpro concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva [erlotinib], Tagrisso [osimertinib], Iressa [gefitinib])

Effective: 07/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DALFAMPRIDINE

Generic	Brand			
DALFAMPRIDINE	AMPYRA, DALFAMPRIDINE ER			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DALFAMPRIDINE (Ampyra)** requires the following rule(s) be met for approval:

- A. You have multiple sclerosis (MS: a type of nerve disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
- D. You have symptoms of a walking disability such as mild to moderate bilateral (both sides) lower extremity weakness or unilateral (one side) weakness plus lower extremity or truncal ataxia (impaired balance or coordination)

RENEWAL CRITERIA

Our guideline named **DALFAMPRIDINE (Ampyra)** requires the following rule(s) be met for renewal:

- A. You have multiple sclerosis (MS: a type of nerve disorder)
- B. You have experienced or maintained at least a 15% improvement in walking ability

Effective: 08/29/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DANICOPAN

Generic	Brand				
DANICOPAN	VOYDEYA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DANICOPAN (Voydeya)** requires the following rule(s) be met for approval:

- A. You have paroxysmal nocturnal hemoglobinuria (PNH: a rare blood disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
- D. You will use Voydeya for the treatment of extravascular hemolysis (EVH: break down of blood cells outside of your blood stream)
- E. You have anemia (a hemoglobin [Hgb: a type of protein in red blood cells] level less than or equal to 9.5 g/dL) with an absolute reticulocyte (immature red blood cell) count of at least $120 \times 10^9/L$
- F. You have flow cytometry (a type of lab test) demonstrating at least 2 different GPI-protein deficiencies (you are missing a certain type of protein, such as CD55, CD59) on at least 2 cell lineages (types of cells, such as erythrocytes [red blood cells], granulocytes [a type of white blood cell]) AND a PNH granulocyte clone size of at least 10 percent
- G. You have tried or have a contraindication to (harmful for you to use) Fabhalta (iptacopan)
- H. You will use Voydeya concurrently (at the same time) with C5 complement inhibitor therapy (such as Ultomiris [ravulizumab-cwvz], Soliris [eculizumab], Piasky [crovalimab])
- I. You will NOT use Voydeya concurrently (at the same time) with C3 complement inhibitor therapy (such as Empaveli [pegcetacoplan]) or Factor B inhibitor therapy (such as Fabhalta [iptacopan])

RENEWAL CRITERIA

Our guideline named **DANICOPAN (Voydeya)** requires the following rule(s) be met for renewal:

- A. You have paroxysmal nocturnal hemoglobinuria (PNH: a rare blood disorder)
- B. You have experienced a clinical benefit (such as an improvement in hemoglobin [Hgb: a type of protein in red blood cells] levels) compared to baseline (before you started treatment)
- C. You will use Voydeya concurrently (at the same time) with C5 complement inhibitor therapy (such as Ultomiris [ravulizumab-cwvz], Soliris [eculizumab], Piasky [crovalimab])
- D. You will NOT use Voydeya concurrently (at the same time) with C3 complement inhibitor therapy (such as Empaveli [pegcetacoplan]) or Factor B inhibitor therapy (such as Fabhalta [iptacopan])

Effective: 10/01/24

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DAPRODUSTAT

Generic	Brand				
DAPRODUSTAT	JESDUVROQ				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DAPRODUSTAT (Jesduvroq)** requires the following rule(s) be met for approval:

- A. You have a diagnosis of anemia (low amount of healthy red blood cells) due to chronic kidney disease (CKD: long-term kidney disease)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a nephrologist (a type of kidney doctor)
- D. You have been receiving dialysis (process of removing excess water, toxins from the blood) for at least 4 months
- E. You have an estimated glomerular filtration rate (eGFR: a tool for evaluating kidney function) less than 60 mL/min/1.73m(2), confirming stage 3, 4, or 5 chronic kidney disease (CKD)
- F. You will NOT use Jesduvroq concurrently (at the same time) with other hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) (such as Vafseo [vadadustat])
- G. **If you are NOT currently being treated with an erythropoiesis-stimulating agent (ESA: drugs used to treat anemia such as Epogen or Procrit), approval also requires:**
 - 1. You have a hemoglobin level (a type of blood test) of less than 11 g/dL
- H. **If you are currently being treated with an erythropoiesis-stimulating agent (ESA: drugs used to treat anemia such as Epogen or Procrit), approval also requires:**
 - 1. You have a hemoglobin level (a type of blood test) of less than 12 g/dL
 - 2. You will discontinue ESA therapy before starting Jesduvroq

RENEWAL CRITERIA

Our guideline named **DAPRODUSTAT (Jesduvroq)** requires the following rule(s) be met for renewal:

- A. You have a diagnosis of anemia (low amount of healthy red blood cells) due to chronic kidney disease (CKD: long-term kidney disease)
- B. You meet ONE of the following:
 - 1. You have a hemoglobin level (a type of blood test) of at least 10 g/dL
 - 2. Your hemoglobin level has increased by at least 2 g/dL from your baseline level

Effective: 08/05/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DARBEPOETIN ALFA

Generic	Brand				
DARBEPOETIN ALFA IN POLYSORBAT	ARANESP				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DARBEPOETIN ALFA (Aranesp)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Anemia (low amount of healthy red blood cells) due to chronic kidney disease (CKD)
 2. Anemia due to the effect of concomitantly administered (given at the same time) cancer chemotherapy
 3. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa
- B. **If you have anemia due to chronic kidney disease, approval also requires:**
1. You have tried the preferred medication: Retacrit (epoetin alfa-epbx)
 2. Your hemoglobin level (a type of blood test) is less than 10g/dL
- C. **If you have anemia due to the effect of concomitantly administered cancer chemotherapy, approval also requires:**
1. You have tried the preferred medication: Retacrit (epoetin alfa-epbx)
 2. Your hemoglobin level is less than 11g/dL OR your hemoglobin level has decreased at least 2g/dL below your baseline level
- D. **If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, approval also requires:**
1. You have tried the preferred medication: Retacrit (epoetin alfa-epbx)
 2. You have tried or have a contraindication to (harmful for you to use) a lower ribavirin dose
 3. Your hemoglobin level is less than 10g/dL

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DARBEPOETIN ALFA

RENEWAL CRITERIA

Our guideline named **DARBEPOETIN ALFA (Aranesp)** requires the following rule(s) be met for renewal:

- A. You have **ONE** of the following:
 - 1. Anemia (low amount of healthy red blood cells) due to chronic kidney disease
 - 2. Anemia due to the effect of concomitantly administered (given at the same time) cancer chemotherapy
 - 3. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa
- B. **If you are an adult (you are 18 years of age or older) with anemia due to chronic kidney disease, renewal also requires ONE of the following:**
 - 1. Your hemoglobin level (a type of blood test) is less than 10g/dL if you are not on dialysis (process of removing excess water, toxins from the blood)
 - 2. Your hemoglobin level is less than 11g/dL if you are on dialysis
 - 3. Your hemoglobin has reached 10g/dL (if you are not on dialysis) and your dose is being or has been reduced or interrupted to decrease the need for blood transfusions
 - 4. Your hemoglobin has reached 11g/dL (if you are on dialysis) and your dose is being or has been reduced or interrupted to decrease the need for blood transfusions
- C. **If you are a pediatric patient (you are less than 18 years of age) with anemia due to chronic kidney disease, renewal also requires ONE of the following:**
 - 1. Your hemoglobin level is less than 10g/dL
 - 2. Your hemoglobin level has approached or exceeds 12g/dL and your dose is being or has been reduced or interrupted to decrease the need for blood transfusions
- D. **If you have anemia due to the effect of concomitantly administered cancer chemotherapy, renewal also requires:**
 - 1. Your hemoglobin level is between 10g/dL and 12g/dL
- E. **If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, renewal also requires:**
 - 1. Your hemoglobin level is between 10g/dL and 12g/dL

Effective: 06/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DARIDOREXANT

Generic	Brand				
DARIDOREXANT HCL	QUVIVIQ				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DARIDOREXANT (Quviviq)** requires the following rule(s) be met for approval:

- A. You have insomnia (a type of sleep condition)
- B. You are 18 years of age or older
- C. You have premature awakening (waking up too early) and/or abnormal sleep onset delay (cannot fall asleep) lasting 30 minutes or longer, occurring 3 or more times weekly for the last month for acute (short-term) insomnia or for at least 3 months for chronic (long-term) insomnia
- D. You have daytime impairment despite adequate time attempting to sleep and treatment of any treatable causes
- E. You are NOT using Quviviq at the same time with Z hypnotics (such as eszopiclone, zaleplon, zolpidem) or benzodiazepines (such as estazolam, temazepam, triazolam) for sleep
- F. You do NOT have narcolepsy (a type of sleep condition)
- G. You had a trial of or contraindication (harmful for) to TWO generic insomnia medications (such as eszopiclone, zaleplon, zolpidem) AND Belsomra

RENEWAL CRITERIA

Our guideline named **DARIDOREXANT (Quviviq)** requires the following rule(s) be met for renewal:

- A. You have insomnia (a type of sleep condition)
- B. You have demonstrated improvement of insomnia symptoms but are not currently a candidate for discontinuation
- C. You are NOT using Quviviq at the same time with Z hypnotics (such as eszopiclone, zaleplon, zolpidem) or benzodiazepines (such as estazolam, temazepam, triazolam) for sleep

Effective: 05/09/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DAROLUTAMIDE

Generic	Brand			
DAROLUTAMIDE	NUBEQA			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DAROLUTAMIDE (Nubeqa)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Non-metastatic castration resistant prostate cancer (nmCRPC: prostate cancer that has not spread to other parts of the body and does not respond to hormone therapy)
 - 2. Metastatic hormone-sensitive prostate cancer (mHSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)
- B. You meet ONE of the following:
 - 1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
 - 2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
 - 3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)
- C. **If you have non-metastatic castration resistant prostate cancer, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have high risk prostate cancer (rapidly increasing prostate specific antigen [PSA: lab result that may indicate prostate cancer] levels)
- D. **If you have metastatic hormone-sensitive prostate cancer, approval also requires:**
 - 1. The requested medication will be used in combination with docetaxel

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DAROLUTAMIDE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **DAROLUTAMIDE (Nubeqa)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
 - 1. Non-metastatic castration resistant prostate cancer (nmCRPC: prostate cancer that has not spread to other parts of the body and does not respond to hormone therapy)
 - 2. Metastatic hormone-sensitive prostate cancer (mHSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)
- B. You meet ONE of the following:
 - 1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
 - 2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
 - 3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)
- C. **If you have metastatic hormone-sensitive prostate cancer, approval also requires:**
 - 1. The requested medication will be used in combination with docetaxel

Effective: 01/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DASATINIB

Generic	Brand			
DASATINIB	SPRYCEL			

GUIDELINES FOR USE

Our guideline named **DASATINIB (Sprycel)** requires the following rule(s) be met for approval:

- A. You have **ONE** of the following:
 - 1. Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML: a type of blood cell cancer) in chronic, accelerated, myeloid or lymphoid blast phase
 - 2. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL: a type of blood cell cancer)
- B. **If you have Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, approval also requires ONE of the following:**
 - 1. You are 18 years of age or older AND you are newly diagnosed
 - 2. You are between 1 and 17 years of age
- C. **If you have Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, accelerated phase, myeloid or lymphoid blast phase, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have resistance (medication no longer works as well) or intolerance (side effect) to prior therapy including imatinib (Gleevec)
 - 3. You had a mutational analysis (a type of lab test) prior to start of therapy AND Sprycel is appropriate based on the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1: a type of abnormal gene) profile
- D. **If you have Philadelphia chromosome-positive acute lymphoblastic leukemia, approval also requires ONE of the following:**
 - 1. You are 18 years of age or older AND you have a resistance (medication no longer works as well) or intolerance (side effect) to prior therapy such as imatinib (Gleevec) or nilotinib (Tasigna)
 - 2. You are between 1 and 17 years of age, you are newly diagnosed, AND you will be using Sprycel in combination with chemotherapy (drugs used to treat cancer)

Effective: 09/23/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DATOPOTAMAB DERUXTECAN-DLNK

Generic	Brand				
DATOPOTAMAB DERUXTECAN-DLNK	DATROWAY				

GUIDELINES FOR USE

Our guideline named **DATOPOTAMAB DERUXTECAN-DLNK (Datroway)** requires the following rule(s) be met for approval:

You have unresectable or metastatic breast cancer (a type of breast cancer that cannot be removed by surgery or has spread to other parts of the body)

Your cancer is hormone receptor (HR: a type of protein)-positive, human epidermal growth factor receptor 2 (HER2: a type of protein)-negative (IHC 0, IHC 1+, or IHC 2+/ISH- [type of lab test])

You had prior endocrine (hormone)-based therapy (such as letrozole, anastrozole, tamoxifen) and chemotherapy (medications used to treat cancer) for unresectable or metastatic disease

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DECITABINE/CEDAZURIDINE

Generic	Brand				
DECITABINE/ CEDAZURIDINE	INQOVI				

GUIDELINES FOR USE

Our guideline named **DECITABINE/CEDAZURIDINE (Inqovi)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Myelodysplastic syndromes (MDS: type of blood cancer)
 - 2. Chronic myelomonocytic leukemia (CMML: rare form of blood cancer)
- B. You are 18 years of age or older
- C. **If you have myelodysplastic syndromes (MDS), approval also requires:**
 - 1. You meet ONE of the following International Prognostic Scoring System groups (scoring system used to predict the course of a patient's disease):
 - a. Intermediate-1
 - b. Intermediate-2
 - c. High-risk

Effective: 01/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DEFERASIROX

Generic	Brand			
DEFERASIROX	EXJADE, JADENU, JADENU SPRINKLE, DEFERASIROX			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DEFERASIROX (EXJADE, JADENU, JADENU SPRINKLE, DEFERASIROX)** requires the following rule(s) be met for approval:

- A. You have chronic iron overload due to blood transfusions (you have too much iron from blood transfers) or non-transfusion dependent thalassemia (a blood disorder involving less than normal amounts of an oxygen-carrying protein)
- B. The medication is prescribed by or given in consultation with a hematologist (blood specialty doctor) or hematologist/oncologist (tumor/cancer doctor)
- C. **If you have chronic iron overload due to blood transfusions, approval also requires:**
 - 1. You are 2 years of age or older
 - 2. Your serum ferritin levels (amount of iron-containing blood cell proteins) are regularly greater than 1000mcg/L (we need at least 2 lab values taken within the previous 3 months)
- D. **If you have chronic iron overload resulting from non-transfusion dependent thalassemia (NTDT), approval also requires:**
 - 1. You are 10 years of age or older
 - 2. Your serum ferritin levels (amount of iron-containing blood cell proteins) are regularly greater than 300mcg/L (we need at least 2 lab values taken within the previous 3 months)
 - 3. Your liver iron concentration (LIC) is at least 5mg Fe/g dry weight or greater
- E. Requests for Jadenu sprinkle packets require a trial of equivalent generic Exjade or Jadenu tablets

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DEFERASIROX

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **DEFERASIROX (EXJADE, JADENU, JADENU SPRINKLE, DEFERASIROX)** requires the following rule(s) be met for renewal:

- A. You have chronic iron overload due to blood transfusions (you have too much iron from blood transfers) or non-transfusion dependent thalassemia (a blood disorder involving less than normal amounts of an oxygen-carrying protein)
- B. **If you have chronic Iron overload due to blood transfusions, renewal also requires:**
 - 1. Your serum ferritin levels (amount of iron-containing blood cell proteins) are regularly greater than 500 mcg/L (we need at least 2 lab values taken within the previous 3 months)
- C. **If you have chronic iron overload resulting from non-transfusion dependent thalassemia (NTDT), renewal also requires ONE of the following:**
 - 1. Your serum ferritin levels (amount of iron-containing blood cell proteins) are regularly greater than 300mcg/L (we need at least 2 lab values taken within the previous 3 months)
 - 2. Your liver iron concentration (LIC) is at least 3mg Fe/g dry weight or greater

Effective: 09/07/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DEFERIPRONE

Generic	Brand			
DEFERIPRONE	FERRIPROX			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DEFERIPRONE (Ferriprox)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Transfusional iron overload due to a thalassemia syndrome (you have too much iron in your body due to a type of blood disorder)
 - 2. Transfusional iron overload due to a sickle cell disease or other anemias (you have too much iron in your body due to a type of blood disorder)
- B. Therapy is prescribed by or given in consultation with a hematologist (a type of blood doctor) or hematologist/oncologist (a type of cancer doctor)
- C. You have tried or have a contraindication (harmful for) to at least ONE of the following: Exjade (deferasirox), Jadenu (deferasirox), or Desferal (deferoxamine)
- D. You meet ONE of the following:
 - 1. You are experiencing intolerable toxicities or clinically significant adverse effects or have a contraindication (harmful for) to current chelators (drugs that bind to iron): Exjade (deferasirox), Jadenu (deferasirox), or Desferal (deferoxamine)
 - 2. Current chelation therapy (therapy that lowers iron levels) with Exjade [deferasirox], Jadenu [deferasirox], or Desferal [deferoxamine] is not working well enough
- E. **If the request is for Ferriprox (deferiprone) tablets, approval also requires:**
 - 1. You are 8 years of age or older
- F. **If the request is for Ferriprox oral solution, approval also requires:**
 - 1. You are 3 years of age or older

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DEFERIPRONE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **DEFERIPRONE (Ferriprox)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
 - 1. Transfusional iron overload due to thalassemia syndrome (you have too much iron in your body due to a type of blood disorder)
 - 2. Transfusional iron overload due to a sickle cell disease or other anemias (you have too much iron in your body due to a type of blood disorder)
- B. Your serum ferritin levels (amount of iron-containing blood cell proteins) stay above 500mcg/L (at least 2 lab values in the previous 3 months)
- C. **If the request is for Ferriprox (deferiprone) tablets, approval also requires:**
 - 1. You are 8 years of age or older
- D. **If the request is for Ferriprox oral solution, approval also requires:**
 - 1. You are 3 years of age or older

Effective: 04/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DEFEROXAMINE

Generic	Brand			
DEFEROXAMINE MESYLATE	DESFERAL, DEFEROXAMINE MESYLATE			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DEFEROXAMINE (Desferal)** requires the following rule(s) be met for approval:

- A. You have chronic iron overload due to transfusion-dependent anemias (blood doesn't have enough healthy red blood cells)
- B. Therapy is prescribed by or given in consultation with a hematologist (blood specialty doctor) or hematologist-oncologist (tumor/cancer doctor)
- C. You are 3 years of age or older
- D. Your serum ferritin levels (amount of iron-containing blood cell proteins) stay greater than 1000mcg/L (shown by at least 2 lab values in the previous 3 months)

RENEWAL CRITERIA

Our guideline named **DEFEROXAMINE (Desferal)** requires the following rules be met for renewal:

- A. You have chronic iron overload due to transfusion-dependent anemias (blood doesn't have enough healthy red blood cells)
- B. Your serum ferritin levels (amount of iron-containing blood cell proteins) stay greater than 500mcg/L (at least 2 lab values in the previous 3 months)

Effective: 04/17/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DEFLAZACORT

Generic	Brand			
DEFLAZACORT	EMFLAZA, DEFLAZACORT			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DEFLAZACORT (Emflaza)** requires the following rule(s) be met for approval:

- A. You have Duchenne muscular dystrophy (DMD: a type of muscle disorder)
- B. You are 2 years of age or older
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor) specializing in the treatment of Duchenne muscular dystrophy (DMD) at a DMD treatment center
- D. Your diagnosis of DMD is confirmed by genetic testing
- E. You have tried prednisone or prednisolone for at least 6 months
- F. You meet ONE of the following:
 1. Prednisone or prednisolone did not work for you, and you meet **ALL** of the following:
 - a. You are not in Stage 1 of the disease (the pre-symptomatic phase)
 - b. There is no steroid myopathy (muscle disease due to steroid use)
 - c. You have experienced a decrease in ambulation (walking), functional status, or pulmonary (lung) function, while treated with prednisone or prednisolone, that is consistent with advancing disease (stage 2 or higher) and that is assessed by standard measures over time (such as the 6-minute walking distance [6MWD], time to go up or down 4 stairs, time to rise from the floor [Gower's maneuver], 10-meter run/walk time, North Star Ambulatory Assessment [NSAA: a tool for evaluating Duchenne muscular dystrophy], Physician Global Assessment [PGA: an evaluation by a physician], pulmonary function [forced vital capacity, lung function tests], upper limb strength [moving a wheelchair 30 feet])
 2. You have experienced a significant adverse effect (such as weight gain) on prednisone or prednisolone that is negatively impacting a co-existing comorbid condition (such as diabetes [a disorder with high blood sugar])

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DEFLAZACORT

RENEWAL CRITERIA

Our guideline named **DEFLAZACORT (Emflaza)** requires the following rule(s) be met for renewal:

- A. You have Duchenne muscular dystrophy (DMD: a type of muscle disorder)
- B. **If you are currently ambulatory (can walk), approval also requires:**
 - 1. You have shown function or improvement since being on Emflaza as measured by a standard set of ambulatory or functional status measures (such as the 6-minute walking distance [6MWD], time to go up or down 4 stairs, time to rise from the floor [Gower's maneuver], 10-meter run/walk time, North Star Ambulatory Assessment [NSAA: a tool for evaluating Duchenne muscular dystrophy], Physician Global Assessment [PGA: an evaluation by a physician])
- C. **If you are currently non-ambulatory (cannot walk), approval also requires:**
 - 1. You have maintained or had a less than expected decrease in pulmonary (lung) function or upper limb strength since being on Emflaza as assessed by standard measures (such as pulmonary function [forced vital capacity, pulmonary function tests], upper limb strength measures [moving in a wheelchair 30 feet], Physician Global Assessment [PGA: an evaluation by a physician])

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DELAFLORACIN

Generic	Brand			
DELAFLORACIN	BAXDELA			

GUIDELINES FOR USE

Our guideline named **DELAFLORACIN (Baxdela)** requires the following rule(s) be met for approval:

A. You meet ONE of the following:

1. The requested medication is prescribed by or in consultation with an infectious disease (ID) specialist
2. You have an acute bacterial skin and skin structure infection (ABSSSI: a type of skin condition)
3. You have community-acquired bacterial pneumonia (CABP: type of lung infection)

B. **If you have an acute bacterial skin or skin structure infection, approval also requires:**

1. You are 18 years of age or older
2. The infection is caused by any of the following bacteria: *Staphylococcus aureus* (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), *Staphylococcus haemolyticus*, *Staphylococcus lugdunensis*, *Streptococcus agalactiae*, *Streptococcus anginosus* Group (including *Streptococcus anginosus*, *Streptococcus intermedius*, and *Streptococcus constellatus*), *Streptococcus pyogenes*, or *Enterococcus faecalis*, *Escherichia coli*, *Enterobacter cloacae*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*
3. You are NOT using Baxdela for an animal or human bite, necrotizing fasciitis (flesh eating disease), diabetic foot infection, decubitus ulcer formation (pressure/bed ulcer), myonecrosis (dead muscle tissue) or ecthyma gangrenosum (a type of skin lesion)
4. You meet ONE of the following:
 - a. If an antimicrobial susceptibility test (a type of lab test) is available, your results of the test from the infection site show both of the following:
 1. The bacteria is resistant to ONE standard of care medication for acute bacterial skin and skin structure infections (such as sulfamethoxazole/trimethoprim, levofloxacin, clindamycin, cephalexin, vancomycin)
 2. Baxdela (delafloxacin) will work to treat the bacteria
 - b. If an antimicrobial susceptibility test (a type of lab test) is NOT available, you have tried or have a contraindication to (harmful for you to use) ONE of the following medications: a gram positive targeting antibiotic (such as linezolid, clindamycin, doxycycline, sulfamethoxazole/trimethoprim, vancomycin), a penicillin (such as amoxicillin), a fluoroquinolone (such as levofloxacin, ciprofloxacin, moxifloxacin), a cephalosporin (such as ceftriaxone, cephalexin, cefazolin)

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DELAFLORACIN

GUIDELINES FOR USE (CONTINUED)

C. If you have community-acquired bacterial pneumonia, approval also requires:

1. You are 18 years of age or older
2. The infection is caused by any of the following bacteria: *Streptococcus pneumoniae*, *Staphylococcus aureus* (methicillin-susceptible [MSSA] isolates only), *Klebsiella pneumoniae*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Haemophilus influenzae*, *Haemophilus parainfluenzae*, *Chlamydia pneumoniae*, *Legionella pneumophila* or *Mycoplasma pneumoniae*
3. You meet ONE of the following:
 - a. If an antimicrobial susceptibility test (a type of lab test) is available, your results of the test from the infection site show both of the following:
 1. The bacteria is resistant to TWO standard of care medications for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone, linezolid)
 2. Baxdela (delafloxacin) will work to treat the bacteria
 - b. If an antimicrobial susceptibility test (a type of lab test) is NOT available, you have tried or have a contraindication to (harmful for you to use) TWO standard of care medications for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone, linezolid)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DESIRUDIN

Generic	Brand			
DESIRUDIN	IPRIVASK			

GUIDELINES FOR USE

Our guideline named **DESIRUDIN (Iprivask)** requires that you are receiving Iprivask for the prevention of deep vein thrombosis (DVT; blood clot in a deep vein, usually in the legs) and you are undergoing elective hip replacement surgery.

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DEUCRAVACITINIB

Generic	Brand				
DEUCRAVACITINIB	SOTYKTU				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DEUCRAVACITINIB (Sotyktu)** requires the following rule(s) be met for approval:

- A. You have moderate to severe plaque psoriasis (PsO: a type of skin condition)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
- D. You have psoriasis covering 3 percent or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, face, genital area, or scalp
- E. You will NOT use Sotyktu concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
- F. You meet ONE of the following:
 - 1. You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) OR PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis
 - 2. You have a contraindication (harmful for you to use) or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) AND PUVA (phototherapy) for the treatment of plaque psoriasis
 - 3. You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DEUCRAVACITINIB

RENEWAL CRITERIA

Our guideline named **DEUCRAVACITINIB (Sotyktu)** requires the following rule(s) be met for renewal:

- A. You have moderate to severe plaque psoriasis (PsO: a type of skin condition)
- B. You have achieved or maintained clear or minimal disease OR a decrease in PASI (Psoriasis Area and Severity Index: a tool for evaluating the severity of psoriasis) of at least 50 percent or more while on therapy
- C. You will NOT use Sotyktu concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DEURUXOLITINIB

Generic	Brand				
DEURUXOLITINIB PHOSPHATE	LEQSELVI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DEURUXOLITINIB (Leqselvi)** requires the following rule(s) be met for approval:

- A. You have severe alopecia areata (a type of hair loss)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
- D. You have had at least 50 percent scalp hair loss, as measured by the Severity of Alopecia Tool (SALT: a type of disease evaluation tool), for more than 6 months
- E. You will NOT use Leqselvi concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Litfulo (ritlecitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of alopecia areata
- F. You have tried or have a contraindication to (harmful for you to use) BOTH of the following preferred medications: Litfulo (ritlecitinib), Olumiant (baricitinib)
- G. You have tried or have a contraindication to TWO of the following (from different categories):
 - 1. Intralesional corticosteroid (such as triamcinolone acetonide)
 - 2. Topical corticosteroid (such as fluocinolone acetonide, betamethasone dipropionate, clobetasol propionate)
 - 3. Minoxidil (such as minoxidil 5 percent solution)
 - 4. Short contact anthralin
 - 5. Topical immunotherapy (such as squaric acid dibutyl ester, diphencyprone/diphenylcyclopropenone)
 - 6. Systemic treatments (such as psoralen plus UV-A [PUVA: a type of light therapy], prednisone, cyclosporine, methotrexate)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DEURUXOLITINIB

RENEWAL CRITERIA

Our guideline named **DEURUXOLITINIB (Leqselvi)** requires the following rule(s) be met for renewal:

- A. You have severe alopecia areata (a type of hair loss)
- B. You have experienced improvement while on therapy (such as scalp hair coverage)
- C. You will NOT use Leqselvi concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Litfulo (ritlecitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of alopecia areata
- D. You have tried or have a contraindication to (harmful for you to use) BOTH of the following preferred medications: Litfulo (ritlecitinib), Olumiant (baricitinib)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DEUTETRABENAZINE

Generic	Brand				
DEUTETRABENAZINE	AUSTEDO, AUSTEDO XR				

GUIDELINES FOR USE

Our guideline named **DEUTETRABENAZINE (Austedo)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Chorea (involuntary muscle movements) associated with Huntington's disease
 - 2. Moderate to severe tardive dyskinesia (TD: uncontrolled body movements)
- B. **If you have chorea associated with Huntington's disease, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor) or movement disorder specialist
- C. **If you have moderate to severe tardive dyskinesia, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Your moderate to severe tardive dyskinesia (uncontrolled body movements) has been present for at least 3 months
 - 3. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor), movement disorder specialist, or psychiatrist (a type of mental health doctor)
 - 4. You have a prior history of using antipsychotic medications (such as aripiprazole, haloperidol, ziprasidone) or metoclopramide for at least 3 months (or at least 1 month if you are 60 years of age or older) as documented in your prescription claims history

Effective: 08/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DEXMEDETOMIDINE

Generic	Brand				
DEXMEDETOMIDINE HCL	IGALMI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DEXMEDETOMIDINE (Igalmi)** requires the following rule(s) be met for approval:

- A. You have acute (short-term) agitation associated with schizophrenia (a type of mental health disorder) or bipolar I or II disorder (a type of mood disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
- D. You had a trial and failure of or contraindication (harmful for) to THREE antipsychotics (such as olanzapine, ziprasidone, haloperidol)

RENEWAL CRITERIA

Our guideline named **DEXMEDETOMIDINE (Igalmi)** requires the following rule(s) be met for renewal:

- A. You have acute (short-term) agitation associated with schizophrenia (a type of mental health disorder) or bipolar I or II disorder (a type of mood disorder)
- B. You meet ONE of the following:
 - 1. Your maintenance therapy for the underlying psychiatric (mental) disorder is currently being adjusted/optimized to reduce or eliminate the need for continued PRN medications (as needed drugs) for acute agitation
 - 2. Attempts to adjust medications have been exhausted AND your physician (doctor) has determined that chronic PRN medications (long-term as needed drugs) are required for the continued safety of you or your caregivers

Effective: 06/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DEXTROMETHORPHAN-QUINIDINE

Generic	Brand			
DEXTROMETHORPHAN HBR/QUINIDINE	NUEDEXTA			

GUIDELINES FOR USE

Our guideline named **DEXTROMETHORPHAN-QUINIDINE (Nuedexta)** requires the following rule(s) be met for approval:

- A. You have pseudobulbar affect (uncontrollable, inappropriate laughing and/or crying due to a nervous system disorder)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DIABETIC TEST STRIPS

Generic	Brand			
BLOOD SUGAR DIAGNOSTIC, BLOOD SUGAR DIAGNOSTIC, DISC, BLOOD SUGAR DIAGNOSTIC, DRUM	DIABETIC TEST STRIPS VARIOUS			

GUIDELINES FOR USE

Our guideline named **DIABETIC TEST STRIPS** requires ONE of following rules be met for approval:

- A. You have tried ONE preferred blood glucose (diabetic) meter and test strips. The preferred meters and test strips are FreeStyle and Precision by Abbott
- B. You require a non-preferred blood glucose test strip due to significant visual and/or cognitive impairment (problems with sight and/or memory and thinking)
- C. You require a non-preferred blood glucose test strip because you use another manufacturer's companion insulin pump

Request for non-preferred test strips will not be approved if due to a need for data management software. Please note that data management software is available for the formulary test strip products. Please contact Abbott for data management software and a connection cable for the meter.

Effective: 02/08/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DIAZOXIDE CHOLINE

Generic	Brand				
DIAZOXIDE CHOLINE	VYKAT XR				

GUIDELINES FOR USE

Our guideline named **DIAZOXIDE CHOLINE (Vykat XR)** requires the following rule(s) be met for approval:

You have hyperphagia (extreme hunger)

You are 4 years of age or older

You have genetically confirmed Prader-Willi syndrome (PWS: a type of generic disorder)

Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor), geneticist (doctor who treats gene disorders), or neurologist (a type of brain and nervous system doctor)

RENEWAL CRITERIA

Our guideline named **DIAZOXIDE CHOLINE (Vykat XR)** requires the following rule(s) be met for renewal:

You have hyperphagia (extreme hunger)

Your hyperphagia is associated with Prader-Willi syndrome (PWS: a type of generic disorder)

You have had clinical improvement

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DICHLORPHENAMIDE

Generic	Brand			
DICHLORPHENAMIDE	KEVEYIS, ORMALVI, DICHLORPHENAMIDE			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DICHLORPHENAMIDE (Keveyis, Ormalvi)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Primary hyperkalemic periodic paralysis (extreme muscle weakness with high potassium levels in your blood) or related variants
 2. Primary hypokalemic periodic paralysis (extreme muscle weakness with low potassium levels in your blood) or related variants
- B. **If you have primary hyperkalemic periodic paralysis or related variants, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
 3. You have tried acetazolamide AND a thiazide diuretic (hydrochlorothiazide)
 4. You do NOT have hepatic insufficiency (liver failure), pulmonary obstruction (difficulty breathing due to blockage of airflow), or a health condition that requires you to use high-dose aspirin at the same time
- C. **If you have primary hypokalemic periodic paralysis or related variants, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
 3. You have tried acetazolamide AND a potassium-sparing diuretic (spironolactone, triamterene)
 4. You do NOT have hepatic insufficiency (liver failure), pulmonary obstruction (difficulty breathing due to blockage of airflow), or a health condition that requires you to use high-dose aspirin at the same time

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DICHLORPHENAMIDE

RENEWAL CRITERIA

Our guideline named **DICHLORPHENAMIDE (Keveyis, Ormalvi)** requires the following rule(s) be met for renewal:

- A. You have primary hyperkalemic periodic paralysis (extreme muscle weakness with high potassium levels in your blood), primary hypokalemic periodic paralysis (extreme muscle weakness with low potassium levels in your blood), or related variants
- B. You have experienced at least TWO fewer attacks per week from baseline (before you started treatment)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DIGOXIN

Generic	Brand				
DIGOXIN	DIGOXIN				

GUIDELINES FOR USE

Our guideline named **DIGOXIN** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Heart failure (a type of heart condition)
 - 2. Chronic atrial fibrillation (a type of heart condition)
- B. **If you have chronic atrial fibrillation, approval also requires:**
 - 1. You are 18 years of age or older

Effective: 07/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DIMETHYL FUMARATE

Generic	Brand			
DIMETHYL FUMARATE	TECFIDERA, DIMETHYL FUMARATE			

GUIDELINES FOR USE

Our guideline named **DIMETHYL FUMARATE (Tecfidera)** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms or disease goes away and returns), or active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older
- C. **If you are requesting brand Tecfidera, approval also requires:**
 - 1. You have tried generic dimethyl fumarate

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DIROXIMEL FUMARATE

Generic	Brand			
DIROXIMEL FUMARATE	VUMERITY			

GUIDELINES FOR USE

Our guideline named **DIROXIMEL FUMARATE (Vumerity)** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms or disease goes away and returns), or active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DONEPEZIL

Generic	Brand				
DONEPEZIL HCL	ADLARITY				

GUIDELINES FOR USE

Our guideline named **DONEPEZIL (Adlarity)** requires the following rule(s) be met for approval:

- A. You have dementia (a type of memory disorder) associated with Alzheimer's disease (a type of brain disorder)
- B. You have tried or have a contraindication to (harmful for you to use) TWO generic oral acetylcholinesterase inhibitors (such as donepezil, galantamine)
- C. You have tried or have a contraindication to (harmful for you to use) ONE generic acetylcholinesterase inhibitor patch (such as rivastigmine)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DORNASE ALFA

Generic	Brand			
DORNASE ALFA	PULMOZYME			

GUIDELINES FOR USE

Our guideline named **DORNASE ALFA (Pulmozyme)** requires the following rule(s) be met for approval:

- A. You have cystic fibrosis (CF: an inherited disorder that damages lung and digestive system with fluid build up)
- B. If you are requesting twice daily dosing, we require that you have tried and failed once daily dosing

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DOXYCYCLINE

Generic	Brand				
DOXYCYCLINE MONOHYDRATE	ORACEA, DOXYCYCLINE IR-DR				

GUIDELINES FOR USE

Our guideline named **DOXYCYCLINE (Oracea, Doxycycline IR-DR)** requires the following rule(s) be met for approval:

- A. You have rosacea (a type of skin condition)
- B. You are 18 years of age or older
- C. You have inflammatory lesions (papules and pustules: small bumps on the skin) associated with rosacea
- D. You have tried or have a contraindication to (harmful for you to use) ONE generic oral minocycline or doxycycline

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DROXIDOPA

Generic	Brand			
DROXIDOPA	NORTHERA, DROXIDOPA			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DROXIDOPA (Northera)** requires the following rules be met for approval:

- A. You have neurogenic orthostatic hypotension (a type of low blood pressure)
- B. You are 18 years of age or older
- C. You have a documented diagnosis of neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency (you are missing a type of enzyme), or non-diabetic autonomic neuropathy (nerve pain/damage)
- D. You have previously tried midodrine OR fludrocortisone, unless there is a medical reason why you cannot (contraindication)
- E. Therapy is prescribed or given in consultation with a neurologist (nerve doctor) or cardiologist (heart doctor)
- F. Your doctor performed baseline blood pressure readings while you are sitting and also within 3 minutes of standing from a supine (lying face up) position
- G. You have a documented decrease of at least 20 mmHg in systolic blood pressure or 10 mmHg diastolic blood pressure within 3 minutes after standing from a sitting position
- H. You have persistent symptoms of neurogenic orthostatic hypotension which includes dizziness, lightheadedness, and the feeling of 'blacking out'

RENEWAL CRITERIA

Our guideline named **DROXIDOPA (Northera)** requires the following rule(s) be met for renewal:

- A. You have neurogenic orthostatic hypotension (NOH)
- B. You have demonstrated improvement in severity from baseline symptoms of dizziness, lightheadedness, feeling faint, or feeling like you may black out
- C. You had an increase in systolic blood pressure from baseline of at least 10mmHg upon standing from a supine (lying face up) position

Effective: 03/15/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DUPILUMAB

Generic	Brand				
DUPILUMAB	DUPIXENT				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DUPILUMAB (Dupixent)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Moderate to severe atopic dermatitis (AD: a type of skin condition)
2. Moderate to severe asthma (a type of lung condition)
3. Chronic rhinosinusitis with nasal polyps (CRSwNP: inflammation of nasal and sinus ways with small growths in the nose)
4. Eosinophilic esophagitis (EoE: a type of immune system disorder)
5. Prurigo nodularis (PN: a type of skin condition)
6. Chronic obstructive pulmonary disease (COPD: a type of long-term lung condition)
7. Chronic spontaneous urticaria (also called chronic idiopathic urticaria) [severe itching with unknown cause]

B. If you have moderate to severe atopic dermatitis, approval also requires:

1. You are 6 months of age or older
2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
3. You will NOT use Dupixent concurrently (at the same time) with another systemic biologic (such as Adbry [tralokinumab-ldrm]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Eucrisa (crisaborole)]) for the treatment of atopic dermatitis
4. You meet ONE of the following:
 - a. You were previously stable on another biologic (such as Rinvoq [upadacitinib]) and are switching to Dupixent
 - b. You have atopic dermatitis involving at least 10 percent of body surface area (BSA)
 - c. You have atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas (between skin folds)
5. You have tried or have a contraindication to (harmful for you to use) ONE of the following: topical corticosteroid (such as hydrocortisone, clobetasol propionate, halobetasol propionate), topical calcineurin inhibitor (such as Elidel [pimecrolimus], Protopic [tacrolimus]), topical PDE-4 inhibitor (such as Eucrisa [crisaborole]), topical JAK inhibitor (such as Opzelura [ruxolitinib]), phototherapy (light therapy)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DUPILUMAB

INITIAL CRITERIA (CONTINUED)

C. If you have moderate to severe asthma, approval also requires:

1. You are 6 years of age or older
2. Therapy is prescribed by or in consultation with a physician specializing in pulmonary (relating to lungs/breathing) medicine or allergy medicine
3. You meet ONE of the following:
 - i. You have an eosinophilic phenotype asthma (a type of inflammatory asthma) and meet all of the following:
 - i. You have a pre-treatment blood eosinophil level (a type of lab test) of 150 to 1500 cells/mcL
 - ii. You will NOT use Dupixent concurrently (at the same time) with another systemic biologic (such as Nucala [mepolizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of eosinophilic phenotype asthma
 - ii. You have oral corticosteroid-dependent asthma, AND you will NOT use Dupixent concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of oral corticosteroid-dependent asthma
4. Dupixent will be used in combination with a medium, high-dose, or maximally tolerated dose of an inhaled corticosteroid (such as beclomethasone, mometasone, budesonide) AND at least ONE other maintenance medication (taken on a regular basis) (such as a long-acting inhaled beta2-agonist [such as salmeterol, formoterol], a long-acting muscarinic antagonist [such as Tudorza (aclidinium), Spiriva (tiotropium), Incruse Ellipta (umeclidinium)], a leukotriene receptor antagonist [such as montelukast, zafirlukast], theophylline)
5. You meet ONE of the following:
 - a. You have experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid (such as prednisone) burst lasting at least 3 days within the past 12 months
 - b. You have experienced at least ONE serious asthma exacerbation requiring a hospitalization or an emergency room visit within the past 12 months
 - c. You have poor symptom control despite current therapy as shown by at least THREE of the following within the past 4 weeks:
 - i. Daytime asthma symptoms more than twice per week
 - ii. Any night waking due to asthma
 - iii. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
 - iv. Any activity limitation due to asthma

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DUPILUMAB

INITIAL CRITERIA (CONTINUED)

D. If you have chronic rhinosinusitis with nasal polyps, approval also requires:

1. You are 12 years of age or older
2. Therapy is prescribed by or in consultation with an otolaryngologist (ear, nose, and throat doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
3. There is evidence of nasal polyps (non-cancerous growths) by direct examination, endoscopy (using a small camera), or sinus computed tomography (CT) scan (a type of imaging test)
4. You have inadequately controlled disease
5. You had a 56-day trial of ONE intranasal corticosteroid (such as mometasone nasal spray)
6. Dupixent will be used as add-on maintenance treatment (in conjunction [together] with maintenance intranasal steroids [a type of medication used in the nose])
7. You will NOT use Dupixent concurrently (at the same time) with another systemic biologic (such as Nucala [mepolizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of chronic rhinosinusitis with nasal polyps

E. If you have eosinophilic esophagitis, approval also requires:

1. You are 1 year of age or older
2. You weigh at least 15 kilograms (33 pounds)
3. Therapy is prescribed by or in consultation with a gastroenterologist (a type of doctor who treats digestive conditions), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
4. You have tried or have a contraindication to (harmful for you to use) dietary therapy
5. You have tried or have a contraindication to (harmful for you to use) a proton pump inhibitor (such as omeprazole, lansoprazole, pantoprazole)
6. You will NOT use Dupixent concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of eosinophilic esophagitis

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DUPILUMAB

INITIAL CRITERIA (CONTINUED)

F. If you have prurigo nodularis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), immunologist (a type of immune system doctor), or allergist (a type of allergy doctor)
3. You have multiple pruriginous lesions (wounds)
4. You have tried or have a contraindication to (harmful for you to use) ONE of the following: topical capsaicin, topical ketamine/amitriptyline/lidocaine, gabapentinoids (such as gabapentin, pregabalin), antidepressants (serotonin-norepinephrine reuptake inhibitor [SNRI], selective serotonin reuptake inhibitor [SSRI], tricyclic antidepressant [TCA]), κ -opioid receptor antagonists (such as naltrexone, buprenorphine), thalidomide, topical corticosteroids (such as hydrocortisone), topical calcineurin inhibitors (such as Elidel [pimecrolimus]), topical calcipotriol, intralesional corticosteroids, phototherapy (light therapy), methotrexate, cyclosporine, azathioprine
5. You will NOT use Dupixent concurrently (at the same time) with another systemic biologic (such as Nemlivo [nemolizumab-ilto]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of prurigo nodularis

G. If you have chronic obstructive pulmonary disease, approval also requires:

1. You are 18 years of age or older
2. You have an eosinophilic phenotype chronic obstructive pulmonary disease (COPD) (a type of inflammatory long-term lung condition)
3. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor)
4. Dupixent will be used in combination with a long-acting muscarinic antagonist (LAMA)/long-acting beta-2-agonist (LABA)/inhaled corticosteroid (ICS) (such as Trelegy Ellipta, Breztri Aerosphere)
5. You will NOT use Dupixent concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Daliresp (roflumilast)]) for the treatment of eosinophilic phenotype COPD

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DUPILUMAB

INITIAL CRITERIA (CONTINUED)

H. If you have chronic spontaneous urticaria (chronic idiopathic urticaria), approval also requires:

1. You are 12 years of age or older
2. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), dermatologist (a type of skin doctor), or immunologist (a type of immune system doctor)
3. You still experience hives or angioedema (a type of swelling) on most days of the week for at least 6 weeks
4. You have tried and are maintained on (continue to use on a regular basis), OR you have a contraindication to (harmful for you to use), a second generation H1 antihistamine (type of allergy medication) (Zyrtec [cetirizine], Xyzal [levocetirizine], Claritin [loratadine], Clarinex [desloratadine], or Allegra [fexofenadine])
5. You will NOT use Dupixent concurrently (at the same time) with another systemic biologic (such as Xolair [omalizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of chronic spontaneous urticaria (chronic idiopathic urticaria)

RENEWAL CRITERIA

Our guideline named **DUPILUMAB (Dupixent)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Moderate to severe atopic dermatitis (AD: a type of skin condition)
2. Moderate to severe asthma (a type of lung condition)
3. Chronic rhinosinusitis with nasal polyps (CRSwNP: inflammation of nasal and sinus ways with small growths in the nose)
4. Eosinophilic esophagitis (EoE: a type of immune system disorder)
5. Prurigo nodularis (PN: a type of skin condition)
6. Chronic obstructive pulmonary disease (COPD: a type of long-term lung condition)
7. Chronic spontaneous urticaria (also called chronic idiopathic urticaria) [severe itching with unknown cause]

B. If you have moderate to severe atopic dermatitis, renewal also requires:

1. You have shown improvement while on Dupixent
2. You will NOT use Dupixent concurrently (at the same time) with another systemic biologic (such as Adbry [tralokinumab-ldrm]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Eucrisa (crisaborole)]) for the treatment of atopic dermatitis

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DUPIUMAB

RENEWAL CRITERIA (CONTINUED)

C. If you have moderate to severe asthma, renewal also requires:

1. You meet ONE of the following:
 - a. You have an eosinophilic phenotype asthma (a type of inflammatory asthma), AND you will NOT use Dupixent concurrently (at the same time) with another systemic biologic (such as Nucala [mepolizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of eosinophilic phenotype asthma
 - b. You have oral corticosteroid-dependent asthma, AND you will NOT use Dupixent concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of oral corticosteroid-dependent asthma
2. You will continue to use an inhaled corticosteroid (such as beclomethasone, mometasone, budesonide) AND at least ONE other maintenance medication (taken on a regular basis) (such as a long-acting inhaled beta2-agonist [such as salmeterol, formoterol], a long-acting muscarinic antagonist [such as Tudorza (aclidinium), Spiriva (tiotropium), Incruse Ellipta (umeclidinium)], a leukotriene receptor antagonist [such as montelukast, zafirlukast], theophylline)
3. You have shown a clinical response as evidenced by ONE of the following:
 - a. You have experienced a decrease in asthma exacerbations (worsening of symptoms) from baseline (before starting Dupixent)
 - b. You have decreased your use of rescue medications (such as albuterol)
 - c. You have an increase in the percent predicted FEV1 (a type of lung test) from pre-treatment baseline (before starting Dupixent)
 - d. You have a decrease in the severity or frequency of asthma-related symptoms (such as wheezing, shortness of breath, coughing)

D. If you have chronic rhinosinusitis with nasal polyps, renewal also requires:

1. You have shown a clinical benefit compared to baseline (such as improvements in nasal congestion, sense of smell, size of polyps)
2. You will NOT use Dupixent concurrently (at the same time) with another systemic biologic (such as Nucala [mepolizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of chronic rhinosinusitis with nasal polyps

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DUPILUMAB

RENEWAL CRITERIA (CONTINUED)

E. If you have eosinophilic esophagitis, renewal also requires:

1. You have shown improvement while on Dupixent (such as symptom improvement or achieving histological remission defined as peak esophageal intraepithelial eosinophil count of 6 eos/hpf or less [a type of test that evaluates disease status])
2. You will NOT use Dupixent concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of eosinophilic esophagitis

F. If you have prurigo nodularis, renewal also requires:

1. You have had prurigo nodularis improvement or reduction of pruritus (itching) or pruriginous lesions (wounds)
2. You will NOT use Dupixent concurrently (at the same time) with another systemic biologic (such as Nemluvio [nemolizumab-ilto]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of prurigo nodularis

G. If you have chronic obstructive pulmonary disease, renewal also requires:

1. You have an eosinophilic phenotype chronic obstructive pulmonary disease (COPD) (a type of inflammatory long-term lung condition)
2. Dupixent will be used in combination with a long-acting muscarinic antagonist (LAMA)/long-acting beta-2-agonist (LABA)/inhaled corticosteroid (ICS) (such as Trelegy Ellipta, Breztri Aerosphere)
3. You will NOT use Dupixent concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Daliresp (roflumilast)]) for the treatment of eosinophilic phenotype COPD
4. You have shown a clinical response as evidenced by ONE of the following:
 - a. You have a reduction (decrease) in COPD exacerbations (worsening of symptoms) from baseline (before starting Dupixent)
 - b. You have a reduction in severity or frequency of COPD-related symptoms (such as wheezing, shortness of breath, coughing, sputum [mucus] production)
 - c. You have had an increase in FEV1 (a type of lung test) by at least 5 percent from pretreatment baseline (before starting Dupixent)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DUPILUMAB

RENEWAL CRITERIA (CONTINUED)

- H. If you have chronic spontaneous urticaria (chronic idiopathic urticaria), renewal also requires:**
1. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), dermatologist (a type of skin doctor), or immunologist (a type of immune system doctor)
 2. You are maintained on (continue to use on a regular basis), OR you have a contraindication to (harmful for you to use), a second generation H1 antihistamine (type of allergy medication) (Zyrtec [cetirizine], Xyzal [levocetirizine], Claritin [loratadine], Clarinex [desloratadine], or Allegra [fexofenadine])
 3. You will NOT use Dupixent concurrently (at the same time) with another systemic biologic (such as Xolair [omalizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of chronic spontaneous urticaria (chronic idiopathic urticaria)

Effective: 05/12/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DURVALUMAB

Generic	Brand				
DURVALUMAB	IMFINZI				

GUIDELINES FOR USE

Our guideline named **DURVALUMAB (Imfinzi)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Non-small cell lung cancer (NSCLC: a type of lung cancer)
2. Small cell lung cancer (SCLC: a type of lung cancer)
3. Locally advanced or metastatic biliary tract cancer (a type of biliary tract cancer that has spread from where it started to nearby tissue or lymph nodes or has spread to other parts of the body)
4. Unresectable hepatocellular carcinoma (a type of liver cancer that cannot be completely removed by surgery)
5. Primary advanced or recurrent endometrial cancer (a type of uterus cancer that has spread or has returned after treatment)
6. Bladder cancer

B. If you have non-small cell lung cancer, approval also requires:

1. You are 18 years of age or older
2. You meet ONE of the following:
 - a. Your cancer is resectable (can be removed by surgery) (node positive [has spread to the lymph nodes] or tumors are at least 4 cm); you have no known epidermal growth factor receptor (EGFR: a type of protein) mutations (abnormal change in a type of gene) or anaplastic lymphoma kinase (ALK: a type of enzyme) rearrangements; and Imfinzi will be used in combination with platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin) as neoadjuvant treatment (given before main treatment), OR as a single agent as adjuvant treatment (additional treatment) after surgery and previous use in combination with platinum-containing chemotherapy
 - b. Your cancer is Stage III and unresectable (cannot be completely removed by surgery); and your disease has NOT progressed (worsened) after using concurrent (at the same time) platinum-based chemotherapy (such as cisplatin, carboplatin, oxaliplatin) and radiation therapy (cCRT: concurrent chemoradiotherapy)
 - c. Your cancer is metastatic (cancer that has spread to other parts of the body); you do NOT have sensitizing epidermal growth factor receptor (EGFR: a type of protein) mutations (abnormal change in a type of gene) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations (a type of abnormal gene); and Imfinzi will be used in combination with Imjudo (tremelimumab-actl) and platinum-based chemotherapy (such as cisplatin, carboplatin, oxaliplatin)

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DURVALUMAB

GUIDELINES FOR USE (CONTINUED)

- C. If you have small cell lung cancer, approval also requires:**
1. You are 18 years of age or older
 2. You meet ONE of the following:
 - a. You have limited-stage cancer (LS: cancer that is contained in a single area on one side of the chest) AND your disease has NOT progressed (worsened) following concurrent (at the same time) platinum-based chemotherapy (such as cisplatin, carboplatin, oxaliplatin) and radiation therapy (cCRT: concurrent chemoradiotherapy)
 - b. You have extensive-stage cancer (ES: cancer that has spread widely throughout the lungs or other parts of the body) and Imfinzi will be used in combination with etoposide, AND either carboplatin or cisplatin
- D. If you have locally advanced or metastatic biliary tract cancer, approval also requires:**
1. You are 18 years of age or older
 2. Imfinzi will be used in combination with gemcitabine and cisplatin
- E. If you have unresectable hepatocellular carcinoma, approval also requires:**
1. You are 18 years of age or older
 2. Imfinzi will be used in combination with Imjudo (tremelimumab-actl)
- F. If you have primary advanced or recurrent endometrial cancer, approval also requires:**
1. You are 18 years of age or older
 2. Your cancer is mismatch repair deficient (dMMR: a type of gene mutation [abnormal change]), as determined by a Food and Drug Administration (FDA)-approved test
 3. Imfinzi will be used in combination with carboplatin and paclitaxel, OR as a single agent after previous use in combination with carboplatin and paclitaxel
- G. If you have bladder cancer, approval also requires:**
1. You are 18 years of age or older
 2. You have muscle invasive bladder cancer (MIBC: bladder cancer that has spread to the muscles)
 3. Imfinzi will be used in combination with gemcitabine and cisplatin as neoadjuvant treatment (given before main treatment), OR as a single agent as adjuvant treatment (additional treatment) following radical cystectomy (bladder removal surgery) and previous use in combination with gemcitabine and cisplatin

Effective: 05/12/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DUVELISIB

Generic	Brand			
DUVELISIB	COPIKTRA			

GUIDELINES FOR USE

Our guideline named **DUVELISIB (Copiktra)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Relapsed or refractory chronic lymphocytic leukemia (CLL: a type of blood cancer that has returned after treatment or did not fully respond to treatment)
 - 2. Small lymphocytic lymphoma (SLL: a type of blood cancer)
- B. You are 18 years of age or older
- C. You have received at least two prior therapies for chronic lymphocytic leukemia or small lymphocytic lymphoma

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ECALLANTIDE

Generic	Brand				
ECALLANTIDE	KALBITOR				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ECALLANTIDE (Kalbitor)** requires the following rule(s) be met for approval:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You are 12 years of age or older
- C. Kalbitor will be used for the treatment of acute (sudden and severe) attacks of hereditary angioedema
- D. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor), hematologist (a type of blood doctor), or pulmonologist (lung/breathing doctor) Your diagnosis is confirmed by ONE of the following complement tests: C1-INH protein levels, C4 protein levels, C1-INH functional levels, C1q (a type of lab test)
- E. Kalbitor will be administered by a healthcare professional with appropriate medical support to manage anaphylaxis (severe, possible life-threatening allergic reaction) and/or angioedema (a type of swelling)
- F. You will NOT use Kalbitor concurrently (at the same time) with other medications used for the treatment of acute HAE attacks (such as Berinert [C1 esterase inhibitor], Ruconest [C1 esterase inhibitor], Firazyr [icatibant])

RENEWAL CRITERIA

Our guideline named **ECALLANTIDE (Kalbitor)** requires the following rule(s) be met for renewal:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You have experienced a reduction (decrease) in the severity or duration of HAE attacks

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ECULIZUMAB

Generic	Brand				
ECULIZUMAB	SOLIRIS				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ECULIZUMAB (Soliris)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Paroxysmal nocturnal hemoglobinuria (PNH: a rare blood disorder)
 - 2. Atypical hemolytic uremic syndrome (aHUS: a rare blood disorder)
 - 3. Generalized myasthenia gravis (gMG: a chronic autoimmune disorder)
 - 4. Neuromyelitis optica spectrum disorder (NMOSD: a type of brain disorder)
- B. Soliris (eculizumab) is NOT being used for the treatment of hemolytic uremic syndrome related to Shiga toxin E. coli (a bacteria)
- C. **If you have paroxysmal nocturnal hemoglobinuria, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
 - 3. You have flow cytometry (a type of lab test) demonstrating at least 2 different GPI-protein deficiencies (you are missing a certain type of protein, such as CD55, CD59) on at least 2 cell lineages (types of cells, such as erythrocytes [red blood cells], granulocytes [a type of white blood cell]) AND a PNH granulocyte clone size of at least 10 percent
 - 4. You have tried and failed (as shown by hemoglobin [Hgb: a type of protein in red blood cells] levels less than 10.5 g/dL immediately following at least 3 months of stable dosing) or have a contraindication to (harmful for you to use) Fabhalta (iptacopan) or Ultomiris (ravulizumab-cwvz)
 - 5. You will NOT use Soliris concurrently (at the same time) with C5 complement inhibitor therapy (such as Ultomiris [ravulizumab-cwvz], Piasky [crovalimab-akkz]), C3 complement inhibitor therapy (such as Empaveli [pegcetacoplan]) or Factor B inhibitor therapy (such as Fabhalta [iptacopan])

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ECULIZUMAB

INITIAL CRITERIA (CONTINUED)

D. If you have generalized myasthenia gravis, approval also requires:

1. You are 6 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
3. You have a positive serologic test for the anti-acetylcholine receptor antibody (AChR-Ab+; a type of blood test that shows you have myasthenia gravis)
4. You have Myasthenia Gravis Foundation of America class II, III, or IV (types of severity of disease)
5. You have tried or have a contraindication to (harmful for you to use) ONE corticosteroid (such as prednisone)
6. You will NOT use Soliris concurrently (at the same time) with another neonatal Fc receptor blocker (such as Rystiggo [rozanolixizumab-noli], Vyvgart [efgartigimod alfa-fcab]) or complement inhibitor (such as Ultomiris [ravulizumab-cwvz], Zilbrysq [zilucoplan]) for the treatment of generalized myasthenia gravis
7. You meet ONE of the following:
 - a. You have tried or have a contraindication to (harmful for you to use) TWO non-steroidal immunosuppressive therapies (such as azathioprine, cyclophosphamide, methotrexate)
 - b. You have tried or have a contraindication to ONE non-steroidal immunosuppressive therapy if you are on chronic plasmapheresis or plasma exchange (types of blood therapy)
8. If you are 18 years of age or older, approval also requires:
 - a. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Rystiggo [rozanolixizumab-noli], Vyvgart [efgartigimod alfa-fcab]/Vyvgart Hytrulo [efgartigimod-hyaluronidase-qvfc]

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ECULIZUMAB

INITIAL CRITERIA (CONTINUED)

- E. If you have neuromyelitis optica spectrum disorder, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
 3. You have a positive test for anti-aquaporin-4 (AQP4: a type of protein) antibodies
 4. You have tried or have a contraindication to (harmful for you to use) Ultomiris (ravulizumab-cwvz)
 5. You will NOT use Soliris concurrently (at the same time) with another NMOSD medication (such as Rituxan [rituximab], Enspryng [satralizumab-mwge], Uplizna [inebilizumab-cdon], Ultomiris [ravulizumab-cwvz])
 6. You have at least ONE of the following core clinical characteristics:
 - a. Optic neuritis (a type of brain disorder)
 - b. Acute myelitis (a type of brain disorder)
 - c. Area postrema syndrome (a type of brain disorder)
 - d. Acute brainstem syndrome (a type of brain disorder)
 - e. Symptomatic narcolepsy (a type of sleep condition) or acute diencephalic clinical syndrome (tumor in a part of the brain) with NMOSD-typical diencephalic magnetic resonance imaging (MRI: a type of imaging lab) lesions (affected areas)
 - f. Symptomatic cerebral syndrome with NMOSD-typical brain lesions

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ECULIZUMAB

RENEWAL CRITERIA

Our guideline named **ECULIZUMAB (Soliris)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Paroxysmal nocturnal hemoglobinuria (PNH: a rare blood disorder)
2. Atypical hemolytic uremic syndrome (aHUS: a rare blood disorder)
3. Generalized myasthenia gravis (gMG: a chronic autoimmune disorder)
4. Neuromyelitis optica spectrum disorder (NMOSD: a type of brain disorder)

B. **If you have paroxysmal nocturnal hemoglobinuria, renewal also requires:**

1. You have experienced a clinical benefit (such as a reduction in the number of blood transfusions [adding blood to your body], improvement/stabilization of lactate dehydrogenase [LDH: a type of enzyme] levels and hemoglobin [Hgb: a type of protein in red blood cells] levels) compared to baseline (before treatment)
2. You will NOT use Soliris concurrently (at the same time) with C5 complement inhibitor therapy (such as Ultomiris [ravulizumab-cwvz], Piasky [crovalimab-akkz]), C3 complement inhibitor therapy (such as Empaveli [pegcetacoplan]) or Factor B inhibitor therapy (such as Fabhalta [iptacopan])

C. **If you have generalized myasthenia gravis, renewal also requires:**

1. You have experienced a clinical benefit compared to baseline (before treatment) according to validated gMG instruments (such as Myasthenia Gravis Activities of Daily Living tool, Quantitative Myasthenia Gravis tool)
2. You will NOT use Soliris concurrently (at the same time) with another neonatal Fc receptor blocker (such as Rystiggo [rozanolixizumab-noli], Vyvgart [efgartigimod alfa-fcab]) or complement inhibitor (such as Ultomiris [ravulizumab-cwvz], Zilbrysq [zilucoplan]) for the treatment of generalized myasthenia gravis

D. **If you have neuromyelitis optica spectrum disorder, renewal also requires:**

1. You have experienced a reduction in relapse frequency compared to baseline (before treatment)
2. You will NOT use Soliris concurrently (at the same time) with another NMOSD medication (such as Rituxan [rituximab], Enspryng [satralizumab-mwge], Uplizna [inebilizumab-cdon], Ultomiris [ravulizumab-cwvz])

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ECULIZUMAB-AAGH

Generic	Brand				
ECULIZUMAB-AAGH	EPYSQLI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ECULIZUMAB-AAGH (Epysqli)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Paroxysmal nocturnal hemoglobinuria (PNH: a rare blood disorder)
 2. Atypical hemolytic uremic syndrome (aHUS: a rare blood disorder)
 3. Generalized myasthenia gravis (gMG: a chronic autoimmune disorder)
 4. Neuromyelitis optica spectrum disorder (NMOSD: a type of brain disorder)
- B. Epysqli (eculizumab-aagh) is NOT being used for the treatment of hemolytic uremic syndrome related to Shiga toxin E. coli (a bacteria)
- C. **If you have paroxysmal nocturnal hemoglobinuria, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
 3. You have flow cytometry (a type of lab test) demonstrating at least 2 different GPI-protein deficiencies (you are missing a certain type of protein, such as CD55, CD59) on at least 2 cell lineages (types of cells, such as erythrocytes [red blood cells], granulocytes [a type of white blood cell]) AND a PNH granulocyte clone size of at least 10 percent
 4. You have tried and failed (as shown by hemoglobin [Hgb: a type of protein in red blood cells] levels less than 10.5 g/dL immediately following at least 3 months of stable dosing) or have a contraindication to (harmful for you to use) Fabhalta (iptacopan) or Ultomiris (ravulizumab-cwvz)
 5. You will NOT use Epysqli concurrently (at the same time) with C5 complement inhibitor therapy (such as Ultomiris [ravulizumab-cwvz], Piasky [crovalimab-akkz]), C3 complement inhibitor therapy (such as Empaveli [pegcetacoplan]) or Factor B inhibitor therapy (such as Fabhalta [iptacopan])

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ECULIZUMAB-AAGH

INITIAL CRITERIA (CONTINUED)

D. If you have generalized myasthenia gravis, approval also requires:

1. You are 6 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
3. You have a positive serologic test for the anti-acetylcholine receptor antibody (AChR-Ab+; a type of blood test that shows you have myasthenia gravis)
4. You have Myasthenia Gravis Foundation of America class II, III, or IV (types of severity of disease)
5. You have tried or have a contraindication to (harmful for you to use) ONE corticosteroid (such as prednisone)
6. You will NOT use Epysqli concurrently (at the same time) with another neonatal Fc receptor blocker (such as Rystiggo [rozanolixizumab-noli], Vyvgart [efgartigimod alfa-fcab]) or complement inhibitor (such as Ultomiris [ravulizumab-cwvz], Zilbrysq [zilucoplan]) for the treatment of generalized myasthenia gravis
7. You meet ONE of the following:
 - a. You have tried or have a contraindication to (harmful for you to use) TWO non-steroidal immunosuppressive therapies (such as azathioprine, cyclophosphamide, methotrexate)
 - b. You have tried or have a contraindication to ONE non-steroidal immunosuppressive therapy if you are on chronic plasmapheresis or plasma exchange (types of blood therapy)
8. If you are 18 years of age or older, approval also requires:
 - a. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Rystiggo (rozanolixizumab-noli), Vyvgart (efgartigimod alfa-fcab)/Vyvgart Hytrulo (efgartigimod-hyaluronidase-qvfc)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ECULIZUMAB-AAGH

INITIAL CRITERIA (CONTINUED)

E. If you have neuromyelitis optica spectrum disorder, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
3. You have a positive test for anti-aquaporin-4 (AQP4: a type of protein) antibodies
4. You have tried or have a contraindication to (harmful for you to use) Ultomiris (ravulizumab-cwvz)
5. You will NOT use Epysqli concurrently (at the same time) with another NMOSD medication (such as Rituxan [rituximab], Enspryng [satralizumab-mwge], Uplizna [inebilizumab-cdon], Ultomiris [ravulizumab-cwvz])
6. You have at least ONE of the following core clinical characteristics:
 - a. Optic neuritis (a type of brain disorder)
 - b. Acute myelitis (a type of brain disorder)
 - c. Area postrema syndrome (a type of brain disorder)
 - d. Acute brainstem syndrome (a type of brain disorder)
 - e. Symptomatic narcolepsy (a type of sleep condition) or acute diencephalic clinical syndrome (tumor in a part of the brain) with NMOSD-typical diencephalic magnetic resonance imaging (MRI: a type of imaging lab) lesions (affected areas)
 - f. Symptomatic cerebral syndrome with NMOSD-typical brain lesions

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ECULIZUMAB-AAGH

RENEWAL CRITERIA

Our guideline named **ECULIZUMAB-AAGH (Epysqli)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Paroxysmal nocturnal hemoglobinuria (PNH: a rare blood disorder)
2. Atypical hemolytic uremic syndrome (aHUS: a rare blood disorder)
3. Generalized myasthenia gravis (gMG: a chronic autoimmune disorder)
4. Neuromyelitis optica spectrum disorder (NMOSD: a type of brain disorder)

B. **If you have paroxysmal nocturnal hemoglobinuria, renewal also requires:**

1. You have experienced a clinical benefit (such as a reduction in the number of blood transfusions [adding blood to your body], improvement/stabilization of lactate dehydrogenase [LDH: a type of enzyme] levels and hemoglobin [Hgb: a type of protein in red blood cells] levels) compared to baseline (before treatment)
2. You will NOT use Epysqli concurrently (at the same time) with C5 complement inhibitor therapy (such as Ultomiris [ravulizumab-cwvz], Piasky [crovalimab-akkz]), C3 complement inhibitor therapy (such as Empaveli [pegcetacoplan]) or Factor B inhibitor therapy (such as Fabhalta [iptacopan])

C. **If you have generalized myasthenia gravis, renewal also requires:**

1. You have experienced a clinical benefit compared to baseline (before treatment) according to validated gMG instruments (such as Myasthenia Gravis Activities of Daily Living tool, Quantitative Myasthenia Gravis tool)
2. You will NOT use Epysqli concurrently (at the same time) with another neonatal Fc receptor blocker (such as Rystiggo [rozanolixizumab-noli], Vyvgart [efgartigimod alfa-fcab]) or complement inhibitor (such as Ultomiris [ravulizumab-cwvz], Zilbrysq [zilucoplan]) for the treatment of generalized myasthenia gravis

D. **If you have neuromyelitis optica spectrum disorder, renewal also requires:**

1. You have experienced a reduction in relapse frequency compared to baseline (before treatment)
2. You will NOT use Epysqli concurrently (at the same time) with another NMOSD medication (such as Rituxan [rituximab], Enspryng [satralizumab-mwge], Uplizna [inebilizumab-cdon], Ultomiris [ravulizumab-cwvz])

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EDARAVONE ORAL

Generic	Brand				
EDARAVONE	RADICAVA ORS				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **EDARAVONE ORAL (Radicava ORS)** requires the following rule(s) be met for approval:

- A. You have amyotrophic lateral sclerosis (ALS: a type of brain and nerve condition)
- B. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor) or ALS specialist at an ALS Specialty Center or Care Clinic
- C. You have had ALS (from onset of symptoms) for 3 years or less
- D. You have a forced vital capacity (FVC: amount of air exhaled from lungs) of greater than 70 percent
- E. You have tried riluzole OR are currently taking riluzole
- F. You have mild to moderate ALS with a score of 2 or higher in all of the following 12 items of the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R: a tool for evaluating functional status): speech, salivation, swallowing, handwriting, cutting food, dressing and hygiene, turning in bed, walking, climbing stairs, dyspnea (difficulty breathing), orthopnea (shortness of breath while lying down), respiratory insufficiency (a type of breathing condition)

RENEWAL CRITERIA

Our guideline named **EDARAVONE ORAL (Radicava ORS)** requires the following rule(s) be met for renewal:

- A. You have amyotrophic lateral sclerosis (ALS: a type of brain and nerve condition)
- B. You do not require invasive ventilation (inserting a breathing tube into your throat)
- C. You have improved baseline functional ability OR you have maintained a score of 2 or greater in all 12 items of the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R)

Effective: 06/15/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EFBEMALENOGRASTIM ALFA-VUXW

Generic	Brand				
EFBEMALENOGRA STIM ALFA-VUXW	RYZNEUTA				

GUIDELINES FOR USE

Our guideline named **EFBEMALENOGRASTIM ALFA-VUXW (Ryzneuta)** requires the following rule(s) be met for approval:

- A. You are receiving myelosuppressive anti-cancer medications (medications that decrease bone marrow activity) associated with a clinically significant incidence of febrile neutropenia (a type of blood condition with fever)
- B. You are 18 years of age or older
- C. You have a non-myeloid malignancy (cancer not affecting bone marrow)
- D. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
- E. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Ziextenzo (pegfilgrastim-bmez)

Effective: 06/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EFGARTIGIMOD

Generic	Brand				
EFGARTIGIMOD ALFA-FCAB	VYVGART				
EFGARTIGIMOD- HYALURONIDAS- QVFC	VYVGART HYTRULO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **EFGARTIGIMOD (Vyvgart, Vyvgart Hytrulo)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Generalized myasthenia gravis (gMG: a chronic autoimmune disorder)
 2. Chronic inflammatory demyelinating polyneuropathy (CIDP: a type of nerve disorder)
- B. **If you have generalized myasthenia gravis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
 3. You have a positive serologic test for the anti-acetylcholine receptor antibody (AChR-Ab+: a type of blood test that shows you have myasthenia gravis)
 4. You have Myasthenia Gravis Foundation of America class II, III, or IV (type of severity of disease)
 5. You have tried or have a contraindication to (harmful for you to use) ONE corticosteroid (such as prednisone)
 6. You will NOT use the requested medication concurrently (at the same time) with another neonatal Fc receptor blocker (such as Rystiggo [rozanolixizumab-noli], Imaavy [nipocalimab-aahu] or complement inhibitor (such as Soliris [eculizumab], Zilbrysq [zilucoplan]) for the treatment of generalized myasthenia gravis
 7. You meet ONE of the following:
 - a. You have tried or have a contraindication to (harmful for you to use) TWO non-steroidal immunosuppressive therapies (such as azathioprine, cyclophosphamide, methotrexate)
 - b. You have tried or have a contraindication to ONE non-steroidal immunosuppressive therapy if you are on chronic plasmapheresis or plasma exchange (types of blood therapy)
- C. **If you have chronic inflammatory demyelinating polyneuropathy, approval also requires:**
1. You are 18 years of age or older
 2. The request is for Vyvgart Hytrulo

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EFGARTIGIMOD

RENEWAL CRITERIA

NOTE: For the diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP), please refer to the Initial Criteria section.

Our guideline named **EFGARTIGIMOD (Vyvgart, Vyvgart Hytrulo)** requires the following rule(s) be met for renewal:

- A. You have generalized myasthenia gravis (gMG: a chronic autoimmune disorder)
- B. You have had clinical benefit compared to baseline (before treatment) according to validated gMG instruments (such as Myasthenia Gravis Activities of Daily Living tool, Quantitative Myasthenia Gravis tool)
- C. You will NOT use the requested medication concurrently (at the same time) with another neonatal Fc receptor blocker (such as Rystiggo [rozanolixizumab-noli], Imaavy [nipocalimab-aahu]) or complement inhibitor (such as Soliris [eculizumab], Zilbrysq [zilucoplan]) for the treatment of generalized myasthenia gravis

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EFINACONAZOLE

Generic	Brand			
EFINACONAZOLE	JUBLIA			

GUIDELINES FOR USE

Our guideline named **EFINACONAZOLE (Jublia)** requires the following rule(s) be met for approval:

- A. You have onychomycosis of the toenail(s) (toenail fungus)
- B. You have previously tried the following unless contraindicated (a medical reason why you cannot use): ciclopirox topical solution AND either oral terbinafine OR oral itraconazole
- C. You have at least ONE of the following conditions:
 - 1. Diabetes, peripheral vascular disease (narrowed blood vessels reduce blood flow to the limbs), or immunosuppression (weakened immune system)
 - 2. Pain surrounding the nail or soft tissue involvement

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EFLAPEGRASTIM-XNST

Generic	Brand				
EFLAPEGRASTIM-XNST	ROLVEDON				

GUIDELINES FOR USE

Our guideline named **EFLAPEGRASTIM-XNST (Rolvedon)** requires the following rule(s) be met for approval:

- A. You are receiving myelosuppressive anti-cancer medications (medications that decrease bone marrow activity) associated with a clinically significant incidence of febrile neutropenia (a type of blood condition with fever)
- B. You are 18 years of age or older
- C. You have a non-myeloid malignancy (cancer not affecting bone marrow)
- D. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
- E. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Ziextenzo (pegfilgrastim-bmez)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EFLORNITHINE

Generic	Brand				
EFLORNITHINE HCL	IWILFIN				

GUIDELINES FOR USE

Our guideline named **EFLORNITHINE (Iwilfin)** requires the following rule(s) be met for approval:

You have high-risk neuroblastoma (HRNB: a type of rare cancer)

You have shown a partial response (the cancer partly responded to treatment, but still did not go away) to prior therapy, including anti-GD2 immunotherapy (such as Unituxin [dinutuximab])

Effective: 01/15/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ELACESTRANT

Generic	Brand				
ELACESTRANT HYDROCHLORIDE	ORSERDU				

GUIDELINES FOR USE

Our guideline named **ELACESTRANT (Orserdu)** requires the following rule(s) be met for approval:

- A. You have advanced or metastatic breast cancer (breast cancer that has spread to other parts of the body)
- B. Your breast cancer is estrogen receptor (ER: type of protein)-positive, human epidermal growth factor receptor 2 (HER2: type of protein)-negative with estrogen receptor 1 (ESR1: a gene) mutation(s)
- C. You have disease progression following endocrine therapy (disease has worsened after using a type of hormone therapy)

Effective: 07/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ELAFIBRANOR

Generic	Brand				
ELAFIBRANOR	IQIRVO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ELAFIBRANOR (Iqirvo)** requires the following rule(s) be met for approval:

- A. You have primary biliary cholangitis (PBC: a type of immune system disorder that destroys the bile duct), as confirmed by TWO of the following:
 - 1. You have an elevated (high) alkaline phosphatase (ALP) level (a type of lab test)
 - 2. You have the presence of antimitochondrial antibodies (AMA: indicator of the body attacking its own cells) or other PBC-specific autoantibodies (indicator of the body attacking its own cells), including sp100 or gp210, if AMA is negative
 - 3. You have histologic evidence (lab data obtained by liver biopsy [removal of cells or tissue from the liver for examination]) of non-suppurative destructive cholangitis and destruction of interlobular bile ducts (symptoms of liver disease)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions) or hepatologist (a type of liver doctor)
- D. You do not have decompensated cirrhosis (a condition where there is liver damage and scarring with major symptoms) (Child-Pugh B or C: a score that evaluates the severity of liver damage) OR a prior decompensation event (liver stops working properly)
- E. You do NOT have compensated cirrhosis (a condition where there is liver damage and scarring without any major symptoms) with evidence of portal hypertension (high blood pressure in the major vein that leads to the liver)
- F. You will NOT use Iqirvo concurrently (at the same time) with any other second-line therapy for PBC (Ocaliva [obeticholic acid], Livdelzi [seladelpar])
- G. You meet ONE of the following:
 - 1. Iqirvo will be used as monotherapy (one drug treatment) if you are unable to tolerate ursodiol (ursodeoxycholic acid)
 - 2. Iqirvo will be used in combination (together) with ursodiol (ursodeoxycholic acid) if you had an inadequate (poor) response to at least 1 year of treatment with ursodiol (ursodeoxycholic acid) monotherapy (one drug treatment)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ELAFIBRANOR

RENEWAL CRITERIA

Our guideline named **ELAFIBRANOR (Iqirvo)** requires the following rule(s) be met for renewal:

- A. You have primary biliary cholangitis (PBC: a type of immune system disorder that destroys the bile duct)
- B. You have an alkaline phosphatase (ALP) level (a type of lab test) that is less than 1.67-times the upper limit of normal AND which has decreased by at least 15 percent from baseline while on treatment with Iqirvo
- C. You will NOT use Iqirvo concurrently (at the same time) with any other second-line therapy for PBC (Ocaliva [obeticholic acid], Livdelzi [seladelpar])

Effective: 09/16/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ELAGOLIX

Generic	Brand			
ELAGOLIX	ORILISSA			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ELAGOLIX (Orilissa)** requires the following rule(s) be met for approval:

- A. You have moderate to severe pain associated with endometriosis (condition affecting the uterus)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with an obstetrician/gynecologist (a type of women's health doctor)
- D. Your diagnosis of endometriosis is confirmed by surgical or direct visualization (such as pelvic ultrasound [type of imaging]) or histopathological (tissue) confirmation (such as laparoscopy [type of surgery] or laparotomy [type of surgery]) in the last 10 years
- E. Orilissa will NOT be used at the same time with another GnRH-modulating agent (such as Lupron Depot [leuprolide], Synarel [nafarelin], Zoladex [goserelin])
- F. Requests for Orilissa 200mg twice daily will only be approved if you have normal liver function or mild hepatic (liver) impairment (Child-Pugh Class A)
- G. Requests will not be approved if you previously received ONE of the following:
 - 1. A 6-month course of Orilissa 200mg twice daily
 - 2. A 6-month course of Orilissa 150mg once daily and you have moderate hepatic (liver) impairment (Child-Pugh Class B)
 - 3. A 24-month course of Orilissa 150mg once daily and you have normal liver function or mild (liver) hepatic impairment (Child-Pugh Class A)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ELAGOLIX

RENEWAL CRITERIA

Our guideline named **ELAGOLIX (Orilissa)** requires the following rule(s) be met for renewal:

- A. You have moderate to severe pain associated with endometriosis (condition affecting the uterus)
- B. You have improvement of pain related to endometriosis while on therapy
- C. You have normal liver function or mild hepatic (liver) impairment (Child-Pugh Class A)
- D. Orilissa will NOT be used at the same time with another GnRH-modulating agent (such as Lupron Depot [leuprolide], Synarel [nafarelin], Zoladex [goserelin])
- E. Requests will not be approved if you previously received ONE of the following:
 - 1. A 6-month course of Orilissa 200mg twice daily
 - 2. A 6-month course of Orilissa 150mg once daily and you have moderate hepatic (liver) impairment (Child-Pugh Class B)
 - 3. A 24-month course of Orilissa 150mg once daily and you have normal liver function or mild (liver) hepatic impairment (Child-Pugh Class A)

Effective: 10/09/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ELAGOLIX/ESTRADIOL/NORETHINDRONE

Generic	Brand				
ELAGOLIX AND ESTRADIOL AND NORETHINDRONE	ORIAHNN				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ELAGOLIX/ESTRADIOL/NORETHINDRONE (OriaHnn)** requires the following rule(s) be met for approval:

- A. The request is for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids: non-cancerous growths in the uterus)
- B. You are 18 years of age or older
- C. You are a premenopausal woman
- D. Therapy is prescribed by or given in consultation with an obstetrician or gynecologist (OB/GYN: doctor who specializes in women's reproductive system)
- E. You have not received a total of 24 months cumulative treatment with OriaHnn

RENEWAL CRITERIA

Our guideline named **ELAGOLIX/ESTRADIOL/NORETHISTERONE (OriaHnn)** requires the following rule(s) be met for renewal:

- A. The request is for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids: non-cancerous growths in the uterus)
- B. You had improvement of heavy menstrual bleeding on therapy
- C. You have not received a total of 24 months cumulative treatment with OriaHnn

Effective: 01/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ELAPEGADEMASE-LVLR

Generic	Brand			
ELAPEGADEMASE-LVLR	REVCovi			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ELAPEGADEMASE-LVLR (Revcovi)** requires the following rule(s) be met for approval:

- A. You have adenosine deaminase severe combined immune deficiency (ADA-SCID: an inherited disorder that damages the immune system) as shown by ONE of the following:
 - 1. You have a confirmatory genetic test
 - 2. You have suggestive laboratory findings (such as elevated deoxyadenosine nucleotide levels, lymphopenia [low levels of a type of white blood cell]) AND you have hallmark signs/symptoms (such as recurrent infections, failure to thrive, persistent diarrhea)
- B. Therapy is prescribed by or in consultation with an immunologist (a type of immune system doctor), hematologist-oncologist (a type of blood-cancer doctor), or physician specializing in inherited metabolic disorders
- C. You meet ONE of the following:
 - 1. You have failed or are not a candidate for hematopoietic cell transplant (blood cell transplant from bone marrow)
 - 2. Revcovi will be used as a bridging therapy prior to planned hematopoietic cell transplant or gene therapy

RENEWAL CRITERIA

Our guideline named **ELAPEGADEMASE-LVLR (Revcovi)** requires the following rule(s) be met for renewal:

- A. You have adenosine deaminase severe combined immune deficiency (ADA-SCID: an inherited disorder that damages the immune system)
- B. You have a trough plasma adenosine deaminase (ADA) activity of at least 30 mmol/hr/L AND trough deoxyadenosine nucleotide (dAXP) levels less than 0.02 mmol/L
- C. You have shown improvement in or maintenance of immune function from baseline (such as a decrease in the number and severity of infections)
- D. You have NOT received successful hematopoietic cell transplantation (HCT: blood cell transplant from bone marrow) or gene therapy

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ELBASVIR/GRAZOPREVIR

Generic	Brand			
ELBASVIR/GRAZOPREVIR	ZEPATIER			

GUIDELINES FOR USE

Our guideline for **ELBASVIR/GRAZOPREVIR (Zepatier)** requires the following rule(s) be met for approval:

- A. You have chronic hepatitis C virus (HCV: liver inflammation caused by a type of virus)
- B. You are 12 years of age or older OR weigh at least 30 kilograms (66 pounds)
- C. You have genotype 1 or 4 hepatitis C infection (types of hepatitis C virus)
- D. You have an HCV RNA level (a measure of the amount of hepatitis C virus in the blood) within the past 6 months
- E. You do NOT have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (having two or more diseases at the same time)
- F. You do NOT have moderate or severe liver impairment (decompensated cirrhosis [a condition where there is liver damage and scarring with major symptoms]; Child-Pugh B or C [a score that evaluates the severity of liver damage])
- G. You will NOT use Zepatier concurrently (at the same time) with any medication with drug interactions that are contraindicated (harmful for you to use) or not recommended per the prescribing information (such as phenytoin, carbamazepine, rifampin, efavirenz [such as Atripla, Sustiva], atazanavir [such as Evotaz, Reyataz], darunavir [such as Prezcofix, Prezista], lopinavir, saquinavir, Aptivus [tipranavir], cyclosporine, nafcillin, ketoconazole, modafinil, bosentan, etravirine, elvitegravir/cobicistat/emtricitabine/tenofovir [such as Stribild, Genvoya], atorvastatin at doses greater than 20mg daily, rosuvastatin at doses greater than 10mg daily, St. John's wort)
- H. You will NOT use Zepatier concurrently (at the same time) with Sovaldi (sofosbuvir; as a single agent), Epclusa (velpatasvir/sofosbuvir), Harvoni (ledipasvir/sofosbuvir), Mavyret (glecaprevir/pibrentasvir), or Vosevi (velpatasvir/sofosbuvir/voxilaprevir)
- I. You had an intolerance (side effect) or contraindication to (harmful for you to use) ONE of the following preferred medications: Epclusa, Harvoni

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ELBASVIR/GRAZOPREVIR

GUIDELINES FOR USE (CONTINUED)

- J. If you are treatment-naïve (no prior treatment), approval also requires ONE of the following:**
1. You have genotype 1a infection AND you do not have baseline NS5A polymorphisms (variations in a type of hepatitis C virus protein)
 2. You have genotype 1b infection
 3. You have genotype 4 infection
 4. You received a kidney transplant (replaced your kidney) AND you do not have baseline NS5A resistance-associated substitution (RAS) polymorphisms (variations in a type of hepatitis C virus protein)
 5. You have genotype 1a infection, with baseline NS5A polymorphisms, AND Zepatier will be used with ribavirin
- K. If you are treatment-experienced (failed prior treatment), approval also requires ONE of the following:**
1. You have genotype 1a infection, without baseline NS5A polymorphisms (variations in a type of hepatitis C virus protein), AND were previously treated with peginterferon/ribavirin
 2. You have genotype 1b infection AND were previously treated with peginterferon/ribavirin
 3. You have genotype 1 infection, were previously treated with a peginterferon/ribavirin/protease inhibitor triple regimen, AND Zepatier will be used with ribavirin
 4. You have genotype 1a infection with baseline NS5A polymorphisms, were previously treated with peginterferon/ribavirin, AND Zepatier will be used with ribavirin
 5. You have genotype 4 infection, were previously treated with peginterferon/ribavirin, AND Zepatier will be used with ribavirin
 6. You received a kidney transplant (replaced your kidney), were previously treated with a non-direct acting antiviral (such as interferon), AND you do not have baseline NS5A resistance-associated substitution (RAS) polymorphisms (variations in a type of hepatitis C virus protein)
- L. Zepatier will also be approved for any other regimen/condition not listed above that is recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment**

Effective: 07/22/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ELEXACAFTOR-TEZACAFTOR-IVACAFTOR

Generic	Brand				
ELEXACAFTOR/ TEZACAFTOR/ IVACAFTOR	TRIKAFTA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ELEXACAFTOR-TEZACAFTOR-IVACAFTOR (Trikafta)** requires the following rule(s) be met for approval:

- A. You have cystic fibrosis (CF: a type of lung disorder)
- B. You are 2 years of age or older
- C. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or cystic fibrosis expert
- D. You will NOT use Trikafta concurrently (at the same time) with another cystic fibrosis transmembrane conductance regulator (CFTR) modulator (such as medications containing vanzacaftor, deutivacaftor, ivacaftor, lumacaftor, tezacaftor, or elexacaftor)
- E. You have at least ONE F508del mutation (abnormal change) or a responsive mutation in the CFTR gene (abnormal change in a type of gene that can be treated with Trikafta)

RENEWAL CRITERIA

Our guideline named **ELEXACAFTOR-TEZACAFTOR-IVACAFTOR (Trikafta)** requires the following rule(s) be met for renewal:

- A. You have cystic fibrosis (CF: a type of lung disorder)
- B. You have experienced an improvement in your clinical status
- C. You will NOT use Trikafta concurrently (at the same time) with another cystic fibrosis transmembrane conductance regulator (CFTR) modulator (such as medications containing vanzacaftor, deutivacaftor, ivacaftor, lumacaftor, tezacaftor, or elexacaftor)

Effective: 01/28/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ELTROMBOPAG - ALVAIZ

Generic	Brand				
ELTROMBOPAG CHOLINE	ALVAIZ				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ELTROMBOPAG - ALVAIZ** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Persistent or chronic immune (idiopathic) thrombocytopenia (ITP: a type of blood disorder)
2. Thrombocytopenia (a type of blood disorder) due to chronic hepatitis C (a type of liver infection)
3. Severe aplastic anemia (a type of blood disorder)

B. **If you have persistent or chronic immune (idiopathic) thrombocytopenia, approval also requires:**

1. You are 6 years of age or older
2. You have tried or have a contraindication to (harmful for you to use) corticosteroids or immunoglobulins, OR you did not have a good enough response to a splenectomy (spleen removal)
3. You will NOT use Alvaiz concurrently (at the same time) with other thrombopoietin receptor agonists (TPO-RAs, such as Promacta [eltrombopag], Doptelet [avatrombopag], Nplate [romiplostim]) or a spleen tyrosine kinase (SYK) inhibitor (such as Tavalisse [fostamatinib])
4. You have tried or have a contraindication to (harmful for you to use) Promacta (eltrombopag)
5. You meet ONE of the following:
 - c. You have a platelet (a type of blood cell) count of less than $30 \times 10^9/L$
 - d. You have a platelet count of less than $50 \times 10^9/L$ AND a prior bleeding event

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ELTROMBOPAG - ALVAIZ

INITIAL CRITERIA (CONTINUED)

C. If you have thrombocytopenia due to chronic hepatitis C, approval also requires:

1. You are 18 years of age or older
2. Your thrombocytopenia does not allow you to start interferon-based therapy (a type of drug for hepatitis) or limits your ability to maintain interferon-based therapy
3. You have tried or have a contraindication to (harmful for you to use) Promacta (eltrombopag)

D. If you have severe aplastic anemia, approval also requires:

1. You are 18 years of age or older
2. You did not have a good enough response to immunosuppressive therapy (treatment that lowers the activity of the body's immune system)
3. You have tried or have a contraindication to (harmful for you to use) Promacta (eltrombopag)

RENEWAL CRITERIA

NOTE: For the diagnoses of thrombocytopenia due to chronic hepatitis C or severe aplastic anemia, please refer to the Initial Criteria section.

Our guideline named **ELTROMBOPAG - ALVAIZ** requires the following rules be met for renewal:

- A. You have persistent or chronic immune (idiopathic) thrombocytopenia (ITP: a type of blood disorder)
- B. You have shown a clinical response to therapy, defined as having an improvement in platelet (a type of blood cell) count from baseline (before starting Alvaiz) OR a decrease in bleeding events
- C. You will NOT use Alvaiz concurrently (at the same time) with other thrombopoietin receptor agonists (TPO-RAs, such as Promacta [eltrombopag], Doptelet [avatrombopag], Nplate [romiplostim]) or a spleen tyrosine kinase (SYK) inhibitor (such as Tavalisse [fostamatinib])

Effective: 10/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EMICIZUMAB-KXWH

Generic	Brand			
EMICIZUMAB-KXWH	HEMLIBRA			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **EMICIZUMAB-KXWH (Hemlibra)** requires the following rule(s) be met for approval:

- A. You have hemophilia A (congenital factor VIII deficiency: a type of bleeding disorder)
- B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
- C. Hemlibra will be used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes
- D. You will NOT use Hemlibra concurrently (at the same time) with another non-factor prophylaxis therapy (such as Hympavzi [marstacimab-hncq])
- E. **If you have hemophilia A with factor VIII inhibitors (a type of protein), approval also requires:**
 - 1. You have a history of a high titer (concentration) of factor VIII inhibitor, defined as at least 5 Bethesda units per milliliter
- F. **If you have hemophilia A without factor VIII inhibitors (a type of protein), approval also requires ONE of the following:**
 - 1. You have moderate to severe hemophilia A, defined as less than 5 percent factor VIII activity compared to normal
 - 2. You have mild hemophilia A, defined as 5 percent - 40 percent factor VIII activity compared to normal, and meet ONE of the following:
 - a. You have experienced severe, traumatic, or spontaneous (sudden) bleeding episode(s) (may occur in joint or muscle)
 - b. You have experienced a life-threatening bleed (such as intracranial hemorrhage [ICH: a type of bleeding in the head])
 - c. It is difficult to access your veins which prevents or delays you in receiving regular clotting factor infusions

RENEWAL CRITERIA

Our guideline named **EMICIZUMAB-KXWH (Hemlibra)** requires the following rule(s) be met for renewal:

- A. You have hemophilia A (congenital factor VIII deficiency: a type of bleeding disorder)
- B. You have shown a clinical benefit compared to baseline (before starting Hemlibra)
- C. You will NOT use Hemlibra concurrently (at the same time) with another non-factor prophylaxis therapy (such as Hympavzi [marstacimab-hncq])

Effective: 11/25/24

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ENASIDENIB

Generic	Brand			
ENASIDENIB	IDHIFA			

GUIDELINES FOR USE

Our guideline named **ENASIDENIB (Idhifa)** requires the following rule(s) be met for approval:

- A. You have relapsed or refractory acute myeloid leukemia (a type of blood and bone marrow cancer that has returned after or is resistant to treatment)
- B. You are 18 years of age or older
- C. You are isocitrate dehydrogenase-2 (a type of enzyme) mutation positive as detected by an FDA (Food and Drug Administration)-approved diagnostic test

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ENCORAFENIB

Generic	Brand			
ENCORAFENIB	BRAFTOVI			

GUIDELINES FOR USE

Our guideline named **ENCORAFENIB (Braftovi)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Unresectable or metastatic melanoma (a type of skin cancer that cannot be completely removed with surgery or has spread to other parts of the body)
 - 2. Metastatic colorectal cancer (mCRC: a type of digestive cancer that has spread to other parts of the body)
 - 3. Metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to other parts of the body)
- B. **If you have unresectable or metastatic melanoma, approval also requires:**
 - 1. You have a BRAF V600E or V600K mutation (abnormal change in types of genes), as detected by a Food and Drug Administration (FDA)-approved test
 - 2. Braftovi will be used in combination with Mektovi (binimetinib)
- C. **If you have metastatic colorectal cancer, approval also requires:**
 - 1. You have a BRAF V600E mutation (abnormal change in a type of gene), as detected by a Food and Drug Administration (FDA)-approved test
 - 2. You meet ONE of the following:
 - a. Braftovi will be used in combination with Erbitux (cetuximab) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin)
 - b. Braftovi will be used in combination with Erbitux (cetuximab), you are 18 years of age or older, and you have previously received treatment (such as irinotecan)
- D. **If you have metastatic non-small cell lung cancer, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have a BRAF V600E mutation (abnormal change in a type of gene), as detected by a Food and Drug Administration (FDA)-approved test
 - 3. Braftovi will be used in combination with Mektovi (binimetinib)

Effective: 01/17/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ENSARTINIB

Generic	Brand				
ENSARTINIB HYDROCHLORIDE	ENSACOVE				

GUIDELINES FOR USE

Our guideline named **ENSARTINIB (Ensacove)** requires the following rule(s) be met for approval:

- A. You have locally advanced or metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread from where it started to nearby tissue/lymph nodes or other parts of the body)
- B. You are 18 years of age or older
- C. Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme)-positive
- D. You have NOT previously received an ALK-inhibitor (such as Xalkori [crizotinib], Alecensa [alectinib])

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ENSIFENTRINE

Generic	Brand				
ENSIFENTRINE	OHTUVAYRE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ENSIFENTRINE (Ohtuvayre)** requires the following rule(s) be met for approval:

- A. You have chronic obstructive pulmonary disease (COPD: a type of long-term lung condition)
- B. You are 18 years of age or older
- C. Ohtuvayre will be used as maintenance treatment (taken on a regular basis)
- D. Therapy is prescribed by or in consultation with a pulmonologist (a type of lung/breathing doctor)
- E. You have a history of and will continue on, or you had a contraindication (harmful for you to use) or failure (drug did not work) to ONE of the following standard of care therapies:
 - 1. LAMA (long-acting antimuscarinic)/LABA (long-acting beta-2-agonist) combination drug (such as Stiolto Respimat, Anoro Ellipta)
 - 2. LAMA/LABA/ICS (inhaled corticosteroid) combination drug (such as Trelegy Ellipta, Breztri Aerosphere) if you have a blood eosinophil level of 100 cells/microliter or greater

RENEWAL CRITERIA

Our guideline named **ENSIFENTRINE (Ohtuvayre)** requires the following rule(s) be met for renewal:

- A. You have chronic obstructive pulmonary disease (COPD: a type of long-term lung condition)
- B. You have a history of and will continue on, or you had a contraindication (harmful for you to use) or failure (drug did not work) to ONE of the following standard of care therapies:
 - 1. LAMA (long-acting antimuscarinic)/LABA (long-acting beta-2-agonist) combination drug (such as Stiolto Respimat, Anoro Ellipta)
 - 2. LAMA/LABA/ICS (inhaled corticosteroid) combination drug (such as Trelegy Ellipta, Breztri Aerosphere) if you have a blood eosinophil level of 100 cells/microliter or greater
- C. You have shown a clinical response as evidenced by ONE of the following:
 - 1. You have a reduction (decrease) in COPD exacerbations (worsening of symptoms) from baseline (before starting Ohtuvayre)
 - 2. You have a reduction in severity or frequency of COPD-related symptoms (such as wheezing, shortness of breath, coughing, sputum (mucus) production, etc.)
 - 3. You have an increase in FEV1 (a type of lung test) by at least 5 percent from pretreatment baseline (before starting Ohtuvayre)

Effective: 08/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ENTRECTINIB

Generic	Brand			
ENTRECTINIB	ROZLYTREK			

GUIDELINES FOR USE

Our guideline named **ENTRECTINIB (Rozlytrek)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to other parts of the body)
2. Solid tumors (an abnormal mass)

B. **If you have metastatic non-small cell lung cancer, approval also requires:**

1. You are 18 years of age or older
2. You have ROS1-positive (abnormal change in a type of gene) tumors, as detected by a Food and Drug Administration (FDA)-approved test

C. **If you have solid tumors, approval also requires:**

1. You are 1 month of age or older
2. The tumor has a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation (you have an abnormal change in a type of gene that does not have any known resistance), as detected by a Food and Drug Administration (FDA)-approved test
3. Your tumor is metastatic (has spread to other parts of the body) or surgical resection (removal) is likely to result in severe morbidity (disease)
4. You have progressed (gotten worse) after treatment or there are no satisfactory alternative treatments

D. **If the request is for Rozlytrek 50mg pellets, approval also requires:**

1. You have tried or have a contraindication to (harmful for you to use) Rozlytrek capsules that are used to make an oral suspension
2. You have difficulty or are not able to swallow capsules

Effective: 12/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EPLONTERSEN

Generic	Brand				
EPLONTERSEN SODIUM	WAINUA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **EPLONTERSEN (Wainua)** requires the following rule(s) be met for approval:

- A. You have hereditary transthyretin-mediated amyloidosis with polyneuropathy (hATTR-PN: a rare genetic disorder with widespread nerve pain/damage)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nerve doctor), cardiologist (a type of heart doctor), hATTR specialist, or medical geneticist (doctor who treats gene disorders)
- D. You are ambulatory (able to walk) (you have Familial Amyloid Polyneuropathy [FAP: a tool used to evaluate disease severity] stage 1 to 2 or Polyneuropathy Disability [PND: a tool used to evaluate disease severity] Stage I to IIIb polyneuropathy)
- E. You will NOT use Wainua concurrently (at the same time) with other hATTR-PN medications (such as Tegsedi [inotersen], Amvuttra [vutrisiran], Onpattro [patisiran])
- F. Your diagnosis is confirmed by ONE of the following:
 - 1. Biopsy (removal of cells from the body for examination) of tissue/organ to confirm amyloid (a type of abnormal protein) presence AND chemical typing to confirm the presence of TTR (*transthyretin*) protein
 - 2. DNA genetic sequencing (a type of lab test) to confirm hATTR mutation (a type of abnormal gene)

RENEWAL CRITERIA

Our guideline named **EPLONTERSEN (Wainua)** requires the following rule(s) be met for renewal:

- A. You have hereditary transthyretin-mediated amyloidosis with polyneuropathy (hATTR-PN: a rare genetic disorder with widespread nerve pain/damage)
- B. You have not progressed to Familial Amyloid Polyneuropathy (FAP: a tool used to evaluate disease severity) stage 3 or Polyneuropathy Disability (PND: a tool used to evaluate disease severity) stage IV polyneuropathy as shown by functional decline (such as being wheelchair-bound or bedridden)
- C. You will NOT use Wainua concurrently (at the same time) with other hATTR-PN medications (such as Tegsedi [inotersen], Amvuttra [vutrisiran], Onpattro [patisiran])

Effective: 07/01/24

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 6/11/2025

Page 280 of 1007



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EPOETIN ALFA

Generic	Brand				
EPOETIN ALFA	EPOGEN, PROCRT				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **EPOETIN ALFA (Procrit, Epogen)** requires the following rules be met for approval:

- A. You have ONE of the following:
1. Anemia (low amount of healthy red blood cells) due to chronic kidney disease (CKD)
 2. Anemia due to the effect of concomitantly administered (given at the same time) cancer chemotherapy
 3. Anemia related to zidovudine (Retrovir) therapy (a type of drug to treat human immunodeficiency virus)
 4. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa
 5. You are undergoing elective, noncardiac, nonvascular surgery (surgery not relating to the heart or blood vessels)
- B. **If you have anemia due to chronic kidney disease, approval also requires:**
1. You have tried the preferred medication: Retacrit (epoetin alfa-epbx)
 2. Your hemoglobin level (a type of blood test) is less than 10g/dL
- C. **If you have anemia due to the effect of concomitantly administered cancer chemotherapy, approval also requires:**
1. You have tried the preferred medication: Retacrit (epoetin alfa-epbx)
 2. Your hemoglobin level is less than 11g/dL OR your hemoglobin level has decreased at least 2g/dL below your baseline level
- D. **If you have anemia related to zidovudine (Retrovir) therapy, approval also requires:**
1. You have tried the preferred medication: Retacrit (epoetin alfa-epbx)
 2. Your hemoglobin level is less than 10g/dL
- E. **If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, approval also requires:**
1. You have tried the preferred medication: Retacrit (epoetin alfa-epbx)
 2. You have tried or have a contraindication to (harmful for you to use) a lower ribavirin dose
 3. Your hemoglobin level is less than 10g/dL
- F. **If you are undergoing elective, noncardiac, nonvascular surgery, approval also requires:**
1. You have tried the preferred medication: Retacrit (epoetin alfa-epbx)
 2. Your hemoglobin level is less than 13g/dL

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EPOETIN ALFA

RENEWAL CRITERIA

NOTE: Requests for patients undergoing elective, noncardiac, nonvascular surgery, please refer to the Initial Criteria section.

Our guideline named **EPOETIN ALFA (Procrit, Epogen)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Anemia (low amount of healthy red blood cells) due to chronic kidney disease (CKD)
 - 2. Anemia due to the effect of concomitantly administered (given at the same time) cancer chemotherapy
 - 3. Anemia related to zidovudine (Retrovir) therapy (a type of drug to treat human immunodeficiency virus)
 - 4. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa
- B. **If you are an adult (you are 18 years of age or older) with anemia due to chronic kidney disease, renewal also requires ONE of the following:**
 - 1. Your hemoglobin level (a type of blood test) is less than 10g/dL if you are not on dialysis (process of removing excess water, toxins from the blood)
 - 2. Your hemoglobin level is less than 11g/dL if you are on dialysis
 - 3. Your hemoglobin level has reached 10g/dL (if you are not on dialysis) and your dose is being or has been reduced/interrupted to decrease the need for blood transfusions
 - 4. Your hemoglobin level has reached 11g/dL (if you are on dialysis) and your dose is being or has been reduced or interrupted to decrease the need for blood transfusions
- C. **If you are a pediatric patient (you are less than 18 years of age) with anemia due to chronic kidney disease, renewal also requires ONE of the following:**
 - 1. Your hemoglobin level is less than 10g/dL
 - 2. Your hemoglobin level has approached or exceeds 12g/dL and your dose is being or has been reduced/interrupted to decrease the need for blood transfusions
- D. **If you have anemia due to the effect of concomitantly administered cancer chemotherapy, renewal also requires:**
 - 1. Your hemoglobin level is between 10g/dL and 12g/dL
- E. **If you have anemia related to zidovudine (Retrovir) therapy, renewal also requires:**
 - 1. Your hemoglobin level is between 10g/dL and 12g/dL
- F. **If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, renewal also requires:**
 - 1. Your hemoglobin level is between 10g/dL and 12g/dL

Effective: 06/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EPOETIN ALFA-EPBX

Generic	Brand				
EPOETIN ALFA-EPBX	RETACRIT				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **EPOETIN ALFA-EPBX (Retacrit)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Anemia (a type of blood condition) due to chronic kidney disease (CKD: a long-term kidney disease)
 2. Anemia due to the effect of concomitantly administered (given at the same time) cancer chemotherapy
 3. Anemia related to zidovudine (Retrovir) therapy (a type of drug to treat human immunodeficiency virus)
 4. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa
 2. You are undergoing elective, noncardiac, nonvascular surgery (surgery not relating to the heart or blood vessels)
- B. **If you have anemia due to chronic kidney disease, approval also requires:**
1. Your hemoglobin level (a type of blood test) is less than 10g/dL
- C. **If you have anemia due to the effect of concomitantly administered cancer chemotherapy, approval also requires ONE of the following:**
1. Your hemoglobin level is less than 11g/dL
 2. Your hemoglobin level has decreased at least 2g/dL below your baseline level
- D. **If you have anemia related to zidovudine (Retrovir) therapy, approval also requires:**
1. Your hemoglobin level is less than 10g/dL
- E. **If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, approval also requires:**
1. You have tried or have a contraindication to (harmful for you to use) a lower ribavirin dose
 2. Your hemoglobin level is less than 10g/dL
- F. **If you are undergoing elective, noncardiac, nonvascular surgery, approval also requires:**
1. Your hemoglobin level is less than 13g/dL

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EPOETIN ALFA-EPBX

RENEWAL CRITERIA

NOTE: Requests for patients undergoing elective, noncardiac, nonvascular surgery, please refer to the Initial Criteria section.

Our guideline named **EPOETIN ALFA-EPBX (Retacrit)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Anemia (a type of blood condition) due to chronic kidney disease (CKD: a long-term kidney disease)
 - 2. Anemia due to the effect of concomitantly administered (given at the same time) cancer chemotherapy
 - 3. Anemia related to zidovudine (Retrovir) therapy (a type of drug to treat human immunodeficiency virus)
 - 4. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa
- B. **If you are an adult (you are 18 years of age or older) with anemia due to chronic kidney disease, renewal also requires ONE of the following:**
 - 1. Your hemoglobin level (a type of blood test) is less than 10g/dL if you are not on dialysis (process of removing excess water, toxins from the blood)
 - 2. Your hemoglobin level is less than 11g/dL if you are on dialysis
 - 3. Your hemoglobin level has reached 10g/dL (if you are not on dialysis) and your dose is being or has been reduced or interrupted to decrease the need for blood transfusions
 - 4. Your hemoglobin level has reached 11g/dL (if you are on dialysis) and your dose is being or has been reduced or interrupted to decrease the need for blood transfusions
- C. **If you are a pediatric patient (you are less than 18 years of age) with anemia due to chronic kidney disease, renewal also requires ONE of the following:**
 - 1. Your hemoglobin level is less than 10g/dL
 - 2. Your hemoglobin level has approached or exceeds 12g/dL and your dose is being or has been reduced or interrupted to decrease the need for blood transfusions
- D. **If you have anemia due to the effect of concomitantly administered cancer chemotherapy, renewal also requires:**
 - 1. Your hemoglobin level is between 10g/dL and 12g/dL
- E. **If you have anemia related to zidovudine (Retrovir) therapy, renewal also requires:**
 - 1. Your hemoglobin level is between 10g/dL and 12g/dL
- F. **If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, renewal also requires:**
 - 1. Your hemoglobin level is between 10g/dL and 12g/dL

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ERDAFITINIB

Generic	Brand			
ERDAFITINIB	BALVERSA			

GUIDELINES FOR USE

Our guideline named **ERDAFITINIB (Balversa)** requires the following rule(s) be met for approval:

- A. You have locally advanced or metastatic urothelial carcinoma (a type of bladder cancer that has spread to nearby tissue or other parts of the body)
- B. You are 18 years of age or older
- C. You have a susceptible (can be treated with the drug) fibroblast growth factor receptor 3 (FGFR3: a type of protein) genetic alteration (mutation) as detected by a Food and Drug Administration (FDA)-approved companion diagnostic test
- D. You have disease progression (condition has worsened) on or after at least one line of prior systemic therapy (treatment that targets the entire body, such as cisplatin, Keytruda [pembrolizumab])

Effective: 02/12/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ERENUMAB-AOOE

Generic	Brand			
ERENUMAB-AOOE	AIMOVIG			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ERENUMAB-AOOE (Aimovig)** requires the following rule(s) be met for approval:

- A. You have migraines (a type of headache)
- B. **If you have episodic migraines (0-14 headache days per month), approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Aimovig is prescribed for the preventive treatment of migraines
 - 3. You will NOT use Aimovig concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy [fremanezumab-vfrm], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet], Qulipta [atogepant]) for migraine prevention
 - 4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol
- C. **If you have chronic migraines (15 or more headache days per month), approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Aimovig is prescribed for the preventive treatment of migraines
 - 3. You will NOT use Aimovig concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy [fremanezumab-vfrm], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet], Qulipta [atogepant]) for migraine prevention
 - 4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [Note: For Botox, previous trial of only National Drug Code (NDC) 00023-1145-01 or NDC 00023-3921-02 are allowable]

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ERENUMAB-AOOE

RENEWAL CRITERIA

Our guideline named **ERENUMAB-AOOE (Aimovig)** requires the following rule(s) be met for renewal:

- A. Aimovig is being prescribed for the preventive treatment of migraines
- B. You will NOT use Aimovig concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy [fremanezumab-vfrm], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet], Qulipta [atogepant]) for migraine prevention
- C. You meet ONE of the following:
 - 1. You have experienced less migraines or headache attacks by at least 2 days per month with Aimovig therapy
 - 2. You have experienced a lessening in migraine severity with Aimovig therapy
 - 3. You have experienced a lessening in migraine duration with Aimovig therapy

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ERGOTAMINE-CAFFEINE

Generic	Brand				
ERGOTAMINE TARTRATE/CAFFEINE	MIGERGOT				

GUIDELINES FOR USE

Our guideline named **ERGOTAMINE-CAFFEINE (Migergot)** requires the following rule(s) be met for approval:

- A. Migergot is being used to abort (stop) or prevent vascular headaches (such as migraines, migraine variants, so-called 'histaminic cephalalgia' [types of headaches])
- B. You cannot swallow ergotamine/caffeine tablets
- C. You had a trial of or contraindication (harmful for) to generic ergotamine/caffeine tablets
AND two triptans (such as sumatriptan, rizatriptan)

Effective:04/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ERLOTINIB

Generic	Brand			
ERLOTINIB HCL	TARCEVA, ERLOTINIB HCL			

GUIDELINES FOR USE

Our guideline named **ERLOTINIB (Tarceva)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Metastatic non-small cell lung cancer (type of lung cancer that has spread to other parts of the body)
 - 2. Locally advanced, unresectable, or metastatic pancreatic cancer (pancreas cancer that has spread or cannot be completely removed by surgery)
- B. **If you have metastatic non-small cell lung cancer, approval also requires:**
 - 1. Your tumor has epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (types of gene mutations or permanent change in the DNA that makes up a gene) as detected by an FDA (Food and Drug Administration)-approved test
 - 2. You will NOT be using Tarceva (erlotinib) concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (e.g., Gilotrif, Tagrisso, Iressa, Vizimpro)
- C. **If you have locally advanced, unresectable, or metastatic pancreatic cancer, approval also requires:**
 - 1. The requested medication will be used in combination with gemcitabine
 - 2. The medication will be used as a first line treatment

Effective: 07/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ESKETAMINE

Generic	Brand				
ESKETAMINE HCL	SPRAVATO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ESKETAMINE (Spravato)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Treatment-resistant depression (TRD: depressive symptoms are not responding to treatment)
2. Major depressive disorder (MDD: a type of mental illness)

B. If you have treatment-resistant depression, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
3. You have non-psychotic, unipolar depression (you have no other mental health conditions except depression)
4. You do NOT have active substance (drug) abuse

C. If you have major depressive disorder, approval also requires:

1. You are 18 years of age or older
2. Spravato will be used in combination with an oral antidepressant (such as Zoloft [sertraline], Cymbalta [duloxetine])
3. You have acute (short-term) suicidal ideation or behavior (thoughts of killing yourself)
4. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
5. You have non-psychotic, unipolar depression (you have no other mental health conditions except depression)
6. You do NOT have active substance (drug) abuse

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ESKETAMINE

RENEWAL CRITERIA

Our guideline named **ESKETAMINE (Spravato)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Treatment-resistant depression (TRD: depressive symptoms are not responding to treatment)
 - 2. Major depressive disorder (MDD: a type of mental illness)
- B. You have demonstrated clinical benefit (improvement in depression) compared to baseline (before treatment)

Effective: 02/17/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ETANERCEPT

Generic	Brand			
ETANERCEPT	ENBREL			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ETANERCEPT (Enbrel)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
 2. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
 3. Psoriatic arthritis (PsA: a type of skin and joint condition)
 4. Ankylosing spondylitis (AS: a type of joint condition)
 5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
- B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use Enbrel concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
 4. You have tried at least 3 months of or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
- C. **If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:**
1. You are 2 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use Enbrel concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ETANERCEPT

INITIAL CRITERIA (CONTINUED)

D. If you have psoriatic arthritis, approval also requires:

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
3. You will NOT use Enbrel concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

E. If you have ankylosing spondylitis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Enbrel concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
4. You have tried or have a contraindication to (harmful for you to use) an NSAID (non-steroidal anti-inflammatory drug, such as naproxen, ibuprofen, meloxicam)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ETANERCEPT

INITIAL CRITERIA (CONTINUED)

- F. If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 4 years of age or older
 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 3. You will NOT use Enbrel concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
 4. You meet ONE of the following:
 - a. You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis
 - b. You have a contraindication (harmful for you to use) or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) and PUVA (phototherapy) for the treatment of plaque psoriasis
 - c. You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication
 5. You meet ONE of the following:
 - a. You were previously stable on another biologic and are switching to Enbrel
 - b. You have psoriasis covering 3 percent or more of body surface area (BSA)
 - c. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, face, or scalp

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ETANERCEPT

RENEWAL CRITERIA

Our guideline named **ETANERCEPT (Enbrel)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
 - 2. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
 - 3. Psoriatic arthritis (PsA: a type of skin and joint condition)
 - 4. Ankylosing spondylitis (AS: a type of joint condition)
 - 5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
- B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**
 - 1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 - 2. You will NOT use Enbrel concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
- C. **If you have moderate to severe polyarticular juvenile idiopathic arthritis, renewal also requires:**
 - 1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 - 2. You will NOT use Enbrel concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
- D. **If you have psoriatic arthritis, renewal also requires:**
 - 1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 - 2. You will NOT use Enbrel concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ETANERCEPT

RENEWAL CRITERIA (CONTINUED)

E. If you have ankylosing spondylitis, renewal also requires:

1. You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
2. You will NOT use Enbrel concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis

F. If you have moderate to severe plaque psoriasis, renewal also requires:

1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50 percent or more while on therapy
2. You will NOT use Enbrel concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ETEPLIRSEN

Generic	Brand				
ETEPLIRSEN	EXONDYS-51				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ETEPLIRSEN (Exondys 51)** requires the following rule(s) be met for approval:

- A. You have Duchenne muscular dystrophy (DMD: a type of muscle disorder)
- B. You have a confirmed mutation (abnormal change in a type of gene) in the DMD gene that will respond to exon 51 skipping therapy (a type of therapy to treat DMD)
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor) specializing in the treatment of DMD at a DMD treatment center
- D. You are ambulatory (able to walk)
- E. You are currently receiving treatment with or you have a contraindication to (harmful for you to use) corticosteroids (such as prednisone, prednisolone)

RENEWAL CRITERIA

Our guideline named **ETEPLIRSEN (Exondys 51)** requires ONE of the following rule(s) be met for renewal:

- A. You have maintained or demonstrated a less than expected decline in ambulatory ability (ability to walk) based on muscle function assessments (such as the 6-minute walk test)
- B. You have maintained or demonstrated a less than expected decline in other muscle function (pulmonary [lung] or cardiac [heart] function)

Effective: 02/24/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ETHACRYNIC ACID

Generic	Brand				
ETHACRYNIC ACID	EDECIN, ETHACRYNIC ACID				

GUIDELINES FOR USE

Our guideline named **ETHACRYNIC ACID (Edecrin)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Edema (swelling caused by fluid build-up in the body) associated with congestive heart failure (a type of heart condition), cirrhosis (liver damage), or renal disease (including nephrotic syndrome [a type of kidney disorder])
 - 2. Ascites (accumulation of fluid in the abdominal cavity) due to malignancy (cancer), idiopathic (unknown cause) edema, or lymphedema (swelling in an arm or leg due to build-up of lymph fluid)
- B. You had a trial of or contraindication (harmful for) to TWO generic loop diuretics (such as furosemide, bumetanide, torsemide)

Effective: 07/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ETRASIMOD

Generic	Brand				
ETRASIMOD ARGININE	VELSIPITY				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ETRASIMOD (Velsipity)** requires the following rule(s) be met for approval:

- A. You have moderate to severe ulcerative colitis (UC: a type of digestive disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
- D. You will NOT use Velsipity concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
- E. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ETRASIMOD

RENEWAL CRITERIA

Our guideline named **ETRASIMOD (Velsipity)** requires the following rule(s) be met for renewal:

- A. You have moderate to severe ulcerative colitis (UC: a type of digestive disorder)
- B. You will NOT use Velsipity concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
- C. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EVEROLIMUS-AFINITOR DISPERZ

Generic	Brand				
EVEROLIMUS	AFINITOR DISPERZ, EVEROLIMUS				

GUIDELINES FOR USE

Our guideline named **EVEROLIMUS (Afinitor Disperz)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Tuberous sclerosis complex (TSC: a rare type of tumor disorder)-associated subependymal giant cell astrocytoma (SEGA: a type of brain tumor)
 - 2. Tuberous sclerosis complex (TSC: a rare type of tumor disorder)-associated partial-onset seizures
- B. **If you have tuberous sclerosis complex (TSC)-subependymal giant cell astrocytoma (SEGA), approval also requires:**
 - 1. You are 1 year of age or older
 - 2. Your diagnosis requires therapeutic intervention but cannot be curatively resected (completely remove with surgery)
- C. **If you have tuberous sclerosis complex (TSC)-associated partial-onset seizures, approval also requires:**
 - 1. You are 2 years of age or older
 - 2. Afinitor Disperz will be used as adjunctive (add-on) treatment

Effective: 04/10/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EVEROLIMUS-AFINITOR

Generic	Brand				
EVEROLIMUS	AFINITOR, TORPENZ, EVEROLIMUS				

GUIDELINES FOR USE

Our guideline named **EVEROLIMUS (Afinitor, Torpenz)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Advanced hormone receptor-positive (HR: a type of protein), human epidermal growth factor receptor 2 (HER2: a type of protein)-negative breast cancer
 2. Progressive, neuroendocrine tumors (NET: a rare type of tumor) with unresectable (unable to remove by surgery), locally advanced (cancer that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (cancer that has spread to other parts of the body)
 3. Advanced renal cell carcinoma (RCC: type of kidney cancer)
 4. Tuberous sclerosis complex (TSC: a rare type of tumor disorder)-associated renal angiomyolipoma (type of kidney tumor)
 5. Tuberous sclerosis complex (TSC: a rare type of tumor disorder)-associated subependymal giant cell astrocytoma (SEGA: a type of brain tumor)
- B. **If you have advanced hormone receptor-positive, HER2-negative breast cancer, approval also requires:**
1. You are a postmenopausal woman
 2. The requested medication will be used in combination with Aromasin (exemestane)
 3. You have failed or have a contraindication to (harmful for you to use) treatment with Femara (letrozole) or Arimidex (anastrozole)
- C. **If you have progressive, neuroendocrine tumors (NET) with unresectable, locally advanced or metastatic disease, approval also requires:**
1. You are 18 years of age or older
 2. You meet ONE of the following:
 - a. You have neuroendocrine tumors of pancreatic origin (PNET: tumor in the pancreas)
 - b. You have well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI: relating to the digestive system) or lung origin
- D. **If you have advanced renal cell carcinoma, approval also requires:**
1. You are 18 years of age or older
- E. **If you have tuberous sclerosis complex (TSC)-associated renal angiomyolipoma, approval also requires:**
1. You are 18 years of age or older
 2. You do NOT require immediate surgery

(Criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EVEROLIMUS-AFINITOR

GUIDELINES FOR USE (CONTINUED)

- F. If you have tuberous sclerosis complex (TSC)-associated subependymal giant cell astrocytoma (SEGA), approval also requires:**
1. You are 1 year of age or older
 2. Your diagnosis requires therapeutic intervention but cannot be curatively resected (completely removed with surgery)

Effective: 08/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FAM-TRASTUZUMAB DERUXTECAN-NXKI

Generic	Brand				
FAM-TRASTUZUMAB DERUXTECAN-NXKI	ENHERTU				

GUIDELINES FOR USE

Our guideline named **FAM-TRASTUZUMAB DERUXTECAN-NXKI (Enhertu)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Unresectable or metastatic breast cancer (a type of cancer that cannot be removed by surgery or has spread to other parts of the body)
2. Unresectable or metastatic non-small cell lung cancer (NSCLC) (a type of lung cancer that cannot be removed by surgery or has spread to other parts of the body)
3. Locally advanced or metastatic gastric OR gastroesophageal junction (GEJ) adenocarcinoma (a type of digestive system cancer that has spread to nearby tissue or lymph nodes, or has spread to other parts of the body)
4. Unresectable or metastatic solid tumors (a type of abnormal mass that cannot be removed by surgery or has spread to other parts of the body)

B. If you have unresectable or metastatic breast cancer, approval also requires ONE of the following:

1. Your cancer is human epidermal growth factor receptor 2 (HER2: a type of protein)-positive (IHC 3+ or ISH positive), and you meet ONE of the following:
 - a. You have received a prior anti-HER2-based regimen (such as Herceptin [trastuzumab], Kadcyla [ado-trastuzumab emtansine]) in the metastatic setting (cancer has spread to other parts of the body)
 - b. You have received a prior anti-HER2-based regimen (such as Herceptin [trastuzumab], Kadcyla [ado-trastuzumab emtansine]) in the neoadjuvant (given before main treatment) or adjuvant (additional treatment) setting AND the disease returned during or within 6 months of completing therapy
2. Your cancer is hormone receptor (HR: a type of protein)-positive, human epidermal growth factor receptor 2 (HER2: a type of protein)-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining), AND your disease has progressed (worsened) while on at least one endocrine therapy (such as letrozole, anastrozole, tamoxifen) in the metastatic setting (cancer has spread to other parts of the body)
3. Your cancer is human epidermal growth factor receptor 2 (HER2: a type of protein)-low (IHC 1+ or IHC 2+/ISH-), and you meet ONE of the following:
 - a. You have received a prior chemotherapy (a type of cancer treatment) in the metastatic setting (cancer has spread to other parts of the body)
 - b. You have developed disease recurrence (disease has returned) during or within 6 months of completing adjuvant (additional) chemotherapy

(Criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FAM-TRASTUZUMAB DERUXTECAN-NXKI

GUIDELINES FOR USE (CONTINUED)

- C. If you have unresectable or metastatic non-small cell lung cancer, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Your tumors have activating HER2 (ERBB2) mutations (abnormal change in a type of gene)
 - 3. You have received a prior systemic therapy (treatment that targets the entire body)
- D. If you have locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Your cancer is human epidermal growth factor receptor 2 (HER2: a type of protein)-positive (IHC 3+ or IHC 2+/ISH positive)
 - 3. You have received a prior trastuzumab-based (type of medication) regimen
- E. If you have unresectable or metastatic solid tumors, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Your cancer is human epidermal growth factor receptor 2 (HER2: a type of protein)-positive (IHC 3+)
 - 3. You have received previous systemic treatment (therapy that targets the entire body) and have no other satisfactory treatment options

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FECAL MICROBIOTA CAPSULE

Generic	Brand				
FECAL MICROBIO SPORE, LIVE-BRPK	VOWST				

GUIDELINES FOR USE

Our guideline named **FECAL MICROBIOTA CAPSULE (Vowst)** requires the following rule(s) be met for approval:

- A. You are using the requested medication for the prevention of recurrent *Clostridioides difficile* (*C. difficile*) infection (CDI: a bacterial infection)
- B. You are 18 years of age or older
- C. **If you have NOT previously received Vowst, approval also requires:**
 - 1. You have completed antibiotic (such as vancomycin [Vancocin], fidaxomicin [Dificid]) treatment for recurrent CDI (defined as at least 3 CDI episodes)
- D. **If you have been previously treated with Vowst, approval also requires:**
 - 1. You had treatment failure, defined as the presence of CDI diarrhea within 8 weeks of the first dose of Vowst, AND a positive stool test for *C. difficile*
 - 2. You have not previously received more than 1 treatment course of Vowst AND the start of that treatment course was at least 12 days and not more than 8 weeks prior

Effective: 06/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FECAL MICROBIOTA SUSPENSION

Generic	Brand				
FECAL MICROBIOTA, LIVE-JSLM	REBYOTA				

GUIDELINES FOR USE

Our guideline named **FECAL MICROBIOTA SUSPENSION (Rebyota)** requires the following rule(s) be met for approval:

- A. You are using the requested medication for the prevention of recurrent *Clostridioides difficile* (*C. difficile*) infection (CDI: a bacterial infection)
- B. You are 18 years of age or older
- C. **If you have NOT previously received Rebyota, approval also requires:**
 - 1. You have completed antibiotic (such as vancomycin [Vancocin]) treatment for recurrent CDI (defined as at least 3 CDI episodes) at least 24 hours prior
- D. **If you have been previously treated with Rebyota, approval also requires:**
 - 1. You had treatment failure, defined as the presence of CDI diarrhea within 8 weeks of the first dose of Rebyota AND a positive stool test for *C. difficile*
 - 2. You have not previously received more than 1 dose of Rebyota AND that dose was at least 7 days and not more than 8 weeks prior

Effective:05/22/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FEDRATINIB

Generic	Brand				
FEDRATINIB DIHYDROCHLORID E	INREBIC				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **FEDRATINIB (Inrebic)** requires the following rule(s) be met for approval:

- You have intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (type of bone marrow cancer)
- You are 18 years of age or older
- You previously had a trial of or contraindication (medical reason why you cannot use) to Jakafi (ruxolitinib)

RENEWAL CRITERIA

Our guideline named **FEDRATINIB (Inrebic)** requires the following rule(s) be met for renewal:

- You have intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (type of bone marrow cancer)
- You have shown symptom improvement by meeting ONE of the following:
 - You have a spleen volume reduction of 35% or greater from baseline
 - You have a 50% or greater reduction in total symptom score (such as Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
 - You have a 50% or greater reduction in palpable (can be felt by external examination) spleen length

Effective: 01/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FENFLURAMINE

Generic	Brand				
FENFLURAMINE	FINTEPLA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **FENFLURAMINE (Fintepla)** requires the following rule(s) be met for approval:

- A. You have seizures associated with ONE of the following:
 - 1. Dravet syndrome (a rare type of seizure)
 - 2. Lennox-Gastaut syndrome (LGS: a type of seizure disorder in young children)
- B. **If you have Dravet syndrome, approval also requires:**
 - 1. You are 2 years of age or older
 - 2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
 - 3. You had a trial of or contraindication (harmful for) to TWO of the following: valproic acid derivative, clobazam, topiramate
- C. **If you have Lennox-Gastaut syndrome, approval also requires:**
 - 1. You are 2 years of age or older
 - 2. Therapy is prescribed by or given in consultation with a neurologist (a type of brain doctor)
 - 3. You had a trial of or contraindication (harmful for) to valproic acid or derivatives
 - 4. You had a trial of or contraindication (harmful for) to TWO of the following: Epidiolex, rufinamide, felbamate, clobazam, topiramate, lamotrigine, clonazepam

RENEWAL CRITERIA

Our guideline named **FENFLURAMINE (Fintepla)** requires the following rule(s) be met for approval:

- A. You have seizures associated with Dravet syndrome (a rare type of seizure)
- B. You have shown continued clinical benefit (such as reduction of seizures, reduced length of seizures, seizure control maintained) while on therapy

Effective: 07/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FENTANYL NASAL SPRAY

Generic	Brand			
FENTANYL NASAL SPRAY	LAZANDA			

GUIDELINES FOR USE

Our guideline named **FENTANYL NASAL SPRAY (Lazanda)** requires the following rule(s) to be met for approval:

- A. You have a diagnosis of cancer-related pain
- B. You are currently taking a maintenance dose of a controlled-release pain medication (such as MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Kadian, Avinza or the generic forms of any of these drugs)
- C. You had a trial of an oral immediate-release pain medication (such as morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these), unless you have difficulty swallowing tablets or capsules OR there is a medical reason why you cannot (contraindication)
- D. You had a trial of generic fentanyl citrate lozenge (which also requires a prior authorization), unless there is a medical reason why you cannot (contraindication)
- E. You had a trial of Abstral or Fentora (which also requires a prior authorization), unless there is a medical reason why you cannot (contraindication)

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FENTANYL SUBLINGUAL SPRAY

Generic	Brand			
FENTANYL SUBLINGUAL SPRAY	SUBSYS			

GUIDELINES FOR USE

Our guideline named **FENTANYL SUBLINGUAL SPRAY (Subsys)** requires the following rule(s) be met for approval:

- A. You have cancer-related pain
- B. You are currently using the requested medication with a controlled-release pain medication (MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Kadian, Avinza or the generic forms of any of these drugs)
- C. You had a trial of an oral immediate-release pain medication (morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these), unless you have difficulty swallowing tablets or capsules OR there is a medical reason why you cannot (contraindication)
- D. You had a trial of generic fentanyl citrate lozenge (which also requires a prior authorization), unless there is a medical reason why you cannot (contraindication)
- E. You had a trial of Abstral or Fentora, all of which may also require a prior authorization, unless there is a medical reason why you cannot (contraindication)

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FENTANYL TRANSDERMAL PATCH

Generic	Brand			
FENTANYL	DURAGESIC, FENTANYL			

GUIDELINES FOR USE

Our guideline named **FENTANYL TRANSDERMAL PATCH (Duragesic)** requires the following rule(s) be met for approval:

- A. You meet the definition of opioid tolerance. This is defined as those who are taking, for one week or longer, at least 60mg oral morphine per day, 25mcg transdermal fentanyl/hour, 30mg oral oxycodone/day, 25mg oral oxymorphone/day, 8mg oral hydromorphone/day, or an equianalgesic dose (equal pain-relieving dose) of another opioid
- B. The requested medication is not prescribed on an 'as needed' basis
- C. Requests for every 48 hours dosing requires a trial of transdermal (absorbed through the skin) fentanyl patch dosed every 72 hours

Effective: 10/14/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FENTANYL TRANSMUCOSAL AGENTS

Generic	Brand			
FENTANYL CITRATE	ACTIQ, ABSTRAL, FENTORA			

GUIDELINES FOR USE

Our guideline named **FENTANYL TRANSMUCOSAL AGENTS (Actiq, Fentora, Abstral)** requires the following rule(s) be met for approval:

- A. You have cancer-related pain
- B. You are currently using the requested medication with a controlled-release pain medication (MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Avinza or the generic forms of any of these drugs)
- C. You had a trial of an oral immediate-release pain medication (such as morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these), unless you have difficulty swallowing tablets or capsules OR there is a medical reason why you cannot (contraindication)
- D. You had a trial of generic fentanyl citrate lozenge (which also requires a prior authorization) unless there is a medical reason why you cannot (contraindication)

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FILGRASTIM

Generic	Brand				
FILGRASTIM	NEUPOGEN				

GUIDELINES FOR USE

Our guideline named **FILGRASTIM (Neupogen)** requires the following rule(s) be met for approval:

A. You meet ONE of the following:

1. You have a non-myeloid malignancy (cancer not affecting bone marrow) and are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
2. You have acute myeloid leukemia (AML: a type of blood cancer) and are undergoing induction or consolidation chemotherapy treatment (you are starting therapy so there is no sign of cancer cells or you have therapy to kill any remaining cancer cells in the body)
3. You have a non-myeloid malignancy (cancer not affecting bone marrow), are undergoing myeloablative chemotherapy (high-dose drugs used to treat cancer) followed by bone marrow transplantation, and are experiencing neutropenia (a type of blood condition) and/or neutropenia-related clinical symptoms (such as febrile neutropenia [a type of blood condition with fever])
4. You will be using Neupogen for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis (a type of blood cell is stimulated to be collected by a process where it is separated from the blood)
5. You have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia (low levels of a type of white blood cell at birth, in cycles, or due to unknown cause)
6. You will be using Neupogen to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (doses that decrease bone marrow activity)

B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)

C. You had a trial of or contraindication (harmful for) to the preferred medication: Nivestym (filgrastim-aafi)

Effective: 07/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FILGRASTIM-AAFI

Generic	Brand				
FILGRASTIM-AAFI	NIVESTYM				

GUIDELINES FOR USE

Our guideline named **FILGRASTIM-AAFI (Nivestym)** requires the following rule(s) be met for approval:

A. You meet ONE of the following:

1. You have a non-myeloid malignancy (cancer not affecting bone marrow) and are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
2. You have acute myeloid leukemia (AML: a type of blood cancer) and are undergoing induction or consolidation chemotherapy treatment (you are starting therapy so there is no sign of cancer cells or you have therapy to kill any remaining cancer cells in the body)
3. You have a non-myeloid malignancy (cancer not affecting bone marrow), are undergoing myeloablative chemotherapy (high-dose drugs used to treat cancer) followed by bone marrow transplantation, and are experiencing neutropenia (a type of blood condition) and/or neutropenia-related clinical symptoms (such as febrile neutropenia [a type of blood condition with fever])
4. You will be using Nivestym for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis (a type of blood cell is stimulated to be collected by a process where it is separated from the blood)
5. You have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia (low amount of a type of white blood cell at birth, in cycles or due to unknown cause)
6. You will be using Nivestym to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (doses that decrease bone marrow activity)

B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)

Effective: 07/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FILGRASTIM-AYOW

Generic	Brand				
FILGRASTIM-AYOW	RELEUKO				

GUIDELINES FOR USE

Our guideline named **FILGRASTIM-AYOW (Releuko)** requires the following rule(s) be met for approval:

- A. The request is for ONE of the following:
1. You have a nonmyeloid malignancy (a type of cancer) and are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
 2. You have acute myeloid leukemia (AML: a type of blood cancer) and are undergoing induction or consolidation chemotherapy treatment (you are starting therapy so there is no sign of cancer cells or you have therapy to kill any remaining cancer cells in the body)
 3. You have a nonmyeloid malignancy (cancer not affecting bone marrow), are undergoing myeloablative chemotherapy (drugs used to treat cancer) followed by bone marrow transplantation, and are experiencing neutropenia (a type of blood condition) and/or neutropenia-related clinical symptoms (such as febrile neutropenia [a type of blood condition with fever])
 4. You will be using Releuko for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis (a type of blood cell is stimulated to be collected by a process where it is separated from the blood)
 5. You have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia (low amount of a type of white blood cell at birth, in cycles, or due to unknown cause)
 6. You will be using Releuko to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (doses that decrease bone marrow activity)
- B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
- C. You had a trial of or contraindication (harmful for) to the preferred medication: Nivestym (filgrastim-aafi)

Effective: 07/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FILGRASTIM-SNDZ

Generic	Brand				
FILGRASTIM-SNDZ	ZARXIO				

GUIDELINES FOR USE

Our guideline named **FILGRASTIM-SNDZ (Zarxio)** requires the following rule(s) be met for approval:

A. You meet ONE of the following:

1. You have a non-myeloid malignancy (cancer not affecting bone marrow) and are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
2. You have acute myeloid leukemia (AML: a type of blood cancer) and are undergoing induction or consolidation chemotherapy treatment (you are starting therapy so there is no sign of cancer cells or you have therapy to kill any remaining cancer cells in the body)
3. You have a non-myeloid malignancy (cancer not affecting bone marrow), are undergoing myeloablative chemotherapy (high-dose drugs used to treat cancer) followed by bone marrow transplantation, and are experiencing neutropenia (a type of blood condition) and/or neutropenia-related clinical symptoms (such as febrile neutropenia [a type of blood condition with fever])
4. You will be using Zarxio for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis (a type of blood cell is stimulated to be collected by a process where it is separated from the blood)
5. You have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia (low levels of a type of white blood cell at birth, in cycles, or due to unknown cause)
6. You will be using Zarxio to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (doses that decrease bone marrow activity)

B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)

C. You had a trial of or contraindication (harmful for) to the preferred medication: Nivestym (filgrastim-aafi)

Effective: 07/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FILGRASTIM-TXID

Generic	Brand				
FILGRASTIM-TXID	NYPOZI				

GUIDELINES FOR USE

Our guideline named **FILGRASTIM-TXID (Nypozi)** requires the following rule(s) be met for approval:

- A. You meet ONE of the following:
1. You are receiving myelosuppressive anti-cancer medications (medications that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever, and you have non-myeloid malignancy (cancer not affecting the bone marrow)
 2. You have undergone or are undergoing induction or consolidation chemotherapy (you are starting cancer treatment or receiving treatment following initial therapy) for acute myeloid leukemia (AML: a type of blood cancer)
 3. You are undergoing myeloablative chemotherapy (high-dose medications used to treat cancer) followed by bone marrow transplantation (procedure to get healthy blood-forming cells), and you have non-myeloid malignancy (cancer not affecting the bone marrow)
 4. You are undergoing autologous peripheral blood progenitor cell collection and therapy (a type of blood cancer treatment)
 5. You have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia (low levels of a type of white blood cell at birth, in cycles, or due to unknown causes)
 6. You have been acutely exposed to myelosuppressive doses (doses that decrease bone marrow activity) of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]: an illness that happens after whole body radiation)
- B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
- C. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Nivestym (filgrastim-aafi)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FINASTERIDE-TADALAFIL

Generic	Brand				
FINASTERIDE/TADALAFIL	ENTADFI, FINASTERI DE- TADALAFIL				

GUIDELINES FOR USE

Our guideline named **FINASTERIDE-TADALAFIL (Entadfi)** requires the following rule(s) be met for approval:

- A. You have benign prostatic hyperplasia (BPH: a type of prostate condition)
- B. You are 18 years of age or older
- C. You are a male
- D. You have NOT previously received a 26-week course of Entadfi (finasteride-tadalafil)
- E. You have tried or have a contraindication to (harmful for you to use) TWO alpha blockers (such as terazosin, doxazosin, tamsulosin)
- F. You have tried or have a contraindication to ONE 5-alpha-reductase inhibitor (such as finasteride, dutasteride)
- G. You have tried or have a contraindication to tadalafil 2.5 mg OR tadalafil 5 mg

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FINERENONE

Generic	Brand				
FINERENONE	KERENDIA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **FINERENONE (Kerendia)** requires the following rule(s) be met for approval:

- A. You have chronic kidney disease (CKD: long-term kidney disease) associated with type 2 diabetes (T2D: a disorder with high blood sugar)
- B. You are 18 years of age or older
- C. You have a history of and will continue to use, or you have a contraindication to (harmful for you to use), an angiotensin converting enzyme inhibitor (ACE-I, such as benazepril, lisinopril) or an angiotensin receptor blocker (ARB, such as losartan, valsartan)
- D. You have tried or have a contraindication to (harmful for you to use) a sodium-glucose co-transporter 2 inhibitor (SGLT2i, such as Farxiga [dapagliflozin], Invokana [canagliflozin], Jardiance [empagliflozin])

RENEWAL CRITERIA

Our guideline named **FINERENONE (Kerendia)** requires the following rule(s) be met for renewal:

- A. You have chronic kidney disease (CKD: long-term kidney disease) associated with type 2 diabetes (T2D: a disorder with high blood sugar)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FINGOLIMOD

Generic	Brand			
FINGOLIMOD	GILENYA, FINGOLIMOD			

GUIDELINES FOR USE

Our guideline named **FINGOLIMOD (Gilenya)** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
- B. You are 10 years of age or older
- C. You do NOT have ANY of the following contraindications to (harmful for you to use) Gilenya:
 - 1. A recent (within the past 6 months) occurrence of myocardial infarction (heart attack), unstable angina (chest pain), stroke (a type of brain damage), transient ischemic attack (a type of stroke), decompensated heart failure (a type of heart condition) requiring hospitalization, or Class III/IV heart failure (a type of heart condition)
 - 2. A history or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome (types of irregular heartbeats), unless you have a functioning pacemaker (a small device that is placed [implanted] in your chest to help control your heartbeat)
 - 3. A baseline QTc interval of 500 msec or above (a measure of the speed of electrical conduction in the heart)
 - 4. Current treatment with Class Ia (quinidine, procainamide, or disopyramide) or Class III anti-arrhythmic drugs (amiodarone, dofetilide, dronedarone, ibutilide, or sotalol)

Effective: 06/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FINGOLIMOD LAURYL SULFATE

Generic	Brand				
FINGOLIMOD LAURYL SULFATE	TASCENSO ODT				

GUIDELINES FOR USE

Our guideline named **FINGOLIMOD LAURYL SULFATE (Tascenso ODT)** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (a type of nerve disorder), to include clinically isolated syndrome (a type of nerve disorder that occurs once), relapsing-remitting disease (symptoms or disease returns and goes away) and active secondary progressive disease (advanced disease)
- B. You are 10 years of age or older
- C. You had a trial of fingolimod capsules
- D. You are unable to swallow fingolimod capsules
- E. You had a trial of or contraindication (harmful for) to one other agent indicated for the treatment of multiple sclerosis
- F. You do not have any of the following contraindications (harmful for) to Tascenso ODT:
 - 1. A recent (within past 6 months) occurrence of myocardial infarction (heart attack), unstable angina (chest pain), stroke, transient ischemic attack (short stroke-like attack), decompensated heart failure requiring hospitalization, or Class III/IV heart failure
 - 2. A history or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome (types of irregular heartbeats), unless you have a functioning pacemaker
 - 3. A baseline QTc interval of 500 msec or greater (a measure of the speed of electrical conduction in the heart)
 - 4. Current treatment with Class Ia (quinidine, procainamide, or disopyramide) or Class III anti-arrhythmic drugs (amiodarone, dofetilide, dronedarone, ibutilide, or sotalol)

Effective: 01/16/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FITUSIRAN

Generic	Brand				
FITUSIRAN SODIUM	QFITLIA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **FITUSIRAN (Qfitlia)** requires the following rule(s) be met for approval:
You have ONE of the following:

Hemophilia A (a type of bleeding disorder)

Hemophilia B (a type of bleeding disorder)

If you have hemophilia A, approval also requires:

You are 12 years of age or older

Qfitlia will be used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes

Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)

You will NOT use Qfitlia concurrently (at the same time) with another non-factor prophylaxis therapy (such as Hemlibra [emicizumab-kxwh], Hympavzi [marstacimab-hncq], Alhemo [concizumab-mtci])

If you have hemophilia B, approval also requires:

You are 12 years of age or older

Qfitlia will be used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes

Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)

You will NOT use Qfitlia concurrently (at the same time) with another non-factor prophylaxis therapy (such as Hemlibra [emicizumab-kxwh], Hympavzi [marstacimab-hncq], Alhemo [concizumab-mtci])

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FITUSIRAN

RENEWAL CRITERIA

Our guideline named **FITUSIRAN (Qfitlia)** requires the following rule(s) be met for renewal:

You have ONE of the following:

Hemophilia A (a type of bleeding disorder)

Hemophilia B (a type of bleeding disorder)

If you have hemophilia A, renewal also requires:

You have shown a clinical benefit compared to baseline (before starting Qfitlia)

You will NOT use Qfitlia concurrently (at the same time) with another non-factor prophylaxis therapy (such as Hemlibra [emicizumab-kxwh], Hympavzi [marstacimab-hncq], Alhemo [concizumab-mtci])

If you have hemophilia B, renewal also requires:

You have shown a clinical benefit compared to baseline (before starting Qfitlia)

You will NOT use Qfitlia concurrently (at the same time) with another non-factor prophylaxis therapy (such as Hemlibra [emicizumab-kxwh], Hympavzi [marstacimab-hncq], Alhemo [concizumab-mtci])

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FLIBANSERIN

Generic	Brand			
FLIBANSERIN	ADDYI			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

Our guideline named **FLIBANSERIN (Addyi)** requires the following rule(s) be met for approval:

- A. You have acquired, generalized hypoactive sexual desire disorder (HSDD; lack or absence of sexual desire). This is also referred to as female sexual interest/arousal disorder per DSM-5 (a diagnostic tool for mental disorders), as defined by **ALL** of the following criteria:
 - 1. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
 - 2. Hypoactive sexual desire disorder is not a result of a co-existing medical or psychiatric condition, a problem within the relationship or the effects of a medication or drug substance
 - 3. Hypoactive sexual desire disorder symptom causes marked distress or interpersonal difficulty
- B. You are a premenopausal female
- C. You are 18 years of age or older
- D. You previously had a trial of bupropion, unless there is a medical reason why you cannot (contraindication)
- E. You are not currently using Vyleesi (bremelanotide)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FLIBANSERIN

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline for **FLIBANSERIN (Addyi)** requires the following rule(s) be met for renewal:

- A. You have acquired, generalized hypoactive sexual desire disorder (HSDD; lack or absence of sexual desire). This is also referred to as female sexual interest/arousal disorder per DSM-5 (a diagnostic tool for mental disorders), as defined by **ALL** of the following criteria:
 - 1. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
 - 2. Hypoactive sexual desire disorder is not a result of a co-existing medical or psychiatric condition, a problem within the relationship or the effects of a medication or drug substance
 - 3. Hypoactive sexual desire disorder symptom causes marked distress or interpersonal difficulty
- B. You are a premenopausal female
- C. You are 18 years of age or older
- D. You are not currently using Vyleesi (bremelanotide)
- E. You have demonstrated continued improvement in symptoms of hypoactive sexual desire disorder/female sexual interest and arousal disorder (such as increased sexual desire, lessened distress)

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FLUOROURACIL CREAM

Generic	Brand				
FLUOROURACIL 0.5%	CARAC, FLUOROURACIL				
FLUOROURACIL 1%	FLUOROPLEX				

**** Please use the criteria for the specific drug requested ****

GUIDELINE FOR USE

CARAC

Our guideline named **FLUOROURACIL CREAM (Carac)** requires the following rule(s) be met for approval:

- A. You have actinic or solar keratosis (AK: rough, scaly patch on the skin caused by years of sun exposure) of the face and anterior (front) scalp
- B. You have tried TWO generic topical (applied to skin) agents for AK (such as fluorouracil 5%, imiquimod, diclofenac 3%)

FLUOROPLEX

Our guideline named **FLUOROURACIL CREAM (Fluoroplex)** requires the following rule(s) be met for approval:

- A. You have actinic or solar keratosis (AK: rough, scaly patch on the skin caused by years of sun exposure)
- B. You have tried TWO generic topical (applied to skin) agents for AK (such as fluorouracil, imiquimod, diclofenac 3%)

Effective: 05/17/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FOSCARBIDOPA-FOSLEVODOPA

Generic	Brand				
FOSCARBIDOPA/ FOSLEVODOPA	VYALEV				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **FOSCARBIDOPA-FOSLEVODOPA (Vyalev)** requires the following rule(s) be met for approval:

- A. You have advanced Parkinson's disease (PD: a type of movement disorder)
- B. Vyalev will be used for the treatment of motor fluctuations (changes in the ability to move) associated with Parkinson's disease
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
- D. Your disease is responsive to treatment with levodopa
- E. You are currently being treated with at least 400mg of levodopa per day
- F. Your motor symptoms are currently uncontrolled (defined as an average 'off' time of at least 2.5 hours per day over 3 consecutive days, with a minimum of 2 hours each day)
- G. You meet ONE of the following:
 - 1. You are unable to swallow extended-release tablets or administer extended-release capsules through a feeding tube
 - 2. You have failed to adhere to (keep up with) an oral carbidopa/levodopa regimen or tolerate a carbidopa/levodopa regimen through a feeding tube

RENEWAL CRITERIA

Our guideline named **FOSCARBIDOPA-FOSLEVODOPA (Vyalev)** requires the following rule(s) be met for renewal:

- A. You have advanced Parkinson's disease (PD: a type of movement disorder)
- B. You have experienced improvement in motor symptoms with the use of Vyalev

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FOSDENOPTERIN

Generic	Brand				
FOSDENOPTERIN HYDROBROMIDE	NULIBRY				

GUIDELINES FOR USE

Our guideline named **FOSDENOPTERIN (Nulibry)** requires the following rule(s) be met for approval:

- A. You have molybdenum cofactor deficiency (MoCD) Type A (rare condition characterized by brain dysfunction)

Effective: 07/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FOSTAMATINIB

Generic	Brand			
FOSTAMATINIB	TAVALISSE			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **FOSTAMATINIB (Tavalisse)** requires the following rule(s) be met for approval:

- A. You have chronic immune thrombocytopenia (cITP: a type of blood disorder)
- B. You are 18 years of age or older
- C. You have tried or have a contraindication to (harmful for you to use) corticosteroids or immunoglobulins, OR you did not have a good enough response to a splenectomy (spleen removal)
- D. You will NOT use Tavalisse concurrently (at the same time) with other thrombopoietin receptor agonists (TPO-RAs, such as Doptelet [avatrombopag], Nplate [romiplostim], Promacta [eltrombopag], Alvaiz [eltrombopag])
- E. You meet ONE of the following:
 - 1. You have a platelet (a type of blood cell) count of less than $30 \times 10^9/L$
 - 2. You have a platelet count of less than $50 \times 10^9/L$ AND a prior bleeding event

RENEWAL CRITERIA

Our guideline named **FOSTAMATINIB (Tavalisse)** requires the following rule(s) be met for renewal:

- A. You have chronic immune thrombocytopenia (cITP: a type of blood disorder)
- B. You have shown a clinical response to therapy, defined as having an improvement in platelet (a type of blood cell) count from baseline (before starting Tavalisse) OR a decrease in bleeding events
- C. You will NOT use Tavalisse concurrently (at the same time) with other thrombopoietin receptor agonists (TPO-RAs, such as Doptelet [avatrombopag], Nplate [romiplostim], Promacta [eltrombopag], Alvaiz [eltrombopag])

Effective: 10/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FOSTEMSAVIR

Generic	Brand				
FOSTEMSAVIR	RUKOBIA				

GUIDELINES FOR USE

Our guideline named **FOSTEMSAVIR (Rukobia)** requires the following rule(s) be met for approval:

- A. You have human immunodeficiency virus type 1 (HIV-1) infection (a virus that attacks the body's immune system and if untreated, can lead to AIDS [acquired immunodeficiency syndrome])
- B. You are 18 years of age or older
- C. The requested medication will be used in combination with other antiretroviral(s) (class of medication used to treat HIV)
- D. You are treatment experienced (previously treated)
- E. You have multidrug-resistant HIV-1 infection (your virus is resistant to more than one HIV medication)
- F. You are failing your current antiretroviral regimen due to resistance, intolerance, or safety considerations

Effective: 08/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FREMANEZUMAB-VFRM

Generic	Brand			
FREMANEZUMAB-VFRM	AJOVY			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **FREMANEZUMAB-VFRM (Ajoovy)** requires the following rule(s) be met for approval:

- A. You have migraines (a type of headache)
- B. **If you have episodic migraines (0-14 headache days per month), approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Ajoovy is prescribed for the preventive treatment of migraines
 - 3. You will NOT use Ajoovy concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Aimovig [erenumab-aooe], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant], Qulipta [atogepant]) for migraine prevention
 - 4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol
- C. **If you have chronic migraines (at least 15 headache days per month), approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Ajoovy is prescribed for the preventive treatment of migraines
 - 3. You will NOT use Ajoovy concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Aimovig [erenumab-aooe], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant], Qulipta [atogepant]) for migraine prevention
 - 4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [**Note:** For Botox, previous trial of only NDCs 00023-1145-01 or 00023-3921-02 are allowable]

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FREMANEZUMAB-VFRM

RENEWAL CRITERIA

Our guideline named **FREMANEZUMAB-VFRM (Ajovy)** requires the following rule(s) be met for renewal:

- A. Ajovy is prescribed for the preventive treatment of migraines (a type of headache)
- B. You will NOT use Ajovy concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Aimovig [erenumab-aooe], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant], Qulipta [atogepant]) for migraine prevention
- C. You meet ONE of the following:
 - 1. You have experienced a decrease in migraine or headache frequency of at least 2 days per month with Ajovy therapy
 - 2. You have experienced a decrease in migraine severity with Ajovy therapy
 - 3. You have experienced a decrease in migraine duration (length of time) with Ajovy therapy

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FULVESTRANT

Generic	Brand				
FULVESTRANT	FASLODEX FULVESTRANT				

GUIDELINES FOR USE

Our guideline named **FULVESTRANT (Faslodex)** requires the following rule(s) be met for approval:

- A. You have breast cancer
- B. **If you have hormone receptor (HR: a type of protein)-positive breast cancer, approval also requires:**
 - 1. Your cancer is advanced
 - 2. You are a female and postmenopausal (after menopause)
 - 3. The requested medication will be used as monotherapy (one medication treatment)
 - 4. You have experienced disease progression (worsening) following endocrine (hormone) therapy (such as letrozole, anastrozole, tamoxifen)
- C. **If you have hormone receptor (HR: a type of protein)-positive, human epidermal growth factor receptor 2 (HER2: a type of protein)-negative breast cancer, approval also requires ONE of the following:**
 - 1. The requested medication will be used as monotherapy (one medication treatment) and you meet ALL of the following:
 - a. Your cancer is advanced
 - b. You are a female and postmenopausal (after menopause)
 - c. You have NOT previously been treated with an endocrine (hormone) therapy (such as letrozole, anastrozole, tamoxifen)
 - 2. The requested medication will be used in combination with Kisqali (ribociclib) and you meet ALL of the following:
 - a. Your cancer is advanced or metastatic (has spread to other parts of the body)
 - b. You are a female and postmenopausal
 - c. You have NOT received a prior endocrine based therapy (such as letrozole, anastrozole, tamoxifen) OR you have experienced disease progression (worsening) on endocrine therapy

(Denial text continued on the next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FULVESTRANT

GUIDELINES FOR USE (CONTINUED)

3. The requested medication will be used in combination with Itovebi (inavolisib) and Ibrance (palbociclib) and you meet ALL of the following:
 - a. Your cancer is locally advanced or metastatic (cancer that has spread from where it started to nearby tissue or lymph nodes or to other parts of the body)
 - b. Your tumor has a PIK3CA mutation (abnormal change in a type of gene), as detected by a Food and Drug Administration (FDA)-approved test
 - c. You have experienced disease recurrence (disease has returned) on or after completing adjuvant (add-on) endocrine (hormone) therapy (such as letrozole, anastrozole, tamoxifen)
4. The requested medication will be used in combination with Ibrance (palbociclib) or Verzenio (abemaciclib) and you meet ALL of the following:
 - a. Your cancer is advanced or metastatic
 - b. You are a female
 - c. You have experienced disease progression after an endocrine therapy (such as letrozole, anastrozole, tamoxifen)

Effective: 05/26/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FUTIBATINIB

Generic	Brand				
FUTIBATINIB	LYTGobi				

GUIDELINES FOR USE

Our guideline named **FUTIBATINIB (Lytgobi)** requires the following rule(s) be met for approval:

- A. You have unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA) (a type of bile duct cancer inside the liver that is unable to be removed by surgery, has spread from where it started to nearby tissue/lymph nodes or to other parts of the body)
- B. You are 18 years of age or older
- C. You have been previously treated for unresectable, locally advanced or metastatic iCCA
- D. You have fibroblast growth factor receptor 2 (FGFR2: a type of protein) gene fusions or other rearrangements
- E. You will complete a comprehensive ophthalmological examination (eye exam), including optical coherence tomography (OCT: a type of eye imaging test), before starting Lytgobi and at the recommended scheduled times

Effective: 11/14/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GALCANEZUMAB-GNLM

Generic	Brand			
GALCANEZUMAB-GNLM	EMGALITY			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **GALCANEZUMAB-GNLM (Emgality)** requires the following rule(s) be met for approval:

- A. You have migraines or episodic cluster headaches (very painful headaches that occur in patterns)
- B. **If you have episodic migraines (0-14 headache days per month), approval also requires:**
 1. You are 18 years of age or older
 2. Emgality is prescribed for the preventive treatment of migraines
 3. You will NOT use Emgality concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy [fremanezumab-vfrm], Aimovig [erenumab-aooe], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant], Qulipta [atogepant]) for migraine prevention
 4. You have tried ONE of the following preventive migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol
- C. **If you have chronic migraines (15 or more headache days per month), approval also requires:**
 1. You are 18 years of age or older
 2. Emgality is prescribed for the preventive treatment of migraines
 3. You will NOT use Emgality concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy [fremanezumab-vfrm], Aimovig [erenumab-aooe], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant], Qulipta [atogepant]) for migraine prevention
 4. You have tried ONE of the following preventive migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [**Note:** For Botox, previous trial of only NDCs 00023-1145-01 or 00023-3921-02 are allowable]
- D. **If you have episodic cluster headaches, approval also requires:**
 1. You are 18 years of age or older

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GALCANEZUMAB-GNLM

RENEWAL CRITERIA

Our guideline named **GALCANEZUMAB-GNLM (Emgality)** requires the following rule(s) be met for renewal:

- A. Emgality is being prescribed for preventive treatment of migraines OR for the treatment of episodic cluster headache (very painful headaches that occur in patterns)
- B. **If you have migraines, renewal also requires:**
 - 1. You will NOT use Emgality concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy [fremanezumab-vfrm], Aimovig [erenumab-aooe], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant], Qulipta [atogepant]) for migraine prevention
 - 2. You meet ONE of the following:
 - a. You have experienced a reduction in migraine or headache frequency of at least 2 days per month with Emgality therapy
 - b. You have experienced a reduction in migraine severity with Emgality therapy
 - c. You have experienced a reduction in migraine duration with Emgality therapy
- C. **If you have episodic cluster headaches, renewal also requires:**
 - 1. You had improvement in episodic cluster headache frequency as compared to baseline

Effective: 04/15/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GANAXOLONE

Generic	Brand				
GANAXOLONE	ZTALMY				

GUIDELINES FOR USE

Our guideline named **GANAXOLONE (Ztalmy)** requires the following rule(s) be met for approval:

- A. You have seizures
- B. You are 2 years of age or older
- C. Your seizures are associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD: a type of genetic disorder)

Effective: 10/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GEFITINIB

Generic	Brand			
GEFITINIB	IRESSA, GEFITINIB			

GUIDELINES FOR USE

Our guideline named **GEFITINIB (Iressa)** requires the following rule(s) be met for approval:

- A. You have metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
- B. Your tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (abnormal changes in a gene) as detected by an FDA (Food and Drug Administration)-approved test
- C. You will NOT be using Iressa (gefitinib) concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva [erlotinib], Tagrisso [osimertinib], Gilotrif [afatinib], Vizimpro [dacomitinib])

Effective: 05/22/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GILTERITINIB

Generic	Brand			
GILTERITINIB FUMARATE	XOSPATA			

GUIDELINES FOR USE

Our guideline named **GILTERITINIB (Xospata)** requires the following rule(s) be met for approval:

- A. You have relapsed or refractory acute myeloid leukemia (AML: type of white blood cell cancer)
- B. You are 18 years of age or older
- C. You have FMS-like tyrosine kinase 3 (type of gene) mutation (change in the DNA gene) as detected by a Food and Drug Administration-approved test

Effective: 04/10/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GIVINOSTAT

Generic	Brand				
GIVINOSTAT HYDROCHLORIDE	DUVYZAT				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **GIVINOSTAT (Duvyzat)** requires the following rule(s) be met for approval:

- A. You have Duchenne muscular dystrophy (DMD: a type of muscle disorder)
- B. You are 6 years of age or older
- C. Therapy is prescribed by or in consultation with a neurologist (nerve system doctor) specializing in the treatment of Duchenne muscular dystrophy (DMD) at a DMD treatment center
- D. Your diagnosis of DMD is confirmed by genetic testing
- E. You have been on a stable dose of corticosteroids for at least 6 months AND will continue steroid therapy with Duvyzat

RENEWAL CRITERIA

Our guideline named **GIVINOSTAT (Duvyzat)** requires the following rule(s) be met for renewal:

- A. You have Duchenne muscular dystrophy (DMD: a type of muscle disorder)
- B. You have been on a stable dose of corticosteroids for at least 6 months AND will continue steroid therapy with Duvyzat
- C. **If you are currently ambulatory (can walk), approval also requires:**
 - 1. You have shown improvement since starting Duvyzat, as measured by a standard set of ambulatory or functional status measures (such as 6-minute walking distance [6MWD], going up or down 4 stairs, time to rise from the floor [Gower's maneuver], 10-meter [30 feet] run/walk time, North Star Ambulatory Assessment [NSAA: a tool for evaluating Duchenne muscular dystrophy])
- D. **If you are currently non-ambulatory (cannot walk), approval also requires:**
 - 1. You have maintained or had a less than expected decrease in pulmonary (lung) function or upper limb strength since starting Duvyzat, as assessed by standard measures (such as pulmonary function [forced vital capacity, pulmonary function tests], upper limb strength)

Effective: 08/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GLASDEGIB

Generic	Brand			
GLASDEGIB MALEATE	DAURISMO			

GUIDELINES FOR USE

Our guideline named **GLASDEGIB (Daurismo)** requires the following rule(s) be met for approval:

- A. You have newly-diagnosed acute myeloid leukemia (AML: type of white blood cell cancer)
- B. The requested medication will be used in combination with low-dose cytarabine
- C. You are 75 years of age or older, **OR** you have comorbidities (having more than one disease) that prevents the use of intensive induction chemotherapy

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GLATIRAMER ACETATE

Generic	Brand			
GLATIRAMER ACETATE	COPAXONE, GLATOPA, GLATIRAMER ACETATE			

GUIDELINES FOR USE

Our guideline named **GLATIRAMER ACETATE (Copaxone, Glatopa)** requires the following rule(s) be met for approval:

1. You have a relapsing form of multiple sclerosis (MS: an illness where the immune system eats away at the protective covering of the nerves), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
2. You are 18 years of age or older

Effective: 01/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GLECAPREVIR/PIBRENTASVIR

Generic	Brand			
GLECAPREVIR/ PIBRENTASVIR	MAVYRET			

GUIDELINES FOR USE

Our guideline named **GLECAPREVIR/PIBRENTASVIR (Mavyret)** requires the following rule(s) be met for approval:

- A. You have chronic hepatitis C virus (HCV: liver inflammation caused by a type of virus)
- B. You are 3 years of age or older
- C. You have a genotype 1, 2, 3, 4, 5, or 6 infection (types of hepatitis C virus)
- D. You have an HCV RNA level (a measure of the amount of hepatitis C virus in your blood) within the past 6 months
- E. You do NOT have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (having two or more diseases at the same time)
- F. You do NOT have moderate or severe liver impairment (decompensated cirrhosis [a condition where there is liver damage and scarring with major symptoms]; Child-Pugh B or C [a score that evaluates the severity of liver damage])
- G. You will NOT use Mavyret concurrently (at the same time) with any medication with drug interactions that are contraindicated (harmful for you to use) or not recommended per the prescribing information (such as rifampin, atazanavir, carbamazepine, phenytoin, efavirenz, darunavir, lopinavir, ritonavir, atorvastatin, lovastatin, simvastatin, rosuvastatin at doses greater than 10mg, cyclosporine at doses greater than 100mg/day, medications containing more than 20mcg of ethinyl estradiol, St. John's wort)
- H. You will NOT use Mavyret concurrently (at the same time) with Epclusa (velpatasvir/sofosbuvir), Harvoni (ledipasvir/sofosbuvir), Vosevi (velpatasvir/sofosbuvir/voxilaprevir), or Zepatier (elbasvir/grazoprevir)
- I. **If you are treatment naive (no prior treatment), approval also requires ALL of the following:**
 1. You meet ONE of the following:
 - a. You do not have cirrhosis (liver damage or scarring)
 - b. You have compensated cirrhosis (a condition where there is liver damage and scarring without any major symptoms) (Child-Pugh A: a score that evaluates the severity of liver damage)
 - c. You received a liver transplant (replaced your liver)
 - d. You received a kidney transplant (replaced your kidney)
 2. You had an intolerance (side effect) or contraindication to (harmful for you to use) ONE of the following preferred medications: Epclusa or Harvoni, if you have a genotype 1, 4, 5, or 6 infection, OR you had an intolerance or contraindication to the preferred medication: Epclusa, if you have a genotype 2 or 3 infection

(Criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GLECAPREVIR/PIBRENTASVIR

GUIDELINES FOR USE (CONTINUED)

- J. If you are treatment-experienced (failed prior treatment) and prior therapy did not contain an NS5A inhibitor, approval also requires ONE of the following:**
1. You have a genotype 1, 2, 4, 5, or 6 infection, and you have compensated cirrhosis (a condition where there is liver damage and scarring without major symptoms) (Child-Pugh A: a score that evaluates the severity of liver damage) or you do not have cirrhosis (liver damage and scarring), and you have prior treatment experience with regimens containing interferon/peginterferon, ribavirin and/or Sovaldi (sofosbuvir), and you do not have prior treatment experience with an NS3/4A protease inhibitor (such as Olysio [simeprevir], Zepatier [elbasvir/grazoprevir]) or an NS5A inhibitor (such as Harvoni [ledipasvir/sofosbuvir], Epclusa [velpatasvir/sofosbuvir])
 2. You have genotype 1 OR genotype 2, 3, 4, 5, or 6 and are less than 18 years of age, and you have compensated cirrhosis (Child-Pugh A) OR you do not have cirrhosis, and you have prior treatment experience with an NS3/4A protease inhibitor (such as Olysio [simeprevir], Zepatier [elbasvir/grazoprevir]), and you do not have prior treatment experience with an NS5A inhibitor (such as Harvoni [ledipasvir/sofosbuvir], Epclusa [velpatasvir/sofosbuvir])
 3. You have a genotype 3 infection, and you have compensated cirrhosis (Child-Pugh A) OR you do not have cirrhosis, and you have prior treatment experience with regimens containing interferon/peginterferon, ribavirin, and/or Sovaldi (sofosbuvir), and you do not have prior treatment experience with an NS3/4A protease inhibitor (such as Olysio [simeprevir], Zepatier [elbasvir/grazoprevir]) or an NS5A inhibitor (such as Harvoni [ledipasvir/sofosbuvir], Epclusa [velpatasvir/sofosbuvir])
- (Criteria continued on next page)**

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GLECAPREVIR/PIBRENTASVIR

GUIDELINES FOR USE (CONTINUED)

- K. If you are treatment-experienced (failed prior treatment), approval also requires ALL of the following:**
1. You meet ONE of the following:
 - a. You are less than 18 years of age AND had prior treatment with an interferon
 - b. You have genotype 1 OR genotype 2, 3, 4, 5, or 6 and are less than 18 years of age, and you have compensated cirrhosis (a condition where there is liver damage and scarring without any major symptoms) (Child-Pugh A: a score that evaluates the severity of liver damage) OR you do not have cirrhosis (liver damage and scarring), and you have prior treatment experience with an NS5A inhibitor (such as Harvoni [ledipasvir/sofosbuvir], Epclusa [velpatasvir/sofosbuvir]), and you do not have prior treatment experience with an NS3/4A protease inhibitor (such as Olysio [simeprevir], Zepatier [elbasvir/grazoprevir])
 - c. You have failed prior treatment with a sofosbuvir-based regimen with no NS3/4A protease inhibitor (such as Epclusa [velpatasvir/sofosbuvir], Harvoni [ledipasvir/sofosbuvir], Sovaldi [sofosbuvir])
 - d. You have failed Mavyret AND Mavyret will be used with Sovaldi (sofosbuvir) and ribavirin
 - e. You have failed Vosevi (sofosbuvir/velpatasvir/voxilaprevir) AND Mavyret will be used with Sovaldi (sofosbuvir) and ribavirin
 - f. You are less than 18 years of age, have genotype 3, AND you had prior treatment with an interferon
 2. You had an intolerance (side effect) or contraindication to (harmful for you to use) ONE of the following preferred medications: Epclusa or Harvoni, if you have a genotype 1, 4, 5, or 6 infection, OR you had an intolerance or contraindication to the preferred medication Epclusa, if you have a genotype 2 or 3 infection
- L. Mavyret will also be approved for any other regimen/condition not listed above that is recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment**

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GLP-1 AGONIST

Generic	Brand				
EXENATIDE MICROSPHERES	BYDUREON BCISE				
EXENATIDE	BYETTA, EXENATIDE				
TIRZEPATIDE	MOUNJARO				
SEMAGLUTIDE	OZEMPIC, RYBELSUS				
DULAGLUTIDE	TRULICITY				
LIRAGLUTIDE	VICTOZA, LIRAGLUTIDE				

GUIDELINES FOR USE

Our guideline named **GLP-1 AGONIST (Bydureon BCise, Byetta [exenatide], Mounjaro, Ozempic, Rybelsus, Trulicity, Victoza [liraglutide])** requires the following rule(s) be met for approval:

- A. You have type 2 diabetes (a disorder with high blood sugar)
- B. Your diagnosis of type 2 diabetes is confirmed by medical records OR chart notes

Effective: 04/22/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GLYCEROL PHENYLBUTYRATE

Generic	Brand			
GLYCEROL PHENYLBUTYRATE	RAVICTI			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **GLYCEROL PHENYLBUTYRATE (Ravicti)** requires the following rule(s) be met for approval:

- A. You have a urea cycle disorder (UCD: a genetic disorder that causes high ammonia levels in the blood)
- B. Your disorder cannot be managed by dietary protein restriction and/or amino acid supplementation alone
- C. Your disorder is confirmed by enzymatic, biochemical or genetic testing (types of lab tests)
- D. Ravicti will be used as adjunctive (add-on) therapy along with dietary protein restriction
- E. You do NOT have a deficiency (low level) of N-acetylglutamate synthetase (NAGS: a type of enzyme) or acute hyperammonemia (sudden and short-term increase in ammonia levels to a critical level)
- F. You have tried or have a contraindication to (harmful for you to use) Buphenyl (sodium phenylbutyrate)

RENEWAL CRITERIA

Our guideline named **GLYCEROL PHENYLBUTYRATE (Ravicti)** requires the following rule(s) be met for renewal:

- A. You have a urea cycle disorder (UCD: a genetic disorder that causes high ammonia levels in the blood)
- B. You had a clinical benefit compared to baseline (such as normal fasting glutamine, low-normal fasting ammonia levels, or mental status clarity)

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GLYCOPYRRONIUM TOPICAL

Generic	Brand			
GLYCOPYRRONIUM 2.4% CLOTH	QBREXZA			

GUIDELINES FOR USE

Our guideline named **GLYCOPYRRONIUM TOPICAL (Qbrexza)** requires the following rule(s) be met for approval:

- A. You have primary axillary hyperhidrosis (excessive underarm sweating)
- B. You are 9 years of age or older
- C. You have tried a prescription strength aluminum chloride product (such as Drysol)
- D. You will NOT use Qbrexza concurrently (at the same time) with other topical anticholinergics indicated for primary axillary hyperhidrosis (such as Sofdra [sofipirionium bromide])

Effective: 08/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GOLIMUMAB - IV

Generic	Brand				
GOLIMUMAB	SIMPONI ARIA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **GOLIMUMAB - IV (Simponi Aria)** requires the following rule(s) be met for approval:

You have ONE of the following:

Moderate to severe rheumatoid arthritis (RA: a type of joint condition)

Psoriatic arthritis (PsA: a type of skin and joint condition)

Ankylosing spondylitis (AS: a type of joint condition)

Polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)

If you have moderate to severe rheumatoid arthritis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)

You are concurrently (at the same time) using or have a contraindication to (harmful for you to use) methotrexate

You will NOT use Simponi Aria concurrently with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis

You have tried at least 3 months of or have a contraindication to ONE conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

You meet ONE of the following:

You have tried or have a contraindication to TWO of the following preferred medications:

Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)

You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GOLIMUMAB - IV

INITIAL CRITERIA (CONTINUED)

If you have psoriatic arthritis, approval also requires:

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)

You will NOT use Simponi Aria concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

You meet ONE of the following:

You are 2 to 5 years of age AND have tried or have a contraindication to (harmful for you to use) BOTH of the preferred medications: Enbrel (etanercept), Rinvoq (upadacitinib)

You are 6 to 17 years of age AND have tried or have a contraindication to TWO of the following preferred medications: Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Enbrel (etanercept), Rinvoq (upadacitinib)

You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

If you have ankylosing spondylitis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)

You will NOT use Simponi Aria concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis

You have tried or have a contraindication to (harmful for you to use) an NSAID (non-steroidal anti-inflammatory drug such as ibuprofen, naproxen, meloxicam)

You have tried or have a contraindication to TWO of the following preferred medications:

Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GOLIMUMAB - IV

INITIAL CRITERIA (CONTINUED)

If you have polyarticular juvenile idiopathic arthritis, approval also requires:

You are 2 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)

You will NOT use Simponi Aria concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis

You have tried or have a contraindication to TWO of the following preferred medications:
Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz IR (tofacitinib immediate-release), Rinvoq (upadacitinib)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

RENEWAL CRITERIA

Our guideline named **GOLIMUMAB - IV (Simponi Aria)** requires the following rule(s) be met for renewal:

You have ONE of the following:

Moderate to severe rheumatoid arthritis (RA: a type of joint condition)

Psoriatic arthritis (PsA: a type of skin and joint condition)

Ankylosing spondylitis (AS: a type of joint condition)

Polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)

If you have moderate to severe rheumatoid arthritis, renewal also requires:

You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy

You are concurrently (at the same time) using or have a contraindication to (harmful for you to use) methotrexate

You will NOT use Simponi Aria concurrently with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GOLIMUMAB - IV

RENEWAL CRITERIA (CONTINUED)

You meet ONE of the following:

You have tried or have a contraindication to TWO of the following preferred medications:

Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)

You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

If you have psoriatic arthritis, renewal also requires:

You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy

You will NOT use Simponi Aria concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

You meet ONE of the following:

You are 2 to 5 years of age AND have tried or have a contraindication to (harmful for you to use) BOTH of the preferred medications: Enbrel (etanercept), Rinvoq (upadacitinib)

You are 6 to 17 years of age AND have tried or have a contraindication to TWO of the following preferred medications: Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Enbrel (etanercept), Rinvoq (upadacitinib)

You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GOLIMUMAB - IV

RENEWAL CRITERIA (CONTINUED)

If you have ankylosing spondylitis, renewal also requires:

- You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
- You will NOT use Simponi Aria concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
- You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

If you have polyarticular juvenile idiopathic arthritis, renewal also requires:

- You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
- You will NOT use Simponi Aria concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
- You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz IR (tofacitinib immediate-release), Rinvoq (upadacitinib)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GOLIMUMAB - SQ

Generic	Brand			
GOLIMUMAB - SQ	SIMPONI - SQ			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **GOLIMUMAB-SQ (Simponi)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Psoriatic arthritis (PsA: a type of skin and joint condition)
3. Moderate to severe ankylosing spondylitis (AS: a type of joint condition)
4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You are concurrently (at the same time) using or have a contraindication to (harmful for you to use) methotrexate
4. You will NOT use Simponi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
5. You have tried at least 3 months of or have a contraindication to ONE conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
6. You meet ONE of the following:
 - a. You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GOLIMUMAB - SQ

INITIAL CRITERIA (CONTINUED)

C. If you have psoriatic arthritis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
3. You will NOT use Simponi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
4. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

D. If you have moderate to severe ankylosing spondylitis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Simponi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
4. You have tried or have a contraindication to (harmful for you to use) an NSAID (non-steroidal anti-inflammatory drug such as ibuprofen, naproxen, meloxicam)
5. You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GOLIMUMAB - SQ

INITIAL CRITERIA (CONTINUED)

E. If you have moderate to severe ulcerative colitis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
3. You will NOT use Simponi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
4. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

RENEWAL CRITERIA

Our guideline named **GOLIMUMAB-SQ (Simponi)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Psoriatic arthritis (PsA: a type of skin and joint condition)
3. Moderate to severe ankylosing spondylitis (AS: a type of joint condition)
4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GOLIMUMAB - SQ

RENEWAL CRITERIA (CONTINUED)

B. If you have moderate to severe rheumatoid arthritis, renewal also requires:

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You are concurrently (at the same time) using or have a contraindication to (harmful for you to use) methotrexate
3. You will NOT use Simponi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
4. You meet ONE of the following:
 - a. You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

C. If you have psoriatic arthritis, renewal also requires:

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Simponi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
3. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GOLIMUMAB - SQ

RENEWAL CRITERIA (CONTINUED)

D. If you have moderate to severe ankylosing spondylitis, renewal also requires:

1. You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: a type of disease evaluation tool) score while on therapy
2. You will NOT use Simponi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
3. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

E. If you have moderate to severe ulcerative colitis, renewal also requires:

1. You will NOT use Simponi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
2. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GOLODIRSEN

Generic	Brand				
GOLODIRSEN	VYONDYS-53				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **GOLODIRSEN (Vyondys 53)** requires the following rule(s) be met for approval:

- A. You have Duchenne muscular dystrophy (DMD: a type of inherited muscle disorder)
- B. You have a confirmed mutation (abnormal change in a type of gene) in the DMD gene that will respond to exon 53 skipping therapy (a type of therapy to treat DMD)
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor) specializing in the treatment of DMD at a DMD treatment center
- D. You are ambulatory (able to walk)
- E. You are currently receiving treatment with or you have a contraindication to (harmful for you to use) corticosteroids (such as prednisone, prednisolone)

RENEWAL CRITERIA

Our guideline named **GOLODIRSEN (Vyondys 53)** requires ONE of the following rule(s) be met for renewal:

- A. You have maintained or demonstrated a less than expected decline in ambulatory ability (ability to walk) based on muscle function assessments (such as the 6-minute walk test)
- B. You have maintained or demonstrated a less than expected decline in other muscle function (pulmonary [lung] or cardiac [heart] function)

Effective: 02/24/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GUSELKUMAB

Generic	Brand			
GUSELKUMAB	TREMFYA			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **GUSELKUMAB (Tremfya)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
 2. Psoriatic arthritis (PsA: a type of skin and joint condition)
 3. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
 4. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
- B. **If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 3. You will NOT use Tremfya concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
 4. You meet ONE of the following:
 - a. You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis
 - b. You have a contraindication (harmful for you to use) or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) and PUVA (phototherapy) for the treatment of plaque psoriasis
 - c. You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication
 5. You meet ONE of the following:
 - a. You were previously stable on another biologic and are switching to Tremfya
 - b. You have psoriasis covering 3 percent or more of body surface area (BSA)
 - c. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, face, or scalp

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GUSELKUMAB

INITIAL CRITERIA (CONTINUED)

- C. If you have psoriatic arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
 3. You will NOT use Tremfya concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
- D. If you have moderate to severe ulcerative colitis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 3. You will NOT use Tremfya concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
- E. If you have moderate to severe Crohn's disease, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 3. You will NOT use Tremfya concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GUSELKUMAB

RENEWAL CRITERIA

Our guideline named **GUSELKUMAB (Tremfya)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
 - 2. Psoriatic arthritis (PsA: a type of skin and joint condition)
 - 3. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
 - 4. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
- B. **If you have moderate to severe plaque psoriasis, renewal also requires:**
 - 1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50 percent or more while on therapy
 - 2. You will NOT use Tremfya concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
- C. **If you have psoriatic arthritis, renewal also requires:**
 - 1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 - 2. You will NOT use Tremfya concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
- D. **If you have moderate to severe ulcerative colitis, renewal also requires:**
 - 1. You will NOT use Tremfya concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
- E. **If you have moderate to severe Crohn's disease, renewal also requires:**
 - 1. You will NOT use Tremfya concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease

Effective: 05/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

HIGH CONCENTRATION OPIOID ORAL SOLUTIONS

Generic	Brand				
MORPHINE SULFATE	MORPHINE SULFATE				
OXYCODONE HCL	OXYCODONE HCL				

GUIDELINES FOR USE

Our guideline named **HIGH CONCENTRATION OPIOID ORAL SOLUTIONS (morphine sulfate, oxycodone hydrochloride)** requires the following rule(s) be met for approval:

- A. You have pain severe enough to require opioid analgesic and for which alternative treatments are inadequate
- B. You meet ONE of the following:
 - 1. You are enrolled in hospice OR you are receiving palliative care or end-of-life care
 - 2. You meet ALL of the following:
 - a. You have previous use of at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid
 - b. You have trouble swallowing opioid tablets, capsules, or large volumes of liquid

Effective: 10/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

HYDROCHLOROTHIAZIDE

Generic	Brand				
HYDROCHLOROTHIAZIDE	INZIRQO				

GUIDELINES FOR USE

Our guideline named **HYDROCHLOROTHIAZIDE (Inzirqo)** requires the following rule(s) be met for approval:

You have ONE of the following:

Hypertension (high blood pressure)

Edema (swelling caused by fluid build-up in the body) associated with congestive heart failure (a type of heart condition), hepatic cirrhosis (liver damage and scarring), or renal (kidney) disease (including nephrotic syndrome [a type of kidney disorder])

If you have hypertension, approval also requires:

You have a contraindication to (harmful for you to use) or are unable to swallow hydrochlorothiazide tablets

If you have edema associated with congestive heart failure, hepatic cirrhosis, or renal disease (including nephrotic syndrome), approval also requires:

You have a contraindication to (harmful for you to use) or are unable to swallow hydrochlorothiazide tablets

Effective: 04/07/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

HYDROCORTISONE

Generic	Brand				
HYDROCORTISONE	ALKINDI SPRINKLE				

GUIDELINES FOR USE

Our guideline named **HYDROCORTISONE (Alkindi Sprinkle)** requires the following rule(s) be met for approval:

- A. You have adrenocortical insufficiency (your body does not produce enough of certain hormones)
- B. You are less than 18 years of age
- C. You are unable to take the tablet form of hydrocortisone (for example you need a lower strength, or you have difficulty swallowing)

Effective: 04/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

HYDROMORPHONE ER

Generic	Brand			
HYDROMORPHONE HCL	EXALGO, HYDROMORPHONE ER			

GUIDELINES FOR USE

Our guideline named **HYDROMORPHONE ER (Exalgo)** requires the following rule(s) be met for approval:

- A. You meet the definition of opioid tolerance. This is defined as those who are taking, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 25 mg oral oxymorphone/day, 8 mg oral hydromorphone/day, or an equianalgesic dose (equal pain relieving dose) of another opioid
- B. The requested medication is not prescribed on an as-needed basis
- C. Dosages above 16mg require recommendation from a pain specialist

Effective: 03/04/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

HYDROXYUREA

Generic	Brand				
HYDROXYUREA	XROMI				

GUIDELINES FOR USE

Our guideline named **HYDROXYUREA (Xromi)** requires the following rule(s) be met for approval:

- A. You have sickle cell anemia (a type of blood disorder)
- B. You are 6 months to 17 years of age
- C. You have recurrent moderate to severe painful crises (repeated episodes of extreme pain)
- D. You have tried, have a contraindication to (harmful for you to use), or are unable to swallow generic hydroxyurea capsules

Effective: 03/10/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IBREXAFUNGERP

Generic	Brand				
IBREXAFUNGERP CITRATE	BREXAFEMME				

GUIDELINES FOR USE

Our guideline named **IBREXAFUNGERP (Brexafemme)** requires the following rule(s) be met for approval:

- A. The request is for ONE of the following:
 - 1. Treatment of vulvovaginal candidiasis (VVC: vaginal yeast infection)
 - 2. Reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC: repeated vaginal yeast infection)
- B. **If you are using Brexafemme for the treatment of vulvovaginal candidiasis, approval also requires:**
 - 1. You are a post-menarchal (you have started having your period) female
 - 2. You have tried or have a contraindication to (harmful for) oral fluconazole AND an intravaginal azole (type of drug that is inserted into the vagina and used to treat yeast infections such as terconazole cream)
- C. **If you are using Brexafemme for the reduction in the incidence of recurrent vulvovaginal candidiasis, approval also requires:**
 - 1. You are a post-menarchal (you have started having your period) female
 - 2. You have tried or have a contraindication to (harmful for) oral fluconazole (you had a breakthrough episode of VVC while taking fluconazole 150 mg weekly)
 - 3. You are NOT currently on oteseconazole for RVVC
 - 4. You meet ONE of the following:
 - a. You have not previously received Brexafemme AND you had 3 or more episodes of RVVC in the past 12 months
 - b. You have been previously treated with Brexafemme and meet ALL of the following:
 - i. You have successfully completed a course of Brexafemme for prevention of RVVC
 - ii. You are either being treated or have just completed treatment for a new recurrence of VVC

Effective: 04/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IBRUTINIB

Generic	Brand			
IBRUTINIB	IMBRUVICA			

GUIDELINES FOR USE

Our guideline named **IBRUTINIB (Imbruvica)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
 - 2. Small lymphocytic lymphoma (SLL: a type of blood cancer)
 - 3. Waldenstrom's macroglobulinemia (WM: a type of blood cancer)
 - 4. Chronic graft-versus-host disease (cGVHD: a type of long-term immune disorder)
- B. **If you have chronic lymphocytic leukemia, small lymphocytic lymphoma, or Waldenstrom's macroglobulinemia, approval also requires:**
 - 1. You are 18 years of age or older
- C. **If you have chronic graft-versus-host disease, approval also requires:**
 - 1. You are 1 year of age or older
 - 2. You have failed at least ONE line of systemic therapy (treatment that targets the entire body, such as prednisone, methotrexate, mycophenolate mofetil)
 - 3. You will NOT use Imbruvica concurrently (at the same time) with Jakafi (ruxolitinib), Niktimvo (axatilimab-csfr), or Rezurock (belumosudil)

NOTE: Requests for Imbruvica (ibrutinib) 560 mg tablet will not be approved. This strength does not have a Food and Drug Administration (FDA)-approved indication.

Effective: 02/24/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ICATIBANT

Generic	Brand			
ICATIBANT ACETATE	FIRAZYR, SAJAZIR, ICATIBANT ACETATE			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ICATIBANT (Firazyr, Sajazir)** requires the following rule(s) be met for approval:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You are 18 years of age or older
- C. The requested medication will be used for the treatment of acute (sudden and severe) attacks of hereditary angioedema
- D. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor), hematologist (a type of blood doctor), or pulmonologist (lung/breathing doctor)
- E. Your diagnosis is confirmed by ONE of the following complement tests: C1-INH protein levels, C4 protein levels, C1-INH functional levels, C1q (a type of lab test)
- F. You will NOT use the requested medication concurrently (at the same time) with other medications used for the treatment of acute HAE attacks (such as Berinert [C1 esterase inhibitor], Ruconest [C1 esterase inhibitor], Kalbitor [ecallantide])

RENEWAL CRITERIA

Our guideline named **ICATIBANT (Firazyr, Sajazir)** requires the following rule(s) be met for renewal:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You have experienced a reduction (decrease) in the severity or duration of HAE attacks

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IDELALISIB

Generic	Brand			
IDELALISIB	ZYDELIG			

GUIDELINES FOR USE

Our guideline named **IDELALISIB (Zydelig)** requires the following rule(s) be met for approval:

- A. You have relapsed chronic lymphocytic leukemia (CLL: a type of blood cancer)
- B. Zydelig will be used in combination with rituximab

Effective: 04/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ILOPROST

Generic	Brand				
ILOPROST TROMETHAMINE	VENTAVIS				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ILOPROST (Ventavis)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
- C. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
 2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
 3. Pulmonary vascular resistance (PVR) greater than 2 Wood units
- D. You have tried or have a contraindication to (harmful for you to use) TWO of the following medications from different drug classes:
 1. Oral endothelin receptor antagonist (such as Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
 2. Oral phosphodiesterase-5 inhibitor for PAH (such as Revatio [sildenafil], Adcirca [tadalafil])
 3. Oral cGMP stimulator (such as Adempas [riociguat])
 4. Intravenous or subcutaneous prostacyclin (such as Flolan [epoprostenol], Remodulin [treprostinil])

RENEWAL CRITERIA

Our guideline named **ILOPROST (Ventavis)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)

Effective: 11/25/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IMATINIB

Generic	Brand			
IMATINIB MESYLATE	GLEEVEC, IMKELDI, IMATINIB MESYLATE			

GUIDELINES FOR USE

Our guideline named **IMATINIB (Gleevec, Imkeldi)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML: a type of blood cancer)
2. Relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (type of blood cancer that has returned or did not respond to treatment)
3. Newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (type of blood cancer)
4. Myelodysplastic/myeloproliferative disease (MDS/MPD: type of blood cancer)
5. Aggressive systemic mastocytosis (ASM: a type of blood disorder)
6. Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) (types of inflammatory cancer)
7. Unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans (DFSP: type of rare skin tumor that cannot be completely removed by surgery, has returned, and/or has spread to other parts of the body)
8. Unresectable and/or metastatic malignant gastrointestinal stromal tumor (GIST: type of digestive tumor that cannot be completely removed by surgery and/or has spread to other parts of the body)
9. Gastrointestinal stromal tumor (GIST: type of digestive tumor)

B. If the request is for Imkeldi solution, approval also requires that you are unable to swallow generic imatinib tablets

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IMATINIB

GUIDELINES FOR USE (CONTINUED)

- C. If you have Philadelphia chromosome positive chronic myeloid leukemia, approval also requires:**
1. You meet ONE of the following:
 - a. You have newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML: type of blood cancer) in chronic phase
 - b. You have Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy
 2. You have NOT received previous treatment with another tyrosine kinase inhibitor, such as Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Iclusig (ponatinib)
- D. If you have relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), approval also requires:**
1. You are 18 years of age or older
- E. If you have newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), approval also requires:**
1. The requested medication will be used in combination with chemotherapy (a type of cancer treatment)
- F. If you have myelodysplastic/myeloproliferative disease, approval also requires:**
1. You are 18 years of age or older
 2. Your disease is associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements (a type of gene mutation)
- G. If you have aggressive systemic mastocytosis, approval also requires:**
1. You are 18 years of age or older
 2. Your disease is without the D816V c-Kit mutation (abnormal change in a type of gene) or c-Kit mutational status is unknown
- H. If you have hypereosinophilic syndrome and/or chronic eosinophilic leukemia, approval also requires:**
1. You are 18 years of age or older
- I. If you have unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans, approval also requires:**
1. You are 18 years of age or older
- (Criteria continued on next page)**

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IMATINIB

GUIDELINES FOR USE (CONTINUED)

- J. If you have unresectable and/or metastatic malignant gastrointestinal stromal tumor, approval also requires:**
 - 1. Your tumor is Kit (CD117: a type of protein) positive
 - 2. For request of Gleevec 400mg twice daily, approval requires a trial of Gleevec 400mg once daily OR a gastrointestinal stromal tumor (GIST) expressing a KIT exon 9 mutation (abnormal change in a type of gene)
- K. If you have gastrointestinal stromal tumor, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. The request is for adjuvant (additional) treatment following complete gross resection of Kit (CD117: a type of protein) positive gastrointestinal stromal tumor (GIST)
 - 3. For request of Gleevec 400mg twice daily, approval requires a trial of Gleevec 400mg once daily OR a GIST tumor expressing a KIT exon 9 mutation (abnormal change in a type of gene)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IMMUNE GLOBULIN - CUTAQUIG

Generic	Brand				
IMMUN GLOB G(IGG)- HIPP/MALTOSE	CUTAQUIG				

GUIDELINES FOR USE

Our guideline named **IMMUNE GLOBULIN - CUTAQUIG** requires the following rule(s) be met for approval:

- A. You have primary immunodeficiency disease (genetic disease where the immune system is weak)

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IMMUNE GLOBULIN - CUVITRU

Generic	Brand				
IMMUN GLOB G(IGG)/GLY/IGA OV50	CUVITRU				

GUIDELINES FOR USE

Our guideline named **IMMUNE GLOBULIN - CUVITRU** requires the following rule(s) be met for approval:

- A. You have primary immunodeficiency disease (genetic disease where the immune system is weak)

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IMMUNE GLOBULIN - HIZENTRA

Generic	Brand				
IMMUN GLOB G(IGG)/PRO/IGA 0-50	HIZENTRA				

GUIDELINES FOR USE

Our guideline named **IMMUNE GLOBULIN - HIZENTRA** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Primary immunodeficiency disease (genetic disease where the immune system is weak)
2. Chronic inflammatory demyelinating polyneuropathy (a nerve disorder with increasing weakness and loss of sensory function in the legs and arms)

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IMMUNE GLOBULIN - HYQVIA

Generic	Brand				
IGG/HYALURONIDASE, RECOMBINANT	HYQVIA				

GUIDELINES FOR USE

Our guideline named **IMMUNE GLOBULIN - HYQVIA** requires the following rule(s) be met for approval:

2. You have ONE of the following:
 - A. Primary immunodeficiency disease (genetic disease where the immune system is weak)
 - B. Chronic inflammatory demyelinating polyneuropathy (a nerve disorder with increasing weakness and loss of sensory function in the legs and arms)

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IMMUNE GLOBULIN - IV/SQ

Generic	Brand				
IMMUN GLOB G(IGG)/GLY/IGA OV50	GAMMAGARD LIQUID				
IMMUNE GLOBUL G/GLY/IGA AVG 46	GAMMAKED, GAMUNEX-C				

GUIDELINES FOR USE

Our guideline named **IMMUNE GLOBULIN - IV/SQ (Gammagard Liquid, Gammaked, Gammunex-C)** requires the following rule(s) be met for approval:

A. For subcutaneous (SQ) injection, approval requires:

1. You have primary immunodeficiency disease (genetic disease where the immune system is weak)

B. For intravenous (IV) injection, approval requires:

1. You have ONE of the following:
 - a. Primary immunodeficiency disease (genetic disease where the immune system is weak)
 - b. Immune (idiopathic) thrombocytopenic purpura (a type of blood disorder)
 - c. Chronic inflammatory demyelinating polyneuropathy (a nerve disorder with increasing weakness and loss of sensory function in the legs and arms)
 - d. Multifocal motor neuropathy (a nerve disorder with increasing muscle weakness)
 - e. Kawasaki syndrome (inflammation in the walls of blood vessels in the body)
 - f. B-cell chronic lymphocytic leukemia (blood and bone marrow cancer of immune cells) with hypogammaglobulinemia (low levels of immunoglobulins)
 - g. Autoimmune hemolytic anemia (body destroys red blood cells more rapidly than it produces them)
 - h. Pure red cell aplasia (bone marrow stops making red blood cells)
 - i. Guillain-Barre syndrome (immune system attacks the nerves)
 - j. Myasthenia gravis (a type of chronic autoimmune disorder)
 - k. Autoimmune Graves' ophthalmopathy (a type of eye disease)
 - l. Cytomegalovirus-induced pneumonitis (lung tissue inflammation caused by a virus) related to a solid organ transplant
 - m. Prevention of bacterial infection in an HIV (human immunodeficiency virus: an immune system disease caused by a virus)- infected child
 - n. Reduction of secondary infections in pediatric HIV infections
 - o. Dermatomyositis (a type of muscle and skin disorder) or polymyositis (a type of inflammatory muscle disease)

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IMMUNE GLOBULIN - IV/SQ

GUIDELINES FOR USE (CONTINUED)

- p. Autoimmune uveitis (birdshot retinochoroidopathy; inflammation of the middle layer of the eye)
- q. Lambert-Eaton myasthenic syndrome (a type of muscle disorder)
- r. IgM (immunoglobulin M) anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathy (a type of nerve damage)
- s. Stiff-man syndrome (a nerve disorder with increasing muscle stiffness [rigidity] and repeated episodes of painful muscle spasms)
- t. Neonatal sepsis (blood infection in infants)
- u. Rotaviral enterocolitis (severe diarrhea among infants and young children)
- v. Toxic shock syndrome (a life-threatening complication of certain bacterial infections)
- w. Enteroviral meningoencephalitis (inflammation of the brain and surrounding tissues caused by a virus)
- x. Toxic epidermal necrolysis or Stevens-Johnson syndrome (types of serious bacterial skin infections)
- y. Autoimmune mucocutaneous blistering disease (group of serious skin conditions that start with blisters on the skin) such as pemphigus vulgaris, bullous pemphigoid, mucous membrane pemphigoid, or epidermolysis bullosa acquisita
- 2. If the request is for Gammaked or Gammunex-C, approval also requires:
 - a. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Gammaplex, Gammagard S-D, Gammagard Liquid, Octagam, Panzyga, Privigen

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IMMUNE GLOBULIN - XEMBIFY

Generic	Brand				
IMMUNE GLOBULIN, GAMMA(IGG)KLHW	XEMBIFY				

GUIDELINES FOR USE

Our guideline named **IMMUNE GLOBULIN - XEMBIFY** requires the following rule(s) be met for approval:

- A. You have primary immunodeficiency disease (genetic disease where the immune system is weak)

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INAVOLISIB

Generic	Brand				
INAVOLISIB	ITOVEBI				

GUIDELINES FOR USE

Our guideline named **INAVOLISIB (Itovebi)** requires the following rule(s) be met for approval:

- A. You have locally advanced or metastatic breast cancer (cancer that has spread from where it started to nearby tissue or lymph nodes or to other parts of the body)
- B. Your cancer is hormone receptor (HR: a type of protein)-positive, human epidermal growth factor receptor 2 (HER2: a type of protein)-negative
- C. Your tumor has a PIK3CA mutation (abnormal change in a type of gene), as detected by a Food and Drug Administration (FDA)-approved test
- D. Itovebi will be used in combination with palbociclib (Ibrance) and fulvestrant (Faslodex)
- E. You have experienced disease recurrence (disease has returned) on or after completing adjuvant (add-on) endocrine (hormone) therapy (such as letrozole, anastrozole, tamoxifen)

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INCLISIRAN

Generic	Brand				
INCLISIRAN SODIUM	LEQVIO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **INCLISIRAN (Leqvio)** requires the following rule(s) be met for approval:

- A. You have primary hyperlipidemia (high levels of fat in the blood), which includes heterozygous familial hypercholesterolemia (HeFH: a type of inherited high cholesterol disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor), endocrinologist (a type of hormone doctor), or lipidologist (a type of cholesterol doctor)
- D. You have a low density lipoprotein cholesterol (LDL-C: bad cholesterol) level of at least 70 mg/dL at the start of Leqvio therapy
- E. You had tried or have a contraindication to (harmful for you to use) Zetia (ezetimibe)
- F. You had tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Praluent (alirocumab), Repatha (evolocumab)
- G. You will NOT use Leqvio concurrently (at the same time) with a PCSK9 inhibitor (such as Praluent [alirocumab], Repatha [evolocumab])
- H. **If you are statin tolerant, approval also requires:**
 - 1. You will continue statin treatment in combination with Leqvio
 - 2. You meet ONE of the following:
 - a. You are currently taking a high-intensity statin (atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily) AND have been taking it for a duration of at least 8 weeks
 - b. You are currently taking a maximally tolerated dose of any statin AND have been taking it for a duration of at least 8 weeks, given that you did not tolerate a high-intensity statin

(Initial criteria continued on the next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INCLISIRAN

INITIAL CRITERIA (CONTINUED)

- I. **If you are statin intolerant, approval also requires ONE of the following:**
 1. You have an absolute contraindication to (harmful for you to use) statin therapy (such as, active decompensated liver disease [symptoms related to liver damage], nursing (breastfeeding) female, pregnancy or plans to become pregnant, hypersensitivity [allergic] reaction)
 2. You have complete statin intolerance (defined by severe and intolerable adverse effects) that have occurred with trials of at least TWO separate statins, AND the adverse effects have improved when you stopped each statin. Some adverse effects include: creatine kinase (type of protein) elevation greater than or equal to 10 times the upper limit of normal, liver function test elevation greater than or equal to 3 times the upper limit of normal, rhabdomyolysis (severe muscle break down), severe muscle weakness leading to temporary disability, fall, or inability to use a major muscle group

RENEWAL CRITERIA

Our guideline named **INCLISIRAN (Leqvio)** requires the following rule(s) be met for renewal:

- A. You have primary hyperlipidemia (high levels of fat in the blood), which includes heterozygous familial hypercholesterolemia (HeFH: a type of inherited high cholesterol disorder)
- B. You will NOT use Leqvio concurrently (at the same time) with a PCSK9 inhibitor (such as Praluent [alirocumab], Repatha [evolocumab])
- C. You meet ONE of the following:
 1. You have continued to take a high-intensity statin (atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily) along with Leqvio
 2. You have continued to take a maximally tolerated dose of ANY statin along with Leqvio
 3. You have an absolute contraindication to (harmful for you to use) statin therapy
 4. You have complete statin intolerance (severe and intolerable adverse effects)

Effective: 03/17/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INEBILIZUMAB-CDON

Generic	Brand				
INEBILIZUMAB-CDON	UPLIZNA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **INEBILIZUMAB-CDON (Uplizna)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Neuromyelitis optica spectrum disorder (NMOSD: a type of brain disorder)
 2. Immunoglobulin G4-related disease (IgG4-RD: a type of inflammatory disorder)
- B. **If you have neuromyelitis optica spectrum disorder, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
 3. You have a positive serologic (blood) test for the anti-aquaporin-4 (AQP4: a type of protein) antibody
 4. You will NOT use Uplizna concurrently (at the same time) with another NMOSD medication (such as Rituxan [rituximab], Enspryng [satralizumab-mwge], Ultomiris [ravulizumab-cwvz], Soliris [eculizumab])
 5. You have at least ONE of the following core clinical characteristics:
 - i. Optic neuritis (a type of brain disorder)
 - ii. Acute myelitis (a type of brain disorder)
 - iii. Area postrema syndrome (a type of brain disorder)
 - iv. Acute brainstem syndrome (a type of brain disorder)
 - v. Symptomatic narcolepsy (a type of sleep condition) or acute diencephalic clinical syndrome (a type of brain disorder) with NMOSD-typical diencephalic magnetic resonance imaging (MRI: a type of imaging lab) lesions (affected areas)
 - vi. Symptomatic cerebral syndrome with NMOSD-typical brain lesions
- C. **If you have immunoglobulin G4-related disease, approval also requires:**
1. You are 18 years of age or older

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INEBILIZUMAB-CDON

RENEWAL CRITERIA

NOTE: For the diagnosis of Immunoglobulin G4-related disease, please refer to the Initial Criteria section.

Our guideline named **INEBILIZUMAB-CDON (Uplizna)** requires the following rule(s) be met for renewal:

- A. You have neuromyelitis optica spectrum disorder (NMOSD: a type of brain disorder)
- B. You have experienced a clinical benefit (such as reduction in relapse frequency from baseline [before treatment] or a decrease in NMOSD-related hospitalizations)
- C. You will NOT use Uplizna concurrently (at the same time) with another NMOSD medication (such as Rituxan [rituximab], Enspryng [satralizumab-mwge], Ultomiris [ravulizumab-cwvz], Soliris [eculizumab])

Effective: 05/12/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB

Generic	Brand				
INFLIXIMAB	REMICADE, INFLIXIMAB				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **INFLIXIMAB (Remicade)** requires the following rule(s) be met for approval:

You have **ONE** of the following:

Moderate to severe rheumatoid arthritis (RA: a type of joint condition)

Psoriatic arthritis (PsA: a type of skin and joint condition)

Ankylosing spondylitis (AS: a type of joint condition)

Severe plaque psoriasis (PsO: a type of skin condition)

Moderate to severe Crohn's disease (CD: a type of bowel disorder)

Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

If you have moderate to severe rheumatoid arthritis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)

You are currently using or have a contraindication to (harmful for you to use) methotrexate

You will **NOT** use the requested medication concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq [upadacitinib]], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis

You have tried at least 3 months of or have a contraindication to **ONE** conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

You meet **ONE** of the following:

You have tried or have a contraindication to **TWO** of the following preferred medications:

Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)

You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) **AND** your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB

INITIAL CRITERIA (CONTINUED)

If you have psoriatic arthritis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)

You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

If you have ankylosing spondylitis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)

You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis

You have tried or have a contraindication to (harmful for you to use) an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)

You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB

INITIAL CRITERIA (CONTINUED)

If you have severe plaque psoriasis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)

You have psoriasis covering 3 percent or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, face, genital area, or scalp

You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)

You meet ONE of the following:

You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis

You have a contraindication or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) and PUVA (phototherapy) for the treatment of plaque psoriasis

You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB

INITIAL CRITERIA (CONTINUED)

If you have moderate to severe Crohn's disease, approval also requires:

Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)

You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease

You meet ONE of the following:

You are 6 to 17 years of age AND have tried or have a contraindication to (harmful for you to use) the preferred medication: Humira (adalimumab), adalimumab-adaz, or Simlandi

You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)

If you have moderate to severe ulcerative colitis, approval also requires:

Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)

You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

You meet ONE of the following:

You are 6 to 17 years of age AND have tried or have a contraindication to (harmful for you to use) the preferred medication: Humira (adalimumab), adalimumab-adaz, or Simlandi

You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB

RENEWAL CRITERIA

Our guideline named **INFLIXIMAB (Remicade)** requires the following rule(s) be met for renewal:

You have ONE of the following:

Moderate to severe rheumatoid arthritis (RA: a type of joint condition)

Psoriatic arthritis (PsA: a type of skin and joint condition)

Ankylosing spondylitis (AS: a type of joint condition)

Severe plaque psoriasis (PsO: a type of skin condition)

Moderate to severe Crohn's disease (CD: a type of bowel disorder)

Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

If you have moderate to severe rheumatoid arthritis, renewal also requires:

You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy

You are currently using or have a contraindication to (harmful for you to use) methotrexate

You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis

You meet ONE of the following:

You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)

You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB

RENEWAL CRITERIA (CONTINUED)

If you have psoriatic arthritis, renewal also requires:

- You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
- You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
- You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

If you have ankylosing spondylitis, renewal also requires:

- You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index: diagnostic test which allows a physician to determine the effectiveness of a current medication) score while on therapy
- You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
- You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB

RENEWAL CRITERIA (CONTINUED)

If you have severe plaque psoriasis, renewal also requires:

- You have achieved or maintained clear or minimal disease OR you have experienced a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50 percent or more while on therapy
- You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
- You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)

If you have moderate to severe Crohn's disease, renewal also requires:

- You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
- You meet ONE of the following:
 - You are 6 to 17 years of age AND have tried or have a contraindication to (harmful for you to use) the preferred medication: Humira (adalimumab), adalimumab-adaz, or Simlandi
 - You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB

RENEWAL CRITERIA (CONTINUED)

If you have moderate to severe ulcerative colitis, renewal also requires:

You will NOT use the requested medication concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

You meet ONE of the following:

You are 6 to 17 years of age AND have tried or have a contraindication to (harmful for you to use) the preferred medication: Humira (adalimumab), adalimumab-adaz, or Simlandi

You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 05/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-ABDA

Generic	Brand				
INFLIXIMAB-ABDA	RENFLEXIS				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **INFLIXIMAB-ABDA (Renflexis)** requires the following rule(s) be met for approval:

You have **ONE** of the following:

Moderate to severe rheumatoid arthritis (RA: a type of joint condition)

Psoriatic arthritis (PsA: a type of skin and joint condition)

Ankylosing spondylitis (AS: a type of joint condition)

Severe plaque psoriasis (PsO: a type of skin condition)

Moderate to severe Crohn's disease (CD: a type of bowel disorder)

Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

If you have moderate to severe rheumatoid arthritis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)

You are currently using or have a contraindication to (harmful for you to use) methotrexate

You will **NOT** use Renflexis concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis

You have tried at least 3 months of or have a contraindication to **ONE** conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

You meet **ONE** of the following:

You have tried or have a contraindication to **TWO** of the following preferred medications:

Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)

You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) **AND** your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-ABDA

INITIAL CRITERIA (CONTINUED)

If you have psoriatic arthritis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)

You will NOT use Renflexis concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

If you have ankylosing spondylitis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)

You will NOT use Renflexis concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis

You have tried or have a contraindication to (harmful for you to use) an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)

You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-ABDA

INITIAL CRITERIA (CONTINUED)

If you have severe plaque psoriasis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)

You have psoriasis covering 3 percent or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, face, genital area, or scalp

You will NOT use Renflexis concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)

You meet ONE of the following:

You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis

You have a contraindication or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) and PUVA (phototherapy) for the treatment of plaque psoriasis

You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication

If you have moderate to severe Crohn's disease, approval also requires:

Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)

You will NOT use Renflexis concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-ABDA

INITIAL CRITERIA (CONTINUED)

You meet ONE of the following:

You are 6 to 17 years of age AND have tried or have a contraindication to (harmful for you to use) the preferred medication: Humira (adalimumab), adalimumab-adaz, or Simlandi

You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)

If you have moderate to severe ulcerative colitis, approval also requires:

Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)

You will NOT use Renflexis concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

You meet ONE of the following:

You are 6 to 17 years of age AND have tried or have a contraindication to (harmful for you to use) the preferred medication: Humira (adalimumab), adalimumab-adaz, or Simlandi

You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-ABDA

RENEWAL CRITERIA

Our guideline named **INFLIXIMAB-ABDA (Renflexis)** requires the following rule(s) be met for renewal:

You have ONE of the following:

Moderate to severe rheumatoid arthritis (RA: a type of joint condition)

Psoriatic arthritis (PsA: a type of skin and joint condition)

Ankylosing spondylitis (AS: a type of joint condition)

Severe plaque psoriasis (PsO: a type of skin condition)

Moderate to severe Crohn's disease (CD: a type of bowel disorder)

Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

If you have moderate to severe rheumatoid arthritis, renewal also requires:

You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy

You are currently using or have a contraindication to (harmful for you to use) methotrexate

You will NOT use Renflexis concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis

You meet ONE of the following:

You have tried or have a contraindication to TWO of the following preferred medications:

Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)

You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-ABDA

RENEWAL CRITERIA (CONTINUED)

If you have psoriatic arthritis, renewal also requires:

- You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
- You will NOT use Renflexis concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
- You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

If you have ankylosing spondylitis, renewal also requires:

- You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index: diagnostic test which allows a physician to determine the effectiveness of a current medication) score while on therapy
- You will NOT use Renflexis concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
- You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-ABDA

RENEWAL CRITERIA (CONTINUED)

If you have severe plaque psoriasis, renewal also requires:

- You have achieved or maintained clear or minimal disease OR you have experienced a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50 percent or more while on therapy
- You will NOT use Renflexis concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
- You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)

If you have moderate to severe Crohn's disease, renewal also requires:

- You will NOT use Renflexis concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
- You meet ONE of the following:
 - You are 6 to 17 years of age AND have tried or have a contraindication to (harmful for you to use) the preferred medication: Humira (adalimumab), adalimumab-adaz, or Simlandi
 - You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-ABDA

RENEWAL CRITERIA (CONTINUED)

If you have moderate to severe ulcerative colitis, renewal also requires:

You will NOT use Renflexis concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

You meet ONE of the following:

You are 6 to 17 years of age AND have tried or have a contraindication to (harmful for you to use) the preferred medication: Humira (adalimumab), adalimumab-adaz, or Simlandi

You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 05/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-AXXQ

Generic	Brand				
INFLIXIMAB-AXXQ	AVSOLA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **INFLIXIMAB-AXXQ (Avsola)** requires the following rule(s) be met for approval:

You have **ONE** of the following:

Moderate to severe rheumatoid arthritis (RA: a type of joint condition)

Psoriatic arthritis (PsA: a type of skin and joint condition)

Ankylosing spondylitis (AS: a type of joint condition)

Severe plaque psoriasis (PsO: a type of skin condition)

Moderate to severe Crohn's disease (CD: a type of bowel disorder)

Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

If you have moderate to severe rheumatoid arthritis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)

You are currently using or have a contraindication to (harmful for you to use) methotrexate

You will **NOT** use Avsola concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis

You have tried at least 3 months of or have a contraindication to **ONE** conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

You meet **ONE** of the following:

You have tried or have a contraindication to **TWO** of the following preferred medications:

Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)

You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) **AND** your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-AXXQ

INITIAL CRITERIA (CONTINUED)

If you have psoriatic arthritis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)

You will NOT use Avsola concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

If you have ankylosing spondylitis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)

You will NOT use Avsola concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis

You have tried or have a contraindication to (harmful for you to use) an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)

You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-AXXQ

INITIAL CRITERIA (CONTINUED)

If you have severe plaque psoriasis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)

You have psoriasis covering 3 percent or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, face, genital area, or scalp

You will NOT use Avsola concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)

You meet ONE of the following:

You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis

You have a contraindication or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) and PUVA (phototherapy) for the treatment of plaque psoriasis

You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication

If you have moderate to severe Crohn's disease, approval also requires:

Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)

You will NOT use Avsola concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-AXXQ

INITIAL CRITERIA (CONTINUED)

You meet ONE of the following:

You are 6 to 17 years of age AND have tried or have a contraindication to (harmful for you to use) the preferred medication: Humira (adalimumab), adalimumab-adaz, or Simlandi

You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)

If you have moderate to severe ulcerative colitis, approval also requires:

Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)

You will NOT use Avsola concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

You meet ONE of the following:

You are 6 to 17 years of age AND have tried or have a contraindication to (harmful for you to use) the preferred medication: Humira (adalimumab), adalimumab-adaz, or Simlandi

You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-AXXQ

RENEWAL CRITERIA

Our guideline named **INFLIXIMAB-AXXQ (Avsola)** requires the following rule(s) be met for renewal:

You have ONE of the following:

Moderate to severe rheumatoid arthritis (RA: a type of joint condition)

Psoriatic arthritis (PsA: a type of skin and joint condition)

Ankylosing spondylitis (AS: a type of joint condition)

Severe plaque psoriasis (PsO: a type of skin condition)

Moderate to severe Crohn's disease (CD: a type of bowel disorder)

Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

If you have moderate to severe rheumatoid arthritis, renewal also requires:

You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy

You are currently using or have a contraindication to (harmful for you to use) methotrexate

You will NOT use Avsola concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis

You meet ONE of the following:

You have tried or have a contraindication to TWO of the following preferred medications:
Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)

You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-AXXQ

RENEWAL CRITERIA (CONTINUED)

If you have psoriatic arthritis, renewal also requires:

You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy

You will NOT use Avsola concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

If you have ankylosing spondylitis, renewal also requires:

You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index: diagnostic test which allows a physician to determine the effectiveness of a current medication) score while on therapy

You will NOT use Avsola concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-AXXQ

RENEWAL CRITERIA (CONTINUED)

If you have severe plaque psoriasis, renewal also requires:

- You have achieved or maintained clear or minimal disease OR you have experienced a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50 percent or more while on therapy
- You will NOT use Avsola concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
- You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)

If you have moderate to severe Crohn's disease, renewal also requires:

- You will NOT use Avsola concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
- You meet ONE of the following:
 - You are 6 to 17 years of age AND have tried or have a contraindication to (harmful for you to use) the preferred medication: Humira (adalimumab), adalimumab-adaz, or Simlandi
 - You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-AXXQ

RENEWAL CRITERIA (CONTINUED)

If you have moderate to severe ulcerative colitis, renewal also requires:

You will NOT use Avsola concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

You meet ONE of the following:

You are 6 to 17 years of age AND have tried or have a contraindication to (harmful for you to use) the preferred medication: Humira (adalimumab), adalimumab-adaz, or Simlandi

You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 05/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-DYYB - IV

Generic	Brand				
INFLIXIMAB-DYYB	INFLECTRA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **INFLIXIMAB-DYYB - IV (Inflectra)** requires the following rule(s) be met for approval:

You have ONE of the following:

Moderate to severe rheumatoid arthritis (RA: a type of joint condition)

Psoriatic arthritis (PsA: a type of skin and joint condition)

Ankylosing spondylitis (AS: a type of joint condition)

Severe plaque psoriasis (PsO: a type of skin condition)

Moderate to severe Crohn's disease (CD: a type of bowel disorder)

Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

If you have moderate to severe rheumatoid arthritis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)

You are currently using or have a contraindication to (harmful for you to use) methotrexate

You will NOT use Inflectra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis

You have tried at least 3 months of or have a contraindication to ONE conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

You meet ONE of the following:

You have tried or have a contraindication to TWO of the following preferred medications:

Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)

You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-DYYB - IV

INITIAL CRITERIA (CONTINUED)

If you have psoriatic arthritis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)

You will NOT use Inflectra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

If you have ankylosing spondylitis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)

You will NOT use Inflectra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis

You have tried or have a contraindication to (harmful for you to use) an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)

You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-DYYB - IV

INITIAL CRITERIA (CONTINUED)

If you have severe plaque psoriasis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)

You have psoriasis covering 3 percent or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, face, genital area, or scalp

You will NOT use Inflectra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)

You meet ONE of the following:

You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis

You have a contraindication or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) and PUVA (phototherapy) for the treatment of plaque psoriasis

You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-DYYB - IV

INITIAL CRITERIA (CONTINUED)

If you have moderate to severe Crohn's disease, approval also requires:

Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)

You will NOT use Inflectra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease

You meet ONE of the following:

You are 6 to 17 years of age AND have tried or have a contraindication to (harmful for you to use) the preferred medication: Humira (adalimumab), adalimumab-adaz, or Simlandi

You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)

If you have moderate to severe ulcerative colitis, approval also requires:

Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)

You will NOT use Inflectra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

You meet ONE of the following:

You are 6 to 17 years of age AND have tried or have a contraindication to (harmful for you to use) the preferred medication: Humira (adalimumab), adalimumab-adaz, or Simlandi

You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-DYYB - IV

RENEWAL CRITERIA

Our guideline named **INFLIXIMAB-DYYB - IV (Inflectra)** requires the following rule(s) be met for renewal:

You have ONE of the following:

Moderate to severe rheumatoid arthritis (RA: a type of joint condition)

Psoriatic arthritis (PsA: a type of skin and joint condition)

Ankylosing spondylitis (AS: a type of joint condition)

Severe plaque psoriasis (PsO: a type of skin condition)

Moderate to severe Crohn's disease (CD: a type of bowel disorder)

Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

If you have moderate to severe rheumatoid arthritis, renewal also requires:

You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy

You are currently using or have a contraindication to (harmful for you to use) methotrexate

You will NOT use Inflectra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis

You meet ONE of the following:

You have tried or have a contraindication to TWO of the following preferred medications:

Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)

You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-DYYB - IV

RENEWAL CRITERIA (CONTINUED)

If you have psoriatic arthritis, renewal also requires:

- You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
- You will NOT use Inflectra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
- You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

If you have ankylosing spondylitis, renewal also requires:

- You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index: diagnostic test which allows a physician to determine the effectiveness of a current medication) score while on therapy
- You will NOT use Inflectra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
- You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-DYYB - IV

RENEWAL CRITERIA (CONTINUED)

If you have severe plaque psoriasis, renewal also requires:

- You have achieved or maintained clear or minimal disease OR you have experienced a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50 percent or more while on therapy
- You will NOT use Inflectra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
- You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)

If you have moderate to severe Crohn's disease, renewal also requires:

- You will NOT use Inflectra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
- You meet ONE of the following:
 - You are 6 to 17 years of age AND have tried or have a contraindication to (harmful for you to use) the preferred medication: Humira (adalimumab), adalimumab-adaz, or Simlandi
 - You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-DYYB - IV

RENEWAL CRITERIA (CONTINUED)

If you have moderate to severe ulcerative colitis, renewal also requires:

You will NOT use Inflectra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

You meet ONE of the following:

You are 6 to 17 years of age AND have tried or have a contraindication to (harmful for you to use) the preferred medication: Humira (adalimumab), adalimumab-adaz, or Simlandi

You are 18 years of age or older AND have tried or have a contraindication to TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 05/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-DYYB - SQ

Generic	Brand				
INFLIXIMAB-DYYB	ZYMFENTRA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **INFLIXIMAB-DYYB - SQ (Zymfentra)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
 2. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
- B. **If you have moderate to severe ulcerative colitis, approval also requires:**
1. You are 18 years of age or older
 2. Zymfentra will be used following treatment with an intravenous (injection into the vein) infliximab medication (such as Remicade, Renflexis, Avsola)
 3. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 4. You will NOT use Zymfentra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
 5. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

(Initial criteria continued on the next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-DYYB - SQ

INITIAL CRITERIA (CONTINUED)

C. If you have moderate to severe Crohn's disease, approval also requires:

1. You are 18 years of age or older
2. Zymfentra will be used following treatment with an intravenous (injection into the vein) infliximab medication (such as Remicade, Renflexis, Avsola)
3. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
4. You will NOT use Zymfentra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
5. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFLIXIMAB-DYYB - SQ

RENEWAL CRITERIA

Our guideline named **INFLIXIMAB-DYYB - SQ (Zymfentra)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
2. Moderate to severe Crohn's disease (CD: a type of bowel disorder)

B. **If you have moderate to severe ulcerative colitis, renewal also requires:**

1. You will NOT use Zymfentra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
2. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

C. **If you have moderate to severe Crohn's disease, renewal also requires:**

1. You will NOT use Zymfentra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
2. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 05/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INGENOL

Generic	Brand				
INGENOL MEBUTATE	PICATO				

GUIDELINES FOR USE

Do not approve requests for Picato gel.

(NOTE: Picato discontinued due to safety concerns and increased risk of cancer.)

Effective: 10/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INHALED INSULIN

Generic	Brand			
INSULIN REGULAR, HUMAN	AFREZZA			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **INHALED INSULIN (Afrezza)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Type 1 diabetes mellitus (a disorder with high blood sugar)
2. Type 2 diabetes mellitus (a disorder with high blood sugar)

B. **If you have type 1 diabetes mellitus, approval also requires:**

1. You are 18 years of age or older
2. You had a baseline spirometry (a type of breathing test) to measure forced expiratory volume (FEV1: amount of air exhaled in one second)
3. Afrezza will be used concurrently (at the same time) with a long-acting insulin (such as Toujeo, Tresiba, Semglee)
4. You have tried ONE of the following preferred rapid-acting insulins: insulin lispro (Humalog), Lyumjev

C. **If you have type 2 diabetes mellitus, approval also requires:**

1. You are 18 years of age or older
2. You had a baseline spirometry (a type of breathing test) to measure forced expiratory volume (FEV1: amount of air exhaled in one second)
3. You have tried ONE of the following preferred rapid-acting insulins: insulin lispro (Humalog), Lyumjev
4. Your prescriber has indicated that you are physically unable to or unwilling to use injectable insulin

NOTE: Afrezza will NOT be approved if you have any of the following conditions: chronic lung disease (type of long-term lung disease), active lung cancer, currently in diabetic ketoacidosis (condition where body breaks down fat too fast), you are currently smoking or you quit smoking within the past 6 months.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INHALED INSULIN

RENEWAL CRITERIA

Our guideline named **INHALED INSULIN (Afrezza)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Type 1 diabetes mellitus (a disorder with high blood sugar)
2. Type 2 diabetes mellitus (a disorder with high blood sugar)

B. **If you have type 1 diabetes, renewal also requires:**

1. You have had a follow up spirometry (a type of breathing test) to measure your forced expiratory volume (FEV1: amount of air exhaled in one second) after 6 months of treatment and then annually (every year)
2. Your FEV1 has NOT declined by 20 percent or more from baseline (before treatment)
3. Afrezza will be used concurrently (at the same time) with a long-acting insulin (such as Toujeo, Tresiba, Semglee)

C. **If you have type 2 diabetes, renewal also requires:**

1. You have had a follow up spirometry (a type of breathing test) to measure your forced expiratory volume (FEV1: amount of air exhaled in one second) after 6 months of treatment and then annually (every year)
2. Your FEV1 has NOT declined by 20 percent or more from baseline (before treatment)

Effective: 09/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INOTERSEN

Generic	Brand			
INOTERSEN SODIUM	TEGSEDI			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **INOTERSEN (Tegsedi)** requires the following rule(s) be met for approval:

- A. You have hereditary transthyretin-mediated amyloidosis with polyneuropathy (hATTR-PN: a rare genetic disorder with widespread nerve pain/damage)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nerve doctor), cardiologist (a type of heart doctor), hATTR specialist, or medical geneticist (doctor who treats gene disorders)
- D. You are ambulatory (able to walk) (you have Familial Amyloid Polyneuropathy [FAP: a tool used to evaluate disease severity] stage 1 to 2 or Polyneuropathy Disability [PND: a tool used to evaluate disease severity] Stage I to IIIb polyneuropathy)
- E. You will NOT use Tegsedi concurrently (at the same time) with other hATTR-PN medications (such as Wainua [eplontersen], Amvuttra [vutrisiran], Onpattro [patisiran])
- F. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Amvuttra
- G. Your diagnosis is confirmed by ONE of the following:
 - 1. Biopsy (removal of cells from the body for examination) of tissue/organ to confirm amyloid (a type of abnormal protein) presence AND chemical typing to confirm the presence of TTR (*transthyretin*) protein
 - 2. DNA genetic sequencing (a type of lab test) to confirm hATTR mutation (a type of abnormal gene)

RENEWAL CRITERIA

Our guideline named **INOTERSEN (Tegsedi)** requires the following rule(s) be met for renewal:

- A. You have hereditary transthyretin-mediated amyloidosis with polyneuropathy (hATTR-PN: a rare genetic disorder with widespread nerve pain/damage)
- B. You have NOT progressed to Familial Amyloid Polyneuropathy (FAP: a tool used to evaluate disease severity) stage 3 OR Polyneuropathy Disability (PND: a tool used to evaluate disease severity) stage IV polyneuropathy as shown by functional decline (such as being wheelchair-bound or bedridden)
- C. You will NOT use Tegsedi concurrently (at the same time) with other hATTR-PN medications (such as Wainua [eplontersen], Amvuttra [vutrisiran], Onpattro [patisiran])

Effective: 07/01/24

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 6/11/2025

Page 428 of 1007



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INSULIN PUMPS

Generic	Brand				
SUBCUTANEOUS INSULIN PUMP	T:SLIM X2, T:SLIM X2 CONTROL-IQ, T:SLIM X2 WITH BASAL-IQ, TANDEM MOBI SYSTEM, MINIMED 670G, MINIMED 770G, MINIMED 780G, MINIMED 630G, ILET INSULIN PUMP				

GUIDELINES FOR USE

Our guideline named **INSULIN PUMPS** requires the following rule(s) be met for approval:

- A. The requested insulin pump is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
 - B. You have completed a comprehensive diabetes education program within the previous 24 months
 - C. You follow a maintenance program of at least 3 injections of insulin per day and require frequent self-adjustments of your insulin dose for the past 6 months
 - D. You require glucose self-testing of at least 4 times per day on average in the previous 2 months
 - E. You have NOT received an insulin pump within the last 4 years (Exception: your pump is malfunctioning, not repairable, and not under warranty)
 - F. You are on a multiple daily insulin injection regimen and meet ONE of the following:
 1. You have a glycosylated hemoglobin level (HbA1c: a type of lab test) greater than 7 percent
 2. You have a history of recurring hypoglycemia (low blood sugar)
 3. You have wide fluctuations in blood sugar before mealtime
 4. You experience the dawn phenomenon (abnormal early morning increase in blood sugar, usually between 2 a.m. and 8 a.m.) with fasting blood glucose levels frequently exceeding 200 mg/Dl
 5. You have a history of severe glycemic excursions (sudden spikes in blood sugar levels)
 - G. **If you are requesting the T: Slim X2 OR T: Slim X2 with Basal-IQ, approval also requires:**
 1. You are 6 years of age or older
- (Criteria continued on next page)**

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INSULIN PUMPS

GUIDELINES FOR USE (CONTINUED)

- H. **If you are requesting the T: Slim X2 with Control-IQ, approval also requires:**
 - 1. You are 6 years of age or older
- I. **If you are requesting the Tandem Mobi System, approval also requires:**
 - 1. You have type 1 diabetes mellitus (a disorder with high blood sugar)
 - 2. You are 6 years of age or older
- J. **If you are requesting the MiniMed 670G, approval also requires:**
 - 1. You have type 1 diabetes mellitus (a disorder with high blood sugar)
 - 2. You are 7 years of age or older
- K. **If you are requesting the MiniMed 770G, approval also requires:**
 - 1. You have type 1 diabetes mellitus (a disorder with high blood sugar)
 - 2. You are 2 years of age or older
- L. **If you are requesting the MiniMed 780G, approval also requires:**
 - 1. You have type 1 diabetes mellitus (a disorder with high blood sugar)
 - 2. You are 7 years of age or older
- M. **If you are requesting the MiniMed 630G, approval also requires:**
 - 1. You have type 1 diabetes mellitus (a disorder with high blood sugar)
 - 2. You are 14 years of age or older
- N. **If you are requesting the iLet Bionic Pancreas insulin pump, approval also requires:**
 - 1. You have type 1 diabetes mellitus (a disorder with high blood sugar)
 - 2. You are 6 years of age or older

Effective: 02/17/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INTERFERON ALFA-2B

Generic	Brand			
INTERFERON ALFA-2B	INTRON A			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **INTERFERON ALFA-2B (Intron A)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Chronic hepatitis C (type of liver inflammation)
 2. Hairy cell leukemia (bone marrow cancer that makes too many white blood cells)
 3. Condylomata acuminata (genital warts)
 4. AIDS (acquired immunodeficiency syndrome)-related Kaposi's sarcoma (cancer in those with weak immune system that causes tumors of lymph nodes/skin)
 5. Chronic hepatitis B (type of liver inflammation)
 6. Non-Hodgkin's lymphoma (cancer that starts in your lymphatic system- the disease-fighting network in the body)
 7. Malignant melanoma (serious type of skin cancer)
 8. Chronic phase, Philadelphia chromosome (type of abnormal gene) positive chronic myelogenous leukemia (type of blood cell cancer that starts in bone marrow) who are minimally treated (within 1 year of diagnosis)
 9. Follicular lymphoma (type of lymphatic system cancer)
 10. Angioblastoma (certain blood-vessel tumors of the brain)
 11. Carcinoid (cancer) tumor
 12. Chronic myeloid leukemia (type of cancer that starts in immature white blood cells)
 13. Laryngeal papillomatosis (tumors form along the pathways for breathing/digestion)
 14. Multiple myeloma (plasma cell cancer)
 15. Neoplasm of conjunctiva-neoplasm of cornea (eye tumors)
 16. Ovarian cancer
 17. Polycythemia vera (cancer where bone marrow makes too many red blood cells)
 18. Renal cell carcinoma (type of kidney cancer)
 19. Skin cancer, thrombocytosis (your body makes too many platelets)
 20. Thrombocytosis (high level of platelets (cells that helps blood clot and stop bleeding) in your blood)
 21. Vulvar vestibulitis (type of pain around the female sex organ called the vulva)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INTERFERON ALFA-2B

INITIAL CRITERIA (CONTINUED)

- B. If you have chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6, approval also requires:**
1. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions), infectious disease specialist (a doctor who specializes in the treatment of infections), or a physician specializing in the treatment of hepatitis (such as a hepatologist: a type of liver doctor)
 2. You have a detectable pretreatment HCV (hepatitis C virus) RNA level/viral load (amount of virus in your blood) of 50 IU/mL or higher
 3. The requested medication will be used with ribavirin or you have a contraindication (harmful for)
 4. You had a trial of or contraindication (harmful for) to peginterferon alfa-2a or peginterferon alfa-2b

RENEWAL CRITERIA

Our guideline named **INTERFERON ALFA-2B (Intron A)** requires the following rule(s) be met for renewal:

- A.** The request is for continuation of current therapy or renewal with Intron A therapy
- B. If you have chronic hepatitis C (type of liver inflammation), renewal also requires:**
1. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions), infectious disease specialist (a doctor who specializes in the treatment of infections), or a physician specializing in the treatment of hepatitis (such as a hepatologist: a type of liver doctor)
 2. If you already received 24 weeks or more of interferon treatment, your HCV (hepatitis C virus) RNA level (amount of virus in your blood) is undetectable (less than 50 IU/mL) at 24 weeks

Effective: 06/15/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INTERFERON FOR MS - AVONEX

Generic	Brand				
INTERFERON BETA-1A	AVONEX, AVONEX PEN				

GUIDELINES FOR USE

Our guideline named **INTERFERON FOR MS - AVONEX** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older

Effective: 11/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INTERFERON FOR MS - BETASERON

Generic	Brand				
INTERFERON BETA-1B	BETASERON				

GUIDELINES FOR USE

Our guideline named **INTERFERON FOR MS - BETASERON** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older

Effective: 11/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INTERFERON FOR MS - EXTAVIA

Generic	Brand				
INTERFERON BETA-1B	EXTAVIA				

GUIDELINES FOR USE

Our guideline named **INTERFERON FOR MS - EXTAVIA** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older
- C. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Avonex (interferon beta-1a), Copaxone/Glatiramer/Glatopa (glatiramer), fingolimod, Plegridy (peginterferon beta-1a), Rebif (interferon beta-1a/albumin), Betaseron (interferon beta-1b), dimethyl fumarate, Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Aubagio (teriflunomide), Kesimpta (ofatumumab), Zeposia (ozanimod)
(PLEASE NOTE: these medications may also require prior authorization)

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INTERFERON FOR MS - PLEGRIDY

Generic	Brand				
PEGINTERFERON BETA-1A	PLEGRIDY, PLEGRIDY PEN				

GUIDELINES FOR USE

Our guideline named **INTERFERON FOR MS - PLEGRIDY** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older

Effective: 11/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INTERFERON FOR MS - REBIF

Generic	Brand				
INTERFERON BETA- 1A/ALBUMIN	REBIF, REBIF REBIDOSE				

GUIDELINES FOR USE

Our guideline named **INTERFERON FOR MS - REBIF** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older

Effective: 11/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INTERFERON GAMMA-1B, RECOMB

Generic	Brand				
INTERFERON GAMMA-1B, RECOMB.	ACTIMMUNE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **INTERFERON GAMMA-1B, RECOMB (Actimmune)** requires the following rules be met for approval:

A. You have ONE of the following:

1. Chronic granulomatous disease (CGD: a type of immune disorder)
2. Severe malignant osteopetrosis (SMO: a type of bone condition)

B. **If you have chronic granulomatous disease, approval also requires:**

1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor), infectious disease specialist (a doctor that specializes in treating infections), or immunologist (a type of immune system doctor)

C. **If you have severe malignant osteopetrosis, approval also requires:**

1. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor) or hematologist (a type of blood doctor)

RENEWAL CRITERIA

Our guideline named **INTERFERON GAMMA-1B, RECOMB (Actimmune)** requires the following rules be met for renewal:

A. You have ONE of the following:

1. Chronic granulomatous disease (CGD: a type of immune disorder)
2. Severe malignant osteopetrosis (SMO: a type of bone condition)

B. You have shown clinical benefit compared to baseline (such as reduction in frequency and severity of serious infections)

C. You have NOT received hematopoietic cell transplantation (bone marrow transplant)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IPILIMUMAB

Generic	Brand				
IPILIMUMAB	YERVOY				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **IPILIMUMAB (Yervoy)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Unresectable or metastatic melanoma (a type of skin cancer that cannot be completely removed by surgery or has spread to other parts of the body)
2. Cutaneous melanoma (a type of skin cancer)
3. Advanced renal cell carcinoma (a type of kidney cancer)
4. Unresectable or metastatic colorectal cancer (type of digestive tract cancer that cannot be completely removed by surgery or has spread to other parts of the body)
5. Unresectable or metastatic hepatocellular carcinoma (a type of liver cancer that cannot be completely removed by surgery or has spread to other parts of the body)
6. Metastatic or recurrent non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to other parts of the body or has returned)
7. Unresectable (cannot be removed by surgery) malignant pleural mesothelioma (a tumor of the tissue that has spread and lines the lungs, stomach, heart, and other organs)
8. Unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC: a type of digestive cancer that cannot be removed by surgery or has spread to other parts of the body)

B. If you have unresectable or metastatic melanoma, approval also requires:

1. You are 12 years of age or older
2. Yervoy will be used as a single medication OR in combination with Opdivo (nivolumab)

C. If you have cutaneous melanoma, approval also requires:

1. Yervoy will be used for adjuvant (add-on) treatment
2. There is pathologic (disease) involvement of regional lymph nodes of more than 1mm
3. You have undergone complete resection (surgery to completely remove cancer), including total lymphadenectomy (lymph glands are surgically removed)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IPILIMUMAB

INITIAL CRITERIA (CONTINUED)

- D. If you have advanced renal cell carcinoma, approval also requires:**
 - 1. Yervoy will be used in combination with Opdivo (nivolumab)
 - 2. You have intermediate or poor risk disease
- E. If you have unresectable or metastatic colorectal cancer, approval also requires:**
 - 1. You are 12 years of age or older
 - 2. Yervoy will be used in combination with Opdivo (nivolumab)
 - 3. Your cancer is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) (types of genetic abnormalities)
- F. If you have unresectable or metastatic hepatocellular carcinoma, approval also requires ONE of the following:**
 - 1. Yervoy will be used in combination with Opdivo (nivolumab) as first-line treatment
 - 2. Yervoy will be used in combination with Opdivo (nivolumab), AND you have previously been treated with Nexavar (sorafenib)
- G. If you have metastatic or recurrent non-small cell lung cancer, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Your tumor does NOT have epidermal growth factor receptor (EGFR: type of protein) or anaplastic lymphoma kinase (ALK: type of protein) genomic tumor aberrations (types of gene mutations)
 - 3. You meet ONE of the following:
 - a. **For metastatic NSCLC**, Yervoy will be used in combination with Opdivo (nivolumab) AND your tumor expresses programmed death-ligand 1 (PD-L1: type of protein) (at least 1%), as determined by an FDA (Food and Drug Administration)-approved test
 - b. **For metastatic or recurrent NSCLC**, Yervoy will be used in combination with Opdivo (nivolumab) and 2 cycles of platinum-doublet chemotherapy (type of cancer medication)
- H. If you have unresectable malignant pleural mesothelioma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Yervoy will be used in combination with Opdivo (nivolumab)
- I. If you have unresectable advanced or metastatic esophageal squamous cell carcinoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Yervoy will be used in combination with Opdivo (nivolumab)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IPILIMUMAB

RENEWAL CRITERIA

NOTE: For the diagnoses of unresectable or metastatic melanoma, advanced renal cell carcinoma, unresectable or metastatic colorectal cancer, unresectable or metastatic hepatocellular carcinoma, metastatic/recurrent non-small cell lung cancer (NSCLC), unresectable malignant pleural mesothelioma, or unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC), please refer to the Initial Criteria section.

Our guideline named **IPILIMUMAB (Yervoy)** requires the following rule(s) be met for renewal:

- A. You have cutaneous melanoma (a type of skin cancer)
- B. Yervoy will be used for adjuvant (add-on) treatment
- C. You do NOT have any disease recurrence (defined as the appearance of one or more new melanoma lesions: local, regional or distant metastasis [cancer has spread from original site])

Effective: 05/12/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IPTACOPAN

Generic	Brand				
IPTACOPAN HCL	FABHALTA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **IPTACOPAN (Fabhalta)** requires the following rule(s) be met for approval:
You have ONE of the following:

- Paroxysmal nocturnal hemoglobinuria (PNH: a rare blood disorder)
- Primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
- Complement 3 glomerulopathy (C3G: a type of kidney disease)

If you have paroxysmal nocturnal hemoglobinuria, approval also requires:

- You are 18 years of age or older
- Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
- Your PNH diagnosis is confirmed by flow cytometry (a type of lab test) that shows ALL of the following:
 - You have a PNH granulocyte clone size of at least 10 percent
 - You have at least 2 different GPI-protein deficiencies (a certain type of protein is missing, such as CD55, CD59) on at least 2 cell lineages (types of cells, such as erythrocytes [red blood cells], granulocytes [a type of white blood cell])
- You will NOT use Fabhalta concurrently (at the same time) with a C5 complement inhibitor (such as Ultomiris [ravulizumab-cwvz], Soliris [eculizumab], Piasky [crovalimab-akkz]), C3 complement inhibitor (such as Empaveli [pegcetacoplan]) or Factor D inhibitor (such as Voydeya [danicoplan])

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IPTACOPAN

INITIAL CRITERIA (CONTINUED)

If you have primary immunoglobulin A nephropathy, approval also requires:

- You are 18 years of age or older
- You are at risk of rapid disease progression (such as a urine protein-to-creatinine ratio [UPCR: a test that measures the amount of protein in urine] of at least 1.5 g/g)
- Therapy is prescribed by or in consultation with a nephrologist (a type of kidney doctor)
- Your diagnosis is confirmed by a renal biopsy (removal of cells or tissue from the kidney for examination)
- You have an estimated glomerular filtration rate (eGFR: a tool for evaluating kidney function) of at least 20 mL/min/1.73 m(2)
- You have tried an angiotensin converting enzyme inhibitor (ACE-I: a type of medication used to protect kidneys, such as benazepril, lisinopril) or an angiotensin receptor blocker (ARB: a type of medication used to protect kidneys, such as losartan, valsartan) for at least 3 months at a maximum tolerated dose and will continue use, OR you have a contraindication to (harmful for you to use) both of these medication classes
- You have tried a sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor: a type of medication used to protect kidneys, such as Farxiga [dapagliflozin], Jardiance [empagliflozin]) and will continue use, OR you have a contraindication to an SGLT2 inhibitor
- You will NOT use Fabhalta concurrently (at the same time) with Filspari (sparsentan) or Vanrafia (atrasentan)

If you have complement 3 glomerulopathy, approval also requires:

- You are 18 years of age or older

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IPTACOPAN

RENEWAL CRITERIA

NOTE: For the diagnosis of complement 3 glomerulopathy (C3G), please refer to the Initial Criteria section.

Our guideline named **IPTACOPAN (Fabhalta)** requires the following rule(s) be met for renewal:
You have ONE of the following:

- Paroxysmal nocturnal hemoglobinuria (PNH: a rare blood disorder)
- Primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)

If you have paroxysmal nocturnal hemoglobinuria, renewal also requires:

You have experienced a clinical benefit (such as a reduction in the number of blood transfusions [adding blood to the body], improvement/stabilization of lactate dehydrogenase [LDH: a type of enzyme] levels and hemoglobin [type of protein in red blood cells] levels) compared to baseline (before treatment)

You will NOT use Fabhalta concurrently (at the same time) with a C5 complement inhibitor (such as Ultomiris [ravulizumab-cwvz], Soliris [eculizumab], Plasky [crovalimab-akkz]), C3 complement inhibitor (such as Empaveli [pegcetacoplan]) or Factor D inhibitor (such as Voydeya [danicopan])

If you have primary immunoglobulin A nephropathy, renewal also requires:

You have improved, or stable kidney function compared to baseline (before starting Fabhalta) OR you have a reduction (decrease) in proteinuria (a condition with high levels of protein in the urine)

You will NOT use Fabhalta concurrently (at the same time) with Filspari (sparsentan) or Vanrafia (atrasentan)

Effective: 05/12/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ISAVUCONAZONIUM

Generic	Brand				
ISAVUCONAZONIUM	CRESEMBA				

GUIDELINES FOR USE

Our guideline named **ISAVUCONAZONIUM (Cresemba)** requires the following rule(s) be met for approval:

A. You meet ONE of the following:

1. This is a request for continuation of therapy after you were started on Cresemba in the hospital
2. You have invasive aspergillosis (a type of fungal infection)
3. You have invasive mucormycosis (a type of fungal infection)

B. If you have invasive aspergillosis, approval also requires:

1. You are 6 years of age or older and weigh at least 16 kilograms (35.2 pounds)
2. Therapy is prescribed by or in consultation with an infectious disease specialist (a doctor who specializes in the treatment of infections)
3. You have tried or have a contraindication to (harmful for you to use) voriconazole

C. If you have invasive mucormycosis, approval also requires:

1. You are 6 years of age or older and weigh at least 16 kilograms (35.2 pounds)
2. Therapy is prescribed by or in consultation with an infectious disease specialist (a doctor who specializes in the treatment of infections)

Effective: 10/12/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ISTRADefYLLINE

Generic	Brand			
ISTRADefYLLINE	NOURIANZ			

GUIDELINES FOR USE

Our guideline named **ISTRADefYLLINE (Nourianz)** requires the following rule(s) be met for approval:

- A. You have Parkinson's disease (a nerve system disorder that affects movement)
- B. You are 18 years of age or older
- C. You are experiencing 'OFF' episodes (times when medication wears off and you have movement problems)
- D. Nourianz will be used along with levodopa/carbidopa
- E. You had a previous trial of or contraindication to (medical reason why you cannot use) **TWO** Parkinson's agents from **TWO** different drug classes:
 - 1. Dopamine agonists (such as ropinirole, pramipexole, rotigotine)
 - 2. Monoamine oxidase-inhibitors (such as selegiline, rasagiline)
 - 3. Catechol-O-methyl transferase inhibitors (such as entacapone, tolcapone)

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ITRACONAZOLE - TOLSURA

Generic	Brand			
ITRACONAZOLE	TOLSURA			

GUIDELINES FOR USE

Our guideline named **ITRACONAZOLE (Tolsura)** requires the following rule(s) be met for approval:

- A. You have **ONE** of the following fungal infections:
 - 1. Blastomycosis, pulmonary and extrapulmonary (type of fungal infection affecting in and outside of the lungs)
 - 2. Histoplasmosis (type of fungal infection), including chronic cavitary pulmonary (affecting the lungs) disease and disseminated, nonmeningeal (not affecting spinal cord and brain membranes) histoplasmosis
 - 3. Aspergillosis, pulmonary and extrapulmonary (type of fungal infection in and outside of the lungs), **AND** you are intolerant to or refractory to (not responsive to) amphotericin B therapy
- B. You are 18 years of age or older
- C. Therapy is prescribed by or given in consultation with an infectious disease specialist
- D. You had a previous trial of a generic itraconazole formulation
- E. Tolsura is prescribed because you had a poor clinical response to other formulations of itraconazole due to poor bioavailability (amount of drug in the body that has an effect)

Effective: 07/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IVACAFTOR

Generic	Brand			
IVACAFTOR	KALYDECO			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **IVACAFTOR (Kalydeco)** requires the following rule(s) be met for approval:

- A. You have cystic fibrosis (CF: a type of lung disorder)
- B. You are 1 month of age or older
- C. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or cystic fibrosis expert
- D. You will NOT use Kalydeco concurrently (at the same time) with another cystic fibrosis transmembrane conductance regulator (CFTR) modulator (such as medications containing vanzacaftor, deutivacaftor, ivacaftor, lumacaftor, tezacaftor, or elexacaftor)
- E. You have a responsive mutation in the CFTR gene (abnormal change in a type of gene that can be treated with Kalydeco)
- F. You are NOT homozygous (have two copies of the same gene) for the F508del mutation (abnormal change) in the CFTR gene

RENEWAL CRITERIA

Our guideline named **IVACAFTOR (Kalydeco)** requires the following rule(s) be met for renewal:

- A. You have cystic fibrosis (CF: a type of lung disorder)
- B. You have experienced an improvement in your clinical status
- C. You will NOT use Kalydeco concurrently (at the same time) with another cystic fibrosis transmembrane conductance regulator (CFTR) modulator (such as medications containing vanzacaftor, deutivacaftor, ivacaftor, lumacaftor, tezacaftor, or elexacaftor)

Effective: 01/28/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IVOSIDENIB

Generic	Brand			
IVOSIDENIB	TIBSOVO			

GUIDELINES FOR USE

Our guideline named **IVOSIDENIB (Tibsovo)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Newly diagnosed acute myeloid leukemia (AML: a type of blood cancer)
 2. Relapsed or refractory acute myeloid leukemia (AML: a type of blood cancer that has returned or has not responded to treatment)
 3. Relapsed or refractory myelodysplastic syndromes (MDS: a type of blood cancer that has returned or has not respond to treatment)
 4. Locally advanced or metastatic cholangiocarcinoma (bile duct cancer that has spread from where it started to nearby tissue/lymph nodes or to other parts of the body)
- B. **If you have a new diagnosis of acute myeloid leukemia, approval also requires:**
1. Tibsovo will be used in combination with azacitidine or as monotherapy (one drug treatment)
 2. Your cancer has a susceptible isocitrate dehydrogenase-1 (IDH1) mutation (a type of enzyme mutation that can be treated with Tibsovo), as detected by a Food and Drug Administration (FDA)-approved test
 3. You meet ONE of the following:
 - a. You are 75 years of age or older
 - b. You are 18 years of age or older AND have comorbidities (additional diseases) that prevent the use of intensive induction chemotherapy (a type of therapy to treat cancer)
- C. **If you have relapsed or refractory acute myeloid leukemia, approval also requires:**
1. You are 18 years of age or older
 2. Your cancer has a susceptible isocitrate dehydrogenase-1 (IDH1) mutation (a type of enzyme mutation that can be treated with Tibsovo), as detected by a Food and Drug Administration (FDA)-approved test

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IVOSIDENIB

GUIDELINES FOR USE (CONTINUED)

- D. If you have relapsed or refractory myelodysplastic syndromes, approval also requires:**
1. You are 18 years of age or older
 2. Your cancer has a susceptible isocitrate dehydrogenase-1 (IDH1) mutation (a type of enzyme mutation that can be treated with Tibsovo), as detected by a Food and Drug Administration (FDA)-approved test
- E. If you have locally advanced or metastatic cholangiocarcinoma, approval also requires:**
1. You are 18 years of age or older
 2. Your cancer has an isocitrate dehydrogenase-1 (IDH1) mutation (type of enzyme mutation), as detected by a Food and Drug Administration (FDA)-approved test
 3. Your cancer has been previously treated

Effective: 11/13/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IXAZOMIB

Generic	Brand			
IXAZOMIB CITRATE	NINLARO			

GUIDELINES FOR USE

Our guideline named **IXAZOMIB (Ninlaro)** requires the following rule(s) be met for approval:

- A. You have multiple myeloma (plasma cell cancer)
- B. The requested medication will be used in combination with lenalidomide and dexamethasone
- C. You have received at least one prior therapy such as bortezomib, carfilzomib, thalidomide, lenalidomide, melphalan or stem cell transplantation

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IXEKIZUMAB

Generic	Brand			
IXEKIZUMAB	TALTZ SYRINGE, TALTZ AUTOINJECTOR			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **IXEKIZUMAB (Taltz)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
 2. Psoriatic arthritis (PsA: a type of skin and joint condition)
 3. Ankylosing spondylitis (AS: a type of joint condition)
 4. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
- B. **If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 6 years of age or older
 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 3. You will NOT use Taltz concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
 4. You meet ONE of the following:
 - a. You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis
 - b. You have a contraindication (harmful for you to use) or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) and PUVA (phototherapy) for the treatment of plaque psoriasis
 - c. You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication
 5. You meet ONE of the following:
 - a. You were previously stable on another biologic and are switching to Taltz
 - b. You have psoriasis covering 3 percent or more of body surface area (BSA)
 - c. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, face, or scalp

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IXEKIZUMAB

INITIAL CRITERIA (CONTINUED)

- C. If you have psoriatic arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
 3. You will NOT use Taltz concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
- D. If you have ankylosing spondylitis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use Taltz concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
 4. You have tried or have a contraindication to (harmful for you to use) an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)
- E. If you have non-radiographic axial spondyloarthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use Taltz concurrently (at the same time) with another systemic biologic (such as Cimzia [certolizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of non-radiographic axial spondyloarthritis
 4. You have tried or have a contraindication to (harmful for you to use) an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)
 5. You meet ONE of the following:
 - a. You were previously stable on another biologic and are switching to Taltz
 - b. You have C-reactive protein (CRP: a measure of how much inflammation is in the body) levels above the upper limit of normal
 - c. You have sacroiliitis (a type of inflammation where lower spine and pelvis connect) on magnetic resonance imaging (MRI: a type of imaging lab)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IXEKIZUMAB

RENEWAL CRITERIA

Our guideline named **IXEKIZUMAB (Taltz)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
2. Psoriatic arthritis (PsA: a type of skin and joint condition)
3. Ankylosing spondylitis (AS: a type of joint condition)
4. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)

B. If you have moderate to severe plaque psoriasis, renewal also requires:

1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50 percent or more while on therapy
2. You will NOT use Taltz concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis

C. If you have psoriatic arthritis, renewal also requires:

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Taltz concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

D. If you have ankylosing spondylitis, renewal also requires:

1. You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) score while on therapy
2. You will NOT use Taltz concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

IXEKIZUMAB

RENEWAL CRITERIA (CONTINUED)

- E. If you have non-radiographic axial spondyloarthritis, renewal also requires:**
1. You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) score while on therapy
 2. You will NOT use Taltz concurrently (at the same time) with another systemic biologic (such as Cimzia [certolizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of non-radiographic axial spondyloarthritis

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LACOSAMIDE

Generic	Brand				
LACOSAMIDE	MOTPOLY XR				

GUIDELINES FOR USE

Our guideline named **LACOSAMIDE (Motpoly XR)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Partial-onset seizures (a type of seizure)
 - 2. Primary generalized tonic-clonic seizures (a type of seizure)
- B. **If you have primary-onset seizures, approval also requires:**
 - 1. You weigh at least 50 kilograms (110 pounds)
 - 2. You have tried or have a contraindication to (harmful for you to use) THREE generic anti-seizure medications (such as carbamazepine, divalproex sodium, valproic acid, oxcarbazepine, levetiracetam immediate-release or extended-release, gabapentin, zonisamide, topiramate, lamotrigine)
 - 3. You are not able to tolerate lacosamide immediate-release
- C. **If you have primary generalized tonic-clonic seizures, approval also requires:**
 - 1. You weigh at least 50 kilograms (110 pounds)
 - 2. Motpoly XR will be used as adjunctive (add-on) treatment
 - 3. You have tried or have a contraindication to (harmful for you to use) THREE generic anti-seizure medications (such as carbamazepine, divalproex sodium, valproic acid, oxcarbazepine, levetiracetam immediate-release or extended-release, gabapentin, zonisamide, topiramate, lamotrigine)
 - 4. You are not able to tolerate lacosamide immediate-release

Effective: 03/17/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LACTIC ACID/CITRIC/POTASSIUM

Generic	Brand				
LACTIC ACID/CITRIC/POTASSIUM	PHEXXI				

Please refer to CONTRACEPTIVE ZERO COST SHARE OVERRIDE section below if the request is also for zero copay override.

GUIDELINES FOR USE

Our guideline named **LACTIC ACID/CITRIC/POTASSIUM (Phexxi)** requires the following rule(s) be met for approval:

- A. You are a female patient with reproductive potential using the requested medication for prevention of pregnancy
- B. You are not using vaginal ring products (such as Annovera or Nuvaring) together with Phexxi
- C. You had a previous trial of two contraceptive agents (such as an intrauterine device, hormonal implant, injection, patch, or oral products), unless there is a medical reason you cannot (contraindication)

CONTRACEPTIVE ZERO COST SHARE OVERRIDE CRITERIA

Our guideline named **CONTRACEPTIVE ZERO COST SHARE OVERRIDE** requires that the following rules be met for approval:

- A. The request is for ONE of the following:
 1. A generic contraceptive agent
 2. A single-source brand (SSB) contraceptive agent that has no preferred generic agents or therapeutically equivalent products available
 3. A multi-source brand (MSB) contraceptive agent
- B. **If the request is for a single-source brand or multi-source brand contraceptive medication, approval also requires ONE of the following:**
 1. Two preferred medications are medically inappropriate for you (or one if only one agent is available)
 2. You have tried or have a documented medical contraindication (harmful for) to two preferred medications (or one if only one agent is available)
 3. Your doctor has provided documentation confirming that the requested drug is considered medically necessary for you (considerations may include severity of side effects, differences in durability and reversibility of contraceptive and ability to adhere to the appropriate use)

Effective: 09/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LANADELUMAB-FLYO

Generic	Brand			
LANADELUMAB-FLYO	TAKHZYRO			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **LANADELUMAB-FLYO (Takhzyro)** requires the following rule(s) be met for approval:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You are 2 years of age or older
- C. Takhzyro will be used for the prevention of hereditary angioedema attacks
- D. Your diagnosis is confirmed by ONE of the following complement tests: C1-INH protein levels, C4 protein levels, C1-INH functional levels, C1q (a type of blood test)
- E. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor), hematologist (a type of blood doctor), or pulmonologist (lung/breathing doctor)
- F. You will NOT use Takhzyro concurrently (at the same time) with an alternative preventive medication for HAE (such as Cinryze [C1 esterase inhibitor], Haegarda [C1 esterase inhibitor], danazol, Orladeyo [berotralstat])

RENEWAL CRITERIA

Our guideline named **LANADELUMAB-FLYO (Takhzyro)** requires the following rule(s) be met for renewal:

- A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
- B. You have experienced an improvement in hereditary angioedema attacks (reductions in attack frequency or attack severity) compared to baseline
- C. You will NOT use Takhzyro concurrently (at the same time) with an alternative preventive medication for HAE (such as Cinryze [C1 esterase inhibitor], Haegarda [C1 esterase inhibitor], danazol, Orladeyo [berotralstat])

Effective: 03/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LAPATINIB

Generic	Brand			
LAPATINIB DITOSYLATE	TYKERB			

GUIDELINES FOR USE

Our guideline named **LAPATINIB (Tykerb)** requires the following rule(s) be met for approval:

- A. You have advanced or metastatic breast cancer (breast cancer that has progressed or has spread to other parts of your body)
- B. Your breast cancer is human epidermal growth factor receptor 2 (HER2: gene/protein in breast cancer) positive
- C. **If you have advanced or metastatic breast cancer, approval also requires:**
 - 1. The requested medication will be used in combination with Xeloda (capecitabine)
 - 2. You have previously received treatment with Herceptin (trastuzumab), an anthracycline (such as daunorubicin, doxorubicin, epirubicin, idarubicin), AND a taxane (such as paclitaxel, docetaxel)
- D. **If you have metastatic breast cancer, approval also requires:**
 - 1. Your tumor is hormone receptor-positive
 - 2. The requested medication will be used in combination with Femara (letrozole)
 - 3. You are a postmenopausal woman

Effective: 04/10/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LAROTRECTINIB

Generic	Brand			
LAROTRECTINIB	VITRAKVI			

GUIDELINES FOR USE

Our guideline named **LAROTRECTINIB (Vitrakvi)** requires the following rule(s) be met for approval:

- A. You have a solid tumor (abnormal mass of tissue that usually does not contain cysts or liquid)
- B. Your tumor has a neurotrophic receptor tyrosine kinase (*NTRK*) gene fusion without a known acquired resistance mutation (you have a type of enzyme that doesn't have a mutation)
- C. Your tumor is metastatic (spreads to other parts of body) or surgical resection (removal) is likely to result in severe morbidity (illness)
- D. There are no satisfactory alternative treatments, or your tumor has gotten worse after treatment
- E. **Requests for Vitrakvi oral solution also require ONE of the following:**
 - 1. You are a pediatric patient (less than 18 years of age)
 - 2. You are unable to take Vitrakvi capsules due to difficulty swallowing (or dysphagia)
 - 3. You have other medical need for the oral solution

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LASMIDITAN

Generic	Brand			
LASMIDITAN SUCCINATE	REYVOW			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **LASMIDITAN (Reyvow)** requires the following rule(s) be met for approval:

- A. The request is for acute (quick onset) treatment of migraines (a type of headache)
- B. You are 18 years of age or older
- C. You have tried or have a contraindication to (harmful for you to use) ONE triptan (such as Imitrex [sumatriptan], Maxalt [rizatriptan])

RENEWAL CRITERIA

Our guideline named **LASMIDITAN (Reyvow)** requires the following rule(s) be met for renewal:

- A. The request is for acute (quick onset) treatment of migraines (a type of headache)
- B. You meet ONE of the following:
 - 1. You have experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (assessment tool used to help guide treatment such as Migraine Assessment of Current Therapy [MIGRAINE-ACT])
 - 2. You have experienced clinical improvement as defined by ONE of the following:
 - a. Ability to function normally within 2 hours of dose
 - b. Headache pain disappears within 2 hours of dose
 - c. Treatment works consistently in majority of migraine attacks

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LAZERTINIB

Generic	Brand				
LAZERTINIB MESYLATE	LAZCLUZE				

GUIDELINES FOR USE

Our guideline named **LAZERTINIB (Lazcluze)** requires the following rule(s) be met for approval:

- A. You have locally advanced or metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to nearby tissue or lymph nodes or that has spread to other parts of the body)
- B. You are 18 years of age or older
- C. Lazcluze will be used in combination with Rybrevant (amivantamab-vmjw)
- D. Your tumor has epidermal growth factor receptor (EGFR: a type of protein) exon 19 deletions or exon 21 L858R substitution mutations (abnormal changes in a type of gene), as detected by a Food and Drug Administration (FDA)-approved test

Effective: 09/09/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LEBRIKIZUMAB-LBKZ

Generic	Brand				
LEBRIKIZUMAB-LBKZ	EBGLYSS				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **LEBRIKIZUMAB-LBKZ (Ebglyss)** requires the following rule(s) be met for approval:

- A. You have moderate to severe atopic dermatitis (AD: a type of skin condition)
- B. You are 12 years of age or older
- C. You weigh at least 40 kilograms (88 pounds)
- D. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
- E. You have atopic dermatitis involving at least 10 percent of body surface area (BSA) OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas (areas between skin folds)
- F. You have TWO of the following: intractable pruritus (severe itching), cracking and oozing/bleeding of affected skin, impaired activities of daily living
- G. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Dupixent (dupilumab), Rinvoq (upadacitinib), Adbry (tralokinumab-ldrm)
- H. You will NOT use Ebglyss concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Eucrisa (crisaborole)]) for the treatment of atopic dermatitis
- I. You have tried or have a contraindication to (harmful for you to use) TWO of the following:
 - 1. High potency topical corticosteroid (such as halobetasol propionate 0.01% lotion, triamcinolone acetonide 0.5% cream or ointment) or a super-high potency topical corticosteroid (such as fluocinonide 0.1% cream, clobetasol propionate 0.05% cream or ointment)
 - 2. Topical calcineurin inhibitor (such as Protopic [tacrolimus], Elidel [pimecrolimus])
 - 3. Topical PDE-4 (phosphodiesterase-4) inhibitor (such as Eucrisa [crisaborole])
 - 4. Topical JAK (Janus kinase) inhibitor (such as Opzelura [ruxolitinib])
 - 5. Phototherapy (a type of light therapy)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LEBRIKIZUMAB-LBKZ

RENEWAL CRITERIA

Our guideline named **LEBRIKIZUMAB-LBKZ (Ebglyss)** requires the following rule(s) be met for renewal:

- A. You have moderate to severe atopic dermatitis (AD: a type of skin condition)
- B. You have shown improvement while on Ebglyss
- C. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Dupixent (dupilumab), Rinvoq (upadacitinib), Adbry (tralokinumab-ldrm)
- D. You will NOT use Ebglyss concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Eucrisa (crisaborole)]) for the treatment of atopic dermatitis

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

L-GLUTAMINE

Generic	Brand			
GLUTAMINE (L-GLUTAMINE)	ENDARI, GLUTAMINE (L- GLUTAMINE)			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **L-GLUTAMINE (Endari)** requires the following rule(s) be met for approval:

- A. You have sickle cell disease (a type of blood disorder)
- B. You are 5 years of age or older
- C. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
- D. The patient had a trial of or contraindication to (harmful for you to use) hydroxyurea
- E. **If you are 18 years of age or older, approval also requires ONE of the following:**
 1. You had at least 2 sickle cell crises in the past year (a sickle cell crisis is defined as a visit to an emergency room/medical facility for sickle cell disease-related pain which was treated with a parenterally administered [injected into the vein] narcotic [a class of drugs used to treat pain] or parenterally administered ketorolac, the occurrence of chest syndrome, priapism [prolonged erection of penis], or splenic sequestration [sickle-shaped blood cells trapped in spleen])
 2. You are having sickle-cell associated symptoms (such as pain or anemia [a type of blood condition]) which are interfering with activities of daily living
 3. You have a history of or have recurrent acute chest syndrome (ACS: chest pain, cough, fever, low oxygen level)

RENEWAL CRITERIA

Our guideline named **L-GLUTAMINE (Endari)** requires the following rule(s) be met for renewal:

- A. You have sickle cell disease (a type of blood disorder)
- B. You have maintained or experienced a reduction in acute (short-term) complications of sickle cell disease (such as the number of sickle cell crises, hospitalizations, acute chest syndrome [ACS: chest pain, cough, fever, low oxygen level])

Effective: 08/05/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LEDIPASVIR/SOFOSBUVIR

Generic	Brand			
LEDIPASVIR/ SOFOSBUVIR	HARVONI, LEDIPASVIR/ SOFOSBUVIR			

GUIDELINES FOR USE

Our guideline named **LEDIPASVIR/SOFOSBUVIR (Harvoni)** requires the following rule(s) be met for approval:

- A. You have chronic hepatitis C virus (HCV: liver inflammation caused by a type of virus)
- B. You are 3 years of age or older
- C. You have genotype 1, 4, 5, or 6 hepatitis C infection (types of hepatitis C virus)
- D. You have an HCV RNA level (a measure of the amount of hepatitis C virus in the blood) within the past 6 months
- E. You do NOT have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (having two or more diseases at the same time)
- F. You will NOT use Harvoni concurrently (at the same time) with any medication with drug interactions that are contraindicated (harmful for you to use) or not recommended per the prescribing information (such as amiodarone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, Priftin [rifapentine], rosuvastatin, Olysio [simeprevir], Stribild [elvitegravir/cobicistat/emtricitabine/tenofovir], Aptivus [tipranavir]/ritonavir, St. John's wort)
- G. You will NOT use Harvoni concurrently (at the same time) with Sovaldi (sofosbuvir; as a single agent), Mavyret (pibrentasvir/glecaprevir), Epclusa (velpatasvir/sofosbuvir), Zepatier (elbasvir/grazoprevir), or Vosevi (velpatasvir/sofosbuvir/voxilaprevir)
- H. If the request is for Harvoni 45mg/200mg pellets, approval also requires:
 1. You are unable to swallow tablets
- I. **If you are treatment-naïve (no prior treatment), approval also requires ONE of the following:**
 1. You do not have cirrhosis (liver damage and scarring)
 2. You have compensated cirrhosis (a condition where there is liver damage and scarring without any major symptoms) (Child-Pugh A: a score that evaluates the severity of liver damage)
 3. You have decompensated cirrhosis (a condition where there is liver damage and scarring with major symptoms) (Child-Pugh B or C: a score that evaluates the severity of liver damage) AND Harvoni will be used with ribavirin, unless you have a contraindication to (harmful for you to use) ribavirin
 4. You have genotype 1 or 4 infection, received a liver transplant (replaced your liver), do not have cirrhosis, AND Harvoni will be used with ribavirin
 5. You have genotype 1 or 4 infection, received a liver transplant, have compensated cirrhosis (Child-Pugh A), AND Harvoni will be used with ribavirin

(Criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LEDIPASVIR/SOFOSBUVIR

GUIDELINES FOR USE (CONTINUED)

- J. If you are treatment-experienced (failed prior treatment), approval also requires ONE of the following:**
1. You do not have cirrhosis (liver damage and scarring) AND were previously treated with a peginterferon alfa-based regimen
 2. You have compensated cirrhosis (a condition where there is liver damage and scarring without any major symptoms) (Child-Pugh A: a score that evaluates the severity of liver damage) AND were previously treated with a peginterferon alfa-based regimen
 3. You have decompensated cirrhosis (a condition where there is liver damage and scarring with major symptoms) (Child-Pugh B or C: a score that evaluates the severity of liver damage) AND Harvoni will be used with ribavirin, unless you have a contraindication to (harmful for you to use) ribavirin
 4. You have genotype 1 or 4 infection, received a liver transplant (replaced your liver), do not have cirrhosis, had prior treatment with a peginterferon alfa-based regimen, AND Harvoni will be used with ribavirin
 5. You have genotype 1 or 4 infection, received a liver transplant, have compensated cirrhosis (Child-Pugh A), had prior treatment with a peginterferon alfa-based regimen, AND Harvoni will be used with ribavirin
 6. You have decompensated cirrhosis, failed prior treatment with a sofosbuvir-based regimen (such as Epclusa [sofosbuvir/velpatasvir]) AND Harvoni will be used with ribavirin
 7. You have received a liver transplant, have decompensated cirrhosis, AND Harvoni will be used with ribavirin
- K. Harvoni will also be approved for any other regimen/condition not listed above that is recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment**

Effective: 07/22/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LEFAMULIN

Generic	Brand			
LEFAMULIN	XENLETA			

GUIDELINES FOR USE

Our guideline named **LEFAMULIN (Xenleta)** requires the following rule(s) be met for approval:

- A. You have community-acquired bacterial pneumonia (type of lung infection)
- B. You are 18 years of age or older
- C. The infection is caused by any of the following susceptible microorganisms (bacteria that the drug can kill): *Streptococcus pneumoniae*, *Staphylococcus aureus* (methicillin-susceptible isolates), *Haemophilus influenzae*, *Legionella pneumophila*, *Mycoplasma pneumoniae*, or *Chlamydia pneumoniae*
- D. You meet **ONE** of the following criteria:
 - 1. The requested medication is prescribed by or given in consultation with an Infectious Disease (ID) specialist
 - 2. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is available, and the infection site culture results indicate pathogenic (disease-causing) organism(s) with a) resistance to at least **TWO** standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone), **AND** b) susceptibility to Xenleta
 - 3. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is unavailable, and you had a trial of at least **TWO** standard of care agents (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone, linezolid) for community-acquired bacterial pneumonia, unless there is a medical reason why you cannot (contraindication)

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LENACAPAVIR

Generic	Brand				
LENACAPAVIR SODIUM	SUNLENCA				

GUIDELINES FOR USE

Our guideline named **LENACAPAVIR (Sunlenca)** requires the following rule(s) be met for approval:

- A. You have human immunodeficiency virus type 1 (HIV-1: a type of immune disorder)
- B. You are 18 years of age or older
- C. You are treatment-experienced
- D. You have a multidrug resistant (not responding to treatment) HIV-1 infection and have failed your current antiretroviral regimen (HIV treatment) due to resistance, intolerance (side effects), or safety considerations

Effective: 06/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LENALIDOMIDE

Generic	Brand				
LENALIDOMIDE	REVLIMID, LENALIDOMIDE				

GUIDELINES FOR USE

Our guideline named **LENALIDOMIDE (Revlimid)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Multiple myeloma (MM: a type of blood cancer)
 - 2. Anemia (a type of blood condition) due to a myelodysplastic syndrome (MDS: a type of blood cancer)
 - 3. Mantle cell lymphoma (MCL: a type of blood cell)
 - 4. Follicular lymphoma (FL: a type of blood cancer)
 - 5. Marginal zone lymphoma (MZL: a type of blood cancer)
 - 6. The requested medication will be used in combination with another chemotherapy agent(s) for a Food and Drug Administration (FDA)-approved indication
- B. **If you have multiple myeloma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. The requested medication will be used as induction, consolidation, or maintenance treatment for multiple myeloma
- C. **If you have anemia due to a myelodysplastic syndrome, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Your myelodysplastic syndrome is associated with a deletion 5q abnormality (a type of gene mutation)
- D. **If you have mantle cell lymphoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have relapsed or progressed (disease has returned or worsened) after two prior therapies, one of which included Velcade (bortezomib)
- E. **If you have follicular lymphoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have previously been treated for follicular lymphoma
 - 3. The requested medication will be used in combination with a rituximab product (a type of cancer drug)
- F. **If you have marginal zone lymphoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have previously been treated for marginal zone lymphoma
 - 3. The requested medication will be used in combination with a rituximab product (a type of cancer drug)

Effective: 03/10/25

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 6/11/2025

Page 470 of 1007



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LENIOLISIB

Generic	Brand				
LENIOLISIB PHOSPHATE	JOENJA				

GUIDELINES FOR USE

Our guideline named **LENIOLISIB (Joenja)** requires the following rule(s) be met for approval:

- A. You have activated phosphoinositide 3-kinase delta (PI3Kdelta) syndrome (APDS: a type of mutation that impacts the immune system)
- B. You are 12 years of age or older

Effective: 07/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LENVATINIB

Generic	Brand			
LENVATINIB MESYLATE	LENVIMA			

GUIDELINES FOR USE

Our guideline named **LENVATINIB (Lenvima)** requires the following rule(s) be met for approval:

- A. You have **ONE** of the following:
 - 1. Differentiated thyroid cancer (DTC: a type of thyroid cancer)
 - 2. Advanced renal cell carcinoma (RCC: a type of kidney cancer)
 - 3. Hepatocellular carcinoma (HCC: a type of liver cancer)
 - 4. Advanced endometrial carcinoma (EC: a type of uterus cancer)
- B. **If you have differentiated thyroid cancer, approval also requires:**
 - 1. Your thyroid cancer is locally recurrent (re-appears in the same spot) or metastatic (has spread to other parts of the body)
 - 2. Your thyroid cancer is progressive (getting worse)
 - 3. Your thyroid cancer is refractory (has not responded) to radioactive iodine therapy
- C. **If you have advanced renal cell carcinoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You meet ONE of the following:
 - a. Lenvima will be used in combination with pembrolizumab (Keytruda)
 - b. Lenvima will be used in combination with everolimus (Afinitor) AND you have tried one anti-angiogenic therapy (treatment that stop tumors from growing their own blood vessels, such as Sutent [sunitinib], Votrient [pazopanib], Inlyta [axitinib], Nexavar [sorafenib])
- D. **If you have hepatocellular carcinoma, approval also requires:**
 - 1. Your cancer is unresectable (cannot be removed by surgery)
- E. **If you have advanced endometrial carcinoma, approval also requires:**
 - 1. Lenvima will be used in combination with pembrolizumab (Keytruda)
 - 2. Your cancer is mismatch repair proficient (pMMR: your tumor has normal expression of types of protein) OR is not microsatellite instability-high (MSI-H: a type of mutation), as determined by a Food and Drug Administration (FDA)-approved test
 - 3. You have experienced disease progression (worsening) following prior systemic therapy (treatment that targets the entire body)
 - 4. You are not a candidate for curative (to cure) surgery or radiation

Effective: 03/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LETERMOVIR

Generic	Brand				
LETERMOVIR	PREVYMIS				

GUIDELINES FOR USE

Our guideline named **LETERMOVIR (Prevymis)** requires the following rule(s) be met for approval:

- A. The request is for ONE of the following:
 - 1. Prophylaxis (prevention) of cytomegalovirus (CMV: a type of virus) infection and disease in an allogeneic hematopoietic stem cell transplant (HSCT: cells transplanted from a matching donor) recipient
 - 2. Prophylaxis of cytomegalovirus (CMV) disease in a kidney transplant recipient
- B. **If the request is for prophylaxis of cytomegalovirus infection and disease in an allogeneic hematopoietic stem cell transplant recipient, approval also requires:**
 - 1. You are 6 months of age or older AND weigh at least 6 kilograms (13.2 pounds)
 - 2. You are a CMV-seropositive recipient [R+] of an allogeneic HSCT
 - 3. You will start or have started Prevymis between Day 0 and Day 28 post-transplant (before or after engraftment [a type of transplant])
 - 4. You meet ONE of the following:
 - a. You are NOT at risk for late CMV infection and disease, AND you will not receive Prevymis beyond 100 days post (after)-transplant
 - b. You are at risk for late CMV infection and disease, AND you will not receive Prevymis beyond 200 days post (after)-transplant
- C. **If the request is for prophylaxis of cytomegalovirus disease in a kidney transplant recipient, approval also requires:**
 - 1. You are 12 years of age or older AND weigh at least 40 kilograms (88 pounds)
 - 2. You are a kidney transplant recipient at high risk (donor is CMV seropositive, recipient is CMV seronegative [D+/R-])
 - 3. You will start or have started Prevymis between Day 0 and Day 7 post (after)-transplant
 - 4. You will not receive Prevymis beyond 200 days post-transplant

Effective: 03/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LEUPROLIDE

Generic	Brand				
LEUPROLIDE ACETATE	LEUPROLIDE ACETATE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **LEUPROLIDE** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
2. Advanced prostate cancer (prostate cancer that has spread to nearby tissue or organs)
3. Central precocious puberty (CPP: early sexual development in girls and boys)

B. If you are female and have central precocious puberty, approval also requires:

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a pediatric endocrinologist (a type of hormone doctor)
3. You have high levels of follicle-stimulating hormone (FSH) (level greater than 4.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
4. You are/were younger than 8 years of age when your condition started
5. You have been evaluated for pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for breast development (stage 2 or above) AND pubic hair growth (stage 2 or above)

C. If you are male and have central precocious puberty, approval also requires:

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a pediatric endocrinologist (a type of hormone doctor)
3. You have high levels of follicle-stimulating hormone (FSH) (level greater than 5.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
4. You are/were younger than 9 years of age when your condition started
5. You have been evaluated for pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for genital development (stage 2 or above) AND pubic hair growth (stage 2 or above)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LEUPROLIDE

RENEWAL CRITERIA

NOTE: For the diagnoses of gender dysphoria or advanced prostate cancer, please refer to the Initial Criteria section.

Our guideline named **LEUPROLIDE** requires the following rule(s) be met for renewal:

- A. You have central precocious puberty (CPP: early sexual development in girls and boys)
- B. Your Tanner scale staging (scale of physical measurements of development based on external sex characteristics) at initial diagnosis of CPP has stabilized or regressed (lowered) during three separate medical visits in the previous year
- C. You have NOT reached the actual age which corresponds to your current pubertal age

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LEUPROLIDE-ELIGARD

Generic	Brand				
LEUPROLIDE ACETATE	ELIGARD				

GUIDELINES FOR USE

Our guideline named **LEUPROLIDE-ELIGARD** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
 2. Advanced prostate cancer (prostate cancer that has spread to nearby tissue or organs)

Effective: 01/23/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LEVACETYLLEUCINE

Generic	Brand				
LEVACETYLLEUCINE	AQNEURSA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **LEVACETYLLEUCINE (Aqneursa)** requires the following rule(s) be met for approval:

- A. You have Niemann-Pick disease type C (NPC: a type of genetic condition)
- B. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor) or geneticist (a doctor who treats gene disorders)

RENEWAL CRITERIA

Our guideline named **LEVACETYLLEUCINE (Aqneursa)** requires the following rule(s) be met for renewal:

- A. You have Niemann-Pick disease type C (NPC: a type of genetic condition)
- B. You have shown disease improvement or a reduction in disease progression

Effective: 10/14/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LEVAMLODIPINE

Generic	Brand				
LEVAMLODIPINE MALEATE	CONJUPRI, LEVAMLODI PINE MALEATE				

GUIDELINES FOR USE

Our guideline named **LEVAMLODIPINE (Conjupri)** requires the following rule(s) be met for approval:

- A. You have hypertension (high blood pressure)
- B. You are 6 years of age or older
- C. You have tried or have a contraindication (harmful for) to TWO generic dihydropyridine calcium channel blockers (such as amlodipine, felodipine, nicardipine)
- D. You have tried or have a contraindication (harmful for) to TWO other antihypertensive agents in another class (such as hydrochlorothiazide, lisinopril, losartan)

Effective: 06/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LEVETIRACETAM

Generic	Brand				
LEVETIRACETAM	SPRITAM				

GUIDELINES FOR USE

Our guideline named **LEVETIRACETAM (Spritam)** requires the following rules be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Partial-onset seizures (type of seizure)
 - 2. Myoclonic seizures in juvenile myoclonic epilepsy (type of seizure in childhood)
 - 3. Primary generalized tonic-clonic seizures (type of seizure)
- B. **If you have partial-onset seizures, approval also requires:**
 - 1. You are 4 years of age or older
 - 2. You are unable to swallow levetiracetam tablets
 - 3. You had a trial of levetiracetam oral solution
- C. **If you have myoclonic seizures in juvenile myoclonic epilepsy, approval also requires:**
 - 1. You are 12 years of age or older
 - 2. Spritam will be used as adjunctive (add-on) therapy
 - 3. You are unable to swallow levetiracetam tablets
 - 4. You had a trial of levetiracetam oral solution
- D. **If you have primary generalized tonic-clonic seizures, approval also requires:**
 - 1. You are 6 years of age or older
 - 2. Spritam will be used as adjunctive (add-on) therapy
 - 3. You are unable to swallow levetiracetam tablets
 - 4. You had a trial of levetiracetam oral solution

Effective: 04/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LEVODOPA

Generic	Brand			
LEVODOPA	INBRIJA			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **LEVODOPA INHALATION (Inbrija)** requires the following rule(s) be met for approval:

- H. You have Parkinson's disease (a nerve system disorder that affects movement)
- I. Inbrija is being used for intermittent treatment of OFF episodes (times when you have symptoms return due to medication wearing off) associated with Parkinson's disease
- J. You are currently being treated with carbidopa/levodopa
- K. The requested medication is prescribed by or given in consultation with a neurologist (nerve doctor)
- L. You are **NOT** currently taking more than 1600mg of levodopa per day
- M. Your doctor has optimized drug therapy as evidenced by **BOTH** of the following:
 - 1. Change in levodopa/carbidopa dosing strategy or formulation
 - 2. Trial of or contraindication to (medical reason why you cannot use) at least **TWO** Parkinson's agents from **TWO** different classes of the following: dopamine agonist (such as ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitors (MAO-I) (such as selegiline, rasagiline), catechol-O-methyl transferase (COMT) inhibitors (such as entacapone, tolcapone), adenosine receptor antagonist A_{2A} (such as istradefylline)

RENEWAL CRITERIA

Our guideline named **LEVODOPA INHALATION (Inbrija)** requires the following rule(s) be met for renewal approval:

- C. You have Parkinson's disease (a nerve system disorder that affects movement)
- D. You had improvement with motor fluctuations during OFF episodes (times when you have symptoms return due to medication wearing off) with the use of Inbrija. Improvements can be in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair.

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LEVOKETOCONAZOLE

Generic	Brand				
LEVOKETOCONAZOLE	RECORLEV				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **LEVOKETOCONAZOLE (Recorlev)** requires the following rule(s) be met for approval:

- A. You have Cushing's syndrome (a type of hormone disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
- D. You are not a candidate for surgery or surgery has not been curative
- E. You have tried or have a contraindication (harmful for) to oral ketoconazole

RENEWAL CRITERIA

Our guideline named **LEVOKETOCONAZOLE (Recorlev)** requires the following rule(s) be met for renewal:

- A. You have Cushing's syndrome (a type of hormone disorder)
- B. You continue to have improvement of Cushing's syndrome (such as clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of your disease)
- C. You continue to tolerate treatment with Recorlev

Effective: 02/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LEVOTHYROXINE-ERMEZA

Generic	Brand				
LEVOTHYROXINE SODIUM	ERMEZA				

GUIDELINES FOR USE

Our guideline named **LEVOTHYROXINE-ERMEZA** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Congenital (present from birth) or acquired hypothyroidism (low thyroid function)
 - 2. Thyrotropin (a type of thyroid hormone)-dependent well-differentiated thyroid cancer
- B. You had a trial and failure (drug did not work) of Thyquidity
- C. You had a trial and failure (drug did not work) of generic levothyroxine tablets
- D. You are unable to swallow levothyroxine tablets or capsules
- E. **If you have thyrotropin-dependent well-differentiated thyroid cancer, approval also requires:**
 - 1. The requested medication will be used as an adjunct (add-on) to surgery and radioiodine therapy (a type of radiation therapy)

Effective: 04/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LEVOTHYROXINE-TIROSINT

Generic	Brand				
LEVOTHYROXINE SODIUM	TIROSINT, LEVOTHYROXINE				

GUIDELINES FOR USE

Our guideline named **LEVOTHYROXINE-TIROSINT** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Congenital (present from birth) or acquired hypothyroidism (low thyroid function)
 - 2. Thyrotropin (a type of thyroid hormone)-dependent well-differentiated thyroid cancer
- B. **If you have congenital or acquired hypothyroidism, approval also requires:**
 - 1. You are 6 years of age or older
 - 2. You have tried and failed (drug did not work) generic levothyroxine tablets
 - 3. There is a rationale (reason) for NOT using generic levothyroxine tablets
- C. **If you have thyrotropin-dependent well-differentiated thyroid cancer, approval also requires:**
 - 1. You are 6 years of age or older
 - 2. The requested medication will be used as an adjunct (add-on) to surgery and radioiodine therapy (a type of radiation therapy)
 - 3. You have tried and failed (drug did not work) generic levothyroxine tablets
 - 4. There is a rationale (reason) for NOT using generic levothyroxine tablets

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LEVOTHYROXINE-TIROSINT-SOL

Generic	Brand				
LEVOTHYROXINE SODIUM	TIROSINT-SOL				

GUIDELINES FOR USE

Our guideline named **LEVOTHYROXINE-TIROSINT-SOL** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Congenital (present from birth) or acquired hypothyroidism (low thyroid function)
 - 2. Thyrotropin (a type of thyroid hormone)-dependent well-differentiated thyroid cancer
- B. **If you have congenital or acquired hypothyroidism, approval also requires:**
 - 1. You have tried and failed (drug did not work) Thyquidity
 - 2. You have tried and failed (drug did not work) or have a contraindication to (harmful for you to use) generic levothyroxine tablets
 - 3. There is a rationale (reason) for not using Thyquidity and generic levothyroxine tablets
- C. **If you have thyrotropin-dependent well-differentiated thyroid cancer, approval also requires:**
 - 1. Tirosint-Sol will be used as an adjunct (add-on) to surgery and radioiodine therapy (a type of radiation therapy)
 - 2. You have tried and failed (drug did not work) Thyquidity
 - 3. You have tried and failed (drug did not work) or have a contraindication to (harmful for you to use) generic levothyroxine tablets
 - 4. There is a rationale (reason) for not using Thyquidity and generic levothyroxine tablets

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LIRAGLUTIDE - SAXENDA

Generic	Brand				
LIRAGLUTIDE	SAXENDA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **LIRAGLUTIDE - SAXENDA** requires the following rule(s) be met for approval:

- A. The request is for weight loss OR weight loss management
- B. You are 12 years of age or older
- C. You have evidence of active enrollment in an exercise and caloric reduction program, which may include other optional weight loss/behavioral modification programs
- D. You will NOT use Saxenda concurrently (at the same time) with a GLP-1 receptor agonist (a type of drug such as Victoza [liraglutide], Ozempic [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release])
- E. **If you are 18 years of age or older, approval also requires ONE of the following:**
 - 1. You have a body mass index (BMI: a tool for evaluating body fat) of at least 30 kg/m(2)
 - 2. You have a BMI of at least 27 kg/m(2) AND at least ONE weight-related comorbidity (disease) (such as hypertension [high blood pressure], type 2 diabetes mellitus [a disorder with high blood sugar], dyslipidemia [abnormal levels of fat], cardiovascular disease [condition of the heart or blood vessels], coronary artery disease [CAD: a type of heart condition], sleep apnea [a type of sleep condition with difficulty breathing], osteoarthritis [a type of joint condition] of the knee[s], polycystic ovarian syndrome [a hormonal disorder], non-alcoholic steatohepatitis/non-alcoholic fatty liver disease [inflammation in the liver], asthma [a type of lung condition], and chronic obstructive pulmonary disease [COPD: a type of lung condition])
- F. **If you are 12 to 17 years of age, approval also requires:**
 - 1. You have a body weight greater than 60 kg
 - 2. You have an initial BMI corresponding to 30 kg/m(2) for adults

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LIRAGLUTIDE - SAXENDA

RENEWAL CRITERIA

Our guideline named **LIRAGLUTIDE - SAXENDA** requires the following rule(s) be met for renewal:

- A. The request is for weight loss OR weight loss management
- B. You are 12 years of age or older
- C. **If you are 18 years of age or older, approval also requires:**
 - 1. You have achieved or maintained at least a 5 percent weight loss of baseline body weight after 16 weeks of treatment
- D. **If you are 12 to 17 years of age, approval also requires:**
 - 1. You have achieved or maintained at least a 1 percent weight loss of baseline body mass index (BMI: a tool for evaluating body fat) after at least 12 weeks of treatment on your maximally tolerated dose

Effective: 10/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LIXISENATIDE

Generic	Brand				
LIXISENATIDE	ADLYXIN				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **LIXISENATIDE (Adlyxin)** requires the following rule(s) be met for approval:

You have type 2 diabetes (a disorder with high blood sugar)

You are 18 years of age or older

Adlyxin is prescribed by or in consultation with an endocrinologist (a type of hormone doctor), cardiologist (a type of heart doctor), nephrologist (a type of kidney doctor), family practice, internal medicine, or another healthcare provider who specializes in diabetic management

You have tried metformin (immediate-release/ extended-release), a sulfonylurea (such as glipizide, glimepiride), pioglitazone, or a preferred combination product containing any of the above medications (such as glipizide-metformin, pioglitazone-metformin)

You have tried a preferred GLP-1 agonist (such as Byetta [exenatide], Bydureon [exenatide microspheres], Victoza [liraglutide])

Adlyxin will NOT be used together with a DPP-4 inhibitor (such as Januvia [sitagliptin], alogliptin, saxagliptin)

RENEWAL CRITERIA

Our guideline named **LIXISENATIDE (Adlyxin)** requires the following rule(s) be met for approval:

You have type 2 diabetes (a disorder with high blood sugar)

Adlyxin is prescribed by or in consultation with an endocrinologist (a type of hormone doctor), cardiologist (a type of heart doctor), nephrologist (a type of kidney doctor), family practice, internal medicine, or another healthcare provider who specializes in diabetic management

Adlyxin will NOT be used together with a DPP-4 inhibitor (such as Januvia [sitagliptin], alogliptin, saxagliptin)

Effective: 01/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LOFEXIDINE

Generic	Brand			
LOFEXIDINE HCL	LUCEMYRA, LOFEXIDINE HCL			

GUIDELINES FOR USE

Our guideline name **LOFEXIDINE (Lucemyra)** requires the following rule(s) be met for approval:

- A. Lucemyra will be used to reduce opioid withdrawal symptoms to help abrupt opioid discontinuation
- B. You are 18 years of age or older
- C. You are in a setting with close monitoring of Lucemyra (lofexidine) treatment and will be treated with Lucemyra (lofexidine) for a maximum of 18 days
- D. Lucemyra will be used as part of an opioid discontinuation plan that includes other withdrawal symptom management medications (such as stool softeners, sleep aids) and psychosocial support is in place to help prevent relapse

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LOMITAPIDE

Generic	Brand			
LOMITAPIDE	JUXTAPID			

GUIDELINES FOR USE

Our guideline named **LOMITAPIDE (Juxtapid)** requires the following rule(s) be met for approval:

- A. You have homozygous familial hypercholesterolemia (HoFH: type of inherited high cholesterol)
- B. Your diagnosis is determined by meeting ONE of the following:
 - 1. You have Simon Broome diagnostic criteria (definite) (a tool for diagnosing homozygous familial hypercholesterolemia)
 - 2. You have a Dutch Lipid Network (a tool for diagnosing homozygous familial hypercholesterolemia) criteria with a score of at least 8
 - 3. You have a clinical diagnosis based on a history of an untreated low density lipoprotein - cholesterol (LDL-C: bad cholesterol) level greater than 500 mg/dL AND you have either xanthoma (a type of skin condition) before 10 years of age or there is evidence of heterozygous familial hypercholesterolemia (HeFH: type of inherited high cholesterol) in both parents
- C. Therapy is prescribed by or in consultation with a cardiologist (heart doctor), endocrinologist (hormone doctor), or lipidologist (cholesterol management doctor)
- D. You have a low density lipoprotein cholesterol (LDL-C: bad cholesterol) level of at least 70 mg/dL while on maximally tolerated statin (medication used for cholesterol) treatment
- E. You have tried Repatha (evolocumab) OR you do not have a functional LDL (low density lipoprotein) receptors
- F. **If you are statin tolerant, approval also requires:**
 - 1. You meet ONE of the following:
 - a. You are currently taking a high-intensity statin (atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily) AND have been taking it for a duration of at least 8 weeks
 - b. You did not tolerate a high-intensity statin (atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily), but you are currently taking a maximally tolerated dose of any statin AND have been taking it for a duration of at least 8 weeks
 - 2. You will continue statin (medication used for cholesterol) treatment in combination with Juxtapid

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LOMITAPIDE

GUIDELINES FOR USE (CONTINUED)

G. If you are statin intolerant, approval also requires ONE of the following:

1. You have an absolute contraindication to (harmful for you to use) statin therapy (medication used for cholesterol) (such as active decompensated liver disease [symptoms related to liver damage], nursing [breastfeeding] female, pregnancy or plans to become pregnant, hypersensitivity [allergic] reaction)
2. You have complete statin intolerance (defined by severe and intolerable adverse effects) that have occurred with trials of at least TWO separate statins, AND the side effects have improved when you stopped each statin. Some adverse effects include: creatine kinase (type of protein) elevation greater than or equal to 10 times the upper limit of normal, liver function test elevation greater than or equal to 3 times the upper limit of normal, rhabdomyolysis (breakdown of muscle tissue), severe muscle weakness leading to temporary disability, fall, or inability to use a major muscle group.

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LOMUSTINE

Generic	Brand			
LOMUSTINE	GLEOSTINE			

GUIDELINES FOR USE

Our guideline named **LOMUSTINE (Gleostine)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Hodgkin's lymphoma (type of immune system cancer)
 - 2. Primary and metastatic brain tumors (tumor that has spread to other parts of body)
- B. **If you have primary and metastatic brain tumors, approval also requires:**
 - 1. You have previously received appropriate surgical and/or radiotherapeutic procedures
 - 2. The requested medication will be used as a part of the PCV regimen (procarbazine, lomustine, and vincristine)

Effective: 01/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LONAFARNIB

Generic	Brand				
LONAFARNIB	ZOKINVY				

GUIDELINES FOR USE

Our guideline named **LONAFARNIB (Zokinvy)** requires the following rule(s) be met for approval:

- A. You have Hutchinson-Gilford progeria syndrome (HGPS) OR processing-deficient progeroid laminopathies (rare genetic disorders that cause premature aging in children)
- B. You are 1 year of age or older
- C. You have a body surface area (BSA) of 0.39 meters squared or more
- D. **If you have processing-deficient progeroid laminopathies, approval also requires you have ONE of the following:**
 - 1. Heterozygous LMNA (type of gene) mutation with progerin-like protein accumulation
 - 2. Homozygous or compound heterozygous ZMPSTE24 (type of gene) mutations

Effective: 04/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LONAPEG SOMATROPIN-TCGD

Generic	Brand				
LONAPEG SOMATROPIN -TCGD	SKYTROFA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **LONAPEG SOMATROPIN-TCGD (Skytrofa)** requires the following rule(s) be met for approval:

- A. You have growth failure due to an inadequate secretion (release) of endogenous (from your own body) growth hormone (GH)
- B. You are 1 to 17 years of age and weigh at least 11.5 kilograms (25.3 pounds)
- C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
- D. Your epiphyses (end part of long bone) are NOT closed, as confirmed by a radiograph (type of imaging test) of the wrist and hand
- E. You will NOT use Skytrofa concurrently (at the same time) with Increlex (mecasermin)
- F. You meet ONE of the following:
 - 1. Your height is at least 2 standard deviations (SD: a measure of variation from the average) below the mean (average) height for children of the same age and gender
 - 2. Your height velocity is less than the 25th percentile for your age
 - 3. You have a low peak growth hormone level (less than 10 ng/mL) on TWO growth hormone stimulation tests, OR an insulin-like growth factor 1 (IGF-1) level that is at least 2 standard deviations below the mean for your age and gender
- G. Request for Skytrofa will NOT be approved for athletic enhancement (to perform better in sports), anti-aging purposes, or idiopathic short stature (ISS: a type of growth condition)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LONAPEGSOMATROPIN-TCGD

RENEWAL CRITERIA

Our guideline named **LONAPEGSOMATROPIN-TCGD (Skytrofa)** requires the following rule(s) be met for renewal:

- A. You have growth failure due to an inadequate secretion (release) of endogenous (from your own body) growth hormone (GH)
- B. You are 1 to 17 years of age and weigh at least 11.5 kilograms (25.3 pounds)
- C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
- D. Your epiphyses (end part of long bone) are NOT closed, as confirmed by a radiograph (type of imaging test) of the wrist and hand, OR you have not completed prepubertal growth
- E. You will NOT use Skytrofa concurrently (at the same time) with Increlex (mecasermin)
- F. You meet ONE of the following:
 - 1. Your annual growth velocity (rate of growth) is at least 2 cm compared with what was observed from the previous year
 - 2. Your annual growth velocity is at least 1 cm compared with what was observed from the previous year if you are close to the terminal (final) phase of puberty
- G. Request for Skytrofa will NOT be approved for athletic enhancement (to perform better in sports), anti-aging purposes, or idiopathic short stature (ISS: a type of growth condition)

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LORCASERIN

Generic	Brand				
LORCASERIN HCL	BELVIQ, BELVIQ XR				

GUIDELINES FOR USE

Do not approve requests for Belviq or Belviq XR.

(NOTE: Safety concerns [increased risk of cancer] have prompted market withdrawal of Belviq and Belviq XR.)

Effective: 10/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LORLATINIB

Generic	Brand			
LORLATINIB	LORBRENA			

GUIDELINES FOR USE

Our guideline named **LORLATINIB (Lorbrena)** requires the following rule(s) be met for approval:

- A. You have metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
- B. You are 18 years of age or older
- C. Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme)-positive, as detected by an Food and Drug Administration (FDA)-approved test

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LOSARTAN

Generic	Brand				
LOSARTAN POTASSIUM	ARB LI				

GUIDELINES FOR USE

Our guideline named **LOSARTAN (Arbli)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Hypertension (high blood pressure)
2. Hypertension with left ventricular hypertrophy (a type of heart condition)
3. Type 2 diabetes (a disorder with high blood sugar) with diabetic nephropathy (a type of kidney disease caused by high blood sugar)

B. If you have hypertension, approval also requires:

1. You have a contraindication to (harmful for you to use) or are unable to swallow losartan tablets

C. If you have hypertension with left ventricular hypertrophy, approval also requires:

1. You have a contraindication to (harmful for you to use) or are unable to swallow losartan tablets

D. If you have type 2 diabetes with diabetic nephropathy, approval also requires:

1. You have a history of hypertension (high blood pressure)
2. You have an elevated serum creatinine (a type of lab test to measure kidney function) level and proteinuria (a condition with high levels of protein in the urine) (urinary albumin to creatinine ratio of at least 300mg/g)
3. You have a contraindication to (harmful for you to use) or are unable to swallow losartan tablets

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LOTEPREDNOL

Generic	Brand				
LOTEPREDNOL ETABONATE	EYSUVIS				

GUIDELINES FOR USE

Our guideline named **LOTEPREDNOL (Eysuvis)** requires the following rule(s) be met for approval:

- A. You have dry eye disease
- B. You have tried or have a contraindication to (harmful for you to use) one generic loteprednol ophthalmic (eye) medication (such as loteprednol 0.2%, loteprednol 0.5%) AND one non-loteprednol ophthalmic corticosteroid (such as fluorometholone, dexamethasone, prednisolone)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LOTILANER

Generic	Brand				
LOTILANER	XDEMZY				

GUIDELINES FOR USE

Our guideline named **LOTILANER (Xdemzy)** requires the following rule(s) be met for approval:

- A. You have Demodex blepharitis (a type of inflammatory eye condition)
- B. You are 18 years of age or older

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LU-177 VIPIVOTIDE TETRAXETAN

Generic	Brand				
LU-177 VIPIVOTIDE TETRAXETAN	PLUVICTO				

GUIDELINES FOR USE

Our guideline named **LU-177 VIPIVOTIDE TETRAXETAN (Pluvicto)** requires the following rule(s) be met for approval:

You have metastatic castration-resistant prostate cancer (mCRPC: a type of prostate cancer that has spread to other parts of the body and no longer responds to testosterone lowering treatment)

You are 18 years of age or older

Your cancer is prostate-specific membrane antigen (PSMA)-positive (a type of test)

You have been treated with androgen receptor pathway inhibitor (ARPI) therapy (such as enzalutamide, abiraterone)

You meet ONE of the following:

It is appropriate to delay taxane-based chemotherapy (medications used to treat cancer such as docetaxel, cabazitaxel)

You have received prior taxane-based chemotherapy

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LUMACAFITOR/IVACAFITOR

Generic	Brand			
LUMACAFITOR/IVACAFITOR	ORKAMBI			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

Our guideline named **LUMACAFITOR-IVACAFITOR (Orkambi)** requires the following rule(s) be met for approval:

- A. You have cystic fibrosis (CF: a type of lung disorder)
- B. You are 1 year of age or older
- C. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or cystic fibrosis expert
- D. You will NOT use Orkambi concurrently (at the same time) with another cystic fibrosis transmembrane conductance regulator (CFTR) modulator (such as medications containing vanzacaftor, deutivacaftor, ivacaftor, lumacaftor, tezacaftor, or elexacaftor)
- E. You are homozygous (have two copies of the same gene) for the F508del mutation (abnormal change) in the CFTR gene

RENEWAL CRITERIA

Our guideline named **LUMACAFITOR-IVACAFITOR (Orkambi)** requires the following rule(s) be met for renewal:

- A. You have cystic fibrosis (CF: a type of lung disorder)
- B. You have experienced an improvement in your clinical status
- C. You will NOT use Orkambi concurrently (at the same time) with another cystic fibrosis transmembrane conductance regulator (CFTR) modulator (such as medications containing vanzacaftor, deutivacaftor, ivacaftor, lumacaftor, tezacaftor, or elexacaftor)

Effective: 02/10/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LUSUTROMBOPAG

Generic	Brand			
LUSUTROMBOPAG	MULPLETA			

GUIDELINES FOR USE

Our guideline named **LUSUTROMBOPAG (Mulpleta)** requires the following rule(s) be met for approval:

- A. You have thrombocytopenia (a type of blood disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor), gastroenterologist (a doctor who treats digestive conditions), hepatologist (a type of liver doctor), immunologist (a type of immune system doctor), endocrinologist (a type of hormone doctor), or surgeon
- D. You have chronic liver disease
- E. You are scheduled to undergo a procedure 8 to 14 days after starting Mulpleta (lusutrombopag) therapy
- F. You have a platelet count of less than 50×10^9 cells/L measured within the last 30 days
- G. You are not receiving other thrombopoietin receptor agonist therapy, such as avatrombopag, romiplostim, eltrombopag

Effective: 04/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MACITENTAN

Generic	Brand				
MACITENTAN	OPSUMIT				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **MACITENTAN (Opsumit)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
- C. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
 2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
 3. Pulmonary vascular resistance (PVR) greater than 2 Wood units

RENEWAL CRITERIA

Our guideline named **MACITENTAN (Opsumit)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MACITENTAN-TADALAFIL

Generic	Brand				
MACITENTAN/ TADALAFIL	OPSYNVI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **MACITENTAN-TADALAFIL (Opsynvi)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. You are 18 years of age or older
- C. You have WHO Functional Class II-III symptoms (a way to classify how limited physical activity)
- D. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
- E. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - 1. Mean pulmonary artery pressure (PAP: a type of measurement for pulmonary arterial hypertension) greater than 20 mmHg
 - 2. Pulmonary capillary wedge pressure (PCWP: a type of measurement for pulmonary arterial hypertension) less than or equal to 15 mmHg
 - 3. Pulmonary vascular resistance (PVR: a type of measurement for pulmonary arterial hypertension) greater than 2 Wood units
- F. You will NOT use Opsynvi concurrently (at the same time) or intermittently (off and on) with oral erectile dysfunction medications (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
- G. You will NOT use Opsynvi concurrently (at the same time) with guanylate cyclase stimulators (such as Adempas [riociguat])

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MACITENTAN-TADALAFIL

RENEWAL CRITERIA

Our guideline named **MACITENTAN-TADALAFIL (Opsynvi)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1: a way to classify the severity of disease)
- B. You will NOT use Opsynvi concurrently (at the same time) or intermittently (off and on) with oral erectile dysfunction medications (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
- C. You will NOT use Opsynvi concurrently (at the same time) with guanylate cyclase stimulators (such as Adempas [riociguat])

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MARALIXIBAT

Generic	Brand				
MARALIXIBAT CHLORIDE	LIVMARLI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **MARALIXIBAT (Livmarli)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Cholestatic pruritus (itching caused by liver disease) associated with Alagille syndrome (ALGS: a type of genetic disorder)
 2. Cholestatic pruritus (itching caused by liver disease) associated with progressive familial intrahepatic cholestasis (PFIC: a type of genetic disorder)
- B. **If you have cholestatic pruritus associated with Alagille syndrome, approval also requires:**
1. You are 3 months of age or older
 2. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor), gastroenterologist (a doctor who treats digestive conditions), or physician (doctor) who specializes in ALGS cholestasis
 3. You will NOT use Livmarli concurrently (at the same time) with another ileal bile acid transporter (IBAT) inhibitor (such as Bylvay [odevixibat])
- C. **If you have cholestatic pruritus associated with progressive familial intrahepatic cholestasis, approval also requires:**
1. You are 12 months of age or older
 2. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor), gastroenterologist (a doctor who treats digestive conditions), or physician (doctor) who specializes in PFIC cholestasis
 3. You will NOT use Livmarli concurrently (at the same time) with another ileal bile acid transporter (IBAT) inhibitor (such as Bylvay [odevixibat])

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MARALIXIBAT

RENEWAL CRITERIA

Our guideline named **MARALIXIBAT (Livmarli)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Cholestatic pruritus (itching caused by liver disease) associated with Alagille syndrome (ALGS: a type of genetic disorder)
 - 2. Cholestatic pruritus (itching caused by liver disease) associated with progressive familial intrahepatic cholestasis (PFIC: a type of genetic disorder)
- B. **If you have cholestatic pruritus associated with Alagille syndrome, renewal also requires:**
 - 1. You have shown a clinical response to therapy, defined as improvement in pruritus (itching) symptoms AND a reduction of serum bile acid (a type of blood test) from baseline (before starting Livmarli)
 - 2. You will NOT use Livmarli concurrently (at the same time) with another ileal bile acid transporter (IBAT) inhibitor (such as Bylvay [odevixibat])
- C. **If you have cholestatic pruritus associated with progressive familial intrahepatic cholestasis, renewal also requires:**
 - 1. You have shown a clinical response to therapy, defined as improvement in pruritus (itching) symptoms AND a reduction of serum bile acid (a type of blood test) from baseline (before starting Livmarli)
 - 2. You do NOT have PFIC type 2 with specific ABCB11 variants (a type of abnormal gene) that would result in nonfunctional (does not work), or the complete absence of, bile salt export pump (BSEP: a type of protein)
 - 3. You will NOT use Livmarli concurrently (at the same time) with another ileal bile acid transporter (IBAT) inhibitor (such as Bylvay [odevixibat])

Effective: 06/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MARIBAVIR

Generic	Brand				
MARIBAVIR	LIVTENCITY				

GUIDELINES FOR USE

Our guideline named **MARIBAVIR (Livtencity)** requires the following rule(s) be met for approval:

- A. You have a post-transplant cytomegalovirus (CMV) infection (a type of viral infection)
- B. You are 12 years of age or older
- C. Your infection is refractory (has not responded) to prior therapy with ganciclovir, valganciclovir, cidofovir or foscarnet

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MARSTACIMAB-HNCQ

Generic	Brand				
MARSTACIMAB-HNCQ	HYMPAVZI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **MARSTACIMAB-HNCQ (Hypmavzi)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Hemophilia A (congenital factor VIII deficiency: a type of bleeding disorder)
2. Hemophilia B (congenital factor IX deficiency: a type of bleeding disorder)

B. If you have hemophilia A (congenital factor VIII deficiency), approval also requires:

1. You are 12 years of age or older
2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
3. Your hemophilia is without factor VIII inhibitors (a type of protein)
4. Hypmavzi will be used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes
5. You will NOT use Hypmavzi concurrently (at the same time) with another non-factor prophylaxis therapy (such as Hemlibra [emicizumab-kxwh])

C. If you have hemophilia B (congenital factor IX deficiency), approval also requires

1. You are 12 years of age or older
2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
3. Your hemophilia is without factor IX inhibitors (a type of protein)
4. Hypmavzi will be used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes
5. You will NOT use Hypmavzi concurrently (at the same time) with another non-factor prophylaxis therapy (such as Hemlibra [emicizumab-kxwh])

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MARSTACIMAB-HNCQ

RENEWAL CRITERIA

Our guideline named **MARSTACIMAB-HNCQ (Hypmavzi)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Hemophilia A (congenital factor VIII deficiency: a type of bleeding disorder)
 - 2. Hemophilia B (congenital factor IX deficiency: a type of bleeding disorder)
- B. **If you have hemophilia A (congenital factor VIII deficiency), renewal also requires:**
 - 1. Your hemophilia is without factor VIII inhibitors (a type of protein)
 - 2. You have shown a clinical benefit compared to baseline (before starting Hypmavzi)
 - 3. You will NOT use Hypmavzi concurrently (at the same time) with another non-factor prophylaxis therapy (such as Hemlibra [emicizumab-kxwh])
- C. **If you have hemophilia B (congenital factor IX deficiency), renewal also requires:**
 - 1. Your hemophilia is without factor IX inhibitors (a type of protein)
 - 2. You have shown a clinical benefit compared to baseline (before starting Hypmavzi)
 - 3. You will NOT use Hypmavzi concurrently (at the same time) with another non-factor prophylaxis therapy (such as Hemlibra [emicizumab-kxwh])

Effective: 11/25/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MAVACAMTEN

Generic	Brand				
MAVACAMTEN	CAMZYOS				

GUIDELINES FOR USE

NITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **MAVACAMTEN (Camzyos)** requires the following rule(s) be met for approval:

- A. You have symptomatic obstructive hypertrophic cardiomyopathy (HCM: a type of heart condition)
- B. You are 18 years of age or older
- C. You have New York Heart Association (NYHA) class II-III (classification system for heart failure) symptoms
- D. You have a left ventricular outflow track gradient (a predictor of heart failure and cardiovascular death) of 50 mmHg or higher
- E. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor)
- F. You had a trial of or contraindication (harmful for) to beta-blockers (such as metoprolol, carvedilol) AND non-dihydropyridine calcium channel blockers (such as verapamil, diltiazem)

RENEWAL CRITERIA

Our guideline named **MAVACAMTEN (Camzyos)** requires the following rule(s) be met for renewal:

- A. You have symptomatic obstructive hypertrophic cardiomyopathy (HCM: a type of heart condition)
- B. You have experienced continued clinical benefit (such as reduction of symptoms, NYHA classification improvement)

Effective:06/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MAVORIXAFOR

Generic	Brand				
MAVORIXAFOR	XOLREMDI				

GUIDELINES FOR USE

Our guideline named **MAVORIXAFOR (Xolremdi)** requires the following rule(s) be met for approval:

- A. You have WHIM (warts, hypogammaglobulinemia [low levels of antibodies in the blood], infections, and myelokathexis [low white blood cell count]) syndrome (a rare genetic disorder of the immune system)
- B. You are 12 years of age or older

Effective: 05/27/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MEBENDAZOLE

Generic	Brand			
MEBENDAZOLE	EMVERM			

GUIDELINES FOR USE

Our guideline named **MEBENDAZOLE (Emverm)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. *Enterobius vermicularis* (pinworm) infection
 - 2. *Trichuris trichiura* (whipworm) infection
 - 3. *Ascaris lumbricoides* (roundworm) infection
 - 4. *Ancylostoma duodenale* (hookworm) infection
 - 5. *Necator americanus* (hookworm) infection
- B. **If you have *Enterobius vermicularis* (pinworm) infection, approval also requires:**
 - 1. You are 2 years of age or older
 - 2. You have tried or have a contraindication to (harmful for you to use) over-the-counter (OTC) pyrantel pamoate
- C. **If you have *Trichuris trichiura* (whipworm) or *Ascaris lumbricoides* (roundworm) infection, approval also requires:**
 - 1. You are 2 years of age or older
 - 2. You have tried or have a contraindication to (harmful for you to use) albendazole (Albenza)
- D. **If you have *Ancylostoma duodenale* (hookworm) or *Necator americanus* (hookworm) infection, approval also requires:**
 - 1. You are 2 years of age or older
 - 2. You have tried or have a contraindication to (harmful for you to use) albendazole (Albenza) OR over-the-counter (OTC) pyrantel pamoate

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MECAMYLAMINE HYDROCHLORIDE

Generic	Brand			
MECAMYLAMINE HCL	VECAMYL			

GUIDELINES FOR USE

Our guideline named **MECAMYLAMINE HYDROCHLORIDE (Vecamyl)** requires the following rule(s) be met for approval:

- A. The requested medication will be used for the management of moderately severe to severe essential (or primary) hypertension or in uncomplicated cases of malignant hypertension
- B. You have had a trial of at least three of the following, unless there is a medical reason why you cannot (contraindication): angiotensin converting enzyme inhibitor (ACE-I) or ACE-I combination, angiotensin receptor blocker (ARB) or ARB combination, Beta Blocker, or Calcium Channel Blocker, such as benazepril, benazepril-HCTZ, captopril, captopril-HCTZ, enalapril, enalapril-HCTZ, fosinopril, fosinopril-HCTZ, lisinopril, lisinopril-HCTZ, quinapril, ramipril, moexipril, moexipril-HCTZ, perindopril erbumine, quinapril, quinapril-HCTZ, trandolapril, trandolapril/verapamil, losartan, losartan-HCTZ, irbesartan, irbesartan-HCTZ, olmesartan, olmesartan-HCTZ, olmesartan-amlodipine-HCTZ, valsartan, valsartan-HCTZ, diltiazem HCL, diltiazem sustained release (generics only), verapamil, verapamil sustained release (generics only), atenolol, atenolol-chlorthalidone, bisoprolol, bisoprolol-HCTZ, carvedilol, metoprolol tartrate, nadolol, acebutolol, betaxolol, labetalol, metoprolol succinate, metoprolol-HCTZ, pindolol, propranolol, propranolol-HCTZ, sotalol, timolol maleate, or nebivolol.

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MECASERMIN

Generic	Brand			
MECASERMIN	INCRELEX			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **MECASERMIN (Increlex)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Severe primary insulin-like growth factor 1 deficiency (IGF-1: hormone levels that promote normal bone and tissue growth and development are extremely low or undetectable in the blood)
 - 2. Growth hormone gene deletion (not growth hormone-deficient short stature) with neutralizing antibodies to growth hormone
- B. You are 2 years to less than 18 years of age
- C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor) or nephrologist (a type of kidney doctor)
- D. You have a height standard deviation score of less than or equal to -3.0
- E. You have a basal IGF-1 (insulin-like growth factor 1) standard deviation score of less than or equal to -3.0
- F. You have normal or elevated growth hormone (serum growth hormone level of at least 10ngm/mL to at least 2 stimuli [insulin, levodopa, arginine, clonidine or glucagon])
- G. Your bone growth plates (epiphyses) are open (as confirmed by radiograph [a type of imaging] of the wrist and hand)
- H. You will NOT use Increlex concurrently (at the same time) with another growth hormone medication (somatropin [Genotropin, Humatrope, Norditropin, Nutropin AQ, Omnitrope, Saizen, Serostim, Zomacton], Ngenla [somatrogen-ghla], Sogroya [somapacitan-beco], Skytrofa [lonapegsomatropin-tcgd])

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MECASERMIN

RENEWAL CRITERIA

Our guideline named **MECASERMIN (Increlex)** requires the following rule(s) be met for renewal:

- A. You will NOT use Increlex concurrently (at the same time) with another growth hormone medication (somatropin [Genotropin, Humatrope, Norditropin, Nutropin AQ, Omnitrope, Saizen, Serostim, Zomacton], Ngenla [somatrogen-ghla], Sogroya [somapacitan-beco], Skytrofa [lonapegsomatropin-tcgd])
- B. You meet ONE of the following:
 - a. Your annual growth velocity is at least 2 cm compared with what was observed from the previous year
 - b. Your annual growth velocity is at least 1 cm compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MECHLORETHAMINE

Generic	Brand			
MECHLORETHAMINE HCL	VALCHLOR			

GUIDELINES FOR USE

Our guideline named **MECHLORETHAMINE (Valchlor)** requires the following rule(s) be met for approval:

- A. You have stage IA or IB mycosis fungoides-type cutaneous T-cell lymphoma (type of immune system cancer)
- B. You had prior skin-directed therapy such as corticosteroids, carmustine, topical retinoids (Targretin, Tazorac), imiquimod, or local radiation therapy

Effective: 04/10/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MEPOLIZUMAB

Generic	Brand				
MEPOLIZUMAB	NUCALA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **MEPOLIZUMAB (Nucala)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Severe asthma with an eosinophilic phenotype (a type of lung condition with inflammation)
2. Chronic rhinosinusitis with nasal polyps (CRSwNP: inflammation of nasal and sinus passages with small growths in the nose)
3. Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome (a type of immune system disorder with inflammation of blood vessels)
4. Hypereosinophilic syndrome (HES: a type of blood disorder)
5. Chronic obstructive pulmonary disease (COPD: a type of long-term lung condition)

B. If you have severe asthma with an eosinophilic phenotype, approval also requires:

1. You are 6 years of age or older
2. Therapy is prescribed by or in consultation with a physician specializing in pulmonary (relating to lungs/breathing) or allergy medicine
3. You have a blood eosinophil level (a type of lab test) of at least 150 cells/mcL within the past 12 months
4. Nucala will be used in combination with a medium, high-dose, or maximally tolerated dose of an inhaled corticosteroid (such as beclomethasone, mometasone, budesonide) AND at least ONE other maintenance medication (taken on a regular basis), such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as Tudorza [aclidinium], Spiriva [tiotropium], Incruse Ellipta [umeclidinium]), a leukotriene receptor antagonist (such as montelukast, zafirlukast), theophylline, or an oral corticosteroid (such as prednisone)
5. You will NOT use Nucala concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of eosinophilic phenotype asthma

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MEPOLIZUMAB

INITIAL CRITERIA (CONTINUED)

6. You meet ONE of the following:

- a. You have experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid (such as prednisone) burst lasting at least 3 days within the past 12 months
- b. You have experienced at least ONE serious asthma exacerbation requiring a hospitalization or an emergency room visit within the past 12 months
- c. You have poor symptom control despite current therapy as shown by at least THREE of the following within the past 4 weeks:
 - i. Daytime asthma symptoms more than twice per week
 - ii. Any night waking due to asthma
 - iii. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
 - iv. Any activity limitation due to asthma

C. If you have chronic rhinosinusitis with nasal polyps, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with an otolaryngologist (ear, nose, and throat doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
3. There is evidence of nasal polyps (non-cancerous growths) by direct examination, endoscopy (using a small camera), or sinus computed tomography (CT) scan (a type of imaging test)
4. You have inadequately controlled disease
5. You had a 56-day trial of ONE intranasal corticosteroid (such as mometasone nasal spray)
6. Nucala will be used as add-on maintenance treatment (taken on a regular basis)
7. You will NOT use Nucala concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of chronic rhinosinusitis with nasal polyps

D. If you have eosinophilic granulomatosis with polyangiitis, approval also requires:

1. You are 18 years of age or older
2. You will NOT use Nucala concurrently (at the same time) with another systemic biologic (such as Fasenra [benralizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of eosinophilic granulomatosis with polyangiitis

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MEPOLIZUMAB

INITIAL CRITERIA (CONTINUED)

E. If you have hypereosinophilic syndrome, approval also requires:

1. You are 12 years of age or older
2. You have had hypereosinophilic syndrome (HES) for at least 6 months without an identifiable non-hematologic (not present in the blood) secondary cause (HES is not caused by another condition)
3. You will NOT use Nucala concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK inhibitor, PDE-4 inhibitor) for the treatment of hypereosinophilic syndrome

F. If you have chronic obstructive pulmonary disease, approval also requires:

1. You are 18 years of age or older
2. You have an eosinophilic phenotype of chronic obstructive pulmonary disease (COPD: a type of inflammatory long-term lung condition)
3. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor)
4. Nucala will be used in combination with a long-acting muscarinic antagonist (LAMA)/long-acting beta-2-agonist (LABA)/inhaled corticosteroid (ICS) (such as Trelegy Ellipta, Breztri Aerosphere)
5. You will NOT use Nucala concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Daliresp (roflumilast)]) for the treatment of eosinophilic phenotype COPD

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MEPOLIZUMAB

RENEWAL CRITERIA

NOTE: For the diagnosis of hypereosinophilic syndrome (HES), please refer to the Initial Criteria section.

Our guideline named **MEPOLIZUMAB (Nucala)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Severe asthma with an eosinophilic phenotype (a type of lung condition with inflammation)
2. Chronic rhinosinusitis with nasal polyps (CRSwNP: inflammation of nasal and sinus passages with small growths in the nose)
3. Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome (a type of immune system disorder with inflammation of blood vessels)
4. Chronic obstructive pulmonary disease (COPD: a type of long-term lung condition)

B. **If you have severe asthma with an eosinophilic phenotype, renewal also requires:**

1. You will continue to use an inhaled corticosteroid (such as beclomethasone, mometasone, budesonide) AND at least ONE other maintenance medication (taken on a regular basis), such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as Tudorza [aclidinium], Spiriva [tiotropium], Incruse Ellipta [umeclidinium]), a leukotriene receptor antagonist (such as montelukast, zafirlukast), theophylline, or an oral corticosteroid (such as prednisone)
2. You will NOT use Nucala concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of eosinophilic phenotype asthma
3. You have shown a clinical response as evidenced by ONE of the following:
 - a. You have experienced a decrease in asthma exacerbations (worsening of symptoms) from baseline (before starting Nucala)
 - b. You have decreased your use of rescue medications (such as albuterol)
 - c. You have an increase in the percent predicted FEV1 (a type of lung test) from pre-treatment baseline (before starting Nucala)
 - d. You have a decrease in the severity or frequency of asthma-related symptoms (such as wheezing, shortness of breath, coughing)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MEPOLIZUMAB

RENEWAL CRITERIA (CONTINUED)

C. If you have chronic rhinosinusitis with nasal polyps, renewal also requires:

1. You have shown a clinical benefit compared to baseline (before starting Nucala) (such as improvements in nasal congestion, sense of smell, size of polyps)
2. You will NOT use Nucala concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of chronic rhinosinusitis with nasal polyps

D. If you have eosinophilic granulomatosis with polyangiitis, renewal also requires:

1. You have shown a reduction in eosinophilic granulomatosis with polyangiitis (EGPA) symptoms compared to baseline (before starting Nucala), OR you have been able to decrease or eliminate (stop) corticosteroid use
2. You will NOT use Nucala concurrently (at the same time) with another systemic biologic (such as Fasenra [benralizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of EGPA

E. If you have chronic, obstructive pulmonary disease, renewal also requires:

1. You have an eosinophilic phenotype of chronic obstructive pulmonary disease (COPD: a type of inflammatory long-term lung condition)
2. Nucala will be used in combination with a long-acting muscarinic antagonist (LAMA)/long-acting beta-2-agonist (LABA)/inhaled corticosteroid (ICS) (such as Trelegy Ellipta, Breztri Aerosphere)
3. You will NOT use Nucala concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Daliresp (roflumilast)]) for the treatment of eosinophilic phenotype COPD
4. You have shown a clinical response as evidenced by ONE of the following:
 - a. You have a reduction (decrease) in COPD exacerbations (worsening of symptoms) from baseline (before starting Nucala)
 - b. You have a reduction in severity or frequency of COPD-related symptoms (such as wheezing, shortness of breath, coughing, sputum [mucus] production)
 - c. You have had an increase in FEV1 (a type of lung test) by at least 5% from pretreatment baseline

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

METHOTREXATE - JYLAMVO

Generic	Brand				
METHOTREXATE	JYLAMVO				

GUIDELINES FOR USE

Our guideline named **METHOTREXATE - JYLAMVO** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Acute lymphoblastic leukemia (ALL: a type of blood cancer)
 - 2. Mycosis fungoides (cutaneous T-cell lymphoma) (a type of blood cancer affecting the skin)
 - 3. Relapsed or refractory non-Hodgkin lymphoma (a type of blood cancer that has returned or did not respond to treatment)
 - 4. Rheumatoid arthritis (a type of joint condition)
 - 5. Polyarticular juvenile idiopathic arthritis (pJIA: a type of joint condition)
 - 6. Severe psoriasis (a type of skin condition)
- B. **If you have acute lymphoblastic leukemia, approval also requires:**
 - 1. Jylamvo will be used as part of a combination chemotherapy maintenance regimen (a type of therapy to treat cancer)
 - 2. You cannot swallow generic methotrexate tablets
- C. **If you have mycosis fungoides (cutaneous T-cell lymphoma), approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You cannot swallow generic methotrexate tablets
- D. **If you have relapsed or refractory non-Hodgkin lymphoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Jylamvo will be used as part of a metronomic combination chemotherapy regimen (a type of therapy to treat cancer where lower doses are given over a long period to reduce side effects)
 - 3. You cannot swallow generic methotrexate tablets
- E. **If you have rheumatoid arthritis, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You cannot swallow generic methotrexate tablets
- F. **If you have polyarticular juvenile idiopathic arthritis, approval also requires:**
 - 1. You cannot swallow generic methotrexate tablets
- G. **If you have severe psoriasis, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You cannot swallow generic methotrexate tablets

Effective: 11/25/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

METHOXY PEG-EPOETIN BETA

Generic	Brand				
METHOXY PEG-EPOETIN BETA	MIRCERA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **METHOXY PEG-EPOETIN BETA (Mircera)** requires the following rule(s) be met for approval:

- A. You have anemia (low amount of healthy red blood cells) associated with chronic kidney disease
- B. **If you are 18 years of age or older, approval also requires:**
 - 1. You have tried the preferred medication: Retacrit (epoetin alfa-epbx)
 - 2. Your hemoglobin level (type of blood test) is less than 10g/dL
- C. **If you are between 3 months and 17 years of age, approval also requires:**
 - 1. You are changing from another erythropoiesis-stimulating agent (ESA, such as Epogen [epoetin alfa], Aranesp [darbepoetin alfa]) after your hemoglobin level (type of blood test) has been stabilized with the ESA

RENEWAL CRITERIA

Our guideline named **METHOXY PEG-EPOETIN BETA (Mircera)** requires the following rule(s) be met for renewal:

- A. You have anemia (low amount of healthy red blood cells) associated with chronic kidney disease
- B. **If you are 18 years of age or older, renewal also requires ONE of the following:**
 - 1. Your hemoglobin level (type of blood test) is less than 10g/dL if you are not on dialysis (process of removing excess water, toxins from the blood)
 - 2. Your hemoglobin level is less than 11g/dL if you are on dialysis
 - 3. Your hemoglobin level has reached 10g/dL (if you are not on dialysis) and your dose is being or has been reduced/interrupted to decrease the need for blood transfusions
 - 4. Your hemoglobin level has reached 11g/dL (if you are on dialysis) and your dose is being or has been reduced/interrupted to decrease the need for blood transfusions
- C. **If you are between 3 months and 17 years of age, renewal also requires ONE of the following:**
 - 1. Your hemoglobin level (type of blood test) is less than 12g/dL
 - 2. Your hemoglobin level has reached 12g/dL and your dose is being or has been reduced/interrupted to decrease the need for blood transfusions

Effective: 06/01/24

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 6/11/2025

Page 524 of 1007



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

METHYLNALTREXONE

Generic	Brand			
METHYLNALTREXONE BROMIDE	RELISTOR			

GUIDELINES FOR USE

Our guideline named **METHYLNALTREXONE (Relistor)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Opioid-induced constipation (a type of bowel disorder caused by drugs used to treat pain) with chronic (long-term) non-cancer pain
 - 2. Opioid-induced constipation with advanced illness or pain caused by active cancer
- B. **If you have opioid-induced constipation with chronic non-cancer pain, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have chronic non-cancer pain, including chronic pain related to prior cancer or its treatment
 - 3. You do NOT require frequent opioid dosage escalation (increase)
 - 4. You have been taking opioids for at least four weeks
 - 5. You have tried or have a contraindication to (harmful for you to use) the preferred medications: Symproic (naldemedine) AND Movantik (naloxegol)
- C. **If you have opioid-induced constipation with advanced illness or pain caused by active cancer, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Your request is for Relistor injection
 - 3. You require opioid dosage escalation (increase) for palliative care (treatment for comfort from symptoms)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

METHYLTESTOSTERONE

Generic	Brand				
METHYLTESTOSTERONE	TESTRED, ANDROID, METHITEST, METHYLTESTOS- TERONE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **METHYLTESTOSTERONE (Testred, Android, Methitest)** requires the following rule(s) be met for approval:

You have **ONE** of the following:

- Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
- Delayed puberty not due to a pathological disorder (not due to a disease) in a male
- Metastatic breast cancer (cancer that has spread to other parts of the body) in a female
- Gender dysphoria (your gender identity conflicts with your sex assigned at birth)

If you are a male with primary or secondary hypogonadism, approval also requires:

You meet **ONE** of the following:

- You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy
- You meet **ONE** of the following criteria showing you have low testosterone levels:
 - You have at least **TWO** total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
 - You have a free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
- You have tried or have a contraindication to (harmful for you to use) **TWO** preferred medications: intramuscular [injected into the muscle] testosterone cypionate, intramuscular testosterone enanthate

If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

If you are a male with delayed puberty not secondary to a pathological disorder, approval also requires:

- You have tried or have a contraindication to (harmful for you to use) intramuscular (injected into the muscle) testosterone enanthate

(Initial criteria continues on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

METHYLTESTOSTERONE

INITIAL CRITERIA (CONTINUED)

If you are a female with metastatic breast cancer, approval also requires:

You have tried or have a contraindication to (harmful for you to use) intramuscular (injected into the muscle) testosterone enanthate

You meet ONE of the following:

You are postmenopausal (after menopause)

You are premenopausal (before menopause), you have benefited from an oophorectomy (surgical removal of the ovaries), and your tumor is hormone-responsive

If you have gender dysphoria, approval also requires:

Only medications supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for the treatment of gender dysphoria may be approved

RENEWAL CRITERIA

Our guideline named **METHYLTESTOSTERONE (Testred, Android, Methitest)** requires the following rule(s) be met for renewal:

You have ONE of the following:

Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)

Delayed puberty not due to a pathological disorder (not due to a disease) in a male

Metastatic breast cancer (cancer that has spread to other parts of the body) in a female

Gender dysphoria (your gender identity conflicts with your sex assigned at birth)

If you are a male with primary or secondary hypogonadism, renewal also requires:

You have shown improvement in your symptoms compared to baseline (before treatment) and tolerance to treatment

Your serum testosterone level and hematocrit concentration (types of blood tests) have normalized compared to baseline

If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

If you are a male with delayed puberty not secondary to a pathological disorder, renewal also requires:

You have NOT received more than two 6-month courses of testosterone replacement therapy

(Renewal criteria continues on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

METHYLTESTOSTERONE

RENEWAL CRITERIA (CONTINUED)

If you are a female with metastatic breast cancer, renewal also requires ONE of the following:

You are postmenopausal (after menopause)

You are premenopausal (before menopause), you have benefited from an oophorectomy (surgical removal of the ovaries), and your tumor is hormone-responsive

If you have gender dysphoria, renewal also requires:

Only medications supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for the treatment of gender dysphoria may be approved

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

METOCLOPRAMIDE

Generic	Brand				
METOCLOPRAMIDE HCL	GIMOTI				

GUIDELINES FOR USE

Our guideline named **METOCLOPRAMIDE (Gimoti)** requires the following rule(s) be met for approval:

- A. You have acute (short duration) and recurrent (occurring repeatedly) diabetic gastroparesis (a disorder from high blood sugar that causes delayed emptying of food from the stomach)
- B. You are 18 years of age or older
- C. You have tried or have a contraindication to (harmful for you to use) metoclopramide ODT (orally disintegrating tablet)

Effective: 08/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

METRONIDAZOLE

Generic	Brand				
METRONIDAZOLE	LIKMEZ				

GUIDELINES FOR USE

Our guideline named **METRONIDAZOLE (Likmez)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Trichomoniasis (a type of infection caused by a parasite)
 - 2. Acute intestinal amebiasis (amoebic dysentery: a type of infection of the intestines) OR amebic liver abscess (a collection of pus in the liver caused by a parasite)
 - 3. Serious infections caused by susceptible anaerobic bacteria, such as *Bacteroides* species, *Clostridium* species, *Peptococcus* species (infections caused by types of bacteria that can be treated with Likmez)
- B. You have tried or have a contraindication to (harmful for you to use) generic metronidazole tablets
- C. You are unable to swallow metronidazole tablets
- D. **For the treatment of trichomoniasis or serious infections caused by susceptible anaerobic bacteria, approval also requires:**
 - 1. You are 18 years of age or older

Effective: 02/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

METYROSINE

Generic	Brand				
METYROSINE	DEMSEER, METYROSINE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **METYROSINE (Demser)** requires the following rule(s) be met for approval:

- A. You have pheochromocytoma (a type of rare tumor)
- B. You will be using the requested medication for ONE of the following:
 - 1. Preoperative preparation for surgery
 - 2. Management of malignant (cancerous) pheochromocytoma when surgery is contraindicated (harmful for you to have)
 - 3. Chronic (long term) treatment of malignant pheochromocytoma
- C. You have a non-metastatic pheochromocytoma (tumor has not spread to other parts of the body)
- D. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor), an endocrine surgeon (surgeon specializing in removal of glands such as adrenal glands), or a hematologist-oncologist (a type of cancer doctor)
- E. **If you are awaiting surgery, approval also requires:**
 - 1. The requested medication will be in combination with an alpha-adrenergic receptor blocker (such as doxazosin, terazosin, prazosin, phenoxybenzamine)

RENEWAL CRITERIA

NOTE: For the request of pre-operative preparation for surgery, please refer to the Initial Criteria section.

Our guideline named **METYROSINE (Demser)** requires the following rule(s) be met for renewal:

- A. You have pheochromocytoma (a type of rare tumor)
- B. You will be using the requested medication for ONE of the following:
 - 1. Management of malignant (cancerous) pheochromocytoma when surgery is contraindicated (harmful for you to have)
 - 2. Chronic (long term) treatment of malignant pheochromocytoma
- C. You are stable or have shown clinical improvement while on therapy (treatment)

Effective: 05/12/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MIDOSTAURIN

Generic	Brand			
MIDOSTAURIN	RYDAPT			

GUIDELINES FOR USE

Our guideline named **MIDOSTAURIN (Rydapt)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Newly diagnosed acute myeloid leukemia (AML: a type of blood cancer)
 - 2. Aggressive systemic mastocytosis (ASM: a type of blood disorder)
 - 3. Systemic mastocytosis with associated hematological neoplasm (SM-AHN: type of blood cancer)
 - 4. Mast cell leukemia (MCL: type of blood cell cancer)
- B. **If you have newly diagnosed acute myeloid leukemia, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You are FLT3 (type of gene) mutation-positive as detected by a Food and Drug Administration (FDA)-approved diagnostic test
 - 3. The requested medication will be used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation (cancer drugs)
 - 4. The requested medication will not be used by itself to start treatment (single-agent induction therapy)
- C. **If you have aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia, approval also requires:**
 - 1. You are 18 years of age or older

Effective: 04/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MIFEPRISTONE

Generic	Brand			
MIFEPRISTONE	KORLYM			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **MIFEPRISTONE (Korlym)** requires the following rule(s) be met for approval:

- A. You have endogenous Cushing's syndrome (CS: a type of hormone disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
- D. Your diagnosis is confirmed by ONE of the following:
 - 1. 24-hour urine free cortisol (a type of test that measures the amount of cortisol in the urine) (at least 2 or more tests to confirm)
 - 2. Overnight 1mg dexamethasone test (a type of diagnostic test)
 - 3. Late-night salivary cortisol (a type of test that measures the amount of cortisol in the saliva at night) (at least 2 or more tests to confirm)
- E. Your hypercortisolism (high levels of cortisol) is NOT due to chronic glucocorticoids (long-term use of a class of drugs that consists of steroids, such as prednisone)
- F. You also have type 2 diabetes mellitus (a disorder with high blood sugar) OR glucose intolerance (a condition that results in high blood sugar)
- G. You have failed surgical treatment (surgery did not work) for Cushing's syndrome OR you are NOT a candidate for surgery

RENEWAL CRITERIA

Our guideline named **MIFEPRISTONE (Korlym)** requires the following rule(s) be met for renewal:

- A. You have endogenous Cushing's syndrome (CS: a type of hormone disorder)
- B. You continue to have improvement of glucose tolerance or stable glucose tolerance (such as reduced hemoglobin A1C level [a type of lab test], improved fasting glucose)
- C. You continue to tolerate Korlym
- D. You are NOT a candidate for surgery OR have failed surgery (surgery did not work) for Cushing's syndrome

Effective: 02/12/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MIGALASTAT

Generic	Brand			
MIGALASTAT	GALAFOLD			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **MIGALASTAT (Galafold)** requires the following rule(s) be met for approval:

- A. You have Fabry disease (a rare genetic disease)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a nephrologist (a type of kidney doctor), cardiologist (a type of heart doctor), or a doctor specializing in genetics or inherited metabolic disorders
- D. You have an amenable (responsive) galactosidase alpha (GLA) gene variant (abnormal change in a type of gene) based on in vitro assay data (data collected from lab test tubes or cultures) that is interpreted by a clinical genetics professional as the cause of disease (pathogenic or likely pathogenic)
- E. You will NOT use Galafold concurrently (at the same time) with another Fabry disease medication (such as Fabrazyme [agalsidase beta], Elfabrio [pegunigalsidase alfa-iwx])
- F. You are symptomatic OR have evidence of injury from GL-3 (globotriaosylceramide: a type of fat) to the kidney, heart, or central nervous system recognized by laboratory, histological (viewed by microscope), or imaging findings. Evidence of injury may include decreased GFR (glomerular filtration rate: a tool for evaluating kidney function) for age, persistent albuminuria (protein in urine), cerebral white matter lesions on brain MRI (magnetic resonance imaging: type of imaging lab), cardiac fibrosis (abnormal thickening of heart valves) on contrast cardiac MRI
- G. **If you are a female, approval also requires:**
 - 1. You have a galactosidase alpha (GLA) gene mutation (abnormal change in a type of gene) as shown by genetic testing
- H. **If you are a male, approval also requires ONE of the following:**
 - 1. You do NOT have enough alpha galactosidase A (a-Gal-A: a type of protein) as indicated by an enzyme assay (a type of lab test)
 - 2. You have a galactosidase alpha (GLA) gene mutation (abnormal change in a type of gene) as shown by genetic testing

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MIGALASTAT

RENEWAL CRITERIA

Our guideline named **MIGALASTAT (Galafold)** requires the following rule(s) be met for renewal:

- A. You have Fabry disease (a rare genetic disease)
- B. You will NOT use Galafold concurrently (at the same time) with another Fabry disease medication (such as Fabrazyme [agalsidase beta], Elfabrio [pegunigalsidase alfa-iwx])
- C. You have demonstrated improvement, maintenance, or stabilization in ONE of the following while on therapy:
 - 1. Symptoms (such as pain, hypohidrosis [less sweating]/anhidrosis [no sweating], exercise intolerance, gastrointestinal [GI] symptoms, angiokeratomas [dark red-blue raised spots on the skin], abnormal cornea [a part of the eye], tinnitus [ringing in the ears]/hearing loss)
 - 2. Imaging (such as brain/cardiac MRI [magnetic resonance imaging: type of imaging lab], DEXA [a type of bone scan], renal [kidney] ultrasound)
 - 3. Laboratory or histological (viewed by microscope) testing (such as GL-3 [globotriaosylceramide: a type of fat] in plasma/urine, renal biopsy [removal of cells or tissue from the body for examination])

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MIGLUSTAT-OPFOLDA

Generic	Brand				
MIGLUSTAT	OPFOLDA				

GUIDELINES FOR USE

Our guideline named **MIGLUSTAT-OPFOLDA** requires the following rule(s) be met for approval:

- A. You have late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) (a type of genetic disorder)
- B. You are 18 years of age or older
- C. You weigh at least 40 kilograms (88 pounds)
- D. You are NOT improving on your current enzyme replacement therapy (ERT) (such as Lumizyme [alglucosidase alfa])
- E. Opfolda will be used in combination with Pombiliti (cipaglucosidase alfa-atga)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MIGLUSTAT-ZAVESCA

Generic	Brand				
MIGLUSTAT	ZAVESCA, YARGESA, MIGLUSTAT				

GUIDELINES FOR USE

Our guideline named **MIGLUSTAT-ZAVESCA (Yargesa)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Mild to moderate type 1 Gaucher disease (a type of genetic condition)
 - 2. Niemann-Pick disease type C (NPC: a type of genetic condition)
- B. **If you have mild to moderate type 1 Gaucher disease, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. The requested medication will be used as monotherapy (one drug treatment)
 - 3. Enzyme replacement therapy (a type of treatment) is not a therapeutic option for you (due to reasons such as allergy, hypersensitivity [allergic reaction], poor access to veins)
- C. **If you have Niemann-Pick disease type C, approval also requires:**
 - 1. The requested medication will be used in combination with Miplyffa (arimoclomol)

Effective: 10/14/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MILTEFOSINE

Generic	Brand			
MILTEFOSINE	IMPAVIDO			

GUIDELINES FOR USE

Our guideline for **MILTEFOSINE (Impavido)** requires the following rule(s) be met for approval:

- A. You have Leishmaniasis (type of parasite disease) with ONE of the following types of infection:
 - 1. Visceral leishmaniasis (affects your organs) caused by *Leishmania donovani* (type of parasite)
 - 2. Cutaneous leishmaniasis (affects your skin layers) caused by any of the following types of parasites:
 - a. *Leishmania braziliensis*
 - b. *Leishmania guyanensis*
 - c. *Leishmania panamensis*
 - 3. Mucosal leishmaniasis (affects inside mouth, throat and nose) caused by *Leishmania braziliensis*
- B. Species identification must be confirmed via ONE of the following CDC (Center for Disease Control and Prevention) recommended tests:
 - 1. Stained slides (using tissue from biopsy specimens, impression smears or dermal scrapings)
 - 2. Culture medium
 - 3. Polymerase chain reaction (lab method to make copies of genes)
 - 4. Serologic testing (testing your blood and body fluids such as rK39 Rapid Test)

Effective: 11/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MINOCYCLINE

Generic	Brand				
MINOCYCLINE HCL	EMROSI				

GUIDELINES FOR USE

Our guideline named **MINOCYCLINE (Emrosi)** requires the following rule(s) be met for approval:

- A. You have rosacea (a type of skin condition)
- B. You are 18 years of age or older
- C. You have inflammatory lesions (papules and pustules: small bumps on the skin) associated with rosacea
- D. You have tried or have a contraindication to (harmful for you to use) ONE generic oral minocycline or doxycycline

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MINOCYCLINE MICROSPHERES

Generic	Brand			
MINOCYCLINE HCL MICROSPHERES	ARESTIN			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: SEE RENEWAL CRITERIA BELOW)

Our guideline named **MINOCYCLINE MICROSPHERES (Arestin)** requires the following rule(s) be met for approval:

- A. You have a confirmed diagnosis of periodontitis (inflammation and infection of the gums)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with an oral health care professional
- D. You do NOT have a history of minocycline or tetracycline sensitivity or allergy
- E. You do NOT have a history of candidiasis (a type of fungal infection) or active oral candidiasis
- F. Arestin will be administered by an oral health care professional
- G. Arestin will be used as an adjunct (add-on therapy) to scaling and root planing procedures OR used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing
- H. Arestin will NOT be used for an acutely abscessed periodontal pocket (infection with pus-filled pocket)
- I. Arestin will NOT be used in an immunocompromised individual (your immune system is weakened), such as those immunocompromised by any of the following conditions:
 - 1. Uncontrolled diabetes mellitus (a disorder with high blood sugar)
 - 2. Chemotherapy (a type of drug used to treat cancer)
 - 3. Radiation therapy
 - 4. HIV (human immunodeficiency virus) infection
- J. Arestin will NOT be used in the regeneration (reconstruction) of alveolar bone (part of the bone that has tooth sockets), either in preparation for or in conjunction (together) with the placement of endosseous (dental) implants or in the treatment of failing implants

RENEWAL CRITERIA

Our guideline named **MINOCYCLINE MICROSPHERES (Arestin)** requires the following rule(s) be met for renewal:

- A. You have a confirmed diagnosis of periodontitis (inflammation and infection of the gums)
- B. Arestin will be used as an adjunct (add-on therapy) to scaling and root planing procedures OR used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing

Effective: 01/01/25

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 6/11/2025

Page 540 of 1007



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MIRDAMETINIB

Generic	Brand				
MIRDAMETINIB	GOMEKLI				

GUIDELINES FOR USE

Our guideline named **MIRDAMETINIB (Gomekli)** requires the following rule(s) be met for approval:

- A. You have neurofibromatosis type 1 (NF1: a type of skin and nervous system disorder)
- B. You are 2 years of age or older
- C. You have symptomatic plexiform neurofibromas (PN: tumors that grow along the nerves) that cannot be completely resected (cannot be completely removed by surgery)

Effective: 03/10/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MIRIKIZUMAB-MRKZ

Generic	Brand				
MIRIKIZUMAB-MRKZ	OMVOH				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **MIRIKIZUMAB-MRKZ (Omvoh)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
 2. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
- B. **If you have moderate to severe ulcerative colitis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 3. You will NOT use Omvoh concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
 4. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)
- C. **If you have moderate to severe Crohn's disease, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 3. You will NOT use Omvoh concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
 4. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MIRIKIZUMAB-MRKZ

RENEWAL CRITERIA

Our guideline named **MIRIKIZUMAB-MRKZ (Omvo)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
 - 2. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
- B. **If you have moderate to severe ulcerative colitis, renewal also requires:**
 - 1. You will NOT use Omvo concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
 - 2. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)
- C. **If you have moderate to severe Crohn's disease, renewal also requires:**
 - 1. You will NOT use Omvo concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
 - 2. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 05/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MITAPIVAT

Generic	Brand				
MITAPIVAT SULFATE	PYRUKYND				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **MITAPIVAT (Pyrukynd)** requires the following rule(s) be met for approval:

- A. You have hemolytic anemia (a type of blood condition)
- B. You are 18 years of age or older
- C. You have pyruvate kinase (PK: a type of enzyme) deficiency

RENEWAL CRITERIA

Our guideline named **MITAPIVAT (Pyrukynd)** requires the following rule(s) be met for renewal:

- A. You have hemolytic anemia (a type of blood condition)
- B. You have pyruvate kinase (PK: a type of enzyme) deficiency
- C. You have had clinical benefit while on Pyrukynd

Effective: 07/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MOMELOTINIB

Generic	Brand				
MOMELOTINIB DIHYDROCHLORIDE	OJJAARA				

GUIDELINES FOR USE

Our guideline named **MOMELOTINIB (Ojjaara)** requires the following rule(s) be met for approval:

- A. You have intermediate or high-risk myelofibrosis (MF: a type of blood cancer), including primary MF (MF that developed on its own) or secondary MF (MF that developed from another blood disorder, such as post-polycythemia vera [PV: a type of blood cancer] or post-essential thrombocythemia [ET: a type of blood disease])
- B. You are 18 years of age or older
- C. You have anemia (a type of blood condition)

Effective: 12/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MOMETASONE SINUS IMPLANT (NSA)

Generic	Brand			
MOMETASONE FUROATE	SINUVA			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **MOMETASONE IMPLANT (Sinuva)** requires the following rule(s) be met for approval:

- A. You have nasal polyps (small growths inside the nose)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or given in consultation with an otolaryngologist (ear, nose and throat doctor)
- D. You previously had ethmoid sinus surgery (process to remove blockage in your sinuses)
- E. You are a candidate for repeat ethmoid sinus surgery due to refractory moderate to severe symptoms (symptoms return and do not respond to surgery) of nasal obstruction, nasal congestion or nasal polyps in both ethmoid sinuses
- F. You previously had a 90-day trial of ONE intranasal corticosteroid (such as fluticasone, beclomethasone, flunisolide, ciclesonide, mometasone)
- G. You have not received 4 implants (2 per nostril) in your lifetime

RENEWAL CRITERIA

Our guideline named **MOMETASONE IMPLANT (Sinuva)** requires the following rule(s) be met for approval:

- A. You have nasal polyps (small growths inside the nose)
- B. You have ethmoid sinus polyps grade 1 or greater on any side
- C. You do not have extensive ethmoid sinus polyp grade (grade 4 on at least one side) or extensive adhesions/synechiae (scar tissue) (grade 3 or 4)
- D. You have not previously received 4 implants (2 per nostril) in your lifetime

Effective: 10/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MONOMETHYL FUMARATE

Generic	Brand				
MONOMETHYL FUMARATE	BAFIERTAM				

GUIDELINES FOR USE

Our guideline named **MONOMETHYL FUMARATE (Bafiertam)** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: immune system eats away at the protective covering of the nerves), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
 - B. You are 18 years of age or older
 - C. You have previously tried or have a contraindication to (medical reason why you cannot take) dimethyl fumarate AND ONE of the following: Avonex, Betaseron, Copaxone/Glatiramer/Glatopa, Plegridy, Rebif, Aubagio, Vumerity, Kesimpta
- (Please note:** Other multiple sclerosis medications may also require prior authorization)

Effective: 01/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MYCOPHENOLATE

Generic	Brand				
MYCOPHENOLATE MOFETIL	MYHIBBIN				

GUIDELINES FOR USE

Our guideline named **MYCOPHENOLATE (Myhibbin)** requires the following rule(s) be met for approval:

- A. The request is for the prophylaxis (prevention) of an organ rejection
- B. You have a history of an allogeneic (from a donor) kidney, heart or liver transplant
- C. Myhibbin will be used in combination with other immunosuppressants (such as cyclosporine)
- D. You have tried or have a contraindication to (harmful for you to use) generic mycophenolate mofetil tablets
- E. You are unable to swallow mycophenolate mofetil tablets

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NAFARELIN

Generic	Brand				
NAFARELIN ACETATE	SYNAREL				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **NAFARELIN (Synarel)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
 2. Moderate to severe pain from endometriosis (condition affecting the uterus)
 3. Central precocious puberty (CPP: early sexual development in girls and boys)
- B. **If you have moderate to severe pain from endometriosis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with an obstetrician/gynecologist (a type of women's health doctor)
 3. Your diagnosis is confirmed by surgical or direct visualization (such as pelvic ultrasound [type of imaging]) or histopathological (tissue) confirmation (such as laparoscopy [type of surgery] or laparotomy [type of surgery]) in the last 10 years
 4. You have tried or have a contraindication to (harmful for you to use) a nonsteroidal anti-inflammatory drug (NSAID) AND a progestin-containing contraceptive preparation (such as combination hormonal contraceptive preparation, progestin-only contraceptive preparation)
 5. You are NOT using Synarel concurrently (at the same time) with another gonadotropin-releasing hormone (GnRH)-modulating agent (such as Orilissa [elagolix], Myfembree [relugolix-estradiol-norethindrone acetate], Lupron Depot [leuprolide])
 6. You have NOT received more than 6 months of treatment with Synarel per lifetime
- C. **If you are female and have central precocious puberty, approval also requires:**
1. You are 2 years of age or older
 2. Therapy is prescribed by or in consultation with a pediatric endocrinologist (a type of hormone doctor)
 3. You have high levels of follicle-stimulating hormone (FSH) (level greater than 4.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
 4. You are/were younger than 8 years of age when your condition started
 5. You have been evaluated for pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for breast development (stage 2 or above) AND pubic hair growth (stage 2 or above)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NAFARELIN

INITIAL CRITERIA (CONTINUED)

D. If you are male and have central precocious puberty, approval also requires:

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a pediatric endocrinologist (a type of hormone doctor)
3. You have high levels of follicle-stimulating hormone (FSH) (level greater than 5.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
4. You are/were younger than 9 years of age when your condition started
5. You have been evaluated for pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for genital development (stage 2 or above) AND pubic hair growth (stage 2 or above)

RENEWAL CRITERIA

NOTE: For the diagnoses of gender dysphoria or pain from endometriosis, please refer to the Initial Criteria section.

Our guideline named **NAFARELIN (Synarel)** requires the following rule(s) be met for renewal:

- A. You have central precocious puberty (CPP: early sexual development in girls and boys)
- B. Your Tanner scale staging (scale of physical measurements of development based on external sex characteristics) at initial diagnosis of CPP has stabilized or regressed (lowered) during three separate medical visits in the previous year
- C. You have NOT reached the actual age which corresponds to your current pubertal age

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NALTREXONE - BUPROPION

Generic	Brand				
NALTREXONE HCL/ BUPROPION HCL	CONTRACE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **NALTREXONE - BUPROPION (Contrave)** requires the following rule(s) be met for approval:

- A. The request is for weight loss OR weight loss management
- B. You are 18 years of age or older
- C. You have evidence of active enrollment in an exercise and caloric reduction program OR a weight loss/behavioral modification program
- D. You meet ONE of the following:
 - 1. You have a body mass index (BMI: a tool for evaluating body fat) of at least 30 kg/m(2)
 - 2. You have a BMI of at least 27 kg/m(2) AND at least ONE weight-related comorbidity (disease) (such as hypertension [high blood pressure], type 2 diabetes mellitus [a disorder with high blood sugar], or hyperlipidemia [high cholesterol])

RENEWAL CRITERIA

Our guideline named **NALTREXONE - BUPROPION (Contrave)** requires the following rule(s) be met for renewal:

- A. The request is for weight loss OR weight loss management
- B. You have achieved or maintained at least a 5 percent weight loss of baseline body weight after 3 months of treatment at the maintenance dose (two 8/90mg tablets two times a day)

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NATALIZUMAB

Generic	Brand				
NATALIZUMAB	TYSABRI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **NATALIZUMAB (Tysabri)** requires the following rule(s) be met for approval:

You have ONE of the following:

Moderate to severe Crohn's disease (CD: a type of bowel disorder)

A relapsing form of multiple sclerosis (MS: a type of nerve disorder), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms or disease returns and goes away), or active secondary progressive disease (advanced disease)

If you have moderate to severe Crohn's disease, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)

You will NOT use Tysabri concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)

If you have a relapsing form of multiple sclerosis, approval also requires:

You are 18 years of age or older

Tysabri will be used as monotherapy (one drug treatment)

You will NOT use Tysabri concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of a relapsing form of multiple sclerosis

You have tried TWO medications indicated for the treatment of multiple sclerosis (such as Avonex [interferon beta-1a], Copaxone/Glatiramer/Glatopa, Gilenya [fingolimod hcl])

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NATALIZUMAB

RENEWAL CRITERIA

Our guideline named **NATALIZUMAB (Tysabri)** requires the following rule(s) be met for renewal:

You have ONE of the following:

Moderate to severe Crohn's disease (CD: a type of bowel disorder)

A relapsing form of multiple sclerosis (MS: a type of nerve disorder), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms or disease returns and goes away), or active secondary progressive disease (advanced disease)

If you have moderate to severe Crohn's disease, renewal also requires ONE of the following:

If you have received at least 12 months of Tysabri therapy, renewal also requires:

You have NOT received more than 3 months of corticosteroids within the past 12 months to control your Crohn's disease while on Tysabri

You will NOT use Tysabri concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)

If you have only received 6 months of Tysabri therapy, renewal also requires:

You are NOT currently on corticosteroid therapy (you have slowly lowered the dose and stopped taking corticosteroids during the first 6 months of Tysabri therapy)

You will NOT use Tysabri concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NATALIZUMAB

RENEWAL CRITERIA (CONTINUED)

If you have a relapsing form of multiple sclerosis, renewal also requires:

You will NOT use Tysabri concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of a relapsing form of multiple sclerosis

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 05/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NEDOSIRAN

Generic	Brand				
NEDOSIRAN SODIUM	RIVFLOZA				

GUIDELINES FOR USE

Our guideline named **NEDOSIRAN (Rivfloza)** requires the following rule(s) be met for approval:
You have primary hyperoxaluria type 1 (PH1: a type of rare genetic disorder)
You are 9 years of age and older
You have relatively preserved kidney function (such as an estimated glomerular filtration rate [eGFR: a tool for evaluating kidney function] of at least 30mL/min/1.73m(2))

Effective: 02/12/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NEMOLIZUMAB-ILTO

Generic	Brand				
NEMOLIZUMAB-ILTO	NEMLUVIO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **NEMOLIZUMAB-ILTO (Nemluvio)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Prurigo nodularis (PN: a type of skin condition)
 - 2. Moderate to severe atopic dermatitis (AD: a type of skin condition)
- B. **If you have prurigo nodularis, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), immunologist (a type of immune system doctor), or allergist (a type of allergy doctor)
 - 3. You have multiple pruriginous lesions (wounds)
 - 4. You have tried or have a contraindication to (harmful for you to use) ONE of the following: topical capsaicin, topical ketamine/amitriptyline/lidocaine, gabapentinoids (such as gabapentin, pregabalin), antidepressants (serotonin-norepinephrine reuptake inhibitor [SNRI], selective serotonin reuptake inhibitor [SSRI], tricyclic antidepressant [TCA]), k-/mu-opioid receptor antagonists (such as naltrexone, bupropion), thalidomide, topical corticosteroids (such as hydrocortisone), topical calcineurin inhibitors (such as Elidel [pimecrolimus]), topical calcipotriol, intralesional corticosteroids, phototherapy (light therapy), methotrexate, cyclosporine, azathioprine
 - 5. You have tried or have a contraindication to the preferred medication: Dupixent (dupilumab)
 - 6. You will NOT use Nemluvio concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of prurigo nodularis

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NEMOLIZUMAB-ILTO

INITIAL CRITERIA (CONTINUED)

C. If you have moderate to severe atopic dermatitis, approval also requires:

1. You are 12 years of age or older
2. You will use Nemluvio in combination with a topical corticosteroid (such as triamcinolone, clobetasol) and/or calcineurin inhibitor (such as tacrolimus, pimecrolimus)
3. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
4. You have atopic dermatitis covering at least 10% of body surface area (BSA), OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas (areas between skin folds)
5. You have TWO of the following: intractable pruritus (severe itching), cracking/oozing/bleeding of the affected skin, impaired activities of daily living
6. You have tried or have a contraindication to (harmful for you to use) THREE preferred medications: Dupixent (dupilumab), Rinvoq (upadacitinib), Adbry (tralokinumab-ldrm)
7. You will NOT use Nemluvio concurrently (at the same time) with other systemic biologics (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK inhibitor [such as Rinvoq (upadacitinib)], PDE-4 inhibitor [such as Eucrisa (crisaborole)]) for the treatment of AD

[NOTE: Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

RENEWAL CRITERIA

Our guideline named **NEMOLIZUMAB-ILTO (Nemluvio)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Prurigo nodularis (PN: a type of skin condition)
2. Moderate to severe atopic dermatitis (AD: a type of skin condition)

B. If you have prurigo nodularis, renewal also requires:

1. You have had prurigo nodularis improvement or reduction of pruritus (itching) or pruriginous lesions (wounds)
2. You will NOT use Nemluvio concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of prurigo nodularis

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NEMOLIZUMAB-ILTO

RENEWAL CRITERIA (CONTINUED)

- C. If you have moderate to severe atopic dermatitis, renewal also requires:**
1. You have shown improvement while on Nemludio
 2. You have tried or have a contraindication to (harmful for you to use) THREE preferred medications: Dupixent (dupilumab), Rinvoq (upadacitinib), Adbry (tralokinumab-ldrm)
 3. You will NOT use Nemludio concurrently (at the same time) with other systemic biologics (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK inhibitor [such as Rinvoq (upadacitinib)], PDE-4 inhibitor [such as Eucrisa (crisaborole)]) for the treatment of atopic dermatitis
- [NOTE:** Pharmaceutical samples acquired from the prescriber or manufacturer assistance program do not qualify]

Effective: 01/17/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NERATINIB

Generic	Brand			
NERATINIB MALEATE	NERLYNX			

GUIDELINES FOR USE

Our guideline named **NERATINIB (Nerlynx)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Early stage (stage I-III) breast cancer
 - 2. Advanced or metastatic breast cancer
- B. **If you have early stage (stage I-III) breast cancer, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have a HER2-overexpressed/amplified (HER2-positive) tumor
 - 3. The requested medication will be used as a single agent for extended adjuvant therapy following Herceptin- (trastuzumab-) based therapy
 - 4. The medication is being requested within 2 years of completing the last trastuzumab dose
- C. **If you have advanced or metastatic breast cancer, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have a HER2-overexpressed/amplified (HER2-positive) tumor
 - 3. The requested medication will be used in combination with capecitabine
 - 4. You have received two or more prior anti-HER2 based regimens in the metastatic setting

Effective: 04/10/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NILOTINIB

Generic	Brand				
NILOTINIB HCL	TASIGNA, NILOTINIB HCL				
NILOTINIB TARTRATE	DANZITEN				

GUIDELINES FOR USE

Our guideline named **NILOTINIB (Tasigna, Danziten)** requires the following rule(s) be met for approval:

- A. You have Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML: a type of blood cell cancer)
- B. **If your cancer is newly diagnosed, approval also requires:**
 1. You are 1 year of age or older
 2. Your cancer is in chronic phase
- C. **If your cancer has been previously treated, approval also requires:**
 1. Your cancer is in chronic phase or accelerated phase
 2. You meet ONE of the following:
 - a. You are 1 to 17 years of age AND you are resistant (not responding to treatment) or intolerant (side effect) to prior treatment with other tyrosine kinase inhibitors (TKIs, such as Gleevec [imatinib], Sprycel [dasatinib], Bosulif [bosutinib])
 - b. You are 18 years of age or older AND you are resistant or intolerant to prior treatment that included Gleevec (imatinib)
 3. You had a mutational analysis (a type of lab test) prior to the start of treatment AND the requested medication is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1: a type of abnormal gene) profile

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NIMODIPINE SOLUTION

Generic	Brand			
NIMODIPINE	NYMALIZE, NIMODIPINE			

GUIDELINES FOR USE

Our guideline named **NIMODIPINE SOLUTION (Nymalize)** requires the following rule(s) be met for approval:

- A. You have a history of a subarachnoid hemorrhage (SAH: bleeding in the space surrounding your brain)
- B. You are 18 years of age or older
- C. Your SAH is from a ruptured intracranial berry aneurysm (part of blood vessel in your brain has expanded and burst) within the past 21 days
- D. You are unable to swallow nimodipine oral capsules

Effective: 10/14/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NINTEDANIB

Generic	Brand			
NINTEDANIB	OFEV			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **NINTEDANIB (Ofev)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Idiopathic pulmonary fibrosis (IPF: scarring of the lungs with an unknown cause)
 2. Systemic sclerosis-associated interstitial lung disease (SSc-ILD: disorder that causes hardening of lung tissue)
 3. Chronic fibrosing interstitial lung disease (ILDs) with a progressive phenotype (PF-ILD: scarring of the lungs caused by different underlying diseases or conditions that worsens over time)
- B. **If you have idiopathic pulmonary fibrosis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor)
 3. You have a usual interstitial pneumonia pattern as evidenced by high-resolution computed tomography (HRCT: type of imaging test) alone or via a combination of surgical lung biopsy and HRCT
 4. You do NOT have other known causes of interstitial lung disease, such as connective tissue disease, drug toxicity, asbestos or beryllium exposure, hypersensitivity pneumonitis (lung inflammation from inhaled substances), systemic sclerosis (an immune system disorder), rheumatoid arthritis (joint pain and inflammation), radiation, sarcoidosis (growth of inflammatory cells in the body), bronchiolitis obliterans organizing pneumonia (type of lung infection), human immunodeficiency virus infection, viral hepatitis (type of liver inflammation), or cancer
 5. You have a predicted forced vital capacity (FVC: amount of air that can be forcefully exhaled) of at least 50 percent at baseline

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NINTEDANIB

INITIAL CRITERIA (CONTINUED)

C. If you have systemic sclerosis-associated interstitial lung disease, approval also requires:

1. You have systemic sclerosis (SSc) according to the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)
2. You are 18 years of age or older
3. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or rheumatologist (a type of immune system doctor)
4. You have at least 10 percent fibrosis (tissue scarring) on a chest high resolution computed tomography (HRCT: type of imaging testing)
5. You have a baseline forced vital capacity (FVC: amount of air that can be forcefully exhaled) of at least 40 percent of predicted value
6. Other causes of interstitial lung disease have been ruled out. Other causes may include heart failure/fluid overload, drug-induced lung toxicity [cyclophosphamide, methotrexate, ACE-inhibitors (class of blood pressure medications)], recurrent aspiration (inhaling) such as from GERD (acid reflux), pulmonary vascular disease (affecting blood vessels in lungs), pulmonary edema (excess fluid in the lungs), pneumonia (type of lung infection), chronic pulmonary thromboembolism (blood clot in lungs), alveolar hemorrhage (bleeding of a part of the lungs) or interstitial lung disease caused by another rheumatic (inflammatory) disease, such as mixed connective tissue disease (MCTD)

D. If you have chronic fibrosing interstitial lung disease with progressive phenotype, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or rheumatologist (a type of immune system doctor)
3. Your lung function and respiratory (breathing) symptoms OR chest imaging have worsened/progressed despite treatment with medications used in clinical practice for interstitial lung disease (not caused by comorbidities such as infection, heart failure)
4. You have at least 10 percent fibrosis (tissue scarring) on a chest high resolution computed tomography (HRCT: type of imaging testing)
5. You have a baseline forced vital capacity (FVC: amount of air that can be forcefully exhaled) of at least 45 percent of predicted value

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NINTEDANIB

RENEWAL CRITERIA

Our guideline named **NINTEDANIB (Ofev)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
 - 1. Idiopathic pulmonary fibrosis (IPF: scarring of the lungs with an unknown cause)
 - 2. Systemic sclerosis-associated interstitial lung disease (SSc-ILD: disorder that causes hardening of lung tissue)
 - 3. Chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (PF-ILD: scarring of the lungs caused by different underlying diseases or conditions that worsens over time)
- B. You have experienced a clinically meaningful improvement or maintenance in annual rate of decline

Effective: 08/28/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NIPOCALIMAB-AAHU

Generic	Brand				
NIPOCALIMAB-AAHU	IMAAVY				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **NIPOCALIMAB-AAHU (Imaavy)** requires the following rule(s) be met for approval:

- A. You have generalized myasthenia gravis (gMG: a chronic autoimmune disorder)
- B. You are 12 years of age or older
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
- D. Your diagnosis is confirmed by a positive serologic test (a type of blood test) for anti-acetylcholine receptor antibody (AChR-Ab+: an indicator of myasthenia gravis) OR anti-muscle-specific tyrosine kinase antibody (MuSK-Ab+: an indicator of myasthenia gravis)
- E. You have Myasthenia Gravis Foundation of America class II, III, or IV (types of severity of disease)
- F. You have tried or have a contraindication to (harmful for you to use) ONE corticosteroid (such as prednisone)
- G. You will NOT use Imaavy concurrently (at the same time) with another neonatal Fc receptor blocker (such as Vyvgart [efgartigimod alfa-fcab], Rystiggo [rozanolixizumab-noli]) or complement inhibitor (such as Soliris [eculizumab], Zilbrysq [zilucoplan]) for the treatment of generalized myasthenia gravis
- H. You meet ONE of the following:
 1. You have tried or have a contraindication to (harmful for you to use) TWO non-steroidal immunosuppressive therapies (such as azathioprine, cyclophosphamide, methotrexate)
 2. You have tried or have a contraindication to (harmful for you to use) ONE non-steroidal immunosuppressive therapy if you are on chronic plasmapheresis or plasma exchange (types of blood therapy)
- I. If you are 18 years of age or older, approval also requires:
 1. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Rystiggo (rozanolixizumab-noli), Vyvgart (efgartigimod alfa-fcab)/Vyvgart Hytrulo (efgartigimod-hyaluronidase-qvfc)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NIPOCALIMAB-AAHU

RENEWAL CRITERIA

Our guideline named **NIPOCALIMAB-AAHU (Imaavy)** requires the following rule(s) be met for renewal:

- A. You have generalized myasthenia gravis (gMG: a chronic autoimmune disorder)
- B. You have shown a clinical benefit compared to baseline according to validated gMG instruments (such as Myasthenia Gravis Activities of Daily Living tool, Quantitative Myasthenia Gravis tool)
- C. You will NOT use Imaavy concurrently (at the same time) with another neonatal Fc receptor blocker (such as Vyvgart [efgartigimod alfa-fcab], Rystiggo [rozanolixizumab-noli]) or complement inhibitor (such as Soliris [eculizumab], Zilbrysq [zilucoplan]) for the treatment of generalized myasthenia gravis

Effective: 05/12/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NIRAPARIB

Generic	Brand			
NIRAPARIB TOSYLATE	ZEJULA			

GUIDELINES FOR USE

Our guideline named **NIRAPARIB (Zejula)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Advanced epithelial ovarian (cancer that forms on the surface of the ovary), fallopian tube, or primary peritoneal cancer (type of abdominal cancer)
 2. Recurrent (returning) epithelial ovarian (cancer that forms on the surface of the ovary), fallopian tube, or primary peritoneal cancer (type of abdominal cancer)
- B. **If you have advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:**
1. You are 18 years of age or older
 2. You are in complete or partial response to first-line platinum based-chemotherapy (such as cisplatin, carboplatin)
 3. The requested medication will be used for maintenance treatment (*treatment* to prevent cancer from coming back after it has disappeared after initial *therapy*)
- C. **If you have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:**
1. You are 18 years of age or older
 2. You are in complete or partial response to platinum-based chemotherapy (such as cisplatin, carboplatin)
 3. The requested medication will be used for maintenance treatment (*treatment* to prevent cancer from coming back after it has disappeared after initial *therapy*)
 4. Your cancer has deleterious or suspected deleterious germline *BRCA*-mutation (*gBRCAmut*: a type of gene mutation [abnormal change]) based on a Food and Drug Administration (FDA)-approved companion diagnostic for Zejula
 5. The requested medication will be used as monotherapy (used by itself for treatment)
 6. The requested medication is started no later than 8 weeks after your most recent platinum-containing regimen (such as cisplatin, carboplatin)
 7. You have completed at least two lines of platinum-based chemotherapy (such as cisplatin, carboplatin)

Effective: 10/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NIRAPARIB-ABIRATERONE

Generic	Brand				
NIRAPARIB-ABIRATERONE	AKEEGA				

GUIDELINES FOR USE

Our guideline named **NIRAPARIB-ABIRATERONE (Akeega)** requires the following rule(s) be met for approval:

- A. You have metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and no longer responds to testosterone lowering treatment)
- B. Your cancer has a deleterious (harmful) or suspected deleterious BRCA mutation (BRCAm: abnormal change in gene) based on a Food and Drug Administration (FDA)-approved test for Akeega
- C. Akeega will be used in combination with an oral corticosteroid (such as prednisone, prednisolone, methylprednisolone)
- D. You meet ONE of the following:
 - 1. You had a bilateral orchiectomy (both testicles have been surgically removed)
 - 2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
 - 3. Akeega will be used together with a gonadotropin-releasing hormone (GnRH) analog (such as Lupron Depot [leuprolide], Zoladex [goserelin], Firmagon [degarelix])

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NIROGACESTAT

Generic	Brand				
NIROGACESTAT HYDROBROMIDE	OGSIVEO				

GUIDELINES FOR USE

Our guideline named **NIROGACESTAT (Ogsiveo)** requires the following rule(s) be met for approval:

- A. You have progressing desmoid tumors (noncancerous growths in the connective tissue)
- B. You are 18 years of age or older
- C. You require systemic treatment (therapy that targets the entire body)

Effective: 05/06/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NITISINONE

Generic	Brand			
NITISINONE	ORFADIN, NITYR, NITISINONE			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **NITISINONE (Orfadin, Nityr)** requires the following rule(s) be met for approval:

- A. You have hereditary tyrosinemia type 1 (HT-1: a type of genetic disorder where you cannot breakdown an important component in proteins)
- B. Your diagnosis is confirmed by elevated urinary or plasma succinylacetone levels (a chemical that is present in hereditary tyrosinemia) OR a mutation in the fumarylacetoacetate hydrolase gene
- C. Therapy is prescribed by or in consultation with a prescriber specializing in inherited metabolic diseases
- D. You have been counseled on maintaining dietary restriction of tyrosine and phenylalanine
- E. **If you are requesting Nityr tablets; brand Orfadin 2mg, 5mg, 10 mg, 20 mg capsules; or Orfadin oral suspension, approval also requires:**
 - 1. You have tried or have a contraindication (harmful for) to generic nitisinone capsules

RENEWAL CRITERIA

Our guideline named **NITISINONE (Orfadin, Nityr)** requires the following rule(s) be met for renewal:

- A. You have hereditary tyrosinemia type 1 (HT-1: a type of genetic disorder where you cannot breakdown an important component in proteins)
- B. Your urinary or plasma succinylacetone levels (a chemical that is present in hereditary tyrosinemia) have decreased from baseline while on treatment with nitisinone

Effective: 04/17/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NITROFURANTOIN SUSPENSION

Generic	Brand				
NITROFURANTOIN	FURADANTIN, NITROFURANTOIN				

GUIDELINES FOR USE

Our guideline named **NITROFURANTOIN (Furadantin)** requires the following rule(s) be met for approval:

- A. You have a urinary tract infection (UTI: a type of infection)
- B. Your infection is caused by susceptible (can be treated with the drug) strains of *Escherichia coli*, *enterococci*, *Staphylococcus aureus*, *Klebsiella* or *Enterobacter* species (types of bacteria)
- C. You have tried or have a contraindication to (harmful for you to use) nitrofurantoin capsules
- D. You are not able to swallow nitrofurantoin capsules

Effective: 08/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NIVOLUMAB

Generic	Brand				
NIVOLUMAB	OPDIVO				

GUIDELINES FOR USE

Our guideline named **NIVOLUMAB (Opdivo)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Unresectable or metastatic melanoma (type of skin cancer that cannot be removed by surgery or has spread to other parts of the body)
2. Stage IIB, IIC, III, or IV melanoma (a type of skin cancer)
3. Resectable (node positive or tumor is 4 cm or greater) non-small cell lung cancer (NSCLC) (a type of lung cancer that can be removed by surgery)
4. Metastatic non-small cell lung cancer (NSCLC) (a type of lung cancer that has spread to other parts of the body)
5. Recurrent non-small cell lung cancer (NSCLC) (a type of lung cancer that has returned)
6. Unresectable malignant pleural mesothelioma (a tumor of the tissue lining the lungs and chest wall that cannot be removed by surgery)
7. Advanced renal cell carcinoma (RCC: type of kidney cancer)
8. Classical Hodgkin lymphoma (cHL: a type of blood cancer)
9. Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN: type of head/neck cancer that has returned or spread to other parts of the body)
10. Urothelial carcinoma (UC: urinary system cancer)
11. Unresectable or metastatic urothelial carcinoma (urinary system cancer that cannot be removed by surgery or has spread to other parts of the body)
12. Locally advanced or metastatic urothelial carcinoma (urinary system cancer that has spread to nearby tissue or lymph nodes or that has spread to other parts of the body)
13. Colorectal cancer (a type of digestive cancer)
14. Unresectable or metastatic hepatocellular carcinoma (HCC: a type of liver cancer that cannot be removed by surgery or has spread to other parts of the body)
15. Completely resected esophageal or gastroesophageal junction cancer (types of digestive system cancer that has been removed by surgery)
16. Unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC: type of digestive system cancer that cannot be removed by surgery, and has returned or has spread to other parts of the body)
17. Unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC: type of digestive system cancer that cannot be removed by surgery and has spread to other parts of the body)
18. Advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (types of digestive system cancer that has spread to other parts of the body)

(Criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NIVOLUMAB

GUIDELINES FOR USE (CONTINUED)

- B. If you have unresectable or metastatic melanoma, approval also requires:**
1. You are 12 years of age or older
 2. Opdivo will be used alone OR in combination with Yervoy (ipilimumab)
 3. Opdivo will NOT be used concurrently (at the same time) with a targeted therapy (BRAF inhibitors [such as Braftovi (encorafenib), Tafinlar (dabrafenib)], MEK inhibitors [such as Mekinist (trametinib)], and NTRK inhibitors [such as Vitrekvi (larotrectinib), Rozlytrek (entrectinib)])
- C. If you have stage IIB, IIC, III, or IV melanoma, approval also requires:**
1. You are 12 years of age or older
 2. You have undergone complete resection (completely removed by surgery)
 3. Opdivo will be used as an adjuvant (add-on) treatment
- D. If you have resectable (node positive or tumor is 4 cm or greater) non-small cell lung cancer, approval also requires:**
1. You are 18 years of age or older
 2. You meet ONE of the following:
 - a. Opdivo will be used in combination with platinum-doublet chemotherapy (a type of cancer treatment, such as carboplatin/paclitaxel, cisplatin/pemetrexed, cisplatin/gemcitabine) as neoadjuvant treatment (given before main treatment) only
 - b. Your cancer has NO known epidermal growth factor receptor (EGFR: a type of protein) mutations (abnormal change in a type of gene) or anaplastic lymphoma kinase (ALK: a type of enzyme) rearrangements (type of gene mutation); AND Opdivo will be used in combination with platinum-doublet chemotherapy (such as carboplatin/paclitaxel, cisplatin/pemetrexed, carboplatin/pemetrexed, cisplatin/docetaxel) as neoadjuvant treatment (given before main treatment), OR as a single medication as adjuvant (add-on) treatment after surgery and prior use with platinum-doublet chemotherapy as neoadjuvant treatment

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NIVOLUMAB

GUIDELINES FOR USE (CONTINUED)

E. If you have metastatic non-small cell lung cancer, approval also requires:

1. You are 18 years of age or older
2. You meet ONE of the following:
 - a. Your tumors have programmed death-ligand 1 (PD-L1: a type of protein [of at least 1 percent]) as determined by a Food and Drug Administration (FDA)-approved test; your tumor does NOT have epidermal growth factor receptor (EGFR: a type of protein) or anaplastic lymphoma kinase (ALK: a type of enzyme) genomic tumor aberrations (types of abnormal gene); AND Opdivo will be used in combination with Yervoy (ipilimumab)
 - b. Your tumor does NOT have epidermal growth factor receptor (EGFR: a type of protein) or anaplastic lymphoma kinase (ALK: a type of enzyme) genomic tumor aberrations (types of abnormal gene) AND Opdivo will be used in combination with Yervoy (ipilimumab) and 2 cycles of platinum-doublet chemotherapy (a type of cancer treatment, such as carboplatin/pemetrexed, cisplatin/pemetrexed, carboplatin/paclitaxel)
 - c. Your disease has worsened while on or after platinum-based chemotherapy (a type of cancer treatment, such as cisplatin, carboplatin, oxaliplatin), and you meet ONE of the following:
 - i. Your tumor does NOT have epidermal growth factor receptor (EGFR: type of protein) or anaplastic lymphoma kinase (ALK: type of enzyme) genomic tumor aberrations (types of abnormal gene)
 - ii. Your tumor has an ALK mutation, and your disease has worsened after treatment with an FDA-approved ALK-directed therapy (such as Xalkori [crizotinib], Zykadia [ceritinib])
 - iii. Your tumor has an EGFR mutation, and your disease has worsened after treatment with an FDA-approved EGFR-directed therapy (such as Tarceva [erlotinib], Iressa [gefitinib], Gilotrif [afatinib])

F. If you have recurrent non-small cell lung cancer, approval also requires:

1. You are 18 years of age or older
2. Your tumor does NOT have epidermal growth factor receptor (EGFR: a type of protein) or anaplastic lymphoma kinase (ALK: a type of enzyme) genomic tumor aberrations (types of abnormal gene)
3. Opdivo will be used in combination with Yervoy (ipilimumab) AND 2 cycles of platinum-doublet chemotherapy (a type of cancer treatment, such as carboplatin/pemetrexed, cisplatin/pemetrexed, carboplatin/paclitaxel)

G. If you have unresectable malignant pleural mesothelioma, approval also requires:

1. You are 18 years of age or older
2. Opdivo will be used in combination with Yervoy (ipilimumab)

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NIVOLUMAB

GUIDELINES FOR USE (CONTINUED)

H. If you have advanced renal cell carcinoma, approval also requires:

1. You are 18 years of age or older
2. You meet ONE of the following:
 - a. You have intermediate or poor risk disease AND Opdivo will be used in combination with Yervoy (ipilimumab)
 - b. Opdivo will be used in combination with Cabometyx (cabozantinib)
 - c. You have received prior anti-angiogenic therapy (medication that stops tumors from growing their own blood vessels such as Sutent [sunitinib], Votrient [pazopanib], Cabometyx [cabozantinib])

I. If you have classical Hodgkin lymphoma, approval also requires:

1. You are 18 years of age or older
2. Your disease has relapsed (returned) or worsened after receiving ONE of the following:
 - a. Autologous hematopoietic stem cell transplantation (HSCT: a type of procedure to replace damaged bone marrow with your own healthy blood-forming cells) and Adcetris (brentuximab vedotin)
 - b. Three or more lines of systemic therapy (treatment that targets the entire body) that includes autologous hematopoietic stem cell transplantation (HSCT)

J. If you have recurrent or metastatic squamous cell carcinoma of the head and neck, approval also requires:

1. You are 18 years of age or older
2. Your disease has worsened on or after treatment with a platinum-containing chemotherapy (a type of cancer treatment, such as cisplatin, carboplatin, oxaliplatin)

K. If you have urothelial carcinoma, approval also requires:

1. You are 18 years of age or older
2. Opdivo will be used as an adjuvant (add-on) treatment
3. You are at high risk of recurrence (disease returning) after undergoing radical resection (tumor removal) of urothelial carcinoma

L. If you have unresectable or metastatic urothelial carcinoma, approval also requires:

1. You are 18 years of age or older
2. You will be using Opdivo in combination with cisplatin and gemcitabine

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NIVOLUMAB

GUIDELINES FOR USE (CONTINUED)

- M. If you have locally advanced or metastatic urothelial carcinoma, approval also requires:**
1. You are 18 years of age or older
 2. You meet ONE of the following:
 - a. Your disease has worsened during or after platinum-containing chemotherapy (a type of cancer treatment, such as cisplatin, carboplatin, oxaliplatin)
 - b. Your disease has worsened within 12 months of neoadjuvant (given before main treatment) or adjuvant (add-on) treatment with platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin)
- N. If you have colorectal cancer, approval also requires:**
1. You are 12 years of age or older
 2. Your cancer is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) (types of genetic abnormalities)
 3. You meet ONE of the following:
 - a. Your cancer is unresectable (cannot be removed by surgery); AND Opdivo will be used in combination with Yervoy (ipilimumab)
 - b. Your cancer is metastatic (has spread to other parts of the body), and you meet ONE of the following:
 - i. Opdivo will be used in combination with Yervoy (ipilimumab)
 - ii. Opdivo will be used as a single medication; AND your disease has worsened after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan
- O. If you have unresectable or metastatic hepatocellular carcinoma, approval also requires ONE of the following:**
1. You will be using Opdivo in combination with Yervoy (ipilimumab) as first-line treatment
 2. You will be using Opdivo in combination with Yervoy (ipilimumab), AND you have been previously treated with Nexavar (sorafenib)
- P. If you have completely resected esophageal or gastroesophageal junction cancer, approval also requires:**
1. You are 18 years of age or older
 2. Opdivo will be used as an adjuvant (add-on) treatment
 3. You have a residual pathologic disease (disease is still present) and have received neoadjuvant chemoradiotherapy (CRT) (a type of cancer treatment given before surgery)
- (Criteria continued on next page)**

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NIVOLUMAB

GUIDELINES FOR USE (CONTINUED)

- Q. If you have unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have previously received treatment with fluoropyrimidine- and platinum-based chemotherapy (a type of cancer treatment, such as cisplatin, carboplatin, oxaliplatin)
- R. If you have unresectable advanced or metastatic esophageal squamous cell carcinoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You meet ONE of the following:
 - a. You will be using Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy (a type of cancer treatment, such as cisplatin, carboplatin, oxaliplatin)
 - b. You will be using Opdivo in combination with Yervoy (ipilimumab)
- S. If you have advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You will be using Opdivo in combination with fluoropyrimidine and platinum-containing chemotherapy (a type of cancer treatment, such as cisplatin, carboplatin, oxaliplatin)

Effective: 05/12/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NIVOLUMAB-HYALURONIDASE-NVHY

Generic	Brand				
NIVOLUMAB-HYALURONIDASE-NVHY	OPDIVO QVANTIG				

GUIDELINES FOR USE

Our guideline named **NIVOLUMAB-HYALURONIDASE-NVHY (Opdivo Qvantig)** requires the following rule(s) be met for approval:

T. You have ONE of the following:

19. Advanced renal cell carcinoma (RCC) (a type of kidney cancer)
20. Melanoma (a type of skin cancer)
21. Non-small cell lung cancer (NSCLC) (a type of lung cancer)
22. Metastatic non-small cell lung cancer (NSCLC) (a type of lung cancer that has spread to other parts of the body)
23. Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) (a type of head/neck cancer that has returned or has spread to other parts of the body)
24. Urothelial carcinoma (UC: urinary system cancer)
25. Metastatic colorectal cancer (CRC) (a type of digestive cancer that has spread to other parts of the body)
26. Hepatocellular carcinoma (HCC: a type of liver cancer)
27. Esophageal or gastroesophageal junction cancer (types of digestive system cancer)
28. Esophageal squamous cell carcinoma (ESCC) (a type of digestive system cancer)
29. Advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (types of digestive system cancer that has spread to other parts of the body)

U. If you have advanced renal cell carcinoma, approval also requires:

3. You are 18 years of age or older
4. You meet ONE of the following:
 - d. You have intermediate or poor risk disease, and Opdivo Qvantig will be used following treatment with intravenous (injection into the vein) Opdivo (nivolumab) and Yervoy (ipilimumab) combination therapy
 - e. Opdivo Qvantig will be used in combination with Cabometyx (cabozantinib)
 - f. You have received prior anti-angiogenic therapy (a type of medication that stops tumors from growing new blood vessels, such as Sutent [sunitinib], Votrient [pazopanib])

(Criteria continued on the next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NIVOLUMAB-HYALURONIDASE-NVHY

GUIDELINES FOR USE (CONTINUED)

V. If you have melanoma, approval also requires:

4. You are 18 years of age or older
5. You meet ONE of the following:
 - a. Your cancer is unresectable (cannot be removed by surgery) or metastatic (has spread to other parts of the body)
 - b. Your cancer is stage IIB, IIC, III, or IV; you have undergone complete resection (removal by surgery); and Opdivo Qvantig will be used as an adjuvant (add-on) treatment

W. If you have non-small cell lung cancer, approval also requires:

3. You are 18 years of age or older
4. Your cancer is resectable (node positive or tumor is at least 4 cm) (can be removed by surgery)
5. You meet ONE of the following:
 - a. Opdivo Qvantig will be used in combination with platinum-doublet chemotherapy (a type of cancer treatment, such as carboplatin/paclitaxel, cisplatin/pemetrexed, cisplatin/gemcitabine) as neoadjuvant treatment (given before main treatment)
 - b. Your cancer has no known epidermal growth factor receptor (EGFR: a type of protein) mutations (abnormal change in a type of gene) or anaplastic lymphoma kinase (ALK: a type of enzyme) rearrangements (type of gene mutation), and you meet ONE of the following:
 - i. Opdivo Qvantig will be used in combination with platinum-doublet chemotherapy (such as carboplatin/paclitaxel, cisplatin/pemetrexed, carboplatin/pemetrexed, cisplatin/docetaxel) as neoadjuvant treatment (given before main treatment)
 - ii. Opdivo Qvantig will be used alone as adjuvant (add-on) treatment after surgical resection (removal by surgery) and prior use with platinum-doublet chemotherapy as neoadjuvant treatment

(Criteria continued on the next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NIVOLUMAB-HYALURONIDASE-NVHY

GUIDELINES FOR USE (CONTINUED)

- X. If you have metastatic non-small cell lung cancer, approval also requires:**
3. You are 18 years of age or older
 4. Your disease has worsened while on or after platinum-based chemotherapy (a type of cancer treatment, such as cisplatin, carboplatin, oxaliplatin), and you meet ONE of the following:
 - a. Your tumor does NOT have epidermal growth factor receptor (EGFR: type of protein) or anaplastic lymphoma kinase (ALK: type of enzyme) genomic aberrations (types of abnormal gene)
 - b. Your tumor has an EGFR mutation (abnormal change in a type of gene), and your disease has worsened after treatment with a Food and Drug Administration (FDA)-approved EGFR-directed therapy (such as Tarceva [erlotinib], Iressa [gefitinib], Gilotrif [afatinib])
 - c. Your tumor has an ALK mutation, and your disease has worsened after treatment with an FDA-approved ALK-directed therapy (such as Xalkori [crizotinib], Zykadia [ceritinib])
- Y. If you have recurrent or metastatic squamous cell carcinoma of the head and neck, approval also requires:**
3. You are 18 years of age or older
 4. Your disease has worsened while on or after treatment with a platinum-based chemotherapy (a type of cancer treatment, such as cisplatin, carboplatin, oxaliplatin)
- Z. If you have urothelial carcinoma, approval also requires:**
4. You are 18 years of age or older
 5. You meet ONE of the following:
 - a. You are at high risk of recurrence (disease returning) after undergoing radical resection (tumor removal) of urothelial carcinoma, and Opdivo Qvantig will be used as an adjuvant (add-on) treatment
 - b. Your cancer is unresectable (cannot be removed by surgery) or metastatic (has spread to other parts of the body), and Opdivo Qvantig will be used in combination with cisplatin and gemcitabine
 - c. Your cancer is locally advanced (has spread to nearby tissue or lymph nodes) or metastatic (has spread to other parts of the body), and you meet ONE of the following:
 - c. Your disease has worsened during or following platinum-containing chemotherapy (a type of cancer treatment, such as cisplatin, carboplatin, oxaliplatin)
 - d. Your disease has worsened within 12 months of neoadjuvant (given before main treatment) or adjuvant (add-on) treatment with platinum-containing chemotherapy (a type of cancer treatment, such as cisplatin, carboplatin, oxaliplatin)

(Criteria continued on the next page)

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NIVOLUMAB-HYALURONIDASE-NVHY

GUIDELINES FOR USE (CONTINUED)

AA.If you have metastatic colorectal cancer, approval also requires:

4. You are 18 years of age or older
5. Your cancer is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) (types of genetic abnormalities)
6. Your disease has worsened after treatment with a fluoropyrimidine (a type of cancer treatment, such as fluorouracil, capecitabine), oxaliplatin, and irinotecan

BB.If you have hepatocellular carcinoma, approval also requires:

3. You are 18 years of age or older
4. Opdivo Qvantig will be used following treatment with intravenous (injection into the vein) Opdivo (nivolumab) and Yervoy (ipilimumab)
5. You have been previously treated with Nexavar (sorafenib)

CC. If you have esophageal or gastroesophageal junction cancer, approval also requires:

4. You are 18 years of age or older
5. You have undergone complete resection (removal by surgery)
6. Opdivo Qvantig will be used as an adjuvant (add-on) treatment
7. You have a residual pathologic disease (disease is still present)
8. You have received neoadjuvant chemoradiotherapy (CRT) (a type of cancer treatment given before surgery)

DD. If you have esophageal squamous cell carcinoma, approval also requires:

3. You are 18 years of age or older
4. You meet ONE of the following:
 - a. Your cancer is unresectable (cannot be removed by surgery) advanced or metastatic (has spread to other parts of the body), and Opdivo Qvantig will be used in combination with fluoropyrimidine- (a type of cancer treatment, such as fluorouracil, capecitabine) and platinum-containing chemotherapy (a type of cancer treatment, such as cisplatin, carboplatin, oxaliplatin)
 - b. Your cancer is unresectable advanced, recurrent (has returned) or metastatic and you have previously received treatment with fluoropyrimidine- (a type of cancer treatment, such as fluorouracil, capecitabine) and platinum-based chemotherapy (a type of cancer treatment, such as cisplatin, carboplatin, oxaliplatin)

EE.If you have advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma, approval also requires:

3. You are 18 years of age or older
4. Opdivo Qvantig will be used in combination with fluoropyrimidine- (a type of cancer treatment, such as fluorouracil, capecitabine) and platinum-containing chemotherapy (a type of cancer treatment, such as cisplatin, carboplatin, oxaliplatin)

Effective: 02/10/25

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 6/11/2025

Page 581 of 1007



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OBETICHOLIC ACID

Generic	Brand				
OBETICHOLIC ACID	OCALIVA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **OBETICHOLIC ACID (Ocaliva)** requires the following rule(s) be met for approval:

- A. You have primary biliary cholangitis (PBC: a type of immune system disorder that destroys the bile duct), as confirmed by TWO of the following:
 - 1. You have an elevated (high) alkaline phosphatase (ALP) level (a type of lab test)
 - 2. You have the presence of antimitochondrial antibodies (AMA: indicator of the body attacking its own cells) or other PBC-specific autoantibodies (indicator of the body attacking its own cells), including sp100 or gp210 if AMA is negative
 - 3. You have histologic evidence (lab data obtained by liver biopsy [removal of cells or tissue from the liver for examination]) of non-suppurative destructive cholangitis and destruction of interlobular bile ducts (symptoms of liver disease)
- B. You are 18 years of age or older
- C. You do not have cirrhosis (liver damage and scarring) OR you have compensated cirrhosis (a condition where there is liver damage and scarring without any major symptoms) with no evidence of portal hypertension (high blood pressure in the major vein that leads to the liver)
- D. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions) or hepatologist (a type of liver doctor)
- E. You do NOT have complete biliary obstruction (blockage of bile ducts)
- F. You will NOT use Ocaliva concurrently (at the same time) with any other second-line therapy for PBC (Iqirvo [elafibranor], Livdelzi [seladelpar])
- G. You meet ONE of the following:
 - 1. Ocaliva will be used as monotherapy (one drug treatment) if you are unable to tolerate ursodiol (ursodeoxycholic acid)
 - 2. Ocaliva will be used in combination (together) with ursodiol (ursodeoxycholic acid) if you had an inadequate (poor) response to at least 1 year of treatment with ursodiol (ursodeoxycholic acid) monotherapy (one drug treatment)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OBETICHOLIC ACID

RENEWAL CRITERIA

Our guideline named **OBETICHOLIC ACID (Ocaliva)** requires the following rule(s) be met for renewal:

- A. You have primary biliary cholangitis (PBC: a type of immune system disorder that destroys the bile duct)
- B. You have an alkaline phosphatase (ALP) level (a type of lab test) that is less than 1.67-times the upper limit of normal AND which has decreased by at least 15 percent from baseline while on treatment with Ocaliva
- C. You have NOT developed complete biliary obstruction (blockage of bile ducts)
- D. You will NOT use Ocaliva concurrently (at the same time) with any other second-line therapy for PBC (Iqirvo [elafibranor], Livdelzi [seladelpar])

Effective: 09/16/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OCTREOTIDE - IM

Generic	Brand				
OCTREOTIDE ACETATE, MI- SPHERES	SANDOSTATIN LAR DEPOT, OCTREOTIDE ACETATE ER				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **OCTREOTIDE - IM (Sandostatin LAR Depot)** requires the following rule(s) be met for approval:

You have **ONE** of the following:

Acromegaly (a type of hormone disorder)

Severe diarrhea and flushing episodes associated with metastatic carcinoid tumors (a type of slow growing cancer that has spread to other parts of the body)

Profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-secreting tumors (a type of tumor that starts from hormone producing cells)

If you have acromegaly, approval also requires:

Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)

You had an inadequate response (did not work) to surgery or radiotherapy (a type of cancer treatment), OR surgery or radiotherapy is not an option for you

You had a prior response to and tolerated subcutaneous octreotide injection for at least 2 weeks

If you have severe diarrhea and flushing episodes associated with metastatic carcinoid tumors, approval also requires:

You had a prior response to and tolerated subcutaneous octreotide injection for at least 2 weeks

If you have profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-secreting tumors, approval also requires:

You had a prior response to and tolerated subcutaneous octreotide injection for at least 2 weeks

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OCTREOTIDE - IM

RENEWAL CRITERIA

Our guideline named **OCTREOTIDE - IM (Sandostatin LAR Depot)** requires the following rule(s) be met for renewal:

You have ONE of the following:

- Acromegaly (a type of hormone disorder)

- Severe diarrhea and flushing episodes associated with metastatic carcinoid tumors (a type of slow growing cancer that has spread to other parts of the body)

- Profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-secreting tumors (a type of tumor that starts from hormone producing cells)

If you have acromegaly, renewal also requires:

- You have had a reduction, normalization, or maintenance of insulin-like growth factor (IGF-1: a type of hormone) levels based on your age and gender

- You have shown improvement or sustained remission (symptoms have gone away) of clinical symptoms of acromegaly

If you have severe diarrhea and flushing episodes associated with metastatic carcinoid tumors, renewal also requires:

- You have shown improvement or sustained remission (reduction or disappearance) of clinical symptoms

If you have profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-secreting tumors, renewal also requires:

- You have shown improvement or sustained remission (reduction or disappearance) of clinical symptoms

Effective: 05/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OCTREOTIDE - ORAL

Generic	Brand				
OCTREOTIDE	MYCAPSSA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **OCTREOTIDE - ORAL (Mycapssa)** requires the following rule(s) be met for approval:

- A. You have acromegaly (a type of hormone disorder)
- B. Therapy is prescribed by or in consultation with an endocrinologist (doctor who specializes in hormones)
- C. You have responded to and tolerated treatment with octreotide or lanreotide

RENEWAL CRITERIA

Our guideline named **OCTREOTIDE - ORAL (Mycapssa)** requires the following rule(s) be met for renewal:

- A. You have acromegaly (a type of hormone disorder)
- B. You have had a reduction, normalization, or maintenance of insulin-like growth factor 1 (IGF-1: a type of hormone) levels based on your age and gender
- C. You have shown an improvement or sustained remission (symptoms have gone away) of clinical symptoms of acromegaly

Effective: 10/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OCTREOTIDE - SQ

Generic	Brand				
OCTREOTIDE ACETATE	BYNFEZIA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **OCTREOTIDE - SQ (Bynfezia)** requires the following rule(s) be met for approval:

- A. You have **ONE** of the following diagnoses:
1. Acromegaly (a type of hormone disorder)
 2. Severe diarrhea and flushing episodes associated with metastatic carcinoid tumor (a type of slow growing cancer that has spread to different parts of the body)
 3. Profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma: a type of cancer that starts from hormone producing cells)
- B. **If you have acromegaly, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
 3. You had a trial of or contraindication (harmful for) to **ONE** generic octreotide product (such as octreotide acetate)
 4. You had an inadequate response to or cannot be treated with **ALL** of the following:
 - i. Surgical resection (removal by surgery)
 - ii. Pituitary irradiation (radiation therapy directed at the pituitary)
 - iii. Bromocriptine mesylate at maximally tolerated doses
- C. **If you have severe diarrhea and flushing episodes associated with metastatic carcinoid tumor, approval also requires:**
1. You are 18 years of age or older
 2. You had a trial of or contraindication (harmful for) to **ONE** generic octreotide product (such as octreotide acetate)
- D. **If you have profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma), approval also requires:**
1. You are 18 years of age or older
 2. You had a trial of or contraindication (harmful for) to **ONE** generic octreotide product (such as octreotide acetate)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OCTREOTIDE - SQ

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **OCTREOTIDE - SQ (Bynfezia)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following diagnoses:
 - 1. Acromegaly (a type of hormone disorder)
 - 2. Severe diarrhea and flushing episodes associated with metastatic carcinoid tumor (a type of slow growing cancer that has spread to different parts of the body)
 - 3. Profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma: a type of cancer that starts from hormone producing cells)
- B. **If you have acromegaly, renewal also requires:**
 - 1. You have a reduction, normalization or maintenance of insulin-like growth factor (IGF-1: a growth hormone) levels based on age and gender
 - 2. You have shown an improvement or sustained remission (symptoms have gone away) of clinical symptoms of acromegaly
- C. **If you have severe diarrhea and flushing episodes associated with metastatic carcinoid tumor OR profuse watery diarrhea associated with vasoactive intestinal peptide tumor, renewal also requires:**
 - 1. You have an improvement or sustained remission (symptoms have gone away) of clinical symptoms

Effective: 10/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ODEVIXIBAT

Generic	Brand				
ODEVIXIBAT	BYLVAY				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ODEVIXIBAT (Bylvay)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Cholestatic pruritus (itching caused by liver disease) associated with progressive familial intrahepatic cholestasis (PFIC: a type of genetic disorder)
 2. Cholestatic pruritus (itching caused by liver disease) associated with Alagille syndrome (ALGS: a type of genetic disorder)
- B. **If you have cholestatic pruritus associated with progressive familial intrahepatic cholestasis, approval also requires:**
1. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor), gastroenterologist (a doctor who treats digestive conditions), or physician (doctor) who specializes in PFIC cholestasis
 2. You will NOT use Bylvay concurrently (at the same time) with another ileal bile acid transporter (IBAT) inhibitor (such as Livmarli [maralixibat])
 3. You meet ONE of the following:
 - a. You are 3 months to 11 months of age
 - b. You are 12 months of age or older AND have tried or have a contraindication to (harmful for you to use) the preferred medication: Livmarli (maralixibat)
- C. **If you have cholestatic pruritus associated with Alagille syndrome, approval also requires:**
1. You are 12 months of age or older
 2. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor), gastroenterologist (a doctor who treats digestive conditions), or physician (doctor) who specializes in ALGS cholestasis
 3. You will NOT use Bylvay concurrently (at the same time) with another ileal bile acid transporter (IBAT) inhibitor (such as Livmarli [maralixibat])
 4. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Livmarli (maralixibat)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ODEVIXIBAT

RENEWAL CRITERIA (CONTINUED)

Our guideline named **ODEVIXIBAT (Bylvay)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Cholestatic pruritus (itching caused by liver disease) associated with progressive familial intrahepatic cholestasis (PFIC: a type of genetic disorder)
2. Cholestatic pruritus (itching caused by liver disease) associated with Alagille syndrome (ALGS: a type of genetic disorder)

B. **If you have cholestatic pruritus associated with progressive familial intrahepatic cholestasis, renewal also requires:**

1. You have shown a clinical response to therapy, defined as improvement in pruritus (itching) symptoms AND a reduction of serum bile acid (a type of blood test) from baseline (before starting Bylvay)
2. You do NOT have PFIC type 2 with specific ABCB11 variants (a type of abnormal gene) that would result in nonfunctional (does not work), or the complete absence of, bile salt export pump (BSEP: a type of protein)
3. You will NOT use Bylvay concurrently (at the same time) with another ileal bile acid transporter (IBAT) inhibitor (such as Livmarli [maralixibat])

C. **If you have cholestatic pruritus associated with Alagille syndrome, renewal also requires:**

1. You have shown a clinical response to therapy, defined as improvement in pruritus (itching) symptoms AND a reduction of serum bile acid (a type of blood test) from baseline (before starting Bylvay)
2. You will NOT use Bylvay concurrently (at the same time) with another ileal bile acid transporter (IBAT) inhibitor (such as Livmarli [maralixibat])

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OFATUMUMAB-SQ

Generic	Brand				
OFATUMUMAB	KESIMPTA				

GUIDELINES FOR USE

Our guideline named **OFATUMUMAB-SQ (Kesimpta)** requires the following rules be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: an illness where the immune system eats away at the protective covering of the nerves), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older

Effective: 01/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OLANZAPINE/SAMIDORPHAN

Generic	Brand				
OLANZAPINE/ SAMIDORPHAN MALATE	LYBALVI				

GUIDELINES FOR USE

Our guideline named **OLANZAPINE/SAMIDORPHAN (Lybalvi)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Schizophrenia (type of mental health disorder)
 - 2. Bipolar I disorder (type of mood disorder)
- B. **If you have schizophrenia, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
 - 3. You are at high risk for weight gain
 - 4. You have tried and failed or have a contraindication to (harmful for you to use) ONE of the following preferred brand medications: Vraylar, Rexulti
- C. **If you have bipolar I disorder, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Lybalvi will be used for acute treatment of manic or mixed episodes as monotherapy or as adjunct to lithium or valproate, OR used as maintenance monotherapy treatment
 - 3. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
 - 4. You are at high risk for weight gain
 - 5. You have tried and failed or have a contraindication to (harmful for you to use) ONE of the following preferred brand medications: Vraylar, Rexulti

Effective: 08/12/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OLAPARIB

Generic	Brand			
OLAPARIB	LYNPARZA			

GUIDELINES FOR USE

Our guideline named **OLAPARIB (Lynparza)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Recurrent (returning) or advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (types of reproductive system cancers)
2. HER2 ((human epidermal growth factor receptor 2: a type of protein)-negative high risk early breast cancer (a type of breast cancer)
3. HER2-negative metastatic breast cancer (a type of breast cancer that has spread to other parts of the body)
4. Metastatic pancreatic adenocarcinoma (a type of pancreas cancer that has spread to other parts of the body)
5. Homologous recombination repair (HRR) gene-mutated (type of mutation) metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and does not respond to hormone therapy)
6. BRCA-mutated (type of mutation) metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and does not respond to hormone therapy)

B. **If you have advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:**

1. You are 18 years of age or older
2. Lynparza will be used for maintenance treatment
3. You are in complete or partial response to first-line platinum-based chemotherapy (such as paclitaxel, docetaxel, cisplatin, carboplatin)
4. Your diagnosis is confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic for Lynparza
5. You meet ONE of the following:
 - a. Your cancer has a deleterious or suspected deleterious germline or somatic BRCA mutation (a type of gene mutation)
 - b. Your cancer is associated with a homologous recombination deficiency (HRD: type of gene mutation) positive status as defined by either a deleterious or suspected deleterious BRCA mutation (type of gene mutation), and/or genomic instability (high rate of gene mutation), AND Lynparza will be used in combination with bevacizumab

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OLAPARIB

GUIDELINES FOR USE (CONTINUED)

- C. If you have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:**
1. You are 18 years of age or older
 2. Your cancer has a deleterious or suspected deleterious germline or somatic BRCA mutation (a type of gene mutation), as confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic for Lynparza
 3. You are in complete or partial response to your most recent platinum-based chemotherapy (such as paclitaxel, docetaxel, cisplatin, carboplatin)
 4. You have completed at least two or more lines of platinum-based chemotherapy such as paclitaxel, docetaxel, cisplatin, carboplatin
 5. Lynparza will be used as monotherapy (used alone) for maintenance treatment
- D. If you have HER2-negative high risk early breast cancer, approval also requires:**
1. You are 18 years of age or older
 2. Lynparza will be used as adjuvant (add-on) treatment
 3. Your cancer has a deleterious or suspected deleterious germline BRCA mutation (gBRCAm: a type of gene mutation) as confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic for Lynparza
 4. You have been treated with neoadjuvant or adjuvant chemotherapy (cancer treatment given before main treatment or as add-on therapy such as doxorubicin, paclitaxel)
- E. If you have HER2-negative metastatic breast cancer, approval also requires:**
1. You are 18 years of age or older
 2. Your cancer has a deleterious or suspected deleterious germline BRCA mutation (gBRCAm: a type of gene mutation) as confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic for Lynparza
 3. You have been treated with chemotherapy (such as doxorubicin, docetaxel) in the neoadjuvant (given before main treatment), adjuvant (add-on to main treatment), or metastatic setting (to treat disease that has spread to other parts of the body)
 4. You meet ONE of the following:
 - a. You do not have hormone receptor (HR)-positive breast cancer
 - b. You have hormone receptor (HR)-positive breast cancer and you have been treated with a prior endocrine (hormone) therapy (such as tamoxifen, Arimidex [anastrozole]) or endocrine therapy is considered inappropriate for you

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OLAPARIB

GUIDELINES FOR USE (CONTINUED)

F. If you have metastatic pancreatic adenocarcinoma, approval also requires:

1. You are 18 years of age or older
2. Lynparza will be used for maintenance treatment
3. Your cancer has a deleterious or suspected deleterious germline BRCA mutation (gBRCAm: a type of gene mutation) as confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic for Lynparza
4. Your disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen (such as paclitaxel, docetaxel, cisplatin, carboplatin)

G. If you have homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, approval also requires:

1. You are 18 years of age or older
2. Your cancer has a deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutation (type of mutation) as confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic for Lynparza
3. Your disease has worsened following prior treatment with enzalutamide (Xtandi) or abiraterone (Yonsa or Zytiga)
4. You meet ONE of the following:
 - a. You previously had a bilateral orchiectomy (both testicles have been surgically removed)
 - b. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
 - c. Lynparza will be used together with a gonadotropin-releasing hormone (GnRH) analog (such as Lupron Depot [leuprolide], Zoladex [goserelin], Firmagon [degarelix])

H. If you have BRCA-mutated metastatic castration-resistant prostate cancer, approval also requires, approval also requires:

1. You are 18 years of age or older
2. Lynparza will be used in combination with abiraterone (Yonsa or Zytiga) AND prednisone or prednisolone
3. Your cancer has a deleterious or suspected deleterious BRCA mutation (BRCAm: a type of gene mutation) as confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic for Lynparza
4. You meet ONE of the following:
 - a. You previously had a bilateral orchiectomy (both testicles have been surgically removed)
 - b. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
 - c. Lynparza will be used together with a gonadotropin-releasing hormone (GnRH) analog (such as Lupron Depot [leuprolide], Zoladex [goserelin], Firmagon [degarelix])

Effective: 10/23/23

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OLEZARSEN

Generic	Brand				
OLEZARSEN SODIUM	TRYNGOLZA				

GUIDELINES FOR USE

Our guideline named **OLEZARSEN (Tryngolza)** requires the following rule(s) be met for approval:

- A. You have familial chylomicronemia syndrome (FCS: a type of rare genetic condition)
- B. You are 18 years of age or older
- C. Tryngolza will be used as an adjunct (add-on) therapy to diet

Effective: 01/17/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OLUTASIDENIB

Generic	Brand				
OLUTASIDENIB	REZLIDHIA				

GUIDELINES FOR USE

Our guideline named **OLUTASIDENIB (Rezlidhia)** requires the following rule(s) be met for approval:

- A. You have relapsed or refractory acute myeloid leukemia (AML: a type of blood cancer that has returned or did not respond to treatment)
- B. You are 18 years of age or older
- C. You have a susceptible (can be treated with the drug) isocitrate dehydrogenase-1 (IDH1: a type of enzyme) mutation as detected by a Food and Drug Administration (FDA)-approved test

Effective: 04/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OMACETAXINE

Generic	Brand			
OMACETAXINE MEPESUCCINATE	SYNRIBO			

GUIDELINES FOR USE

Our guideline named **OMACETAXINE (Synribo)** requires the following rule(s) be met for approval:

- A. You have chronic or accelerated phase chronic myeloid leukemia (CML: type of blood cell cancer)
- B. You are 18 years of age or older
- C. You had a resistance or intolerance to TWO or more tyrosine kinase inhibitors (such as Gleevec, Sprycel, Tassigna, Bosulif, Iclusig)

Effective: 04/11/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OMADACYCLINE

Generic	Brand			
OMADACYCLINE	NUZYRA			

GUIDELINES FOR USE

Our guideline named **OMADACYCLINE (Nuzyra)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Community-acquired bacterial pneumonia (CABP: type of lung infection)
 - 2. Acute (severe and sudden) bacterial skin or skin structure infection (ABSSSI)
- B. **If you have community-acquired bacterial pneumonia, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. The infection is caused by any of the following bacteria: *Streptococcus pneumoniae*, *Staphylococcus aureus* (methicillin-susceptible isolates), *Haemophilus influenzae*, *Haemophilus parainfluenzae*, *Klebsiella pneumoniae*, *Legionella pneumoniae*, *Mycoplasma pneumoniae*, or *Chlamydia pneumoniae*
 - 3. You meet ONE of the following criteria:
 - a. The requested medication is prescribed by or given in consultation with an Infectious Disease (ID) specialist
 - b. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is available, and the infection site culture results indicate pathogenic (disease-causing) organism(s) with 1) resistance to at least TWO standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone), AND 2) Nuzyra will work against the bacteria
 - c. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is unavailable, and you have had a trial of or contraindication (medical reason why you cannot use) to at least TWO standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone)

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OMADACYCLINE

GUIDELINES FOR USE (CONTINUED)

C. If you have acute bacterial skin or skin structure infection (ABSSSI), approval also requires:

1. You are 18 years of age or older
2. The infection is caused by any of the following bacteria: *Staphylococcus aureus* (methicillin-susceptible and -resistant isolates), *Staphylococcus lugdunensis*, *Streptococcus pyogenes*, *Streptococcus anginosus* grp. (Includes *S. anginosus*, *S. intermedius*, and *S. constellatus*), *Enterococcus faecalis*, *Enterobacter cloacae*, or *Klebsiella pneumoniae*
3. You meet ONE of the following criteria:
 - a. The requested medication is prescribed by or given in consultation with an Infectious Disease (ID) specialist
 - b. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is available, and the infection site culture results indicate pathogenic (disease-causing) organism(s) with 1) resistance to at least TWO standard of care agents for acute bacterial skin or skin structure infection (such as linezolid, clindamycin, doxycycline, sulfamethoxazole/trimethoprim, vancomycin, amoxicillin, nafcillin, ceftriaxone, cephalexin, cefazolin), AND 2) Nuzyra will work against the bacteria
 - c. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is unavailable, and you had a trial of or contraindication to at least TWO standard of care agents for acute bacterial skin or skin structure infection (such as linezolid, clindamycin, doxycycline, sulfamethoxazole/trimethoprim, vancomycin, amoxicillin, nafcillin, ceftriaxone, cephalexin, cefazolin)

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OMALIZUMAB

Generic	Brand				
OMALIZUMAB	XOLAIR				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **OMALIZUMAB (Xolair)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Moderate to severe persistent asthma (a type of lung condition)
2. Chronic rhinosinusitis with nasal polyps (CRSwNP: inflammation of nasal and sinus ways with small growths in the nose)
3. IgE-mediated food allergy (body's reaction to a food allergy)
4. Chronic spontaneous urticaria (also called chronic idiopathic urticaria) [severe itching with unknown cause]

B. If you have moderate to severe persistent asthma, approval also requires:

1. You are 6 years of age or older
2. Therapy is prescribed by or in consultation with a physician specializing in pulmonary (relating to lungs/breathing) medicine or allergy medicine
3. You have a positive skin prick or blood test, such as ELISA or FEIA (types of blood tests to identify allergies), to a perennial aeroallergen (airborne particles that cause allergies year-round)
4. You have a baseline IgE (type of antibody that is produced by the immune system if there is an allergy) serum (blood) level of at least 30 IU/mL
5. Xolair will be used in combination with a medium, high-dose, or maximally tolerated dose of an inhaled corticosteroid (such as beclomethasone, mometasone, budesonide) AND at least ONE other maintenance medication (taken on a regular basis) such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as Tudorza [aclidinium], Spiriva [tiotropium], Incruse Ellipta [umeclidinium]), a leukotriene receptor antagonist (such as montelukast, zafirlukast), theophylline, or an oral corticosteroid (such as prednisone)
6. You will NOT use Xolair concurrently (at the same time) with another systemic biologic (such as Tezspire [tezepelumab-ekko]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of asthma

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OMALIZUMAB

INITIAL CRITERIA (CONTINUED)

7. You meet ONE of the following:
 - a. You have experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid (such as prednisone) burst lasting at least 3 days within the past 12 months
 - b. You have experienced at least ONE serious asthma exacerbation requiring a hospitalization or an emergency room visit within the past 12 months
 - c. You have poor symptom control despite current therapy as shown by at least THREE of the following within the past 4 weeks:
 - i. Daytime asthma symptoms more than twice per week
 - ii. Any night waking due to asthma
 - iii. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
 - iv. Any activity limitation due to asthma
- C. **If you have chronic rhinosinusitis with nasal polyps, approval also requires:**
 1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with an otolaryngologist (ear, nose, and throat doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
 3. There is evidence of nasal polyps (non-cancerous growths) by direct examination, endoscopy (using a small camera), or sinus computed tomography (CT) scan (a type of imaging test)
 4. You have inadequately controlled disease
 5. You had a 56-day trial of ONE intranasal corticosteroid (such as mometasone nasal spray)
 6. Xolair will be used as add-on maintenance treatment (taken on a regular basis)
 7. You will NOT use Xolair concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of chronic rhinosinusitis with nasal polyps

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OMALIZUMAB

INITIAL CRITERIA (CONTINUED)

D. If you have an IgE-mediated food allergy, approval also requires:

1. You are 1 year of age or older
2. You will continue to avoid food allergens (not eating or coming into contact with food that causes an allergic reaction) while on Xolair
3. You have an IgE (type of antibody that is produced by the immune system if there is an allergy) serum (blood) level of at least 30 IU/mL
4. You have an allergen specific IgE serum level of at least 6 kUA/L to at least one food, OR a positive skin prick test (a type of allergy test) to at least one food, OR a positive medically monitored food challenge to at least one food
5. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor) or immunologist (a type of immune system doctor)
6. You have an active prescription for epinephrine auto-injector/injection while on Xolair
7. You will NOT use Xolair concurrently (at the same time) with another systemic biologic (such as Palforzia) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of IgE-mediated food allergy

E. If you have chronic spontaneous urticaria (chronic idiopathic urticaria), approval also requires:

1. You are 12 years of age or older
2. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), dermatologist (a type of skin doctor), or immunologist (a type of immune system doctor)
3. You still experience hives or angioedema (a type of swelling) on most days of the week for at least 6 weeks
4. You have tried and are maintained on (continue to use on a regular basis), OR you have a contraindication to (harmful for you to use), a second generation H1 antihistamine (type of allergy medication) (Zyrtec [cetirizine], Xyzal [levocetirizine], Claritin [loratadine], Clarinex [desloratadine], or Allegra [fexofenadine])
5. You will NOT use Xolair concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of chronic spontaneous urticaria (chronic idiopathic urticaria)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OMALIZUMAB

RENEWAL CRITERIA

Our guideline named **OMALIZUMAB (Xolair)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Moderate to severe persistent asthma (a type of lung condition)
2. Chronic rhinosinusitis with nasal polyps (CRSwNP: inflammation of nasal and sinus ways with small growths in the nose)
3. IgE-mediated food allergy (body's reaction to a food allergy)
4. Chronic spontaneous urticaria (also called chronic idiopathic urticaria) [severe itching with unknown cause]

B. If you have moderate to severe persistent asthma, renewal also requires:

1. You will continue to use an inhaled corticosteroid (such as beclomethasone, mometasone, budesonide) AND at least ONE other maintenance medication (taken on a regular basis) such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as Tudorza [aclidinium], Spiriva [tiotropium], Incruse Ellipta [umeclidinium]), a leukotriene receptor antagonist (such as montelukast, zafirlukast), theophylline, or an oral corticosteroid (such as prednisone)
2. You will NOT use Xolair concurrently (at the same time) with another systemic biologic (such as Tezspire [tezepelumab-ekko]), or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of asthma
3. You have shown a clinical response as evidenced by ONE of the following:
 - a. You have experienced a decrease in asthma exacerbations (worsening of symptoms) from baseline (before starting Xolair)
 - b. You have decreased your use of rescue medications (such as albuterol)
 - c. You have an increase in percent predicted FEV1 (type of lung test) from pre-treatment baseline (before starting Xolair)
 - d. You have a decrease in the severity or frequency of asthma-related symptoms (such as wheezing, shortness of breath, coughing)

C. If you have chronic rhinosinusitis with nasal polyps, renewal also requires:

1. You have shown a clinical benefit compared to baseline (before starting Xolair) (such as improvements in nasal congestion, sense of smell, size of polyps)
2. You will NOT use Xolair concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of chronic rhinosinusitis with nasal polyps

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OMALIZUMAB

RENEWAL CRITERIA (CONTINUED)

D. If you have an IgE-mediated food allergy, renewal also requires:

1. You have persistent IgE-mediated food allergy
2. You have an active prescription for epinephrine auto-injector/injection while on Xolair
3. You will NOT use Xolair concurrently (at the same time) with another systemic biologic (such as Palforzia) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of IgE-mediated food allergy

E. If you have chronic spontaneous urticaria (chronic idiopathic urticaria), renewal also requires:

1. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), dermatologist (a type of skin doctor), or immunologist (a type of immune system doctor)
2. You are maintained on (continue to use on a regular basis), OR you have a contraindication to (harmful for you to use), a second generation H1 antihistamine (type of allergy medication) (Zyrtec [cetirizine], Xyzal [levocetirizine], Claritin [loratadine], Clarinex [desloratadine], or Allegra [fexofenadine])
3. You will NOT use Xolair concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of chronic spontaneous urticaria (chronic idiopathic urticaria)

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OMAVELOXOLONE

Generic	Brand				
OMAVELOXOLONE	SKYCLARYS				

GUIDELINES FOR USE

Our guideline named **OMAVELOXOLONE (Skyclarys)** requires the following rule(s) be met for approval:

- A. You have Friedreich's ataxia (a type of nervous system and movement disorder)
- B. You are 16 years of age or older

Effective: 07/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OPICAPONE

Generic	Brand				
OPICAPONE	ONGENTYS				

GUIDELINES FOR USE

Our guideline named **OPICAPONE (Ongentys)** requires the following rule(s) be met for approval:

- A. You have Parkinson's disease (PD: a nerve system disorder that affects movement)
- B. You are 18 years of age or older
- C. You are experiencing 'OFF' episodes (times when you have symptoms return due to medication wearing off)
- D. You are currently being treated with carbidopa/levodopa
- E. You have tried or failed or have a contraindication (medical reason why you cannot use) to TWO Parkinson's disease medications from TWO different classes of medications:
 - 1. Dopamine agonist (such as ropinirole, pramipexole, rotigotine)
 - 2. Monoamine oxidase-inhibitors (MAO-I) (such as selegiline, rasagiline)
 - 3. Adenosine receptor antagonist A2A (such as istradefylline)
 - 4. Catechol-O-methyltransferase (COMT) inhibitors (such as entacapone, tolcapone)

Effective: 01/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OPIOID-ANTIPSYCHOTIC CONCURRENT USE

Generic	Brand			
N/A	N/A			

GUIDELINES FOR USE

Our guideline named **OPIOID-ANTIPSYCHOTIC CONCURRENT USE** allows an approval for use of an opioid with an antipsychotic medication (type of mental health drug) together when one of the following criteria is met:

- A. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
- B. You are enrolled in a hospice (end of life care)
- C. You are a resident of a long-term care facility or intermediate care for intellectually disabled
- D. You have sickle cell disease (a type of blood disorder)
- E. Your doctor confirms that the use of an opioid and an antipsychotic medication together is intended and clinically appropriate for you
- F. You are being treated for cancer-related pain which includes: you are undergoing active cancer treatment, you are a cancer survivor with chronic (long-term) pain and have completed cancer treatment, you are in clinical remission (reduction or disappearance of the signs and symptoms of a disease), or you are under cancer surveillance (monitoring) only

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OPIOID-BENZODIAZEPINE CONCURRENT USE

Generic	Brand			
N/A	N/A			

GUIDELINES FOR USE

Our guideline named **OPIOID-BENZODIAZEPINE CONCURRENT USE** allows for an approval of use of an opioid with a benzodiazepine together when ONE of the following criteria is met:

- A. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
- B. You are enrolled in a hospice (end of life care)
- C. You are a resident of (living in) a long-term care facility or intermediate care for intellectually disabled
- D. You have sickle cell disease (a type of blood disorder)
- E. Your doctor agrees to proceed with the concurrent use (at the same time) of an opioid and a benzodiazepine for a clinically appropriate indication (reason)
- F. You are being treated for cancer-related pain which includes: you are undergoing active cancer treatment, you are a cancer survivor with chronic (long-term) pain and have completed cancer treatment, you are in clinical remission (reduction or disappearance of the signs and symptoms of a disease), or you are under cancer surveillance (monitoring) only

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OPIOID-BUPRENORPHINE CONCURRENT USE

Generic	Brand			
N/A	N/A			

GUIDELINES FOR USE

Our guideline named **OPIOID-BUPRENORPHINE CONCURRENT USE** allows approval for use of an opioid with buprenorphine or a buprenorphine-containing agent together when ONE of the following rule(s) is met:

- A. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
- B. You are enrolled in a hospice (end of life care)
- C. You are a resident of (living in) a long-term care facility or intermediate care for intellectually disabled
- D. You have sickle cell disease (a type of blood disorder)
- E. Your doctor confirms (attests) that you have discontinued or will be discontinuing opioid dependency treatment with buprenorphine or buprenorphine-containing agents and you need to resume chronic opioid treatment. Consultation with an addiction medicine specialist is recommended.
- F. Your doctor is aware that you are currently receiving buprenorphine or a buprenorphine-containing agent for treatment of opioid dependency and has confirmed to proceed with opioid treatment for an acute, clinically appropriate indication. Consultation with an addiction medicine specialist is recommended

You are being treated for cancer-related pain which includes: you are undergoing active cancer treatment, you are a cancer survivor with chronic (long-term) pain and have completed cancer treatment, you are in clinical remission (reduction or disappearance of the signs and symptoms of a disease), or you are under cancer surveillance (monitoring) only

Effective: 01/23/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OPIOID CUMULATIVE DOSING OVERRIDE

Generic	Brand			
N/A	N/A			

GUIDELINES FOR USE

A claim for a pain medication will be denied when there are two or more providers prescribing opioid medications for a patient who is receiving a high quantity of these agents. Our guideline named **OPIOID CUMULATIVE DOSING OVERRIDE** will allow you to receive a higher quantity of an opioid medication if ONE of the following rules (A or B) is met:

- A. You have ONE of the following conditions:
 - 1. You are receiving palliative care (treatment for comfort from symptoms) or end-of life care
 - 2. You are enrolled in a hospice (end of life care)
 - 3. You are a resident of a long-term care facility or intermediate care for intellectually disabled
 - 4. You have sickle cell disease (a type of blood disorder)
 - 5. You are being treated for cancer-related pain which includes: you are undergoing active cancer treatment, you are a cancer survivor with chronic (long-term) pain and have completed cancer treatment, you are in clinical remission (reduction or disappearance of the signs and symptoms of a disease), or you are under cancer surveillance (monitoring) only
- B. Your prescriber is aware that there is more than one provider prescribing opiates for you, AND you meet **TWO** of the following:
 - 1. Your current level of opioid use is necessary and required for your level of pain management needed
 - 2. You have been evaluated by a pain specialist, and/or the request is based on the recommendation of a pain specialist
 - 3. You have a pain contract in place
 - 4. You do NOT have a history of substance abuse or addiction
 - 5. Your prescriber has committed to monitoring the state's Prescription Monitoring Program to make sure your controlled substance history is consistent with prescribing record

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OPIOID LONG-ACTING DUPLICATIVE THERAPY

Generic	Brand			
N/A	N/A			

GUIDELINES FOR USE

Our guideline named **OPIOID LONG ACTING DUPLICATIVE THERAPY** allows approval of the requested drug taken together with other long-acting opioid drug(s) from different prescribers when ONE of the following conditions are met:

- A. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
- B. You are enrolled in a hospice (end of life care)
- C. You are a resident of a long-term care facility or intermediate care for intellectually disabled
- D. You have sickle cell disease (a type of blood disorder)
- E. Your doctor confirms that they are aware that you are concurrently receiving more than one long-acting opioid medication
- F. You are being treated for cancer-related pain which includes: you are undergoing active cancer treatment, you are a cancer survivor with chronic (long-term) pain and have completed cancer treatment, you are in clinical remission (reduction or disappearance of the signs and symptoms of a disease), or you are under cancer surveillance (monitoring) only

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OPIOID-NAIVE CUMULATIVE DOSING (ONCD)

Generic	Brand			
N/A	N/A			

GUIDELINES FOR USE

Our guideline named **OPIOID-NAIVE CUMULATIVE DOSING** allows approval of a higher quantity of an opioid medication if at least ONE of the following conditions is met:

- You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
 - You are enrolled in hospice (end of life care)
 - You are a resident of (living in) a long-term care facility or intermediate care for intellectually disabled
 - You have sickle cell disease (a type of blood disorder)
 - You are not opioid naive (you have been consistently using opioid pain medications)
 - You are being treated for cancer-related pain which includes: you are undergoing active cancer treatment, you are a cancer survivor with chronic (long-term) pain and have completed cancer treatment, you are in clinical remission (reduction or disappearance of the signs and symptoms of a disease), or you are under cancer surveillance (monitoring) only
- If none of these conditions apply, BOTH of the following criteria must be met:
- The provider has indicated that your current level of opioid utilization (use) is necessary and required for the level of pain management needed
 - The provider has committed to monitoring the state's Prescription Monitoring Program to ensure controlled substance history is consistent with prescribing record

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OPIOID-NAIVE DAY SUPPLY LIMITATION

Generic	Brand			
N/A	N/A			

GUIDELINES FOR USE

Our guideline named **OPIOID-NAIVE DAY SUPPLY LIMITATION** allows approval of the requested drug for a longer day supply when you meet at least **ONE** of the following conditions:

- A. You are enrolled in hospice (end of life care)
- B. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
- C. You are a resident of a long-term care facility or intermediate care for intellectually disabled
- D. You have sickle cell disease (a type of blood disorder)
- E. You are NOT opioid naïve (you have been consistently using opioid pain medications)
- F. Your doctor confirms (attests) that the prescribed dose of opioids with the requested day supply is intended and medically necessary
- G. You are being treated for cancer-related pain which includes: you are undergoing active cancer treatment, you are a cancer survivor with chronic (long-term) pain and have completed cancer treatment, you are in clinical remission (reduction or disappearance of the signs and symptoms of a disease), or you are under cancer surveillance (monitoring) only

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OPIOID NAIVE FILL LIMIT

Generic	Brand			
N/A	N/A			

GUIDELINES FOR USE

Our guideline named **OPIOID NAIVE FILL LIMIT** allows an approval of the requested drug when it exceeds the fill limit for an initially opioid-naïve patient (those who have not used opioid drugs within the past 60 days) when ONE of the following conditions is met:

- A. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
- B. You are enrolled in a hospice (end of life care)
- C. You are a resident of a long-term care facility or intermediate care for intellectually disabled
- D. You have sickle cell disease (a type of blood disorder)
- E. Your doctor confirms that the additional fill of the requested opioid medication is intended and clinically appropriate for you
- F. You are being treated for cancer-related pain which includes: you are undergoing active cancer treatment, you are a cancer survivor with chronic (long-term) pain and have completed cancer treatment, you are in clinical remission (reduction or disappearance of the signs and symptoms of a disease), or you are under cancer surveillance (monitoring) only

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OPIOID SINGLE CLAIM DOSING AT POS (OSCDP)

Generic	Brand			
OPIOIDS	OPIOIDS			

GUIDELINES FOR USE

Our guideline named **OPIOID SINGLE CLAIM DOSING AT POS** allows for an override of an opioid product equal to or exceeding the soft-stop threshold of **[enter soft stop threshold]**-mg morphine milligram equivalent (MME) at the pharmacy or by a prior authorization. The hard-stop threshold of **[enter hard stop threshold]**-mg morphine milligram equivalent (MME) is not overridable and requires a prior authorization.

An override will be provided if ONE (A or B) of the following rule(s) are met:

- A. You meet ONE of the following conditions:
 - 1. You are receiving treatment for palliative care (treatment for comfort from symptoms)
 - 2. You have sickle cell disease (a type of blood disorder)
 - 3. You are enrolled in a hospice (end of life care)
 - 4. Your doctor is a pain management specialist
 - 5. You are being treated for cancer-related pain which includes: you are undergoing active cancer treatment, you are a cancer survivor with chronic (long-term) pain and have completed cancer treatment, you are in clinical remission (reduction or disappearance of the signs and symptoms of a disease), or you are under cancer surveillance (monitoring) only
- B. Your physician confirms that the requested high dose is considered medically necessary.
 - 1. If the requested dose is lower than 300 MME, your prescriber must provide a maximum opioid threshold. If your prescriber does not provide a maximum threshold and the request is for an opioid with an MME equal to or exceeding **[enter hard-stop threshold]**-mg morphine milligram equivalent (MME), the claim will be approved up to 25 percent greater than the previously approved MME.
 - 2. If the requested dose is equal to or greater than 300 MME, approval will be granted if you are stable on the dose.

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OPIOID-SOMA-BENZODIAZEPINE CONCURRENT USE

Generic	Brand			
N/A	N/A			

GUIDELINES FOR USE

Our guideline named **OPIOID-SOMA-BENZODIAZEPINE CONCURRENT USE** allows an approval for use of an opioid with Soma (carisoprodol) and a benzodiazepine medication together when one of the following criteria is met:

- A. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
- B. You are enrolled in a hospice
- C. You are a resident of a long-term care facility or intermediate care for intellectually disabled
- D. Your doctor confirms that the use of an opioid with Soma (carisoprodol) and a benzodiazepine medication together is intended and clinically appropriate for you
- E. You are being treated for cancer-related pain which includes: you are undergoing active cancer treatment, you are a cancer survivor with chronic (long-term) pain and have completed cancer treatment, you are in clinical remission (reduction or disappearance of the signs and symptoms of a disease), or you are under cancer surveillance (monitoring) only

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ORLISTAT

Generic	Brand				
ORLISTAT	XENICAL, ORLISTAT				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ORLISTAT (Xenical)** requires the following rule(s) be met for approval:

- A. The request is for weight loss OR weight loss management
- B. You have evidence of active enrollment in an exercise and caloric reduction program OR a weight loss/behavioral modification program
- C. You meet ONE of the following:
 - 1. You have a body mass index (BMI: a tool for evaluating body fat) of at least 30 kg/m(2)
 - 2. You have a BMI of at least 27 kg/m(2) AND at least ONE weight-related comorbidity (disease) (such as hypertension [high blood pressure], type 2 diabetes mellitus [a disorder with high blood sugar], or hyperlipidemia [high cholesterol])

RENEWAL CRITERIA

Our guideline named **ORLISTAT (Xenical)** requires the following rule(s) be met for renewal:

- A. The request is for weight loss OR weight loss management
- B. **If you are 18 years of age or older, approval also requires:**
 - 1. You have achieved or maintained at least a 5 percent weight loss of baseline body weight after 3 months of treatment
- C. **If you are younger than 18 years of age, approval also requires:**
 - 1. You have achieved or maintained at least a 5 percent decrease from baseline body mass index (BMI: a tool for evaluating body fat) after 3 months of treatment

Effective: 10/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OSILODROSTAT

Generic	Brand				
OSILODROSTAT	ISTURISA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **OSILODROSTAT (Isturisa)** requires the following rule(s) be met for approval:

- A. You have Cushing's disease (a type of hormone disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
- D. Pituitary (major hormone gland) surgery is not an option or has not cured your condition
- E. You had a trial of or contraindication (harmful for) to oral ketoconazole

RENEWAL CRITERIA

Our guideline named **OSILODROSTAT (Isturisa)** requires the following rule(s) be met for renewal:

- A. You have Cushing's disease (a type hormone disorder)
- B. You continue to have improvement of Cushing's disease (such as clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of disease)
- C. You continue to tolerate treatment with Isturisa

Effective: 08/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OSIMERTINIB

Generic	Brand			
OSIMERTINIB MESYLATE	TAGRISSO			

GUIDELINES FOR USE

Our guideline named **OSIMERTINIB (Tagrisso)** requires the following rule(s) be met for approval:

- A. You have non-small cell lung cancer (NSCLC: a type of lung cancer)
- B. You are 18 years of age or older
- C. You meet ONE of the following:
 - 1. Tagrisso will be used as adjuvant therapy (add-on treatment) after tumor resection (surgical removal of a tumor), and your tumor has epidermal growth factor receptor (EGFR: type of protein) exon 19 deletions or exon 21 L858R mutations (abnormal changes in a type of gene), as detected by a Food and Drug Administration (FDA)-approved test
 - 2. Your cancer is locally advanced and unresectable (stage III) (cancer that has spread to nearby tissue or lymph nodes and cannot be surgically removed), and you meet ALL of the following:
 - a. Your disease has NOT worsened during or following concurrent (at the same time) or sequential (one after the other) platinum-based (such as cisplatin, carboplatin) chemoradiation therapy (a type of treatment that combines chemotherapy and radiation)
 - b. Your tumor has epidermal growth factor receptor (EGFR: type of protein) exon 19 deletions or exon 21 L858R mutations (abnormal changes in a type of gene), as detected by a Food and Drug Administration (FDA)-approved test
 - 3. Your cancer is metastatic (cancer that has spread to other parts of the body), and you meet ONE of the following:
 - a. Your tumor has epidermal growth factor receptor (EGFR: type of protein) exon 19 deletions or exon 21 L858R mutations (abnormal changes in a type of gene), as detected by a Food and Drug Administration (FDA)-approved test
 - b. Your tumor has an epidermal growth factor receptor (EGFR) T790M mutation (abnormal change in a type of gene), as detected by a Food and Drug Administration (FDA)-approved test, AND your disease has worsened while on or after EGFR tyrosine kinase-inhibitor therapy (such as Tarceva [erlotinib], Iressa [gefitinib], Gilotrif [afatinib])

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OSIMERTINIB

GUIDELINES FOR USE (CONTINUED)

4. Your cancer is locally advanced or metastatic (cancer that has spread from where it started to nearby tissue, lymph nodes, or other parts of the body), and you meet ALL of the following:
 - a. Tagrisso will be used in combination with pemetrexed and platinum-based chemotherapy (such as cisplatin, carboplatin)
 - b. Your tumor has epidermal growth factor receptor (EGFR: type of protein) exon 19 deletions or exon 21 L858R mutations (abnormal changes in a type of gene), as detected by a Food and Drug Administration (FDA)-approved test

Effective: 10/21/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OTESECONAZOLE

Generic	Brand					
OTESECONAZOLE	VIVJOA					

GUIDELINES FOR USE

Our guideline named **OTESECONAZOLE (Vivjoa)** requires the following rule(s) be met for approval:

- A. You have recurrent vulvovaginal candidiasis (RVVC: a repeating vaginal fungal infection)
- B. You are female
- C. You are not able to reproduce, which means you are a biological female and are postmenopausal (after menopause) or you have another reason for permanent infertility (such as tubal ligation [having tubes tied], hysterectomy [removal of the uterus], salpingo-oophorectomy [removal of an ovary and its fallopian tube])
- D. You are NOT currently on ibrexafungerp for RVVC
- E. **If you have not previously received Vivjoa, approval also requires:**
 - 1. You had 3 or more episodes of RVVC in the past 12 months
- F. **If you have previously received Vivjoa, approval also requires:**
 - 1. You have successfully completed a course of Vivjoa for prevention of RVVC
 - 2. You are either being treated or have just completed treatment for a new recurrence of VVC

Effective: 04/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OXYMETAZOLINE

Generic	Brand				
OXYMETAZOLINE HCL/PF	UPNEEQ				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **OXYMETAZOLINE (Upneeq)** requires the following rule(s) be met for approval:

- A. You have blepharoptosis (drooping of the upper eyelid)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or optometrist (a type of eye doctor)
- D. You have been evaluated for surgical intervention
- E. You had a trial of TWO ophthalmic alpha-adrenergic agonists (such as apraclonidine, tetrahydrozoline, naphazoline)

RENEWAL CRITERIA

Our guideline named **OXYMETAZOLINE (Upneeq)** requires the following rule(s) be met for renewal:

- D. You have blepharoptosis (drooping of the upper eyelid)
- E. You continue to have benefit from Upneeq

Effective: 04/01/221



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OZANIMOD

Generic	Brand				
OZANIMOD	ZEPOSIA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **OZANIMOD (Zeposia)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. A relapsing form of multiple sclerosis (MS: a type of nerve disorder), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms or disease returns and goes away), or active secondary progressive disease (advanced disease)
 2. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
- B. **If you have a relapsing form of multiple sclerosis, approval also requires:**
1. You are 18 years of age or older
 2. You will NOT use Zeposia concurrently (at the same time) with another systemic biologic (such as Tysabri [natalizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of a relapsing form of multiple sclerosis
- C. **If you have moderate to severe ulcerative colitis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 3. You will NOT use Zeposia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
 4. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

OZANIMOD

RENEWAL CRITERIA

NOTE: For the diagnosis of multiple sclerosis, please refer to the Initial Criteria section.

Our guideline named **OZANIMOD (Zeposia)** requires the following rule(s) be met for renewal:

- F. You have moderate to severe ulcerative colitis (UC: a type of digestive disorder)
- G. You will NOT use Zeposia concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
- H. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PACRITINIB

Generic	Brand				
PACRITINIB CITRATE	VONJO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **PACRITINIB (Vonjo)** requires the following rule(s) be met for approval:

- A. You have intermediate- or high-risk primary or secondary (post-polycythemia vera [type of blood cell disorder] or post-essential thrombocythemia [type of blood cell disorder]) myelofibrosis (type of bone marrow cancer)
- B. You are 18 years of age or older
- C. You have a platelet count below 50,000/uL

RENEWAL CRITERIA

Our guideline named **PACRITINIB (Vonjo)** requires the following rule(s) be met for renewal:

- A. You have intermediate- or high-risk primary or secondary (post-polycythemia vera [type of blood cell disorder] or post-essential thrombocythemia [type of blood cell disorder]) myelofibrosis (type of bone marrow cancer)
- B. You have shown symptom improvement by meeting ONE of the following:
 - 1. You have a spleen volume reduction of 35% or greater from baseline
 - 2. You have a 50% or greater reduction in total symptom score (such as Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
 - 3. You have a 50% or greater reduction in palpable (can be felt by external examination) spleen length

Effective: 04/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PALBOCICLIB

Generic	Brand			
PALBOCICLIB	IBRANCE			

GUIDELINES FOR USE

Our guideline named **PALBOCICLIB (Ibrance)** requires the following rule(s) be met for approval:

- A. You have breast cancer
- B. Your cancer is hormone receptor (HR: a type of protein)-positive, human epidermal growth factor receptor 2 (HER2: a type of protein)-negative
- C. **If you are using Ibrance in combination with an aromatase inhibitor (such as anastrozole, letrozole, exemestane) as initial endocrine (hormone)-based therapy, approval also requires:**
 - 1. Your cancer is advanced or metastatic (cancer that has progressed or has spread to other parts of the body)
 - 2. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Kisqali (ribociclib), Verzenio (abemaciclib)
- D. **If you are using Ibrance in combination with fulvestrant (Faslodex), approval also requires:**
 - 1. Your cancer is advanced or metastatic (cancer that has progressed or has spread to other parts of the body)
 - 2. Your disease has worsened after endocrine (hormone) therapy (such as anastrozole, letrozole, tamoxifen)
 - 3. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Kisqali (ribociclib), Verzenio (abemaciclib)
- E. **If you are using Ibrance in combination with Itovebi (inavolisib) and fulvestrant (Faslodex), approval also requires:**
 - 1. Your cancer is locally advanced or metastatic (cancer that has spread from where it started to nearby tissue or lymph nodes or to other parts of the body)
 - 2. Your tumor has a PIK3CA mutation (abnormal change in a type of gene), as detected by a Food and Drug Administration (FDA)-approved test
 - 3. You have experienced disease recurrence (disease has returned) on or after completing adjuvant (add-on) endocrine (hormone) therapy (such as anastrozole, letrozole, tamoxifen)

Effective: 05/26/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PALOPEGTERIPARATIDE

Generic	Brand				
PALOPEGTERIPARATIDE	YORVIPATH				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **PALOPEGTERIPARATIDE (Yorvipath)** requires the following rule(s) be met for approval:

- A. You have hypoparathyroidism (low levels of parathyroid hormone)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
- D. Your hypoparathyroidism is NOT due to impaired responsiveness to parathyroid hormone or a history of disease that affects calcium metabolism or calcium-phosphate homeostasis (balance)
- E. You have tried activated vitamin D (such as calcitriol) and calcium

RENEWAL CRITERIA

Our guideline named **PALOPEGTERIPARATIDE (Yorvipath)** requires the following rule(s) be met for renewal:

- A. You have hypoparathyroidism (low levels of parathyroid hormone)
- B. You are independent of or managed on a lowered dose of vitamin D and calcium supplements

Effective: 09/23/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PALOVAROTENE

Generic	Brand				
PALOVAROTENE	SOHONOS				

GUIDELINES FOR USE

Our guideline named **PALOVAROTENE (Sohonos)** requires the following rule(s) be met for approval:

- A. You have fibrodysplasia ossificans progressiva (FOP: a type of rare genetic tissue disorder)
- B. You meet ONE of the following:
 - 1. You are female and 8 years of age or older
 - 2. You are male and 10 years of age or older

Effective: 12/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PANITUMUMAB

Generic	Brand				
PANITUMUMAB	VECTIBIX				

GUIDELINES FOR USE

Our guideline named **PANITUMUMAB (Vectibix)** requires the following rule(s) be met for approval:

- A. You have metastatic colorectal cancer (mCRC: a type of digestive cancer that has spread to other parts of the body)
- B. You are 18 years of age or older
- C. Your cancer is wild-type RAS (defined as wild-type in both KRAS and NRAS [types of genes without a specific mutation]), OR you have a KRAS G12C-mutation [type of abnormal change in a gene], as determined by a Food and Drug Administration (FDA)-approved test
- D. **If your cancer is wild-type RAS, approval also requires ONE of the following:**
 - 1. Vectibix will be used in combination with FOLFOX (treatment regimen containing leucovorin calcium [folinic acid], fluorouracil, oxaliplatin)
 - 2. Vectibix will be used as monotherapy (one drug treatment) AND you have disease progression (worsening) after treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy (drugs used to treat cancer)
- E. **If your cancer has a KRAS G12C-mutation, approval also requires:**
 - 1. Vectibix will be used in combination with Lumakras (sotorasib)
 - 2. You have received previous treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy

Effective: 02/24/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PARATHYROID HORMONE

Generic	Brand			
PARATHYROID HORMONE	NATPARA			

GUIDELINES FOR USE

Our guideline for **PARATHYROID HORMONE** requires the following rule(s) be met for approval:

- A. You have hypocalcemia secondary to hypoparathyroidism (low blood calcium due to low levels of a type of hormone)
- B. You have previously tried activated vitamin D (calcitriol) and calcium
- C. Your hypoparathyroidism (low levels of a type of hormone) is not due to a calcium sensing receptor (CSR) mutation (changes in your DNA that make up your gene)
- D. Your hypoparathyroidism is not considered acute post-surgical hypoparathyroidism (not sudden and severe due to surgery in past 30 days)
- E. Therapy is prescribed by or given in consultation with an endocrinologist (hormone specialist)

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PASIREOTIDE

Generic	Brand			
PASIREOTIDE	SIGNIFOR			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **PASIREOTIDE (Signifor)** requires the following rule(s) be met for approval:

- A. You have Cushing's disease (CD: a condition in which the pituitary gland releases too much of a hormone called adrenocorticotrophic hormone [ACTH])
- B. You are 18 years of age or older
- C. Therapy is prescribed by or given in consultation with an endocrinologist (doctor who specializes in hormones)
- D. You have undergone pituitary (a major hormone gland) surgery OR pituitary surgery is not an option
- E. You have previously tried oral ketoconazole, unless there is a medical reason you are cannot (contraindication)

RENEWAL CRITERIA

Our guideline named **PASIREOTIDE (Signifor)** requires the following rule(s) be met for renewal:

- A. You have Cushing's disease (CD: a condition in which the pituitary gland releases too much of a hormone called adrenocorticotrophic hormone [ACTH])
- B. You continue to have improvement of Cushing's disease (such as clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of your disease)
- C. You continue to tolerate treatment with Signifor

Effective: 10/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PATROMER

Generic	Brand			
PATROMER CALCIUM SORBITEX	VELTASSA			

GUIDELINES FOR USE

Our guideline named **PATROMER (Veltassa)** requires the following rule(s) be met for approval:

- A. You have hyperkalemia (high level of potassium in the blood)
- B. You are 12 years of age or older
- C. Therapy is prescribed by or in consultation with a nephrologist (a type of kidney doctor) or cardiologist (a type of heart doctor)
- D. Veltassa is NOT being used as an emergency treatment for life-threatening hyperkalemia (high level of potassium in the blood)
- E. You are NOT currently receiving dialysis (process of removing excess water, toxins from the blood)
- F. You have tried ONE of the following to lower the risks for hyperkalemia (high level of potassium in the blood):
 - 1. You are not taking both an angiotensin converting enzyme inhibitor (ACE-I, such as lisinopril, benazepril) and an angiotensin receptor blocker (ARB, such as valsartan, losartan) at the same time
 - 2. You have lowered the dose of a renin-angiotensin-aldosterone system (RAAS) inhibitor (such as lisinopril, valsartan, spironolactone)
- G. You meet ONE of the following:
 - 1. Your estimated glomerular filtration rate (eGFR: a tool for evaluating kidney function) is less than 30mL/min/1.73m², AND you have tried a loop diuretic (such as bumetanide, ethacrynic acid, furosemide, torsemide)
 - 2. Your estimated glomerular filtration rate (eGFR) is at least 30 mL/min/1.73m², AND you have tried a loop diuretic (such as bumetanide, ethacrynic acid, furosemide, torsemide) OR a thiazide diuretic (such as chlorthalidone, hydrochlorothiazide, metolazone)
- H. If you are 18 years of age or older, you have tried Lokelma (sodium zirconium cyclosilicate)

Effective: 10/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PAZOPANIB

Generic	Brand			
PAZOPANIB HCL	VOTRIENT, PAZOPANIB HCL			

GUIDELINES FOR USE

Our guideline named **PAZOPANIB (Votrient)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Advanced renal cell carcinoma (RCC: a type of kidney cancer)
 - 2. Advanced soft tissue sarcoma (STS: cancer that starts in soft tissues [muscle, tendons, fat, lymph vessels, blood vessels, nerves])
- B. **If you have advanced renal cell carcinoma, approval also requires:**
 - 1. You are 18 years of age or older
- C. **If you have advanced soft tissue sarcoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have received prior chemotherapy (a type of cancer therapy such as anthracycline treatment)
 - 3. You do NOT have adipocytic soft tissue sarcoma (STS: a type of fat cell cancer) or gastrointestinal stromal tumors (GIST: a type of digestive tumor)

Effective: 11/06/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEANUT ALLERGEN POWDER-DNFP

Generic	Brand				
PEANUT ALLERGEN POWDER-DNFP	PALFORZIA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **PEANUT ALLERGEN POWDER-DNFP (Palforzia)** requires the following rule(s) be met for approval:

- A. You have an allergy to peanuts
- B. You are 1 to 17 years of age
- C. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor) or immunologist (a type of immune system doctor)
- D. You have a clinical history of an allergic reaction to peanuts
- E. Palforzia will be used together with a peanut-avoidance diet
- F. Palforzia will NOT be used concurrently (at the same time) with peanut-specific immunotherapy (such as Viaskin Peanut)
- G. Your diagnosis is confirmed by ONE of the following:
 1. If you have completed a purposeful food challenge (a type of test): you had a positive skin prick test (a skin test to check for peanut allergy) with a wheal diameter of at least 3 mm within the past 24 months, OR you have had a peanut-specific immunoglobulin E (IgE) (a blood test that indicates an allergy to peanuts) level of at least 0.35 kUA/L within the past 24 months
 2. If you have NOT completed a purposeful food challenge (a type of test): you had a positive skin prick test (a skin test to check for peanut allergy) with a wheal diameter of at least 8 mm within the past 24 months, OR you have had a peanut-specific immunoglobulin E (IgE) (a blood test that indicates an allergy to peanuts) level of at least 14 kUA/L within the past 24 months

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEANUT ALLERGEN POWDER-DNFP

RENEWAL CRITERIA

Our guideline named **PEANUT ALLERGEN POWDER-DNFP (Palforzia)** requires the following rule(s) be met for renewal:

- A. You have an allergy to peanuts
- B. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor) or immunologist (a type of immune system doctor)
- C. Palforzia will be used together with a peanut-avoidance diet
- D. Palforzia will NOT be used concurrently (at the same time) with peanut-specific immunotherapy (such as Viaskin Peanut)
- E. You meet ONE of the following:
 - 1. If you have completed a purposeful food challenge (a type of test): you have a persistent peanut allergy based on a positive skin prick test (a skin test to check for peanut allergy) with a wheal diameter of at least 3 mm within the past 24 months, OR based on a peanut-specific immunoglobulin E (IgE) (a blood test that indicates an allergy to peanuts) level of at least 0.35 kUA/L within the past 24 months
 - 2. If you have NOT completed a purposeful food challenge (a type of test): you have a persistent peanut allergy based on a positive skin prick test (a skin test to check for peanut allergy) with a wheal diameter of at least 8 mm within the past 24 months, OR based on a peanut-specific immunoglobulin E (IgE) (a blood test that indicates an allergy to peanuts) level of at least 14 kUA/L within the past 24 months

Effective: 04/07/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEGCETACOPLAN - SQ

Generic	Brand				
PEGCETACOPLAN	EMPAVELI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **PEGCETACOPLAN - SQ (Empaveli)** requires the following rule(s) be met for approval:

- A. You have paroxysmal nocturnal hemoglobinuria (PNH: a rare blood disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
- D. You have flow cytometry (a type of lab test) demonstrating at least 2 different GPI-protein deficiencies (you are missing a certain type of protein, such as CD55, CD59) on at least 2 cell lineages (types of cells, such as erythrocytes [red blood cells], granulocytes [a type of white blood cell]) AND a PNH granulocyte clone size of at least 10 percent
- E. You have tried and failed (as shown by hemoglobin [Hgb: a type of protein in red blood cells] levels less than 10.5 g/dL immediately following at least 3 months of stable dosing) or have a contraindication to (harmful for you to use) Ultomiris (ravulizumab-cwvz) or Soliris (eculizumab)
- F. You will NOT use Empaveli concurrently (at the same time) with C5 complement inhibitor therapy (such as Ultomiris [ravulizumab-cwvz], Soliris [eculizumab], Piasky [crovalimab-akkz]), Factor B inhibitor therapy (such as Fabhalta [iptacopan]) or Factor D inhibitor therapy (such as Voydeya [danicopan])

RENEWAL CRITERIA

Our guideline named **PEGCETACOPLAN - SQ (Empaveli)** requires the following rule(s) be met for renewal:

- A. You have paroxysmal nocturnal hemoglobinuria (PNH: a rare blood disorder)
- B. You have experienced a clinical benefit (such as a reduction in the number of blood transfusions [adding blood to your body], improvement/stabilization of lactate dehydrogenase [LDH: a type of enzyme] levels and hemoglobin [Hgb: a type of protein in red blood cells] levels) compared to baseline (baseline is defined as your condition after treatment with Soliris [eculizumab] or Ultomiris [ravulizumab-cwvz])
- C. You will NOT use Empaveli concurrently (at the same time) with C5 complement inhibitor therapy (such as Ultomiris [ravulizumab-cwvz], Soliris [eculizumab], Piasky [crovalimab-akkz]), Factor B inhibitor therapy (such as Fabhalta [iptacopan]) or Factor D inhibitor therapy (such as Voydeya [danicopan])

Effective: 10/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEGFILGRASTIM

Generic	Brand				
PEGFILGRASTIM	NEULASTA, NEULASTA ONPRO				

GUIDELINES FOR USE

Our guideline named **PEGFILGRASTIM (Neulasta, Neulasta Onpro)** requires the following rule(s) be met for approval:

- A. You meet ONE of the following:
1. You are receiving myelosuppressive anti-cancer medications (medications that decrease bone marrow activity) associated with a clinically significant incidence of febrile neutropenia (a type of blood condition with fever)
 2. You have been acutely exposed to myelosuppressive doses (doses that decrease bone marrow activity) of radiation (hematopoietic subsyndrome of acute radiation syndrome [H-ARS]: an illness that happens after whole body radiation)
- B. **If you are receiving myelosuppressive anti-cancer medications associated with a clinically significant incidence of febrile neutropenia, approval also requires:**
1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
 2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
 3. You meet ONE of the following:
 - a. You are requesting Neulasta AND you have tried or have a contraindication to (harmful for you to use) the preferred medication: Ziextenzo (pegfilgrastim-bmez)
 - b. You are requesting Neulasta Onpro AND you have tried or have a contraindication to (harmful for you to use) the preferred medication: Udenyca Onbody (pegfilgrastim-cbqv)
- C. **If you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:**
1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
 2. You meet ONE of the following:
 - a. You are requesting Neulasta AND you have tried or have a contraindication to (harmful for you to use) the preferred medication: Ziextenzo (pegfilgrastim-bmez)
 - b. You are requesting Neulasta Onpro AND you have tried or have a contraindication to (harmful for you to use) the preferred medication: Udenyca Onbody (pegfilgrastim-cbqv)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEGFILGRASTIM - APGF

Generic	Brand				
PEGFILGRASTIM-APGF	NYVEPRIA				

GUIDELINES FOR USE

Our guideline named **PEGFILGRASTIM-APGF (Nyvepria)** requires the following rule(s) be met for approval:

- A. You meet ONE of the following:
1. You are receiving myelosuppressive anti-cancer medications (medications that decrease bone marrow activity) associated with a clinically significant incidence of febrile neutropenia (a type of blood condition with fever)
 2. You have been acutely exposed to myelosuppressive doses (doses that decrease bone marrow activity) of radiation (hematopoietic subsyndrome of acute radiation syndrome [H-ARS]: an illness that happens after whole body radiation)
- B. **If you are receiving myelosuppressive anti-cancer medications associated with a clinically significant incidence of febrile neutropenia, approval also requires:**
1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
 2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
 3. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Ziextenzo (pegfilgrastim-bmez)
- C. **If you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:**
1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
 2. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Ziextenzo (pegfilgrastim-bmez)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEGFILGRASTIM - BMEZ

Generic	Brand				
PEGFILGRASTIM-BMEZ	ZIEXTENZO				

GUIDELINES FOR USE

Our guideline named **PEGFILGRASTIM-BMEZ (Ziextenzo)** requires the following rule(s) be met for approval:

- A. You meet ONE of the following:
 - 1. You are receiving myelosuppressive anti-cancer medications (medications that decrease bone marrow activity) associated with a clinically significant incidence of febrile neutropenia (a type of blood condition with fever)
 - 2. You have been acutely exposed to myelosuppressive doses (doses that decrease bone marrow activity) of radiation (hematopoietic subsyndrome of acute radiation syndrome [H-ARS]: an illness that happens after whole body radiation)
- B. **If you are receiving myelosuppressive anti-cancer medications associated with a clinically significant incidence of febrile neutropenia, approval also requires:**
 - 1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
 - 2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
- C. **If you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:**
 - 1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEGFILGRASTIM - CBQV

Generic	Brand				
PEGFILGRASTIM-CBQV	UDENYCA, UDENYCA ONBODY				

GUIDELINES FOR USE

Our guideline named **PEGFILGRASTIM - CBQV (Udenyca, Udenyca Onbody)** requires the following rule(s) be met for approval:

- A. You meet ONE of the following:
1. You are receiving myelosuppressive anti-cancer medications (medications that decrease bone marrow activity) associated with a clinically significant incidence of febrile neutropenia (a type of blood condition with fever)
 2. You have been acutely exposed to myelosuppressive doses (doses that decrease bone marrow activity) of radiation (hematopoietic subsyndrome of acute radiation syndrome [H-ARS]: an illness that happens after whole body radiation)
- B. **If you are receiving myelosuppressive anti-cancer medications associated with a clinically significant incidence of febrile neutropenia, approval also requires:**
1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
 2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
 3. If you are requesting Udenyca, approval also requires you have tried or have a contraindication to (harmful for you to use) the preferred medication: Ziextenzo (pegfilgrastim-bmez)
- C. **If you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:**
1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
 2. If you are requesting Udenyca, approval also requires you have tried or have a contraindication to (harmful for you to use) the preferred medication: Ziextenzo (pegfilgrastim-bmez)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEGFILGRASTIM-FPGK

Generic	Brand				
PEGFILGRASTIM-FPGK	STIMUFEND				

GUIDELINES FOR USE

Our guideline named **PEGFILGRASTIM-FPGK (Stimufend)** requires the following rule(s) be met for approval:

A. You meet ONE of the following:

1. You are receiving myelosuppressive anti-cancer medications (medications that decrease bone marrow activity) associated with a clinically significant incidence of febrile neutropenia (a type of blood condition with fever)
2. You have been acutely exposed to myelosuppressive doses (doses that decrease bone marrow activity) of radiation (hematopoietic subsyndrome of acute radiation syndrome [H-ARS]: an illness that happens after whole body radiation)

B. If you are receiving myelosuppressive anti-cancer medications associated with a clinically significant incidence of febrile neutropenia, approval also requires:

1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
3. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Ziextenzo (pegfilgrastim-bmez)

C. If you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:

1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
2. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Ziextenzo (pegfilgrastim-bmez)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEGFILGRASTIM-JMDB

Generic	Brand				
PEGFILGRASTIM-JMDB	FULPHILA				

GUIDELINES FOR USE

Our guideline named **PEGFILGRASTIM-JMDB (Fulphila)** requires the following rule(s) be met for approval:

- A. You meet ONE of the following:
1. You are receiving myelosuppressive anti-cancer medications (medications that decrease bone marrow activity) associated with a clinically significant incidence of febrile neutropenia (a type of blood condition with fever)
 2. You have been acutely exposed to myelosuppressive doses (doses that decrease bone marrow activity) of radiation (hematopoietic subsyndrome of acute radiation syndrome [H-ARS]: an illness that happens after whole body radiation)
- B. **If you are receiving myelosuppressive anti-cancer medications associated with a clinically significant incidence of febrile neutropenia, approval also requires:**
1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
 2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
 3. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Ziextenzo (pegfilgrastim-bmez)
- C. **If you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:**
1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
 2. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Ziextenzo (pegfilgrastim-bmez)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEGFILGRASTIM-PBBK

Generic	Brand				
PEGFILGRASTIM-PBBK	FYLNETRA				

GUIDELINES FOR USE

Our guideline named **PEGFILGRASTIM-PBBK (Fynetra)** requires the following rule(s) be met for approval:

- A. You meet ONE of the following:
1. You are receiving myelosuppressive anti-cancer medications (medications that decrease bone marrow activity) associated with a clinically significant incidence of febrile neutropenia (a type of blood condition with fever)
 2. You have been acutely exposed to myelosuppressive doses (doses that decrease bone marrow activity) of radiation (hematopoietic subsyndrome of acute radiation syndrome [H-ARS]: an illness that happens after whole body radiation)
- B. **If you are receiving myelosuppressive anti-cancer medications associated with a clinically significant incidence of febrile neutropenia, approval also requires:**
1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
 2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
 3. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Ziextenzo (pegfilgrastim-bmez)
- C. **If you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:**
1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
 2. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Ziextenzo (pegfilgrastim-bmez)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEG-INTERFERON ALFA-2B

Generic	Brand			
PEG-INTERFERON ALFA-2B	SYLATRON, SYLATRON 4-PACK			

GUIDELINES FOR USE

Our guideline named **PEG-INTERFERON ALFA-2B (Sylatron)** requires the following rule(s) be met for approval:

- A. You meet ONE of the following:
1. You are currently taking Sylatron and have NOT received 5 years of treatment with Sylatron
 2. You have melanoma (skin cancer) with the presence of cancer cells in your lymph nodes (microscopic or gross nodal involvement), within 84 days of surgical removal of the cancer

Effective: 10/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEGINTERFERON ALFA 2A OR 2B (PEGASYS OR PEGINTRON)

Generic	Brand			
PEGINTERFERON ALFA-2A	PEGASYS, PEGASYS PROCLICK			
PEGINTERFERON ALFA-2B	PEGINTRON			

GUIDELINES FOR USE

Our guideline named **PEGINTERFERON ALFA-2A or 2B (Pegasys, PegIntron)** requires the following rule(s) be met for approval:

- A. You have chronic hepatitis B (a type of liver infection)
- B. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive condition), infectious disease specialist (a doctor who specializes in the treatment of infections), a doctor specializing in the treatment of hepatitis such as a hepatologist (liver doctor), or a specially trained group such as ECHO (Extension for Community Healthcare Outcomes) model
- C. **If you are between 3 to 17 years of age, approval also requires:**
 - 1. You do NOT have cirrhosis (liver damage)
 - 2. Your blood test shows you have HBeAg (marker of active virus multiplying in the body)-positive chronic hepatitis B
 - 3. You have evidence of viral replication (virus is multiplying in the body) with elevated serum alanine aminotransferase (ALT: a type of liver enzyme test)
- D. **If you are 18 years of age or older, approval also requires:**
 - 1. Your blood test shows you have HBeAg (marker of active virus multiplying in the body)-positive or HBeAg-negative chronic hepatitis B
 - 2. You have compensated liver disease (a type of liver condition) with evidence of viral replication and liver inflammation

Note: Pegasys and PegIntron will not be approved for the treatment of hepatitis C.

Effective: 05/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEGVALIASE-PQPZ

Generic	Brand			
PEGVALIASE-PQPZ	PALYNZIQ			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **PEGVALIASE-PQPZ (Palynziq)** requires the following rules be met for approval:

- A. You have phenylketonuria (PKU: a type of birth defect that causes buildup of a chemical called phenylalanine)
- B. You are 18 years of age or older
- C. You have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management, as confirmed by a measurement in the last 30 days
- D. You have tried Kuvan (sapropterin)
- E. You are NOT receiving Kuvan (sapropterin) at the same time as Palynziq (pegvaliase)

RENEWAL CRITERIA

Our guideline named **PEGVALIASE-PQPZ (Palynziq)** requires the following rules be met for renewal:

- A. You have phenylketonuria (PKU: a type of birth defect that causes buildup of a chemical called phenylalanine)
- B. Your phenylalanine levels have dropped by at least 20% from baseline or to a level under 600 micromol/L

Effective: 04/10/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEMETREXED DIPOTASSIUM

Generic	Brand				
PEMETREXED DIPOTASSIUM	AXTLE, PEMETREXED DIPOTASSIUM				

GUIDELINES FOR USE

Our guideline named **PEMETREXED DIPOTASSIUM (Axtle)** requires the following rule(s) be met for approval:

- A. The request is for ONE of the following:
 - 1. Locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC) (a type of lung cancer that has spread to nearby tissue or lymph nodes or other parts of the body)
 - 2. Recurrent, metastatic, non-squamous, non-small cell lung cancer (NSCLC) (a type of lung cancer that has returned and spread to other parts of the body)
 - 3. Malignant pleural mesothelioma (a type of cancer)
 - 4. The requested medication is being used in combination with another chemotherapy agent(s) for a Food and Drug Administration (FDA)-approved indication
- B. **If you have locally advanced or metastatic, non-squamous, non-small cell lung cancer, approval also requires ONE of the following:**
 - 1. The requested medication will be used in combination with cisplatin
 - 2. The requested medication will be used as a single agent, for maintenance therapy AND your disease has not progressed (gotten worse) after four cycles of platinum-based first-line chemotherapy (a type of therapy to treat cancer such as cisplatin, carboplatin)
- C. **If you have recurrent, metastatic non-squamous, non-small cell lung cancer, approval also requires:**
 - 1. The requested medication will be used as a single agent
 - 2. You have received prior chemotherapy
- D. **If you have malignant pleural mesothelioma, approval also requires:**
 - 1. The requested medication will be used in combination with cisplatin
 - 2. Your disease is unresectable (cannot be completely removed by surgery) OR you are not a candidate for curative surgery

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEMIGATINIB

Generic	Brand				
PEMIGATINIB	PEMAZYRE				

GUIDELINES FOR USE

Our guideline named **PEMIGATINIB (Pemazyre)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer that has spread to nearby tissue and lymph nodes and cannot be removed by surgery, or it has spread to other parts of the body)
 - 2. Relapsed or refractory myeloid/lymphoid neoplasms (a type of blood cancer that has returned or did not respond to treatment)
- B. **If you have unresectable locally advanced or metastatic cholangiocarcinoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have previously been treated for unresectable locally advanced or metastatic cholangiocarcinoma
 - 3. You have a fibroblast growth factor receptor 2 (FGFR2: a type of protein) fusion or other rearrangement as detected by a Food and Drug Administration (FDA)-approved test
 - 4. You will complete a comprehensive ophthalmological examination (eye exam), including optical coherence tomography (OCT: a type of eye imaging test), before starting the medication and at the recommended scheduled times
- C. **If you have relapsed or refractory myeloid/lymphoid neoplasms, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have a fibroblast growth factor receptor 1 (FGFR1: a type of protein) rearrangement
 - 3. You will complete a comprehensive ophthalmological examination (eye exam), including optical coherence tomography (OCT: a type of eye imaging test), before starting the medication and at the recommended scheduled times

Effective: 01/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PENICILLAMINE

Generic	Brand			
PENICILLAMINE	CUPRIMINE, PENICILLAMINE			
PENICILLAMINE	DEPEN, PENICILLAMINE			
PENICILLAMINE	D-PENAMINE			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **PENICILLAMINE (Cuprimine, Depen, D-Penamine)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
2. Cystinuria (a type of genetic metabolic disorder)
3. Active rheumatoid arthritis (a type of joint condition)

B. **If you have Wilson's disease, approval also requires:**

1. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor) or gastroenterologist (a type of digestive system doctor)
2. You have a Leipzig score of 4 or greater (a type of diagnostic score)
3. You are willing to follow a diet avoiding high copper foods (such as shellfish, nuts, chocolate, mushrooms, organ meat)
4. If you are requesting Cuprimine, you had a trial of or have a contraindication (harmful for) to Depen (penicillamine) or D-Penamine (penicillamine)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PENICILLAMINE

INITIAL CRITERIA (CONTINUED)

C. If you have cystinuria, approval also requires:

1. Therapy is prescribed by or in consultation with a nephrologist (kidney doctor)
2. You have a daily cystine output greater than 300mg per 24 hours after urine cystine excretion testing
3. You have failed to respond to an adequate trial of or has a contraindication (harmful for) to conventional therapy which includes ALL of the following:
 - a. Increased fluid intake
 - b. Modest reductions in sodium and protein intake
 - c. Urinary alkalization (a process that makes urine basic)
4. You have nephrolithiasis (kidney stones) and ONE of the following:
 - a. Your kidney stone analysis shows that there is a presence of cystine (an amino acid)
 - b. Your urine analysis shows that there are hexagonal cystine crystals in your urine that are pathognomonic (signs relating to the disease)
 - c. You have a family history of cystinuria and positive test results in the cyanide-nitroprusside screen (a test to determine the amount of cysteine in your body)
5. If you are requesting Cuprimine, you had a trial of or have a contraindication (harmful for) to Depen (penicillamine) or D-Penamine (penicillamine) AND Thiola (tiopronin)

D. If you have active rheumatoid arthritis, approval requires:

1. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
2. You do not have a history or other evidence of renal insufficiency (kidney problems)
3. You have failed to respond to an adequate trial of at least 3 months of conventional therapy including at least ONE of the following DMARD (disease-modifying antirheumatic drug) agents: methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
4. If you are requesting Cuprimine, you had a trial of or have a contraindication (harmful for) to Depen (penicillamine) or D-Penamine (penicillamine)

E. If you have an active prior authorization approval for Depen, D-Penamine will be approved without meeting additional criteria during the period of Depen shortage.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PENICILLAMINE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **PENICILLAMINE (Cuprimine, Depen, D-Penamine)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:

1. Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
2. Cystinuria (a type of genetic metabolic disorder)
3. Active rheumatoid arthritis (a type of joint condition)

B. **If you have Wilson's disease, approval also requires:**

1. You have achieved a free serum copper of less than 10 mcg/dL

C. **If you have cystinuria, approval also requires:**

1. You have achieved a cystine excretion of less than 200 mg/day

D. **If you have active rheumatoid arthritis, approval also requires:**

1. You do not have a history of or other evidence of renal insufficiency (kidney problems)
2. You have experienced or maintained improvement in tender joint count or swollen joint count while on therapy compared to baseline

Effective: 05/08/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PENTOSAN POLYSULFATE

Generic	Brand				
PENTOSAN POLYSULFATE SODIUM	ELMIRON				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **PENTOSAN POLYSULFATE (Elmiron)** requires the following rule(s) be met for approval:

- A. You have a diagnosis of interstitial cystitis/bladder (painful bladder condition) pain syndrome ongoing for at least six weeks

RENEWAL CRITERIA

Our guideline named **PENTOSAN POLYSULFATE (Elmiron)** requires the following rule(s) be met for renewal:

- A. You have experienced clinical improvement from baseline secondary to treatment

Effective: 04/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PEXIDARTINIB

Generic	Brand			
PEXIDARTINIB	TURALIO			

GUIDELINES FOR USE

Our guideline named **PEXIDARTINIB (Turalio)** requires the following rules be met for approval:

- A. You have symptomatic tenosynovial giant cell tumor (TGCT: type of non-cancerous growth in or around a joint causing tissue damage and reducing function)
- B. TGCT is associated with severe morbidity (disease) or functional limitations
- C. TGCT is NOT responsive to improvement with surgery
- D. You are 18 years of age or older

Effective: 04/10/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PHENOXYBENZAMINE

Generic	Brand			
PHENOXYBENZAMINE HCL	DIBENZYLINE, PHENOXYBENZ A-MINE HCL			

GUIDELINES FOR USE

Our guideline named **PHENOXYBENZAMINE (Dibenzyliline)** requires the following rules be met for approval:

- A. You have pheochromocytoma (a type of rare tumor)
- B. The requested medication will be used before surgery to remove the tumor
- C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor), an endocrine surgeon (surgeon specializing in removal of glands such as adrenal glands), or a hematologist-oncologist (a type of cancer doctor)
- D. You have tried or have a contraindication to (harmful for you to use) an alpha-1 selective adrenergic receptor blocker (such as doxazosin, terazosin, prazosin)

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PHENTERMINE - TOPIRAMATE

Generic	Brand				
PHENTERMINE/ TOPIRAMATE	QSYMIA, PHENTERMINE -TOPIRAMATE ER				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **PHENTERMINE - TOPIRAMATE (Qsymia)** requires the following rule(s) be met for approval:

- A. The request is for weight loss OR weight loss management
- B. You are 12 years of age or older
- C. You are actively enrolled in an exercise and caloric reduction program which may include use of an optional weight loss/behavioral modification program
- D. **If you are 18 years of age or older, approval also requires:**
 - 1. You meet ONE of the following:
 - a. You have a body mass index (BMI: a tool for evaluating body fat) of at least 30 kg/m(2)
 - b. You have a BMI of at least 27 kg/m(2) AND at least ONE weight-related comorbidity (disease) (such as hypertension [high blood pressure], type 2 diabetes mellitus [a disorder with high blood sugar], or hyperlipidemia [high cholesterol])
- E. **If you are 12 to 17 years of age, approval also requires:**
 - 1. Your initial body mass index (BMI: a tool for evaluating body fat) is in the 95th percentile or greater for age and sex

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PHENTERMINE - TOPIRAMATE

RENEWAL CRITERIA

Our guideline named **PHENTERMINE - TOPIRAMATE (Qsymia)** requires the following rule(s) be met for renewal:

- A. The request is for weight loss OR weight loss management
- B. **If you are requesting Qsymia (phentermine-topiramate ER) 7.5/46mg, renewal also requires ONE of the following:**
 - 1. You are 18 years of age or older AND have achieved or maintained at least a 5% weight loss of baseline body weight after 3 months of treatment
 - 2. You are 12 to 17 years of age AND have achieved or maintained at least a 3% weight loss of baseline body mass index (BMI: a tool for evaluating body fat) after at least 3 months of treatment
- C. **If you are requesting Qsymia (phentermine-topiramate ER) 15/92mg, renewal also requires ONE of the following:**
 - 1. You are 18 years of age or older AND have achieved or maintained at least a 5% weight loss of baseline body weight after 3 months of treatment
 - 2. You are 12 to 17 years of age AND have achieved or maintained at least a 5% weight loss of baseline body mass index (BMI: a tool for evaluating body fat) after 3 months of treatment

Effective: 06/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PILOCARPINE

Generic	Brand				
PILOCARPINE HCL	VUITY, PILOCA RPINE HCL				
PILOCARPINE HCL	QLOSI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **PILOCARPINE (Vuity, Qlosi)** requires the following rule(s) be met for approval:

- A. You have presbyopia (not able to focus on nearby objects)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or optometrist (a type of eye doctor)
- D. You are not using corrective lenses OR corrective lenses are insufficient to completely correct your vision
- E. You have tried or have a contraindication to (harmful for you to use) generic pilocarpine ophthalmic (eye) solution
- F. You will NOT use the requested medication concurrently (at the same time) with another pilocarpine eyedrop

RENEWAL CRITERIA

Our guideline named **PILOCARPINE (Vuity, Qlosi)** requires the following rule(s) be met for renewal:

- A. You have presbyopia (not able to focus on nearby objects)
- B. You are not using corrective lenses OR corrective lenses are insufficient to completely correct your vision
- C. You will NOT use the requested medication concurrently (at the same time) with another pilocarpine eyedrop
- D. You continue to experience benefit from the requested medication

Effective: 06/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PIMAVANSERIN

Generic	Brand			
PIMAVANSERIN	NUPLAZID			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named drug named **PIMAVANSERIN (Nuplazid)** requires you to meet the following rule(s) for approval:

- A. You have a diagnosis of psychosis associated with Parkinson's disease (a mental disorder that causes you to have false beliefs or to hear or see things that are not really there and is related to a movement disorder)
- B. You are at least 18 years old; and
- C. The drug is prescribed by a doctor specializing in one of the following areas: neurology (brain doctor), geriatric medicine (specialty that focuses on health care of elderly people), or behavioral health (such as a psychiatrist).

RENEWAL CRITERIA

Our guideline named **PIMAVANSERIN (Nuplazid)** requires that you have experienced an improvement in psychosis symptoms (mental issues such as false beliefs or hearing or seeing things that are not really there) from baseline during the past 12 months of therapy and you show a continued need for treatment.

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PIRFENIDONE

Generic	Brand			
PIRFENIDONE	ESBRIET, PIRFENIDONE			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **PIRFENIDONE (Esbriet)** requires the following rule(s) be met for approval:

- A. You have idiopathic pulmonary fibrosis (IPF: a type of lung condition)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor)
- D. You do NOT have other known causes of interstitial lung disease. Other causes may include connective tissue disease, drug toxicity, asbestos or beryllium exposure, hypersensitivity pneumonitis (type of lung infection), systemic sclerosis (chronic hardening and tightening of the skin and connective tissues), rheumatoid arthritis (a type of joint condition), radiation, sarcoidosis (a type of inflammatory disorder), bronchiolitis obliterans organizing pneumonia (infection affecting the small airways of the lung), human immunodeficiency virus infection (HIV: a type of immune disorder), viral hepatitis (a type of liver inflammation), or cancer
- E. You have a usual interstitial pneumonia (type of lung infection) pattern as evidenced by high-resolution computed tomography (HRCT: type of imaging test) alone or via a combination of surgical lung biopsy (removal of cells or tissue from the body for examination) and HRCT
- F. You have a predicted forced vital capacity (FVC: amount of air exhaled from lungs) of at least 50% at baseline
- G. You do NOT currently smoke cigarettes

RENEWAL CRITERIA

Our guideline named **PIRFENIDONE (Esbriet)** requires the following rule(s) be met for renewal:

- A. You have idiopathic pulmonary fibrosis (IPF: a type of lung condition)
- B. You have experienced a clinically meaningful improvement or maintenance in annual rate of decline.

Effective: 01/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PIRTOBRUTINIB

Generic	Brand				
PIRTOBRUTINIB	JAYPIRCA				

GUIDELINES FOR USE

Our guideline named **PIRTOBRUTINIB (Jaypirca)** requires the following rule(s) be met for approval:

You have ONE of the following:

- Relapsed or refractory mantle cell lymphoma (MCL: type of white blood cell cancer)
- Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (types of blood cancers)

If you have relapsed or refractory mantle cell lymphoma, approval also requires:

You are 18 years of age or older

You have previously received at least TWO lines of systemic therapy (treatment that targets the entire body) for mantle cell lymphoma, including a BTK inhibitor (Bruton's tyrosine kinase inhibitor such as Imbruvica [ibrutinib], Calquence [acalabrutinib], Brukinsa [zanubrutinib])

If you have chronic lymphocytic leukemia or small lymphocytic lymphoma, approval also requires:

You are 18 years of age or older

You have previously received at least TWO prior lines of therapy (treatment that targets the entire body), including a BTK inhibitor (Bruton's tyrosine kinase inhibitor such as Imbruvica [ibrutinib], Calquence [acalabrutinib], Brukinsa [zanubrutinib]) AND a BCL-2 inhibitor (B-cell lymphoma-2 inhibitor such as Venclexta [venetoclax])

Effective: 01/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PITOLISANT

Generic	Brand			
PITOLISANT HCL	WAKIX			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **PITOLISANT (Wakix)** requires the following rule(s) be met for approval:

- A. You have one of the following:
1. Excessive daytime sleepiness (EDS) with narcolepsy (sleep disorder with extreme drowsiness)
 2. Narcolepsy as demonstrated by cataplexy (sleep disorder with extreme drowsiness with sudden and uncontrollable muscle weakness)
- B. **If you have excessive daytime sleepiness with narcolepsy, approval also requires:**
1. You have narcolepsy that is confirmed by **ONE** of the following:
 - a. A Multiple Sleep Latency Test showing a both an average sleep latency of 8 minutes or less **AND** 2 or more early-onset rapid eye movement (REM) sleep test periods
 - b. A Multiple Sleep Latency Test (MSLT) showing both an average sleep latency of 8 minutes or less **AND** one early-onset rapid eye movement (REM) sleep test period (SOREMP) **AND** additionally one SOREMP (within approximately 15 minutes) on a polysomnography (type of sleep test) the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness
 - c. You have low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay (test showing you have low levels of a chemical that helps with staying awake)
 2. You have excessive daytime sleepiness (EDS) lasting for at least 3 months and Epworth Sleepiness Scale (type of sleepiness test) score of more than 10
 3. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
 4. You had a trial of one generic typical stimulant (such as amphetamine sulfate, methylphenidate, etc.) **AND** solriamfetol, armodafinil, or modafinil, unless there is a medical reason why you cannot (contraindication)
- C. **If you have cataplexy with narcolepsy, approval also requires:**
1. Wakix is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
 2. You have tried TWO of the following: venlafaxine, fluoxetine, or a TCA (tricyclic antidepressant such as clomipramine, imipramine)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PITOLISANT

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **PITOLISANT (Wakix)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Excessive daytime sleepiness (EDS) with narcolepsy (sleep disorder with extreme drowsiness)
2. Narcolepsy as demonstrated by cataplexy (sleep disorder with extreme drowsiness with sudden and uncontrollable muscle weakness)

B. You meet ONE of the following:

1. You have demonstrated 25% or more improvement in Epworth Sleepiness Scale (type of sleepiness test) scores compared to baseline
2. You have shown improvement in cataplexy (sudden and uncontrollable muscle weakness) symptoms compared to baseline
3. You have demonstrated improvement in sleep latency (the amount of time it takes to fall asleep) from baseline

Effective: 01/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PIVMECILLINAM

Generic	Brand				
PIVMECILLINAM HCL	PIVYA				

GUIDELINES FOR USE

Our guideline named **PIVMECILLINAM (Pivya)** requires the following rule(s) be met for approval:

- A. You have uncomplicated urinary tract infection (uUTI: a type of bacterial infection)
- B. You are 18 years of age or older
- C. You are a female
- D. You meet ONE of the following:
 - 1. Therapy is prescribed by or in consultation with an Infectious Disease (ID) specialist (a doctor who specializes in the treatment of infections)
 - 2. Therapy is a continuation of care from an inpatient setting
 - 3. You meet ALL of the following:
 - a. There is a culture (a type of laboratory test) that shows your infection is caused by a multidrug-resistant (other medications did not work well) bacteria
 - b. Pivya will work against the bacteria from the culture
 - c. The bacteria is resistant (other medication did not work well), or you have a contraindication to (harmful for you to use) other beta-lactams medications (such as cefdinir, cefaclor), fluoroquinolone medications (such as ciprofloxacin, levofloxacin), cephalosporins, penicillins, nitrofurantoin, and sulfamethoxazole/trimethoprim medications

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PLASMINOGEN

Generic	Brand				
PLASMINOGEN HUMAN-TVMH	RYPLAZIM				

GUIDELINES FOR USE

Our guideline named **PLASMINOGEN (Ryplazim)** requires the following rule(s) be met for approval:

- A. You have a diagnosis of plasminogen deficiency type 1 (hypoplasminogenemia: a type of genetic condition)

Effective: 04/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

POMALIDOMIDE

Generic	Brand			
POMALIDOMIDE	POMALYST			

GUIDELINES FOR USE

Our guideline named **POMALIDOMIDE (Pomalyst)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Multiple myeloma (MM: cancer that forms in your white blood cells)
 - 2. Kaposi sarcoma (KS: cancer that forms from the cells in your lymph or blood vessels)
- B. **If you have multiple myeloma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. The requested medication is used in combination with dexamethasone
 - 3. You have tried at least two drugs including Revlimid (lenalidomide) and a proteasome inhibitor (type of cancer drug such as Velcade [bortezomib], Kyprolis [carfilzomib], or Ninlaro [ixazomib])
- C. **If you have Kaposi sarcoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You meet ONE of the following:
 - a. You have acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma after failing highly active antiretroviral therapy (HAART: medications used to treat human immunodeficiency virus [HIV])
 - b. You are human immunodeficiency virus (HIV)-negative

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PONATINIB

Generic	Brand			
PONATINIB HCL	ICLUSIG			

GUIDELINES FOR USE

Our guideline named **PONATINIB (Iclusig)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Chronic myeloid leukemia (CML: type of blood cancer)
 2. Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL: a type of white blood cell cancer)
- B. **If you have chronic myeloid leukemia, approval also requires:**
1. You are 18 years of age or older
 2. You had a mutational analysis (a type of test) before starting therapy AND Iclusig is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1; a type of abnormal gene) profile
 3. You meet ONE of the following:
 - a. You have T315I-positive (a genetic mutation) CML (chronic phase, accelerated phase, or blast phase)
 - b. You have chronic phase CML AND have a resistance to or are not able to safely use at least TWO prior kinase inhibitor treatments such as Tasisign (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib)
 - c. You have accelerated phase or blast phase CML AND there are no other kinase inhibitors, such as Tasisign (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib), that can be used for your disease
- C. **If you have Philadelphia chromosome positive acute lymphoblastic leukemia, approval also requires:**
1. You are 18 years of age or older
 2. You meet ONE of the following:
 - a. Your cancer is positive for the T315I mutation (a type of abnormal gene)
 - b. There are no other kinase inhibitors [e.g., Tasisign (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib)] indicated for the patient
 - c. You are newly diagnosed AND Iclusig will be used in combination with chemotherapy

Effective: 04/15/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PONESIMOD

Generic	Brand				
PONESIMOD	PONVORY				

GUIDELINES FOR USE

Our guideline named **PONESIMOD (Ponvory)** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older
- C. You have tried ONE sphingosine-1-phosphate receptor modulator (such as fingolimod, Mayzent [siponimod]) AND ONE other medication indicated for the treatment of multiple sclerosis (PLEASE NOTE: these medications may also require prior authorization)

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

POSACONAZOLE

Generic	Brand				
POSACONAZOLE	NOXAFIL, POSACONAZOLE				

GUIDELINES FOR USE

Our guideline named **POSACONAZOLE (Noxafil)** requires the following rule(s) be met for approval:

- A. The request is for ONE of the following:
 - 1. Continuation of therapy after hospital discharge
 - 2. Treatment of invasive aspergillosis (type of fungal infection)
 - 3. Prophylaxis (prevention) of invasive aspergillus or candida infections (types of fungal infection)
 - 4. Oropharyngeal candidiasis (fungal infection of the throat)
 - 5. Esophageal candidiasis (fungal infection in the tube connecting the throat and stomach)
- B. **If the request is for treatment of invasive aspergillosis, approval also requires:**
 - 1. You are 13 years of age or older
 - 2. You are requesting Noxafil (posaconazole) tablets
- C. **If the request is for prophylaxis of invasive aspergillus or candida infections, approval also requires:**
 - 1. You are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplantation (HSCT: bone marrow transplant) recipient with graft versus host disease (GVHD: a type of immune disorder) or you have hematologic malignancies (cancer affecting the blood) with prolonged neutropenia (low levels of a type of white blood cell) from chemotherapy (cancer treatment)
 - 2. If the request is for posaconazole (Noxafil) tablets, you meet ONE of the following:
 - You are 18 years of age or older
 - You are 2 years of age or older AND weigh greater than 40 kg
 - 3. If the request is for posaconazole (Noxafil) suspension, you meet ALL of the following:
 - You are 13 years of age or older
 - You are unable to swallow tablets
 - 4. If the request is for posaconazole (Noxafil) PowderMix, you meet the following:
 - You are 2 to 18 years of age AND weigh less than 40 kg
 - You are unable to swallow tablets
- D. **If the request is for oropharyngeal candidiasis, approval also requires:**
 - 1. You are 13 years of age or older
 - 2. You had a trial of or contraindication (harmful for) to fluconazole OR itraconazole
 - 3. You are requesting Noxafil (posaconazole) oral suspension

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

POSACONAZOLE

GUIDELINES FOR USE (CONTINUED)

E. If the request is for esophageal candidiasis, approval also requires:

1. You are 13 years of age or older
2. You had a trial and failure of or contraindication (harmful for) to TWO of the following:
fluconazole, itraconazole solution, or voriconazole

Effective: 01/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PRALSETINIB

Generic	Brand				
PRALSETINIB	GAVRETO				

GUIDELINES FOR USE

Our guideline named **PRALSETINIB (Gavreto)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
2. Advanced or metastatic thyroid cancer (thyroid cancer that has spread to other parts of the body)

B. **If you have metastatic non-small cell lung cancer, approval also requires:**

1. You are 18 years of age or older
2. You have a rearranged during transfection (*RET*) fusion-positive (a type of gene mutation) tumor that has been detected by a Food and Drug Administration (FDA)-approved test

C. **If you have advanced or metastatic thyroid cancer, approval also requires:**

1. You are 12 years of age or older
2. You have a rearranged during transfection (*RET*) fusion-positive (a type of gene mutation) tumor
3. You need systemic therapy (treatment that targets the entire body)
4. You have received treatment with radioactive iodine, and it did not work or is no longer working (if radioactive iodine is an appropriate treatment option)

Effective: 09/11/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PYRIMETHAMINE

Generic	Brand			
PYRIMETHAMINE	DARAPRIM			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

Our guideline for **PYRIMETHAMINE (Daraprim)** requires the following rule(s) be met for approval:

- A. The request is ONE of the following:
 - 1. Acute treatment of toxoplasmosis (sudden and severe type of parasite infection)
 - 2. Chronic maintenance therapy for toxoplasmosis
 - 3. Primary prophylaxis of toxoplasmosis (prevention of a type of parasite infection)
 - 4. Congenital toxoplasmosis (the infection was passed on to you as a baby from your mother)
- B. **If you are being treated for acute toxoplasmosis, approval also requires:**
 - 1. The medication is prescribed by or given in consultation with an infectious disease specialist (doctor that specializes in treating infections)
- C. **If you are being treated for chronic maintenance for toxoplasmosis, approval also requires:**
 - 1. You are also infected with human immunodeficiency virus (HIV: a virus that weakens your immune system with a parasite infection)
 - 2. You have successfully completed treatment for acute toxoplasmosis for at least 6 weeks treatment duration
 - 3. The medication is prescribed by or given in consultation with an infectious disease specialist (doctor that specializes in treating infections)
- D. **If you are being treated for primary prophylaxis of toxoplasmosis, approval also requires:**
 - 1. You are also infected with human immunodeficiency virus (HIV)
 - 2. The medication is prescribed by or given in consultation with an infectious disease specialist (doctor that specializes in treating infections)
 - 3. You had a previous trial of Bactrim (sulfamethoxazole and trimethoprim), unless there is a medication reason why cannot (contraindication)
 - 4. You tested positive for *Toxoplasma gondii* (a type of parasite) Immunoglobulins (IgG) (i.e., you had a current or past infection with *Toxoplasma gondii*)
 - 5. Your CD4 count (an indicator of how weak your immune system is) is less than 100 cells/mm(3)
- E. **If you have congenital toxoplasmosis, approval also requires:**
 - 1. The medication is prescribed by or given in consultation with a neonatologist (doctor that specializes in sick and premature newborn infants) or pediatric (children and adolescents) infectious disease specialist

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PYRIMETHAMINE

RENEWAL CRITERIA

NOTE: For the diagnosis of congenital toxoplasmosis, please refer to Initial Criteria section.

Our guideline for **PYRIMETHAMINE (Daraprim)** requires the following rule(s) be met for renewal:

A. The request is ONE of the following:

1. Acute treatment of toxoplasmosis (sudden and severe type of parasite infection)
2. Chronic maintenance therapy for toxoplasmosis
3. Primary prophylaxis of toxoplasmosis (prevention of a type of parasite infection)

B. **If you are being treated for acute toxoplasmosis, renewal also requires:**

1. You have persistent clinical disease (headache, neurological symptoms, or fever) and persistent radiographic disease (one or more mass lesions on brain imaging)

C. **If you are being treated for chronic maintenance of toxoplasmosis OR primary prophylaxis for toxoplasmosis, renewal also requires:**

1. You are also infected with human immunodeficiency virus (HIV: a virus that weakens your immune system with a parasite infection)
2. Your CD4 count (an indicator of how weak your immune system is) is less than 200 cells/mm(3)
3. You are currently taking ART (anti-retroviral therapy)

Effective: 04/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

QUIZARTINIB

Generic	Brand				
QUIZARTINIB DIHYDROCHLORIDE	VANFLYTA				

GUIDELINES FOR USE

Our guideline named **QUIZARTINIB (Vanflyta)** requires the following rule(s) be met for approval:

- A. You have newly diagnosed acute myeloid leukemia (AML: a type of blood cancer)
- B. You are 18 years of age or older
- C. Your cancer is FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD: a type of mutation) positive as detected by a Food and Drug Administration (FDA)-approved test
- D. You meet ONE of the following:
 - 1. Vanflyta will be used in combination with standard cytarabine and anthracycline (such as daunorubicin, idarubicin) as induction therapy (a type of therapy to treat cancer), followed by use with cytarabine as consolidation therapy (type of therapy to treat cancer)
 - 2. Vanflyta will be used as maintenance monotherapy (one drug treatment) following consolidation chemotherapy

Effective: 12/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RANIBIZUMAB-SUSVIMO

Generic	Brand				
RANIBIZUMAB, RANIBIZUMAB/INIT FILL NEEDLE	SUSVIMO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **RANIBIZUMAB (Susvimo)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Neovascular (wet) age-related macular degeneration (nAMD: a type of eye condition)
 - 2. Diabetic macular edema (DME: a type of eye condition caused by high blood sugar)
- B. **If you have neovascular (wet) age-related macular degeneration, approval also requires:**
 - 1. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or retina (a part of the eye) specialist
 - 2. You have previously responded to at least TWO intravitreal (into the eye) injections of a vascular endothelial growth factor (VEGF) inhibitor (such as Eylea [aflibercept], Lucentis [ranibizumab], Beovu [brolucizumab-dbll])
 - 3. You will NOT use Susvimo concurrently (at the same time) with other intravitreal VEGF inhibitors (such as Eylea [aflibercept], Lucentis [ranibizumab], Beovu [brolucizumab-dbll]) for the treatment of neovascular (wet) age-related macular degeneration
- C. **If you have diabetic macular edema, approval also requires:**
 - 1. You have previously responded to at least TWO intravitreal (into the eye) injections of a vascular endothelial growth factor (VEGF) inhibitor (such as Eylea [aflibercept], Lucentis [ranibizumab], Beovu [brolucizumab-dbll])

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RANIBIZUMAB-SUSVIMO

RENEWAL CRITERIA

NOTE: For the diagnosis of diabetic macular edema (DME), please refer to the Initial Criteria section.

Our guideline named **RANIBIZUMAB (Susvimo)** requires the following rule(s) be met for renewal:

- A. You have neovascular (wet) age-related macular degeneration (nAMD: a type of eye condition)
- B. You have maintenance or improvement of visual acuity (vision clarity or sharpness)
- C. You will NOT use Susvimo concurrently (at the same time) with other intravitreal (into the eye) vascular endothelial growth factor (VEGF) inhibitors (such as Eylea [aflibercept], Lucentis [ranibizumab], Beovu [brolucizumab-dblj]) for the treatment of neovascular (wet) age-related macular degeneration

Effective: 02/24/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RANOLAZINE

Generic	Brand				
RANOLAZINE	ASPRUZYO SPRINKLE				

GUIDELINES FOR USE

Our guideline named **RANOLAZINE (Aspruzyo Sprinkle)** requires the following rule(s) be met for approval:

- A. You have chronic angina (a type of heart condition)
- B. You had a trial of or contraindication (harmful for) to ranolazine ER (extended release) tablets
- C. You are unable to swallow ranolazine ER tablets
- D. You had a trial of or contraindication (harmful for) to a nitrate (such as nitroglycerin, isosorbide mononitrate, isosorbide dinitrate)

Effective: 10/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RAVULIZUMAB-CWVZ

Generic	Brand				
RAVULIZUMAB-CWVZ	ULTOMIRIS				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **RAVULIZUMAB-CWVZ (Ultomiris)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Paroxysmal nocturnal hemoglobinuria (PNH: a rare blood disorder)
2. Atypical hemolytic uremic syndrome (aHUS: a rare blood disorder)
3. Generalized myasthenia gravis (gMG: a chronic autoimmune disorder)
4. Neuromyelitis optica spectrum disorder (NMOSD: a type of brain disorder)

B. If you have paroxysmal nocturnal hemoglobinuria, approval also requires:

1. You are 1 month of age or older
2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
3. You have flow cytometry (a type of lab test) demonstrating at least 2 different GPI-protein deficiencies (you are missing a certain type of protein, such as CD55, CD59) on at least 2 cell lineages (types of cells, such as erythrocytes [red blood cells], granulocytes [a type of white blood cell]) AND a PNH granulocyte clone size of at least 10 percent
4. You will NOT use Ultomiris concurrently (at the same time) with C5 complement inhibitor therapy (such as Soliris [eculizumab], Piasky [crovalimab-akkz]), C3 complement inhibitor therapy (such as Empaveli [pegcetacoplan]) or Factor B inhibitor therapy (such as Fabhalta [iptacopan])

C. If you have atypical hemolytic uremic syndrome, approval also requires:

1. You are 1 month of age or older

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RAVULIZUMAB-CWVZ

INITIAL CRITERIA (CONTINUED)

D. If you have generalized myasthenia gravis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
3. You have a positive serologic test for the anti-acetylcholine receptor antibody (AChR-Ab+; a type of blood test that shows you have myasthenia gravis)
4. You have Myasthenia Gravis Foundation of America class II, III, or IV (types of severity of disease)
5. You have tried or have a contraindication to (harmful for you to use) ONE corticosteroid (such as prednisone)
6. You have tried or have a contraindication to ONE of the following preferred medications: Rystiggo (rozanolixizumab-noli), Vyvgart (efgartigimod alfa-fcab)/Vyvgart Hytrulo (efgartigimod-hyaluronidase-qvfc)
7. You will NOT use Ultomiris concurrently (at the same time) with another neonatal Fc receptor blocker (such as Rystiggo [rozanolixizumab-noli], Vyvgart [efgartigimod alfa-fcab]) or complement inhibitor (such as Soliris [eculizumab], Zilbrysq [zilucoplan]) for the treatment of generalized myasthenia gravis
8. You meet ONE of the following:
 - a. You have tried or have a contraindication to (harmful for you to use) TWO non-steroidal immunosuppressive therapies (such as azathioprine, cyclophosphamide, methotrexate)
 - b. You have tried or have a contraindication to ONE non-steroidal immunosuppressive therapy if you are on chronic plasmapheresis or plasma exchange (types of blood therapy)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RAVULIZUMAB-CWVZ

INITIAL CRITERIA (CONTINUED)

- E. If you have neuromyelitis optica spectrum disorder (NMOSD), approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
 3. You are positive for anti-aquaporin-4 (AQP4: a type of protein) antibodies
 4. You will NOT use Ultomiris concurrently (at the same time) with another NMOSD medication (such as Rituxan [rituximab], Enspryng [satralizumab-mwge], Uplizna [inebilizumab-cdon], Soliris [eculizumab])
 5. You have at least ONE of the following core clinical characteristics:
 - a. Optic neuritis (a type of brain disorder)
 - b. Acute myelitis (a type of brain disorder)
 - c. Area postrema syndrome (a type of brain disorder)
 - d. Acute brainstem syndrome (a type of brain disorder)
 - e. Symptomatic narcolepsy (a type of sleep condition) or acute diencephalic clinical syndrome (tumor in a part of the brain) with NMOSD-typical diencephalic magnetic resonance imaging (MRI: a type of imaging lab) lesions (affected areas)
 - f. Symptomatic cerebral syndrome with NMOSD-typical brain lesions

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RAVULIZUMAB-CWVZ

RENEWAL CRITERIA

Our guideline named **RAVULIZUMAB-CWVZ (Ultomiris)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Paroxysmal nocturnal hemoglobinuria (PNH: a rare blood disorder)
 - 2. Atypical hemolytic uremic syndrome (aHUS: a rare blood disorder)
 - 3. Generalized myasthenia gravis (gMG: a chronic autoimmune disorder)
 - 4. Neuromyelitis optica spectrum disorder (NMOSD: a type of brain disorder)
- B. **If you have paroxysmal nocturnal hemoglobinuria, renewal also requires:**
 - 1. You have experienced a clinical benefit (such as a reduction in the number of blood transfusions [adding blood to your body], improvement/stabilization of lactate dehydrogenase [LDH: a type of enzyme] levels and hemoglobin [Hgb: a type of protein in red blood cells] levels) compared to baseline (before treatment)
 - 2. You will NOT use Ultomiris concurrently (at the same time) with C5 complement inhibitor therapy (such as Soliris [eculizumab], Piasky [crovalimab-akkz]), C3 complement inhibitor therapy (such as Empaveli [pegcetacoplan]) or Factor B inhibitor therapy (such as Fabhalta [iptacopan])
- C. **If you have generalized myasthenia gravis, renewal also requires:**
 - 1. You have experienced a clinical benefit compared to baseline (before treatment) according to validated gMG instruments (such as Myasthenia Gravis Activities of Daily Living tool, Quantitative Myasthenia Gravis tool)
 - 2. You will NOT use Ultomiris concurrently (at the same time) with another neonatal Fc receptor blocker (such as Rystiggo [rozanolixizumab-noli], Vyvgart [efgartigimod alfa-fcab]) or complement inhibitor (such as Soliris [eculizumab], Zilbrysq [zilucoplan]) for the treatment of generalized myasthenia gravis
- D. **If you have neuromyelitis optica spectrum disorder, renewal also requires:**
 - 1. You have experienced a clinical benefit (reduction in relapse frequency compared to baseline [before treatment] or a decrease in NMOSD-related hospitalizations)
 - 2. You will NOT use Ultomiris concurrently (at the same time) with another NMOSD medication (such as Rituxan [rituximab], Enspryng [satralizumab-mwge], Uplizna [inebilizumab-cdon], Soliris [eculizumab])

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

REGORAFENIB

Generic	Brand			
REGORAFENIB	STIVARGA			

GUIDELINES FOR USE

Our guideline named **REGORAFENIB (Stivarga)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Metastatic colorectal cancer (CRC: a type of digestive cancer that has spread to other parts of the body)
2. Locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST: a type of digestive tumor that has spread from where it started to nearby tissue or lymph nodes, unable to remove by surgery, or has spread to other parts of the body)
3. Hepatocellular carcinoma (HCC: a type of liver cancer)

B. **If you have metastatic colorectal cancer, approval also requires:**

1. You had previous treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy such as FOLFOX, FOLFIRI, FOLFOXIRI, CapeOx, infusional 5-FU/LV, capecitabine
2. You had previous treatment with an anti-VEGF therapy such as Avastin (bevacizumab), Zaltrap (ziv-aflibercept)
3. If you have RAS wild-type (a type of unmutated gene) metastatic colorectal cancer, approval also requires you had previous treatment with an anti-EGFR therapy such as Erbitux (cetuximab), Vectibix (panitumumab)

C. **If you have locally advanced, unresectable, or metastatic gastrointestinal stromal tumor, approval also requires:**

1. You had previous treatment with Gleevec (imatinib) and Sutent (sunitinib)

D. **If you have hepatocellular carcinoma, approval also requires:**

1. You had previous treatment with Nexavar (sorafenib)

Effective: 04/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RELUGOLIX

Generic	Brand				
RELUGOLIX	ORGOVYX				

GUIDELINES FOR USE

Our guideline named **RELUGOLIX (Orgovyx)** requires the following rule(s) be met for approval:

- A. You have advanced prostate cancer
- B. You are 18 years of age or older

Effective: 04/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RELUGOLIX-ESTRADIOL-NORETHINDRONE

Generic	Brand				
RELUGOLIX/ ESTRADIOL/ NORETHINDRONE ACETATE	MYFEMBREE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **RELUGOLIX-ESTRADIOL-NORETHINDRONE (Myfembree)** requires the following rule(s) be met for approval:

- A. The request is for ONE of the following:
 - 1. Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids: non-cancerous growths in the uterus)
 - 2. Management of moderate to severe pain associated with endometriosis (condition affecting the uterus)
- B. **If the request is for management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids), approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You are a premenopausal (before menopause) woman
 - 3. Therapy is prescribed by or in consultation with an obstetrician or gynecologist (OB/GYN: a type of women's health doctor)
 - 4. You have not received a total of 24 months cumulative (total) treatment with Myfembree
- C. **If the request is for management of moderate to severe pain associated with endometriosis, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You are a premenopausal (before menopause) woman
 - 3. Therapy is prescribed by or in consultation with an obstetrician or gynecologist (OB/GYN: a type of women's health doctor)
 - 4. Your diagnosis of endometriosis is confirmed via surgical or direct visualization (such as pelvic ultrasound [type of imaging]) or histopathological (tissue) confirmation (such as laparoscopy [type of surgery] or laparotomy [type of surgery]) in the last 10 years
 - 5. Myfembree will NOT be used concurrently (at the same time) with another GnRH-modulating agent (such as Orilissa, Lupron Depot, Synarel)
 - 6. You have not received a total of 24 months cumulative (total) treatment with Myfembree

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RELUGOLIX-ESTRADIOL-NORETHINDRONE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **RELUGOLIX-ESTRADIOL-NORETHINDRONE (Myfembree)** requires the following rule(s) be met for renewal:

- A. The request is for ONE of the following:
 - 1. Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids: non-cancerous growths in the uterus)
 - 2. Management of moderate to severe pain associated with endometriosis (condition affecting the uterus)
- B. **If the request is for management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids), renewal also requires:**
 - 1. You had improvement of heavy menstrual bleeding on therapy
 - 2. You have not received a total of 24 months cumulative (total) treatment with Myfembree
- C. **If the request is for management of moderate to severe pain associated with endometriosis, renewal also requires:**
 - 1. You have had improvement in pain related to endometriosis while on therapy
 - 2. Myfembree will NOT be used concurrently (at the same time) with another GnRH-modulating agent (such as Orilissa, Lupron Depot, Synarel)
 - 3. You have not received a total of 24 months cumulative (total) treatment with Myfembree

Effective: 09/12/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

REPOTRECTINIB

Generic	Brand				
REPOTRECTINIB	AUGTYRO				

GUIDELINES FOR USE

Our guideline named **REPOTRECTINIB (Augtyro)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Locally advanced or metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread from where it started to nearby tissue or lymph nodes or to other parts of the body)
 - 2. Solid tumors
- B. **If you have non-small cell lung cancer, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have *ROS1*-positive (abnormal change in a type of gene) tumors
- C. **If you have solid tumors, approval also requires:**
 - 1. You are 12 years of age and older
 - 2. Your tumors have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion (abnormal change in a type of gene)
 - 3. Yours tumors are locally advanced or metastatic (cancer that has spread from where it started to nearby tissue or lymph nodes or to other parts of the body), OR surgical resection (removal by surgery) is likely to result in severe morbidity (illness)
 - 4. You have progressed following treatment OR have no satisfactory alternative (other) therapy

Effective: 08/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RESMETIROM

Generic	Brand				
RESMETIROM	REZDIFFRA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **RESMETIROM (Rezdiffra)** requires the following rule(s) be met for approval:

- A. You have non-alcoholic steatohepatitis (NASH: a type of liver disease)/metabolic dysfunction-associated steatohepatitis (MASH: a type of liver disease)
- B. You are 18 years of age or older
- C. You do NOT have cirrhosis (liver damage and scarring)
- D. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor) or gastroenterologist (doctor who treats digestive conditions)
- E. You are enrolled in or have already completed a lifestyle intervention (such as dietary, exercise, psychology)
- F. You will NOT use Rezdiffra concurrently (at the same time) with Wegovy
- G. You have had a biopsy (removal of cells or tissue from the body for examination) or non-invasive test (such as elastography [type of imaging test]) in the past 12 months which demonstrates ONE of the following:
 - 1. You have liver fibrosis stage 2 or 3 (scoring system to measure liver damage)
 - 2. You have a non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS: a scoring system used to measure disease activity and severity) of at least 4
- H. **If Wegovy is covered by your plan, approval also requires:**
 - 1. You have tried or have a contraindication to (harmful for you to use) Wegovy

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RESMETIROM

RENEWAL CRITERIA

Our guideline named **RESMETIROM (Rezdiffra)** requires the following rule(s) be met for renewal:

- A. You have non-alcoholic steatohepatitis (NASH: a type of liver disease)/metabolic dysfunction-associated steatohepatitis (MASH: a type of liver disease)
- B. You will NOT use Rezdiffra concurrently (at the same time) with Wegovy
- C. You do NOT meet any of the following:
 - 1. You are a non-responder (defined as no reduction [no improvement] in liver fibrosis stage [scoring system to measure liver damage] AND your NAFLD [non-alcoholic fatty liver disease] Activity Score [NAS: a scoring system used to measure disease activity and severity] has NOT decreased by at least 2 points from baseline [before start of treatment])
 - 2. You have experienced NASH/MASH resolution (defined as liver fibrosis stage 0 to 1 AND NAFLD Activity Score [NAS] of less than or equal to 3)

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RETIFANLIMAB-DLWR

Generic	Brand				
RETIFANLIMAB-DLWR	ZYNYZ				

GUIDELINES FOR USE

Our guideline named **RETIFANLIMAB-DLWR (Zynyz)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Metastatic or recurrent locally advanced Merkel cell carcinoma (MCC: a type of skin cancer that has spread to other parts of the body or has returned and spread from where it started to nearby tissue or lymph nodes)
2. Locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC: a type of cancer of the anal canal that has returned from where it started or has spread to other parts of the body)

B. **If you have metastatic or recurrent locally advanced Merkel cell carcinoma, approval also requires:**

1. You are 18 years of age or older

C. **If you have locally recurrent or metastatic squamous cell carcinoma of the anal canal, approval also requires:**

1. You are 18 years of age or older
2. You meet ONE of the following:
 - a. Zynyz will be used in combination with carboplatin and paclitaxel AND your cancer is inoperable (not able to operate on)
 - b. Zynyz will be used as a single agent (used alone) AND your disease has progressed (worsened) while on platinum-based chemotherapy (such as paclitaxel, docetaxel, cisplatin, carboplatin) or you are intolerant (side effects) to platinum-based chemotherapy

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

REVUMENIB

Generic	Brand				
REVUMENIB CITRATE	REVUFORJ				

GUIDELINES FOR USE

Our guideline named **REVUMENIB (Revuforj)** requires the following rule(s) be met for approval:

- H. You have relapsed or refractory acute leukemia (a type of blood cancer that has returned or did not respond to treatment)
- I. You are 1 year of age or older
- J. You have a lysine methyltransferase 2A gene (KMT2A) translocation (a type of gene abnormality)

Effective: 04/07/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RIFAXIMIN

Generic	Brand				
RIFAXIMIN	XIFAXAN				

**** Please use the criteria for the specific drug requested ****

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

XIFAXAN 550MG TABLETS

Our guideline named **RIFAXIMIN (Xifaxan 550mg tablets)** requires the following rule(s) be met for approval:

- A. The request is for ONE of the following:
 - 1. Reduction in risk of overt hepatic encephalopathy (HE: a type of brain condition caused by liver damage) recurrence (return)
 - 2. Irritable bowel syndrome with diarrhea (IBS-D: a type of bowel disease)
- B. **For reduction in risk of overt hepatic encephalopathy recurrence, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor)
 - 3. You have tried lactulose or you are currently taking lactulose monotherapy (one drug treatment)
- C. **If you have irritable bowel syndrome with diarrhea, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
 - 3. You have tried or have a contraindication to (harmful for you to use) a tricyclic anti-depressant (such as amitriptyline, nortriptyline) or dicyclomine
 - 4. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Viberzi (eluxadoline)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RIFAXIMIN

INITIAL CRITERIA (CONTINUED)

XIFAXAN 200MG TABLETS

Our guideline named **RIFAXIMIN (Xifaxan 200mg tablets)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Travelers' diarrhea
 - 2. Overt hepatic encephalopathy (HE: a type of brain condition caused by liver damage)
 - 3. *Clostridium difficile* infection (a type of bacterial infection)
- B. **If you have traveler's diarrhea, approval also requires:**
 - 1. You are 12 years of age or older
 - 2. You have tried or have a contraindication to (harmful for you to use) oral azithromycin, ciprofloxacin, ofloxacin, or levofloxacin
- C. **If you have overt hepatic encephalopathy, approval also requires:**
 - 1. Xifaxan will be used in combination with lactulose
- D. **If you have *Clostridium difficile* infection, approval also requires:**
 - 1. Therapy is prescribed by or in consultation with an infectious disease specialist (a doctor who specializes in the treatment of infections)
 - 2. You had at least one previous occurrence of *Clostridium difficile* infection
 - 3. You have been treated with vancomycin for the current *Clostridium difficile* infection

RENEWAL CRITERIA (CONTINUED)

Our guideline named **RIFAXIMIN (Xifaxan 550mg tablets)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Reduction in risk of overt hepatic encephalopathy (HE: a type of brain condition caused by liver damage) recurrence (return)
 - 2. Irritable bowel syndrome with diarrhea (IBS-D: a type of bowel disease)
- B. **If you have irritable bowel syndrome with diarrhea, renewal also requires:**
 - 1. Your last treatment course of Xifaxan was at least 6 weeks ago
 - 2. You have experienced at least a 30 percent decrease in abdominal pain (on a 0-10 point pain scale)
 - 3. You have experienced at least a 50 percent reduction in the number of days per week with a stool consistency of mushy stool (Bristol Stool Scale [a tool that helps assess digestive issues] type 6) or entirely liquid stool (Bristol Stool Scale type 7)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RILONACEPT

Generic	Brand				
RILONACEPT	ARCALYST				

GUIDELINES FOR USE

Our guideline named **RILONACEPT (Arcalyst)** requires the following rule(s) be met for approval:

A. You meet ONE of the following:

1. You have Cryopyrin-Associated Periodic Syndromes (CAPS: a type of immune disorder) including, Familial Cold Autoinflammatory Syndrome (FCAS: a type of immune disorder) or Muckle-Wells Syndrome (MWS: a type of gene disorder)
2. You have Deficiency of Interleukin-1 Receptor Antagonist (DIRA: a type of immune system disorder)
3. Arcalyst will be used for the treatment or reduction in risk of recurrent pericarditis (RP: a type of heart condition that returns)

B. If you have Cryopyrin-Associated Periodic Syndromes including Familial Cold Autoinflammatory Syndrome or Muckle-Wells Syndrome, approval also requires:

1. You are 12 years of age or older
2. You had genetic testing for gain-of-function mutations (abnormal change in gene) in the *NLRP3* gene (a type of gene) OR you have inflammatory markers (elevated C-reactive protein [CRP: a measure of how much inflammation is in the body], erythrocyte sedimentation rate [ESR: a measure of how much inflammation is in the body], serum amyloid A protein [SAA: a type of protein] or S100 proteins [a type of protein])
3. You have TWO of the following: urticarial-like rash (neutrophilic dermatitis: a type of skin condition), cold-triggered episodes, sensorineural hearing loss (SNHL: a type of hearing loss), musculoskeletal symptoms (symptoms related to the skin and bones), chronic aseptic meningitis (inflammation of the brain and spinal cord), and skeletal (bone) abnormalities
4. You will NOT use Arcalyst concurrently (at the same time) with another systemic biologic (such as Ilaris [canakinumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Cryopyrin-Associated Periodic Syndromes

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RILONACEPT

GUIDELINE FOR USE (CONTINUED)

- C. If you have Deficiency of Interleukin-1 Receptor Antagonist, approval also requires:**
1. You had genetic testing for gain-of-function mutations (abnormal change in gene) in the *IL1RN* gene (a type of gene) OR you have inflammatory markers (elevated C-reactive protein [CRP: a measure of how much inflammation is in the body], erythrocyte sedimentation rate [ESR: a measure of how much inflammation is in the body])
 2. You have ONE of the following: pustular psoriasis-like rashes (a type of skin condition), osteomyelitis (bone infection), absence of bacterial osteomyelitis, nail changes (onychomadesis: fungal infection of toenail)
 3. You will NOT use Arcalyst concurrently (at the same time) with another systemic biologic (such as Kineret [anakinra]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Deficiency of Interleukin-1 Receptor Antagonist
- D. If the request is for the treatment or reduction in risk of recurrent pericarditis, approval also requires:**
1. You are 12 years of age or older
 2. You had an episode of acute pericarditis (a type of short-term heart condition)
 3. You have been symptom-free for 4 to 6 weeks
 4. You have TWO of the following: chest pain consistent with pericarditis, pericardial friction rub (a type of heart condition), electrocardiogram (ECG: a type of lab test) showing diffuse ST-segment elevation or PR-segment depression (an abnormal heart test), and new or worsening pericardial effusion (a type of heart condition)
 5. You have tried or have a contraindication to (harmful for you to use) two NSAIDs (non-steroidal anti-inflammatory drugs such as ibuprofen, indomethacin) AND colchicine
 6. You will NOT use Arcalyst concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of recurrent pericarditis

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RILUZOLE

Generic	Brand			
RILUZOLE	EXSERVAN, TIGLUTIK			

GUIDELINES FOR USE

Our guideline named **RILUZOLE (Exservan, Tiglutik)** requires the following rule(s) be met for approval:

- A. You have amyotrophic lateral sclerosis (ALS: nervous system disease that weakens muscles and affects physical function)
- B. You are 18 years of age or older
- C. You have tried riluzole tablets
- D. You are unable to take riluzole tablet formulation

Effective: 06/01/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RIMEGEPANT

Generic	Brand				
RIMEGEPANT	NURTEC ODT				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **RIMEGEPANT (Nurtec ODT)** requires the following rule(s) be met for approval:

D. The request is for ONE of the following:

1. Acute (quick onset) treatment of migraines (a type of headache)
2. Preventive treatment of episodic migraines (a type of headache)

E. **If the request is for the acute treatment of migraines, approval also requires:**

1. You are 18 years of age or older
2. You will NOT use Nurtec ODT concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Zavzpret [zavegepant], Ubrelvy [ubrogepant]) for the acute treatment of migraines
3. You have tried or have a contraindication to (harmful for you to use) ONE triptan (such as Imitrex [sumatriptan], Maxalt [rizatriptan])

F. **If the request is for the preventive treatment of episodic migraines, approval also requires:**

1. You are 18 years of age or older
2. You will NOT use Nurtec ODT concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy [fremanezumab-vfrm], Aimovig [erenumab-aooe], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Qulipta [atogepant]) for migraine prevention
3. You have tried or have a contraindication to (harmful for you to use) ONE of the following preventive migraine treatments: divalproex sodium/sodium valproate, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RIMEGEPANT

RENEWAL CRITERIA

Our guideline named **RIMEGEPANT (Nurtec ODT)** requires the following rule(s) be met for renewal:

- C. The request is for ONE of the following:
 - 1. Acute (quick onset) treatment of migraines (a type of headache)
 - 2. Preventive treatment of episodic migraines (a type of headache)
- D. **If the request is for the acute treatment of migraines, renewal also requires:**
 - 1. You will NOT use Nurtec ODT concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Zavzpret [zavegepant], Ubrelvy [ubrogepant]) for the acute treatment of migraines
 - 2. You meet ONE of the following:
 - a. You have experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (assessment tool used to help guide treatment such as migraine assessment of current therapy [MIGRAINE-ACT])
 - b. You have experienced clinical improvement as defined by ONE of the following:
 - i. Ability to function normally within 2 hours of dose
 - ii. Headache pain disappears within 2 hours of dose
 - iii. Treatment works consistently in a majority of migraine attacks
- E. **If the request is for the preventive treatment of episodic migraines, renewal also requires:**
 - 1. You will NOT use Nurtec ODT concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy [fremanezumab-vfrm], Aimovig [erenumab-aooe], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Qulipta [atogepant]) for migraine prevention
 - 2. You meet ONE of the following:
 - a. You have experienced a reduction in migraine or headache frequency of at least 2 days per month
 - b. You have experienced a reduction in migraine severity
 - c. You have experienced a reduction in migraine duration

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RIOCIGUAT

Generic	Brand				
RIOCIGUAT	ADEMPAS				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **RIOCIGUAT (Adempas)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
 2. Persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH: a type of heart and lung condition) (World Health Organization [WHO] Group 4)
- B. **If you have pulmonary arterial hypertension, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
 3. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
 - b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
 - c. Pulmonary vascular resistance (PVR) greater than 2 Wood units
 4. You will NOT use Adempas concurrently (at the same time) with nitrates or nitric oxide donors (such as amyl nitrate), phosphodiesterase inhibitors (such as Viagra [sildenafil], Cialis [tadalafil], Levitra [vardenafil]), or non-specific phosphodiesterase inhibitors (such as dipyridamole, theophylline)
- C. **If you have chronic thromboembolic pulmonary hypertension, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
 3. You have persistent or recurrent disease after surgical treatment (condition continues to exist or returns after surgery) OR you are not a candidate for surgery OR you have inoperable (not able to operate on) chronic thromboembolic pulmonary hypertension
 4. You have NYHA-WHO Functional Class II to IV symptoms (a way to classify how limited you are during physical activity)
 5. You will NOT use Adempas concurrently (at the same time) with nitrates or nitric oxide donors (such as amyl nitrate), phosphodiesterase inhibitors (such as Viagra [sildenafil], Cialis [tadalafil], Levitra [vardenafil]), or non-specific phosphodiesterase inhibitors (such as dipyridamole, theophylline)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RIOCIGUAT

RENEWAL CRITERIA

Our guideline named **RIOCIGUAT (Adempas)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH: a type of heart and lung condition) (World Health Organization [WHO] Group 4)
 - 2. Pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. You will NOT use Adempas concurrently (at the same time) with nitrates or nitric oxide donors (such as amyl nitrate), phosphodiesterase inhibitors (such as Viagra [sildenafil], Cialis [tadalafil], Levitra [vardenafil]), or non-specific phosphodiesterase inhibitors (such as dipyridamole, theophylline)

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RIPRETINIB

Generic	Brand				
RIPRETINIB	QINLOCK				

GUIDELINES FOR USE

Our guideline named **RIPRETINIB (Qinlock)** requires ALL of the following rule(s) be met for approval:

- A. You have advanced gastrointestinal stromal tumor (GIST: a type of cancer in your digestive tract)
- B. You are 18 years of age or older
- C. You have received prior treatment with 3 or more kinase inhibitors (class of drugs), including imatinib

Effective: 04/10/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RISANKIZUMAB-RZAA

Generic	Brand			
RISANKIZUMAB-RZAA	SKYRIZI			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **RISANKIZUMAB-RZAA (Skyrizi)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
 2. Psoriatic arthritis (PsA: a type of skin and joint condition)
 3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
 4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
- B. **If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 3. You will NOT use Skyrizi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
 4. You meet ONE of the following:
 - a. You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis
 - b. You have a contraindication (harmful for you to use) or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) and PUVA (phototherapy) for the treatment of plaque psoriasis
 - c. You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication
 5. You meet ONE of the following:
 - a. You were previously stable on another biologic and are switching to Skyrizi
 - b. You have psoriasis covering 3 percent or more of body surface area (BSA)
 - c. You have psoriatic lesions (rashes) affecting the hands, feet, face, genital area, or scalp

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RISANKIZUMAB-RZAA

INITIAL CRITERIA (CONTINUED)

- C. If you have psoriatic arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
 3. You will NOT use Skyrizi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
- D. If you have moderate to severe Crohn's disease, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 3. You will NOT use Skyrizi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
- E. If you have moderate to severe ulcerative colitis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 3. You will NOT use Skyrizi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RISANKIZUMAB-RZAA

RENEWAL CRITERIA

Our guideline named **RISANKIZUMAB-RZAA (Skyrizi)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
 - 2. Psoriatic arthritis (PsA: a type of skin and joint condition)
 - 3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
 - 4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
- B. **If you have moderate to severe plaque psoriasis, renewal also requires:**
 - 1. You have achieved or maintained clear or minimal disease OR a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50 percent or more while on therapy
 - 2. You will NOT use Skyrizi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
- C. **If you have psoriatic arthritis, renewal also requires:**
 - 1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 - 2. You will NOT use Skyrizi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
- D. **If you have moderate to severe Crohn's disease, renewal also requires:**
 - 1. You will NOT use Skyrizi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
- E. **If you have moderate to severe ulcerative colitis, renewal also requires:**
 - 1. You will NOT use Skyrizi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RISDIPLAM

Generic	Brand				
RISDIPLAM	EVRYSDI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **RISDIPLAM (Evrysdi)** requires the following rule(s) be met for approval:

- A. You have spinal muscular atrophy (SMA: a type of nerve and muscle movement disorder)
- B. Therapy is prescribed by or in consultation with a neuromuscular (nerve and muscle) specialist or spinal muscular atrophy (SMA) specialist at a SMA Specialty Center
- C. Your diagnosis is confirmed by a gene mutation (abnormal change) analysis indicating mutations or deletions of both alleles of the survival motor neuron 1 (SMN1: type of protein) gene (such as homozygous deletions of SMN1, homozygous mutations of SMN1, compound heterozygous mutations in SMN1 [deletion of SMN1 on one allele and point mutation of SMN1 on the other allele])
- D. **If you are pre-symptomatic (symptoms have not yet appeared), approval also requires:**
 - 1. You have up to (no more than) THREE copies of the survival motor neuron 2 (SMN2: type of protein) gene based on a screening that was done when you were a newborn
- E. **If you are symptomatic (symptoms have appeared), approval also requires:**
 - 1. The onset of spinal muscular atrophy (SMA) symptoms occurred before 20 years of age
 - 2. You had a baseline motor function assessment by a neuromuscular (nerve and muscle) specialist or SMA specialist
 - 3. If you have received prior gene therapy, you experienced a less than expected clinical benefit with gene therapy

RENEWAL CRITERIA

Our guideline named **RISDIPLAM (Evrysdi)** requires the following rule(s) be met for renewal:

- A. You have spinal muscular atrophy (SMA: a type of nerve and muscle movement disorder)
- B. You meet ONE of the following:
 - 1. You have improved, maintained, or demonstrated a less than expected decline in motor function assessments compared to baseline. Some types of motor assessment tests include Hammersmith Infant Neurological Examination (HINE), Hammersmith Functional Motor Scale - Expanded (HFMSE), and Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)
 - 2. You have improved, maintained, or demonstrated a less than expected decline in other muscle function (such as pulmonary [lung/breathing] function)

Effective: 03/03/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITLECITINIB

Generic	Brand				
RITLECITINIB TOSYLATE	LITFULO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **RITLECITINIB (Litfulo)** requires the following rule(s) be met for approval:

- A. You have severe alopecia areata (a type of hair loss)
- B. You are 12 years of age or older
- C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
- D. You have experienced at least 50 percent scalp hair loss, as measured by the Severity of Alopecia Tool (SALT: a type of disease evaluation tool), for at least 6 months
- E. You will NOT use Litfulo concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Olumiant (baricitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of alopecia areata

RENEWAL CRITERIA

Our guideline named **RITLECITINIB (Litfulo)** requires the following rule(s) be met for renewal:

- A. You have severe alopecia areata (a type of hair loss)
- B. You have shown improvement while on therapy (such as scalp hair coverage)
- C. You will NOT use Litfulo concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Olumiant (baricitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of alopecia areata

Effective: 03/17/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB

Generic	Brand				
RITUXIMAB	RITUXAN				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **RITUXIMAB (Rituxan)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Non-Hodgkin's lymphoma (NHL: a type of blood cancer)
3. Previously untreated advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL: a type of blood cancer), Burkitt lymphoma (BL: a type of blood cancer), Burkitt-like lymphoma (BLL: a type of blood cancer), or mature B-cell acute leukemia (B-AL: a type of blood cancer)
4. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
5. Granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) (a condition that affects the blood vessels)
6. Microscopic polyangiitis (MPA: a condition that affects the blood vessels)
7. Moderate to severe pemphigus vulgaris (PV: a type of skin condition)
8. Rituxan will be used in combination with another chemotherapy agent(s) for a Food and Drug Administration (FDA)-approved indication

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB

INITIAL CRITERIA (CONTINUED)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You are currently using or have a contraindication to (harmful for you to use) methotrexate
4. You will NOT use Rituxan concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
5. You have tried at least 3 months of or have a contraindication to ONE conventional synthetic DMARD (disease modifying antirheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
6. You meet ONE of the following:
 - a. You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

C. If you have non-Hodgkin's lymphoma, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor)
3. You will NOT use Rituxan concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of non-Hodgkin's lymphoma
4. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Riabni (rituximab-arxx), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB

INITIAL CRITERIA (CONTINUED)

- D. If you have previously untreated advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia, approval also requires:**
1. You are 6 months to 17 years of age
 2. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor)
 3. Rituxan will be used in combination with chemotherapy (such as CVP [cyclophosphamide-vincristine-prednisolone])
 4. You will NOT use Rituxan concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia
 5. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs)
- E. If you have chronic lymphocytic leukemia, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor)
 3. Rituxan will be used in combination with chemotherapy (such as fludarabine, cyclophosphamide)
 4. You will NOT use Rituxan concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of chronic lymphocytic leukemia
 5. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs)
- F. If you have granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis, approval also requires:**
1. You are 2 years of age or older
 2. Rituxan will be used in combination with glucocorticoids (such as methylprednisolone, prednisone)
 3. You will NOT use Rituxan concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis
 4. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB

INITIAL CRITERIA (CONTINUED)

G. If you have moderate to severe pemphigus vulgaris, approval also requires:

1. You are 18 years of age or older
2. You will NOT use Rituxan concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of pemphigus vulgaris
3. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Riabni (rituximab-arrx), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB

RENEWAL CRITERIA

NOTE: For the diagnoses of non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL), chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis), microscopic polyangiitis (MPA), and moderate to severe pemphigus vulgaris (PV), please refer to the Initial Criteria section.

Our guideline named **RITUXIMAB (Rituxan)** requires the following rule(s) be met for renewal:

- A. You have moderate to severe rheumatoid arthritis (RA: a type of joint condition)
- B. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count from baseline while on therapy
- C. You will NOT use Rituxan concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
- D. You meet ONE of the following:
 - 1. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - 2. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 03/10/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB-ABBS

Generic	Brand				
RITUXIMAB-ABBS	TRUXIMA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **RITUXIMAB-ABBS (Truxima)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Non-Hodgkin's lymphoma (NHL: a type of blood cancer)
 2. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
 3. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
 4. Granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) (a condition that affects the blood vessels)
 5. Microscopic polyangiitis (MPA: a condition that affects the blood vessels)
 6. Moderate to severe pemphigus vulgaris (PV: a type of skin condition)
 7. Previously untreated advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL: a type of blood cancer), Burkitt lymphoma (BL: a type of blood cancer), Burkitt-like lymphoma (BLL: a type of blood cancer), or mature B-cell acute leukemia (B-AL: a type of blood cancer)
 8. Truxima will be used in combination with another chemotherapy agent(s) for a Food and Drug Administration (FDA)-approved indication
- B. **If you have non-Hodgkin's lymphoma, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor)
 3. You will NOT use Truxima concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of non-Hodgkin's lymphoma
- C. **If you have chronic lymphocytic leukemia, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor)
 3. Truxima will be used in combination with chemotherapy (such as fludarabine, cyclophosphamide)
 4. You will NOT use Truxima concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of chronic lymphocytic leukemia

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB-ABBS

INITIAL CRITERIA (CONTINUED)

- D. If you have moderate to severe rheumatoid arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You are currently using or have a contraindication to (harmful for you to use) methotrexate
 4. You will NOT use Truxima concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
 5. You have tried at least 3 months of or have a contraindication to ONE conventional synthetic DMARD (disease-modifying antirheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
 6. You meet ONE of the following:
 - a. You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB-ABBS

INITIAL CRITERIA (CONTINUED)

- E. If you have granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis, approval also requires:**
1. You are 2 years of age or older
 2. Truxima will be used in combination with glucocorticoids (such as methylprednisolone, prednisone)
 3. You will NOT use Truxima concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis
- F. If you have moderate to severe pemphigus vulgaris, approval also requires:**
1. You are 18 years of age or older
 2. You will NOT use Truxima concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of pemphigus vulgaris
- G. If you have previously untreated advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia, approval also requires:**
1. You are 6 months to 17 years of age
 2. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor)
 3. Truxima will be used in combination with chemotherapy (such as CVP [cyclophosphamide-vincristine-prednisolone])
 4. You will NOT use Truxima concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB-ABBS

RENEWAL CRITERIA

NOTE: For the diagnoses of non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL), chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis), microscopic polyangiitis (MPA), and moderate to severe pemphigus vulgaris (PV), please refer to the Initial Criteria section.

Our guideline named **RITUXIMAB-ABBS (Truxima)** requires the following rule(s) be met for renewal:

- A. You have moderate to severe rheumatoid arthritis (RA: a type of joint condition)
- B. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
- C. You will NOT use Truxima concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
- D. You meet ONE of the following:
 - 1. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - 2. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 03/10/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB-ARRX

Generic	Brand				
RITUXIMAB-ARRX	RIABNI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **RITUXIMAB-ARRX (Riabni)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Non-Hodgkin's lymphoma (NHL: a type of blood cancer)
2. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
3. Granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) (a condition that affects the blood vessels)
4. Microscopic polyangiitis (MPA: a condition that affects the blood vessels)
5. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
6. Moderate to severe pemphigus vulgaris (PV: a type of skin condition)
7. Previously untreated advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL: a type of blood cancer), Burkitt lymphoma (BL: a type of blood cancer), Burkitt-like lymphoma (BLL: a type of blood cancer), or mature B-cell acute leukemia (B-AL: a type of blood cancer)
8. Riabni will be used in combination with another chemotherapy agent(s) for a Food and Drug Administration (FDA)-approved indication

B. If you have non-Hodgkin's lymphoma, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor)
3. You will NOT use Riabni concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of non-Hodgkin's lymphoma

C. If you have chronic lymphocytic leukemia, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor)
3. Riabni will be used in combination with chemotherapy (such as fludarabine, cyclophosphamide)
4. You will NOT use Riabni concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of chronic lymphocytic leukemia

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB-ARRX

INITIAL CRITERIA (CONTINUED)

- D. If you have granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis, approval also requires:**
1. You are 2 years of age or older
 2. Riabni will be used in combination with glucocorticoids (such as methylprednisolone, prednisone)
 3. You will NOT use Riabni concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis
- E. If you have moderate to severe rheumatoid arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You are currently using or have a contraindication to (harmful for you to use) methotrexate
 4. You will NOT use Riabni concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
 5. You have tried at least 3 months of or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease-modifying antirheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
 6. You meet ONE of the following:
 - a. You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - c. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB-ARRX

INITIAL CRITERIA (CONTINUED)

- F. If you have moderate to severe pemphigus vulgaris, approval also requires:**
1. You are 18 years of age or older
 2. You will NOT use Riabni concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of pemphigus vulgaris
- G. If you have previously untreated advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia, approval also requires:**
1. You are 6 months to 17 years of age
 2. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor)
 3. Riabni will be used in combination with chemotherapy (such as CVP [cyclophosphamide-vincristine-prednisolone])
 4. You will NOT use Riabni concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB-ARRX

RENEWAL CRITERIA

NOTE: For the diagnoses of non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL), chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis), microscopic polyangiitis (MPA), and moderate to severe pemphigus vulgaris (PV), please refer to the Initial Criteria section.

Our guideline named **RITUXIMAB-ARRX (Riabni)** requires the following rule(s) be met for renewal:

- A. You have moderate to severe rheumatoid arthritis (RA: a type of joint condition)
- B. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
- C. You will NOT use Riabni concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
- D. You meet ONE of the following:
 - 1. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - 2. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 03/10/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB AND HYALURONIDASE HUMAN - SQ

Generic	Brand				
RITUXIMAB/ HYALURONIDASE, HUMAN	RITUXAN HYCELA				

GUIDELINES FOR USE

Our guideline named **RITUXIMAB AND HYALURONIDASE HUMAN - SQ (Rituxan Hycela)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Follicular lymphoma (FL: a type of blood cancer)
2. Diffuse large B-cell lymphoma (DLBCL: a type of blood cancer)
3. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
4. Rituxan Hycela will be used in combination with another chemotherapy agent(s) for a Food and Drug Administration (FDA)-approved indication

B. If you have follicular lymphoma, approval also requires:

1. You are 18 years of age or older
2. You have received or will receive at least one full dose of a rituximab product by intravenous infusion (injection into the vein) before starting Rituxan Hycela
3. You will NOT use Rituxan Hycela concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of follicular lymphoma
4. You meet ONE of the following:
 - a. You have relapsed or refractory follicular lymphoma (cancer that has returned or does not fully respond to treatment)
 - b. You have previously untreated follicular lymphoma AND Rituxan Hycela will be used in combination with chemotherapy (a type of cancer treatment, such as CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone], CVP [cyclophosphamide, vincristine, prednisone])
 - c. You have achieved a complete or partial response to rituximab in combination with chemotherapy (such as R-CHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone])
 - d. You have non-progressing (including stable disease) follicular lymphoma (cancer that is not worsening), AND Rituxan Hycela will be used after cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB AND HYALURONIDASE HUMAN - SQ

GUIDELINES FOR USE (CONTINUED)

C. If you have diffuse large B-cell lymphoma, approval also requires:

1. You are 18 years of age or older
2. You have received or will receive at least one full dose of a rituximab product by intravenous infusion (injection into the vein) before starting Rituxan Hycela
3. You have not been previously treated for diffuse large B-cell lymphoma
4. Rituxan Hycela will be used in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), or another anthracycline-based chemotherapy regimen (a type of cancer treatment)
5. You will NOT use Rituxan Hycela concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of diffuse large B-cell lymphoma

D. If you have chronic lymphocytic leukemia (CLL), approval also requires:

1. You are 18 years of age or older
2. You have received or will receive at least one full dose of a rituximab product by intravenous infusion (injection into the vein) before starting Rituxan Hycela
3. Rituxan Hycela will be used in combination with fludarabine and cyclophosphamide (FC)
4. You will NOT use Rituxan Hycela concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of chronic lymphocytic leukemia

Effective: 03/10/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB-PVVR

Generic	Brand				
RITUXIMAB-PVVR	RUXIENCE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **RITUXIMAB-PVVR (Ruxience)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Non-Hodgkin's lymphoma (NHL: a type of blood cancer)
2. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
3. Granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) (a condition that affects the blood vessels)
4. Microscopic polyangiitis (MPA: a condition that affects the blood vessels)
5. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
6. Moderate to severe pemphigus vulgaris (PV: a type of skin condition)
7. Previously untreated advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL: a type of blood cancer), Burkitt lymphoma (BL: a type of blood cancer), Burkitt-like lymphoma (BLL: a type of blood cancer), or mature B-cell acute leukemia (B-AL: a type of blood cancer)
8. Ruxience will be used in combination with another chemotherapy agent(s) for a Food and Drug Administration (FDA)-approved indication

B. If you have non-Hodgkin's lymphoma, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor)
3. You will NOT use Ruxience concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of non-Hodgkin's lymphoma

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB-PVVR

INITIAL CRITERIA (CONTINUED)

C. If you have chronic lymphocytic leukemia, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor)
3. Ruxience will be used in combination with chemotherapy (such as fludarabine, cyclophosphamide)
4. You will NOT use Ruxience concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of chronic lymphocytic leukemia

D. If you have granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis, approval also requires:

1. You are 2 years of age or older
2. Ruxience will be used in combination with glucocorticoids (such as methylprednisolone, prednisone)
3. You will NOT use Ruxience concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis

E. If you have moderate to severe rheumatoid arthritis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You are currently using or have a contraindication to (harmful for you to use) methotrexate
4. You will NOT use Ruxience concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
5. You have tried at least 3 months of or have a contraindication to ONE conventional synthetic DMARD (disease-modifying antirheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB-PVVR

INITIAL CRITERIA (CONTINUED)

6. You meet ONE of the following:
 - a. You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events
- F. **If you have moderate to severe pemphigus vulgaris, approval also requires:**
 1. You are 18 years of age or older
 2. You will NOT use Ruxience concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of pemphigus vulgaris
- G. **If you have previously untreated advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia, approval also requires:**
 1. You are 6 months to 17 years of age
 2. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor)
 3. Ruxience will be used in combination with chemotherapy (such as CVP [cyclophosphamide-vincristine-prednisolone])
 4. You will NOT use Ruxience concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RITUXIMAB-PVVR

RENEWAL CRITERIA

NOTE: For the diagnoses of non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL), chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis (GPA) Wegener's granulomatosis), microscopic polyangiitis (MPA), and moderate to severe pemphigus vulgaris (PV), please refer to the Initial Criteria section.

Our guideline named **RITUXIMAB-PVVR (Ruxience)** requires the following rule(s) be met for renewal:

- A. You have moderate to severe rheumatoid arthritis (RA: a type of joint condition)
- B. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
- C. You will NOT use Ruxience concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
- D. You meet ONE of the following:
 - 3. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - 4. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated that you cannot use a Janus kinase (JAK) inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 03/10/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ROFLUMILAST 0.15% CREAM

Generic	Brand				
ROFLUMILAST	ZORYVE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ROFLUMILAST 0.15% CREAM (Zoryve)** requires the following rule(s) be met for approval:

- A. You have mild to moderate atopic dermatitis (a type of skin condition)
- B. You are 6 years of age or older
- C. You have tried or have a contraindication to (harmful for you to use) a topical corticosteroid (such as triamcinolone 0.1% cream or ointment, mometasone furoate 0.1% ointment, fluocinonide 0.05% cream, halobetasol propionate 0.05% ointment) OR a topical calcineurin inhibitor (such as Elidel [pimecrolimus], Protopic [tacrolimus])
- D. You have tried or have a contraindication to ONE of the following topical non-steroidal immunomodulating medications (a type of medication): Eucrisa (crisaborole), Opzelura (ruxolitinib)
- E. You will NOT use Zoryve concurrently (at the same time) with ANY of the following for atopic dermatitis:
 - 1. Other non-steroidal topicals (such as calcineurin inhibitors [such as Elidel (pimecrolimus), Protopic (tacrolimus)], PDE-4 [phosphodiesterase-4] inhibitors [such as Eucrisa (crisaborole)], JAK [Janus kinase] inhibitors [such as Opzelura (ruxolitinib)])
 - 2. Systemic therapeutic biologics (such as Dupixent [dupilumab], Adbry [tralokinumab-ldrm])
 - 3. Other JAK (Janus kinase) inhibitors (such as Rinvoq [upadacitinib], Cibinqo [abrocitinib])
 - 4. Potent immunosuppressants (such as azathioprine, cyclosporine)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ROFLUMILAST 0.15% CREAM

RENEWAL CRITERIA

Our guideline named **ROFLUMILAST 0.15% CREAM (Zoryve)** requires the following rule(s) be met for renewal:

- A. You have mild to moderate atopic dermatitis (a type of skin condition)
- B. You have experienced or maintained improvement in pruritus (itchiness), relapsing-remitting (disease returns and goes away) dermatitis, or facial/interdigital (between the fingers or toes) involvement
- C. You will NOT use Zoryve concurrently (at the same time) with ANY of the following for atopic dermatitis:
 - 1. Other non-steroidal topicals (such as calcineurin inhibitors [such as Elidel (pimecrolimus), Protopic (tacrolimus)], PDE-4 [phosphodiesterase-4] inhibitors [such as Eucrisa (crisaborole)], JAK [Janus kinase] inhibitors [such as Opzelura (ruxolitinib)])
 - 2. Systemic therapeutic biologics (such as Dupixent [dupilumab], Adbry [tralokinumab-ldrm])
 - 3. Other JAK (Janus kinase) inhibitors (such as Rinvoq [upadacitinib], Cibinqo [abrocitinib])
 - 4. Potent immunosuppressants (such as azathioprine, cyclosporine)

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ROFLUMILAST 0.3% CREAM

Generic	Brand				
ROFLUMILAST	ZORYVE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ROFLUMILAST 0.3% CREAM (Zoryve)** requires the following rule(s) be met for approval:

- A. You have plaque psoriasis (a type of skin condition)
- B. You are 6 years of age or older
- C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
- D. You have psoriasis covering 2 percent to 20 percent of your body surface area (BSA) (excluding scalp, palms, and soles)
- E. You will NOT use Zoryve concurrently (at the same time) with other systemic immunomodulating medications (such as Stelara [ustekinumab], Otezla [apremilast]), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene)
- F. You have tried or have a contraindication to (harmful for you to use) TWO of the following (from different categories):
 - 1. High potency topical corticosteroid (such as triamcinolone acetonide 0.5% cream or ointment, halobetasol propionate 0.01% lotion) or a super-high potency topical corticosteroid (such as fluocinonide 0.1% cream, clobetasol propionate 0.05% cream or ointment)
 - 2. Topical vitamin D analog (such as calcipotriene cream, calcitriol ointment)
 - 3. Topical calcineurin inhibitor (such as tacrolimus, pimecrolimus)
 - 4. Topical retinoid (such as tazarotene cream/gel)
 - 5. Anthralin

RENEWAL CRITERIA

Our guideline named **ROFLUMILAST 0.3% CREAM (Zoryve)** requires the following rule(s) be met for renewal:

- A. You have plaque psoriasis (a type of skin condition)
- B. You have achieved or maintained clear or minimal disease
- C. You will NOT use Zoryve concurrently (at the same time) with other systemic immunomodulating medications (such as Stelara [ustekinumab], Otezla [apremilast]), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene)

Effective: 04/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ROFLUMILAST - FOAM

Generic	Brand				
ROFLUMILAST	ZORYVE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ROFLUMILAST - FOAM (Zoryve)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Seborrheic dermatitis (a type of skin condition)
2. Plaque psoriasis (a type of skin condition)

B. If you have **seborrheic dermatitis**, approval also requires:

1. You are 9 years of age or older
2. Your seborrheic dermatitis covers less than or equal to 20% of your body surface area (BSA) (may involve scalp, face, trunk [the central part of your body], or intertriginous areas [between skin folds])
3. You meet ONE of the following:
 - a. You have tried or have a contraindication to (harmful for you to use) TWO of the following (from different categories):
 - i. High potency topical corticosteroid (such as triamcinolone acetonide 0.5% cream or ointment, halobetasol propionate 0.01% lotion) or a super-high potency topical corticosteroid (such as fluocinonide 0.1% cream, clobetasol propionate 0.05% cream or ointment)
 - ii. Topical antifungal (such as ketoconazole, ciclopirox)
 - iii. Topical calcineurin inhibitor (such as tacrolimus, pimecrolimus)
 - b. You previously had a successful treatment with roflumilast foam

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ROFLUMILAST - FOAM

INITIAL CRITERIA (CONTINUED)

C. If you have plaque psoriasis, approval also requires:

1. You are 12 years of age or older
2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
3. Your plaque psoriasis covers at least 10% of your total scalp OR does not exceed 20% of your body surface area (BSA) in non-scalp areas of your body
4. You will NOT use Zoryve concurrently (at the same time) with other systemic immunomodulating agents (such as Stelara [ustekinumab], Otezla [apremilast]), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene)
5. You have tried or have a contraindication to (harmful for you to use) TWO of the following (from different categories):
 - a. High potency topical corticosteroid (such as triamcinolone acetonide 0.5% cream or ointment, halobetasol propionate 0.01% lotion) or a super-high potency topical corticosteroid (such as fluocinonide 0.1% cream, clobetasol propionate 0.05% cream or ointment)
 - b. Topical vitamin D analog (such as calcipotriene cream, calcitriol ointment)

RENEWAL CRITERIA

NOTE: For the diagnosis of seborrheic dermatitis, please refer to the Initial Criteria section.

Our guideline named **ROFLUMILAST - FOAM (Zoryve)** requires the following rule(s) be met for renewal:

- A. You have plaque psoriasis (a type of skin condition)
- B. Your plaque psoriasis involves the scalp and/or body
- C. You have achieved or maintained clear or minimal disease
- D. You will NOT use Zoryve concurrently (at the same time) with other systemic immunomodulating medications (such as Stelara [ustekinumab], Otezla [apremilast]), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene)

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ROPEGINTERFERON ALFA-2B-NJFT

Generic	Brand				
ROPEGINTERFERON ALFA-2B-NJFT	BESREMI				

GUIDELINES FOR USE

Our guideline named **ROPEGINTERFERON ALFA-2B-NJFT (Besremi)** requires the following rule(s) be met for approval:

- A. You have polycythemia vera (a type of blood cancer)
- B. You are 18 years of age or older

Effective: 04/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ROZANOLIXIZUMAB-NOLI

Generic	Brand				
ROZANOLIXIZUMAB-NOLI	RYSTIGGO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ROZANOLIXIZUMAB-NOLI (Rystiggo)** requires the following rule(s) be met for approval:

- A. You have generalized myasthenia gravis (gMG: a chronic autoimmune disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
- D. You have a positive serologic test for the anti-acetylcholine receptor antibody (AChR-Ab+) OR anti-muscle-specific tyrosine kinase antibody (MuSK-Ab+) (a type of blood test that shows you have myasthenia gravis)
- E. You have Myasthenia Gravis Foundation of America class II, III, or IV (types of severity of disease)
- F. You have tried or have a contraindication to (harmful for you to use) ONE corticosteroid (such as prednisone)
- G. You will NOT use Rystiggo concurrently (at the same time) with another neonatal Fc receptor blocker (such as Vyvgart [efgartigimod alfa-fcab], Imaavy [nipocalimab-aahu]) or complement inhibitor (such as Soliris [eculizumab], Zilbrysq [zilucoplan]) for the treatment of generalized myasthenia gravis
- H. You meet ONE of the following:
 - 1. You have tried or have a contraindication to (harmful for you to use) TWO non-steroidal immunosuppressive therapies (such as azathioprine, cyclophosphamide, methotrexate)
 - 2. You have tried or have a contraindication to ONE non-steroidal immunosuppressive therapy if you are on chronic plasmapheresis or plasma exchange (types of blood therapy)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ROZANOLIXIZUMAB-NOLI

RENEWAL CRITERIA

Our guideline named **ROZANOLIXIZUMAB-NOLI (Rystiggo)** requires the following rule(s) be met for renewal:

- A. You have generalized myasthenia gravis (gMG: a chronic autoimmune disorder)
- B. You have had clinical benefit compared to baseline (before treatment) according to validated gMG instruments (such as Myasthenia Gravis Activities of Daily Living tool, Quantitative Myasthenia Gravis tool)
- C. You will NOT use Rystiggo concurrently (at the same time) with another neonatal Fc receptor blocker (such as Vyvgart [efgartigimod alfa-fcab], Imaavy [nipocalimab-aahu]) or complement inhibitor (such as Soliris [eculizumab], Zilbrysq [zilucoplan]) for the treatment of generalized myasthenia gravis

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RUCAPARIB

Generic	Brand			
RUCAPARIB	RUBRACA			

GUIDELINES FOR USE

Our guideline named **RUCAPARIB (Rubraca)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (types of reproductive system cancers that has returned)
 2. Metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and no longer responds to testosterone lowering treatment)
- B. **If you have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:**
1. You are 18 years of age or older
 2. Your cancer has a deleterious BRCA mutation (germline and/or somatic) (a type of gene mutation that is passed on from parent to child and/or acquired during life)
 3. You are in complete or partial response to platinum-based chemotherapy (a type of therapy to treat cancer)
 4. The requested medication will be used for maintenance treatment
- C. **If you have metastatic castration-resistant prostate cancer, approval also requires:**
1. You are 18 years of age or older
 2. Your cancer has a deleterious BRCA mutation (germline and/or somatic) (a type of gene mutation that is passed on from parent to child and/or acquired during life) based on a Food and Drug Administration (FDA)-approved companion diagnostic for Rubraca
 3. You have been treated with an androgen receptor-directed therapy and a taxane-based chemotherapy (types of therapy to treat cancer)
 4. You meet ONE of the following:
 - a. You previously received a bilateral orchiectomy (removal of testicles)
 - b. You have a castrate level of testosterone (blood testosterone levels are less than 50 ng/dL)
 - c. The requested medication will be used together with a gonadotropin-releasing hormone (GnRH) analog (such as leuprolide, goserelin, histrelin)

Effective: 01/23/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RUXOLITINIB

Generic	Brand				
RUXOLITINIB PHOSPHATE	JAKAFI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **RUXOLITINIB (Jakafi)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Intermediate or high-risk myelofibrosis, which includes primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis (types of blood cancer)
 - 2. Polycythemia vera (a type of blood cancer)
 - 3. Steroid-refractory Acute graft-versus-host disease (a type of short-term immune disorder that did not respond to a type of treatment)
 - 4. Chronic graft-versus-host disease (a type of long-term immune disorder)
- B. **If you have intermediate or high-risk myelofibrosis, which includes primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis, approval also requires:**
 - 1. You are 18 years of age or older
- C. **If you have polycythemia vera, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have tried or have a contraindication to (harmful for you to use) hydroxyurea
- D. **If you have steroid-refractory acute graft-versus-host disease, approval also requires:**
 - 1. You are 12 years of age or older
- E. **If you have chronic graft-versus-host disease, approval also requires:**
 - 1. You are 12 years of age or older
 - 2. You have failed at least ONE line of systemic therapy (treatment that targets the entire body, such as prednisone, methotrexate, mycophenolate mofetil)
 - 3. You will NOT use Jakafi concurrently (at the same time) with Rezurock (belumosudil), Niktimvo (axatilimab-csfr), or Imbruvica (ibrutinib)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RUXOLITINIB

RENEWAL CRITERIA

NOTE: For the diagnoses of polycythemia vera, steroid-refractory acute graft-versus-host disease, or chronic graft-versus-host disease, please refer to the Initial Criteria section.

Our guideline named **RUXOLITINIB (Jakafi)** requires the following rule(s) be met for renewal:

- A. You have intermediate or high-risk myelofibrosis, which includes primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis (types of blood cancer)
- B. You have shown symptom improvement by meeting ONE of the following:
 - 1. You have had at least a 50 percent reduction in total symptom score (such as Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
 - 2. You have had at least a 50 percent reduction in palpable (can be felt by external examination) spleen length
 - 3. You have had a spleen volume reduction of at least 35 percent from baseline

Effective: 02/24/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RUXOLITINIB TOPICAL

Generic	Brand				
RUXOLITINIB PHOSPHATE	OPZELURA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **RUXOLITINIB TOPICAL (Opzelura)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Mild to moderate atopic dermatitis (a type of skin condition)
 2. Nonsegmental vitiligo (a type of skin condition)
- B. **If you have mild to moderate atopic dermatitis, approval also requires:**
1. You are 12 years of age or older
 2. You are NOT immunocompromised (low immune system)
 3. You have tried or have a contraindication to (harmful for you to use) a topical corticosteroid (such as halobetasol, triamcinolone, fluocinonide) OR a topical non-steroidal immunomodulating agent (such as Elidel [pimecrolimus], Protopic [tacrolimus])
 4. You will NOT use Opzelura concurrently (at the same time) with ANY of the following for the treatment of atopic dermatitis:
 - a. Other non-steroidal topicals (such as calcineurin inhibitors [such as Elidel (pimecrolimus), Protopic (tacrolimus)], PDE-4 [phosphodiesterase-4] inhibitors [such as Eucrisa (crisaborole), Zoryve (roflumilast)])
 - b. Systemic therapeutic biologics (such as Dupixent [dupilumab], Adbry [tralokinumab-ldrm])
 - c. Other JAK (Janus kinase) inhibitors (such as Rinvoq [upadacitinib], Cibinqo [abrocitinib])
 - d. Potent immunosuppressants (such as azathioprine, cyclosporine)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RUXOLITINIB TOPICAL

INITIAL CRITERIA (CONTINUED)

C. If you have nonsegmental vitiligo, approval also requires:

1. You are 12 years of age or older
2. You have depigmented (lightening of the skin) areas covering 10 percent or less of your total body surface area (BSA)
3. You have tried or have a contraindication to (harmful for you to use) a topical corticosteroid (such as halobetasol, triamcinolone, fluocinonide) OR a topical calcineurin inhibitor (such as Elidel [pimecrolimus], Protopic [tacrolimus])
4. You will NOT use Opzelura concurrently (at the same time) with ANY of the following:
 - a. Other non-steroidal topicals (such as calcineurin inhibitors [such as Elidel (pimecrolimus), Protopic (tacrolimus)], PDE-4 [phosphodiesterase-4] inhibitors [such as Eucrisa (crisaborole), Zoryve (roflumilast)])
 - b. Systemic therapeutic biologics (such as Dupixent [dupilumab], Adbry [tralokinumab-ldrm])
 - c. Other JAK (Janus kinase) inhibitors (such as Rinvoq [upadacitinib], Cibinqo [abrocitinib])
 - d. Potent immunosuppressants (such as azathioprine, cyclosporine)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RUXOLITINIB TOPICAL

RENEWAL CRITERIA

Our guideline named **RUXOLITINIB TOPICAL (Opzelura)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Mild to moderate atopic dermatitis (a type of skin condition)
 - 2. Nonsegmental vitiligo (a type of skin condition)
- B. **If you have mild to moderate atopic dermatitis, renewal also requires:**
 - 1. You have experienced or maintained improvement in pruritus (itchiness), relapsing-remitting (symptoms or disease returns and goes away) dermatitis, or facial/interdigital (between the fingers or toes) involvement
 - 2. You will NOT use Opzelura concurrently (at the same time) with ANY of the following for the treatment of atopic dermatitis:
 - a. Other non-steroidal topicals (such as calcineurin inhibitors [such as Elidel (pimecrolimus), Protopic (tacrolimus)], PDE-4 [phosphodiesterase-4] inhibitors [such as Eucrisa (crisaborole), Zoryve (roflumilast)])
 - b. Systemic therapeutic biologics (such as Dupixent [dupilumab], Adbry [tralokinumab-ldrm])
 - c. Other JAK (Janus kinase) inhibitors (such as Rinvoq [upadacitinib], Cibinqo [abrocitinib])
 - d. Potent immunosuppressants (such as azathioprine, cyclosporine)
- C. **If you have nonsegmental vitiligo, renewal also requires:**
 - 1. You have experienced or maintained clinically meaningful repigmentation (recoloration of the skin after loss in color)
 - 2. You will NOT use Opzelura concurrently (at the same time) with ANY of the following:
 - a. Other non-steroidal topicals (such as calcineurin inhibitors [such as Elidel (pimecrolimus), Protopic (tacrolimus)], PDE-4 [phosphodiesterase-4] inhibitors [such as Eucrisa (crisaborole), Zoryve (roflumilast)])
 - b. Systemic therapeutic biologics (such as Dupixent [dupilumab], Adbry [tralokinumab-ldrm])
 - c. Other JAK (Janus kinase) inhibitors (such as Rinvoq [upadacitinib], Cibinqo [abrocitinib])
 - d. Potent immunosuppressants (such as azathioprine, cyclosporine)

Effective: 02/10/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SACITUZUMAB GOVITECAN-HZIY

Generic	Brand				
SACITUZUMAB GOVITECAN-HZIY	TRODELVY				

GUIDELINES FOR USE

Our guideline named **SACITUZUMAB GOVITECAN-HZIY (Trodelvy)** requires the following rule(s) be met for approval:

You have unresectable locally advanced or metastatic breast cancer (a type of breast cancer that cannot be surgically removed and has spread from where it started to nearby tissue or lymph nodes or to other parts of the body)

You meet ONE of the following:

Your breast cancer is triple negative (TNBC: a type of breast cancer that does not have three receptors) AND you have tried two or more previous systemic therapies (treatment that targets the entire body such as docetaxel, paclitaxel), at least one of them for metastatic disease (disease that has spread to other parts of the body)

Your breast cancer is hormone receptor (HR: a type of protein)-positive, human epidermal growth factor receptor 2 (HER2: a type of protein)-negative (IHC 0, IHC 1+ or IHC 2+/ISH- [a type of lab test]), you have received endocrine (hormone)-based therapy (such as tamoxifen, Arimidex [anastrozole]), AND you have received at least two additional systemic therapies (treatment that targets the entire body such as Enhertu [fam-trastuzumab deruxtecan-nxki], Talzena [talazoparib]) in the metastatic setting

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SACROSIDASE

Generic	Brand			
SACROSIDASE	SUCRAID			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SACROSIDASE (Sucraid)** requires the following rule be met for approval:

- A. You have a genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (a type of genetic digestive condition)
- B. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions) or medical geneticist (doctor who treats gene disorders)
- C. Your diagnosis is confirmed by ONE of the following:
 - 1. Small bowel biopsy (removal of cells or tissue from the body for examination)
 - 2. Sucrose breath test
 - 3. Genetic test

RENEWAL CRITERIA

Our guideline named **SACROSIDASE (Sucraid)** requires the following rule(s) be met for renewal:

- A. You have a genetically determined sucrase deficiency which is part of congenital sucrase-isomaltase deficiency (a type of genetic digestive condition)
- B. You have experienced or maintained improvement on treatment

Effective: 07/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SARGRAMOSTIM

Generic	Brand			
SARGRAMOSTIM	LEUKINE			

GUIDELINES FOR USE

Our guideline named **SARGRAMOSTIM (Leukine)** requires the following rule(s) be met for approval:

- A. The requested medication is prescribed by or given in consultation with a hematologist (blood specialist) or oncologist (cancer/tumor doctor), **OR** you meet **ONE** of the following:
1. You have acute myeloid leukemia (AML: type of blood and bone marrow cancer) and are using the requested medication to shorten time to neutrophil (a type of white blood cell) recovery and to reduce the incidence of severe, life-threatening, or fatal infections following induction chemotherapy AND you are 55 years of age or older
 2. You are undergoing autologous transplantation (your own blood-forming stem cells are collected) and using the requested medication for the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis (to collect blood sample and separate white blood cells in a lab test) AND you are 18 years of age or older
 3. You have non-Hodgkin's lymphoma (NHL: type of cancer), acute lymphoblastic leukemia (ALL: type of white blood cell cancer) or Hodgkin's lymphoma (type of cancer) and are using the requested medication for the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation (to help your blood and bone marrow recover) AND you are 2 years of age or older
 4. The requested medication is being used for the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation from HLA-matched related donors (to help your blood and bone marrow recover after using a lab test to match you to the correct donors) AND you are 2 years of age or older
 5. The requested medication is being used for the treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation AND you are 2 years of age or older
 6. You are acutely exposed to myelosuppressive doses (doses that suppress bone marrow activity) of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]) and using the requested medication to increase your survival

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SARILUMAB

Generic	Brand			
SARILUMAB	KEVZARA			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SARILUMAB (Kevzara)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
 2. Polymyalgia rheumatica (PMR: an inflammatory disorder causing muscle pain and stiffness)
 3. Polyarticular juvenile idiopathic arthritis (pJIA: a type of joint condition)
- B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use Kevzara concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
 4. You have tried at least 3 months of or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
 5. You meet ONE of the following:
 - a. You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events
- C. **If you have polymyalgia rheumatica, approval also requires:**
1. You are 18 years of age or older
 2. You had an inadequate response (drug did not work) to corticosteroids (such as prednisone) or cannot tolerate a corticosteroid taper
 3. You will NOT use Kevzara concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polymyalgia rheumatica

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SARILUMAB

INITIAL CRITERIA (CONTINUED)

D. If you have polyarticular juvenile idiopathic arthritis, approval also requires:

1. You weigh at least 63 kilograms (138 pounds)
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Kevzara concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
4. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz IR (tofacitinib immediate-release), Rinvoq (upadacitinib)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

RENEWAL CRITERIA

NOTE: For the diagnosis of polymyalgia rheumatica (PMR), please refer to the Initial Criteria section.

Our guideline named **SARILUMAB (Kevzara)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Polyarticular juvenile idiopathic arthritis (pJIA: a type of joint condition)

B. If you have moderate to severe rheumatoid arthritis, renewal also requires:

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Kevzara concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SARILUMAB

RENEWAL CRITERIA (CONTINUED)

3. You meet ONE of the following:
 - a. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
 - b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancer), and serious cardiovascular (heart-related) events
- C. **If you have polyarticular juvenile idiopathic arthritis, renewal also requires:**
 1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 2. You will NOT use Kevzara concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
 3. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz IR (tofacitinib immediate-release), Rinvoq (upadacitinib)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SATRALIZUMAB-MWGE

Generic	Brand				
SATRALIZUMAB-MWGE	ENSPRYNG				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SATRALIZUMAB-MWGE (Enspryng)** requires the following rule(s) be met for approval:

- A. You have neuromyelitis optica spectrum disorder (NMOSD: a type of brain disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
- D. You have a positive serologic (blood) test for the anti-aquaporin-4 (AQP4: a type of protein) antibody
- E. You will NOT use Enspryng concurrently (at the same time) with another NMOSD medication (such as Rituxan [rituximab], Uplizna [inebilizumab-cdon], Ultomiris [ravulizumab-cwvz], Soliris [eculizumab])
- F. You have at least ONE of the following core clinical characteristics:
 1. Optic neuritis (a type of brain disorder)
 2. Acute myelitis (a type of brain disorder)
 3. Area postrema syndrome (a type of brain disorder)
 4. Acute brainstem syndrome (a type of brain disorder)
 5. Symptomatic narcolepsy (a type of sleep condition) or acute diencephalic clinical syndrome (tumor in a part of the brain) with NMOSD-typical diencephalic MRI lesions (affected areas)
 6. Symptomatic cerebral syndrome with NMOSD-typical brain lesions

RENEWAL CRITERIA

Our guideline named **SATRALIZUMAB-MWGE (Enspryng)** requires the following rule(s) be met for renewal:

- D. You have neuromyelitis optica spectrum disorder (NMOSD: a type of brain disorder)
- E. You have experienced a reduction in relapse frequency from baseline
- F. You will NOT use Enspryng concurrently (at the same time) with another NMOSD medication (such as Rituxan [rituximab], Uplizna [inebilizumab-cdon], Ultomiris [ravulizumab-cwvz], Soliris [eculizumab])

Effective: 10/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SECUKINUMAB

Generic	Brand				
SECUKINUMAB	COSENTYX				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SECUKINUMAB (Cosentyx)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
 2. Psoriatic arthritis (PsA: a type of skin and joint condition)
 3. Ankylosing spondylitis (AS: a type of joint condition)
 4. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
 5. Enthesitis-related arthritis (ERA: a type of joint condition)
 6. Moderate to severe hidradenitis suppurativa (HS: a type of skin condition)
- B. **If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 6 years of age or older
 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 3. You have psoriasis covering 3 percent or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, face, or scalp
 4. You will NOT use Cosentyx concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
 5. You meet ONE of the following:
 - a. You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis
 - b. You have a contraindication (harmful for you to use) or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) and PUVA (phototherapy) for the treatment of plaque psoriasis
 - c. You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SECUKINUMAB

INITIAL CRITERIA (CONTINUED)

6. You meet ONE of the following:
 - a. You are 6 to 17 years of age AND have tried or have a contraindication to FOUR of the preferred medications: Enbrel (etanercept), Taltz (ixekizumab), Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Otezla (apremilast)
 - b. You are 18 years of age or older AND have tried or have a contraindication to FOUR of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)
- C. **If you have psoriatic arthritis, approval also requires:**
 1. You are 2 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
 3. You will NOT use Cosentyx concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
 4. Requests for the 300mg maintenance dosage in psoriatic arthritis without coexisting plaque psoriasis requires that you have tried the 150mg maintenance dosing schedule AND continue to have active psoriatic arthritis
 5. You meet ONE of the following:
 - a. You are 2 to 5 years of age AND have tried or have a contraindication to (harmful for you to use) BOTH of the preferred medications: Enbrel (etanercept), Rinvoq (upadacitinib)
 - b. You are 6 to 17 years of age AND have tried or have a contraindication to THREE of the preferred medications: Enbrel (etanercept), Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Rinvoq (upadacitinib)
 - c. You are 18 years of age or older AND have tried or have a contraindication to THREE of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz IR/XR (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SECUKINUMAB

INITIAL CRITERIA (CONTINUED)

D. If you have ankylosing spondylitis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Cosentyx concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
4. You have tried or have a contraindication to (harmful for you to use) an NSAID (nonsteroidal anti-inflammatory drug such as ibuprofen, naproxen, meloxicam)
5. Requests for the 300mg maintenance dosage requires that you have tried the 150mg maintenance dosage schedule AND continue to have active ankylosing spondylitis
6. You have tried or have a contraindication to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz IR/XR (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

E. If you have non-radiographic axial spondyloarthritis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Cosentyx concurrently (at the same time) with another systemic biologic (such as Taltz [ixekizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of non-radiographic axial spondyloarthritis
4. You have tried or have a contraindication to (harmful for you to use) an NSAID (nonsteroidal anti-inflammatory drug such as ibuprofen, naproxen, meloxicam)
5. You have tried or have a contraindication to TWO of the following preferred medications: Cimzia (certolizumab), Rinvoq (upadacitinib), Taltz (ixekizumab)
6. You have ONE of the following signs of inflammation:
 - a. C-reactive protein (CRP: a measure of how much inflammation is in the body) levels above the upper limit of normal
 - b. Sacroiliitis (a type of inflammation where lower spine and pelvis connect) on magnetic resonance imaging (MRI: a type of imaging lab)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SECUKINUMAB

INITIAL CRITERIA (CONTINUED)

F. If you have enthesitis-related arthritis, approval also requires:

1. You are 4 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Cosentyx concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of enthesitis-related arthritis
4. You have tried or have a contraindication to (harmful for you to use) an NSAID (nonsteroidal anti-inflammatory drug such as ibuprofen, naproxen, meloxicam), sulfasalazine, or methotrexate

G. If you have moderate to severe hidradenitis suppurativa, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
3. You will NOT use Cosentyx concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of hidradenitis suppurativa
4. You have tried or have a contraindication to (harmful for you to use) ONE topical therapy (such as clindamycin, resorcinol, chlorhexidine, zinc pyrithione, benzoyl peroxide) or an oral antibiotic (such as tetracycline, dapsone)
5. You have tried or have a contraindication to ONE of the following preferred medications: Humira (adalimumab), adalimumab-adaz, Simlandi

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SECUKINUMAB

RENEWAL CRITERIA

Our guideline named **SECUKINUMAB (Cosentyx)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
2. Psoriatic arthritis (PsA: a type of skin and joint condition)
3. Ankylosing spondylitis (AS: a type of joint condition)
4. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
5. Enthesitis-related arthritis (ERA: a type of joint condition)
6. Moderate to severe hidradenitis suppurativa (HS: a type of skin condition)

B. **If you have moderate to severe plaque psoriasis, renewal also requires:**

1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50 percent or more while on therapy
2. You will NOT use Cosentyx concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
3. You meet ONE of the following:
 - a. You are 6 to 17 years of age AND have tried or have a contraindication to (harmful for you to use) FOUR of the preferred medications: Enbrel (etanercept), Taltz (ixekizumab), Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Otezla (apremilast)
 - b. You are 18 years of age or older AND have tried or have a contraindication to FOUR of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SECUKINUMAB

RENEWAL CRITERIA (CONTINUED)

C. If you have psoriatic arthritis, renewal also requires:

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Cosentyx concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
3. You meet ONE of the following:
 - a. You are 2 to 5 years of age AND have tried or have a contraindication to (harmful for you to use) BOTH of the preferred medications: Enbrel (etanercept), Rinvoq (upadacitinib)
 - b. You are 6 to 17 years of age AND have tried or have a contraindication to THREE of the preferred medications: Enbrel (etanercept), Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Rinvoq (upadacitinib)
 - c. You are 18 years of age or older AND have tried or have a contraindication to THREE of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

D. If you have ankylosing spondylitis, renewal also requires:

1. You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1 - 10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
2. You will NOT use Cosentyx concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
3. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab)/adalimumab-adaz/Simlandi, Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Taltz (ixekizumab)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SECUKINUMAB

RENEWAL CRITERIA (CONTINUED)

E. If you have non-radiographic axial spondyloarthritis, renewal also requires:

1. You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1 - 10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
2. You will NOT use Cosentyx concurrently (at the same time) with another systemic biologic (such as Taltz [ixekizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of non-radiographic axial spondyloarthritis
3. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Cimzia (certolizumab), Rinvoq (upadacitinib), Taltz (ixekizumab)

F. If you have enthesitis-related arthritis, renewal also requires:

1. You have experienced or maintained an improvement in global assessment of disease activity, functional ability, number of joints with active arthritis, OR number of joints with limited range of motion
2. You will NOT use Cosentyx concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of enthesitis-related arthritis

G. If you have moderate to severe hidradenitis suppurativa, renewal also requires:

1. You have shown improvement in your hidradenitis suppurativa symptoms
2. You will NOT use Cosentyx concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of hidradenitis suppurativa
3. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Humira (adalimumab), adalimumab-adaz, Simlandi

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SELADELPAR

Generic	Brand				
SELADELPAR LYSINE	LIVDELZI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SELADELPAR (Livdelzi)** requires the following rule(s) be met for approval:

- A. You have primary biliary cholangitis (PBC: a type of immune system disorder that destroys the bile duct), as confirmed by TWO of the following:
 - 1. You have an elevated (high) alkaline phosphatase (ALP) level (a type of lab test)
 - 2. You have the presence of antimitochondrial antibodies (AMA: indicator of the body attacking its own cells) or other PBC-specific autoantibodies (indicator of the body attacking its own cells), including sp100 or gp210, if AMA is negative
 - 3. You have histologic evidence (lab data obtained by liver biopsy [removal of cells or tissue from the liver for examination]) of non-suppurative destructive cholangitis and destruction of interlobular bile ducts (symptoms of liver disease)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions) or hepatologist (a type of liver doctor)
- D. You do NOT have decompensated cirrhosis (a condition where there is liver damage and scarring with major symptoms) (Child-Pugh B or C: a score that evaluates the severity of liver damage)
- E. You will NOT use Livdelzi concurrently (at the same time) with any other second-line therapy for PBC (Ocaliva [obeticholic acid], Iqirvo [elafibranor])
- F. You meet ONE of the following:
 - 1. Livdelzi will be used as monotherapy (one medication treatment) if you are unable to tolerate ursodiol (ursodeoxycholic acid)
 - 2. Livdelzi will be used in combination (together) with ursodiol (ursodeoxycholic acid) if you had an inadequate (poor) response to at least 1 year of treatment with ursodiol (ursodeoxycholic acid) monotherapy (one medication treatment)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SELADELPAR

RENEWAL CRITERIA

Our guideline named **SELADELPAR (Livdelzi)** requires the following rule(s) be met for renewal:

- A. You have primary biliary cholangitis (PBC: a type of immune system disorder that destroys the bile duct)
- B. You have an alkaline phosphatase (ALP) level (a type of lab test) that is less than 1.67-times the upper limit of normal AND which has decreased by at least 15 percent from baseline (before treatment) while on treatment with Livdelzi
- C. You will NOT use Livdelzi concurrently (at the same time) with any other second-line therapy for PBC (Ocaliva [obeticholic acid], Iqirvo [elafibranor])

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SELEXIPAG

Generic	Brand				
SELEXIPAG	UPTRAVI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SELEXIPAG (Upravi)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
- C. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - 1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
 - 2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
 - 3. Pulmonary vascular resistance (PVR) greater than 2 Wood units

RENEWAL CRITERIA

Our guideline named **SELEXIPAG (Upravi)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SELINEXOR

Generic	Brand			
SELINEXOR	XPOVIO			

GUIDELINES FOR USE

Our guideline named **SELINEXOR (Xpovio)** requires the following rule(s) be met for approval:

You have ONE of the following:

Multiple myeloma (MM: a type of blood cancer)

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL: a type of blood cancer that has returned or did not respond to treatment), not otherwise specified, including DLBCL arising from follicular lymphoma (a type of blood cancer)

If you have multiple myeloma, approval also requires:

You are 18 years of age or older

You meet ONE of the following:

Xpovio will be used in combination with bortezomib (Velcade) and dexamethasone; and you have received at least one prior therapy

You have relapsed or refractory multiple myeloma (RRMM: a type of blood cancer that has returned or did not respond to treatment); Xpovio will be used in combination with dexamethasone; you have received at least four prior therapies for the treatment of RRMM; AND your disease is refractory (non-responsive) to ALL of the following:

Two proteasome inhibitors (such as bortezomib [Velcade], carfilzomib [Kymprolis])

Two immunomodulatory agents (such as lenalidomide [Revlimid], pomalidomide [Pomalyst])

One anti-CD38 monoclonal antibody (such as daratumumab [Darzalex])

If you have relapsed or refractory diffuse large B-cell lymphoma, approval also requires:

You are 18 years of age or older

You have received at least two lines of systemic therapy (treatment that targets the entire body such as R-CHOP [rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone], GemOx [gemcitabine, oxaliplatin])

Effective: 04/07/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SELPERCATINIB

Generic	Brand				
SELPERCATINIB	RETEVMO				

GUIDELINES FOR USE

Our guideline named **SELPERCATINIB (Retevmo)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Locally advanced or metastatic non-small cell lung cancer (a type of lung cancer that has spread to nearby tissue or lymph nodes, or has spread to other parts of the body)
 2. Advanced or metastatic medullary thyroid cancer (a type of thyroid cancer that has progressed or has spread to other parts of the body)
 3. Advanced or metastatic thyroid cancer (thyroid cancer that has progressed or has spread to other parts of the body)
 4. Locally advanced or metastatic solid tumors (abnormal mass that has spread to nearby tissue or lymph nodes, or has spread to other parts of the body)
- B. **If you have locally advanced or metastatic non-small cell lung cancer, approval also requires:**
1. You are 18 years of age or older
 2. Your cancer has a rearranged during transfection (*RET*) gene fusion (abnormal change in a type of gene), as detected by a Food and Drug Administration (FDA)-approved test
- C. **If you have advanced or metastatic medullary thyroid cancer, approval also requires:**
1. You are 2 years of age or older
 2. Your cancer has a rearranged during transfection (*RET*) mutation (abnormal change in a type of gene), as detected by a Food and Drug Administration (FDA)-approved test
 3. You require systemic therapy (treatment that targets the entire body)
- D. **If you have advanced or metastatic thyroid cancer, approval also requires:**
1. You are 2 years of age or older
 2. Your cancer has a rearranged during transfection (*RET*) gene fusion (abnormal change in a type of gene), as detected by a Food and Drug Administration (FDA)-approved test
 3. You require systemic therapy (treatment that targets the entire body)
 4. Your cancer is refractory (has not responded) to radioactive iodine therapy, if radioactive iodine is appropriate
- E. **If you have a locally advanced or metastatic solid tumors, approval also requires:**
1. You are 2 years of age or older
 2. Your tumor has a rearranged during transfection (*RET*) gene fusion (abnormal change in a type of gene), as detected by a Food and Drug Administration (FDA)-approved test
 3. Your tumor has progressed (worsened) on or following prior systemic treatment (treatment that targets the entire body) OR you have no alternative treatment options

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SELUMETINIB

Generic	Brand				
SELUMETINIB	KOSELUGO				

GUIDELINES FOR USE

Our guideline named **SELUMETINIB (Koselugo)** requires the following rule(s) be met for approval:

- A. You have neurofibromatosis type 1 (NF1: a genetic disorder that causes light brown skin spots and non-cancerous tumors to form on nerve tissue)
- B. You are 2 to 17 years of age
- C. You have symptomatic, inoperable (not treatable by surgery) plexiform neurofibromas (PN: tumors that grow from nerves anywhere in the body)

Effective: 10/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SEMAGLUTIDE - WEGOVY

Generic	Brand				
SEMAGLUTIDE	WEGOVY				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SEMAGLUTIDE - WEGOVY** requires the following rule(s) be met for approval:

- A. The request is for ONE of the following:
1. To reduce the risk of major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction [heart attack], or non-fatal stroke [a type of brain damage])
 2. Metabolic dysfunction-associated steatohepatitis (MASH: a type of liver disease)/non-alcoholic steatohepatitis (NASH: a type of liver disease)
 3. Weight loss or weight management
- B. **If you will use Wegovy to reduce the risk of major adverse cardiovascular events, approval also requires:**
1. You are 18 years of age or older
 2. You are overweight (your BMI [body mass index: a tool for evaluating body fat] is at least 27 kg/m²)
 3. Wegovy will be used in combination with a reduced calorie diet and increased physical activity
 4. You will NOT use Wegovy concurrently (at the same time) with another GLP-1 receptor agonist (a type of drug such as Victoza [liraglutide], Saxenda [liraglutide], Ozempic [semaglutide], Rybelsus [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release]) or a GLP-1/GIP receptor agonist (a type of drug such as Zepbound [tirzepatide], Mounjaro [tirzepatide])
 5. You have established cardiovascular disease as evidenced by ONE of the following:
 - a. Prior myocardial infarction (heart attack)
 - b. Prior stroke (ischemic [stroke caused by blood clot] or hemorrhagic [stroke caused by broken blood vessels in the brain])
 - c. Carotid artery stenosis of at least 50 percent (the blood vessel that transports blood to the brain is blocked)
 - d. Symptomatic peripheral arterial disease (PAD), as evidenced by intermittent claudication (pain caused by too little blood flow) with ankle-brachial index (ABI: a type of test to check blood flow) less than 0.85 (at rest), peripheral arterial revascularization procedure (surgery to restore blood flow in blocked arteries/veins), or amputation due to atherosclerotic disease (buildup of fat)

(Initial criteria continued on the next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SEMAGLUTIDE - WEGOVY

INITIAL CRITERIA (CONTINUED)

6. You have a history of and will continue to use, or you have a contraindication to (harmful for you to use), ALL of the following standard treatments for the secondary prevention (reduce the risk) of a major adverse cardiovascular event:
 - a. An antiplatelet medication (such as aspirin, clopidogrel, ticagrelor, aspirin-dipyridamole), unless you have a history of a hemorrhagic stroke (bleeding in the brain caused by broken blood vessels)
 - b. A HMG-CoA reductase inhibitor (statins) (such as atorvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin)
 - c. A blood pressure medication (such as angiotensin-converting enzyme inhibitors [ACEi such as lisinopril], angiotensin II receptor blockers [ARBs such as losartan], beta blockers [such as propranolol])
- C. **If you will use Wegovy for metabolic dysfunction-associated steatohepatitis/non-alcoholic steatohepatitis, approval also requires:**
 1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor) or gastroenterologist (doctor who treats digestive conditions)
 3. You are enrolled in or have already completed a lifestyle intervention (such as dietary, exercise, psychology)
 4. You will NOT use Wegovy concurrently (at the same time) with Rezdiffra (resmetirom), another GLP-1 receptor agonist (such as Victoza [liraglutide], Saxenda [liraglutide], Ozempic [semaglutide], Rybelsus [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release]), or a GLP-1/GIP receptor agonist (such as Zepbound [tirzepatide], Mounjaro [tirzepatide])
 5. You have had a biopsy (removal of cells or tissue from the body for examination) or non-invasive test (such as elastography [type of imaging test]) in the past 12 months which demonstrates ONE of the following:
 - a. You have liver fibrosis stage 2 or 3 (scoring system to measure liver damage)
 - b. You have a non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS: a scoring system used to measure disease activity and severity) of at least 4
 - c. You have liver fibrosis stage 1b, AND either metabolic syndrome (group of conditions that raises the risk of developing type 2 diabetes [a disorder with high blood sugar], heart disease, stroke [a type of brain damage]) or type 2 diabetes mellitus

(Initial criteria continued on the next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SEMAGLUTIDE - WEGOVY

INITIAL CRITERIA (CONTINUED)

D. If you will use Wegovy for weight loss or weight management, approval also requires:

1. There is evidence of your active enrollment in an exercise and caloric reduction program, which may include other optional weight loss/behavioral modification programs
2. You will NOT use Wegovy concurrently (at the same time) with another GLP-1 receptor agonist (a type of drug such as Victoza [liraglutide], Saxenda [liraglutide], Ozempic [semaglutide], Rybelsus [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release]) or a GLP-1/GIP receptor agonist (a type of drug such as Zepbound [tirzepatide], Mounjaro [tirzepatide])
3. You meet ONE of the following:
 - a. You are 18 years of age or older and meet ONE of the following:
 - i. You have a body mass index (BMI: a tool for evaluating body fat) of at least 30 kg/m²
 - ii. You have a BMI of at least 27 kg/m² AND at least ONE weight-related comorbidity (disease) (such as hypertension [high blood pressure], type 2 diabetes mellitus [a disorder with high blood sugar], dyslipidemia [abnormal levels of fat], cardiovascular disease [condition of the heart or blood vessels], coronary artery disease [CAD: a type of heart condition], sleep apnea [a type of sleep condition with difficulty breathing], osteoarthritis [a type of joint condition] of the knee[s], polycystic ovarian syndrome [a hormonal disorder], non-alcoholic steatohepatitis/non-alcoholic fatty liver disease [a type of liver disease], asthma [a type of lung condition], and chronic obstructive pulmonary disease [COPD: a type of lung condition])
 - b. You are 12 to 17 years of age and meet the following:
 - i. You have an initial body mass index (BMI: a tool for evaluating body fat) in the 95th percentile or greater standardized for your age and sex

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SEMAGLUTIDE - WEGOVY

INITIAL CRITERIA (CONTINUED)

USE THIS DENIAL TEXT FOR BENEFIT EXCLUSION OF WEIGHT LOSS.

Our guideline named **SEMAGLUTIDE - WEGOVY** requires the following rule(s) be met for approval:

- A. The request is for ONE of the following:
1. To reduce the risk of major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction [heart attack], or non-fatal stroke [a type of brain damage])
 2. Metabolic dysfunction-associated steatohepatitis (MASH: a type of liver disease)/non-alcoholic steatohepatitis (NASH: a type of liver disease)
- B. **If you will use Wegovy to reduce the risk of major adverse cardiovascular events, approval also requires:**
1. You are 18 years of age or older
 2. You are overweight (your BMI [body mass index: a tool for evaluating body fat] is at least 27 kg/m²)
 3. Wegovy will be used in combination with a reduced calorie diet and increased physical activity
 4. You will NOT use Wegovy concurrently (at the same time) with another GLP-1 receptor agonist (a type of drug such as Victoza [liraglutide], Saxenda [liraglutide], Ozempic [semaglutide], Rybelsus [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release]) or a GLP-1/GIP receptor agonist (a type of drug such as Zepbound [tirzepatide], Mounjaro [tirzepatide])
 5. You have established cardiovascular disease as evidenced by ONE of the following:
 1. Prior myocardial infarction (heart attack)
 2. Prior stroke (ischemic [stroke caused by blood clot] or hemorrhagic [stroke caused by broken blood vessels in the brain])
 3. Carotid artery stenosis of at least 50 percent (the blood vessel that transports blood to the brain is blocked)
 4. Symptomatic peripheral arterial disease (PAD), as evidenced by intermittent claudication (pain caused by too little blood flow) with ankle-brachial index (ABI: a type of test to check blood flow) less than 0.85 (at rest), peripheral arterial revascularization procedure (surgery to restore blood flow in blocked arteries/veins), or amputation due to atherosclerotic disease (buildup of fat)

(Initial criteria continued on the next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SEMAGLUTIDE - WEGOVY

INITIAL CRITERIA (CONTINUED)

6. You have a history of and will continue to use, or you have a contraindication to (harmful for you to use), ALL of the following standard treatments for the secondary prevention (reduce the risk) of a major adverse cardiovascular event:
 1. An antiplatelet medication (such as aspirin, clopidogrel, ticagrelor, aspirin-dipyridamole), unless you have a history of a hemorrhagic stroke (bleeding in the brain caused by broken blood vessels)
 2. A HMG-CoA reductase inhibitor (statins) (such as atorvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin)
 3. A blood pressure medication (such as angiotensin-converting enzyme inhibitors [ACEi such as lisinopril], angiotensin II receptor blockers [ARBs such as losartan], beta blockers [such as propranolol])
- C. **If you will use Wegovy for metabolic dysfunction-associated steatohepatitis/non-alcoholic steatohepatitis, approval also requires:**
 1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor) or gastroenterologist (doctor who treats digestive conditions)
 3. You are enrolled in or have already completed a lifestyle intervention (such as dietary, exercise, psychology)
 4. You will NOT use Wegovy concurrently (at the same time) with Rezdiffra (resmetirom), another GLP-1 receptor agonist (such as Victoza [liraglutide], Saxenda [liraglutide], Ozempic [semaglutide], Rybelsus [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release]), or a GLP-1/GIP receptor agonist (such as Zepbound [tirzepatide], Mounjaro [tirzepatide])
 5. You have had a biopsy (removal of cells or tissue from the body for examination) or non-invasive test (such as elastography [type of imaging test]) in the past 12 months which demonstrates ONE of the following:
 - a. You have liver fibrosis stage 2 or 3 (scoring system to measure liver damage)
 - b. You have a non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS: a scoring system used to measure disease activity and severity) of at least 4
 - c. You have liver fibrosis stage 1b, AND either metabolic syndrome (group of conditions that raises the risk of developing type 2 diabetes [a disorder with high blood sugar], heart disease, stroke [a type of brain damage]) or type 2 diabetes mellitus

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SEMAGLUTIDE - WEGOVY

RENEWAL CRITERIA

Our guideline named **SEMAGLUTIDE - WEGOVY** requires the following rule(s) be met for renewal:

- A. The request is for ONE of the following:
1. To reduce the risk of cardiovascular death, heart attack, and stroke (a type of brain damage)
 2. Metabolic dysfunction-associated steatohepatitis (MASH: a type of liver disease)/non-alcoholic steatohepatitis (NASH: a type of liver disease)
 3. Weight loss or weight management
- B. **If you will use Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke, renewal also requires:**
1. You have cardiovascular disease (such as prior heart attack, prior stroke, carotid artery stenosis of at least 50 percent [the blood vessel that transports blood to the brain is blocked], symptomatic peripheral arterial disease [PAD])
 2. Wegovy will be used in combination with a reduced calorie diet and increased physical activity
 3. You will NOT use Wegovy concurrently (at the same time) with another GLP-1 receptor agonist (a type of drug such as Victoza [liraglutide], Saxenda [liraglutide], Ozempic [semaglutide], Rybelsus [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release]) or a GLP-1/GIP receptor agonist (a type of drug such as Zepbound [tirzepatide], Mounjaro [tirzepatide])
 4. You have a history of and will continue to use, or you have a contraindication to (harmful for you to use), ALL of the following standard treatments for the secondary prevention (reduce the risk) of a major adverse cardiovascular event (such as a non-fatal myocardial infarction [heart attack], non-fatal stroke [a type of brain damage]):
 - a. An antiplatelet medication (such as aspirin, clopidogrel, ticagrelor, aspirin-dipyridamole), unless you have a history of a hemorrhagic stroke (a type of brain damage caused by broken blood vessels in the brain)
 - b. A HMG-CoA reductase inhibitor (statins) (such as atorvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin)
 - c. A blood pressure medication (such as angiotensin-converting enzyme inhibitors [ACEi such as lisinopril], angiotensin II receptor blockers [ARBs such as losartan], beta blockers [such as propranolol])

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SEMAGLUTIDE - WEGOVY

RENEWAL CRITERIA (CONTINUED)

C. If you will use Wegovy for metabolic dysfunction-associated steatohepatitis/non-alcoholic steatohepatitis, renewal also requires:

1. You will NOT use Wegovy concurrently (at the same time) with Rezdiffra (resmetirom), another GLP-1 receptor agonist (such as Victoza [liraglutide], Saxenda [liraglutide], Ozempic [semaglutide], Rybelsus [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release]), or a GLP-1/GIP receptor agonist (such as Zepbound [tirzepatide], Mounjaro [tirzepatide])
2. You do NOT meet any of the following:
 - a. You are a non-responder (defined as no reduction [no improvement] in liver fibrosis stage [scoring system to measure liver damage] AND your NAFLD [non-alcoholic fatty liver disease] Activity Score [NAS: a scoring system used to measure disease activity and severity] has NOT decreased by at least 2 points from baseline [before start of treatment])
 - b. You have experienced MASH/NASH resolution as defined by ONE of the following:
 - i. If your baseline (before treatment) liver fibrosis was at stage 2 or 3, you now have liver fibrosis stage 0 to 1 AND a NAFLD Activity Score [NAS] of less than or equal to 3
 - ii. If your baseline liver fibrosis was at stage 1b, you now have liver fibrosis stage 0 OR a NAFLD Activity Score [NAS] of less than or equal to 3

D. If you will use Wegovy for weight loss or weight management, renewal also requires:

1. You will NOT use Wegovy concurrently (at the same time) with another GLP-1 receptor agonist (a type of drug such as Victoza [liraglutide], Saxenda [liraglutide], Ozempic [semaglutide], Rybelsus [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release]) or a GLP-1/GIP receptor agonist (a type of drug such as Zepbound [tirzepatide], Mounjaro [tirzepatide])
2. You meet ONE of the following:
 - a. You are 18 years of age or older AND have achieved or maintained at least a 5 percent weight loss of baseline body weight
 - b. You are 12 to 17 years of age AND have achieved or maintained at least a 5 percent weight loss of baseline body mass index (BMI: a tool for evaluating body fat)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SEMAGLUTIDE - WEGOVY

RENEWAL CRITERIA (CONTINUED)

USE THIS DENIAL TEXT FOR BENEFIT EXCLUSION OF WEIGHT LOSS.

Our guideline named **SEMAGLUTIDE - WEGOVY** requires the following rule(s) be met for renewal:

- A. The request is for ONE of the following:
 - 1. To reduce the risk of cardiovascular death, heart attack, and stroke (a type of brain damage)
 - 2. Metabolic dysfunction-associated steatohepatitis (MASH: a type of liver disease)/non-alcoholic steatohepatitis (NASH: a type of liver disease)
- B. **If you will use Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke, renewal also requires:**
 - 1. You have cardiovascular disease (such as prior heart attack, prior stroke, carotid artery stenosis of at least 50 percent [the blood vessel that transports blood to the brain is blocked], symptomatic peripheral arterial disease [PAD])
 - 2. Wegovy will be used in combination with a reduced calorie diet and increased physical activity
 - 3. You will NOT use Wegovy concurrently (at the same time) with another GLP-1 receptor agonist (a type of drug such as Victoza [liraglutide], Saxenda [liraglutide], Ozempic [semaglutide], Rybelsus [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release]) or a GLP-1/GIP receptor agonist (a type of drug such as Zepbound [tirzepatide], Mounjaro [tirzepatide])
 - 4. You have a history of and will continue to use, or you have a contraindication to (harmful for you to use), ALL of the following standard treatments for the secondary prevention (reduce the risk) of a major adverse cardiovascular event (such as a non-fatal myocardial infarction [heart attack], non-fatal stroke [a type of brain damage]):
 - a. An antiplatelet medication (such as aspirin, clopidogrel, ticagrelor, aspirin-dipyridamole), unless you have a history of a hemorrhagic stroke (a type of brain damage caused by broken blood vessels in the brain)
 - b. A HMG-CoA reductase inhibitor (statins) (such as atorvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin)
 - c. A blood pressure medication (such as angiotensin-converting enzyme inhibitors [ACEi such as lisinopril], angiotensin II receptor blockers [ARBs such as losartan], beta blockers [such as propranolol])

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SEMAGLUTIDE - WEGOVY

RENEWAL CRITERIA (CONTINUED)

C. If you will use Wegovy for metabolic dysfunction-associated steatohepatitis/non-alcoholic steatohepatitis, renewal also requires:

1. You will NOT use Wegovy concurrently (at the same time) with Rezdiffra (resmetirom), another GLP-1 receptor agonist (such as Victoza [liraglutide], Saxenda [liraglutide], Ozempic [semaglutide], Rybelsus [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release]), or a GLP-1/GIP receptor agonist (such as Zepbound [tirzepatide], Mounjaro [tirzepatide])
2. You do NOT meet any of the following:
 - a. You are a non-responder (defined as no reduction [no improvement] in liver fibrosis stage [scoring system to measure liver damage] AND your NAFLD [non-alcoholic fatty liver disease] Activity Score [NAS: a scoring system used to measure disease activity and severity] has NOT decreased by at least 2 points from baseline [before start of treatment])
 - b. You have experienced MASH/NASH resolution as defined by ONE of the following:
 - i. If your baseline (before treatment) liver fibrosis was at stage 2 or 3, you now have liver fibrosis stage 0 to 1 AND a NAFLD Activity Score [NAS] of less than or equal to 3
 - ii. If your baseline liver fibrosis was at stage 1b, you now have liver fibrosis stage 0 OR a NAFLD Activity Score [NAS] of less than or equal to 3

NOTE: Your plan does NOT cover Wegovy when it is only used for weight loss or weight management.

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SETMELANOTIDE

Generic	Brand				
SETMELANOTIDE ACETATE	IMCIVREE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SETMELANOTIDE (Imcivree)** requires the following rule(s) be met for approval:

- A. You have a diagnosis of obesity (a condition where you have higher than normal body fat)
- B. You are 2 years of age or older
- C. You have ONE of the following:
 - 1. Bardet-Biedl syndrome (BBS: a genetic disorder)
 - 2. Pro-opiomelanocortin (POMC: type of protein) deficiency (low level), as determined by a Food and Drug Administration (FDA)-approved test
 - 3. Proprotein convertase subtilisin/kexin type 1 (PCSK1: type of protein) deficiency, as determined by an FDA-approved test
 - 4. Leptin receptor (LEPR: type of protein) deficiency, as determined by an FDA-approved test

RENEWAL CRITERIA

Our guideline named **SETMELANOTIDE (Imcivree)** requires the following rule(s) be met for renewal:

- A. You have a diagnosis of obesity (a condition where you have higher than normal body fat)
- B. You have ONE of the following:
 - 1. Bardet-Biedl syndrome (BBS: a genetic disorder)
 - 2. Pro-opiomelanocortin (POMC: type of protein) deficiency (low level)
 - 3. Proprotein convertase subtilisin/kexin type 1 (PCSK1: type of protein) deficiency
 - 4. Leptin receptor (LEPR: type of protein) deficiency
- C. You meet ONE of the following:
 - 1. You are 2 to 17 years of age AND have lost at least 5 percent of your baseline body mass index (BMI: a tool for evaluating body fat)
 - 2. You are 18 years of age or older AND have lost at least 5 percent of your baseline body weight

Effective: 01/17/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SILDENAFIL IV

Generic	Brand				
SILDENAFIL CITRATE	REVATIO, SILDENAFIL CITRATE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SILDENAFIL IV (Revatio)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
- D. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - 1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
 - 2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
 - 3. Pulmonary vascular resistance (PVR) greater than 2 Wood units
- E. You will NOT use the requested medication concurrently (at the same time) or intermittently (off and on) with oral erectile dysfunction medications (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
- F. You will NOT use the requested medication concurrently (at the same time) with guanylate cyclase stimulators (such as Adempas [riociguat])

RENEWAL CRITERIA

Our guideline named **SILDENAFIL IV (Revatio)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. You will NOT use the requested medication concurrently (at the same time) or intermittently (off and on) with oral erectile dysfunction medications (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
- C. You will NOT use the requested medication concurrently (at the same time) with guanylate cyclase stimulators (such as Adempas [riociguat])

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SILDENAFIL SUSPENSION

Generic	Brand				
SILDENAFIL CITRATE	REVATIO, LIQREV, SILDENAFIL CITRATE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SILDENAFIL SUSPENSION (Revatio, Liqrev)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. **If you are 1 to 17 years of age, approval also requires:**
 1. You are requesting Revatio (sildenafil) suspension
 2. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
 3. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
 - b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
 - c. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
 4. You will NOT use the requested medication concurrently (at the same time) or intermittently (off and on) with oral erectile dysfunction medications (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
 5. You will NOT use the requested medication concurrently (at the same time) with guanylate cyclase stimulators (such as Adempas [riociguat])
 6. You are unable to swallow pills AND you have tried crushed sildenafil tablets

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SILDENAFIL SUSPENSION

INITIAL CRITERIA (CONTINUED)

C. If you are 18 years of age or older, approval also requires:

1. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
2. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
 - b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
 - c. Pulmonary vascular resistance (PVR) greater than 2 Wood units
3. You will NOT use the requested medication concurrently (at the same time) or intermittently (off and on) with oral erectile dysfunction medications (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
4. You will NOT use the requested medication concurrently (at the same time) with guanylate cyclase stimulators (such as Adempas [riociguat])
5. If you are requesting Revatio (sildenafil) suspension, you are unable to swallow pills AND you have tried crushed sildenafil tablets
6. If you are requesting Liqrev suspension, you are unable to swallow Revatio (sildenafil) tablets AND you have tried generic sildenafil powder for suspension

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SILDENAFIL SUSPENSION

RENEWAL CRITERIA

Our guideline named **SILDENAFIL SUSPENSION (Revatio, Liqrev)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. **If you are 1 to 17 years of age, approval also requires:**
 - 1. You are requesting Revatio (sildenafil) suspension
 - 2. You will NOT use the requested medication concurrently (at the same time) or intermittently (off and on) with oral erectile dysfunction medications (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
 - 3. You will NOT use the requested medication concurrently (at the same time) with guanylate cyclase stimulators (such as Adempas [riociguat])
- C. **If you are 18 years of age or older, approval also requires:**
 - 1. You will NOT use the requested medication concurrently (at the same time) or intermittently (off and on) with oral erectile dysfunction medications (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
 - 2. You will NOT use the requested medication concurrently (at the same time) with guanylate cyclase stimulators (such as Adempas [riociguat])

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SILDENAFIL TABLET

Generic	Brand				
SILDENAFIL CITRATE	REVATIO, SILDENAFIL CITRATE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SILDENAFIL TABLET (Revatio)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. **If you are 1 to 17 years of age, approval also requires:**
 1. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
 2. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
 - b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
 - c. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
 3. You will NOT use the requested medication concurrently (at the same time) or intermittently (off and on) with oral erectile dysfunction medications (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
 4. You will NOT use the requested medication concurrently (at the same time) with guanylate cyclase stimulators (such as Adempas [riociguat])
- C. **If you are 18 years of age or older, approval also requires:**
 1. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
 2. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
 - b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
 - c. Pulmonary vascular resistance (PVR) greater than 2 Wood units
 3. You will NOT use the requested medication concurrently (at the same time) or intermittently (off and on) with oral erectile dysfunction medications (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
 4. You will NOT use the requested medication concurrently (at the same time) with guanylate cyclase stimulators (such as Adempas [riociguat])

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SILDENAFIL TABLET

RENEWAL CRITERIA

Our guideline named **SILDENAFIL TABLET (Revatio)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. You are 1 year of age or older
- C. You will NOT use the requested medication concurrently (at the same time) or intermittently (off and on) with oral erectile dysfunction medications (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
- D. You will NOT use the requested medication concurrently (at the same time) with guanylate cyclase stimulators (such as Adempas [riociguat])

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SIMVASTATIN 80

Generic	Brand				
EZETIMIBE/ SIMVASTATIN	VYTORIN				
SIMVASTATIN	ZOCOR, SIMVASTATIN				

GUIDELINES FOR USE

Our guideline named **SIMVASTATIN 80 (VYTORIN, ZOCOR)** requires the following rule(s) be met for approval:

- A. You have been taking the medication for at least 12 months

Effective: 05/14/21



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SIMVASTATIN ORAL SUSPENSION

Generic	Brand			
SIMVASTATIN	FLOLIPID			

GUIDELINES FOR USE

Our guideline named **SIMVASTATIN ORAL SUSPENSION (Flolipid)** requires the following rule(s) be met for approval:

- A. You have tried or have a contraindication to (harmful for you to use) simvastatin tablets
- B. You have dysphagia (difficulty swallowing), difficulty swallowing tablets, or a feeding tube (such as a G-tube or J-tube)
- C. Requests for zero-dollar cost share also requires the following:
 - 1. You are between 40 to 75 years old
 - 2. The requested quantity is within the low to moderate intensity daily dosage of 5 to 40 mg
 - 3. You are not concurrently (at the same time) taking any of the below secondary prevention medications for cardiovascular disease (heart disease):
 - a. Aspirin/dipyridamole (Aggrenox)
 - b. Clopidogrel (Plavix)
 - c. Dipyridamole
 - d. Nitroglycerin (oral, sublingual, transdermal, translingual dosage forms)
 - e. Prasugrel (Effient)
 - f. Ticagrelor (Brilinta)
 - g. Ticlopidine
 - h. Vorapaxar (Zontivity)

Effective: 03/03/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SIPONIMOD

Generic	Brand			
SIPONIMOD	MAYZENT			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SIPONIMOD (Mayzent)** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms or disease returns and goes away), or active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older
- C. You have CYP2C9 (type of enzyme) *1/*1, *1/*2, *2/*2, *1/*3, or *2/*3 genotype

RENEWAL CRITERIA

Our guideline named **SIPONIMOD (Mayzent)** requires the following rule(s) be met for renewal:

- A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms or disease returns and goes away), or active secondary progressive disease (advanced disease)
- B. You have demonstrated a clinical benefit compared to pre-treatment baseline
- C. You have CYP2C9 (type of enzyme) *1/*1, *1/*2, *2/*2, *1/*3, or *2/*3 genotype

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SIROLIMUS TOPICAL

Generic	Brand				
SIROLIMUS	HYFTOR				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SIROLIMUS TOPICAL (Hyftor)** requires the following rule(s) be met for approval:

- A. You have facial angiofibroma (a skin condition) associated with tuberous sclerosis (a rare type of tumor disorder)
- B. You are 6 years of age or older

RENEWAL CRITERIA

Our guideline named **SIROLIMUS TOPICAL (Hyftor)** requires the following rule(s) be met for renewal:

- A. You have facial angiofibroma (a skin condition) associated with tuberous sclerosis (a rare type of tumor disorder)

Effective: 08/29/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SODIUM/CALCIUM/MAG/POT OXYBATE

Generic	Brand				
SODIUM, CALCIUM, MAG, POT OXYBATE	XYWAV				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SODIUM/CALCIUM/MAG/POT OXYBATE (Xywav)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Idiopathic hypersomnia (IH: a type of sleep disorder)
 2. Cataplexy in narcolepsy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
 3. Excessive daytime sleepiness (EDS) in narcolepsy (a type of sleep disorder)
- B. You are not concurrently on a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant]
- C. **If you have idiopathic hypersomnia, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
 3. Your diagnosis is confirmed by ALL of the following:
 - a. You do not have cataplexy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
 - b. You have a Multiple Sleep Latency Test (MSLT) showing less than 2 sleep-onset REM sleep periods (SOREMP) OR no SOREMPs if REM sleep latency on polysomnogram (type of sleep test) is 15 minutes or less
 - c. You have 1 or more MSLT mean sleep latency of 8 minutes or less, OR total 24-hour sleep is 660 minutes or more on 24-hour polysomnography or by wrist actigraphy (device that monitors movement) in association with a sleep log
 - d. You have had insufficient sleep syndrome ruled out, AND there is no better explanation by another sleep/medical/psychiatric disorder or use of drugs/medications, AND you have experienced daily periods of irrepressible need to sleep or daytime lapses into sleep for at least 3 months
 4. You tried and failed or have a contraindication (harmful for) to armodafinil OR modafinil

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SODIUM/CALCIUM/MAG/POT OXYBATE

INITIAL CRITERIA (CONTINUED)

D. If you have cataplexy in narcolepsy, approval also requires:

1. You are 7 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
3. You have tried TWO of the following: venlafaxine, fluoxetine, or tricyclic anti-depressants (such as amitriptyline, clomipramine, imipramine)

E. If you have excessive daytime sleepiness in narcolepsy, approval also requires:

1. You are 7 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
3. You have EDS persisting for 3 or more months and an Epworth Sleepiness Scale (tool to measure your sleepiness) score of more than 10
4. Your diagnosis of narcolepsy is confirmed by ONE of the following:
 - a. A Multiple Sleep Latency Test showing both an average sleep latency of 8 minutes or less AND 2 or more early-onset rapid eye movement (REM) sleep test periods
 - b. A Multiple Sleep Latency Test (MSLT) showing both an average sleep latency of 8 minutes or less AND one early-onset rapid eye movement (REM) sleep test period (SOREMP) AND additionally one SOREMP (within approximately 15 minutes) on a polysomnography (type of sleep test) the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness
 - c. You have low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay (test showing you have low levels of a chemical that helps with staying awake)
5. If you are 7 to 17 years old, you tried and failed or have a contraindication (harmful for) to one generic stimulant indicated for EDS in narcolepsy (such as amphetamine, dextroamphetamine, or methylphenidate)
6. If you are 18 years or older, you tried and failed or have a contraindication (harmful for) to one agent from EACH of the following categories:
 - a. Generic typical stimulant (such as amphetamine sulfate, methylphenidate, etc.)
 - b. Armodafinil OR modafinil

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SODIUM/CALCIUM/MAG/POT OXYBATE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **SODIUM/CALCIUM/MAG/POT OXYBATE (Xywav)** requires the following rule(s) be met for renewal:

- A. You have **ONE** of the following diagnoses:
 - 1. Narcolepsy (uncontrollable daytime sleepiness)
 - 2. Idiopathic hypersomnia (IH: a type of sleep disorder)
- B. You are not concurrently (at the same time) on a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant]
- C. **If you have narcolepsy, renewal also requires you meet ONE of the following:**
 - 1. You have demonstrated improvement in cataplexy symptoms (sudden and uncontrollable muscle weakness) compared to baseline
 - 2. You have maintained an improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline
 - 3. You have demonstrated improvement in sleep latency (the amount of time it takes you to fall asleep)
- D. **If you have idiopathic hypersomnia, renewal also requires you meet ONE of the following:**
 - 1. You have demonstrated improvement of idiopathic hypersomnia symptoms compared to baseline
 - 2. You have maintained an improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline

Effective: 01/01/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SODIUM OXYBATE-LUMRYZ

Generic	Brand				
SODIUM OXYBATE	LUMRYZ				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SODIUM OXYBATE-LUMRYZ** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Cataplexy with narcolepsy (a type of sleep condition with extreme drowsiness with sudden and uncontrollable muscle weakness)
2. Excessive daytime sleepiness (EDS) with narcolepsy (a type of sleep condition with overwhelming daytime drowsiness)

B. If you have cataplexy with narcolepsy, approval also requires:

1. You are 7 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor), psychiatrist (a type of mental health doctor), or specialist in sleep medicine
3. You had a trial of generic sodium oxybate
4. You had a trial of TWO of the following: venlafaxine (Effexor), fluoxetine (Prozac), TCA (tricyclic antidepressant, such as amitriptyline [Elavil], clomipramine [Anafranil], imipramine [Tofranil])
5. You will NOT use Lumryz concurrently (at the same time) with a sedative hypnotic medication (medications that make you sleepy) (such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant])

C. If you have excessive daytime sleepiness (EDS) with narcolepsy, approval also requires:

1. You are 7 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor), psychiatrist (a type of mental health doctor), or specialist in sleep medicine
3. You will NOT use Lumryz concurrently (at the same time) with a sedative hypnotic medication (medications that make you sleepy) (such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant])

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SODIUM OXYBATE-LUMRYZ

INITIAL CRITERIA (CONTINUED)

4. You have excessive daytime sleepiness (EDS) persisting for at least 3 months
5. You have an Epworth Sleepiness Scale (ESS: questionnaire used to assess daytime sleepiness) score of greater than 10
6. You had a trial of or contraindication to (harmful for you to use) generic sodium oxybate
7. Your diagnosis is confirmed by ONE of the following:
 - a. You have a Multiple Sleep Latency Test (MSLT) showing both an average sleep latency of 8 minutes or less AND at least 2 early-onset rapid eye movement (REM) sleep test periods (SOREMPs)
 - b. You have a Multiple Sleep Latency Test (MSLT) showing an average sleep latency of 8 minutes or less AND at least one early-onset rapid eye movement (REM) sleep test period (SOREMP) AND additionally one SOREMP (within approximately 15 minutes) on a polysomnography (type of sleep test) the night before the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness (EDS)
 - c. You have low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay (test showing you have low levels of a chemical that helps with staying awake)
8. **If you are 7 to 17 years old, approval also requires:**
 - a. You had a trial of or contraindication to (harmful for you to use) a generic typical stimulant (such as amphetamine [Evekeo], dextroamphetamine [Dexedrine], methylphenidate [Ritalin])
9. **If you are 18 years or older, approval also requires:**
 - a. You had a trial of or contraindication to (harmful for you to use) a generic typical stimulant (such as amphetamine [Evekeo], dextroamphetamine [Dexedrine], methylphenidate [Ritalin])
 - b. You had a trial of or contraindication to (harmful for you to use) armodafinil (Nuvigil) or modafinil (Provigil)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SODIUM OXYBATE-LUMRYZ

RENEWAL CRITERIA

Our guideline named **SODIUM OXYBATE-LUMRYZ** requires the following rule(s) be met for renewal:

- A. You have narcolepsy (a type of sleep condition)
- B. You will NOT use Lumryz concurrently (at the same time) with a sedative hypnotic medication (medications that make you sleepy) (such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant])
- C. You meet ONE of the following:
 - 1. You have demonstrated improvement in cataplexy symptoms (sudden and uncontrollable muscle weakness) compared to baseline
 - 2. You have maintained an improvement in Epworth Sleepiness Scale (ESS: questionnaire used to assess daytime sleepiness) scores by at least 25 percent compared to baseline
 - 3. You have demonstrated improvement in sleep latency (the amount of time it takes you to fall asleep) compared to baseline

Effective: 10/14/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SODIUM OXYBATE-XYREM

Generic	Brand				
SODIUM OXYBATE	XYREM, SODIUM OXYBATE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SODIUM OXYBATE (Xyrem)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Idiopathic hypersomnia (IH: a type of sleep disorder)
 - 2. Cataplexy in narcolepsy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
 - 3. Excessive daytime sleepiness (EDS) in narcolepsy (sleep disorder)
- B. Xyrem (sodium oxybate) will NOT be used concurrently (at the same time) with a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta (eszopiclone), Ambien (zolpidem), or Restoril (temazepam)
- C. **If you have idiopathic hypersomnia, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
 - 3. Your diagnosis is confirmed by ALL of the following:
 - a. You do NOT have cataplexy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
 - b. You have a Multiple Sleep Latency Test (MSLT) showing less than two sleep-onset REM (rapid eye movement) sleep periods (SOREMP) OR no SOREMPs if REM sleep latency on polysomnogram (type of sleep test) is 15 minutes or less
 - c. You have one or more MSLT mean sleep latency of 8 minutes or less, OR total 24-hour sleep is 660 minutes or more on 24-hour polysomnography or by wrist actigraphy (device that monitors movement) in association with a sleep log
 - d. You have had insufficient sleep syndrome ruled out, AND there is no better explanation by another sleep/medical/psychiatric disorder or use of drugs/medications, AND you have experienced daily periods of an irrepressible need to sleep or daytime lapses into sleep for at least 3 months
 - 4. You have tried and failed or have a contraindication (harmful for) to armodafinil (Nuvigil) OR modafinil (Provigil)
 - 5. If you are requesting brand Xyrem, you have tried and failed or have a contraindication (harmful for) to generic sodium oxybate

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SODIUM OXYBATE-XYREM

INITIAL CRITERIA (CONTINUED)

D. If you have cataplexy in narcolepsy, approval also requires:

1. You are 7 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
3. You have tried TWO of the following: venlafaxine (Effexor), fluoxetine (Prozac), a tricyclic anti-depressant (such as amitriptyline [Elavil], clomipramine [Anafranil], imipramine [Tofranil])

E. If you have excessive daytime sleepiness in narcolepsy, approval also requires:

1. You are 7 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
3. You have EDS persisting for 3 or more months
4. You have an Epworth Sleepiness Scale (tool to measure sleepiness) score of more than 10
5. Your diagnosis of narcolepsy is confirmed by ONE of the following:
 - a. A Multiple Sleep Latency Test (MSLT) showing both an average sleep latency of 8 minutes or less AND two or more early-onset rapid eye movement (REM) sleep test periods
 - b. A Multiple Sleep Latency Test showing an average sleep latency of 8 minutes or less AND one early-onset rapid eye movement (REM) sleep test period (SOREMP) AND additionally one SOREMP (within approximately 15 minutes) on a polysomnography (type of sleep test) the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness
 - c. You have low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay (test showing low levels of a chemical that help with staying awake)
6. If you are 7 to 17 years old, you have tried and failed or have a contraindication (harmful for) to one generic stimulant indicated for EDS in narcolepsy (such as amphetamine [Evekeo], dextroamphetamine [Dexedrine], or methylphenidate [Ritalin])
7. If you are 18 years or older, you have tried and failed or have a contraindication (harmful for) to one agent from EACH of the following categories:
 - a. Generic typical stimulant (such as amphetamine sulfate [Evekeo], dextroamphetamine [Dexedrine], methylphenidate [Ritalin])
 - b. Armodafinil (Nuvigil) OR modafinil (Provigil)
 - c. If you are requesting brand Xyrem, you have tried and failed or have a contraindication (harmful for) to generic sodium oxybate

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SODIUM OXYBATE-XYREM

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **SODIUM OXYBATE (Xyrem)** requires the following rule(s) be met for renewal:

- A. You have **ONE** of the following diagnoses:
 - 1. Narcolepsy (uncontrollable daytime sleepiness)
 - 2. Idiopathic hypersomnia (IH: a type of sleep disorder)
- B. Xyrem (sodium oxybate) will **NOT** be used concurrently (at the same time) with a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], or Restoril [temazepam]
- C. **If you have narcolepsy, renewal also requires ONE of the following:**
 - 1. You have demonstrated improvement in cataplexy symptoms (sudden and uncontrollable muscle weakness) compared to baseline
 - 2. You have maintained improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline
 - 3. You have demonstrated improvement in sleep latency (the amount of time it takes to fall asleep)
- D. **If you have idiopathic hypersomnia, renewal also requires ONE of the following:**
 - 1. You have demonstrated improvement of idiopathic hypersomnia symptoms compared to baseline
 - 2. You have maintained an improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline

Effective: 06/12/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SODIUM PHENYLBUTYRATE

Generic	Brand			
SODIUM PHENYLBUTYRATE	BUPHENYL, PHEBURANE, SODIUM PHENYLBUTYRATE			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SODIUM PHENYLBUTYRATE (Buphenyl, Pheburane, Olpruva)** requires the following rule(s) be met for approval:

- A. You have a urea cycle disorder (UCD: a genetic disorder that causes high ammonia levels in the blood)
- B. Your disorder is confirmed by enzymatic, biochemical or genetic testing (types of lab tests)
- C. The requested medication will be used as adjunctive (add-on) therapy along with dietary protein restriction
- D. Your disorder cannot be managed by dietary protein restriction or amino acid supplementation alone
- E. **If your request is for Pheburane or Olpruva, approval also requires:**
 1. You have tried or have a contraindication to (harmful for you to use) generic sodium phenylbutyrate powder
 2. You are unable to swallow Buphenyl (sodium phenylbutyrate) tablet

RENEWAL CRITERIA

Our guideline named **SODIUM PHENYLBUTYRATE (Buphenyl, Pheburane, Olpruva)** requires the following rule(s) be met for renewal:

- A. You have a urea cycle disorder (UCD: a genetic disorder that causes high ammonia levels in the blood)
- B. You have experienced a clinical benefit from baseline (for example you have normal fasting glutamine levels, low-normal fasting ammonia levels, mental status clarity)

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOD PHENYLBUTYRATE-TAURURSODIOL

Generic	Brand				
SOD PHENYLBUTYRAT /TAURURSODIOL	RELYVRIO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SOD PHENYLBUTYRATE-TAURURSODIOL (Relyvrio)** requires the following rule(s) be met for approval:

- A. You have amyotrophic lateral sclerosis (ALS: a type of brain and nerve condition)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor) or ALS specialist or being seen at an ALS Specialty Center or Care Clinic

RENEWAL CRITERIA

Our guideline named **SOD PHENYLBUTYRATE-TAURURSODIOL (Relyvrio)** requires the following rule(s) be met for renewal:

- A. You have amyotrophic lateral sclerosis (ALS: a type of brain and nerve condition)
- B. You do not require invasive ventilation (inserting a breathing tube into your throat)
- C. You have improved or maintained baseline functional ability measured by functional assessments (e.g., Amyotrophic Lateral Sclerosis Functional Rating Scale [ALSFRS: a tool for evaluating functional status])

Effective: 10/24/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOFOSBUVIR

Generic	Brand			
SOFOSBUVIR	SOVALDI			

GUIDELINES FOR USE

Our guideline named **SOFOSBUVIR (Sovaldi)** requires the following rule(s) be met for approval:

- A. You have chronic hepatitis C virus (HCV: liver inflammation caused by a type of virus)
- B. You have genotype 2 or 3 infection (types of hepatitis C virus) and are 3 to 17 years of age
OR you have genotype 1, 2, 3, or 4 infection (types of hepatitis C virus) and are 18 years of age or older
- C. You have an HCV RNA level (a measure of the amount of hepatitis C virus in the blood) within the past 6 months
- D. You do NOT have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions
- E. You will NOT use Sovaldi concurrently (at the same time) with any medication with drug interactions that are contraindicated (harmful for you to use) or not recommended per the prescribing information (such as amiodarone, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, Priftin [rifapentine], St. John's wort, Aptivus [tipranavir]/ritonavir)
- F. You will NOT use Sovaldi concurrently (at the same time) with Epclusa (velpatasvir/sofosbuvir), Harvoni (ledipasvir/sofosbuvir), Vosevi (velpatasvir/sofosbuvir/voxilaprevir), or Zepatier (elbasvir/grazoprevir)
- G. **If you have genotype 2 infection, approval also requires:**
 - 1. You have compensated cirrhosis (a condition where there is liver damage and scarring without any major symptoms) (Child-Pugh A: a score that evaluates the severity of liver damage) OR you do not have cirrhosis (liver damage and scarring)
 - 2. Sovaldi will be used with ribavirin
 - 3. You meet ONE of the following:
 - a. You are 3 to 17 years of age
 - b. You are 18 years of age or older AND had an intolerance (side effect) or contraindication to (harmful for you to use) the preferred medication: Epclusa
- H. **If you have genotype 3 infection, approval also requires:**
 - 1. You have compensated cirrhosis (a condition where there is liver damage and scarring without any major symptoms) (Child-Pugh A: a score that evaluates the severity of liver damage) OR you do not have cirrhosis (liver damage and scarring)
 - 2. Sovaldi will be used with ribavirin
 - 3. You meet ONE of the following:
 - a. You are 3 to 17 years of age
 - b. You are 18 years of age or older AND had an intolerance (side effect) or contraindication to (harmful for you to use) the preferred medication: Epclusa

(Criteria continued on the next page)

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOFOSBUVIR

GUIDELINES FOR USE (CONTINUED)

- I. If you have genotype 1 infection, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You are treatment-naïve (no prior treatment)
 - 3. You have compensated cirrhosis (a condition where there is liver damage and scarring without any major symptoms) (Child-Pugh A: a score that evaluates the severity of liver damage) OR you do not have cirrhosis (liver damage and scarring)
 - 4. Sovaldi will be used with peginterferon alfa and ribavirin OR Sovaldi will be used with ribavirin if you have a contraindication to (harmful for you to use) interferon
 - 5. You had an intolerance (side effect) or contraindication to ONE of the following preferred medications: Harvoni, Epclusa
- J. If you have genotype 4 infection, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You are treatment-naïve (no prior treatment)
 - 3. You have compensated cirrhosis (a condition where there is liver damage and scarring without any major symptoms) (Child-Pugh A: a score that evaluates the severity of liver damage) OR you do not have cirrhosis (liver damage and scarring)
 - 4. Sovaldi will be used with peginterferon alfa and ribavirin
 - 5. You had an intolerance (side effect) or contraindication to (harmful for you to use) ONE of the following preferred medications: Harvoni, Epclusa
- K. If Sovaldi will be used to prevent post-transplant HCV reinfection (getting infected again with HCV after transplant), approval also requires:**
 - 1. You have hepatocellular carcinoma (HCC: a type of liver cancer)
 - 2. You are awaiting liver transplantation (you have not yet replaced your liver)
 - 3. Sovaldi will be used with ribavirin as pre-transplant (before transplant) treatment
- L. If you had a previous treatment failure with Mavyret (glecaprevir/pibrentasvir) OR Vosevi (sofosbuvir/velpatasvir/voxilaprevir), approval also requires:**
 - 1. You have compensated cirrhosis (a condition where there is liver damage and scarring without any major symptoms) (Child-Pugh A: a score that evaluates the severity of liver damage) OR you do not have cirrhosis (liver damage and scarring)
 - 2. Sovaldi will be used with Mavyret (glecaprevir/pibrentasvir) AND ribavirin
- M. Sovaldi will also be approved for any other regimen/condition not listed above that is recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment**

Effective: 05/12/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOFOSBUVIR/VELPATASVIR

Generic	Brand			
SOFOSBUVIR/ VELPATASVIR	EPCLUSA, SOFOSBUVIR/ VELPATASVIR			

GUIDELINES FOR USE

Our guideline named **SOFOSBUVIR/VELPATASVIR (Epclusa)** requires the following rule(s) be met for approval:

- A. You have chronic hepatitis C virus (HCV: liver inflammation caused by a type of virus)
- B. You are 3 years of age or older
- C. You have genotype 1, 2, 3, 4, 5, or 6 hepatitis C infection (types of hepatitis C virus)
- D. You have an HCV RNA level (a measure of the amount of hepatitis C virus in the blood) within the past 6 months
- E. You do NOT have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (having two or more diseases at the same time)
- F. You will NOT use Epclusa concurrently (at the same time) with any medication with drug interactions that are contraindicated (harmful for you to use) or not recommended per the prescribing information (such as amiodarone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, Priftin [rifapentine], efavirenz-containing HIV [human immunodeficiency virus] regimens, rosuvastatin at doses greater than 10mg, Aptivus [tipranavir]/ritonavir, topotecan, St. John's wort)
- G. You will NOT use Epclusa concurrently (at the same time) with Sovaldi (sofosbuvir; as a single agent), Harvoni (ledipasvir/sofosbuvir), Zepatier (elbasvir/grazoprevir), Mavyret (pibrentasvir/glecaprevir), or Vosevi (velpatasvir/sofosbuvir/voxilaprevir)

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOFOSBUVIR/VELPATASVIR

GUIDELINES FOR USE (CONTINUED)

- H. You meet ONE of the following:
 - 1. You do not have cirrhosis (liver damage and scarring)
 - 2. You have compensated cirrhosis (a condition where there is liver damage and scarring without any major symptoms) (Child-Pugh A: a score that evaluates the severity of liver damage)
 - 3. You have decompensated cirrhosis (a condition where there is liver damage and scarring with major symptoms) (moderate or severe liver impairment; Child-Pugh B or C [a score that evaluates the severity of liver damage]), and you meet ONE of the following:
 - a. You will use Epclusa with ribavirin
 - b. You have a contraindication to (harmful for you to use) ribavirin
 - c. You have failed prior treatment with a sofosbuvir-based regimen (such as sofosbuvir/ribavirin) AND Epclusa will be used with ribavirin
 - d. You have failed prior treatment with an NS5A inhibitor-based regimen (such as Harvoni [ledipasvir/sofosbuvir]) AND Epclusa will be used with ribavirin
 - e. You received a liver transplant (replaced your liver), are treatment-experienced (failed prior treatment), AND Epclusa will be used with ribavirin
- I. Epclusa will also be approved for any other regimen/condition not listed above that is recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment

Effective: 07/22/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR

Generic	Brand			
SOFOSBUVIR/VELPATASVIR/ VOXILAPREVIR	VOSEVI			

GUIDELINES FOR USE

Our guideline named **SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR (Vosevi)** requires the following rule(s) be met for approval:

- A. You have chronic hepatitis C virus (HCV: liver inflammation caused by a type of virus)
- B. You are 18 years of age or older
- C. You have genotype 1, 2, 3, 4, 5 or 6 infection (types of hepatitis C virus)
- D. You have an HCV RNA level (a measure of the amount of hepatitis C virus in the blood) within the past 6 months
- E. You do NOT have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (having two or more diseases at the same time)
- F. You do NOT have moderate or severe liver impairment (decompensated cirrhosis [a condition where there is liver damage and scarring with major symptoms]; Child-Pugh B or C [a score that evaluates the severity of liver damage])
- G. You will NOT use Vosevi concurrently (at the same time) with any medication with drug interactions that are contraindicated (harmful for you to use) or not recommended per the prescribing information (such as amiodarone, rifampin, carbamazepine, phenytoin, phenobarbital, rifabutin, Priftin [rifapentine], rosuvastatin, pitavastatin, pravastatin at doses greater than 40mg, cyclosporine, methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, sulfasalazine, topotecan, St. John's wort, HIV (human immunodeficiency virus) regimens containing atazanavir, lopinavir, Aptivus [tipranavir]/ritonavir, or efavirenz)
- H. You will NOT use Vosevi concurrently (at the same time) with Sovaldi (sofosbuvir; as a single agent), Epclusa (velpatasvir/sofosbuvir), Harvoni (ledipasvir/sofosbuvir), Zepatier (elbasvir/grazoprevir), or Mavyret (pibrentasvir/glecaprevir)
- I. **If you are treatment-naïve (no prior treatment), approval also requires:**
 - 1. You have genotype 3 infection
 - 2. You have compensated cirrhosis (a condition where there is liver damage and scarring without any major symptoms)
 - 3. You have NS5A resistance-associated substitution (RAS) Y93H polymorphism (variations in a type of hepatitis C virus protein)

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR

GUIDELINES FOR USE (CONTINUED)

- J. If you are treatment-experienced (failed prior treatment), approval also requires:**
1. You have compensated cirrhosis (a condition where there is liver damage and scarring without any major symptoms) (Child-Pugh A: a score that evaluates the severity of liver damage) OR you do not have cirrhosis (liver damage and scarring)
 2. You meet ONE of the following:
 - a. You have failed a full course of a regimen containing an NS5A inhibitor (such as Harvoni [ledipasvir/sofosbuvir], Mavyret [pibrentasvir/glecaprevir]) or a direct-acting antiviral (such as Olysio [simeprevir]/peginterferon/ribavirin, Epclusa [velpatasvir/sofosbuvir]) if post-liver or kidney transplant (replaced your liver or kidney)
 - b. You have failed prior treatment with a sofosbuvir-based regimen (such as Epclusa [sofosbuvir/velpatasvir], sofosbuvir with ribavirin, sofosbuvir with Olysio [simeprevir])
 - c. You have failed prior treatment with Vosevi AND Vosevi will be used with ribavirin
- K. Vosevi will also be approved for any other regimen/condition not listed above that is recommended by the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidance for Hepatitis C Treatment**

Effective: 07/22/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOFPIRONIUM

Generic	Brand				
SOFPIRONIUM BROMIDE	SOFDRA				

GUIDELINES FOR USE

Our guideline named **SOFPIRONIUM (Sofdra)** requires the following rule(s) be met for approval:

- A. You have primary axillary hyperhidrosis (excessive underarm sweating)
- B. You are 9 years of age or older
- C. You have primary axillary hyperhidrosis as evidenced by focal (limited to a particular area of the body), visible, excessive sweating of at least 6 months duration with all secondary causes (caused by another medical condition) ruled out
- D. You have tried a prescription strength aluminum chloride product (such as Drysol)
- E. You have tried the preferred topical anticholinergic medication: Qbrexza (glycopyrronium tosylate)
- F. You will NOT use Sofdra concurrently (at the same time) with other topical anticholinergics used for primary axillary hyperhidrosis (such as Qbrexza [glycopyrronium tosylate])
- G. You have at least two of the following:
 - 1. Symptoms occur bilaterally (on both sides of the body)
 - 2. Symptoms impair daily activities
 - 3. You have at least one episode per week
 - 4. Onset occurred before you turn(ed) 25 years old
 - 5. You have a family history of primary axillary hyperhidrosis
 - 6. Symptoms do not occur during sleep

Effective: 08/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOLIFENACIN SUSPENSION

Generic	Brand				
SOLIFENACIN SUCCINATE	VESICARE LS				

GUIDELINES FOR USE

Our guideline named **SOLIFENACIN SUSPENSION (Vesicare LS)** requires the following rule(s) be met for approval:

- A. You have neurogenic detrusor overactivity (type of bladder dysfunction)
- B. You are 2 years of age or older
- C. You had a trial of or contraindication (harmful for) to TWO of the following:
 - 1. Anticholinergics (such as oxybutynin)
 - 2. Beta-3 agonists (such as mirabegron)
- D. You are unable to swallow oral solifenacin tablets

Effective: 01/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOLRIAMFETOL

Generic	Brand			
SOLRIAMFETOL	SUNOSI			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SOLRIAMFETOL (Sunosi)** requires the following rule(s) be met for approval:

- A. You have excessive daytime sleepiness (EDS) with narcolepsy (a sleep disorder); or obstructive sleep apnea (OSA: a disorder where airflow is blocked during sleep).
- B. **If you have excessive daytime sleepiness (EDS) with narcolepsy, approval also requires:**
 - Your diagnosis of narcolepsy is confirmed by **ONE** of the following:
 - i. You have a Multiple Sleep Latency Test (MSLT) showing an average sleep latency of 8 minutes or less **AND** two (2) or more early-onset rapid eye movement (REM) sleep test periods (SOREMPs)
 - ii. You have a Multiple Sleep Latency Test (MSLT) showing an average sleep latency of 8 minutes or less **AND** one (1) early-onset rapid eye movement (REM) sleep test period (SOREMP) **AND** one (1) SOREMP (within about 15 minutes) on a sleep study (polysomnography) the night before the MSLT, with the sleep study ruling out non-narcolepsy causes of excessive daytime sleepiness (EDS)
 - iii. You have low orexin levels on a cerebrospinal fluid (CSF) assay (a test to determine the amount of a type of chemical for wakefulness in your brain)
 - You have had Excessive Daytime Sleepiness (EDS) persisting for at least 3 months and Epworth Sleepiness Scale (ESS) score of more than 10
 - Therapy is prescribed by or given in consultation with a neurologist (brain doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
 - You have tried one amphetamine derivative (e.g., amphetamine sulfate, methylphenidate, etc.) **AND** modafinil or armodafinil, unless there is a medical reason why you cannot (contraindication)

(Initial criteria continued on the next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOLRIAMFETOL

INITIAL CRITERIA (CONTINUED)

- C. If you have excessive daytime sleepiness (EDS) with obstructive sleep apnea (OSA), approval also require:**
1. Your diagnosis of OSA is confirmed by a sleep study (polysomnography), home sleep apnea testing devices, or hospital-based bedside monitoring
 2. You have had Excessive Daytime Sleepiness (EDS) for at least 3 months and your Epworth Sleepiness Scale (ESS) score is more than 10
 3. You have tried modafinil or armodafinil, unless there is a medical reason why you cannot (contraindication)
 4. You have been on a treatment for the obstructive causes of OSA, for at least one month since initiation, and you have been counseled on weight-loss intervention [if your BMI (Body Mass Index: a measure of body fat based on height and weight) is greater than 30]

RENEWAL CRITERIA

Our guideline named **SOLRIAMFETOL (Sunosi)** requires the following rule(s) be met for renewal:

- A. You have excessive daytime sleepiness (EDS) with narcolepsy (a sleep disorder); or obstructive sleep apnea (OSA: a disorder where airflow is blocked during sleep).
- B. You have sustained improvement in Epworth Sleepiness Scale (ESS) scores by at least 25% compared to baseline

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOMAPACITAN-BECO

Generic	Brand				
SOMAPACITAN-BECO	SOGROYA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SOMAPACITAN-BECO (Sogroya)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Growth failure due to an inadequate secretion (release) of endogenous (from your own body) growth hormone (GH)
 2. Growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
- B. **If you have growth failure due to an inadequate secretion of endogenous growth hormone, approval also requires:**
1. You are 2.5 to 17 years of age
 2. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
 3. Your epiphyses (end part of long bone) are NOT closed as confirmed by a radiograph (type of imaging test) of the wrist and hand
 4. You meet ONE of the following:
 - a. Your height is at least 2 standard deviations (SD) below the mean (average) height for children of the same age and gender
 - b. Your height velocity is less than the 25th percentile for your age
 - c. You have a low peak growth hormone level (less than 10 ng/mL) on TWO growth hormone stimulation tests, OR an insulin-like growth factor 1 (IGF-1) level that is at least 2 standard deviations below the mean for your age and gender
 5. You will NOT use Sogroya concurrently (at the same time) with Increlex (mecasermin)
- (Initial criteria continued on next page)**

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOMAPACITAN-BECO

INITIAL CRITERIA (CONTINUED)

- C. If you have growth hormone deficiency, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
 3. You meet ONE of the following:
 - i. Your growth hormone deficiency is caused by a congenital (at birth), genetic, or organic disease (such as craniopharyngioma [tumor], pituitary hypoplasia [a type of brain condition], ectopic posterior pituitary [a type of brain condition], previous cranial irradiation [radiation to the brain])
 - ii. Your diagnosis is confirmed by ONE of the following growth hormone stimulation tests (tests that measure the body's ability to produce growth hormone):
 - a. Insulin tolerance test (peak growth hormone of 5 ng/mL or less)
 - b. Glucagon-stimulation test (peak response of 3 ng/mL or less AND your body mass index [BMI: a tool for evaluating body fat] is less than 25 kg/m²; OR peak response of 3 ng/mL or less AND your BMI is between 25 and 30 kg/m² with a high pre-test probability; OR peak response of 1 ng/mL or less AND your BMI is between 25 and 30 kg/m² with a low test probability; OR peak response of 1 ng/mL or less AND your BMI is greater than 30 kg/m²)
 - c. Macimorelin test (peak growth hormone of 2.8 ng/mL or less)
 4. You will NOT use Sogroya concurrently (at the same time) with Increlex (mecasermin)
- D. Request for Sogroya will NOT be approved for athletic enhancement (to perform better in sports), anti-aging purposes, or idiopathic short stature (ISS: a type of growth condition)**

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOMAPACITAN-BECO

RENEWAL CRITERIA

Our guideline named **SOMAPACITAN-BECO (Sogroya)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Growth failure due to an inadequate secretion (release) of endogenous (from your own body) growth hormone (GH)
 - 2. Growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
- B. **If you have growth failure due to an inadequate secretion of endogenous growth hormone, renewal also requires:**
 - 1. You are 2.5 to 17 years of age
 - 2. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
 - 3. Your epiphyses (end part of long bone) are NOT closed as confirmed by a radiograph (type of imaging test) of the wrist and hand, OR you have not completed prepubertal growth
 - 4. You meet ONE of the following:
 - a. Your annual growth velocity (rate of growth) is at least 2 cm compared with what was observed from the previous year
 - b. Your annual growth velocity is at least 1 cm compared with what was observed from the previous year if you are close to the terminal (final) phase of puberty
 - 5. You will NOT use Sogroya concurrently (at the same time) with Increlex (mecasermin)
- C. **If you have growth hormone deficiency, renewal also requires:**
 - 1. You are 18 years of age or older
 - 2. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
 - 3. You have achieved or maintained a response to therapy as evidenced by clinical treatment goals (such as improved body composition, lipid [fat] panel, bone health)
 - 4. You will NOT use Sogroya concurrently (at the same time) with Increlex (mecasermin)
- D. Renewal request for Sogroya will NOT be approved for athletic enhancement (to perform better in sports), anti-aging purposes, or idiopathic short stature (ISS: a type of growth condition)

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOMATROGON-GHLA

Generic	Brand				
SOMATROGON-GHLA	NGENLA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SOMATROGON-GHLA (Ngenla)** requires the following rule(s) be met for approval:

- A. You have growth failure due to an inadequate secretion (release) of endogenous (from your own body) growth hormone (GH)
- B. You are 3 to 17 years of age
- C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
- D. Your epiphyses (end part of long bone) are NOT closed, as confirmed by a radiograph (type of imaging test) of the wrist and hand
- E. You will NOT use Ngenla concurrently (at the same time) with Increlex (mecasermin)
- F. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Skytrofa (lonapegsomatropin-tcgd), Sogroya (somapacitan-beco)
- G. You meet ONE of the following:
 - 1. Your height is at least 2 standard deviations (SD: a measure of variation from the average) below the mean (average) height for children of the same age and gender
 - 2. Your height velocity is less than the 25th percentile for your age
 - 3. You have a low peak growth hormone level (less than 10 ng/mL) on TWO growth hormone stimulation tests, OR an insulin-like growth factor 1 (IGF-1) level that is at least 2 standard deviations below the mean for your age and gender
- H. Request for Ngenla will NOT be approved for athletic enhancement (to perform better in sports), anti-aging purposes, or idiopathic short stature (ISS: a type of growth condition)



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOMATROGON-GHLA

RENEWAL CRITERIA

Our guideline named **SOMATROGON-GHLA (Ngenla)** requires the following rule(s) be met for renewal:

- A. You have growth failure due to an inadequate secretion (release) of endogenous (from your own body) growth hormone (GH)
- B. You are 3 to 17 years of age
- C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
- D. Your epiphyses (end part of long bone) are NOT closed as confirmed by a radiograph (type of imaging test) of the wrist and hand, OR you have not completed prepubertal growth
- E. You will NOT use Ngenla concurrently (at the same time) with Increlex (mecasermin)
- F. You meet ONE of the following:
 - 1. Your annual growth velocity (rate of growth) is at least 2 cm compared with what was observed from the previous year
 - 2. Your annual growth velocity is at least 1 cm compared with what was observed from the previous year if you are close to the terminal (final) phase of puberty
- G. Renewal request for Ngenla will NOT be approved for athletic enhancement (to perform better in sports), anti-aging purposes, or idiopathic short stature (ISS: a type of growth condition)

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOMATROPIN

Generic	Brand				
SOMATROPIN	GENOTROPIN, HUMATROPE, NORDITROPIN FLEXPRO, NUTROPIN AQ NUSPIN, OMNITROPE, ZOMACTON				
	SAIZEN, SAIZEN-SAIZENPREP, SEROSTIM				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SOMATROPIN (Genotropin, Humatrope, Norditropin Flexpro, Nutropin AQ Nuspin, Omnitrope, Saizen/Saizenprep, Serostim, Zomacton)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Human immunodeficiency virus (HIV: an immune system disease caused by a virus) with wasting or cachexia (condition of severe weight and muscle loss)
2. Growth failure due to an inadequate secretion (release) of endogenous (from your own body) growth hormone (GH)
3. Short stature associated with Noonan syndrome (a type of genetic disorder)
4. Short stature or growth failure with short stature homeobox-containing gene (SHOX) deficiency (a type of genetic disorder)
5. Short stature associated with Turner syndrome (a type of genetic disorder)
6. Short stature born small for gestational age (SGA: birth weight is lower than expected for the number of weeks of pregnancy)
7. Growth failure secondary to chronic kidney disease (CKD: long-term kidney disease)
8. Growth hormone deficiency (GHD: type of hormone disorder with low growth hormone)
9. Prader-Willi syndrome (PWS: a type of genetic disorder)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOMATROPIN

INITIAL CRITERIA (CONTINUED)

- B. If you have human immunodeficiency virus with wasting or cachexia, approval also requires:**
1. You have NOT received a total of 48 weeks of cumulative treatment with any somatropin (such as Genotropin, Humatrope, Norditropin)
 2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions), nutritional support specialist, or infectious disease specialist (a doctor who specializes in the treatment of infections)
 3. You are on a HIV anti-retroviral therapy (such as Descovy [emtricitabine-tenofovir], Trumeq [abacavir-dolutegravir- lamivudine])
 4. You have had an inadequate response (drug did not work) to a previous therapy (such as exercise training, nutritional supplements, appetite stimulants or anabolic steroids)
 5. You have had an inadequate response to ONE of the following: cyproheptadine, Marinol (dronabinol), or Megace (megestrol acetate)
 6. Alternative causes of wasting (such as altered metabolism [metabolic and hormonal abnormalities] including testosterone deficiency or peripheral growth hormone resistance, diarrhea, inadequate energy [caloric] intake, malignancies [tumors], or opportunistic infections [an infection that can occur because of a weakened immune system]) have been ruled out
 7. You meet ONE of the following criteria for weight loss:
 - a. You have 10% unintentional weight loss over 12 months
 - b. You have 7.5% unintentional weight loss over 6 months
 - c. You have 5% body cell mass (BCM: a tool for evaluating nutritional status) loss within 6 months
 - d. If you are a male, your body cell mass (BCM) is less than 35% of your total body weight, AND your body mass index (BMI: a tool for evaluating body fat) is less than 27 kg per meter squared
 - e. If you are a female, your body cell mass (BCM) is less than 23% of total body weight, AND your body mass index (BMI) is less than 27 kg per meter squared
 - f. Your body mass index (BMI) is less than 18.5 kg per meter squared
 8. If you have hypogonadism (low testosterone levels), approval also requires:
 - a. You meet ONE of the following criteria for low testosterone:
 - i. You have a total serum testosterone level of less than 300 ng/dL (10.4 nmol/L)
 - ii. You have a low total serum testosterone level as indicated by a lab result, with a reference range, obtained within 90 days
 - iii. You have a free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
 - b. You have tried testosterone therapy (such as testosterone cypionate, AndroGel, Androderm, Axiron, Delatestryl, Fortesta, Striant, Testim, Testopel, Vogelxo, Natesto)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOMATROPIN

INITIAL CRITERIA (CONTINUED)

- C. If you have growth failure due to an inadequate secretion of endogenous growth hormone, approval also requires:**
1. You are a pediatric patient
 2. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
 3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (a type of imaging test) of the wrist and hand
 4. You will NOT use the requested medication concurrently (at the same time) with Increlex (mecasermin)
 5. You meet at least ONE of the following:
 - a. Your height is at least 2 standard deviations (SD: a measure of variation from the average) below the mean (average) height for children of the same age and gender
 - b. Your height velocity is less than the 25th percentile for your age
 - c. You have a low peak growth hormone (less than 10ng/mL) on two growth hormone stimulation tests OR an insulin-like growth factor 1 (IGF-1) of at least 2 standard deviations below the mean for your age and gender
 6. If the request is for Humatrope, Omnitrope, Nutropin AQ, Saizen, or Zomacton, approval also requires:
 - a. You have tried or have a contraindication to (harmful for you to use) BOTH of the following preferred medications: Genotropin (somatropin), Norditropin (somatropin)
- D. If you have short stature associated with Noonan syndrome OR short stature or growth failure with short stature homeobox-containing gene deficiency, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
 2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (a type of imaging test) of the wrist and hand
 3. Your height is at least 2 standard deviations (SD: a measure of variation from the average) below the mean (average) height for children of the same age and gender
 4. You will NOT use the requested medication concurrently (at the same time) with Increlex (mecasermin)
 5. If the request is for Humatrope, Omnitrope, Nutropin AQ, Saizen, or Zomacton, approval also requires:
 - a. You have tried or have a contraindication to (harmful for you to use) BOTH of the following preferred medications: Genotropin (somatropin), Norditropin (somatropin)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOMATROPIN

INITIAL CRITERIA (CONTINUED)

- E. If you have short stature associated with Turner syndrome, approval also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
 2. Your Turner syndrome diagnosis was confirmed by chromosomal analysis (karyotyping: a type of genetic test)
 3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (a type of imaging test) of the wrist and hand
 4. You will NOT use the requested medication concurrently (at the same time) with Increlex (mecasermin)
 5. If the request is for Humatrope, Omnitrope, Nutropin AQ, Saizen, or Zomacton, approval also requires:
 - a. You have tried or have a contraindication to (harmful for you to use) BOTH of the following preferred medications: Genotropin (somatropin), Norditropin (somatropin)
- F. If you have short stature born small for gestational age, approval also requires:**
1. You are 2 years of age or older
 2. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
 3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (a type of imaging test) of the wrist and hand
 4. Your height is at least 2 standard deviations (SD: a measure of variation from the average) below the mean (average) height for children of the same age and gender
 5. You will NOT use the requested medication concurrently (at the same time) with Increlex (mecasermin)
 6. If the request is for Humatrope, Omnitrope, Nutropin AQ, Saizen, or Zomacton, approval also requires:
 - a. You have tried or have a contraindication to (harmful for you to use) BOTH of the following preferred medications: Genotropin (somatropin), Norditropin (somatropin)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOMATROPIN

INITIAL CRITERIA (CONTINUED)

G. If you have growth failure secondary to chronic kidney disease, approval also requires:

1. You are a pediatric patient
2. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor) or nephrologist (kidney doctor)
3. You have not had a renal (kidney) transplant, or it has been at least one year since you had a renal (kidney) transplant
4. You have persistent growth failure (height below the 10th percentile) and has persistent low height velocity (below the 25th percentile)
5. You will NOT use the requested medication concurrently (at the same time) with Increlex (mecasermin)
6. If the request is for Humatrope, Omnitrope, Nutropin AQ, Saizen, or Zomacton, approval also requires:
 - a. You have tried or have a contraindication to (harmful for you to use) BOTH of the following preferred medications: Genotropin (somatropin), Norditropin (somatropin)

H. If you have growth hormone deficiency, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
3. You will NOT use the requested medication concurrently (at the same time) with Increlex (mecasermin)
4. You meet ONE of the following:
 - a. Your growth hormone deficiency is caused by a congenital (at birth), genetic, or organic disease (such as craniopharyngioma [tumor], pituitary hypoplasia [a type of brain condition], ectopic posterior pituitary [a type of brain condition], previous cranial irradiation [radiation to the brain])
 - b. Your diagnosis is confirmed by ONE of the following growth hormone stimulation tests (tests that measure the body's ability to produce growth hormone):
 - i. Insulin tolerance test (peak growth hormone of 5 ng/mL or less)
 - ii. Glucagon-stimulation test (peak response of 3 ng/mL or less AND your body mass index [BMI: a tool for evaluating body fat] is less than 25 kg/m²; OR peak response of 3 ng/mL or less AND your BMI is between 25 and 30 kg/m² with a high pre-test probability; OR peak response of 1 ng/mL or less AND your BMI is between 25 and 30 kg/m² with a low test probability; OR peak response of 1 ng/mL or less AND your BMI is greater than 30 kg/m²)
 - iii. Macimorelin test (peak growth hormone of 2.8 ng/mL or less)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOMATROPIN

INITIAL CRITERIA (CONTINUED)

5. If the request is for Humatrope, Omnitrope, Nutropin AQ, Saizen, or Zomacton, approval also requires:
 - a. You have tried or have a contraindication to (harmful for you to use) BOTH of the following preferred medications: Genotropin (somatropin), Norditropin (somatropin)
- I. **If you have Prader-Willi syndrome, approval also requires:**
 1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
 2. You have a confirmed genetic diagnosis of Prader-Willi syndrome
 3. You will NOT use the requested medication concurrently (at the same time) with Increlex (mecasermin)
4. If the request is for Humatrope, Omnitrope, Nutropin AQ, Saizen, or Zomacton, approval also requires:
 - a. You have tried or have a contraindication to (harmful for you to use) BOTH of the following preferred medications: Genotropin (somatropin), Norditropin (somatropin)
- J. Requests for Serostim will only be approved for human immunodeficiency virus with wasting or cachexia diagnosis
- K. The requested medication will NOT be approved for athletic enhancement (to perform better in sports), anti-aging purposes, or idiopathic short stature (short height due to unknown cause)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOMATROPIN

RENEWAL CRITERIA

Our guideline named **SOMATROPIN (Genotropin, Humatrope, Norditropin Flexpro, Nutropin AQ Nuspin, Omnitrope, Saizen/Saizenprep, Serostim, Zomacton)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Human immunodeficiency virus (HIV: an immune system disease caused by a virus) with wasting or cachexia (condition of severe weight and muscle loss)
2. Growth failure due to an inadequate secretion (release) of endogenous (from your own body) growth hormone (GH)
3. Short stature associated with Noonan syndrome (a type of genetic disorder)
4. Short stature or growth failure with short stature homeobox-containing gene (SHOX) deficiency (a type of genetic disorder)
5. Short stature associated with Turner syndrome (a type of genetic disorder)
6. Short stature born small for gestational age (SGA: birth weight is lower than expected for the number of weeks of pregnancy)
7. Growth failure secondary to chronic kidney disease (CKD: long-term kidney disease)
8. Growth hormone deficiency (GHD: type of hormone disorder with low growth hormone)
9. Prader-Willi syndrome (PWS: a type of genetic disorder)

B. **If you have human immunodeficiency virus with wasting or cachexia, renewal also requires:**

1. You have NOT received a total of 48 weeks of treatment with any somatropin (such as Genotropin, Humatrope, Norditropin)
2. You have shown clinical benefit in muscle mass and weight as indicated by at least a 10 percent increase in weight or body cell mass (BCM: a tool for evaluating nutritional status) from baseline
3. You are currently on a HIV (human immunodeficiency virus) anti-retroviral therapy (such as Descovy [emtricitabine-tenofovir], Triumeq [abacavir-dolutegravir- lamivudine])

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOMATROPIN

RENEWAL CRITERIA (CONTINUED)

- C. If you have growth failure due to an inadequate secretion of endogenous growth hormone, renewal also requires:**
1. You are a pediatric patient
 2. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
 3. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand OR you have not completed prepubertal growth)
 4. You will NOT use the requested medication concurrently (at the same time) with Increlex (mecasermin)
 5. You meet ONE of the following:
 - a. Your annual growth velocity is at least 2 cm compared with what was observed from the previous year
 - b. Your annual growth velocity is at least 1 cm compared with what was observed from the previous year if you are near the terminal (end) phase of puberty
- D. If you have short stature associated with Noonan syndrome, short stature or growth failure with short stature homeobox-containing gene deficiency, short stature associated with Turner syndrome, OR short stature born small for gestational age, renewal also requires:**
1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
 2. Your epiphyses (end part of long bone) are not closed as confirmed by radiograph (a type of imaging test) of the wrist and hand OR you have not completed prepubertal growth
 3. Your growth velocity is at least 2 cm compared with what was observed from the previous year OR your annual growth velocity of at least 1 cm compared with what was observed from the previous year if you are near the terminal (end) phase of puberty
 4. You will NOT use the requested medication concurrently (at the same time) with Increlex (mecasermin)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOMATROPIN

RENEWAL CRITERIA (CONTINUED)

- E. If you have growth failure secondary to chronic kidney disease, renewal also requires:**
 - 1. You are a pediatric patient
 - 2. You have not undergone a renal (kidney) transplantation within the past year
 - 3. You have a growth velocity of at least 2 cm compared with what was observed from the previous year OR annual growth velocity of at least 1 cm compared with what was observed from the previous year for patients that are near the terminal (end) phase of puberty
 - 4. Your epiphyses (end part of long bone) are not closed as confirmed by radiograph (a type of imaging test) of the wrist and hand, or you have not completed prepubertal growth
 - 5. You will NOT use the requested medication concurrently (at the same time) with Increlex (mecasermin)
- F. If you have growth hormone deficiency, renewal also requires:**
 - 1. You are 18 years of age or older
 - 2. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
 - 3. You will NOT use the requested medication concurrently (at the same time) with Increlex (mecasermin)
- G. If you have Prader-Willi syndrome, renewal also requires:**
 - 1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
 - 2. You have shown improvement in body composition
 - 3. You will NOT use the requested medication concurrently (at the same time) with Increlex (mecasermin)
- H. Requests for Serostim will only be approved for human immunodeficiency virus with wasting or cachexia diagnosis**
- I. The requested medication will NOT be approved for athletic enhancement (to perform better in sports), anti-aging purposes, or idiopathic short stature (short height due to unknown cause)**

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOMATROPIN - ZORBTIVE

Generic	Brand				
SOMATROPIN	ZORBTIVE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SOMATROPIN - ZORBTIVE** requires the following rule(s) be met for approval:

- A. You have short bowel syndrome (SBS: the body cannot absorb fluids and nutrients due to a lack of a functional small intestine)
- B. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
- C. You are currently on specialized nutritional support (such as a high carbohydrate, low-fat diet, adjusted for individual requirements and preferences)
- D. Request for Zorbtive will NOT be approved for athletic enhancement (to perform better in sports) or anti-aging purposes.

RENEWAL CRITERIA

Our guideline named **SOMATROPIN - ZORBTIVE** requires the following rule(s) be met for renewal:

- A. You have short bowel syndrome (SBS: the body cannot absorb fluids and nutrients due to a lack of a functional small intestine)
- B. You have NOT been on the requested medication for a total of 4 weeks

Effective: 06/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SONIDEGIB

Generic	Brand				
SONIDEGIB PHOSPHATE	ODOMZO				

GUIDELINES FOR USE

Our guideline named **SONIDEGIB (Odomzo)** requires the following rule(s) be met for approval:

- A. You have locally advanced basal cell carcinoma (BCC: type of skin cancer).
- B. You are 18 years of age or older
- C. This is a recurrence (disease returns) of basal cell carcinoma after surgery or radiation therapy OR you are not a candidate for surgery or radiation therapy
- D. Baseline serum creatine kinase (CK: type of lab test) and serum creatinine levels have been obtained before starting therapy
- E. If you are a female of reproductive potential, you must verify your pregnancy status before starting therapy

Effective: 01/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SORAFENIB

Generic	Brand			
SORAFENIB TOSYLATE	NEXAVAR, SORAFENIB TOSYLATE			

GUIDELINES FOR USE

Our guideline named **SORAFENIB (Nexavar)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
1. Advanced renal cell carcinoma (RCC: type of kidney cancer)
 2. Unresectable hepatocellular carcinoma (liver cancer that cannot be removed with surgery)
 3. Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment (thyroid cancer that has returned or spread, is getting worse and is not responding to a type of treatment)

Effective: 07/18/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOTATERCEPT-CSRK

Generic	Brand				
SOTATERCEPT-CSRK	WINREVAIR				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SOTATERCEPT-CSRK (Winrevair)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. You are 18 years of age and older
- C. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
- D. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 4. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
 5. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
 6. Pulmonary vascular resistance (PVR) greater than 2 Wood units
- E. You meet ONE of the following:
 1. You have been on background PAH therapy (for at least 3 months) with at least TWO of the following medications from different drug classes:
 - a. Oral endothelin receptor antagonist (such as Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
 - b. Oral phosphodiesterase-5 inhibitor for PAH (such as Revatio [sildenafil], Adcirca [tadalafil])
 - c. Oral cGMP stimulator (such as Adempas [riociguat])
 - d. Intravenous or subcutaneous prostacyclin (such as Flolan [epoprostenol], Remodulin [treprostinil])
 2. You are on ONE medication from one of the following drug classes, AND you have a contraindication to (harmful for you to use) or intolerance (side effect) to ALL of the other drug classes:
 - a. Oral endothelin receptor antagonist (such as Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
 - b. Oral phosphodiesterase-5 inhibitor for PAH (such as Revatio [sildenafil], Adcirca [tadalafil])
 - c. Oral cGMP stimulator (such as Adempas [riociguat])
 - d. Intravenous or subcutaneous prostacyclin (such as Flolan [epoprostenol], Remodulin [treprostinil])

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOTATERCEPT-CSRK

RENEWAL CRITERIA

Our guideline named **SOTATERCEPT-CSRK (Winrevair)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOTORASIB

Generic	Brand				
SOTORASIB	LUMAKRAS				

GUIDELINES FOR USE

Our guideline named **SOTORASIB (Lumakras)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Locally advanced or metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread from where it started to nearby tissue or lymph nodes, or has spread to other parts of the body)
 2. Metastatic colorectal cancer (mCRC: a type of digestive tract cancer that has spread to other parts of the body)
- B. **If you have locally advanced or metastatic non-small cell lung cancer, approval also requires:**
1. You are 18 years of age or older
 2. Your cancer has a KRAS G12C-mutation (abnormal change in a type of gene), as determined by a Food and Drug Administration (FDA)-approved test
 3. You have received at least one prior systemic therapy (treatment that targets the entire body)
- C. **If you have metastatic colorectal cancer, approval also requires:**
1. You are 18 years of age or older
 2. Lumakras will be used in combination with Vectibix (panitumumab)
 3. Your cancer has a KRAS G12C-mutation (abnormal change in a type of gene), as determined by a Food and Drug Administration (FDA)-approved test
 4. You have received previous treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (types of cancer treatments)

Effective: 02/24/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SPARSENTAN

Generic	Brand				
SPARSENTAN	FILSPARI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SPARSENTAN (Filspari)** requires the following rule(s) be met for approval:

- A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
- B. You are 18 years of age or older
- C. You are at risk of disease progression (worsening)
- D. Therapy is prescribed by or in consultation with a nephrologist (a type of kidney doctor)
- E. Your diagnosis is confirmed by a biopsy (removal of cells or tissue for examination)
- F. You have proteinuria (high levels of protein in the urine) of at least 1 g/day
- G. You have an estimated glomerular filtration rate (eGFR: a tool for evaluating kidney function) of at least 30 mL/min/1.73 m(2)
- H. You have tried or have a contraindication to (harmful for you to use) at least 12 weeks of treatment with an angiotensin converting enzyme inhibitor (ACE-I: a type of medication used to protect kidneys, such as benazepril, lisinopril) or an angiotensin receptor blocker (ARB: a type of medication used to protect kidneys, such as losartan, valsartan)
- I. You have tried a sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor: a type of medication used to protect kidneys, such as Farxiga [dapagliflozin], Jardiance [empagliflozin]) and will continue use, OR you have a contraindication to an SGLT2 inhibitor
- J. You will NOT use Filspari concurrently (at the same time) with an ACE-I (such as benazepril, lisinopril), an ARB (such as losartan, valsartan), an endothelin receptor antagonist (such as ambrisentan, bosentan), aliskiren, Fabhalta (iptacopan), or Vanrafia (atrasentan)

RENEWAL CRITERIA

Our guideline named **SPARSENTAN (Filspari)** requires the following rule(s) be met for renewal:

- A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
- B. You have improved or stable kidney function compared to baseline (before starting Filspari) OR you have a reduction (decrease) in proteinuria (a condition with high levels of protein in the urine)
- C. You will NOT use Filspari concurrently (at the same time) with an angiotensin converting enzyme inhibitor (ACE-I, such as benazepril, lisinopril), an angiotensin receptor blocker (ARB, such as losartan, valsartan), an endothelin receptor antagonist (such as ambrisentan, bosentan), aliskiren, Fabhalta (iptacopan), or Vanrafia (atrasentan)

Effective: 05/12/25

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 6/11/2025

Page 821 of 1007



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SPESOLIMAB-SBZO - SQ

Generic	Brand				
SPESOLIMAB-SBZO	SPEVIGO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SPESOLIMAB-SBZO - SQ (Spevigo)** requires the following rule(s) be met for approval:

- A. You have generalized pustular psoriasis (GPP: a type of skin condition)
- B. You are 12 years of age or older
- C. You weigh at least 40 kilograms (88 pounds)
- D. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
- E. You have a history of GPP as defined by the presence of sterile, macroscopically visible pustules (blisters with non-infectious pus that can be seen with the naked eye) on non-acral skin (skin in areas of the body such as arms and legs) (per ERASPEN [European Rare and Severe Psoriasis Expert Network] diagnostic criteria)
- F. You will NOT use Spevigo concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of GPP

RENEWAL CRITERIA

Our guideline named **SPESOLIMAB-SBZO - SQ (Spevigo)** requires the following rule(s) be met for renewal:

- A. You have generalized pustular psoriasis (GPP: a type of skin condition)
- B. You have shown a clinical response to therapy
- C. You will NOT use Spevigo concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of GPP

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

STIRIPENTOL

Generic	Brand			
STIRIPENTOL	DIACOMIT			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **STIRIPENTOL (Diacomit)** requires the following rule(s) be met for approval:

- A. You have seizures associated with Dravet syndrome (a rare type of seizure)
- B. You are 6 months of age or older AND weighs 7kg or more
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
- D. You are currently being treated with clobazam (a type of seizure drug)
- E. You had a trial of or contraindication (harmful for) to TWO of the following: valproic acid derivatives, clobazam, topiramate

RENEWAL CRITERIA

Our guideline named **STIRIPENTOL (Diacomit)** requires the following rule(s) be met for renewal:

- A. You have seizures associated with Dravet syndrome (a rare type of seizure)
- B. You are currently being treated with clobazam (type of seizure drug)

Effective: 08/29/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SUNITINIB

Generic	Brand			
SUNITINIB MALATE	SUTENT, SUNITINIB MALATE			

GUIDELINES FOR USE

Our guideline named **SUNITINIB (Sutent)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Advanced renal cell carcinoma (RCC: a type of kidney cancer)
 - 2. Gastrointestinal stromal tumor (GIST: a type of digestive tumor)
 - 3. Unresectable locally advanced or metastatic pancreatic neuroendocrine tumor (pNET: a type of tumor in the pancreas that cannot be completely removed by surgery or has spread to other parts of the body)
 - 4. Renal cell carcinoma
- B. **If you have advanced renal cell carcinoma, approval also requires:**
 - 1. You are 18 years of age or older
- C. **If you have gastrointestinal stromal tumor, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have tried or have a contraindication to (harmful for you to use) imatinib mesylate (Gleevec)
- D. **If you have unresectable locally advanced or metastatic pancreatic neuroendocrine tumor, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Your tumor is progressive (getting worse) and well-differentiated (looks like healthy cells)
- E. **If you have renal cell carcinoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. The requested medication will be used as adjuvant (add-on) treatment
 - 3. You are at high risk of recurrent renal cell carcinoma (cancer returning) following nephrectomy (surgical removal of kidney)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SUZETRIGINE

Generic	Brand				
SUZETRIGINE	JOURNAVX				

GUIDELINES FOR USE

Our guideline named **SUZETRIGINE (Journavx)** requires the following rule(s) be met for approval:

- A. You have moderate to severe acute (short-term) pain
- B. You are 18 years of age or older
- C. **If you have previously received treatment with Journavx, approval also requires:**
 - 1. The request is for the treatment of a new episode of acute pain

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TADALAFIL

Generic	Brand			
TADALAFIL	CIALIS			

GUIDELINES FOR USE

Our guideline named **TADALAFIL (Cialis)** requires the following rule(s) be met for approval:

- A. You have benign prostatic hyperplasia (BPH: your prostate is too big causing difficulty urinating)
OR erectile dysfunction (difficulty getting/keeping an erection)
- B. **If you have benign prostatic hyperplasia (BPH), approval also requires:**
 - 1. You previously tried at least two preferred formulary alternatives, including one medication from each of the following classes:
 - a. 5-alpha-reductase inhibitors: (such as finasteride or dutasteride)
 - b. Alpha blockers: (such as doxazosin, terazosin, tamsulosin, or alfuzosin)
- C. **If you have erectile dysfunction, approval also requires:**
 - 1. You have previously tried generic sildenafil (Viagra)

Effective: 09/07/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TADALAFIL-ADCIRCA, ALYQ

Generic	Brand				
TADALAFIL	ADCIRCA, ALYQ, TADALAFIL				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TADALAFIL-ADCIRCA, ALYQ (Adcirca, Alyq)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
- C. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
 2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
 3. Pulmonary vascular resistance (PVR) greater than 2 Wood units
- D. You will NOT use the requested medication concurrently (at the same time) or intermittently (off and on) with oral erectile dysfunction medications (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
- E. You will NOT use the requested medication concurrently (at the same time) with guanylate cyclase stimulators (such as Adempas [riociguat])

RENEWAL CRITERIA

Our guideline named **TADALAFIL-ADCIRCA, ALYQ (Adcirca, Alyq)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. You will NOT use the requested medication concurrently (at the same time) or intermittently (off and on) with oral erectile dysfunction medications (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
- C. You will NOT use the requested medication concurrently (at the same time) with guanylate cyclase stimulators (such as Adempas [riociguat])

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TADALAFIL-TADLIQ

Generic	Brand				
TADALAFIL	TADLIQ				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TADALAFIL-TADLIQ (Tadliq)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
- C. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - 1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
 - 2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
 - 3. Pulmonary vascular resistance (PVR) greater than 2 Wood units
- D. You will NOT use Tadliq concurrently (at the same time) or intermittently (off and on) with oral erectile dysfunction medications (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
- E. You will NOT use Tadliq concurrently (at the same time) with guanylate cyclase stimulators (such as Adempas [riociguat])
- F. You are unable to swallow tadalafil tablets

RENEWAL CRITERIA

Our guideline named **TADALAFIL-TADLIQ (Tadliq)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1)
- B. You will NOT use Tadliq concurrently (at the same time) or intermittently (off and on) with oral erectile dysfunction medications (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
- C. You will NOT use Tadliq concurrently (at the same time) with guanylate cyclase stimulators (such as Adempas [riociguat])

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TAFAMIDIS

Generic	Brand			
TAFAMIDIS MEGLUMINE	VYNDAQEL			
TAFAMIDIS	VYNDAMAX			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TAFAMIDIS (Vyndaqel, Vyndamax)** requires the following rule(s) be met for approval:

You have cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM: heart disease caused by a build-up of a type of protein)

You are 18 years of age or older

Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor), transthyretin amyloidosis (ATTR) specialist, or medical geneticist (doctor who treats gene disorders)

You have New York Heart Association (NYHA) Class I, II, or III heart failure (classification of heart failure symptoms)

You will NOT use the requested medication concurrently (at the same time) with other ATTR-CM TTR (transthyretin) stabilizers (such as acoramidis [Attruby])

Your diagnosis is confirmed by ONE of the following:

A bone scan (scintigraphy) strongly positive for myocardial uptake of TC-99m-PYP (a type of imaging test) (Note: Strongly positive defined as heart to contralateral lung [H/CL] ratio of at least 1.5 or Grade 2 or greater localization to the heart using the Perugini Grade 1-3 scoring system)

A biopsy of tissue of the affected organ(s) (removal of cells or tissue from the body for examination) (can be heart or non-heart related organs) to confirm amyloid (type of protein) presence AND chemical typing to confirm presence of transthyretin (TTR) protein

RENEWAL CRITERIA

Our guideline named **TAFAMIDIS (Vyndaqel, Vyndamax)** requires the following rule(s) be met for renewal:

You have cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM: heart disease caused by a build-up of a type of protein)

You will NOT use the requested medication concurrently (at the same time) with other ATTR-CM TTR (transthyretin) stabilizers (such as acoramidis [Attruby])

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TALAZOPARIB

Generic	Brand			
TALAZOPARIB TOSYLATE	TALZENNA			

GUIDELINES FOR USE

Our guideline named **TALAZOPARIB (TALZENNA)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Locally advanced or metastatic breast cancer (cancer that has spread to nearby tissue or lymph nodes or other parts of the body)
2. Metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and no longer responds to testosterone lowering treatment)

B. **If you have locally advanced or metastatic breast cancer, approval also requires:**

1. Your cancer is human epidermal growth factor receptor 2 (HER2: a type of protein)-negative
2. You have a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutation (gBRCAm: a type of abnormal change in a gene), as confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic test for Talzenna
3. You have been treated with chemotherapy (such as doxorubicin, docetaxel) in the neoadjuvant (given before main treatment), adjuvant (add-on to main treatment), or metastatic setting (to treat disease that has spread to other parts of the body)
4. You meet ONE of the following:
 - a. You do NOT have hormone receptor (HR: a type of protein)-positive breast cancer
 - b. You have hormone receptor (HR)-positive breast cancer, and you have been treated with prior endocrine (hormone) therapy (such as tamoxifen, Arimidex [anastrozole]), or endocrine therapy is considered to be inappropriate for you

(Criteria continued on next page)

CONTINUE ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TALAZOPARIB

GUIDELINES FOR USE (CONTINUED)

C. If you have prostate cancer, approval also requires:

1. You are 18 years of age or older
2. Talzenna will be used in combination with Xtandi (enzalutamide)
3. Your cancer has a homologous recombination repair (HRR) gene mutation (a type of abnormal change in a gene)
4. You meet ONE of the following:
 - a. You had a bilateral orchiectomy (both testicles have been surgically removed)
 - b. You have a castrate level of testosterone (blood testosterone levels are less than 50 ng/dL)
 - c. Talzenna will be used concurrently (at the same time) with a gonadotropin-releasing hormone (GnRH) analog (such as Lupron-Depot [leuprolide], Zoladex [goserelin], Firmagon [degarelix])

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TAPINAROF

Generic	Brand				
TAPINAROF	VTAMA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TAPINAROF (Vtama)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Plaque psoriasis (a type of skin condition)
 2. Atopic dermatitis (a type of skin condition)
- B. **If you have plaque psoriasis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 3. You have psoriasis covering 3% to 20% of body surface area (BSA) (excluding scalp, palms, fingernails, toenails, and soles)
 4. You will NOT use Vtama concurrently (at the same time) with other systemic immunomodulating agents (such as Stelara [ustekinumab], Otezla [apremilast]), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene)
 5. You had a trial of or contraindication to (harmful for you to use) TWO of the following (from different categories):
 - a. High or super-high potency topical corticosteroid (such as triamcinolone acetonide, fluocinonide, clobetasol propionate, halobetasol propionate)
 - b. Topical vitamin D analog (such as calcipotriene cream, calcitriol ointment)
 - c. Topical calcineurin inhibitor (such as tacrolimus, pimecrolimus)
 - d. Topical retinoid (such as tazarotene cream/gel)
 - e. Anthralin

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TAPINAROF

INITIAL CRITERIA (CONTINUED)

C. If you have atopic dermatitis, approval also requires:

1. You are 2 years of age or older
2. You have tried or have a contraindication to (harmful for you to use) a topical corticosteroid (such as triamcinolone 0.1% cream or ointment, mometasone furoate 0.1% ointment, fluocinonide 0.05% cream, halobetasol propionate 0.05% ointment) OR a topical calcineurin inhibitor (such as Elidel [pimecrolimus], Protopic [tacrolimus])
3. You have tried or have a contraindication to ONE of the following topical non-steroidal immunomodulating medications (a type of medication): Eucrisa (crisaborole), Opzelura (ruxolitinib)
4. You will NOT use Vtama concurrently (at the same time) with ANY of the following for atopic dermatitis:
 - a. Other non-steroidal topicals (such as calcineurin inhibitors [such as Elidel (pimecrolimus), Protopic (tacrolimus)], PDE-4 [phosphodiesterase-4] inhibitors [such as Eucrisa (crisaborole)], JAK [Janus kinase] inhibitors [such as Opzelura (ruxolitinib)])
 - b. Systemic therapeutic biologics (such as Dupixent [dupilumab], Adbry [tralokinumab-ldrm])
 - c. Other JAK (Janus kinase) inhibitors (such as Rinvoq [upadacitinib], Cibinqo [abrocitinib])
 - d. Potent immunosuppressants (such as azathioprine, cyclosporine)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TAPINAROF

RENEWAL CRITERIA

Our guideline named **TAPINAROF (Vtama)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Plaque psoriasis (a type of skin condition)
2. Atopic dermatitis (a type of skin condition)

B. **If you have plaque psoriasis, renewal also requires:**

1. You have achieved or maintained clear or minimal disease
2. You will NOT use Vtama concurrently (at the same time) with other systemic immunomodulating agents (such as Stelara [ustekinumab], Otezla [apremilast]), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene)

C. **If you have atopic dermatitis, renewal also requires:**

1. You have experienced or maintained improvement in pruritus (itchiness), relapsing-remitting (disease returns and goes away) dermatitis, or facial/interdigital (between the fingers or toes) involvement
2. You will NOT use Vtama concurrently (at the same time) with ANY of the following for atopic dermatitis:
 - a. Other non-steroidal topicals (such as calcineurin inhibitors [such as Elidel (pimecrolimus), Protopic (tacrolimus)], PDE-4 [phosphodiesterase-4] inhibitors [such as Eucrisa (crisaborole)], JAK [Janus kinase] inhibitors [such as Opzelura (ruxolitinib)])
 - b. Systemic therapeutic biologics (such as Dupixent [dupilumab], Adbry [tralokinumab-ldrm])
 - c. Other JAK (Janus kinase) inhibitors (such as Rinvoq [upadacitinib], Cibinqo [abrocitinib])
 - d. Potent immunosuppressants (such as azathioprine, cyclosporine)

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TASIMELTEON

Generic	Brand			
TASIMELTEON	HETLIOZ, HETLIOZ LQ, TASIMELTEON			

GUIDELINES FOR USE

Our guideline named **TASIMELTEON (HetlioZ, HetlioZ LQ)** requires the following rule(s) be met for approval:

- A. You have one of the following:
 - 1. Non-24 hour sleep-wake disorder (N24HSWD: a type of sleep condition)
 - 2. Nighttime sleep disturbances in Smith-Magenis syndrome (SMS: a type of developmental disorder that causes sleeping problems)
- B. **If you have non-24 hour sleep-wake disorder, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You are light-insensitive (not affected by light) or have total blindness
 - 3. You have tried and failed maximally-tolerated melatonin therapy
 - 4. You are requesting the capsule
- C. **If you have nighttime sleep disturbances in Smith-Magenis syndrome, approval also requires:**
 - 1. You are requesting brand HetlioZ capsules if you are 16 years of age or older
 - 2. You are requesting HetlioZ LQ oral suspension if you are 3 to 15 years old
 - 3. You have tried and failed maximally-tolerated melatonin therapy

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TAVABOROLE

Generic	Brand			
TAVABOROLE	KERYDIN, TAVABOROLE			

GUIDELINES FOR USE

Our guideline named **TAVABOROLE (Kerydin)** requires the following rule(s) be met for approval:

- A. You have onychomycosis of the toenails (toenail fungus infection)
- B. You meet ONE of the following:
 - 1. You have diabetes (a disorder with high blood sugar), peripheral vascular disease (PVD: a type of blood disorder), or a suppressed immune system
 - 2. You have pain surrounding the nail or soft tissue
- C. You have tried or have a contraindication to (harmful for you to use) the following medications:
 - 1. Oral terbinafine OR oral itraconazole
 - 2. Ciclopirox topical solution

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TAZEMETOSTAT

Generic	Brand				
TAZEMETOSTAT	TAZVERIK				

GUIDELINES FOR USE

Our guideline named **TAZEMETOSTAT (Tazverik)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Metastatic or locally advanced epithelioid sarcoma (a type of soft tissue cancer that has spread to other parts of the body or has spread from where it started to nearby tissue or lymph nodes)
2. Relapsed or refractory follicular lymphoma (a type of blood cancer that has returned or did not respond to treatment)

B. **If you have metastatic or locally advanced epithelioid sarcoma, approval also requires:**

1. You are 16 years of age or older
2. You are not eligible for complete resection (surgically removing all of a tissue/organ)

C. **If you have relapsed or refractory follicular lymphoma, approval also requires:**

1. You are 18 years or older
2. You meet ONE of the following:
 - a. Your tumors are positive for an EZH2 (type of gene) mutation as detected by a Food and Drug Administration (FDA)-approved test AND you have received at least 2 prior systemic therapies (treatment that targets the entire body)
 - b. You have no satisfactory alternative treatment options

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TBO-FILGRASTIM

Generic	Brand				
TBO-FILGRASTIM	GRANIX				

GUIDELINES FOR USE

Our guideline named **TBO-FILGRASTIM (Granix)** requires the following rule(s) be met for approval:

- A. You have a non-myeloid malignancy (cancer not affecting bone marrow)
- B. You are 1 month of age or older
- C. Therapy is prescribed by or in consultation with a hematologist (blood specialist) or oncologist (cancer/tumor doctor)
- D. You are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
- E. You had a trial of or contraindication (harmful for) to the preferred medication: Nivestym

Effective: 11/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TEDIZOLID

Generic	Brand				
TEDIZOLID PHOSPHATE	SIVEXTRO				

GUIDELINES FOR USE

Our guideline named **TEDIZOLID (Sivextro)** requires the following rule(s) be met for approval:

- A. You have an acute bacterial skin and skin structure infection (ABSSSI: a type of skin condition)
- B. You meet ONE of the following:
 - 1. The request is for continuation of therapy of oral or intravenous (IV: injection into the vein) Sivextro
 - 2. You are being transitioned from IV Sivextro to oral Sivextro
 - 3. You had a trial of, contraindication to (harmful for you to use), or resistance to (medication no longer works as well) generic linezolid tablets
- C. If your weight is between 1 kilogram to 34 kilograms (2.2 pounds to 74.8 pounds), only Sivextro intravenous vial will be approved

Effective: 05/12/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TEDUGLUTIDE

Generic	Brand			
TEDUGLUTIDE	GATTEX			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TEDUGLUTIDE (Gattex)** requires the following rule(s) be met for approval:

- A. You have short bowel syndrome (SBS: the body cannot absorb fluids and nutrients due to a lack of a functional small intestine)
- B. You are 1 year of age or older
- C. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
- D. You are dependent on parenteral nutrition (administration of nutrition through a vein), defined as requiring parenteral nutrition at least three times per week

RENEWAL CRITERIA

Our guideline named **TEDUGLUTIDE (Gattex)** requires the following rule(s) be met for renewal:

- A. You have short bowel syndrome (SBS: the body cannot absorb fluids and nutrients due to a lack of a functional small intestine)
- B. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
- C. You have achieved at least a 20 percent reduction in parenteral support (administration of nutrition through a vein) compared to baseline
- D. You have NOT achieved enteral autonomy (you still need nutrition through a tube)

Effective: 10/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TELISOTUZUMAB VEDOTIN-TLLV

Generic	Brand				
TELISOTUZUMAB VEDOTIN-TLLV	EMRELIS				

GUIDELINES FOR USE

Our guideline named **TELISOTUZUMAB VEDOTIN-TLLV (Emrelis)** requires the following rule(s) be met for approval:

- A. You have locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC: a type of lung cancer that has spread from where it started to nearby tissue, lymph nodes, or other parts of the body)
- B. You are 18 years of age or older
- C. Your tumor has high c-Met protein overexpression (at least 50 percent of tumor cells with strong [3+] staining) (too many proteins are made), as determined by a Food and Drug Administration (FDA)-approved test
- D. You have received a prior systemic therapy (such as platinum therapy [a type of therapy to treat cancer])

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TELOTRISTAT

Generic	Brand			
TELOTRISTAT	XERMELO			

GUIDELINES FOR USE

Our guideline named **TELOTRISTAT (Xermelo)** requires the following rule(s) be met for approval:

- A. You have carcinoid syndrome diarrhea (loose stool caused by a type of tumor)
- B. You are 18 years of age or older
- C. Xermelo will be used in combination with a somatostatin analog (such as octreotide)
- D. Therapy is prescribed by or in consultation with an oncologist (a type of cancer doctor) or gastroenterologist (doctor who treats digestive conditions)
- E. You have been receiving a stable dose of long-acting somatostatin analog therapy (such as Sandostatin LAR [octreotide] or Somatuline Depot [lanreotide]) for a minimum of 3 months, unless you have a contraindication (it is harmful for you to use)
- F. You have diarrhea that is inadequately controlled as defined by having at least four bowel movements per day

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TEMOZOLOMIDE

Generic	Brand				
TEMOZOLOMIDE	TEMODAR , TEMOZOLOMIDE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TEMOZOLOMIDE (Temodar)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Anaplastic astrocytoma (a type of brain cancer)
2. Glioblastoma multiforme (a type of brain or spine cancer)
3. Small cell lung cancer (SCLC: a type of lung cancer)
4. Metastatic melanoma (a type of skin cancer that has spread to other parts of the body)

B. **If you have metastatic melanoma, approval also requires:**

1. Temodar will NOT be used concurrently (at the same time) with an immunosuppressive therapy (treatment that lowers the activity of the body's immune system) or a medical therapy for the treatment of melanoma

RENEWAL CRITERIA

NOTE: For the diagnoses of Anaplastic astrocytoma, Glioblastoma multiforme, or Small cell lung cancer (SCLC), please refer to the Initial Criteria section.

Our guideline named **TEMOZOLOMIDE (Temodar)** requires the following rule(s) be met for renewal:

- A. You have metastatic melanoma (a type of skin cancer that has spread to other parts of the body)
- B. Temodar will NOT be used concurrently (at the same time) with an immunosuppressive therapy (treatment that lowers the activity of the body's immune system) or a medical therapy for the treatment of melanoma

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TENAPANOR

Generic	Brand				
TENAPANOR HCL	IBSRELA				

GUIDELINES FOR USE

Our guideline named **TENAPANOR (Ibsrela)** requires the following rule(s) be met for approval:

- A. You have irritable bowel syndrome with constipation (IBS-C: a type of bowel disease)
- B. You are 18 years of age or older
- C. You have tried or have a contraindication to (harmful for you to use) the preferred medications: Linzess (linaclotide) AND Trulance (plecanatide)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TEPOTINIB

Generic	Brand				
TEPOTINIB HCL	TEPMETKO				

GUIDELINES FOR USE

Our guideline named **TEPOTINIB (Tepmetko)** requires the following rule(s) be met for approval:

- A. You have metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to other parts of the body)
- B. You are 18 years of age or older
- C. Your tumors have mesenchymal-epithelial transition (MET) exon 14 skipping alterations (abnormal change in a type of gene)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TERAZOSIN

Generic	Brand				
TERAZOSIN HCL	TEZRULY				

GUIDELINES FOR USE

Our guideline named **TERAZOSIN (Tezruly)** requires the following rule(s) be met for approval:
A. You have a contraindication to (harmful for you to use) or are unable to swallow generic terazosin capsules

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TERIFLUNOMIDE

Generic	Brand			
TERIFLUNOMIDE	AUBAGIO, TERIFLUNOMIDE			

GUIDELINES FOR USE

Our guideline named **TERIFLUNOMIDE (Aubagio)** requires the following rule(s) be met for approval:

- A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return) and active secondary progressive disease (advanced disease)
- B. You are 18 years of age or older

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TERIPARATIDE

Generic	Brand			
TERIPARATIDE	FORTEO, TERIPARATIDE			

GUIDELINES FOR USE

Our guideline named **TERIPARATIDE (Forteo)** requires the following rule(s) be met for approval:

You have ONE of the following:

Postmenopausal osteoporosis (a type of bone condition)

Primary or hypogonadal (low level of sex hormones) osteoporosis (a type of bone condition) in a male patient

Glucocorticoid (steroid)-induced osteoporosis (a type of bone condition)

You meet ONE of the following (1, 2, or 3):

You are at high risk for fractures defined as ONE of the following:

You have a history of osteoporotic (fragility [weakness], low trauma [injury]) fracture(s) (a type of complete or partial break in a bone)

You have TWO or more risk factors for a fracture (such as a history of multiple recent low trauma fractures, bone mineral density [BMD] T-score [a type of lab test] less than or equal to -2.5, corticosteroid [such as prednisone] use, or use of gonadotropin-releasing hormone [GnRH] analogs [such as Synarel (nafarelin)])

You have had no prior treatment for osteoporosis, AND you have a Fracture Risk Assessment Tool (FRAX: a type of test) score of at least 20 percent for any major fracture OR at least 3 percent for a hip fracture

You are unable to use oral therapy due to reasons such as upper gastrointestinal (GI: stomach and intestine) problems (such as unable to tolerate oral medications), lower GI problems (such as unable to absorb oral medications), trouble remembering to take oral medications or coordinating an oral bisphosphonate (such as Fosamax [alendronate]) with other oral medications or your daily routine

You have tried, have an intolerance to (side effect), or have a contraindication to (harmful for you to use) a bisphosphonate (such as Fosamax [alendronate], Actonel [risedronate], Boniva [ibandronate])

You meet ONE of the following:

You have received a total of 24 months or more of treatment with Forteo (teriparatide) AND remain at or have returned to having a high risk for fracture

You have received a total of less than 24 months of treatment with Forteo (teriparatide)

Effective: 06/26/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TESAMORELIN

Generic	Brand			
TESAMORELIN ACETATE	EGRIFTA , EGRIFTA SV			

GUIDELINES FOR USE

Our guideline named **TESAMORELIN (Egrifta, Egrifta SV)** requires the following rule(s) be met for approval:

- A. You have human immunodeficiency virus (HIV: an immune system disease caused by a virus) with lipodystrophy (abnormal distribution of fat in the body)
- B. You are 18 years of age or older
- C. The requested medication will be used for the reduction of excess abdominal fat
- D. You are currently receiving treatment with a protease inhibitor (PI: a type of drug), PI combination (saquinavir, ritonavir, indinavir, nelfinavir, lopinavir/ritonavir, atazanavir, fosamprenavir, or tipranavir), a nucleoside reverse transcriptase inhibitor (NRTI: a type of drug), OR an NRTI combination (zidovudine, didanosine, stavudine, lamivudine, abacavir, tenofovir, emtricitabine, lamivudine/zidovudine, or abacavir/lamivudine/zidovudine, efavirenz/emtricitabine/tenofovir, emtricitabine/tenofovir)

Effective: 01/0125



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TESTOSTERONE

Generic	Brand				
TESTOSTERONE	ANDRODERM, ANDROGEL, AXIRON, FORTESTA, NATESTO, STRIANT, TESTIM, VOGELXO, TESTOSTERONE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TESTOSTERONE** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
 - 2. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
- B. **If you are a male with primary or secondary hypogonadism, approval also requires:**
 - 1. You meet ONE of the following:
 - a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy
 - b. You meet ONE of the following criteria showing you have low testosterone levels:
 - i. You have at least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
 - ii. You have a free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
 - 2. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
- C. If the request is for Androderm, Fortesta, Natesto, or Striant, you have tried or have a contraindication to (harmful for you to use) TWO preferred medications: testosterone cypionate and intramuscular (injected into the muscle) testosterone enanthate
- D. **If you have gender dysphoria, approval also requires:**
 - 1. Only medications supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TESTOSTERONE

RENEWAL CRITERIA

Our guideline named **TESTOSTERONE** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
 - 2. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
- B. **If you are a male with primary or secondary hypogonadism, renewal also requires:**
 - 1. You have shown improvement in your symptoms compared to baseline (before treatment) and tolerance to treatment
 - 2. Your serum testosterone level and hematocrit concentration (types of blood tests) have normalized compared to baseline
 - 3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
- C. **If you have gender dysphoria, renewal also requires:**
 - 1. Only medications supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TESTOSTERONE CYPIONATE - AZMIRO

Generic	Brand				
TESTOSTERONE CYPIONATE	AZMIRO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TESTOSTERONE CYPIONATE - AZMIRO** requires the following rule(s) be met for approval:

You have ONE of the following:

Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)

Gender dysphoria (your gender identity conflicts with your sex assigned at birth)

If you are a male with primary or secondary hypogonadism, approval also requires:

You meet ONE of the following:

You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy

You meet ONE of the following criteria showing you have low testosterone levels:

You have at least TWO total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions

You have a free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

You have tried or have a contraindication to (harmful for you to use) generic testosterone cypionate

If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

If you have gender dysphoria, approval also requires:

You have tried or have a contraindication to (harmful for you to use) generic testosterone cypionate

Only medications supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for the treatment of gender dysphoria may be approved

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TESTOSTERONE CYPIONATE - AZMIRO

RENEWAL CRITERIA

Our guideline named **TESTOSTERONE CYPIONATE - AZMIRO** requires the following rule(s) be met for renewal:

You have ONE of the following:

- Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)

- Gender dysphoria (your gender identity conflicts with your sex assigned at birth)

If you are a male with primary or secondary hypogonadism, renewal also requires:

- You have shown improvement in your symptoms compared to baseline (before treatment) and tolerance to treatment

- Your serum testosterone level and hematocrit concentration (types of blood tests) have normalized compared to baseline

- If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

If you have gender dysphoria, renewal also requires:

- Only medications supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for the treatment of gender dysphoria may be approved

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TESTOSTERONE CYPIONATE - DEPO

Generic	Brand				
TESTOSTERONE CYPIONATE	DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TESTOSTERONE CYPIONATE - DEPO (Depo-Testosterone)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
 - 2. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
- B. **If you are a male with primary or secondary hypogonadism, approval also requires:**
 - 1. You meet ONE of the following:
 - a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy
 - b. You meet ONE of the following showing you have low testosterone levels:
 - i. You have at least TWO total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
 - ii. You have a free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
 - 2. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
- C. **If you have gender dysphoria, approval also requires:**
 - 1. Only medications supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for the treatment of gender dysphoria may be approved

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TESTOSTERONE CYPIONATE - DEPO

RENEWAL CRITERIA

Our guideline named **TESTOSTERONE CYPIONATE - DEPO (Depo-Testosterone)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
 - 2. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
- B. **If you are a male with primary or secondary hypogonadism, renewal also requires:**
 - 1. You have shown improvement in your symptoms compared to baseline (before treatment) and tolerance to treatment
 - 2. Your serum testosterone level and hematocrit concentration (types of blood tests) have normalized compared to baseline
 - 3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
- C. **If you have gender dysphoria, renewal also requires:**
 - 1. Only medications supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for the treatment of gender dysphoria may be approved

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TESTOSTERONE ENANTHATE

Generic	Brand				
TESTOSTERONE ENANTHATE	TESTOSTERONE ENANTHATE, XYOSTED				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TESTOSTERONE ENANTHATE (Xyosted)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
 2. Delayed puberty not due to a pathological disorder (disease) in a male
 3. Metastatic breast cancer (cancer that has spread to other parts of the body) in a female
 4. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
- B. **If you are a male with primary or secondary hypogonadism, approval also requires:**
1. You meet ONE of the following:
 - a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy
 - b. You meet ONE of the following criteria showing you have low testosterone levels:
 - i. You have at least TWO total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
 - ii. A free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
 2. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
 3. If the request is for Xyosted, approval also requires:
 - a. You are 18 years of age or older
 - b. Xyosted will be used for testosterone replacement therapy
- C. **If you are a male with delayed puberty not secondary to a pathological disorder, approval also requires:**
1. The request is for generic intramuscular (injected into the muscle) testosterone enanthate 200 mg/mL

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TESTOSTERONE ENANTHATE

INITIAL CRITERIA (CONTINUED)

D. If you are a female with metastatic breast cancer, approval also requires:

1. You meet ONE of the following:
 - a. You are postmenopausal (after menopause)
 - b. You are premenopausal (before menopause), you have benefited from an oophorectomy (surgical removal of the ovaries), and your tumor is hormone-responsive
2. The request is for generic intramuscular (injected into the muscle) testosterone enanthate 200 mg/mL

E. If you have gender dysphoria, approval also requires:

1. Only medications supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for the treatment of gender dysphoria may be approved

RENEWAL CRITERIA

Our guideline named **TESTOSTERONE ENANTHATE (Xyosted)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
2. Delayed puberty not due to a pathological disorder (not due to a disease) in a male
3. Metastatic breast cancer (cancer that has spread to other parts of the body) in a female
4. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)

B. If you are a male with primary or secondary hypogonadism, renewal also requires:

1. You have shown improvement in your symptoms compared to baseline (before treatment) and tolerance to treatment
2. Your serum testosterone level and hematocrit concentration (types of blood tests) have normalized compared to baseline
3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

C. If you are a male with delayed puberty not secondary to a pathological disorder, renewal also requires:

1. You have NOT received more than two 6-month courses of testosterone replacement therapy
2. The request is for generic intramuscular (injected into the muscle) testosterone enanthate 200 mg/mL

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TESTOSTERONE ENANTHATE

RENEWAL CRITERIA (CONTINUED)

D. If you are a female with metastatic breast cancer, renewal also requires:

1. You meet ONE of the following:
 - a. You are postmenopausal (after menopause)
 - b. You are premenopausal (before menopause), you have benefited from an oophorectomy (surgical removal of the ovaries), and your tumor is hormone-responsive
2. The request is for generic intramuscular (injected into the muscle) testosterone enanthate 200 mg/mL

E. If you have gender dysphoria, renewal also requires:

1. Only medications supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for the treatment of gender dysphoria may be approved

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TESTOSTERONE UNDECANOATE

Generic	Brand				
TESTOSTERONE UNDECANOATE	JATENZO, KYZATREX, TLANDO, UNDECATREX				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TESTOSTERONE UNDECANOATE (Jatenzo, Kyzatrex, Tlando, Undecatrex)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
 2. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
- B. **If you are a male with primary or secondary hypogonadism, approval also requires:**
1. You are 18 years of age or older
 2. You meet ONE of the following:
 - a. You have a previously approved prior authorization for testosterone, OR you have been receiving any form of testosterone replacement therapy
 - b. You meet ONE of the criteria showing you have low testosterone levels:
 - i. You have at least TWO total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
 - ii. You have a free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
 3. If the request is for Jatenzo, Tlando, or Undecatrex, you have tried or have a contraindication to (harmful for you to use) TWO preferred medications: intramuscular (injected into the muscle) testosterone cypionate and intramuscular testosterone enanthate
 4. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
- C. **If you have gender dysphoria, approval also requires:**
1. Only medications supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for the treatment of gender dysphoria may be approved

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TESTOSTERONE UNDECANOATE

RENEWAL CRITERIA

Our guideline named **TESTOSTERONE UNDECANOATE (Jatenzo, Kyzatrex, Tlando, Undecatrex)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
 - 2. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
- B. **If you are a male with primary or secondary hypogonadism, renewal also requires:**
 - 1. You have shown improvement in your symptoms compared to baseline (before treatment) and tolerance to treatment
 - 2. Your serum testosterone level and hematocrit concentration (types of blood tests) have normalized compared to baseline
 - 3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
- C. **If you have gender dysphoria, renewal also requires:**
 - 1. Only medications supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for the treatment of gender dysphoria may be approved

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TETRABENAZINE

Generic	Brand			
TETRABENAZINE	XENAZINE			

GUIDELINES FOR USE

Our guideline named **TETRABENAZINE (Xenazine)** requires the following rule(s) be met for approval:

- A. You have chorea (involuntary movements) associated with Huntington's disease (type of inherited disease that causes nerve cells in brain to break down over time)
- B. The medication has been prescribed or given in consultation with a neurologist (nerve doctor)
- C. If your request is for a tetrabenazine dosage that exceeds 50mg, approval also requires:
 - 1. You have been genotyped for CYP2D6 (type of enzyme) and you are identified as an extensive (EM) or intermediate metabolizer (IM) of CYP2D6.

Effective: 07/01/20



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TEZACAFTOR-IVACAFTOR

Generic	Brand			
TEZACAFTOR/IVACAFTOR	SYMDEKO			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

Our guideline named **TEZACAFTOR-IVACAFTOR (Symdeko)** requires the following rule(s) be met for approval:

- A. You have cystic fibrosis (CF: a type of lung disorder)
- B. You are 6 years of age or older
- C. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or cystic fibrosis expert
- D. You will NOT use Symdeko concurrently (at the same time) with another cystic fibrosis transmembrane conductance regulator (CFTR) modulator (such as medications containing vanzacaftor, deutivacaftor, ivacaftor, lumacaftor, tezacaftor, or elexacaftor)
- E. You are homozygous (have two copies of the same gene) for the F508del mutation (abnormal change) OR you have a responsive mutation in the CFTR gene (abnormal change in a type of gene that can be treated with Symdeko)

RENEWAL CRITERIA

Our guideline named **TEZACAFTOR-IVACAFTOR (Symdeko)** requires the following rule(s) be met for renewal:

- A. You have cystic fibrosis (CF: a type of lung disorder)
- B. You have experienced an improvement in your clinical status
- C. You will NOT use Symdeko concurrently (at the same time) with another cystic fibrosis transmembrane conductance regulator (CFTR) modulator (such as medications containing vanzacaftor, deutivacaftor, ivacaftor, lumacaftor, tezacaftor, or elexacaftor)

Effective: 01/28/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TEZEPELUMAB-EKKO

Generic	Brand				
TEZEPELUMAB-EKKO	TEZSPIRE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TEZEPELUMAB-EKKO (Tezspire)** requires the following rule(s) be met for approval:

- A. You have severe asthma (a type of lung condition)
- B. You are 12 years of age or older
- C. Therapy is prescribed by or in consultation with a doctor specializing in allergy or pulmonary (relating to lungs/breathing) medicine
- D. Tezspire will be used in combination with a medium, high-dose, or maximally tolerated dose of an inhaled corticosteroid (such as beclomethasone, mometasone, budesonide) AND at least ONE other maintenance medication (taken on a regular basis), such as a long-acting inhaled beta2-agonist (such as salmeterol, formoterol), a long-acting muscarinic antagonist (such as Tudorza [aclidinium], Spiriva [tiotropium], Incruse Ellipta [umeclidinium]), a leukotriene receptor antagonist (such as montelukast, zafirlukast), or theophylline
- E. You will NOT use Tezspire concurrently (at the same time) with another systemic biologic (such as Xolair [omalizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of asthma
- F. You meet ONE of the following:
 - 1. You have experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid (such as prednisone) burst lasting at least 3 days within the past 12 months
 - 2. You have experienced at least ONE serious asthma exacerbation requiring a hospitalization or emergency room visit within the past 12 months
 - 3. You have poor symptom control despite current therapy as shown by at least THREE of the following within the past 4 weeks:
 - a. Daytime asthma symptoms more than twice per week
 - b. Any night waking due to asthma
 - c. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
 - d. Any activity limitation due to asthma

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TEZEPELUMAB-EKKO

RENEWAL CRITERIA

Our guideline named **TEZEPELUMAB-EKKO (Tezspire)** requires the following rule(s) be met for renewal:

- A. You have shown a clinical response as evidenced by ONE of the following:
 - 1. You have experienced a decrease in asthma exacerbations (worsening of symptoms) from baseline (before starting Tezspire)
 - 2. You have decreased your use of rescue medications (such as albuterol)
 - 3. You have an increase in the percent predicted FEV1 (a type of lung test) from pretreatment baseline (before starting Tezspire)
 - 4. You have a decrease in the severity or frequency of asthma-related symptoms (such as wheezing, shortness of breath, coughing)
- B. You will continue to use an inhaled corticosteroid (such as beclomethasone, mometasone, budesonide) AND at least ONE other maintenance medication (taken on a regular basis) such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as Tudorza [aclidinium], Spiriva [tiotropium], Incruse Ellipta [umeclidinium]), a leukotriene receptor antagonist (such as montelukast, zafirlukast), or theophylline
- C. You will NOT use Tezspire concurrently (at the same time) with another systemic biologic (such as Xolair [omalizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of asthma

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

THALIDOMIDE

Generic	Brand			
THALIDOMIDE	THALOMID			

GUIDELINES FOR USE

Our guideline named **THALIDOMIDE (Thalomid)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Multiple myeloma (a type of blood cancer)
 - 2. Erythema nodosum leprosum (ENL: a type of immune condition)
 - 3. Anemia due to myelodysplastic syndrome (a type of blood condition due to blood cancer)
 - 4. Waldenström's macroglobulinemia (a type of blood cancer)
- B. **If you have multiple myeloma, approval also requires:**
 - 1. Thalomid will be used in combination with dexamethasone
- C. **If you have anemia due to myelodysplastic syndrome, approval also requires:**
 - 1. You have been treated for anemia due to myelodysplastic syndrome

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TILDRAKIZUMAB-ASMN

Generic	Brand				
TILDRAKIZUMAB-ASMN	ILUMYA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TILDRAKIZUMAB-ASMN (Ilumya)** requires the following rule(s) be met for approval:

You have moderate to severe plaque psoriasis (PsO: a type of skin condition)

You are 18 years of age or older

Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)

You have psoriasis covering 3 percent or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, face, genital area, or scalp

You will NOT use Ilumya concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)

You meet ONE of the following:

You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) OR PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis

You have a contraindication or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) AND PUVA (phototherapy) for the treatment of plaque psoriasis

You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TILDRAKIZUMAB-ASMN

RENEWAL CRITERIA

Our guideline named **TILDRAKIZUMAB-ASMN (Ilumya)** requires the following rule(s) be met for renewal:

You have moderate to severe plaque psoriasis (PsO: a type of skin condition)

You have achieved or maintained clear or minimal disease OR a decrease in PASI (Psoriasis Area and Severity Index: a tool for evaluating the severity of psoriasis) of at least 50 percent or more

You will NOT use Ilumya concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis

You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab), Sotyktu (deucravacitinib)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TIRZEPATIDE - ZEPBOUND

Generic	Brand				
TIRZEPATIDE	ZEPBOUND				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TIRZEPATIDE - ZEPBOUND** requires the following rule(s) be met for approval:

- A. The request is for ONE of the following:
 - 1. Moderate to severe obstructive sleep apnea (OSA: a disorder where airflow is blocked during sleep)
 - 2. Weight loss or weight management
- B. **If you will use Zepbound for moderate to severe obstructive sleep apnea, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You are obese (your BMI [body mass index: a tool for evaluating body fat] is at least 30 kg/m²)
 - 3. You are actively enrolled in an exercise and caloric reduction program, which may include use of an optional weight loss/behavioral modification program
 - 4. You will NOT use Zepbound concurrently (at the same time) with a GLP-1 receptor agonist (a type of drug such as Victoza [liraglutide], Saxenda [liraglutide], Ozempic [semaglutide], Rybelsus [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release])
 - 5. Your OSA is confirmed by documentation of ONE of the following:
 - a. You have an Apnea Hypopnea Index/Respiratory Disturbance Index/Respiratory Event Index (AHI/RDI/REI) of at least 15 events per hour that is predominantly obstructive
 - b. You have an AHI/RDI/REI of at least 5 with at least ONE typical OSA symptom (such as unrefreshing sleep, daytime sleepiness, fatigue or insomnia, awakening with a gasping or choking sensation, loud snoring, witnessed apneas [temporarily stop breathing])

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TIRZEPATIDE - ZEPBOUND

INITIAL CRITERIA (CONTINUED)

- C. If you will use Zepbound for weight loss or weight management, approval also requires:**
1. You are 18 years of age or older
 2. You are actively enrolled in an exercise and caloric reduction program, which may include use of an optional weight loss/behavioral modification program
 3. You will NOT use Zepbound concurrently (at the same time) with a GLP-1 receptor agonist (a type of drug such as Victoza [liraglutide], Saxenda [liraglutide], Ozempic [semaglutide], Rybelsus [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release])
 4. You meet ONE of the following:
 - a. You have a body mass index (BMI: a tool for evaluating body fat) of at least 30 kg/m(2)
 - b. You have a BMI of at least 27 kg/m(2) AND at least ONE weight-related comorbidity (disease) (such as hypertension [high blood pressure], type 2 diabetes mellitus [a disorder with high blood sugar], dyslipidemia [abnormal levels of fat], cardiovascular disease [condition of the heart or blood vessels], coronary artery disease [CAD: a type of heart condition], sleep apnea [a type of sleep condition with difficulty breathing], osteoarthritis [a type of joint condition] of the knee[s], polycystic ovarian syndrome [a hormonal disorder], non-alcoholic steatohepatitis/non-alcoholic fatty liver disease [inflammation in the liver], asthma [a type of lung condition], and chronic obstructive pulmonary disease [COPD: a type of lung condition])

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TIRZEPATIDE - ZEPBOUND

INITIAL CRITERIA (CONTINUED)

USE THIS CRITERIA FOR BENEFIT EXCLUSION OF WEIGHT LOSS

Our guideline named **TIRZEPATIDE - ZEPBOUND** requires the following rule(s) be met for approval:

- A. You have moderate to severe obstructive sleep apnea (OSA: a disorder where airflow is blocked during sleep)
- B. You are 18 years of age or older
- C. You are obese (your BMI [body mass index: a tool for evaluating body fat] is at least 30 kg/m²)
- D. You are actively enrolled in an exercise and caloric reduction program, which may include use of an optional weight loss/behavioral modification program
- E. You will NOT use Zepbound concurrently (at the same time) with a GLP-1 receptor agonist (a type of drug such as Victoza [liraglutide], Saxenda [liraglutide], Ozempic [semaglutide], Rybelsus [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release])
- F. Your OSA is confirmed by documentation of ONE of the following:
 - 1. You have an Apnea Hypopnea Index/Respiratory Disturbance Index/Respiratory Event Index (AHI/RDI/REI) of at least 15 events per hour that is predominantly obstructive
 - 2. You have an AHI/RDI/REI of at least 5 with at least ONE typical OSA symptom (such as unrefreshing sleep, daytime sleepiness, fatigue or insomnia, awakening with a gasping or choking sensation, loud snoring, witnessed apneas [temporarily stop breathing])

NOTE: Your plan does NOT cover Zepbound when it is only used for weight loss or weight management.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RENEWAL CRITERIA

Our guideline named **TIRZEPATIDE - ZEPBOUND** requires the following rule(s) be met for renewal:

- A. The request is for ONE of the following:
 - 1. Moderate to severe obstructive sleep apnea (OSA: a disorder where airflow is blocked during sleep)
 - 2. Weight loss or weight management
- B. **If you will use Zepbound for moderate to severe obstructive sleep apnea, approval also requires:**
 - 1. You will NOT use Zepbound concurrently (at the same time) with a GLP-1 receptor agonist (a type of drug such as Victoza [liraglutide], Saxenda [liraglutide], Ozempic [semaglutide], Rybelsus [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release])
 - 2. You have achieved or maintained a reduction in Apnea Hypopnea Index/Respiratory Disturbance Index/Respiratory Event Index (AHI/RDI/REI) by at least 15 events per hour or by at least 50%
- C. **If you will use Zepbound for weight loss or weight management, approval also requires:**
 - 1. You will NOT use Zepbound concurrently (at the same time) with a GLP-1 receptor agonist (a type of drug such as Victoza [liraglutide], Saxenda [liraglutide], Ozempic [semaglutide], Rybelsus [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release])
 - 2. You have achieved or maintained at least a 5 percent weight loss of baseline (before treatment) body weight

USE THIS CRITERIA FOR BENEFIT EXCLUSION OF WEIGHT LOSS

Our guideline named **TIRZEPATIDE - ZEPBOUND** requires the following rule(s) be met for renewal:

- A. You have moderate to severe obstructive sleep apnea (OSA: a disorder where airflow is blocked during sleep)
- B. You will NOT use Zepbound concurrently (at the same time) with a GLP-1 receptor agonist (a type of drug such as Victoza [liraglutide], Saxenda [liraglutide], Ozempic [semaglutide], Rybelsus [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release])
- C. You have achieved or maintained a reduction in Apnea Hypopnea Index/Respiratory Disturbance Index/Respiratory Event Index (AHI/RDI/REI) by at least 15 events per hour or by at least 50%

NOTE: Your plan does NOT cover Zepbound when it is only used for weight loss or weight management.

Effective: 07/01/25

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 6/11/2025

Page 871 of 1007



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TISLELIZUMAB-JSGR

Generic	Brand				
TISLELIZUMAB-JSGR	TEVIMBRA				

GUIDELINES FOR USE

Our guideline named **TISLELIZUMAB-JSGR (Tevimbra)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Unresectable or metastatic esophageal squamous cell carcinoma (ESCC: a type of digestive system cancer that cannot be removed by surgery or has spread to other parts of the body)
 2. Unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ: a type of digestive system cancer that cannot be removed by surgery or has spread to other parts of the body)
- B. **If you have unresectable or metastatic esophageal squamous cell carcinoma, approval also requires:**
1. You are 18 years of age or older
 2. You meet ONE of the following:
 - a. Tevimbra will be used in combination with platinum (such as cisplatin, oxaliplatin)-containing chemotherapy (medications used to treat cancer) AND your tumor programmed death-ligand 1 (PD-L1: a type of protein) expression is at least 1
 - b. Tevimbra will be used as a single agent (given alone) after a prior systemic chemotherapy (cancer treatment that targets the entire body such as paclitaxel, docetaxel, irinotecan) that did NOT include a PD-(L)1 inhibitor (a type of medication such as Opdivo [nivolumab])
- C. **If you have unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, approval also requires:**
1. You are 18 years of age or older
 2. Your cancer is human epidermal growth factor receptor 2 (HER2: a type of protein)-negative
 3. Tevimbra will be used in combination with platinum (such as cisplatin, oxaliplatin) and fluoropyrimidine-based chemotherapy (such as fluorouracil [5-FU], capecitabine)
 4. Your tumor programmed death-ligand 1 (PD-L1: a type of protein) expression is at least 1

Effective: 05/26/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TIVOZANIB

Generic	Brand				
TIVOZANIB HCL	FOTIVDA				

GUIDELINES FOR USE

- Our guideline named **TIVOZANIB (Fotivda)** requires the following rule(s) be met for approval:
- A. You have relapsed or refractory advanced renal cell carcinoma (a type of kidney cancer that returned or did not respond to treatment)
 - B. You are 18 years of age or older
 - C. You have received two or more systemic therapies (such as Cabometyx [cabozantinib], Keytruda [pembrolizumab], Opdivo [nivolumab])

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOBRAMYCIN INHALED

Generic	Brand				
TOBRAMYCIN	BETHKIS, TOBRAMYCIN				
TOBRAMYCIN IN 0.225% SOD CHLOR	TOBI, TOBRAMYCIN				
TOBRAMYCIN	TOBI PODHALER				
TOBRAMYCIN/NEBULIZER	KITABIS PAK, TOBRAMYCIN				

GUIDELINES FOR USE

Our guideline named **TOBRAMYCIN INHALED (Bethkis, Tobi, Tobi Podhaler, Kitabis Pak)** requires the following rule(s) be met for approval:

- A. You have cystic fibrosis (a type of lung disorder)
- B. You are 6 years of age or older
- C. You have a lung infection with a gram-negative species (a type of bacteria such as *Pseudomonas aeruginosa*)
- D. **If the request is for Tobi Podhaler, approval also requires ONE of the following:**
 - 1. You have tried or have a contraindication to (harmful for you to use) ONE generic inhaled tobramycin product
 - 2. You are not able to tolerate the prolonged administration of nebulizers

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB - IV

Generic	Brand				
TOCILIZUMAB	ACTEMRA				

PAC NOTE: For requests for the SQ dosage form of Actemra, please see the TOCILIZUMAB-SQ PA guideline.

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TOCILIZUMAB - IV (Actemra - intravenous)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Giant cell arteritis (GCA: a type of inflammatory condition)
3. Polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
4. Systemic juvenile idiopathic arthritis (SJIA: a type of joint condition)
5. Chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS: a type of inflammatory response)

B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Actemra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
4. You have tried 3 months of or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB - IV

INITIAL CRITERIA (CONTINUED)

5. You have tried or have a contraindication to THREE of the following preferred medications:
 - a. Enbrel (etanercept)
 - b. Humira (adalimumab)/adalimumab-adaz/Simlandi (**NOTE:** Humira requires additional step through adalimumab-adaz or Simlandi)
 - c. Rinvoq (upadacitinib) (**NOTE:** Rinvoq requires additional criteria of inadequate response [medication did not work] or intolerance [side effect] to a tumor necrosis factor [TNF] blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - d. Xeljanz (tofacitinib immediate release or extended release) (**NOTE:** Xeljanz requires additional criteria of inadequate response or intolerance to a TNF blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - e. Tyenne (tocilizumab-aazg) (**NOTE:** Tyenne requires additional step through Enbrel, Humira/adalimumab-adaz/Simlandi, Rinvoq, or Xeljanz IR/XR)
 - C. **If you have giant cell arteritis, approval also requires:**
 1. You are 18 years of age or older
 2. You have completed, started, or will soon start a tapering course (slowly lowering the dose to stop use) of glucocorticoids (such as prednisone)
 3. You will NOT use Actemra concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of giant cell arteritis
 4. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications:
 - a. Rinvoq (upadacitinib)
 - b. Tyenne (tocilizumab-aazg) (**NOTE:** Tyenne requires additional step through Rinvoq)
- (Initial criteria continued on next page)***

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB - IV

INITIAL CRITERIA (CONTINUED)

D. If you have polyarticular juvenile idiopathic arthritis, approval also requires:

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Actemra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
4. You have tried or have a contraindication to (harmful for you to use) THREE of the following preferred medications:
 - a. Enbrel (etanercept)
 - b. Humira (adalimumab)/adalimumab-adaz/Simlandi (**NOTE:** Humira requires additional step through adalimumab-adaz or Simlandi)
 - c. Xeljanz IR (tofacitinib immediate release) (**NOTE:** Xeljanz requires additional criteria of inadequate response [medication did not work] or intolerance [side effect] to a tumor necrosis factor [TNF] blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - d. Rinvoq (upadacitinib) (**NOTE:** Rinvoq requires additional criteria of inadequate response or intolerance to a TNF blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - e. Tyenne (tocilizumab-aazg) (**NOTE:** Tyenne requires additional step through Enbrel, Humira/adalimumab-adaz/Simlandi, Xeljanz IR, or Rinvoq)

E. If you have systemic juvenile idiopathic arthritis, approval also requires:

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor), dermatologist (a type of skin doctor), or immunologist (a type of immune system doctor)
3. You will NOT use Actemra concurrently (at the same time) with another systemic biologic (such as Ilaris [canakinumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of systemic juvenile idiopathic arthritis
4. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Tyenne (tocilizumab-aazg)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB - IV

INITIAL CRITERIA (CONTINUED)

- F. If you have chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome, approval also requires:**
1. You are 2 years of age or older
 2. You will NOT use Actemra concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of cytokine release syndrome
- G. NOTE:** Actemra will NOT be approved for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults.

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB - IV

RENEWAL CRITERIA

NOTE: For the diagnosis of cytokine release syndrome (CRS), please refer to the Initial Criteria section.

Our guideline named **TOCILIZUMAB - IV (Actemra - intravenous)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
 - 2. Giant cell arteritis (GCA: a type of inflammatory condition)
 - 3. Polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
 - 4. Systemic juvenile idiopathic arthritis (SJIA: a type of joint condition)
- B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**
 - 1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 - 2. You will NOT use Actemra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
 - 3. You have tried or have a contraindication to (harmful for you to use) THREE of the following preferred medications:
 - a. Enbrel (etanercept)
 - b. Humira (adalimumab)/adalimumab-adaz/Simlandi (**NOTE:** Humira requires additional step through adalimumab-adaz or Simlandi)
 - c. Rinvoq (upadacitinib) (**NOTE:** Rinvoq requires additional criteria of inadequate response [medication did not work] or intolerance [side effect] to a tumor necrosis factor [TNF] blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - d. Xeljanz (tofacitinib immediate release or extended release) (**NOTE:** Xeljanz requires additional criteria of inadequate response or intolerance to a TNF blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - e. Tyenne (tocilizumab-aazg) (**NOTE:** Tyenne requires additional step through Enbrel, Humira/adalimumab-adaz/Simlandi, Rinvoq, or Xeljanz IR/XR)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB - IV

RENEWAL CRITERIA (CONTINUED)

C. If you have giant cell arteritis, renewal also requires:

1. You will NOT use Actemra concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of giant cell arteritis
2. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications:
 - a. Rinvoq (upadacitinib)
 - b. Tyenne (tocilizumab-aazg) (**NOTE:** Tyenne requires additional step through Rinvoq)

D. If you have polyarticular juvenile idiopathic arthritis, renewal also requires:

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Actemra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
3. You have tried or have a contraindication to (harmful for you to use) THREE of the following preferred medications:
 - D. Enbrel (etanercept)
 - E. Humira (adalimumab)/adalimumab-adaz/Simlandi (**NOTE:** Humira requires additional step through adalimumab-adaz or Simlandi)
 - F. Xeljanz IR (tofacitinib immediate release) (**NOTE:** Xeljanz requires additional criteria of inadequate response [medication did not work] or intolerance [side effect] to a tumor necrosis factor [TNF] blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - G. Rinvoq (upadacitinib) (**NOTE:** Rinvoq requires additional criteria of inadequate response or intolerance to a TNF blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - H. Tyenne (tocilizumab-aazg) (**NOTE:** Tyenne requires additional step through Enbrel, Humira/adalimumab-adaz/Simlandi, Xeljanz IR, or Rinvoq)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB - IV

RENEWAL CRITERIA (CONTINUED)

E. If you have systemic juvenile idiopathic arthritis, renewal also requires:

1. You will NOT use Actemra concurrently (at the same time) with another systemic biologic (such as Ilaris [canakinumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of systemic juvenile idiopathic arthritis
2. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Tyenne (tocilizumab-aazg)
3. You meet ONE of the following:
 - a. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 - b. You have maintained or improved systemic inflammatory disease (such as fevers, pain, rash, arthritis)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB - SQ

Generic	Brand			
TOCILIZUMAB SQ	ACTEMRA			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TOCILIZUMAB - SQ (Actemra - subcutaneous)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
 2. Giant cell arteritis (GCA: a type of inflammatory condition)
 3. Systemic sclerosis-associated interstitial lung disease (SSc-ILD: a type of lung condition)
 4. Polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
 5. Systemic juvenile idiopathic arthritis (SJIA: a type of joint condition)
- B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use Actemra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
 4. You have tried 3 months of or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
 5. You have tried or have a contraindication to THREE of the following preferred medications:
 - a. Enbrel (etanercept)
 - b. Humira (adalimumab)/adalimumab-adaz/Simlandi (**NOTE:** Humira requires additional step through adalimumab-adaz or Simlandi)
 - c. Rinvoq (upadacitinib) (**NOTE:** Rinvoq requires additional criteria of inadequate response [medication did not work] or intolerance [side effect] to a tumor necrosis factor [TNF] blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - d. Xeljanz (tofacitinib immediate release or extended release) (**NOTE:** Xeljanz requires additional criteria of inadequate response or intolerance to a TNF blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - e. Tyenne (tocilizumab-aazg) (**NOTE:** Tyenne requires additional step through Enbrel, Humira/adalimumab-adaz/Simlandi, Rinvoq, or Xeljanz IR/XR)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB - SQ

INITIAL CRITERIA (CONTINUED)

C. If you have giant cell arteritis, approval also requires:

1. You are 18 years of age or older
2. You have completed, started, or will soon start a tapering course (slowly lowering the dose to stop use) of glucocorticoids (such as prednisone)
3. You will NOT use Actemra concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of giant cell arteritis
4. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications:
 - E. Rinvoq (upadacitinib)
 - F. Tyenne (tocilizumab-aazg) (**NOTE:** Tyenne requires additional step through Rinvoq)

D. If you have systemic sclerosis-associated interstitial lung disease, approval also requires:

1. You are 18 years of age or older
2. Your diagnosis of systemic sclerosis (SSc) is according to the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)
3. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or rheumatologist (a type of immune system doctor)
4. You do not have other causes of interstitial lung disease (such as heart failure or fluid overload, drug-induced lung toxicity [lung damage due to side effects of medications such as cyclophosphamide, methotrexate, angiotensin-converting enzyme (ACE)-inhibitors (a type of blood pressure medication)], recurrent aspiration [something enters the airways accidentally] such as from gastroesophageal reflux disease [GERD: acid reflux], pulmonary vascular disease [a condition affecting blood vessels in the lungs], pulmonary edema [excess fluid in the lungs], pneumonia [type of lung infection], chronic pulmonary thromboembolism [blood clot in the lungs], alveolar hemorrhage [bleeding of a part of the lungs], interstitial lung disease caused by another rheumatic [inflammatory] disease such as mixed connective tissue disease)
5. You will NOT use Actemra concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of systemic sclerosis-associated interstitial lung disease

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB - SQ

INITIAL CRITERIA (CONTINUED)

E. If you have polyarticular juvenile idiopathic arthritis, approval also requires:

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Actemra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
4. You have tried or have a contraindication to (harmful for you to use) THREE of the following preferred medications:
 - a. Enbrel (etanercept)
 - b. Humira (adalimumab)/adalimumab-adaz/Simlandi (**NOTE:** Humira requires additional step through adalimumab-adaz or Simlandi)
 - c. Xeljanz IR (tofacitinib immediate release) (**NOTE:** Xeljanz requires additional criteria of inadequate response [medication did not work] or intolerance [side effect] to a tumor necrosis factor [TNF] blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - d. Rinvoq (upadacitinib) (**NOTE:** Rinvoq requires additional criteria of inadequate response or intolerance to a TNF blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - e. Tyenne (tocilizumab-aazg) (**NOTE:** Tyenne requires additional step through Enbrel, Humira/adalimumab-adaz/Simlandi, Xeljanz IR, or Rinvoq)

F. If you have systemic juvenile idiopathic arthritis, approval also requires:

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor), dermatologist (a type of skin doctor), or immunologist (a type of immune system doctor)
3. You will NOT use Actemra concurrently (at the same time) with another systemic biologic (such as Ilaris [canakinumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of systemic juvenile idiopathic arthritis
4. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Tyenne (tocilizumab-aazg)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB - SQ

RENEWAL CRITERIA

Our guideline named **TOCILIZUMAB - SQ (Actemra - subcutaneous)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Giant cell arteritis (GCA: a type of inflammatory condition)
3. Systemic sclerosis-associated interstitial lung disease (SSc-ILD: a type of lung condition)
4. Polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
5. Systemic juvenile idiopathic arthritis (SJIA: a type of joint condition)

B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Actemra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
3. You have tried or have a contraindication to (harmful for you to use) THREE of the following preferred medications:
 - a. Enbrel (etanercept)
 - b. Humira (adalimumab)/adalimumab-adaz/Simlandi (**NOTE:** Humira requires additional step through adalimumab-adaz or Simlandi)
 - c. Rinvoq (upadacitinib) (**NOTE:** Rinvoq requires additional criteria of inadequate response [medication did not work] or intolerance [side effect] to a tumor necrosis factor [TNF] blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - d. Xeljanz (tofacitinib immediate release or extended release) (**NOTE:** Xeljanz requires additional criteria of inadequate response or intolerance to a TNF blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - e. Tyenne (tocilizumab-aazg) (**NOTE:** Tyenne requires additional step through Enbrel, Humira/adalimumab-adaz/Simlandi, Rinvoq, or Xeljanz IR/XR)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB - SQ

RENEWAL CRITERIA (CONTINUED)

C. If you have giant cell arteritis, renewal also requires:

1. You will NOT use Actemra concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of giant cell arteritis
2. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications:
 - a. Rinvoq (upadacitinib)
 - b. Tyenne (tocilizumab-aazg) (**NOTE:** Tyenne requires additional step through Rinvoq)

D. If you have systemic sclerosis-associated interstitial lung disease, renewal also requires:

1. You have experienced a clinically meaningful improvement or maintenance in annual rate of decline
2. You will NOT use Actemra concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of systemic sclerosis-associated interstitial lung disease

E. If you have polyarticular juvenile idiopathic arthritis, renewal also requires:

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Actemra concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
3. You have tried or have a contraindication to (harmful for you to use) THREE of the following preferred medications:
 - a. Enbrel (etanercept)
 - b. Humira (adalimumab)/adalimumab-adaz/Simlandi (**NOTE:** Humira requires additional step through adalimumab-adaz or Simlandi)
 - c. Xeljanz IR (tofacitinib immediate release) (**NOTE:** Xeljanz requires additional criteria of inadequate response [medication did not work] or intolerance [side effect] to a tumor necrosis factor [TNF] blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - d. Rinvoq (upadacitinib) (**NOTE:** Rinvoq requires additional criteria of inadequate response or intolerance to a TNF blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - e. Tyenne (tocilizumab-aazg) (**NOTE:** Tyenne requires additional step through Enbrel, Humira/adalimumab-adaz/Simlandi, Xeljanz IR, or Rinvoq)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB - SQ

RENEWAL CRITERIA (CONTINUED)

F. If you have systemic juvenile idiopathic arthritis, renewal also requires:

1. You will NOT use Actemra concurrently (at the same time) with another systemic biologic (such as Ilaris [canakinumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of systemic juvenile idiopathic arthritis
2. You have tried or have a contraindication to (harmful for you to use) the following preferred medication: Tyenne (tocilizumab-aazg)
3. You meet ONE of the following:
 - a. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 - b. You have maintained or improved systemic inflammatory disease (such as fevers, pain, rash, arthritis)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB-AAZG - IV

Generic	Brand				
TOCILIZUMAB-AAZG	TYENNE				

PAC NOTE: For requests for the SQ dosage form of Tyenne, please see the TOCILIZUMAB-AAZG-SQ PA guideline.

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TOCILIZUMAB-AAZG - IV (Tyenne - intravenous)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Giant cell arteritis (GCA: a type of inflammatory condition)
3. Polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
4. Systemic juvenile idiopathic arthritis (SJIA: a type of joint condition)
5. Chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS: a type of inflammatory response)

B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
4. You have tried 3 months of or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB-AAZG - IV

INITIAL CRITERIA (CONTINUED)

5. You have tried or have a contraindication to ONE of the following preferred medications:
 - a. Enbrel (etanercept)
 - b. Humira (adalimumab)/adalimumab-adaz/Simlandi (**NOTE:** Humira requires additional step through adalimumab-adaz or Simlandi)
 - c. Rinvoq (upadacitinib) (**NOTE:** Rinvoq requires additional criteria of inadequate response [medication did not work] or intolerance [side effect] to a tumor necrosis factor [TNF] blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - d. Xeljanz (tofacitinib immediate release or extended release) (**NOTE:** Xeljanz requires additional criteria of inadequate response or intolerance to a TNF blocker [such as adalimumab-adaz/Simlandi, Enbrel])
- C. **If you have giant cell arteritis, approval also requires:**
 1. You are 18 years of age or older
 2. You have completed, started, or will soon start a tapering course (slowly lowering the dose to stop use) of glucocorticoids (such as prednisone)
 3. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of giant cell arteritis
 4. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Rinvoq (upadacitinib)
- D. **If you have polyarticular juvenile idiopathic arthritis, approval also requires:**
 1. You are 2 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB-AAZG - IV

INITIAL CRITERIA (CONTINUED)

4. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications:
 - a. Enbrel (etanercept)
 - b. Humira (adalimumab)/adalimumab-adaz/Simlandi (**NOTE:** Humira requires additional step through adalimumab-adaz or Simlandi)
 - c. Xeljanz IR (tofacitinib immediate release) (**NOTE:** Xeljanz requires additional criteria of inadequate response [medication did not work] or intolerance [side effect] to a tumor necrosis factor [TNF] blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - d. Rinvoq (upadacitinib) (**NOTE:** Rinvoq requires additional criteria of inadequate response or intolerance to a TNF blocker [such as adalimumab-adaz/Simlandi, Enbrel])
- E. **If you have systemic juvenile idiopathic arthritis, approval also requires:**
 1. You are 2 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor), dermatologist (a type of skin doctor), or immunologist (a type of immune system doctor)
 3. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic (such as Ilaris [canakinumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of systemic juvenile idiopathic arthritis
- F. **If you have chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome, approval also requires:**
 1. You are 2 years of age or older
 2. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of cytokine release syndrome
- G. **NOTE:** Tyenne will NOT be approved for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults.

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB-AAZG - IV

RENEWAL CRITERIA

NOTE: For the diagnosis of cytokine release syndrome (CRS), please refer to the Initial Criteria section.

Our guideline named **TOCILIZUMAB-AAZG - IV (Tyenne - intravenous)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
 - 2. Giant cell arteritis (GCA: a type of inflammatory condition)
 - 3. Polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
 - 4. Systemic juvenile idiopathic arthritis (SJIA: a type of joint condition)
- B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**
 - 1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 - 2. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
 - 3. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications:
 - a. Enbrel (etanercept)
 - b. Humira (adalimumab)/adalimumab-adaz/Simlandi (**NOTE:** Humira requires additional step through adalimumab-adaz or Simlandi)
 - c. Rinvoq (upadacitinib) (**NOTE:** Rinvoq requires additional criteria of inadequate response [medication did not work] or intolerance [side effect] to a tumor necrosis factor [TNF] blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - d. Xeljanz (tofacitinib immediate release or extended release) (**NOTE:** Xeljanz requires additional criteria of inadequate response or intolerance to a TNF blocker [such as adalimumab-adaz/Simlandi, Enbrel])
- C. **If you have giant cell arteritis, renewal also requires:**
 - 1. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of giant cell arteritis
 - 2. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Rinvoq (upadacitinib)

(Renewal denial text continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB-AAZG - IV

RENEWAL CRITERIA (CONTINUED)

D. If you have polyarticular juvenile idiopathic arthritis, renewal also requires:

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
3. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications:
 - a. Enbrel (etanercept)
 - b. Humira (adalimumab)/adalimumab-adaz/Simlandi (**NOTE:** Humira requires additional step through adalimumab-adaz or Simlandi)
 - c. Xeljanz IR (tofacitinib immediate release) (**NOTE:** Xeljanz requires additional criteria of inadequate response [medication did not work] or intolerance [side effect] to a tumor necrosis factor [TNF] blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - d. Rinvoq (upadacitinib) (**NOTE:** Rinvoq requires additional criteria of inadequate response or intolerance to a TNF blocker [such as adalimumab-adaz/Simlandi, Enbrel])

E. If you have systemic juvenile idiopathic arthritis, renewal also requires:

1. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic (such as Ilaris [canakinumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of systemic juvenile idiopathic arthritis
2. You meet ONE of the following:
 - a. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 - b. You have maintained or improved systemic inflammatory disease (such as fevers, pain, rash, arthritis)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB-AAZG - SQ

Generic	Brand				
TOCILIZUMAB-AAZG	TYENNE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TOCILIZUMAB-AAZG - SQ (Tyenne - subcutaneous)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Giant cell arteritis (GCA: a type of inflammatory condition)
3. Systemic sclerosis-associated interstitial lung disease (SSc-ILD: a type of lung condition)
4. Polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
5. Systemic juvenile idiopathic arthritis (SJIA: a type of joint condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
4. You have tried 3 months of or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
5. You have tried or have a contraindication to ONE of the following preferred medications:
 - a. Enbrel (etanercept)
 - b. Humira (adalimumab)/adalimumab-adaz/Simlandi (**NOTE:** Humira requires additional step through adalimumab-adaz or Simlandi)
 - c. Rinvoq (upadacitinib) (**NOTE:** Rinvoq requires additional criteria of inadequate response [medication did not work] or intolerance [side effect] to a tumor necrosis factor [TNF] blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - d. Xeljanz (tofacitinib immediate release or extended release) (**NOTE:** Xeljanz requires additional criteria of inadequate response or intolerance to a TNF blocker [such as adalimumab-adaz/Simlandi, Enbrel])

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB-AAZG - SQ

INITIAL CRITERIA (CONTINUED)

C. If you have giant cell arteritis, approval also requires:

1. You are 18 years of age or older
2. You have completed, started, or will soon start a tapering course (slowly lowering the dose to stop use) of glucocorticoids (such as prednisone)
3. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of giant cell arteritis
4. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Rinvoq (upadacitinib)

D. If you have systemic sclerosis-associated interstitial lung disease, approval also requires:

1. You are 18 years of age or older
2. Your diagnosis of systemic sclerosis (SSc) is according to the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)
3. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or rheumatologist (a type of immune system doctor)
4. You do not have other causes of interstitial lung disease (such as heart failure or fluid overload, drug-induced lung toxicity [lung damage due to side effects of medications such as cyclophosphamide, methotrexate, angiotensin-converting enzyme (ACE)-inhibitors (a type of blood pressure medication)], recurrent aspiration [something enters the airways accidentally] such as from gastroesophageal reflux disease [GERD: acid reflux], pulmonary vascular disease [a condition affecting blood vessels in the lungs], pulmonary edema [excess fluid in the lungs], pneumonia [type of lung infection], chronic pulmonary thromboembolism [blood clot in the lungs], alveolar hemorrhage [bleeding of a part of the lungs], interstitial lung disease caused by another rheumatic [inflammatory] disease such as mixed connective tissue disease)
5. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of systemic sclerosis-associated interstitial lung disease

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB-AAZG - SQ

INITIAL CRITERIA (CONTINUED)

E. If you have polyarticular juvenile idiopathic arthritis, approval also requires:

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
4. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications:
 - a. Enbrel (etanercept)
 - b. Humira (adalimumab)/adalimumab-adaz/Simlandi (**NOTE:** Humira requires additional step through adalimumab-adaz or Simlandi)
 - c. Xeljanz IR (tofacitinib immediate release) (**NOTE:** Xeljanz requires additional criteria of inadequate response [medication did not work] or intolerance [side effect] to a tumor necrosis factor [TNF] blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - d. Rinvoq (upadacitinib) (**NOTE:** Rinvoq requires additional criteria of inadequate response or intolerance to a TNF blocker [such as adalimumab-adaz/Simlandi, Enbrel])

F. If you have systemic juvenile idiopathic arthritis, approval also requires:

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor), dermatologist (a type of skin doctor), or immunologist (a type of immune system doctor)
3. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic (such as Ilaris [canakinumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of systemic juvenile idiopathic arthritis

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB-AAZG - SQ

RENEWAL CRITERIA

Our guideline named **TOCILIZUMAB-AAZG - SQ (Tyenne - subcutaneous)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Giant cell arteritis (GCA: a type of inflammatory condition)
3. Systemic sclerosis-associated interstitial lung disease (SSc-ILD: a type of lung condition)
4. Polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
5. Systemic juvenile idiopathic arthritis (SJIA: a type of joint condition)

B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
3. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications:
 - a. Enbrel (etanercept)
 - b. Humira (adalimumab)/adalimumab-adaz/Simlandi (**NOTE:** Humira requires additional step through adalimumab-adaz or Simlandi)
 - c. Rinvoq (upadacitinib) (**NOTE:** Rinvoq requires additional criteria of inadequate response [medication did not work] or intolerance [side effect] to a tumor necrosis factor [TNF] blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - d. Xeljanz (tofacitinib immediate release or extended release) (**NOTE:** Xeljanz requires additional criteria of inadequate response or intolerance to a TNF blocker [such as adalimumab-adaz/Simlandi, Enbrel])

C. **If you have giant cell arteritis, renewal also requires:**

1. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of giant cell arteritis
2. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Rinvoq (upadacitinib)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB-AAZG - SQ

RENEWAL CRITERIA (CONTINUED)

D. If you have systemic sclerosis-associated interstitial lung disease, renewal also requires:

1. You have experienced a clinically meaningful improvement or maintenance in annual rate of decline
2. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of systemic sclerosis-associated interstitial lung disease

E. If you have polyarticular juvenile idiopathic arthritis, renewal also requires:

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
3. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications:
 - a. Enbrel (etanercept)
 - b. Humira (adalimumab)/adalimumab-adaz/Simlandi (**NOTE:** Humira requires additional step through adalimumab-adaz or Simlandi)
 - c. Xeljanz IR (tofacitinib immediate release) (**NOTE:** Xeljanz requires additional criteria of inadequate response [medication did not work] or intolerance [side effect] to a tumor necrosis factor [TNF] blocker [such as adalimumab-adaz/Simlandi, Enbrel])
 - d. Rinvoq (upadacitinib) (**NOTE:** Rinvoq requires additional criteria of inadequate response or intolerance to a TNF blocker [such as adalimumab-adaz/Simlandi, Enbrel])

F. If you have systemic juvenile idiopathic arthritis, renewal also requires:

1. You will NOT use Tyenne concurrently (at the same time) with another systemic biologic (such as Ilaris [canakinumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of systemic juvenile idiopathic arthritis
2. You meet ONE of the following:
 - a. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 - b. You have maintained or improved systemic inflammatory disease (such as fevers, pain, rash, arthritis)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOCILIZUMAB-AAZG - SQ

RENEWAL CRITERIA (CONTINUED)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOFACITINIB

Generic	Brand			
TOFACITINIB CITRATE	XELJANZ, XELJANZ XR			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TOFACITINIB (Xeljanz, Xeljanz XR)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Psoriatic arthritis (PsA: a type of skin and joint condition)
3. Ankylosing spondylitis (AS: a type of joint condition)
4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
5. Polyarticular course juvenile idiopathic arthritis (pcJIA: a type of joint condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Xeljanz concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
4. You have tried at least 3 months of or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
5. You had an inadequate response (drug did not work) or intolerance (side effect) to at least ONE tumor necrosis factor (TNF) blocker (such as Humira [adalimumab]/adalimumab-adaz/Simlandi, Enbrel [etanercept])

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOFACITINIB

INITIAL CRITERIA (CONTINUED)

C. If you have psoriatic arthritis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
3. You will NOT use Xeljanz concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
4. You had an inadequate response (drug did not work) or intolerance (side effect) to at least ONE tumor necrosis factor (TNF) blocker (such as Humira [adalimumab]/adalimumab-adaz/Simlandi, Enbrel [etanercept])

D. If you have ankylosing spondylitis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Xeljanz concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
4. You have tried or have a contraindication to (harmful for you to use) an NSAID (nonsteroidal anti-inflammatory drug such as ibuprofen, naproxen, meloxicam, diclofenac)
5. You had an inadequate response (drug did not work) or intolerance (side effect) to at least ONE tumor necrosis factor (TNF) blocker (such as Humira [adalimumab]/adalimumab-adaz/Simlandi, Enbrel [etanercept])

E. If you have moderate to severe ulcerative colitis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
3. You will NOT use Xeljanz concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
4. You had an inadequate response (drug did not work) or intolerance (side effect) to at least ONE tumor necrosis factor (TNF) blocker (such as Humira [adalimumab]/adalimumab-adaz/Simlandi)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOFACITINIB

INITIAL CRITERIA (CONTINUED)

- F. If you have polyarticular course juvenile idiopathic arthritis, approval also requires:**
1. You are 2 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use Xeljanz concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular course juvenile idiopathic arthritis
 4. You had an inadequate response (drug did not work) or intolerance (side effect) to at least ONE tumor necrosis factor (TNF) blocker (such as Humira [adalimumab]/adalimumab-adaz/Simlandi, Enbrel [etanercept])

RENEWAL CRITERIA

Our guideline named **TOFACITINIB (Xeljanz, Xeljanz XR)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:**
1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
 2. Psoriatic arthritis (PsA: a type of skin and joint condition)
 3. Ankylosing spondylitis (AS: a type of joint condition)
 4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
 5. Polyarticular course juvenile idiopathic arthritis (pcJIA: a type of joint condition)
- B. If you have moderate to severe rheumatoid arthritis, renewal also requires:**
1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 2. You will NOT use Xeljanz concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
- C. If you have psoriatic arthritis, renewal also requires:**
1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 2. You will NOT use Xeljanz concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOFACITINIB

RENEWAL CRITERIA (CONTINUED)

D. If you have ankylosing spondylitis, renewal also requires:

1. You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: a type of disease evaluation tool) score while on therapy
2. You will NOT use Xeljanz concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis

E. If you have moderate to severe ulcerative colitis, renewal also requires:

1. You will NOT use Xeljanz concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

F. If you have polyarticular course juvenile idiopathic arthritis, renewal also requires:

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Xeljanz concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular course juvenile idiopathic arthritis

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOLVAPTAN

Generic	Brand			
TOLVAPTAN	JYNARQUE			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TOLVAPTAN (Jynarque)** requires the following rule(s) be met for approval:

- A. You have autosomal dominant polycystic kidney disease (ADPKD: a type of kidney condition)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a nephrologist (a type of kidney doctor)
- D. You do NOT have end-stage renal disease (ESRD: advanced kidney disease), including no renal transplantation (kidney transplant) or dialysis (process of removing excess water, toxins from the blood)

RENEWAL CRITERIA

Our guideline named **TOLVAPTAN (Jynarque)** requires the following rule(s) be met for renewal:

- A. You have autosomal dominant polycystic kidney disease (ADPKD: a type of kidney condition)
- B. You have NOT progressed to end stage renal disease (ESRD: advanced kidney disease)

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOPIRAMATE

Generic	Brand				
TOPIRAMATE	EPRONTIA				

GUIDELINES FOR USE

Our guideline named **TOPIRAMATE (Eprontia)** requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Partial-onset seizures (a type of seizure)
 - 2. Primary generalized tonic-clonic seizures (a type of seizure)
 - 3. Seizures associated with Lennox-Gastaut syndrome (a type of seizure disorder in young children)
 - 4. Migraine
- B. You are unable to take oral tablets or capsules
- C. **If you have partial-onset seizures or primary generalized tonic-clonic seizures, approval also requires:**
 - 1. Eprontia will be used as initial monotherapy OR adjunctive therapy (drugs taken together with)
 - 2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
 - 3. You meet ONE of the following:
 - a. You are 2 to 5 years of age AND had a trial of or contraindication (harmful for) to ONE preferred agent: generic topiramate tablet/sprinkle, topiramate ER sprinkle
 - b. You are 6 years of age or older AND had a trial of or contraindication (harmful for) to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, topiramate ER sprinkle
- D. **If you have seizures associated with Lennox-Gastaut syndrome, approval also requires:**
 - 1. Eprontia will be used as adjunctive therapy (drugs taken together with)
 - 2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
 - 3. You meet ONE of the following:
 - a. You are 2 to 5 years of age AND had a trial of or contraindication (harmful for) to ONE preferred agent: generic topiramate tablet/sprinkle, topiramate ER sprinkle
 - b. You are 6 years of age or older AND had a trial of or contraindication (harmful for) to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, or topiramate ER sprinkle
- E. **If you have migraines, approval also requires:**
 - 1. You are 12 years of age or older
 - 2. Eprontia will be used as preventative treatment of migraines
 - 3. You had a trial of or contraindication (harmful for) to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, topiramate ER sprinkle

Effective: 07/01/22

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOREMIFENE

Generic	Brand			
TOREMIFENE CITRATE	FARESTON, TOREMIFENE CITRATE			

GUIDELINES FOR USE

Our guideline named **TOREMIFENE (Fareston)** requires the following rule(s) be met for approval:

- A. You have metastatic breast cancer (cancer that has spread to other parts of the body)
- B. You are a postmenopausal female (after menopause)
- C. You have estrogen-receptor positive or unknown tumors

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TORSEMIDE

Generic	Brand				
TORSEMIDE	SOAANZ				

GUIDELINES FOR USE

Our guideline named **TORSEMIDE (Soaanz)** requires the following rule(s) be met for approval:

- A. You have edema (swelling caused by fluid build-up in the body) associated with heart failure (a type of heart condition) or renal (kidney) disease
- B. You are 18 years of age or older
- C. You have tried or have a contraindication to (harmful for you to use) TWO generic loop diuretics (such as furosemide, bumetanide)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOVORAFENIB

Generic	Brand				
TOVORAFENIB	OJEMDA				

GUIDELINES FOR USE

Our guideline named **TOVORAFENIB (Ojemda)** requires the following rule(s) be met for approval:

- A. You have relapsed or refractory low-grade glioma (LGG) (a type of brain cancer that has returned or did not respond to treatment)
- B. Your cancer has a BRAF fusion, BRAF rearrangement, or BRAF V600 mutation (types of abnormal changes in genes)

Effective: 06/10/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TRALOKINUMAB-LDRM

Generic	Brand				
TRALOKINUMAB-LDRM	ADBRY				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TRALOKINUMAB-LDRM (Adbry)** requires the following rule(s) be met for approval:

- A. You have moderate to severe atopic dermatitis (AD: a type of skin condition)
- B. You are 12 years of age or older
- C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
- D. You have atopic dermatitis involving at least 10 percent of body surface area (BSA) OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas (areas between skin folds)
- E. You have TWO of the following: intractable pruritus (severe itching), cracking and oozing/bleeding of affected skin, impaired activities of daily living
- F. You will NOT use Adbry concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Eucrisa (crisaborole)]) for the treatment of atopic dermatitis
- G. You have tried or have a contraindication to (harmful for you to use) ONE of the following:
 - 1. High potency topical corticosteroid (such as halobetasol propionate 0.01% lotion, triamcinolone acetonide 0.5% cream or ointment) or a super-high potency topical corticosteroid (such as fluocinonide 0.1% cream, clobetasol propionate 0.05% cream or ointment)
 - 2. Topical calcineurin inhibitor (such as Protopic [tacrolimus], Elidel [pimecrolimus])
 - 3. Topical PDE-4 (phosphodiesterase-4) inhibitor (such as Eucrisa [crisaborole])
 - 4. Topical JAK (Janus kinase) inhibitor (such as Opzelura [ruxolitinib])
 - 5. Phototherapy (light therapy)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TRALOKINUMAB-LDRM

RENEWAL CRITERIA

Our guideline named **TRALOKINUMAB-LDRM (Adbry)** requires the following rule(s) be met for renewal:

- A. You have moderate to severe atopic dermatitis (AD: a type of skin condition)
- B. You have shown improvement while on Adbry
- C. You will NOT use Adbry concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Eucrisa (crisaborole)]) for the treatment of atopic dermatitis

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TRAMADOL

Generic	Brand				
TRAMADOL HCL	QDOLO, TRAMADOL HCL				

GUIDELINES FOR USE

Our guideline named **TRAMADOL (Qdolo)** requires the following rule(s) be met for approval:

The request is for the management of pain

You are 18 years of age or older

Your pain is severe enough to require an opioid analgesic (type of pain medication)

Alternative (other) treatments for your pain are inadequate (did not work)

You have tried or have a contraindication to (harmful for you to use) generic tramadol

immediate-release (IR) tablet or a generic tramadol with acetaminophen product

You are unable to take oral solid formulations (such as a tablet) of tramadol or tramadol with acetaminophen (such as with difficulty swallowing)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TRAMETINIB

Generic	Brand			
TRAMETINIB DIMETHYL SULFOXIDE	MEKINIST			

GUIDELINES FOR USE

Our guideline named **TRAMETINIB (Mekinist)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Unresectable or metastatic melanoma (a type of skin cancer that cannot be removed by surgery or has spread to other parts of the body)
2. Metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to other parts of the body)
3. Melanoma (a type of skin cancer)
4. Locally advanced or metastatic anaplastic thyroid cancer (ATC: a type of thyroid cancer that has spread to nearby tissue or lymph nodes or has spread to other parts of the body)
5. Unresectable or metastatic solid tumor (tumor that cannot be removed by surgery or has spread to other parts of the body)
6. Low-grade glioma (LGG: a type of brain cancer)

B. If you have unresectable or metastatic melanoma, approval also requires:

1. You have a BRAF V600E or V600K mutation (abnormal change in gene) as detected by a Food and Drug Administration (FDA)-approved test
2. Mekinist will be used as a single agent in a BRAF-inhibitor treatment-naïve patient (you have not been previously treated for this cancer) OR in combination with Tafenlar (dabrafenib)

C. If you have metastatic non-small cell lung cancer, approval also requires:

1. You have a BRAF V600E mutation (abnormal change in gene) as detected by a Food and Drug Administration (FDA)-approved test
2. Mekinist will be used in combination with Tafenlar (dabrafenib)

D. If you have melanoma, approval also requires:

1. You have a BRAF V600E or V600K mutation (abnormal change in gene) as detected by a Food and Drug Administration (FDA)-approved test
2. Mekinist will be used as an adjuvant (add-on) therapy in combination with Tafenlar (dabrafenib)
3. There is involvement of lymph node(s), following complete resection (surgical removal)

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TRAMETINIB

GUIDELINES FOR USE (CONTINUED)

- E. If you have locally advanced or metastatic anaplastic thyroid cancer, approval also requires:**
 - 1. You have a BRAF V600E mutation (abnormal change in gene)
 - 2. Mekinist will be used in combination with Tafenlar (dabrafenib)
 - 3. You do not have any satisfactory locoregional treatment options available (treatments that are focused on the affected area)
- F. If you have an unresectable or metastatic solid tumor, approval also requires:**
 - 1. You are 1 year of age or older
 - 2. You have a BRAF V600E mutation (abnormal change in gene)
 - 3. Mekinist will be used in combination with Tafenlar (dabrafenib)
 - 4. Your disease has progressed following prior treatment and have no satisfactory alternative treatment options
- G. If you have low-grade glioma, approval also requires:**
 - 1. You are 1 to 17 years of age
 - 2. You have a BRAF V600E mutation (abnormal change in gene)
 - 3. Mekinist will be used in combination with Tafenlar (dabrafenib)
 - 4. You require systemic therapy (treatment that targets the entire body)
- H. If the request is for the oral solution, approval also requires:**
 - 1. You are unable to swallow Mekinist (trametinib) tablets

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TRASTUZUMAB/TRASTUZUMAB-HYALURONIDASE

Generic	Brand				
TRASTUZUMAB	HERCEPTIN				
TRASTUZUMAB-HYALURONIDASE-OYSK	HERCEPTIN HYLECTA				

GUIDELINES FOR USE

Our guideline named **TRASTUZUMAB/TRASTUZUMAB-HYALURONIDASE (Herceptin, Herceptin Hylecta)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Breast cancer
2. Metastatic gastric or gastroesophageal junction adenocarcinoma (a type of digestive system cancer that has spread to other parts of the body)

B. **If you have breast cancer, approval also requires:**

1. Your cancer is human epidermal growth factor receptor 2 (HER2: a type of protein)-positive, as detected by a Food and Drug Administration (FDA)-approved companion diagnostic test for trastuzumab
2. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Kanjinti (trastuzumab-anns), Trazimera (trastuzumab-qyyp), Ogivri (trastuzumab-dkst)
3. You meet ONE of the following:
 - a. The requested medication will be used as adjuvant (additional) treatment, and you meet ONE of the following:
 - i. The requested medication will be used as part of a treatment plan that includes doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
 - ii. The requested medication will be used as part of a treatment plan with docetaxel and carboplatin
 - iii. The requested medication will be used as a single medication following multi-modality anthracycline based therapy (therapy using a class of cancer medications that combines more than one method of treatment), such as daunorubicin, doxorubicin, Idamycin (idarubicin), Ellence (epirubicin), Valstar (valrubicin)
 - b. Your cancer is metastatic (has spread to other parts of the body), and you meet ONE of the following:
 - i. The requested medication will be used in combination with paclitaxel
 - ii. The requested medication will be used as a single medication if you have received at least one chemotherapy regimen (type of cancer treatment) for metastatic disease

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TRASTUZUMAB/TRASTUZUMAB-HYALURONIDASE

GUIDELINES FOR USE (CONTINUED)

- C. If you have metastatic gastric or gastroesophageal junction adenocarcinoma, approval also requires:**
1. The request is for Herceptin
 2. Your cancer is human epidermal growth factor receptor 2 (HER2: a type of protein)-positive, as detected by a Food and Drug Administration (FDA)-approved companion diagnostic test for trastuzumab
 3. Herceptin will be used in combination with cisplatin AND either Xeloda (capecitabine) or 5-fluorouracil
 4. You have NOT received prior treatment for metastatic disease

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TRASTUZUMAB-STRF

Generic	Brand				
TRASTUZUMAB-STRF	HERCESSI				

GUIDELINES FOR USE

Our guideline named **TRASTUZUMAB-STRF (Hercessi)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Breast cancer
 2. Metastatic gastric or gastroesophageal junction adenocarcinoma (a type of digestive system cancer that has spread to other parts of the body)
- B. **If you have breast cancer, approval also requires:**
1. Your cancer is human epidermal growth factor receptor 2 (HER2: a type of protein)-positive, as detected by a Food and Drug Administration (FDA)-approved companion diagnostic test for a trastuzumab product
 2. You have tried or have a contraindication to (harmful for you to use) ONE of the following preferred medications: Kanjinti (trastuzumab-anns), Trazimera (trastuzumab-qyyp), Ogivri (trastuzumab-dkst)
 3. You meet ONE of the following:
 - a. Hercessi will be used as adjuvant (additional) treatment, and you meet ONE of the following:
 - i. Hercessi will be used as part of a treatment plan that includes doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
 - ii. Hercessi will be used as part of a treatment plan with docetaxel and carboplatin
 - iii. Hercessi will be used as a single medication following multi-modality anthracycline based therapy (therapy using a class of cancer medications that combines more than one method of treatment), such as daunorubicin, doxorubicin, Idamycin (idarubicin), Ellence (epirubicin), Valstar (valrubicin)
 - b. Your cancer is metastatic (has spread to other parts of the body), and you meet ONE of the following:
 - i. Hercessi will be used in combination with paclitaxel
 - ii. Hercessi will be used as a single medication if you have received at least one chemotherapy regimen (type of cancer treatment) for metastatic disease

(Criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TRASTUZUMAB-STRF

GUIDELINES FOR USE (CONTINUED)

- C. If you have metastatic gastric or gastroesophageal junction adenocarcinoma, approval also requires:**
1. Your cancer is human epidermal growth factor receptor 2 (HER2: a type of protein)-positive, as detected by a Food and Drug Administration (FDA)-approved companion diagnostic test for a trastuzumab product
 2. Hercessi will be used in combination with cisplatin AND either Xeloda (capecitabine) or 5-fluorouracil
 3. You have NOT received prior treatment for metastatic disease

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TRAZODONE

Generic	Brand				
TRAZODONE HCL	RALDESY				

GUIDELINES FOR USE

Our guideline named **TRAZODONE (Raldesy)** requires the following rule(s) be met for approval:

You have major depressive disorder (a type of mental illness)

You have a contraindication to (harmful for you to use) OR are unable to swallow trazodone tablets

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TREPROSTINIL-ORENITRAM

Generic	Brand				
TREPROSTINIL DIOLAMINE	ORENITRAM ER				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TREPROSTINIL-ORENITRAM** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1: a way to classify the severity of disease)
- B. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
- C. You do NOT have severe hepatic (liver) impairment
- D. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - 1. Mean pulmonary artery pressure (PAP: a type of measurement for pulmonary hypertension) greater than 20 mmHg
 - 2. Pulmonary capillary wedge pressure (PCWP: a type of measurement for pulmonary hypertension) less than or equal to 15 mmHg
 - 3. Pulmonary vascular resistance (PVR: a type of measurement for pulmonary hypertension) greater than 2 Wood units

RENEWAL CRITERIA

Our guideline named **TREPROSTINIL-ORENITRAM** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1: a way to classify the severity of disease)

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TREPROSTINIL-REMODULIN

Generic	Brand				
TREPROSTINIL SODIUM	REMODULIN, TREPROSTINIL				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TREPROSTINIL-REMODULIN** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1: a way to classify the severity of disease)
- B. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
- C. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 1. Mean pulmonary artery pressure (PAP: a type of measurement for pulmonary hypertension) greater than 20 mmHg
 2. Pulmonary capillary wedge pressure (PCWP: a type of measurement for pulmonary hypertension) less than or equal to 15 mmHg
 3. Pulmonary vascular resistance (PVR: a type of measurement for pulmonary hypertension) greater than 2 Wood units
- D. **For new start requests of Remodulin (treprostinil), approval also requires ONE of the following:**
 1. You are intermediate or high risk
 2. You have tried or have a contraindication to (harmful for you to use) TWO of the following medications from different drug classes:
 - a. Oral endothelin receptor antagonist (such as Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
 - b. Oral phosphodiesterase-5 inhibitor for PAH (such as Revatio [sildenafil], Adcirca [tadalafil])
 - c. Oral cGMP stimulator (such as Adempas [riociguat])
- E. **If you are continuing current Remodulin (treprostinil) therapy from a hospital discharge, there is no additional requirement for approval.**

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TREPROSTINIL-REMODULIN

RENEWAL CRITERIA

Our guideline named **TREPROSTINIL-REMODULIN** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1: a way to classify the severity of disease)

Effective: 06/12/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TREPROSTINIL-TYVASO DPI

Generic	Brand				
TREPROSTINIL	TYVASO DPI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TREPROSTINIL-TYVASO DPI** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1: a way to classify the severity of disease)
 2. Pulmonary hypertension associated with interstitial lung disease (PH-ILD: a type of heart and lung condition) (World Health Organization [WHO] Group 3: a way to classify the severity of disease)
- B. **If you have pulmonary arterial hypertension (WHO Group 1), approval also requires:**
1. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
 2. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - a. Mean pulmonary artery pressure (PAP: a type of measurement for pulmonary hypertension) greater than 20 mmHg
 - b. Pulmonary capillary wedge pressure (PCWP: a type of measurement for pulmonary hypertension) less than or equal to 15 mmHg
 - c. Pulmonary vascular resistance (PVR: a type of measurement for pulmonary hypertension) greater than 2 Wood units
- C. **If you have pulmonary hypertension associated with interstitial lung disease (WHO Group 3), approval also requires:**
1. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
 2. Your pulmonary hypertension diagnosis is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - a. Mean pulmonary artery pressure (PAP: a type of measurement for pulmonary hypertension) greater than 20 mmHg
 - b. Pulmonary capillary wedge pressure (PCWP: a type of measurement for pulmonary hypertension) less than or equal to 15 mmHg
 - c. Pulmonary vascular resistance (PVR: a type of measurement for pulmonary hypertension) greater than 2 Wood units

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TREPROSTINIL-TYVASO DPI

RENEWAL CRITERIA

Our guideline named **TREPROSTINIL-TYVASO DPI** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1: a way to classify the severity of disease)
2. Pulmonary hypertension associated with interstitial lung disease (PH-ILD: a type of heart and lung condition) (World Health Organization [WHO] Group 3: a way to classify the severity of disease)

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TREPROSTINIL-TYVASO

Generic	Brand				
TREPROSTINIL	TYVASO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TREPROSTINIL-TYVASO** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1: a way to classify the severity of disease)
 2. Pulmonary hypertension associated with interstitial lung disease (PH-ILD: a type of heart and lung condition) (World Health Organization [WHO] Group 3: a way to classify the severity of disease)
- B. **If you have pulmonary arterial hypertension (WHO Group 1), approval also requires:**
1. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
 2. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - a. Mean pulmonary artery pressure (PAP: a type of measurement for pulmonary hypertension) greater than 20 mmHg
 - b. Pulmonary capillary wedge pressure (PCWP: a type of measurement for pulmonary hypertension) less than or equal to 15 mmHg
 - c. Pulmonary vascular resistance (PVR: a type of measurement for pulmonary hypertension) greater than 2 Wood units
- C. **If you have pulmonary hypertension associated with interstitial lung disease (WHO Group 3), approval also requires:**
1. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
 2. Your pulmonary hypertension diagnosis is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - a. Mean pulmonary artery pressure (PAP: a type of measurement for pulmonary hypertension) greater than 20 mmHg
 - b. Pulmonary capillary wedge pressure (PCWP: a type of measurement for pulmonary hypertension) less than or equal to 15 mmHg
 - c. Pulmonary vascular resistance (PVR: a type of measurement for pulmonary hypertension) greater than 2 Wood units

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TREPROSTINIL-TYVASO

RENEWAL CRITERIA

Our guideline named **TREPROSTINIL-TYVASO** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1: a way to classify the severity of disease)
2. Pulmonary hypertension associated with interstitial lung disease (PH-ILD: a type of heart and lung condition) (World Health Organization [WHO] Group 3: a way to classify the severity of disease)

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TREPROSTINIL-YUTREPIA

Generic	Brand				
TREPROSTINIL SODIUM	YUTREPIA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TREPROSTINIL-YUTREPIA** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1: a way to classify the severity of disease)
2. Pulmonary hypertension associated with interstitial lung disease (PH-ILD: a type of heart and lung condition) (World Health Organization [WHO] Group 3: a way to classify the severity of disease)

B. **If you have pulmonary arterial hypertension (WHO Group 1), approval also requires:**

1. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
2. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Tyvaso DPI
3. Your pulmonary arterial hypertension is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - a. Mean pulmonary artery pressure (PAP: a type of measurement for pulmonary hypertension) greater than 20 mmHg
 - b. Pulmonary capillary wedge pressure (PCWP: a type of measurement for pulmonary hypertension) less than or equal to 15 mmHg
 - c. Pulmonary vascular resistance (PVR: a type of measurement for pulmonary hypertension) greater than 2 Wood units
4. You have tried or have a contraindication to (harmful for you to use) TWO of the following medications from different medication classes:
 - a. Oral endothelin receptor antagonist (such as Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
 - b. Oral phosphodiesterase-5 inhibitor for PAH (such as Revatio [sildenafil], Adcirca [tadalafil])
 - c. Oral cGMP stimulator (such as Adempas [riociguat])
 - d. Intravenous or subcutaneous prostacyclin (such as Flolan [epoprostenol], Remodulin [treprostinil])

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TREPROSTINIL-YUTREPIA

INITIAL CRITERIA (CONTINUED)

C. If you have pulmonary hypertension associated with interstitial lung disease (WHO Group 3), approval also requires:

1. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
2. You have tried or have a contraindication to (harmful for you to use) the preferred medication: Tyvaso DPI
3. Your pulmonary hypertension diagnosis is confirmed by ALL of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - a. Mean pulmonary artery pressure (PAP: a type of measurement for pulmonary hypertension) greater than 20 mmHg
 - b. Pulmonary capillary wedge pressure (PCWP: a type of measurement for pulmonary hypertension) less than or equal to 15 mmHg
 - c. Pulmonary vascular resistance (PVR: a type of measurement for pulmonary hypertension) greater than 2 Wood units

RENEWAL CRITERIA

Our guideline named **TREPROSTINIL-YUTREPIA** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Pulmonary arterial hypertension (PAH: a type of heart and lung condition) (World Health Organization [WHO] Group 1: a way to classify the severity of disease)
2. Pulmonary hypertension associated with interstitial lung disease (PH-ILD: a type of heart and lung condition) (World Health Organization [WHO] Group 3: a way to classify the severity of disease)

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TRIENTINE CAPSULE

Generic	Brand			
TRIENTINE HCL	SYPRINE, CLOVIQUE, TRIENTINE HCL			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TRIENTINE CAPSULE (Syprine, Clovique)** requires the following rule(s) be met for approval:

- A. You have Wilson's disease (a type of genetic disorder)
- B. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor) or gastroenterologist (a type of digestive system doctor)
- C. You have a Leipzig score (a type of diagnostic score) of 4 or higher
- D. You are willing to follow a diet avoiding high copper foods (such as shellfish, nuts, chocolate, mushrooms, organ meat)
- E. You have tried or have a contraindication to (harmful for you to use) penicillamine (Depen, Cuprimine)

RENEWAL CRITERIA

Our guideline named **TRIENTINE CAPSULE (Syprine, Clovique)** requires the following rules be met for renewal:

- A. You have Wilson's disease (a type of genetic disorder)
- B. You have achieved a free serum copper level (amount of copper in your blood) of less than 10 mcg/dL

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TRIENTINE TABLET

Generic	Brand				
TRIENTINE TETRAHYDROCHLORIDE	CUVRIOR				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TRIENTINE TABLET (Cuvrior)** requires the following rule(s) be met for approval:

- A. You have Wilson's disease (a type of genetic disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor) or gastroenterologist (a type of digestive system doctor)
- D. You have a prior or current Leipzig score (a type of diagnostic score) of 4 or higher
- E. You have a non-ceruloplasmin copper (NCC: a type of test to check copper levels) level between 50 to 150 mcg/L or a 24-hour urinary copper excretion (UCE: a type of test to check copper levels) between 100 to 500 mcg per 24 hours
- F. You are willing to maintain a diet that avoids high copper foods (such as shellfish, nuts, chocolate, mushrooms, organ meat)
- G. You have tried penicillamine (Depen, Cuprimine) for at least one year prior to starting Cuvrior
- H. You have tried trientine hydrochloride (Syprine)

RENEWAL CRITERIA

Our guideline named **TRIENTINE TABLET (Cuvrior)** requires the following rules be met for renewal:

- A. You have Wilson's disease (a type of genetic disorder)
- B. Your body's copper levels are monitored by a non-ceruloplasmin copper (NCC: a type of test to check copper levels) test or 24-hour urinary copper excretion (UCE: a type of test to check copper levels) test

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TRIFLURIDINE/TIPIRACIL

Generic	Brand			
TRIFLURIDINE/ TIPIRACIL HCL	LONSURF			

GUIDELINES FOR USE

Our guideline named **TRIFLURIDINE/TIPIRACIL (Lonsurf)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Metastatic colorectal cancer (a type of digestive system cancer that has spread to other parts of the body)
 2. Metastatic gastric or gastroesophageal junction adenocarcinoma (a type of digestive system cancer that has spread to other parts of the body)
- B. **If you have metastatic colorectal cancer, approval also requires:**
1. You are 18 years of age or older
 2. Lonsurf will be used as a single agent OR in combination with bevacizumab
 3. You had previous treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy (drugs used to treat cancer) in combination with an anti-VEGF biological therapy such as Zaltrap (ziv-aflibercept) or Cyramza (ramucirumab)
 4. If your metastatic colorectal cancer is RAS wild-type (a type of gene), you also had a previous treatment with an anti-EGFR agent such as Erbitux (cetuximab), Vectibix (panitumumab)
- C. **If you have metastatic gastric or gastroesophageal junction adenocarcinoma, approval also requires:**
1. You are 18 years of age or older
 2. You had previous treatment with at least two prior lines of chemotherapy (drugs used to treat cancer) that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2 (type of gene)/neu-targeted therapy

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TRIHEPTANOIN

Generic	Brand				
TRIHEPTANOIN	DOJOLVI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TRIHEPTANOIN (Dojolvi)** requires the following rule(s) be met for approval:

- A. You have a long-chain fatty acid oxidation disorder (LC-FAOD: rare, genetic disorder that affects how the body breaks down fat)
- B. Your diagnosis is confirmed by TWO of the following:
 - 1. Disease-specific elevations of acylcarnitines on a newborn blood spot or in plasma
 - 2. Low enzyme activity in cultured fibroblasts (a type of cell found in the body)
 - 3. One or more known pathogenic mutations (abnormal changes) in CPT2, ACADVL, HADHA, or HADHB (types of genes)
- C. You are symptomatic for LC-FAOD (for example you have rhabdomyolysis [break down of muscle tissue] or cardiomyopathy [a type of heart condition])
- D. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions) or physician specialist in medical genetics/inherited metabolic disorders
- E. You have tried or have a contraindication to (harmful for you to use) commercial MCT oil (a medical food product)

RENEWAL CRITERIA

Our guideline named **TRIHEPTANOIN (Dojolvi)** requires the following rule(s) be met for renewal:

- A. You have a long-chain fatty acid oxidation disorder (LC-FAOD: rare, genetic disorder that affects how the body breaks down fat)
- B. You have experienced a positive clinical response (such as improved exercise tolerance) or stabilization of clinical status compared to baseline

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TROFINETIDE

Generic	Brand				
TROFINETIDE	DAYBUE				

GUIDELINES FOR USE

Our guideline named **TROFINETIDE (Daybue)** requires the following rule(s) be met for approval:

- A. You have Rett syndrome (a type of nervous system disorder)
- B. You are 2 years of age or older

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TUCATINIB

Generic	Brand				
TUCATINIB	TUKYSA				

GUIDELINES FOR USE

Our guideline named **TUCATINIB (Tukysa)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Advanced unresectable or metastatic breast cancer (cancer that cannot be removed with surgery or has spread to other parts of the body)
 - 2. Unresectable or metastatic colorectal cancer (a type of digestive cancer that cannot be removed with surgery or has spread to other parts of the body)
- B. **If you have advanced unresectable or metastatic breast cancer, approval also requires:**
 - 1. Your breast cancer is human epidermal growth factor receptor 2 (HER2: a type of protein)-positive
 - 2. You have received at least one anti-HER2-based treatment (trastuzumab or trastuzumab with pertuzumab) for metastatic (has spread to other parts of the body) disease
 - 3. Tukysa will be used in combination with trastuzumab and capecitabine
- C. **If you have unresectable or metastatic colorectal cancer, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Your colorectal cancer is RAS wild-type (a type of gene), human epidermal growth factor receptor 2 (HER2: a type of protein)-positive
 - 3. Your cancer has progressed (worsened) following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (medications used to treat cancer)
 - 4. Tukysa will be used in combination with trastuzumab

Effective: 05/05/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

UBROGEPANT

Generic	Brand			
UBROGEPANT	UBRELVY			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **UBROGEPANT (Ubrovelvy)** requires the following rule(s) be met for approval:

The request is for the acute (quick onset) treatment of migraines (a type of headache)

You are 18 years of age or older

You will NOT use Ubrovelvy concurrently (at the same time) with other calcitonin gene-related peptide (cGRP) inhibitors (such as Zavzpret [zavegepant]) for the acute treatment of migraines

You have tried or have a contraindication to (harmful for you to use) ONE triptan (such as Imitrex [sumatriptan], Maxalt [rizatriptan])

RENEWAL CRITERIA

Our guideline named **UBROGEPANT (Ubrovelvy)** requires the following rule(s) be met for renewal:

The request is for the acute (quick onset) treatment of migraines (a type of headache)

You will NOT use Ubrovelvy concurrently (at the same time) with other calcitonin gene-related peptide (cGRP) inhibitors (such as Zavzpret [zavegepant]) for the acute treatment of migraines

You meet ONE of the following:

You have experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (assessment tool used to help guide treatment such as Migraine Assessment of Current Therapy [MIGRAINE-ACT])

You have experienced clinical improvement as defined by ONE of the following:

Ability to function normally within 2 hours of dose

Headache pain disappears within 2 hours of dose

Treatment works consistently in the majority of migraine attacks

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

UPADACITINIB

Generic	Brand			
UPADACITINIB	RINVOQ			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **UPADACITINIB (Rinvoq)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Psoriatic arthritis (PsA: a type of skin and joint condition)
3. Moderate to severe atopic dermatitis (AD: a type of skin condition)
4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
6. Ankylosing spondylitis (AS: a type of joint condition)
7. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
8. Polyarticular juvenile idiopathic arthritis (pJIA: a type of joint condition)
9. Giant cell arteritis (GCA: a type of inflammatory condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Xeljanz (tofacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis
4. You have tried at least 3 months of or have a contraindication to (harmful for you to use) ONE conventional synthetic DMARD (disease-modifying anti-rheumatic drug), such as methotrexate dose of at least 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
5. You had an inadequate response (drug did not work) or intolerance (side effect) to at least ONE tumor necrosis factor (TNF) blocker (such as Humira [adalimumab]/adalimumab-adaz/Simlandi, Enbrel [etanercept])

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

UPADACITINIB

INITIAL CRITERIA (CONTINUED)

C. If you have psoriatic arthritis, approval also requires:

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
3. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Xeljanz (tofacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
4. You had an inadequate response (drug did not work) or intolerance (side effect) to at least ONE tumor necrosis factor (TNF) blocker (such as Enbrel [etanercept])

D. If you have moderate to severe atopic dermatitis, approval also requires:

1. You are 12 years of age or older
2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
3. You have at least TWO of the following: intractable pruritus (severe itching), cracking and oozing/bleeding of affected skin, impaired activities of daily living
4. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Opzelura (ruxolitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Eucrisa (crisaborole)]) for the treatment of atopic dermatitis
5. You meet ONE of the following:
 - a. You were previously stable on another biologic (such as Adbry [tralokinumab-ldrm], Dupixent [dupilumab]) and are switching to Rinvoq
 - b. You have atopic dermatitis involving at least 10 percent of body surface area (BSA)
 - c. You have atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas (between skin folds)
6. You have tried or have a contraindication to (harmful for you to use) ONE of the following: topical corticosteroid (such as hydrocortisone, clobetasol propionate, halobetasol propionate), topical calcineurin inhibitor (such as Elidel [pimecrolimus], Protopic [tacrolimus]), topical PDE-4 inhibitor (such as Eucrisa [crisaborole]), topical JAK inhibitor (such as Opzelura [ruxolitinib]), phototherapy (light therapy)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

UPADACITINIB

INITIAL CRITERIA (CONTINUED)

- E. If you have moderate to severe ulcerative colitis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 3. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Xeljanz (tofacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
 4. You had an inadequate response (drug did not work) or intolerance (side effect) to at least ONE tumor necrosis factor (TNF) blocker (such as Humira [adalimumab]/adalimumab-adaz/Simlandi)
- F. If you have moderate to severe Crohn's disease, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 3. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
 4. You had an inadequate response (drug did not work) or intolerance (side effect) to at least ONE tumor necrosis factor (TNF) blocker (such as Humira [adalimumab]/adalimumab-adaz/Simlandi)
- G. If you have ankylosing spondylitis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
 3. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Xeljanz (tofacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
 4. You have tried or have a contraindication to (harmful for you to use) an NSAID (nonsteroidal anti-inflammatory drug such as ibuprofen, naproxen, meloxicam)
 5. You had an inadequate response (drug did not work) or intolerance (side effect) to at least ONE tumor necrosis factor (TNF) blocker (such as Humira [adalimumab]/adalimumab-adaz/Simlandi, Enbrel [etanercept])

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

UPADACITINIB

INITIAL CRITERIA (CONTINUED)

H. If you have non-radiographic axial spondyloarthritis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Taltz [ixekizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of non-radiographic axial spondyloarthritis
4. You had an inadequate response (drug did not work) or intolerance (side effect) to at least ONE tumor necrosis factor (TNF) blocker (such as Cimzia [certolizumab])
5. You have tried or have a contraindication to (harmful for you to use) an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)
6. You meet ONE of the following:
 - a. You were previously stable on another biologic and are switching to Rinvoq
 - b. You have C-reactive protein (CRP: a measure of how much inflammation is in the body) levels above the upper limit of normal
 - c. You have sacroiliitis (a type of inflammation where lower spine and pelvis connect) on magnetic resonance imaging (MRI: a type of imaging lab)

I. If you have polyarticular juvenile idiopathic arthritis, approval also requires:

1. You are 2 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
3. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Xeljanz (tofacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis
4. You had an inadequate response (drug did not work) or intolerance (side effect) to at least ONE tumor necrosis factor (TNF) blocker (such as Humira [adalimumab]/adalimumab-adaz/Simlandi, Enbrel [etanercept])

J. If you have giant cell arteritis, approval also requires:

1. You are 18 years of age or older
2. You have completed, started, or will soon start a tapering course (slowly lowering the dose to stop use) of glucocorticoids (such as prednisone)
3. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Actemra [tocilizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of giant cell arteritis

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

UPADACITINIB

RENEWAL CRITERIA

Our guideline named **UPADACITINIB (Rinvoq)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
2. Psoriatic arthritis (PsA: a type of skin and joint condition)
3. Moderate to severe atopic dermatitis (AD: a type of skin condition)
4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
6. Ankylosing spondylitis (AS: a type of joint condition)
7. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
8. Polyarticular juvenile idiopathic arthritis (pJIA: a type of joint condition)
9. Giant cell arteritis (GCA: a type of inflammatory condition)

B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Xeljanz (tofacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of rheumatoid arthritis

C. **If you have psoriatic arthritis, renewal also requires:**

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Xeljanz (tofacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

D. **If you have moderate to severe atopic dermatitis, renewal also requires:**

4. You have shown improvement while on therapy
5. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Dupixent [dupilumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Opzelura (ruxolitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Eucrisa (crisaborole)]) for the treatment of atopic dermatitis

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

UPADACITINIB

RENEWAL CRITERIA (CONTINUED)

- E. If you have moderate to severe ulcerative colitis, renewal also requires:**
1. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Xeljanz (tofacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
- F. If you have moderate to severe Crohn's disease, renewal also requires:**
1. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
- G. If you have ankylosing spondylitis, renewal also requires:**
1. You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) score while on therapy
 2. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Xeljanz (tofacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ankylosing spondylitis
- H. If you have non-radiographic axial spondyloarthritis, renewal also requires:**
1. You have experienced or maintained an improvement of at least 50 percent or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) score while on therapy
 2. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Taltz [ixekizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of non-radiographic axial spondyloarthritis
- I. If you have polyarticular juvenile idiopathic arthritis, renewal also requires:**
1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 2. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Xeljanz (tofacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of polyarticular juvenile idiopathic arthritis

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

UPADACITINIB

RENEWAL CRITERIA (CONTINUED)

- J. If you have giant cell arteritis, renewal also requires:**
 - 1. You will NOT use Rinvoq concurrently (at the same time) with another systemic biologic (such as Actemra [tocilizumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of giant cell arteritis

Effective: 06/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

URIDINE TRIACETATE

Generic	Brand			
URIDINE TRIACETATE	XURIDEN			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **URIDINE TRIACETATE (Xuriden)** requires the following rule(s) be met for approval:

- A. You have hereditary orotic aciduria (HOA a type of rare genetic disorder)
- B. Therapy is prescribed by or in consultation with a doctor specializing in inherited metabolic diseases (genetic diseases that result in metabolism problems)
- C. Your HOA diagnosis is confirmed by ALL of the following:
 - 1. You have a genetic mutation (abnormal change in gene) in the uridine monophosphate synthase (UMPS) gene
 - 2. You have elevated urine orotic acid levels (high levels of a type of substance in the urine) according to your age-specific reference range

RENEWAL CRITERIA

Our guideline named **URIDINE TRIACETATE (Xuriden)** requires the following rule(s) to be met for renewal:

- A. You have hereditary orotic aciduria (HOA: a type of rare genetic disorder)
- B. You have had improvement from baseline (before treatment) or stabilization of age dependent hematologic parameters (blood lab tests such as neutrophil count, neutrophil percent, white blood cell count, mean corpuscular volume) while on treatment with Xuriden

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

URSODIOL

Generic	Brand				
URSODIOL	RELTONE, URSODIOL				

GUIDELINES FOR USE

Our guideline named **URSODIOL (Reltone)** requires the following rule(s) be met for approval:

- E. You have radiolucent, noncalcified gallbladder stones (hardened deposits of bile, that is barely visible on x-ray, in your gallbladder that do not contain calcium)
- F. Your gallbladder stones are less than 20 mm in diameter
- G. You plan to have elective cholecystectomy (surgery to remove gallbladder) unless you are at increased surgical risk due to systemic (entire body) disease, advanced age, or idiosyncratic reaction (an unexpected adverse reaction) to general anesthesia, OR you refuse surgery
- H. You have tried generic ursodiol (300mg capsule, 250mg tablet, or 500mg tablet)
- I. You are unable to take generic ursodiol (300mg capsule, 250mg tablet, or 500mg tablet) formulations

Effective: 04/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

USTEKINUMAB

Generic	Brand			
USTEKINUMAB	STELARA			

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **USTEKINUMAB (Stelara)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
 2. Psoriatic arthritis (PsA: a type of skin and joint condition)
 3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
 4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
- B. **If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 6 years of age or older
 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 3. You will NOT use Stelara concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
 4. You meet ONE of the following:
 - a. You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis
 - b. You have a contraindication (harmful for you to use) or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) and PUVA (phototherapy) for the treatment of plaque psoriasis
 - c. You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication
 5. You meet ONE of the following:
 - a. You were previously stable on another biologic and are switching to Stelara
 - b. You have psoriasis covering 3 percent or more of body surface area (BSA)
 - c. You have psoriatic lesions (rashes) affecting your hands, feet, face, genital area, or scalp

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

USTEKINUMAB

INITIAL CRITERIA (CONTINUED)

- C. If you have psoriatic arthritis, approval also requires:**
 - 1. You are 6 years of age or older
 - 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
 - 3. You will NOT use Stelara concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
- D. If you have moderate to severe Crohn's disease, approval also requires:**
 - 4. You are 18 years of age or older
 - 5. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 - 6. You will NOT use Stelara concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
- E. If you have moderate to severe ulcerative colitis, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 - 3. You will NOT use Stelara concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

USTEKINUMAB

RENEWAL CRITERIA

Our guideline named **USTEKINUMAB (Stelara)** requires the following rule(s) be met for renewal:

A. You have ONE of the following:

1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
2. Psoriatic arthritis (PsA: a type of skin and joint condition)
3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

B. **If you have moderate to severe plaque psoriasis, renewal also requires:**

1. You have achieved or maintained clear or minimal disease OR a decrease in Psoriasis Area and Severity Index (PASI: used to measure the severity and extent of psoriasis) of at least 50 percent or more
2. You will NOT use Stelara concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis

C. **If you have psoriatic arthritis, renewal also requires:**

1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
2. You will NOT use Stelara concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

D. **If you have moderate to severe Crohn's disease, renewal also requires:**

1. You will NOT use Stelara concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease

E. **If you have moderate to severe ulcerative colitis, renewal also requires:**

1. You will NOT use Stelara concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

USTEKINUMAB-AEKN

Generic	Brand				
USTEKINUMAB-AEKN	SELARSDI				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **USTEKINUMAB-AEKN (Selarsdi)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
 2. Psoriatic arthritis (PsA: a type of skin and joint condition)
 3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
 4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
- B. **If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 6 years of age or older
 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 3. You will NOT use Selarsdi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
 4. You meet ONE of the following:
 - a. You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis
 - b. You have a contraindication (harmful for you to use) or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) and PUVA (phototherapy) for the treatment of plaque psoriasis
 - c. You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication
 5. You meet ONE of the following:
 - a. You were previously stable on another biologic and are switching to Selarsdi
 - b. You have psoriasis covering 3 percent or more of body surface area (BSA)
 - c. You have psoriatic lesions (rashes) affecting your hands, feet, face, genital area, or scalp

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

USTEKINUMAB-AEKN

INITIAL CRITERIA (CONTINUED)

- C. If you have psoriatic arthritis, approval also requires:**
1. You are 6 years of age or older
 2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
 3. You will NOT use Selarsdi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
- D. If you have moderate to severe Crohn's disease, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 3. You will NOT use Selarsdi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
- E. If you have moderate to severe ulcerative colitis, approval also requires:**
1. You are 18 years of age or older
 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 3. You will NOT use Selarsdi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

USTEKINUMAB-AEKN

RENEWAL CRITERIA

Our guideline named **USTEKINUMAB-AEKN (Selarsdi)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
 - 2. Psoriatic arthritis (PsA: a type of skin and joint condition)
 - 3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
 - 4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
- B. **If you have moderate to severe plaque psoriasis, renewal also requires:**
 - 1. You have achieved or maintained clear or minimal disease OR a decrease in Psoriasis Area and Severity Index (PASI: used to measure the severity and extent of psoriasis) of at least 50 percent or more
 - 2. You will NOT use Selarsdi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
- C. **If you have psoriatic arthritis, renewal also requires:**
 - 1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 - 2. You will NOT use Selarsdi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
- D. **If you have moderate to severe Crohn's disease, renewal also requires:**
 - 1. You will NOT use Selarsdi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
- E. **If you have moderate to severe ulcerative colitis, renewal also requires:**
 - 1. You will NOT use Selarsdi concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

Effective: 03/10/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

USTEKINUMAB-KFCE

Generic	Brand				
USTEKINUMAB-KFCE	YESINTEK				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **USTEKINUMAB-KFCE (Yesintek)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
 2. Psoriatic arthritis (PsA: a type of skin and joint condition)
 3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
 4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
- B. **If you have moderate to severe plaque psoriasis, approval also requires:**
1. You are 6 years of age or older
 2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
 3. You will NOT use Yesintek concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
 4. You meet ONE of the following:
 - a. You have had at least a 3-month trial of one oral immunosuppressant (cyclosporine, methotrexate, tacrolimus) or PUVA (phototherapy: a type of light therapy) for the treatment of plaque psoriasis
 - b. You have a contraindication (harmful for you to use) or intolerance (side effect) to both immunosuppressant (a type of drug that decreases the body's immune response) and PUVA (phototherapy) for the treatment of plaque psoriasis
 - c. You are switching from a different biologic (such as Humira [adalimumab]), PDE-4 (phosphodiesterase-4) inhibitor (such as Otezla [apremilast]), or JAK (Janus kinase) inhibitor for the same indication
 5. You meet ONE of the following:
 - a. You were previously stable on another biologic and are switching to Yesintek
 - b. You have psoriasis covering 3 percent or more of body surface area (BSA)
 - c. You have psoriatic lesions (rashes) affecting your hands, feet, face, genital area, or scalp

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

USTEKINUMAB-KFCE

INITIAL CRITERIA (CONTINUED)

C. If you have psoriatic arthritis, approval also requires:

1. You are 6 years of age or older
2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
3. You will NOT use Yesintek concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis

D. If you have moderate to severe Crohn's disease, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
3. You will NOT use Yesintek concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease

E. If you have moderate to severe ulcerative colitis, approval also requires:

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
3. You will NOT use Yesintek concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

USTEKINUMAB-KFCE

RENEWAL CRITERIA

Our guideline named **USTEKINUMAB-KFCE (Yesintek)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
 - 2. Psoriatic arthritis (PsA: a type of skin and joint condition)
 - 3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
 - 4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
- B. **If you have moderate to severe plaque psoriasis, renewal also requires:**
 - 1. You have achieved or maintained clear or minimal disease OR a decrease in Psoriasis Area and Severity Index (PASI: used to measure the severity and extent of psoriasis) of at least 50 percent or more
 - 2. You will NOT use Yesintek concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor, PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of plaque psoriasis
- C. **If you have psoriatic arthritis, renewal also requires:**
 - 1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
 - 2. You will NOT use Yesintek concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor [such as Otezla (apremilast)]) for the treatment of psoriatic arthritis
- D. **If you have moderate to severe Crohn's disease, renewal also requires:**
 - 1. You will NOT use Yesintek concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
- E. **If you have moderate to severe ulcerative colitis, renewal also requires:**
 - 1. You will NOT use Yesintek concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis

Effective: 03/10/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VADADUSTAT

Generic	Brand				
VADADUSTAT	VAFSEO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **VADADUSTAT (Vafseo)** requires the following rule(s) be met for approval:

- A. You have a diagnosis of anemia (low amount of healthy red blood cells) due to chronic kidney disease (CKD: long-term kidney disease)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a nephrologist (a type of kidney doctor)
- D. You have been receiving dialysis (process of removing excess water, toxins from the blood) for at least 3 months
- E. You have an estimated glomerular filtration rate (eGFR: a tool for evaluating kidney function) less than 60 mL/min/1.73m(2), confirming stage 3, 4, or 5 chronic kidney disease (CKD)
- F. You have a hemoglobin level of less than 12 g/dL while treated with an erythropoiesis-stimulating agent (ESA) (such as Epogen, Procrit), and you will discontinue ESA therapy before starting Vafseo
- G. You will NOT use Vafseo concurrently (at the same time) with other hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) (such as Jesduvroq [daprodustat])

RENEWAL CRITERIA

Our guideline named **VADADUSTAT (Vafseo)** requires the following rule(s) be met for renewal:

- A. You have a diagnosis of anemia (low amount of healthy red blood cells) due to chronic kidney disease (CKD: long-term kidney disease)
- B. You meet ONE of the following:
 - 1. You have a hemoglobin level (a type of blood test) of at least 10 g/dL
 - 2. Your hemoglobin level has increased by at least 2 g/dL from your baseline level

Effective: 08/05/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VALBENAZINE

Generic	Brand			
VALBENAZINE	INGREZZA			

GUIDELINES FOR USE

Our guideline named **VALBENAZINE (Ingrezza)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Tardive dyskinesia (TD: uncontrolled body movements)
 - 2. Chorea (involuntary muscle movements) associated with Huntington's disease (a type of brain disorder)
- B. **If you have tardive dyskinesia, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor), movement disorder specialist, or psychiatrist (a type of mental health doctor)
 - 3. Your tardive dyskinesia has been present for at least 3 months
 - 4. You have a history of using antipsychotic medications (such as aripiprazole, haloperidol, ziprasidone) or metoclopramide for at least 3 months (or at least 1 month if you are 60 years of age or older) as documented in your prescription claims history
- C. **If you have chorea associated with Huntington's disease, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor) or movement disorder specialist

Effective: 07/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VAMOROLONE

Generic	Brand				
VAMOROLONE	AGAMREE				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **VAMOROLONE (Agamree)** requires the following rules be met for approval:

- A. You have Duchenne muscular dystrophy (DMD: a type of muscle disorder)
- B. You are 2 years of age and older
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nerve system doctor) specializing in the treatment of Duchenne muscular dystrophy (DMD) at a DMD treatment center
- D. Your diagnosis of DMD is confirmed by genetic testing
- E. You have tried prednisone or prednisolone for at least 6 months
- F. You meet ONE of the following:
 1. Prednisone or prednisolone did not work for you, and you meet ALL of the following:
 - a. You are not in Stage 1 of the disease (the pre-symptomatic phase)
 - b. There is no steroid myopathy (muscle disease due to steroid use)
 - c. You have experienced a decrease in ambulation (walking), functional status, or pulmonary (lung) function, while treated with prednisone or prednisolone, that is consistent with advancing disease (stage 2 or higher) and that is assessed by standard measures over time (such as, the 6-minute walking distance [6MWD], going up or down 4 stairs, time to rise from the floor, 10-meter run/walk time, North Star Ambulatory Assessment [NSAA: a tool for evaluating Duchenne muscular dystrophy])
 2. You have experienced a significant adverse effect (side effects such as weight gain) on prednisone or prednisolone that is negatively impacting a co-existing comorbid condition (such as diabetes [a disorder with high blood sugar])

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VAMOROLONE

RENEWAL CRITERIA

Our guideline named **VAMOROLONE (Agamree)** requires the following rules be met for renewal:

- A. You have Duchenne muscular dystrophy (DMD: a type of muscle disorder)
- B. **If you are currently ambulatory (can walk), approval also requires:**
 - 1. You have shown improvement while on Agamree as measured by a standard set of ambulatory or functional status measures (such as, the 6-minute walking distance [6MWD], going up or down 4 stairs, time to rise from the floor [Gower's maneuver], 10-meter (30 feet) run/walk time, North Star Ambulatory Assessment [NSAA: a tool for evaluating Duchenne muscular dystrophy])
- C. **If you are currently non-ambulatory (cannot walk), approval also requires:**
 - 1. You have maintained or had a less than expected decrease in pulmonary (lung) function or upper limb strength while on Agamree as assessed by standard measures (such as pulmonary function [forced vital capacity, pulmonary function tests], upper limb strength)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VANDETANIB

Generic	Brand			
VANDETANIB	CAPRELSA			

GUIDELINES FOR USE

Our guideline for **VANDETANIB (Caprelsa)** requires **ONE** of the following rule(s) be met for approval:

- A. You are currently stable on the requested medication
- B. You have symptomatic or progressive medullary thyroid cancer with unresectable locally advanced or metastatic disease (advanced thyroid cancer that cannot be removed with surgery and has spread to nearby tissue, lymph nodes, or other parts of the body)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VANZACAFITOR-TEZACAFITOR-DEUTIVACAFITOR

Generic	Brand				
VANZACAFITOR/ TEZACAF/ DEUTIVACAF	ALYFTREK				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **VANZACAFITOR-TEZACAFITOR-DEUTIVACAFITOR (Alyftrek)** requires the following rule(s) be met for approval:

- A. You have cystic fibrosis (CF: a type of lung disorder)
- B. You are 6 years of age or older
- C. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or cystic fibrosis expert
- D. You will NOT use Alyftrek concurrently (at the same time) with another cystic fibrosis transmembrane conductance regulator (CFTR) modulator (such as a type of medication containing vanzacaftor, deutivacaftor, ivacaftor, lumacaftor, tezacaftor, or elexacaftor)
- E. You meet ONE of the following:
 - 1. You have at least ONE *F508del* mutation (abnormal change) in the CFTR gene
 - 2. You have a responsive mutation in the CFTR gene (abnormal change in a type of gene that can be treated with Alyftrek)

RENEWAL CRITERIA

Our guideline named **VANZACAFITOR-TEZACAFITOR-DEUTIVACAFITOR (Alyftrek)** requires the following rule(s) be met for renewal:

- A. You have cystic fibrosis (CF: a type of lung disorder)
- B. You have experienced an improvement in your clinical status
- C. You will NOT use Alyftrek concurrently (at the same time) with another cystic fibrosis transmembrane conductance regulator (CFTR) modulator (such as a type of medication containing vanzacaftor, deutivacaftor, ivacaftor, lumacaftor, tezacaftor, or elexacaftor)

Effective: 01/17/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VARENICLINE

Generic	Brand				
VARENICLINE TARTRATE	TYRVAYA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **VARENICLINE (Tyrvaya)** requires the following rule(s) be met for approval:

- A. You have dry eye disease
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or optometrist (a type of eye doctor)
- D. You have at least one positive diagnostic test (such as tear breakup time, tear film osmolarity, ocular surfacing staining, Schirmer test)

RENEWAL CRITERIA

Our guideline named **VARENICLINE (Tyrvaya)** requires the following rule(s) be met for renewal:

- A. You have dry eye disease
- B. You have demonstrated improvement of dry eye disease

Effective: 10/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VEDOLIZUMAB

Generic	Brand				
VEDOLIZUMAB	ENTYVIO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **VEDOLIZUMAB (Entyvio)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
 - 2. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
- B. **If you have moderate to severe Crohn's disease, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 - 3. You will NOT use Entyvio concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
 - 4. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)
- C. **If you have moderate to severe ulcerative colitis, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
 - 3. You will NOT use Entyvio concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
 - 4. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VEDOLIZUMAB

RENEWAL CRITERIA

Our guideline named **VEDOLIZUMAB (Entyvio)** requires the following rule(s) be met for renewal:

- A. You have ONE of the following:
 - 1. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
 - 2. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
- B. **If you have moderate to severe Crohn's disease, renewal also requires:**
 - 1. You will NOT use Entyvio concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of Crohn's disease
 - 2. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Skyrizi (risankizumab-rzaa), Rinvoq (upadacitinib), Tremfya (guselkumab)
- C. **If you have moderate to severe ulcerative colitis, renewal also requires:**
 - 1. You will NOT use Entyvio concurrently (at the same time) with another systemic biologic (such as Humira [adalimumab]) or targeted small molecules (such as JAK [Janus kinase] inhibitor [such as Rinvoq (upadacitinib)], PDE-4 [phosphodiesterase-4] inhibitor) for the treatment of ulcerative colitis
 - 2. You have tried or have a contraindication to (harmful for you to use) TWO of the following preferred medications: Humira (adalimumab)/adalimumab-adaz/Simlandi, Stelara (ustekinumab)/Yesintek (ustekinumab-kfce)/Selarsdi (ustekinumab-aekn), Xeljanz (tofacitinib immediate-release or extended-release), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Tremfya (guselkumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Effective: 05/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VEMURAFENIB

Generic	Brand			
VEMURAFENIB	ZELBORAF			

GUIDELINES FOR USE

Our guideline named **VEMURAFENIB (Zelboraf)** requires the following rules be met for approval:

- A. You have ONE of the following:
 - 1. Unresectable or metastatic melanoma (a type of skin cancer that cannot be completely removed with surgery or has spread to other parts of the body)
 - 2. Erdheim-Chester Disease (a type of multisystem mutation)
- B. **If you have unresectable or metastatic melanoma, approval also requires:**
 - 1. You have a BRAF V600E mutation (a type of abnormal change in a gene) as detected by a Food and Drug Administration (FDA)-approved test
 - 2. Zelboraf will be used alone or in combination with Cotellic (cobimetinib)
- C. **If you have Erdheim-Chester Disease, approval also requires:**
 - 1. You have a BRAF V600 mutation (a type of abnormal change in a gene)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VENETOCLAX

Generic	Brand			
VENETOCLAX	VENCLEXTA			

GUIDELINES FOR USE

Our guideline named **VENETOCLAX (Venclexta)** requires that the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
 - 2. Small lymphocytic lymphoma (SLL: a type of blood cancer)
 - 3. Acute myeloid leukemia (AML: a type of blood and bone marrow cancer)
- B. **If you have chronic lymphocytic leukemia or small lymphocytic lymphoma, approval also requires:**
 - 1. You are 18 years of age or older
- C. **If you have acute myeloid leukemia, approval also requires:**
 - 1. You have newly-diagnosed acute myeloid leukemia
 - 2. You are 75 years of age or older, OR you are 18 years of age or older with comorbidities (additional diseases) that preclude (prevent) the use of intensive induction chemotherapy (a type of therapy to treat cancer)
 - 3. Venclexta will be used in combination with azacitidine or decitabine or low-dose cytarabine

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VERICIGUAT

Generic	Brand				
VERICIGUAT	VERQUVO				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **VERICIGUAT (Verquvo)** requires the following rule(s) be met for approval:

- A. You have chronic heart failure (a type of heart condition)
- B. You are 18 years of age or older
- C. You have an ejection fraction (heart function) of less than 45 percent
- D. You will not use Verquvo concurrently (at the same time) with long-acting nitrates or nitric oxide donors (such as isosorbide dinitrate, isosorbide mononitrate, transdermal nitroglycerin), Adempas (riociguat), or PDE-5 inhibitors (such as vardenafil, tadalafil)
- E. You have tried or have a contraindication to (harmful for you to use) ONE of the following sodium-glucose transporter-2 inhibitors (SGLT-2 inhibitors: class of drugs): Farxiga (dapagliflozin), Xigduo XR (dapagliflozin-metformin extended release), Jardiance (empagliflozin), Synjardy (empagliflozin-metformin)
- F. You have tried or have a contraindication to ONE agent from EACH of the following classes:
 - i. Angiotensin converting enzyme (ACE) inhibitors (such as enalapril, lisinopril), angiotensin II receptor blockers (ARB: such as valsartan, candesartan), or angiotensin receptor-neprilysin inhibitor (ARNI: such as Entresto [sacubitril/valsartan])
 - ii. Beta-blocker (bisoprolol, carvedilol, metoprolol succinate)
 - iii. Aldosterone antagonists (spironolactone or eplerenone)

RENEWAL CRITERIA

Our guideline named **VERICIGUAT (Verquvo)** requires the following rule(s) be met for renewal:

- A. You have chronic heart failure (a type of heart condition)
- B. You have an ejection fraction (heart function) of less than 45 percent
- C. You will NOT be taking Verquvo concurrently (at the same time) with long-acting nitrates or nitric oxide donors (such as isosorbide dinitrate, isosorbide mononitrate, transdermal nitroglycerin), Adempas (riociguat), or PDE-5 inhibitors (such as vardenafil, tadalafil)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VIGABATRIN

Generic	Brand				
VIGABATRIN	SABRIL, VIGABATRIN, VIGADRONE, VIGPODER				

GUIDELINES FOR USE

Our guideline named **VIGABATRIN (Sabril, Vigadrone, Vigpoder)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. Refractory complex partial seizures (a type of seizure)
2. Infantile spasms (a type of seizure disorder in infancy and childhood)

B. **If you have refractory complex partial seizures, approval also requires:**

1. You are 2 years of age or older
2. The requested medication will be used as adjunctive (add-on) therapy
3. The potential benefits outweigh the risk of vision loss
4. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
5. You have tried or have a contraindication to (harmful for you to use) THREE antiepileptic medications, at least two of which must be generic (drugs used to treat seizures such as carbamazepine, divalproex/valproic acid, oxcarbazepine, levetiracetam immediate-release/extended-release, gabapentin, zonisamide, topiramate, lamotrigine)

C. **If you have infantile spasms, approval also requires:**

1. You are 1 month to 2 years of age
2. The requested medication will be used as monotherapy (one drug treatment)
3. The potential benefits outweigh the potential risk of vision loss
4. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)

Effective: 09/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VIGABATRIN SOLUTION

Generic	Brand				
VIGABATRIN	VIGAFYDE				

GUIDELINES FOR USE

Our guideline named **VIGABATRIN (Vigafyde)** requires the following rule(s) be met for approval:

- A. You have infantile spasms (a type of seizure disorder in infancy and childhood)
- B. You are 1 month to 2 years of age
- C. Vigafyde will be used as monotherapy (one drug treatment)
- D. The potential benefits outweigh the potential risk of vision loss
- E. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
- F. You have tried or have a contraindication to (harmful for you to use) generic vigabatrin powder for solution

Effective: 08/19/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VIMSELTINIB

Generic	Brand				
VIMSELTINIB	ROMVIMZA				

GUIDELINES FOR USE

Our guideline named **VIMSELTINIB (Romvimza)** requires the following rule(s) be met for approval:

You have symptomatic tenosynovial giant cell tumor (TGCT: a type of tumor that affects joints)

You are 18 years of age or older

Surgical resection (removal by surgery) of the tumor may cause worsening functional limitation or severe morbidity (illness)

Effective: 04/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VISMODEGIB

Generic	Brand				
VISMODEGIB	ERIVEDGE				

GUIDELINES FOR USE

Our guideline named **VISMODEGIB (Erivedge)** requires the following rule(s) be met for approval:

- A. You have metastatic basal cell carcinoma or locally advanced basal cell carcinoma (type of skin cancer that has spread in the body or is advanced but has not spread)
- B. You are 18 years of age or older
- C. **If you have locally advanced basal cell carcinoma, approval also requires:**
 - 1. Your cancer has returned after surgery OR you are not a candidate for surgery or radiation

Effective: 01/01/22



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VOCLOSPORIN

Generic	Brand				
VOCLOSPORIN	LUPKYNIS				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **VOCLOSPORIN (Lupkynis)** requires the following rule(s) be met for approval:

You have active lupus nephritis (LN: a type of immune condition that affects the kidneys)

You are 18 years of age or older

Lupkynis will be used in combination with a background immunosuppressive therapy regimen (such as mycophenolate mofetil, corticosteroids [such as prednisone])

Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or nephrologist (a type of kidney doctor)

RENEWAL CRITERIA

Our guideline named **VOCLOSPORIN (Lupkynis)** requires the following rule(s) be met for renewal:

- A. You have active lupus nephritis (LN: inflammation of the kidneys caused by lupus when the immune system attacks its own tissues)
- B. You have improvement in renal response from baseline laboratory values (eGFR [measurement of kidney function] or proteinuria [level of protein in urine]) and/or clinical parameters (such as fluid retention, use of rescue drugs, glucocorticoid use)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VONOPRAZAN

Generic	Brand				
VONOPRAZAN/AMOXICILLIN	VOQUEZNA DUAL PAK				
VONOPRAZAN/AMOXICILLIN /CLARITH	VOQUEZNA TRIPLE PAK				
VONOPRAZAN FUMARATE	VOQUEZNA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **VONOPRAZAN (Voquezna Dual Pak, Voquezna Triple Pak, Voquezna)** requires the following rule(s) be met for approval:

A. You have ONE of the following:

1. *Helicobacter pylori* (*H. pylori*: a type of bacteria) infection
2. Erosive esophagitis (a type of digestive disorder)
3. Non-erosive gastroesophageal reflux disease (a type of digestive disorder)

B. **If you have a *Helicobacter pylori* infection, approval also requires:**

1. You are 18 years of age or older
2. You have tried or have a contraindication to (harmful for you to use) a bismuth-based quadruple regimen (bismuth/tetracycline/metronidazole plus proton pump inhibitor [PPI] [such as omeprazole, lansoprazole])
3. You meet ONE of the following:
 - a. Your request is for Voquezna 20mg in combination with amoxicillin
 - b. Your request is for Voquezna 20mg in combination with amoxicillin and clarithromycin
 - c. Your request is for Voquezna Dual Pak
 - d. Your request is for Voquezna Triple Pak

(Initial criteria continued on the next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VONOPRAZAN

INITIAL CRITERIA (CONTINUED)

C. If you have erosive esophagitis, approval also requires:

1. Your request is for Voquezna
2. You are 18 years of age or older
3. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
4. Your diagnosis is confirmed by endoscopy (a procedure to look inside your body, such as Los Angeles Classification of Reflux Esophagitis Grade A-D [a tool to rate the severity of the disease])
5. You have tried or have a contraindication to (harmful for you to use) TWO proton pump inhibitors (such as omeprazole, lansoprazole, pantoprazole) at a maximum dose for 8 weeks each

D. If you have non-erosive gastroesophageal reflux disease, approval also requires:

1. Your request is for Voquezna 10mg
2. You are 18 years of age or older
3. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
4. Your diagnosis is confirmed by endoscopy (a procedure to look inside your body) AND you do not have the presence of visible (can be seen) erosion (wearing away) (such as not having Los Angeles Classification of Reflux Esophagitis Grade A-D [a tool to rate the severity of the disease])
5. You had no previous treatment failure (drug did not work) with Voquezna in the last 12 months
6. You have tried or have a contraindication to (harmful for you to use) TWO proton pump inhibitors (such as omeprazole, lansoprazole, pantoprazole) at the maximum dose for 8 weeks each

RENEWAL CRITERIA

NOTE: For the diagnosis of *Helicobacter pylori* (*H. pylori*) infection or non-erosive gastroesophageal reflux disease, please refer to the Initial Criteria section.

Our guideline named **VONOPRAZAN (Voquezna)** requires the following rule(s) be met for renewal:

- A. You have erosive esophagitis (a type of digestive disorder)
- B. Your request is for Voquezna
- C. You have maintained a clinical response on Voquezna (the treatment is working)

Effective: 09/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VORASIDENIB

Generic	Brand				
VORASIDENIB CITRATE	VORANIGO				

GUIDELINES FOR USE

Our guideline named **VORASIDENIB (Voranigo)** requires the following rule(s) be met for approval:

- A. You have Grade 2 astrocytoma or oligodendroglioma (types of brain cancer)
- B. You are 12 years of age or older
- C. Your cancer has a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation (abnormal changes in types of genes that increase the risk of certain diseases)
- D. Voranigo will be used following surgery, including biopsy (removal of cells or tissue from the body for examination), sub-total resection (partial removal of tumor), or gross total resection (complete removal of tumor)

Effective: 09/01/24



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VOSORITIDE

Generic	Brand				
VOSORITIDE	VOXZOGO				

GUIDELINES FOR USE

Our guideline named **VOSORITIDE (Voxzogo)** requires the following rule(s) be met for approval:

- A. You have achondroplasia (a type of bone condition)
- B. You have open epiphyses (the end part of a long bone)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VOXELOTOR

Generic	Brand				
VOXELOTOR	OXBRYTA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **VOXELOTOR (Oxbryta)** requires the following rule(s) be met for approval:

- A. You have sickle cell disease (a type of blood disorder)
- B. You are 4 years of age or older
- C. Your hemoglobin (a type of blood cell) is less than 10.5 g/dL
- D. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
- E. You are having symptoms of anemia (a type of blood condition) which are interfering with activities of daily living
- F. You had a trial of or contraindication (harmful for) to hydroxyurea
- G. **If the request is for the 300 mg tablets for oral suspension, approval also requires ONE of the following:**
 - 1. You weigh less than 40 kilograms
 - 2. You weigh 40 kilograms or more and meet ALL of the following:
 - a. You have tried or have a contraindication (harmful for) to Oxbryta 500mg tablets
 - b. You are unable to swallow Oxbryta 500mg tablets

RENEWAL CRITERIA

Our guideline named **VOXELOTOR (Oxbryta)** requires the following rule(s) be met for renewal:

- A. You have sickle cell disease (a type of blood disorder)
- B. You have maintained an improvement in symptoms associated with anemia (a type of blood condition)

Effective: 01/16/23



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VUTRISIRAN

Generic	Brand				
VUTRISIRAN SODIUM	AMVUTTRA				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **VUTRISIRAN (Amvuttra)** requires the following rule(s) be met for approval:

You have ONE of the following:

Hereditary transthyretin-mediated amyloidosis with polyneuropathy (hATTR-PN: a rare genetic disorder with widespread nerve pain/damage)

Cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM: heart disease caused by a build-up of a type of protein)

If you have hereditary transthyretin-mediated amyloidosis with polyneuropathy, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a neurologist (a type of brain and nerve doctor), cardiologist (a type of heart doctor), hATTR specialist, or medical geneticist (doctor who treats gene disorders)

You are ambulatory (able to walk) (you have Familial Amyloid Polyneuropathy [FAP: a tool used to evaluate disease severity] stage 1 to 2 OR Polyneuropathy Disability [PND: a tool used to evaluate disease severity] stage I to IIIb polyneuropathy)

You will NOT use Amvuttra concurrently (at the same time) with other hATTR-PN medications (such as Wainua [eplontersen], Tegsedi [inotersen], Onpattro [patisiran])

Your diagnosis is confirmed by ONE of the following:

Biopsy (removal of cells from the body for examination) of tissue/organ to confirm amyloid (a type of abnormal protein) presence AND chemical typing to confirm presence of TTR (transthyretin) protein

DNA (deoxyribonucleic acid) genetic sequencing (a type of lab test) to confirm hATTR mutation (a type of abnormal gene)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

VUTRISIRAN

INITIAL CRITERIA (CONTINUED)

If you have cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, approval also requires:

You are 18 years of age or older

Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor), transthyretin amyloidosis (ATTR) specialist, or medical geneticist (doctor who treats gene disorders)

You have New York Heart Association (NYHA) Class I, II, or III heart failure (classification of heart failure symptoms)

Your diagnosis is confirmed by ONE of the following:

Bone scan (scintigraphy) strongly positive for myocardial uptake of TC-99m-PYP (a type of imaging test) (Note: Strongly positive defined as heart to contralateral lung [H/CL] ratio of at least 1.5 or Grade 2 or greater localization to the heart using the Perugini Grade 1-3 scoring system)

Biopsy of tissue of the affected organ(s) (removal of cells or tissue from the body for examination) (can be heart or non-heart related organs) to confirm amyloid (type of protein) presence AND chemical typing to confirm presence of transthyretin (TTR) protein

RENEWAL CRITERIA

Our guideline named **VUTRISIRAN (Amvuttra)** requires the following rule(s) be met for renewal:

You have ONE of the following:

Hereditary transthyretin-mediated amyloidosis with polyneuropathy (hATTR-PN: a rare genetic disorder with widespread nerve pain/damage)

Cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM: heart disease caused by a build-up of a type of protein)

If you have hereditary transthyretin-mediated amyloidosis with polyneuropathy, renewal also requires:

You have NOT progressed to Familial Amyloid Polyneuropathy (FAP: a tool used to evaluate disease severity) stage 3 OR Polyneuropathy Disability (PND: a tool used to evaluate disease severity) stage 4 polyneuropathy, as shown by functional decline (such as being wheelchair-bound, being bedridden)

You will NOT use Amvuttra concurrently (at the same time) with other hATTR-PN medications (such as Wainua [eplontersen], Tegsedi [inotersen], Onpattro [patisiran])

Effective: 05/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ZANUBRUTINIB

Generic	Brand				
ZANUBRUTINIB	BRUKINSA				

GUIDELINES FOR USE

Our guideline named **ZANUBRUTINIB (Brukinsa)** requires the following rule(s) be met for approval:

- A. You have ONE of the following:
 - 1. Mantle cell lymphoma (MCL: a type of blood cancer)
 - 2. Waldenstrom's macroglobulinemia (WM: a type of blood cancer)
 - 3. Relapsed or refractory marginal zone lymphoma (MZL: a type of blood cancer that has returned or did not respond to treatment)
 - 4. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
 - 5. Small lymphocytic lymphoma (SLL: a type of blood cancer)
 - 6. Relapsed or refractory follicular lymphoma (FL: a type of blood cancer that has returned or did not respond to treatment)
- B. **If you have mantle cell lymphoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have received at least ONE prior therapy (such as R-CHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone])
- C. **If you have Waldenstrom's macroglobulinemia, approval also requires:**
 - 1. You are 18 years of age or older
- D. **If you have relapsed or refractory marginal zone lymphoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. You have received at least ONE anti-CD20-based regimen (a type of blood cancer treatment plan, such as rituximab)
- E. **If you have chronic lymphocytic leukemia or small lymphocytic lymphoma, approval also requires:**
 - a. You are 18 years of age or older
- F. **If you have relapsed or refractory follicular lymphoma, approval also requires:**
 - 1. You are 18 years of age or older
 - 2. Brukinsa will be used in combination with Gazyva (obinutuzumab)
 - 3. Brukinsa will be used after at least TWO lines of systemic therapy (such as lenalidomide with rituximab)

Effective: 05/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ZAVEGEPANT

Generic	Brand				
ZAVEGEPANT HCL	ZAVZPRET				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ZAVEGEPANT (Zavzpret)** requires the following rule(s) be met for approval:

- A. The request is for the acute (quick onset) treatment of migraines (a type of headache)
- B. You are 18 years of age or older
- C. You will NOT use Zavzpret concurrently (at the same time) with other calcitonin gene-related peptide (cGRP) inhibitors (such as Ubrelvy [ubrogepant]) for the acute treatment of migraines
- D. You have tried or have a contraindication to (harmful for you to use) ONE triptan (such as Imitrex [sumatriptan], Maxalt [rizatriptan])
- E. You have tried or have a contraindication to TWO of the following medications: Reyvow (lasmiditan), Nurtec ODT (rimegepant), Ubrelvy (ubrogepant)
- F. You are NOT able to tolerate oral medications

RENEWAL CRITERIA

Our guideline named **ZAVEGEPANT (Zavzpret)** requires the following rule(s) be met for approval:

- A. The request is for the acute (quick onset) treatment of migraines (a type of headache)
- B. You will NOT use Zavzpret concurrently (at the same time) with other calcitonin gene-related peptide (cGRP) inhibitors (such as Ubrelvy [ubrogepant]) for the acute treatment of migraines
- C. You meet ONE of the following:
 - 1. You have experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (assessment tool used to help guide treatment such as migraine assessment of current therapy [MIGRAINE-ACT])
 - 2. You have experienced clinical improvement as defined by ONE of the following:
 - a. Ability to function normally within 2 hours of dose
 - b. Headache pain disappears within 2 hours of dose
 - c. Treatment works consistently in a majority of migraine attacks

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ZERO COPAY OVERRIDE - ASPIRIN

Generic	Brand				
ASPIRIN	ASPIRIN, ASPIRIN EC, VARIOUS				

GUIDELINES FOR USE

Our guideline named **ZERO COPAY OVERRIDE - ASPIRIN** requires the following rule(s) be met for approval:

A. You meet ONE of the following:

1. Your request is for a generic medication
2. Your request is for a multi-source or single source brand medication (a brand name medication) and your doctor provided a medical reason why you cannot use the generic equivalent of the requested medication

Effective: 03/03/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ZERO COPAY OVERRIDE - BOWEL PREP

Generic	Brand				
SOD PICOSULF/MAG OX/CITRIC AC	CLENPIQ				
BISAC/NACL/NAHCO3/K CL/PEG 3350	PEG-PREP				
PEG3350/SOD SULF,BICARB,CL/KCL	GAVILYTE-C, GAVILYTE-G, GOLYTELY COLYTE WITH FLAVOR PACKS, PEG 3350- ELECTROLYTE, PEG 3350 AND ELECTROLYTES				
SODIUM CHLORIDE/NAHCO3/ KCL/PEG	NULYTELY, NULYTELY WITH FLAVOR PACKS, GAVILYTE-N, PEG 3350- ELECTROLYTE, TRILYTE WITH FLAVOR PACKETS				
PEG3350/SOD/SUL/NACL /KCL/ASB/C	MOVIPREP, PLENVU, PEG3350/SOD SUL/NACL/KCL/ASB/C				
PEG 3350/SOD SULF, CHLR/POT/MAG	SUFLAVE				
SODIUM, POTASSIUM,MAG SULFATES	SUPREP, SODIUM, POTASSIUM,MAG SULFATES				
SOD SULF/POT CHLORIDE/MAG SULF	SUTAB				

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ZERO COPAY OVERRIDE - BOWEL PREP

GUIDELINES FOR USE

Our guideline named **ZERO COPAY OVERRIDE - BOWEL PREP** requires the following rule(s) be met for approval:

- A. The requested medication is being used for colorectal cancer screening
- B. You are between 45 to 75 years of age
- C. You meet ONE of the following:
 - 1. Your request is for a generic medication or single source brand medication (a brand name medication without a generic available)
 - 2. Your request is for a multi-source medication (a brand name medication with a generic available) and your doctor provided a medical reason why you cannot use the generic equivalent of the requested medication

Effective: 03/03/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ZERO COPAY OVERRIDE - BREAST CANCER PREVENTION

Generic	Brand				
ANASTROZOLE	ARIMIDEX, ANASTROZOLE				
EXEMESTANE	AROMASIN, EXEMESTANE				
RALOXIFENE HCL	EVISTA, RALOXIFENE HCL				
TAMOXIFEN CITRATE	TAMOXIFEN CITRATE				

GUIDELINES FOR USE

Our guideline named **ZERO COPAY OVERRIDE - BREAST CANCER PREVENTION** requires the following rule(s) be met for approval:

- A. The requested medication is being used for prevention (risk reduction) of breast cancer
- B. You are 35 years of age or older
- C. You are requesting a quantity of #1 per day
- D. You meet ONE of the following:
 - 3. Your request is for a generic medication
- E. Your request is for a multi-source or single source brand medication (a brand name medication with or without a generic available) and your doctor provided a medical reason why you cannot use the generic equivalent of the requested medication

Effective: 03/03/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ZERO COPAY OVERRIDE - CONTRACEPTIVE

Generic					
CONTRACEPTIVES, ORAL					
CONTRACEPTIVES, TRANSDERMAL					
CONTRACEPTIVES, INTRAVAGINAL, SYSTEMIC					
INTRA-UTERINE DEVICES (IUD'S)					
CONTRACEPTIVES, INJECTABLE					
CONTRACEPTIVES, IMPLANTABLE					
CONTRACEPTIVE, INTRAVAGINAL					
DIAPHRAGMS/CERVICAL CAP					
CONDOMS, VARIED					

GUIDELINES FOR USE

Our guideline named **ZERO COPAY OVERRIDE - CONTRACEPTIVE** requires that the following rule(s) be met for approval:

A. You meet ONE of the following:

1. Your request is for a generic or a single source brand medication (a brand name medication without a generic available)
2. Your request is for a multi-source brand medication (a brand name medication with a generic available) and your doctor provided a medical reason why you cannot use the generic equivalent of the requested medication

B. If your request is for an oral contraceptive, approval also requires ONE of the following:

1. Your request is for a quantity of #1 per day
2. Your request is for a quantity greater than #1 per day AND your doctor has provided medical justification as to why the requested quantity is needed for contraception (such as continuous therapy, skipping placebo pills)

C. If your request is for a condom, approval also requires ONE of the following:

1. Your request is for a quantity of #60 per prescription fill
2. Your request is for a quantity greater than #60 per fill AND your doctor has provided medical justification as to why the requested quantity is needed for contraception

Effective: 03/03/25

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 6/11/2025

Page 982 of 1007



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ZERO COPAY OVERRIDE - FLUORIDE

Generic	Brand				
FLUORIDE (SODIUM)	FLURA-DROPS, SOLUVITA, FLUORIDE, SODIUM FLUORIDE, LUDENT FLUORIDE				

GUIDELINES FOR USE

Our guideline named **ZERO COPAY OVERRIDE - FLUORIDE** requires the following rule(s) be met for approval:

- A. You are 6 months to 6 years of age
- B. You meet ONE of the following:
 - 1. Your request is for a generic medication
 - 2. Your request is for a multi-source or single source brand medication (a brand name medication with or without a generic available) and your doctor provided a medical reason why you cannot use the generic equivalent of the requested medication

Effective: 03/03/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ZERO COPAY OVERRIDE - FOLIC ACID

Generic	Brand				
FOLIC ACID	FOLIC ACID				

GUIDELINES FOR USE

Our guideline named **ZERO COPAY OVERRIDE - FOLIC ACID** requires the following rule(s) be met for approval:

A. You meet ONE of the following:

1. Your request is for a generic medication
2. Your request is for a multi-source or single source brand medication (a brand name medication with or without a generic available) and your doctor provided a medical reason why you cannot use the generic equivalent of the requested medication.

Effective: 03/03/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ZERO COPAY OVERRIDE - PRE-EXPOSURE PROPHYLAXIS

Generic	Brand				
EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE	TRUVADA, EMTRICITABINE/ TENOFOVIR DISOPROXIL FUMARATE				
EMTRICITABINE/TENOFOVIR ALAFENAMIDE FUMARATE	DESCOVY				
TENOFOVIR DISOPROXIL FUMARATE	VIREAD, TENOFOVIR DISOPROXIL FUMARATE				
EMTRICITABINE	EMTRIVA, EMTRICITABINE				
CABOTEGRAVIR	APRETUDE				

GUIDELINES FOR USE

Our guideline named **ZERO COPAY OVERRIDE - PRE-EXPOSURE PROPHYLAXIS** requires the following rule(s) be met for approval:

- A. The requested medication is FDA (Food and Drug Administration)-approved for pre-exposure prophylaxis (PrEP) OR recommended by the CDC (Centers for Disease Control and Prevention) PrEP Guidelines
- B. The requested medication will NOT be used concurrently (at the same time) with another human immunodeficiency virus (HIV) medication for the treatment of HIV
- C. Your request is for a dosing quantity of #1 per day for Truvada (emtricitabine/tenofovir disoproxil fumarate), Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine), and Descovy (emtricitabine and tenofovir alafenamide)
- D. You meet ONE of the following:
 1. Your request is for a generic or a single source brand medication (a brand name medication without a generic available)
 2. Your request is for a multi-source brand medication (a brand name medication with a generic available) and your doctor provided a medical reason why you cannot use the generic equivalent of the requested medication

Effective: 03/03/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ZERO COPAY OVERRIDE - SMOKING CESSATION

Generic	Brand				
BUPROPION HCL	ZYBAN, BUROPION HCL SR				
VARENICLINE TARTRATE	CHANTIX, VARENICLINE TARTRATE				
NICOTINE	NICOTROL, NICOTROL NS, NICOTINE PATCH, NICODERM CQ, NICOTINE				
NICOTINE POLACRILEX	NICOTINE GUM, NICOTINE LOZENGE, NICORETTE, VARIOUS				

GUIDELINES FOR USE

Our guideline named **ZERO COPAY OVERRIDE - SMOKING CESSATION** requires the following rule(s) be met for approval:

- A. You are 18 years of age or older
- B. You meet ONE of the following:
 - 1. Your request is for a generic
 - 2. Your request is for a multi-source medication (a brand name medication with a generic available) and your doctor provided a medical reason why you cannot use the generic equivalent of the requested medication

Effective: 03/03/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ZERO COPAY OVERRIDE - STATIN

Generic	Brand				
ROSUVASTATIN CALCIUM	CRESTOR, EZALLOR SPRINKLE, ROSUVASTATIN CALCIUM				
PRAVASTATIN SODIUM	PRAVACHOL, PRAVASTATIN SODIUM				
SIMVASTATIN	ZOCOR, SIMVASTATIN				
ATORVASTATIN CALCIUM	LIPITOR, ATORVASTATIN CALCIUM				
LOVASTATIN, LOVASTATIN EXTENDED- RELEASE	ALTOPREV, LOVASTATIN				
FLUVASTATIN SODIUM , FLUVASTATIN EXTENDED- RELEASE	LESCOL, FLUVASTATIN SODIUM, LESCOL XL, FLUVASTATIN EXTENDED- RELEASE				
PITAVASTATIN CALCIUM	LIVALO, PITAVASTATIN CALCIUM				
PITAVASTATIN MAGNESIUM	ZYPITAMAG, PITAVASTATIN MAGNESIUM				

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ZERO COPAY OVERRIDE - STATIN

GUIDELINES FOR USE

Our guideline named **ZERO COPAY OVERRIDE - STATIN** requires the following rule(s) be met for approval:

- A. You are between 40 to 75 years old
- B. You are not concurrently (at the same time) taking any of the below secondary prevention medications for cardiovascular disease (heart disease):
 - 1. Aspirin/dipyridamole (Aggrenox)
 - 2. Clopidogrel (Plavix)
 - 3. Dipyridamole
 - 4. Nitroglycerin (oral, sublingual, transdermal, translingual dosage forms)
 - 5. Prasugrel (Effient)
 - 6. Ticagrelor (Brilinta)
 - 7. Ticlopidine
 - 8. Vorapaxar (Zontivity)
- C. The requested quantity is within the low to moderate intensity daily dosage as shown below:
 - 1. Atorvastatin (Lipitor): 10 - 20 mg
 - 2. Fluvastatin (Lescol): 20 - 80 mg (40 mg twice daily)
 - 3. Fluvastatin ER (Lescol XL): 80 mg
 - 4. Lovastatin: 10 - 40 mg
 - 5. Pitavastatin calcium (Livalo): 1 - 4 mg
 - 6. Pravastatin (Pravachol): 10 - 80 mg
 - 7. Rosuvastatin (Crestor): 5 - 10 mg
- D. You meet ONE of the following:
 - 1. Your request is for a generic medication
 - 2. Your request is for a multi-source brand medication (a brand name medication with a generic available) and your doctor provided a medical reason why you cannot use the generic equivalent of the requested medication

Effective: 03/03/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ZILUCOPLAN

Generic	Brand				
ZILUCOPLAN SODIUM	ZILBRYSQ				

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ZILUCOPLAN (Zilbrysq)** requires the following rule(s) be met for approval:

- A. You have generalized myasthenia gravis (gMG: a chronic autoimmune disorder)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with a neurologist (a type of brain and nervous system doctor)
- D. You have a positive serologic test for the anti-acetylcholine receptor antibody (AChR-Ab+: a type of blood test that shows you have myasthenia gravis)
- E. You have Myasthenia Gravis Foundation of America class II, III, or IV (types of severity of disease)
- F. You have tried or have a contraindication to (harmful for you to use) ONE corticosteroid (such as prednisone)
- G. You have tried or have a contraindication to ONE of the following preferred medications: Rystiggo (rozanolixizumab-noli), Vyvgart (efgartigimod alfa-fcab)/Vyvgart Hytrulo (efgartigimod-hyaluronidase-qvfc)
- H. You will NOT use Zilbrysq concurrently (at the same time) with another neonatal Fc receptor blocker (such as Rystiggo [rozanolixizumab-noli], Vyvgart [efgartigimod alfa-fcab]) or complement inhibitor (such as Soliris [eculizumab], Ultomiris [ravulizumab-cwvz]) for the treatment of generalized myasthenia gravis
- I. You meet ONE of the following:
 - 1. You have tried or have a contraindication to (harmful for you to use) TWO non-steroidal immunosuppressive therapies (such as azathioprine, cyclophosphamide, methotrexate)
 - 2. You have tried or have a contraindication to ONE non-steroidal immunosuppressive therapy if you are on chronic plasmapheresis or plasma exchange (types of blood therapy)

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ZILUCOPLAN

RENEWAL CRITERIA

Our guideline named **ZILUCOPLAN (Zilbrysq)** requires the following rule(s) be met for renewal:

- A. You have generalized myasthenia gravis (gMG: a chronic autoimmune disorder)
- B. You have had clinical benefit compared to baseline (before treatment) according to validated gMG instruments (such as the Myasthenia Gravis Activities of Daily Living tool, Quantitative Myasthenia Gravis tool)
- C. You will NOT use Zilbrysq concurrently (at the same time) with another neonatal Fc receptor blocker (such as Rystiggo [rozanolixizumab-noli], Vyvgart [efgartigimod alfa-fcab]) or complement inhibitor (such as Soliris [eculizumab], Ultomiris [ravulizumab-cwvz]) for the treatment of generalized myasthenia gravis

Effective: 07/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ZONISAMIDE

Generic	Brand				
ZONISAMIDE	ZONISADE				

GUIDELINES FOR USE

Our guideline named **ZONISAMIDE (Zonisade)** requires the following rule(s) be met for approval:

- A. You have partial-onset seizures (a type of seizure)
- B. You are 16 years of age or older
- C. Zonisade will be used as adjunctive (add-on) treatment
- D. You are unable to swallow zonisamide capsules

Effective: 03/17/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ZURANOLONE

Generic	Brand				
ZURANOLONE	ZURZUVAE				

GUIDELINES FOR USE

Our guideline named **ZURANOLONE (Zurzuvae)** requires the following rule(s) be met for approval:

- A. You have postpartum depression (PPD: a type of depression that occurs after giving birth)

Effective: 01/01/25



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INDEX

A

ABALOPARATIDE	3
ABATACEPT - SQ.....	10
ABATACEPT/MALTOSE - IV (NSA).....	5
ABEMACICLIB	14
ABILIFY MYCITE	76
ABIRATERONE ACETATE (AKEEGA).....	568
ABROCITINIB	15
ABSTRAL	313
ACALABRUTINIB	17
ACETAMINOPHEN DAILY LIMIT OVERRIDE.....	18
ACNE AGE RESTRICTION OVERRIDE.....	19
ACORAMIDIS HCL	20
ACTEMRA - IV (NSA)	875
ACTEMRA - SQ	882
ACTHAR	185
ACTHAR SELFJECT.....	185
ACTIMMUNE	438
ACTIQ	313
ADAGRASIB	21
ADALIMUMAB	22
ADALIMUMAB-ADAZ	29
ADALIMUMAB-RYVK.....	36
ADAPALENE.....	19
ADAPALENE/BENZOYL/CLINDAMYCIN (CABTREO).....	43
ADBRY	908
ADCETRIS (NSA)	123
ADCIRCA	827
ADDYI	325
ADEMPAS.....	699
ADLARITY	231
ADLYXIN.....	487
ADO-TRASTUZUMAB EMTANSINE (NSA).....	44
AFATINIB DIMALEATE	45
AFINITOR	302
AFINITOR DISPERZ.....	301
AFREZZA.....	426
AGAMREE	954
AIMOVIG.....	286
AJOVY	332
AKEEGA	568
AKLIEF	19
ALECENSA	46
ALECTINIB HCL	46
ALGLUCOSIDASE ALFA (NSA)	47
ALHEMO	180
ALKINDI SPRINKLE.....	367
ALLERGEN EXTRACT - MIXED GRASS POLLEN	49

ALLERGEN EXTRACT - SHORT RAGWEED POLLEN	50
ALLERGEN EXTRACT-HOUSE DUST MITE	48
ALLERGEN EXTRACT-TIMOTHY GRASS POLLEN	51
ALPELISIB	52
ALPELISIB (VIJOICE).....	53
ALTOPREV	987
ALUNBRIG.....	126
ALVAIZ.....	272
ALYFTREK	957
ALYQ	827
AMANTADINE EXTENDED RELEASE.....	54
AMANTADINE HCL	54
AMBRISENTAN	55
AMIFAMPRIDINE.....	56
AMIKACIN LIPOSOMAL/NEB. ACCESSR	57
AMLODIPINE BENZOATE.....	58
AMONDYS-45 (NSA).....	155
AMPHETAMINE SULFATE.....	59
AMPYRA	196
AMVUTTRA (NSA).....	974
ANABOLIC STEROIDS.....	60
ANADROL-50.....	60
ANAKINRA.....	63
ANASTROZOLE	981
ANDRODERM.....	850
ANDROGEL	850
ANDROID	526
APALUTAMIDE.....	66
APOKYN	67
APOMORPHINE - ONAPGO	69
APOMORPHINE - SL.....	68
APOMORPHINE HCL	67
APREMILAST	70
APRETUDE	985
APROCITENTAN	73
AQNEURSA.....	477
ARANESP	199
ARBLI.....	497
ARCALYST	694
ARESTIN (NSA).....	540
ARIKAYCE	57
ARIMIDEX.....	981
ARIMOCLOMOL CITRATE	75
ARIPIRAZOLE TABLETS WITH SENSOR.....	76
AROMASIN	981
ASCIMINIB HYDROCHLORIDE	77
ASFOTASE ALFA	79
ASPARAGINASE ERWINIA-RYWN.....	78
ASPARLAS (NSA)	138
ASPIRIN.....	978

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ASPIRIN EC.....	978
ASPIRIN ER.....	81
ASPIRIN-OMEPRazole.....	82
ASPRUZO SPRINKLE.....	678
ATOGEANT.....	83
ATORVALIQ.....	85
ATORVASTATIN CALCIUM.....	987
ATORVASTATIN CALCIUM (ATORVALIQ).....	85
ATRASENTAN HYDROCHLORIDE.....	87
ATTRUBY.....	20
AUBAGIO.....	847
AUGTYRO.....	687
AUSTEDO.....	221
AUSTEDO XR.....	221
AVACOPAN.....	88
AVAPRITINIB.....	89
AVATROMBOPAG.....	90
AVMAPKI-FAKZYNJA.....	92
AVONEX.....	433
AVONEX PEN.....	433
AVSOLA (NSA).....	406
AVUTOMETINIB-DEFACTINIB.....	92
AXATILIMAB-CSFR.....	93
AXIRON.....	850
AXITINIB.....	94
AYVAKIT.....	89
AZACITIDINE.....	95
AZMIRO (NSA).....	852
AZTREONAM INHALED.....	96
AZTREONAM LYSINE.....	96

B

BACLOFEN (FLEQSUVY).....	97
BACLOFEN (LYVISPAH).....	97
BACLOFEN (OZOBAX).....	97
BAFIERTAM.....	547
BALVERSA.....	285
BARICITINIB.....	98
BAXDELA.....	214
BEDAQUILINE FUMARATE.....	100
BELIMUMAB.....	101
BELUMOSUDIL MESYLATE.....	103
BELVIQ.....	495
BELVIQ XR.....	495
BELZUTIFAN.....	104
BENLYSTA.....	101
BENRALIZUMAB (NSA).....	105
BERDAZIMER SODIUM.....	108
BERINERT.....	133
BEROTRALSTAT HYDROCHLORIDE.....	109
BESREMI.....	731
BETAINE.....	110

BETASERON.....	434
BETHKIS.....	874
BEXAROTENE SOFTGEL.....	111
BEXAROTENE TOPICAL GEL.....	111
BIMEKIZUMAB-BKZX.....	112
BIMZELX.....	112
BINIMETINIB.....	118
BIRCH BARK EXTRACT.....	119
BISAC/NACL/NAHCO3/KCL/PEG 3350.....	979
BLOOD GLUCOSE SENSOR (CGM STEP).....	182
BLOOD SUGAR DIAGNOSTIC.....	224
BLOOD SUGAR DIAGNOSTIC, DISC.....	224
BLOOD SUGAR DIAGNOSTIC, DRUM.....	224
BLOOD-GLUCOSE SENSOR.....	183
BLOOD-GLUCOSE SENSOR (CGM STEP).....	182
BLOOD-GLUCOSE TRANSMITTER.....	183
BLOOD-GLUCOSE TRANSMITTER (CGM STEP).....	182
BOLUS INSULIN PUMP, 200 UNIT.....	158
BOSENTAN.....	120
BOSULIF.....	121
BOSUTINIB.....	121
BRAFTOVI.....	276
BREMELANOTIDE.....	122
BRENTUXIMAB VEDOTIN (NSA).....	123
BREXAFEMME.....	370
BRIGATINIB.....	126
BRODALUMAB.....	127
BRUKINSA.....	976
BUDESONIDE - EOHILIA.....	129
BUDESONIDE (ORTIKOS).....	130
BUDESONIDE (TARPEYO).....	131
BUPHENYL.....	789
BUPRENORPHINE EXTENDED-RELEASE (NSA).....	132
BUPROPION HCL.....	986
BYDUREON BCISE.....	348
BYETTA.....	348
BYLVAY.....	590
BYNFEZIA.....	588

C

C1 ESTERASE INHIBITOR (BERINERT).....	133
C1 ESTERASE INHIBITOR (CINRYZE).....	134
C1 ESTERASE INHIBITOR (HAEGARDA).....	135
C1 ESTERASE INHIBITOR, RECOMBINANT.....	136
CABLVI.....	148
CABOMETYX.....	137
CABOTEGRAVIR.....	985
CABOZANTINIB S-MALATE.....	137
CABTREO.....	43
CALASPARGASE PEGOL-MKNL (NSA).....	138
CALQUENCE.....	17
CAMZYOS.....	511

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

[illegible]

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DESIRUDIN	216	EFLORNITHINE HCL.....	261
DEUCRAVACITINIB.....	217	EGRIFTA	849
DEURUXOLITINIB PHOSPHATE	219	EGRIFTA SV	849
DEUTETRABENAZINE	221	ELACESTRANT	262
DEXCOM G4.....	183	ELAFIBRANOR.....	263
DEXCOM G5.....	183	ELAGOLIX	265
DEXCOM G5-G4 SENSOR.....	183	ELAGOLIX AND ESTRADIOL AND NORETHINDRONE	267
DEXCOM G6.....	182	ELAPEGADEMASE-LVLR	268
DEXCOM G6 TRANSMITTER	182	ELBASVIR/GRAZOPREVIR	269
DEXMETOMIDINE HCL	222	ELEXACFTOR/TEZACFTOR/IVACFTOR.....	271
DEXTROMETHORPHAN HBR/QUINIDINE.....	223	ELIGARD	476
DIABETIC SUPPLIES,MISCELL	158	ELMIRON.....	654
DIABETIC TEST STRIPS.....	224	ELTROMBOPAG CHOLINE	272
DIACOMIT.....	823	ELYXYB	156
DIAPHRAGMS/CERVICAL CAP	982	EMFLAZA	212
DIAZOXIDE CHOLINE	225	EMGALITY	337
DIBENZYLINE.....	656	EMICIZUMAB-KXWH.....	274
DICHLORPHENAMIDE	226	EMPAVELI	638
DIFFERIN	19	EMRELIS	841
DIGOXIN.....	228	EMROSI	539
DIMETHYL FUMARATE	229	EMTRICITABINE	985
DIROXIMEL FUMARATE	230	EMTRICITABINE/TENOFOVIR ALAFENAMIDE	985
DOJOLVI.....	930	FUMARATE	985
DONEPEZIL HCL.....	231	EMTRICITABINE/TENOFOVIR DISOPROXIL	985
DOPTelet	90	EMTRIVA	985
DORNASE ALFA	232	EMVERM	513
DOXYCYCLINE IR-DR.....	233	ENASIDENIB	275
DOXYCYCLINE MONOHYDRATE	233	ENBREL.....	292
D-PENAMINE.....	651	ENCORAFENIB	276
DROXIDOPA.....	234	ENDARI	465
DULAGLUTIDE	348	ENHERTU (NSA).....	304
DUOPA	151	ENSACOVE	277
DUPILUMAB	235	ENSARTINIB HYDROCHLORIDE	277
DUPIXENT	235	ENSIFENTRINE.....	278
DURAGESIC.....	312	ENSPRYNG	746
DURLAZA	81	ENTADFI.....	319
DURVALUMAB (NSA).....	243	ENTRECTINIB	279
DUVELISIB	245	ENTYVIO (NSA).....	959
DUVYZAT	342	EOHILIA	129
E			
EBGLYSS	463	EPCLUSA	793
ECALLANTIDE (NSA).....	246	EPLONTERSEN SODIUM	280
ECULIZUMAB (NSA)	247	EPOETIN ALFA	281
ECULIZUMAB-AAGH.....	251	EPOETIN ALFA-EPBX.....	283
EDARAVONE (ORAL).....	255	EPOGEN.....	281
EDECRIIN	298	EPRONTIA.....	904
EFBEMALENOGRASTIM ALFA-VUXW.....	256	EPYSQLI.....	251
EFGARTIGIMOD ALFA-FCAB (NSA)	257	ERBITUX	170
EFGARTIGIMOD-HYALURONIDAS-QVFC (NSA)	257	ERDAFITINIB.....	285
EFINACONAZOLE	259	ERENUMAB-AOOE	286
EFLAPEGRASTIM-XNST	260	ERGOTAMINE TARTRATE/CAFFEINE	288
		ERIVEDGE	967
		ERLEADA	66

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ERLOTINIB HCL	289
ERMEZA	482
ESBRIET	661
ESKETAMINE HCL (NSA)	290
ETANERCEPT	292
ETEPLIRSEN (NSA)	297
ETHACRYNIC ACID	298
ETRASIMOD ARGININE	299
EVEKEO	59
EVEROLIMUS (AFINITOR DISPERZ)	301
EVEROLIMUS (AFINITOR)	302
EVERSENSE 365 SENSOR	183
EVERSENSE 365 TRANSMITTER	183
EVERSENSE E3 SENSOR-HLDR	183
EVERSENSE E3 SMART TRANSMITTER	183
EVERSENSE SENSOR-HOLDER	183
EVERSENSE SMART TRANSMITTER	183
EVISTA	981
EVRYSDI	705
EXALGO	368
EXEMESTANE	981
EXENATIDE	348
EXENATIDE MICROSPHERES	348
EXJADE	207
EXONDYS-51 (NSA)	297
EXSERVAN	696
EXTAVIA	435
EYSUVIS	498
EZETIMIBE/SIMVASTATIN	776

F

FABHALTA	442
FAM-TRASTUZUMAB DERUXTECAN-NXKI (NSA)	304
FARESTON	905
FASENRA (NSA)	105
FASLODEX (NSA)	334
FECAL MICROBIO SPORE, LIVE-BRPK	306
FECAL MICROBIOTA, LIVE-JSLM	307
FEDRATINIB DIHYDROCHLORIDE	308
FENFLURAMINE	309
FENTANYL	312
FENTANYL CITRATE	313
FENTANYL NASAL SPRAY	310
FENTANYL SUBLINGUAL SPRAY	311
FENTANYL TRANSDERMAL PATCH	312
FENTANYL TRANSMUCOSAL AGENTS	313
FENTORA	313
FERRIPROX	209
FILGRASTIM	314
FILGRASTIM-AAFI	315
FILGRASTIM-AYOW	316
FILGRASTIM-SNDZ	317

FILGRASTIM-TXID	318
FILSPARI	821
FILSUVEZ	119
FINASTERIDE/TADALAFIL	319
FINERENONE	320
FINGOLIMOD	321
FINGOLIMOD LAURYL SULFATE	322
FINTEPLA	309
FIRAZYR	372
FIRDAPSE	56
FITUSIRAN SODIUM	323
FLASH GLUCOSE SCANNING READER (CGM STEP)	182
FLASH GLUCOSE SENSOR (CGM STEP)	182
FLEQSUVY	97
FLIBANSERIN	325
FLOLIPID	777
FLUORIDE (SODIUM) (FLUORIDE ZERO COST SHARE OVERRIDE)	983
FLUOROPLEX	327
FLUOROURACIL 0.5%	327
FLUOROURACIL 1%	327
FLURA-DROPS	983
FLUVASTATIN EXTENDED-RELEASE	987
FLUVASTATIN SODIUM	987
FOLIC ACID	984
FORTEO	848
FORTESTA	850
FOSCARBIDOPA/FOSLEVODOPA	328
FOSDENOPTERIN HYDROBROMIDE	329
FOSTAMATINIB	330
FOSTEMSAVIR	331
FOTIVDA	873
FREESTYLE LIBRE 2, 3 PLUS SENSOR	182
FREESTYLE LIBRE 2, 3, 10, & 14 SENSOR	182
FREESTYLE LIBRE 2, 3, 10, 14 READER	182
FREMANEZUMAB-VFRM	332
FULPHILA	644
FULVESTRANT (NSA)	334
FURADANTIN	571
FUTIBATINIB	336
FYLNETRA	645

G

G7 RECEIVER	182
G7 SENSOR	182
GALAFOLD	534
GALCANEZUMAB-GNLM	337
GAMMAGARD LIQUID (IMMUNE GLOBULIN - IV/SQ)	382
GAMUNEX-C (IMMUNE GLOBULIN - IV/SQ)	382
GANAXOLONE	339
GATTEX	840



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GAVILYTE-C	979
GAVILYTE-G	979
GAVILYTE-N	979
GAVRETO	672
GEFITINIB	340
GENOTROPIN	806
GILENYA	321
GILOTRIF	45
GILTERITINIB FUMARATE	341
GIMOTI	529
GIVINOSTAT HYDROCHLORIDE	342
GLASDEGIB MALEATE	343
GLATIRAMER ACETATE	344
GLATOPA	344
GLECAPREVIR/PIBRENTASVIR	345
GLEEVEC	375
GLEOSTINE	491
GLP-1 AGONIST	348
GLUTAMINE (L-GLUTAMINE)	465
GLYCEROL PHENYLBUTYRATE	349
GLYCOPYRRONIUM 2.4% CLOTH	350
GOCOVRI	54
GOLIMUMAB - IV (NSA)	351
GOLIMUMAB - SQ	356
GOLODIRSEN (NSA)	361
GOLYTELY	979
GOMEKLI	541
GR POL-ORC/SW VER/RYE/KENT/TIM	49
GRANIX	838
GRASS POLLEN-TIMOTHY, STD	51
GRASTEK	51
GUARDIAN 4 GLUCOSE SENSOR	183
GUARDIAN 4 TRANSMITTER	183
GUARDIAN CONNECT TRANSMITTER	183
GUARDIAN LINK 3 TRANSMITTER	183
GUARDIAN SENSOR 3	183
GUSELKUMAB	362

H

HAEGARDA	135
HARVONI	466
HEMLIBRA	274
HERCEPTIN (NSA)	913
HERCEPTIN HYLECTA (NSA)	913
HERCESSI	915
HETLIOZ	835
HETLIOZ LQ	835
HIZENTRA	380
HUMATROPE	806
HUMIRA	22
HYDROCHLOROTHIAZIDE (INZIRQO)	366
HYDROCORTISONE	367

HYDROMORPHONE HCL	368
HYDROXYUREA (XROMI)	369
HYFTOR	779
HYMPAVZI	509
HYQVIA	381

I

IBRANCE	628
IBREXAFUNGERP CITRATE	370
IBRUTINIB	371
IBSRELA	844
ICATIBANT ACETATE	372
ICLUSIG	668
IDELALISIB	373
IDHIFA	275
IGALMI	222
ILARIS (NSA)	139
ILET INSULIN PUMP	429
ILOPROST TROMETHAMINE	374
ILUMYA (NSA)	866
IMAAVY	565
IMATINIB MESYLATE	375
IMBRUVICA	371
IMCIVREE	769
IMFINZI (NSA)	243
IMKELDI	375
IMMUNE GLOBULIN - CUTAQUIG	378
IMMUNE GLOBULIN - CUVITRU	379
IMMUNE GLOBULIN - HIZENTRA	380
IMMUNE GLOBULIN - HYQVIA	381
IMMUNE GLOBULIN - IV/SQ	382
IMMUNE GLOBULIN - XEMBIFY	384
IMPAVIDO	538
INAVOLISIB	385
INBRIJA	480
INCLISIRAN SODIUM (NSA)	386
INCRELEX	515
INEBILIZUMAB-CDON (NSA)	388
INFLECTRA (NSA)	414
INFLIXIMAB (NSA)	390
INFLIXIMAB-ABDA (NSA)	398
INFLIXIMAB-AXXQ (NSA)	406
INFLIXIMAB-DYYB - IV (NSA)	414
INFLIXIMAB-DYYB - SQ	422
INGENOL MEBUTATE	425
INGREZZA	953
INHALED INSULIN	426
INLYTA	94
INOTERSEN SODIUM	428
INQOVI	206
INREBIC	308
INSULIN PUMPS	429

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INSULIN REGULAR, HUMAN (AFREZZA)	426
INTERFERON ALFA-2B	431
INTERFERON BETA-1A (AVONEX)	433
INTERFERON BETA-1A/ALBUMIN	437
INTERFERON BETA-1B	435
INTERFERON BETA-1B (BETASERON)	434
INTERFERON GAMMA-1B, RECOMB	438
INTERFERONS FOR MS - AVONEX	433
INTERFERONS FOR MS - BETASERON	434
INTERFERONS FOR MS - EXTAVIA	435
INTERFERONS FOR MS - PLEGRIDY	436
INTERFERONS FOR MS - REBIF	437
INTRA-UTERINE DEVICES (IUD'S)	982
INTRON A	431
INZIRQO	366
IPILIMUMAB (NSA)	439
IPRIVASK	216
IPTACOPAN HCL	442
IQIRVO	263
IRESSA	340
ISAVUCONAZONIUM	445
ISTRADEFYLLINE	446
ISTURISA	620
ITOVEBI	385
ITRACONAZOLE-TOLSURA	447
IVACAFTOR	448
IVOSIDENIB	449
IWILFIN	261
IXAZOMIB CITRATE	451
IXEKIZUMAB	452

J

JADENU	207
JADENU SPRINKLE	207
JAKAFI	735
JATENZO	859
JAYPIRCA	662
JESDUVROQ	198
JOENJA	471
JOURNAVX	825
JUBLIA	259
JUXTAPID	489
JYLAMVO	523
JYNARQUE	903

K

KALBITOR (NSA)	246
KALYDECO	448
KATERZIA	58
KERENDIA	320
KERYDIN	836

KESIMPTA	592
KEVEYIS	226
KEVZARA	743
KINERET	63
KITABIS PAK	874
KORLYM	533
KOSELUGO	759
KRAZATI	21
KYNMOBI	68
KYZATREX	859

L

LACOSAMIDE	456
LACTIC ACID/CITRIC/ POTASSIUM	457
LANADELUMAB-FLYO	458
LAPATINIB DITOSYLATE	459
LAROTRECTINIB	460
LASMIDITAN SUCCINATE	461
LAZANDA	310
LAZCLUZE	462
LAZERTINIB MESYLATE	462
LEBRIKIZUMAB-LBKZ	463
LEDIPASVIR/SOFOSBUVIR	466
LEFAMULIN	468
LENACAPAVIR SODIUM	469
LENALIDOMIDE	470
LENIOLISIB PHOSPHATE	471
LENVATINIB MESYLATE	472
LENVIMA	472
LEQSELVI	219
LEQVIO (NSA)	386
LESCOL	987
LESCOL XL	987
LETAIRIS	55
LETERMOVIR	473
LEUKINE	742
LEUPROLIDE ACETATE (ELIGARD)	476
LEUPROLIDE ACETATE (GENERIC)	474
LEVACETYLLAUCINE	477
LEVAMLODIPINE MALEATE	478
LEVETIRACETAM (SPRITAM)	479
LEVODOPA	480
LEVOKETOCONAZOLE	481
LEVOTHYROXINE SODIUM (ERMEZA)	482
LEVOTHYROXINE SODIUM (TIROSINT)	483
LEVOTHYROXINE SODIUM (TIROSINT-SOL)	484
LIKMEZ	530
LIPITOR	987
LIQREV	771
LIRAGLUTIDE	348
LIRAGLUTIDE (SAXENDA)	485
LITFULO	706

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LIVALO.....	987
LIVDELZI.....	754
LIVMARLI.....	506
LIVTENCITY.....	508
LIXISENATIDE.....	487
LOFEXIDINE HCL.....	488
LOMITAPIDE.....	489
LOMUSTINE.....	491
LONAFARNIB.....	492
LONAPEGSSOMATROPIN-TCGD.....	493
LONSURF.....	929
LORBRENA.....	496
LORCASERIN HCL.....	495
LORLATINIB.....	496
LOSARTAN POTASSIUM (ARBLI).....	497
LOTEPREDNOL ETABONATE.....	498
LOTILANER.....	499
LOVASTATIN.....	987
LOVASTATIN EXTENDED-RELEASE.....	987
LU-177 VIPIVOTIDE TETRAXETAN (NSA).....	500
LUCEMYRA.....	488
LUDENT FLUORIDE (FLUORIDE ZERO COST SHARE OVERRIDE).....	983
LUMACAFOR/IVACAFOR.....	501
LUMAKRAS.....	820
LUMIZYME (NSA).....	47
LUMRYZ.....	783
LUPKYNIS.....	968
LUSUTROMBOPAG.....	502
LYBALVI.....	593
LYNPARZA.....	594
LYTGOBI.....	336
LYVISPAH.....	97

M

MACITENTAN.....	503
MACITENTAN/.....	504
MARALIXIBAT CHLORIDE.....	506
MARIBAVIR.....	508
MARSTACIMAB-HNCQ.....	509
MAVACAMTEN.....	511
MAVENCLAD.....	175
MAVORIXAFOR.....	512
MAVYRET.....	345
MAYZENT.....	778
MEBENDAZOLE.....	513
MECAMYLAMINE HCL.....	514
MECASERMIN.....	515
MECHLORETHAMINE HCL.....	517
MEKINIST.....	911
MEKTOVI.....	118
MEPOLIZUMAB.....	518

METHITEST.....	526
METHOTREXATE - JYLAMVO.....	523
METHOXY PEG-EPOETIN BETA.....	524
METHYLNALTREXONE BROMIDE.....	525
METHYLTESTOSTERONE.....	526
METOCLOPRAMIDE HCL.....	529
METRONIDAZOLE (LIKMEZ).....	530
METYROSINE.....	531
MIDOSTAURIN.....	532
MIFEPRISTONE.....	533
MIGALASTAT.....	534
MIGERGOT.....	288
MIGLUSTAT.....	537
MIGLUSTAT (OPFOLDA).....	536
MILTEFOSINE.....	538
MINIMED 630G.....	429
MINIMED 670G.....	429
MINIMED 770G.....	429
MINIMED 780G.....	429
MINOCYCLINE HCL (EMROSI).....	539
MINOCYCLINE HCL MICROSPHERES (NSA).....	540
MIPLYFFA.....	75
MIRCERA.....	524
MIRDAMETINIB.....	541
MIRIKIZUMAB-MRKZ.....	542
MITAPIVAT SULFATE.....	544
MITE,D.FARINAE-D.PTERONYSSINUS.....	48
MOMELOTINIB DIHYDROCHLORIDE.....	545
MOMETASONE FUROATE (NSA).....	546
MONOMETHYL FUMARATE.....	547
MORPHINE SULFATE.....	365
MOTPOLY XR.....	456
MOUNJARO.....	348
MOVIPREP.....	979
MULPLETA.....	502
MYCAPSSA.....	587
MYCOPHENOLATE MOFETIL (MYHIBBIN).....	548
MYFEMBREE.....	685
MYHIBBIN.....	548

N

NAFARELIN ACETATE.....	549
NALTREXONE HCL/BUPROPION HCL.....	551
NATALIZUMAB (NSA).....	552
NATESTO.....	850
NATPARA.....	632
NEDOSIRAN SODIUM.....	555
NEMLUVIO.....	556
NEMOLIZUMAB-ILTO.....	556
NERATINIB MALEATE.....	559
NERLYNX.....	559
NEULASTA.....	639

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

NEULASTA ONPRO	639	OCTREOTIDE ACETATE, MI-SPHERES	585
NEUPOGEN	314	ODACTRA	48
NEXAVAR	817	ODEVIXIBAT	590
NGENLA	804	ODOMZO	816
NICODERM CQ	986	OFATUMUMAB-SQ	592
NICORETTE	986	OFEV	562
NICOTINE	986	OGSIVEO	569
NICOTINE GUM	986	OHTUVAYRE	278
NICOTINE LOZENGE	986	OJEMDA	907
NICOTINE PATCH	986	OJJAARA	545
NICOTINE POLACRILEX	986	OLANZAPINE/SAMIDORPHAN MALATE	593
NICOTROL	986	OLAPARIB	594
NICOTROL NS	986	OLEZARSEN SODIUM	597
NIKTIMVO	93	OLUMIANT	98
NILOTINIB HCL	560	OLUTASIDENIB	598
NILOTINIB TARTRATE	560	OMACETAXINE MEPESUCCINATE	599
NIMODIPINE	561	OMADACYCLINE	600
NINLARO	451	OMALIZUMAB	602
NINTEDANIB	562	OMAVELOXOLONE	607
NIPOCALIMAB-AAHU	565	OMNITROPE	806
NIRAPARIB TOSYLATE	567	OMVOH	542
NIROGACESTAT HYDROBROMIDE	569	ONAPGO	69
NITISINONE	570	ONGENTYS	608
NITROFURANTOIN SUSPENSION	571	ONUREG	95
NITYR	570	OPDIVO (NSA)	572
NIVESTYM	315	OPDIVO QVANTIG	578
NIVOLUMAB (NSA)	572	OPFOLDA	536
NIVOLUMAB-HYALURONIDASE-NVHY	578	OPICAPONE	608
NORDITROPIN FLEXPRO	806	OPIOID CUMULATIVE DOSING OVERRIDE	612
NORTHERA	234	OPIOID LONG-ACTING DUPLICATIVE THERAPY	613
NOURIANZ	446	OPIOID NAIVE FILL LIMIT	616
NOXAFIL	670	OPIOID SINGLE CLAIM DOSING AT POS (OSCDP)	617
NUBEQA	202	OPIOID-ANTIPSYCHOTIC CONCURRENT USE	609
NUCALA	518	OPIOID-BENZODIAZEPINE CONCURRENT USE	610
NUDEXTA	223	OPIOID-BUPRENORPHINE CONCURRENT USE	611
NULIBRY	329	OPIOID-NAIVE CUMULATIVE DOSING	614
NULYTELY	979	OPIOID-NAIVE DAY SUPPLY LIMITATION	615
NULYTELY WITH FLAVOR PACKS	979	OPIOID-SOMA-BENZODIAZEPINE CONCURRENT USE	618
NUPLAZID	660	OPSUMIT	503
NURTEC ODT	697	OPSYNVI	504
NUTROPIN AQ NUSPIN	806	OPZELURA	737
NUZYRA	600	ORACEA	233
NYMALIZE	561	ORALAIR	49
NYPOZI	318	ORENCIA - IV (NSA)	5
NYVEPRIA	640	ORENCIA - SQ	10
		ORENCIA CLICKJECT - SQ	10
		ORENITRAM ER	918
		ORFADIN	570
		ORGOVYX	684
		ORIAHNN	267
		ORILISSA	265
		ORKAMBI	501
		ORLADEYO	109
O			
OBETICHOLIC ACID	583		
OICALIVA	583		
OCTREOTIDE - ORAL	587		
OCTREOTIDE ACETATE - SQ	588		
OCTREOTIDE ACETATE ER	585		

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ORLISTAT	619
ORMALVI	226
ORSERDU	262
ORTIKOS	130
OSILODROSTAT	620
OSIMERTINIB MESYLATE	621
OSMOLEX ER	54
OTESECONAZOLE	623
OTEZLA	70
OXANDRIN	60
OXANDROLONE	60
OXBRYTA	973
OXERVATE	157
OXYCODONE HCL	365
OXYMETAZOLINE HCL/PF	624
OXYMETHOLONE	60
OZANIMOD	625
OZEMPIC	348
OZOBAX	97
OZOBAX DS	97

P

PACRITINIB CITRATE	627
PALBOCICLIB	628
PALFORZIA	636
PALOPEGTERIPARATIDE	629
PALOVAROTENE	630
PALYNZIQ	648
PANITUMUMAB (NSA)	631
PARATHYROID HORMONE	632
PASIREOTIDE	633
PATROMER CALCIUM SORBITE	634
PAZOPANIB HCL	635
PEANUT ALLERGEN POWDER-DNFP	636
PEG 3350 AND ELECTROLYTES	979
PEG 3350/SOD SULF, CHLR/POT/MAG	979
PEG 3350-ELECTROLYTE	979
PEG3350/SOD SUL/NACL/KCL/ASB/C	979
PEG3350/SOD SULF,BICARB,CL/KCL	979
PEGASYS	647
PEGASYS PROCLICK	647
PEGCETACOPLAN (EMPAVELI)	638
PEGFILGRASTIM	639
PEGFILGRASTIM-APGF	640
PEGFILGRASTIM-BMEZ	641
PEGFILGRASTIM-CBQV	642
PEGFILGRASTIM-FPGK	643
PEGFILGRASTIM-JMDB	644
PEGFILGRASTIM-PBBK	645
PEGINTERFERON ALFA-2A	647
PEGINTERFERON ALFA-2B	647
PEG-INTERFERON ALFA-2B-SYLATRON	646

PEGINTERFERON BETA-1A	436
PEGINTRON	647
PEG-PREP	979
PEGVALIASE-PQPZ	648
PEMAZYRE	650
PEMETREXED DISODIUM (NSA)	649
PEMIGATINIB	650
PEMRYDI RTU (NSA)	649
PENICILLAMINE	651
PENTOSAN POLYSULFATE SODIUM	654
PEXIDARTINIB	655
PHEBURANE	789
PHENOXYBENZAMINE HCL	656
PHENTERMINE/TOPIRAMATE ER	657
PHEXXI	457
PICATO	425
PILOCARPINE HCL (QLOSI)	659
PILOCARPINE HCL (VUITY)	659
PIMAVANSERIN	660
PIQRAY	52
PIRFENIDONE	661
PIRTOBRUTINIB	662
PITAVASTATIN CALCIUM	987
PITAVASTATIN MAGNESIUM	987
PITOLISANT HCL	663
PIVMECILLINAM HCL	665
PIVYA	665
PLASMINOGEN HUMAN-TVMH	666
PLEGRIDY	436
PLEGRIDY PEN	436
PLENITY	152
PLENVU	979
PLUVICTO (NSA)	500
POMALIDOMIDE	667
POMALYST	667
PONATINIB HCL	668
PONESIMOD	669
PONVORY	669
POSACONAZOLE	670
PRADAXA	192
PRALSETINIB	672
PRAVACHOL	987
PRAVASTATIN SODIUM	987
PREVYMIS	473
PROCRIT	281
PROCYSBI	190
PULMOZYME	232
PYRIMETHAMINE	673
PYRUKYND	544

Q

QBREXZA	350

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

QDOLO	910
QFITLIA.....	323
QINLOCK	701
QSYMIA	657
QUIZARTINIB DIHYDROCHLORIDE.....	675
QULIPTA.....	83
QUTENZA	150
QUVIVIQ	201

R

RADICAVA ORS	255
RAGWITEK	50
RALDESY	917
RALOXIFENE HCL	981
RANIBIZUMAB (SUSVIMO) (NSA)	676
RANIBIZUMAB/INIT FILL NEEDLE (NSA)	676
RANOLAZINE	678
RAVICTI	349
RAVULIZUMAB-CWVZ (NSA)	679
REBIF	437
REBIF REBIDOSE	437
REBYOTA	307
RECORLEV	481
REGORAFENIB	683
RELEUKO	316
RELISTOR	525
RELTONE	942
RELUGOLIX.....	684
RELUGOLIX/ESTRADIOL/NORETHINDRONE ACETATE	685
RELYVRIO	790
REMICADE (NSA).....	390
REMODULIN	919
RENFLEXIS (NSA).....	398
REPOTRECTINIB	687
RESMETIROM	688
RETACRIT	283
RETEVMO	758
RETIFANLIMAB-DLWR (NSA).....	690
RETIN-A MICRO	19
RETIN-A MICRO PUMP	19
REVATIO (IV).....	770
REVATIO (SUSPENSION).....	771
REVATIO (TABLET).....	774
REVCovi	268
REVLIMID	470
REVUFORJ	691
REVUMENIB CITRATE.....	691
REYVOW	461
REZDIFFRA	688
REZLIDHIA	598
REZUROCK	103

RIABNI (NSA)	716
RIFAXIMIN	692
RILONACEPT	694
RILUZOLE SUSPENSION	696
RIMEGEPANT	697
RINVOQ	934
RIOCIGUAT	699
RIPRETINIB	701
RISANKIZUMAB-RZAA	702
RISDIPLAM	705
RITLECITINIB TOSYLATE	706
RITUXAN (NSA).....	707
RITUXAN HYCELA (NSA)	720
RITUXIMAB (NSA).....	707
RITUXIMAB/HYALURONIDASE, HUMAN - SQ (NSA)	720
RITUXIMAB-ABBS (NSA)	712
RITUXIMAB-ARRX (NSA).....	716
RITUXIMAB-PVVR (NSA).....	722
RIVFLOZA	555
ROFLUMILAST (FOAM)	729
ROFLUMILAST 0.15% CREAM	726
ROFLUMILAST 0.3% CREAM	728
ROLVEDON	260
ROMVIMZA.....	966
ROPEGINTERFERON ALFA-2B-NJFT	731
ROSUVASTATIN CALCIUM	987
ROZANOLIXIZUMAB-NOLI (NSA).....	732
ROZLYTREK.....	279
RUBRACA	734
RUCAPARIB	734
RUCONEST	136
RUKOBIA	331
RUXIENCE (NSA).....	722
RUXOLITINIB PHOSPHATE.....	735
RUXOLITINIB PHOSPHATE TOPICAL	737
RUZURGI	56
RYDAPT	532
RYLAZE	78
RYPLAZIM	666
RYSTIGGO (NSA)	732
RYZNEUTA.....	256

S

SABRIL	964
SACITUZUMAB GOVITECAN-HZIY (NSA)	740
SACROSIDASE	741
SAIZEN	806
SAIZEN-SAIZENPREP	806
SAJAZIR	372
SANDOSTATIN LAR DEPOT	585
SANTYL	179
SARGRAMOSTIM.....	742

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

[illegible]

T:SLIM X2	429
T:SLIM X2 CONTROL-IQ	429
T:SLIM X2 WITH BASAL-IQ	429
TABRECTA	149
TADALAFIL (CIALIS)	826
TADALAFIL-ADCIRCA, ALYQ	827
TADALAFIL-TADLIQ	828
TADLIQ	828



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TAFAMIDIS	829	THALOMID	865
TAFAMIDIS MEGLUMINE	829	TIBSOVO	449
TAFINLAR	193	TIGLUTIK	696
TAGRISSO	621	TILDRAKIZUMAB-ASMN (NSA)	866
TAKHZYRO	458	TIROSINT	483
TALAZOPARIB TOSYLATE	830	TIROSINT-SOL	484
TALTZ AUTOINJECTOR	452	TIRZEPATIDE	348
TALTZ SYRINGE	452	TIRZEPATIDE (ZEPBOUND)	868
TALZENNA	830	TISLELIZUMAB-JSGR (NSA)	872
TAMOXIFEN CITRATE	981	TIVOZANIB HCL	873
TANDEM MOBI SYSTEM	429	TLANDO	859
TAPINAROF	832	TOBI	874
TARCEVA	289	TOBI PODHALER	874
TARGRETIN	111	TOBRAMYCIN	874
TARPEYO	131	TOBRAMYCIN IN 0.225% SOD CHLOR	874
TASCENSO ODT	322	TOBRAMYCIN INHALED	874
TASIGNA	560	TOBRAMYCIN/NEBULIZER	874
TASIMELTEON	835	TOCILIZUMAB - IV (NSA)	875
TAVABOROLE	836	TOCILIZUMAB - SQ	882
TAVALISSE	330	TOCILIZUMAB-AAZG - IV (NSA)	888
TAVNEOS	88	TOCILIZUMAB-AAZG - SQ	893
TAZEMETOSTAT	837	TOFACITINIB CITRATE	899
TAZVERIK	837	TOLSURA	447
TBO-FILGRASTIM	838	TOLVAPTAN	903
TECFIDERA	229	TOPIRAMATE (EPRONTIA)	904
TEDIZOLID PHOSPHATE	839	TOREMIFENE CITRATE	905
TEDUGLUTIDE	840	TORPENZ	302
TEGSEDI	428	TORSEMIDE	906
TELISOTUZUMAB VEDOTIN-TLLV	841	TOVORAFENIB	907
TELOTTRISTAT	842	TRACLEER	120
TEMODAR	843	TRALOKINUMAB-LDRM	908
TEMOZOLOMIDE	843	TRAMADOL HCL	910
TENAPANOR HCL	844	TRAMETINIB DIMETHYL SULFOXIDE	911
TENOFOVIR DISOPROXIL FUMARATE	985	TRASTUZUMAB (NSA)	913
TEPMETKO	845	TRASTUZUMAB-HYALURONIDASE-OYSK (NSA)	913
TEPOTINIB HCL	845	TRASTUZUMAB-STRF	915
TERAZOSIN HCL	846	TRAZODONE HCL (RALDESY)	917
TERIFLUNOMIDE	847	TREMFYA	362
TERIPARATIDE	848	TREPROSTINIL	923
TESAMORELIN	849	TREPROSTINIL DIOLAMINE	918
TESTIM	850	TREPROSTINIL DPI	921
TESTOSTERONE	850	TREPROSTINIL SODIUM (REMODULIN)	919
TESTOSTERONE CYPIONATE - AZMIRO (NSA)	852	TREPROSTINIL SODIUM (YUTREPIA)	925
TESTOSTERONE CYPIONATE-DEPO	854	TRETINOIN MICROSPHERES	19
TESTOSTERONE ENANTHATE	856	TRIENTINE HCL	927
TESTOSTERONE UNDECANOATE	859	TRIENTINE TETRAHYDROCHLORIDE	928
TESTRED	526	TRIFAROTENE	19
TETRABENAZINE	861	TRIFLURIDINE/TIPIRACIL HCL	929
TEVIMBRA (NSA)	872	TRIHEPTANOIN	930
TEZACAFOR/IVACAFOR	862	TRIKAFTA	271
TEZEPELUMAB-EKKO (NSA)	863	TRILYTE WITH FLAVOR PACKETS	979
TEZRULY	846	TRODELVY (NSA)	740
TEZSPIRE (NSA)	863	TROFINETIDE	931
THALIDOMIDE	865	TRULICITY	348

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TRUQAP	147
TRUVADA	985
TRUXIMA (NSA)	712
TRYNGOLZA	597
TRYVIO	73
TUCATINIB	932
TUKYSA	932
TURALIO	655
TYENNE	893
TYENNE (NSA)	888
TYKERB	459
TYMLOS	3
TYRVAYA	958
TYSABRI (NSA)	552
TYVASO	923
TYVASO DPI	921

U

UBRELVI	933
UBROGEPANT	933
UDENYCA	642
UDENYCA ONBODY	642
ULTOMIRIS (NSA)	679
UNDECATREX	859
UPADACITINIB	934
UPLIZNA (NSA)	388
UPNEEQ	624
UPTRAVI	756
URIDINE TRIACETATE	941
URSODIOL	942
USTEKINUMAB	943
USTEKINUMAB-AEKN	946
USTEKINUMAB-KFCE	949

V

VADADUSTAT	952
VAFSEO	952
VALBENZIN	953
VALCHLOR	517
VAMOROLONE	954
VANDETANIB	956
VANFLYTA	675
VANRAFIA	87
VANZACAFOR-TEZACAFOR-DEUTIVACAFOR	957
VARENICLINE TARTRATE	986
VARENICLINE TARTRATE (TYRVAYA)	958
VECAMYL	514
VECTIBIX (NSA)	631
VEDOLIZUMAB (NSA)	959
VELSIPITY	299
VELTASSA	634

VEMURAFENIB	961
VENCLEXTA	962
VENETOCLAX	962
VENTAVIS	374
VERICIGUAT	963
VERKAZIA	188
VERQUVO	963
VERZENIO	14
VESICARE LS	798
VEVYE	189
VICTOZA	348
VIGABATRIN	964
VIGABATRIN SOLUTION (VIGAFYDE)	965
VIGADRONE	964
VIGAFYDE	965
VIGPODER	964
VIJOICE	53
VIMSELTINIB	966
VIREAD	985
VISMODEGIB	967
VITRAKVI	460
VIVJOA	623
VIZIMPRO	195
VOCLOSPORIN	968
VOGELXO	850
VONJO	627
VONOPRAZAN FUMARATE	969
VONOPRAZAN/AMOXICILLIN	969
VONOPRAZAN/AMOXICILLIN/CLARITH	969
VOQUEZNA	969
VOQUEZNA DUAL PAK	969
VOQUEZNA TRIPLE PAK	969
VORANIGO	971
VORASIDENIB CITRATE	971
VOSEVI	795
VOSORITIDE	972
VOTRIENT	635
VOWST	306
VOXELOTOR	973
VOXZOGO	972
VOYDEYA	197
VTAMA	832
VUITY	659
VUMERITY	230
VUTRISIRAN SODIUM (NSA)	974
VYALEV	328
VYKAT XR	225
VYLEESI	122
VYNDAMAX	829
VYNDALCEL	829
VYONDYS-53 (NSA)	361
VYTORIN	776
VYVGART (NSA)	257
VYVGART HYTRULO (NSA)	257

Copyright © 2025 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

W

WAINUA.....	280
WAKIX.....	663
WEED POLLEN-SHORT RAGWEED.....	50
WEGOVY.....	760
WELIREG.....	104
WINLEVI.....	176
WINREVAIR.....	818

X

XALKORI.....	187
XDEMYVY.....	499
XELJANZ.....	899
XELJANZ XR.....	899
XELODA.....	145
XENAZINE.....	861
XENICAL.....	619
XENLETA.....	468
XERMELO.....	842
XIFAXAN.....	692
XOLAIR.....	602
XOLREMDI.....	512
XOSPATA.....	341
XPOVIO.....	757
XROMI.....	369
XURIDEN.....	941
XYOSTED.....	856
XYREM.....	786
XYWAV.....	780

Y

YARGESA.....	537
YCANTH.....	144
YERVOY (NSA).....	439
YESINTEK.....	949
YORVIPATH.....	629
YOSPRALA.....	82
YUTREPIA.....	925

Z

ZANUBRUTINIB.....	976

ZARXIO.....	317
ZAVEGEPANT HCL.....	977
ZAVESCA.....	537
ZAVZPRET.....	977
ZEJULA.....	567
ZELBORAF.....	961
ZELSUVMI.....	108
ZEPATIER.....	269
ZEPBOUND.....	868
ZEPOSIA.....	625
ZERO COPAY OVERRIDE - ASPIRIN.....	978
ZERO COPAY OVERRIDE - BOWEL PREP.....	979
ZERO COPAY OVERRIDE - BREAST CANCER PREVENTION.....	981
ZERO COPAY OVERRIDE - CONTRACEPTIVE.....	982
ZERO COPAY OVERRIDE - FLUORIDE.....	983
ZERO COPAY OVERRIDE - FOLIC ACID.....	984
ZERO COPAY OVERRIDE - PRE-EXPOSURE PROPHYLAXIS.....	985
ZERO COPAY OVERRIDE - SMOKING CESSATION.....	986
ZERO COPAY OVERRIDE - STATIN.....	987
ZIEXTENZO.....	641
ZILBRYSQ.....	989
ZILUCOPLAN SODIUM.....	989
ZOCOR.....	987
ZOCOR-SIMVASTATIN 80.....	776
ZOKINVY.....	492
ZOMACTON.....	806
ZONISADE.....	991
ZONISAMIDE.....	991
ZORBTIVE.....	815
ZORYVE (FOAM).....	729
ZORYVE (ROFLUMILAST 0.15% CREAM).....	726
ZORYVE (ROFLUMILAST 0.3% CREAM).....	728
ZTALMY.....	339
ZURANOLONE.....	992
ZURZUVAE.....	992
ZYBAN.....	986
ZYDELIG.....	373
ZYKADIA.....	160
ZYMFENTRA.....	422
ZYNYZ (NSA).....	690
ZYPITAMAG.....	987